Chembl_ID,Smiles_ID,Drug_Name,Clinical_Phase,MOA,UniprotID
CHEMBL1982660,COC1=CC2=NC=CC(=C2C=C1)NC(=O)NC3=CC=CC(=N3)C(F)(F)F,A-1070722,Preclinical,glycogen synthase kinase inhibitor,P49840
CHEMBL4857232,,AZD1080,Phase 1,glycogen synthase kinase inhibitor,P49840
CHEMBL4864281,,CHIR-98014,Preclinical,glycogen synthase kinase inhibitor,P49840
CHEMBL4863895,,CHIR-99021,Preclinical,glycogen synthase kinase inhibitor,P49840
CHEMBL4876058,,GSK-3-inhibitor-IX,Preclinical,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,P49840
CHEMBL1276127,C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O,indirubin,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,P49840
CHEMBL4858767,,SB-216763,Preclinical,glycogen synthase kinase inhibitor,P49840
CHEMBL4856562,,SB-415286,Preclinical,glycogen synthase kinase inhibitor,P49840
CHEMBL1982660,COC1=CC2=NC=CC(=C2C=C1)NC(=O)NC3=CC=CC(=N3)C(F)(F)F,A-1070722,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4866975,,AR-A014418,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4865739,,AT7867,Preclinical,AKT inhibitor,P49841
CHEMBL4857232,,AZD1080,Phase 1,glycogen synthase kinase inhibitor,P49841
CHEMBL4878168,,AZD2858,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P49841
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,P49841
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,P49841
CHEMBL4877650,,CDK1-5-inhibitor,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P49841
CHEMBL4864281,,CHIR-98014,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4863895,,CHIR-99021,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P49841
CHEMBL2107337,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7.Cl,enzastaurin,Phase 3,PKC inhibitor,P49841
CHEMBL4876058,,GSK-3-inhibitor-IX,Preclinical,glycogen synthase kinase inhibitor|lipoxygenase inhibitor,P49841
CHEMBL1496098,C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P49841
CHEMBL1459534,C1C2(COC3(O1)C4=CC=CC=C4NC3=O)COC5(C6=CC=CC=C6NC5=O)OC2,JW-67,Preclinical,WNT pathway inhibitor,P49841
CHEMBL4867858,,kenpaullone,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P49841
CHEMBL4864558,,LY2090314,Phase 2,glycogen synthase kinase inhibitor,P49841
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P49841
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P49841
CHEMBL4859598,,PF-573228,Preclinical,focal adhesion kinase inhibitor,P49841
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P49841
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P49841
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P49841
CHEMBL4858767,,SB-216763,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4856562,,SB-415286,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL600910,CCOC(=O)C1=CC=C(C=C1)NC(=O)C2=NN3C=CC=CC3=C2,TCS-2002,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL3545157,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,tideglusib,Phase 2,glycogen synthase kinase inhibitor,P49841
CHEMBL4872912,,TWS-119,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P49841
CHEMBL4874931,,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,P49841
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P49841
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P49841
CHEMBL4851837,,A-1120,Preclinical,retinoid receptor ligand,P02753
CHEMBL4871364,,A-317491,Preclinical,purinergic receptor antagonist,P56373
CHEMBL4878854,,Ro-3,Preclinical,purinergic receptor antagonist,P56373
CHEMBL4873709,,A-366,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
,,UNC0737,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
CHEMBL4848975,,BIX-01294,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
CHEMBL4866322,,UNC0224,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
CHEMBL4850786,,UNC0638,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
CHEMBL4859603,,UNC0642,Preclinical,histone lysine methyltransferase inhibitor,Q9H9B1
CHEMBL4873709,,A-366,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
,,UNC0737,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4848975,,BIX-01294,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4874522,,BRD4770,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4866322,,UNC0224,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4848311,,UNC0321,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL1829305,CC(C)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)NC4CCN(CC4)CC5CCCCC5)OC)OCCCN6CCCCC6,UNC0631,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4850786,,UNC0638,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4859603,,UNC0642,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL4866515,,UNC0646,Preclinical,histone lysine methyltransferase inhibitor,Q96KQ7
CHEMBL5079817,CC1=CC(=CC=C1)NC(=O)CN2CCC(CC2)C3=CC=CC=N3.Cl.Cl,A-412997,Preclinical,dopamine receptor agonist,P21917
CHEMBL1600943,C1CN(CCN1CC2=NC3=CC=CC=C3N2)C4=CC=CC=N4.Cl.Cl.Cl,ABT-724,Phase 2,dopamine receptor agonist,P21917
CHEMBL4873519,,AJ76-(+),Preclinical,dopamine receptor antagonist,P21917
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P21917
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P21917
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P21917
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P21917
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P21917
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P21917
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P21917
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL1256832,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,dihydrexidine,Phase 2,dopamine receptor agonist,P21917
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P21917
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P21917
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P21917
CHEMBL1256917,CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl.Cl,eticlopride,Preclinical,dopamine receptor antagonist,P21917
CHEMBL1256646,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O.Br,fenoldopam,Launched,dopamine receptor agonist,P21917
CHEMBL231068,C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F,flibanserin,Launched,serotonin receptor agonist,P21917
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P21917
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol-decanoate,Launched,psychoactive drug,P21917
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL4872403,,L-741742,Preclinical,dopamine receptor antagonist,P21917
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P21917
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P21917
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P21917
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P21917
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL4848364,,NADPH,Preclinical,,P21917
CHEMBL4846754,,nemonapride,Launched,dopamine receptor antagonist,P21917
CHEMBL4856622,,NGD-94-1,Phase 1,dopamine receptor antagonist,P21917
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL2105649,CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,P21917
CHEMBL4878444,,PD-168568,Preclinical,dopamine receptor antagonist,P21917
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P21917
CHEMBL1472975,C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54,perospirone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P21917
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P21917
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P21917
CHEMBL1201154,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(CS(=O)(=O)O)S(=O)(=O)O,prochlorperazine,Launched,dopamine receptor antagonist,P21917
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P21917
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P21917
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.O.Cl,remoxipride,Withdrawn,dopamine receptor antagonist,P21917
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL1334895,CC1=NC=C(C(=N1)N)CN2CCC(=CC2)C3=CC=CC=C3.Cl.Cl,Ro-10-5824,Preclinical,dopamine receptor agonist,P21917
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P21917
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P21917
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P21917
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P21917
CHEMBL3989478,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(CC4)C)C=C1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,thiethylperazine,Launched,dopamine receptor antagonist,P21917
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P21917
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P21917
CHEMBL4865280,,UH-232-(+),Preclinical,dopamine receptor antagonist,P21917
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21917
CHEMBL4850555,,2-CMDO,Preclinical,dopamine receptor antagonist,P21917
CHEMBL4858893,,A-438079,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL4871124,,A-804598,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL1628691,C1=CC=C(C(=C1)CNC2=NN=NN2C3=C(C(=CC=C3)Cl)Cl)OC4=CC=CC=N4,A-839977,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL4866845,,AZ-10606120,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL4869867,,A740003,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL112388,CCC(C)C1C(CCC2(O1)CC3CC(O2)C/C=C(/C(C(/C=C/C=C/4\COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)\C)C,ivermectin,Launched,benzodiazepine receptor agonist,Q99572
CHEMBL4864515,,JNJ-47965567,Preclinical,purinergic receptor antagonist,Q99572
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,Q99572
CHEMBL4860160,,A-582941,Preclinical,nicotinic receptor agonist,P36544
CHEMBL4876916,,A-867744,Preclinical,acetylcholine receptor allosteric modulator,P36544
CHEMBL3305985,C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\CO)/C1)CC2,alcuronium,Launched,muscle relaxant,P36544
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P36544
CHEMBL4303235,CC1=NOC(=C1)C(=CNC2=CC=C(C=C2)Cl)C(=O)NC3=CC=C(C=C3)Cl,CCMI,Preclinical,acetylcholine receptor allosteric modulator,P36544
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,P36544
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P36544
CHEMBL1165368,CN(C)C1=CC=C(C=C1)/C=C/2\CCCN=C2C3=CN=CC=C3,DMAB-anabaseine,Preclinical,adrenergic receptor agonist,P36544
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P36544
CHEMBL3785087,,EVP-6124,Phase 3,acetylcholine receptor agonist,P36544
CHEMBL4856777,,GTS21,Phase 1/Phase 2,cholinergic receptor agonist,P36544
CHEMBL112388,CCC(C)C1C(CCC2(O1)CC3CC(O2)C/C=C(/C(C(/C=C/C=C/4\COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)\C)C,ivermectin,Launched,benzodiazepine receptor agonist,P36544
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,P36544
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P36544
CHEMBL4303653,CCN1C[C@@]2(CC[C@@H]([C@@]34[C@@H]1[C@@]([C@H](C23)OC)([C@]5(C[C@@H]([C@H]6C[C@@H]4[C@@H]5[C@H]6OC)OC)O)O)OC)COC(=O)C7=CC=CC=C7N8C(=O)C[C@@H](C8=O)C,methyllycaconitine,Preclinical,acetylcholine receptor antagonist,P36544
CHEMBL4848782,,MG-624,Preclinical,acetylcholine receptor antagonist,P36544
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P36544
CHEMBL4873995,,PHA-568487,Preclinical,nicotinic receptor agonist,P36544
CHEMBL4869824,,PNU-120596,Preclinical,acetylcholine receptor agonist,P36544
CHEMBL4851122,,PNU-282987,Preclinical,cholinergic receptor agonist,P36544
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P36544
CHEMBL3238795,,SSR180711,Phase 2,acetylcholine receptor agonist,P36544
CHEMBL1396,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,varenicline,Launched,acetylcholine receptor agonist,P36544
CHEMBL4303195,C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)Br,4BP-TQS,Preclinical,nicotinic receptor agonist,P36544
CHEMBL2261346,CS(=O)(=O)NC1=C(C=CC2=C1CCCC2C3=NCCN3)O.Br,A-61603,Preclinical,adrenergic receptor agonist,P25100
CHEMBL2261346,CS(=O)(=O)NC1=C(C=CC2=C1CCCC2C3=NCCN3)O.Br,A-61603,Preclinical,adrenergic receptor agonist,P35348
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P25100
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P35348
CHEMBL2103996,CNCC(=O)C1=CC(=C(C=C1)O)O,adrenalone,Launched,adrenergic receptor agonist,P25100
CHEMBL2103996,CNCC(=O)C1=CC(=C(C=C1)O)O,adrenalone,Launched,adrenergic receptor agonist,P35348
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1365675,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,amitraz,Launched,adrenergic receptor agonist,P25100
CHEMBL1365675,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,amitraz,Launched,adrenergic receptor agonist,P35348
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P25100
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P35348
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P25100
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P35348
CHEMBL2165224,CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3,anisodamine,Phase 3,lipid peroxidase inhibitor,P25100
CHEMBL2165224,CN1[C@H]2C[C@@H](C[C@@H]1[C@H](C2)O)OC(=O)[C@H](CO)C3=CC=CC=C3,anisodamine,Phase 3,lipid peroxidase inhibitor,P35348
CHEMBL1200379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,apraclonidine,Launched,adrenergic receptor agonist,P25100
CHEMBL1200379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,apraclonidine,Launched,adrenergic receptor agonist,P35348
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P25100
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P35348
CHEMBL4874887,,A61603,Preclinical,adrenergic receptor agonist,P25100
CHEMBL4874887,,A61603,Preclinical,adrenergic receptor agonist,P35348
CHEMBL1515808,C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC=C(C=C3)O,BE-2254,Phase 2,adrenergic receptor antagonist,P25100
CHEMBL1515808,C1CC2=CC=CC=C2C(=O)C1CNCCC3=CC=C(C=C3)O,BE-2254,Phase 2,adrenergic receptor antagonist,P35348
CHEMBL4846881,,BMY-7378,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL4846881,,BMY-7378,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P25100
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P35348
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P25100
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P35348
CHEMBL188921,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,buflomedil,Launched,adrenergic receptor antagonist|calcium channel blocker,P25100
CHEMBL188921,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,buflomedil,Launched,adrenergic receptor antagonist|calcium channel blocker,P35348
CHEMBL3182014,CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,bunazosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL3182014,CCCC(=O)N1CCCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,bunazosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P25100
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P35348
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P25100
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P35348
CHEMBL1255646,C1CC1C2=CC=CC=C2OCC3=NCCN3.Cl,cirazoline,Preclinical,adrenergic receptor agonist,P25100
CHEMBL1255646,C1CC1C2=CC=CC=C2OCC3=NCCN3.Cl,cirazoline,Preclinical,adrenergic receptor agonist,P35348
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P25100
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P35348
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P25100
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P35348
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P25100
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P35348
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P25100
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P35348
CHEMBL1201044,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4.Cl,dapiprazole,Launched,adrenergic receptor antagonist,P25100
CHEMBL1201044,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4.Cl,dapiprazole,Launched,adrenergic receptor antagonist,P35348
CHEMBL1122253,,deoxyepinephrine,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,P25100
CHEMBL1122253,,deoxyepinephrine,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,P35348
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P25100
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P35348
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P25100
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P35348
CHEMBL1200561,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O,doxazosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL1200561,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O,doxazosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P25100
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P35348
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P25100
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P35348
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P25100
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P35348
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,P25100
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,P35348
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P25100
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P35348
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P25100
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P35348
CHEMBL1213135,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,ergonovine,Launched,adrenergic receptor agonist|serotonin receptor agonist,P25100
CHEMBL1213135,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,ergonovine,Launched,adrenergic receptor agonist|serotonin receptor agonist,P35348
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P25100
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P35348
CHEMBL3187408,CCNCC(C1=CC(=CC=C1)O)O.Cl,etilefrine,Launched,adrenergic receptor agonist,P25100
CHEMBL3187408,CCNCC(C1=CC(=CC=C1)O)O.Cl,etilefrine,Launched,adrenergic receptor agonist,P35348
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P25100
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P35348
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P25100
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P35348
CHEMBL2104941,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,indoramin,Launched,adrenergic receptor antagonist,P25100
CHEMBL2104941,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,indoramin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P25100
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P35348
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P25100
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P35348
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P25100
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P35348
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P25100
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P35348
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P25100
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P35348
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P25100
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P35348
CHEMBL2062262,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N.C(C(C(=O)O)O)(C(=O)O)O,metaraminol,Launched,adrenergic receptor agonist,P25100
CHEMBL2062262,C[C@@H]([C@@H](C1=CC(=CC=C1)O)O)N.C(C(C(=O)O)O)(C(=O)O)O,metaraminol,Launched,adrenergic receptor agonist,P35348
CHEMBL4303366,CC(C(=O)N1CCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC)OC,metazosin,Phase 2,adrenergic receptor antagonist,P25100
CHEMBL4303366,CC(C(=O)N1CCN(CC1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC)OC,metazosin,Phase 2,adrenergic receptor antagonist,P35348
CHEMBL1201103,CC(C(C1=C(C=CC(=C1)OC)OC)O)N.Cl,methoxamine,Launched,adrenergic receptor agonist,P25100
CHEMBL1201103,CC(C(C1=C(C=CC(=C1)OC)OC)O)N.Cl,methoxamine,Launched,adrenergic receptor agonist,P35348
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P25100
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P35348
CHEMBL4873149,,naftopidil,Launched,adrenergic receptor antagonist,P25100
CHEMBL4873149,,naftopidil,Launched,adrenergic receptor antagonist,P35348
CHEMBL4850949,,NAN-190,Preclinical,serotonin receptor agonist,P25100
CHEMBL4850949,,NAN-190,Preclinical,serotonin receptor agonist,P35348
CHEMBL1706,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32.Cl,naphazoline,Launched,adrenergic receptor agonist,P25100
CHEMBL1706,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32.Cl,naphazoline,Launched,adrenergic receptor agonist,P35348
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P25100
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P35348
CHEMBL1372950,CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br,nicergoline,Launched,adrenergic receptor antagonist,P25100
CHEMBL1372950,CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br,nicergoline,Launched,adrenergic receptor antagonist,P35348
CHEMBL4852449,,niguldipine-(S)-(+),Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4852449,,niguldipine-(S)-(+),Preclinical,adrenergic receptor antagonist,P35348
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P25100
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P35348
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P25100
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P35348
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P25100
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P35348
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P25100
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P35348
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P25100
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P35348
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P25100
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P35348
CHEMBL1200339,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,phenylephrine,Launched,adrenergic receptor agonist,P25100
CHEMBL1200339,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,phenylephrine,Launched,adrenergic receptor agonist,P35348
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P25100
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P35348
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P25100
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P35348
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL5090661,CC(C)C1=C(C(=CC=C1)OC)OCC(=O)N2CCN(CC2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC.Cl.Cl,Rec-15/2615,Phase 2,adrenergic receptor antagonist,P25100
CHEMBL5090661,CC(C)C1=C(C(=CC=C1)OC)OCC(=O)N2CCN(CC2)C3=NC4=CC(=C(C=C4C(=N3)N)OC)OC.Cl.Cl,Rec-15/2615,Phase 2,adrenergic receptor antagonist,P35348
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P25100
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P35348
CHEMBL4859022,,RS-100329,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4859022,,RS-100329,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL4864904,,RS-17053,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4864904,,RS-17053,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL4864310,,silodosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL4864310,,silodosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL61479,C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F,siramesine,Phase 2,sigma receptor antagonist,P25100
CHEMBL61479,C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F,siramesine,Phase 2,sigma receptor antagonist,P35348
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL4866493,,SNAP-94847,Preclinical,,P25100
CHEMBL4866493,,SNAP-94847,Preclinical,,P35348
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P25100
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P35348
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P25100
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P35348
CHEMBL4854095,,stobadine,Phase 2,adrenergic receptor antagonist,P25100
CHEMBL4854095,,stobadine,Phase 2,adrenergic receptor antagonist,P35348
CHEMBL33720,CNCC(C1=CC=C(C=C1)O)O,synephrine,Launched,adrenergic receptor agonist,P25100
CHEMBL33720,CNCC(C1=CC=C(C=C1)O)O,synephrine,Launched,adrenergic receptor agonist,P35348
CHEMBL1200914,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,tamsulosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL1200914,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,tamsulosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL3989562,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl,terazosin,Launched,adrenergic receptor antagonist,P25100
CHEMBL3989562,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl,terazosin,Launched,adrenergic receptor antagonist,P35348
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P25100
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P35348
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P25100
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P35348
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P25100
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P35348
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P25100
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P35348
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P25100
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P35348
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P25100
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P35348
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25100
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35348
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P25100
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P35348
CHEMBL1514751,C1CN(CCN1C[C@H]2CN3C(=C4C=CC=CC4=NC3=O)N2)C5=CC=CC=C5,2-PMDQ,Preclinical,adrenergic receptor antagonist,P25100
CHEMBL1514751,C1CN(CCN1C[C@H]2CN3C(=C4C=CC=CC4=NC3=O)N2)C5=CC=CC=C5,2-PMDQ,Preclinical,adrenergic receptor antagonist,P35348
CHEMBL4855885,,3-MPPI,Preclinical,adrenergic receptor ligand,P25100
CHEMBL4855885,,3-MPPI,Preclinical,adrenergic receptor ligand,P35348
CHEMBL2261346,CS(=O)(=O)NC1=C(C=CC2=C1CCCC2C3=NCCN3)O.Br,A-61603,Preclinical,adrenergic receptor agonist,P35368
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P35368
CHEMBL1356346,C1CCN(CC1)C(=N)C[C@H](COC2=CC=CC=C2C3=CC=CC=C3)O,AH11110,Preclinical,adrenergic receptor ligand,P35368
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P35368
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P35368
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P35368
CHEMBL4846881,,BMY-7378,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P35368
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P35368
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P35368
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P35368
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P35368
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P35368
CHEMBL1201044,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4.Cl,dapiprazole,Launched,adrenergic receptor antagonist,P35368
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P35368
CHEMBL1200561,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O,doxazosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P35368
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P35368
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P35368
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P35368
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P35368
CHEMBL2104941,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,indoramin,Launched,adrenergic receptor antagonist,P35368
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P35368
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P35368
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P35368
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P35368
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P35368
CHEMBL1201103,CC(C(C1=C(C=CC(=C1)OC)OC)O)N.Cl,methoxamine,Launched,adrenergic receptor agonist,P35368
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P35368
CHEMBL4850949,,NAN-190,Preclinical,serotonin receptor agonist,P35368
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P35368
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P35368
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P35368
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P35368
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P35368
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P35368
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P35368
CHEMBL1200339,CNC[C@@H](C1=CC(=CC=C1)O)O.Cl,phenylephrine,Launched,adrenergic receptor agonist,P35368
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P35368
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P35368
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P35368
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL4864310,,silodosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL61479,C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F,siramesine,Phase 2,sigma receptor antagonist,P35368
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P35368
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P35368
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P35368
CHEMBL1200914,CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N.Cl,tamsulosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL3989562,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl,terazosin,Launched,adrenergic receptor antagonist,P35368
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P35368
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P35368
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P35368
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35368
CHEMBL4857147,,A-674563,Preclinical,AKT inhibitor,P31749
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P31749
CHEMBL4303566,C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N,API-1,Preclinical,AKT inhibitor,P31749
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,P31749
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,P31749
CHEMBL4874127,,AZD5363,Phase 3,AKT inhibitor,P31749
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P31749
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P31749
CHEMBL1154171,,BMS-754807,Phase 2,IGF-1 inhibitor,P31749
CHEMBL4863026,,CaMKII-IN-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,P31749
CHEMBL4867134,,canertinib,Phase 3,EGFR inhibitor,P31749
CHEMBL2107337,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7.Cl,enzastaurin,Phase 3,PKC inhibitor,P31749
CHEMBL4847961,,GDC-0068,Phase 3,AKT inhibitor,P31749
CHEMBL2219422,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl,GSK2110183,Phase 2,AKT inhibitor,P31749
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,P31749
CHEMBL291481,CC(=O)NCCCCCCNC(=O)C,hexamethylenebisacetamide,Phase 2,AKT inhibitor|differentiation inducer|NFKB pathway inhibitor,P31749
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P31749
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P31749
CHEMBL4863899,,MK-2206,Phase 2,AKT inhibitor,P31749
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P31749
CHEMBL372764,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C,perifosine,Phase 3,AKT inhibitor,P31749
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P31749
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P31749
CHEMBL4863031,,SB-747651A,Preclinical,kinase inhibitor,P31749
CHEMBL3392223,CC1=CC=CC=C1CN2CC3=C(CCN(C3=O)CC4=CC=CC=C4)N5C2=NCC5,TIC10,Phase 2,AKT inhibitor|TRAIL modulator,P31749
CHEMBL4873723,,triciribine,Phase 1/Phase 2,AKT inhibitor,P31749
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P31749
CHEMBL4879093,,uprosertib,Phase 2,AKT inhibitor,P31749
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P31749
CHEMBL4857147,,A-674563,Preclinical,AKT inhibitor,P61925
CHEMBL4865739,,AT7867,Preclinical,AKT inhibitor,P61925
CHEMBL541388,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl,fasudil,Launched,rho associated kinase inhibitor,P61925
CHEMBL4866884,,H-89,Preclinical,PKA inhibitor,P61925
CHEMBL4873908,,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,P61925
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,P61925
CHEMBL4857147,,A-674563,Preclinical,AKT inhibitor,P17252
CHEMBL4857147,,A-674563,Preclinical,AKT inhibitor,P17612
CHEMBL4865739,,AT7867,Preclinical,AKT inhibitor,P17252
CHEMBL4865739,,AT7867,Preclinical,AKT inhibitor,P17612
CHEMBL4303718,CCCC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]4COP(=O)(O[C@H]4O3)[O-])OC(=O)CCC.[Na+],bucladesine,Launched,adenosine receptor agonist|cAMP stimulant,P17252
CHEMBL4303718,CCCC(=O)NC1=C2C(=NC=N1)N(C=N2)[C@H]3[C@@H]([C@@H]4COP(=O)(O[C@H]4O3)[O-])OC(=O)CCC.[Na+],bucladesine,Launched,adenosine receptor agonist|cAMP stimulant,P17612
CHEMBL4303707,COC1=CC2=C(C=NN2C=C1)C3=C(C=C4C(=N3)NN=C4NC(=O)C5=CC=C(C=C5)F)F,CW-008,Preclinical,PKA activator,P17252
CHEMBL4303707,COC1=CC2=C(C=NN2C=C1)C3=C(C=C4C(=N3)NN=C4NC(=O)C5=CC=C(C=C5)F)F,CW-008,Preclinical,PKA activator,P17612
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P17252
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P17612
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P17252
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P17612
CHEMBL541388,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl,fasudil,Launched,rho associated kinase inhibitor,P17252
CHEMBL541388,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl,fasudil,Launched,rho associated kinase inhibitor,P17612
CHEMBL4866884,,H-89,Preclinical,PKA inhibitor,P17252
CHEMBL4866884,,H-89,Preclinical,PKA inhibitor,P17612
CHEMBL4873908,,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,P17252
CHEMBL4873908,,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,P17612
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,P17252
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,P17612
CHEMBL4854061,,A-784168,Preclinical,transient receptor potential channel antagonist,Q8NER1
CHEMBL359965,C=CCSS(=O)CC=C,allicin,Phase 2,cytokine production inhibitor,Q8NER1
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,Q8NER1
CHEMBL4875214,,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,Q8NER1
CHEMBL4865810,,AMG-517,Phase 1,TRPV antagonist,Q8NER1
CHEMBL4858526,,AMG-9810,Preclinical,TRPV antagonist,Q8NER1
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q8NER1
CHEMBL4875727,,aspartame,Launched,,Q8NER1
CHEMBL4852851,,BCTC,Preclinical,TRPV antagonist,Q8NER1
CHEMBL504760,C[C@@]12CC[C@@H](C1(C)C)CC2=O,camphor-(1R),Phase 1,TRPV activator,Q8NER1
CHEMBL294199,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,capsaicin,Launched,TRPV agonist,Q8NER1
CHEMBL4875326,,capsazepine,Preclinical,TRPV agonist,Q8NER1
CHEMBL486598,CN1[C@H]2C3=C(CCN2C(=O)C4=CC=CC=C41)C5=CC=CC=C5N3,evodiamine,Preclinical,ATPase inhibitor|TRPV agonist,Q8NER1
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,Q8NER1
CHEMBL4860154,,JNJ-17203212,Preclinical,TRPV antagonist,Q8NER1
CHEMBL4873943,,MK-2295,Phase 2,TRPV antagonist,Q8NER1
CHEMBL4874398,,nonivamide,Launched,TRPV agonist,Q8NER1
CHEMBL4866771,,olvanil,Preclinical,TRPV agonist,Q8NER1
CHEMBL112,CC(=O)NC1=CC=C(C=C1)O,paracetamol,Launched,cyclooxygenase inhibitor,Q8NER1
CHEMBL3889591,CCCN(CC)C(=O)/C=C/C=C/C1=CC2=C(C=C1)OCO2,piperine,Phase 1,monoamine oxidase inhibitor,Q8NER1
CHEMBL4874259,,SB-366791,Preclinical,TRPV antagonist,Q8NER1
CHEMBL4871082,,SB-452533,Preclinical,TRPV antagonist,Q8NER1
CHEMBL1147814,,SB-705498,Phase 2,TRPV antagonist,Q8NER1
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q8NER1
CHEMBL4862992,,6-iodo-nordihydrocapsaicin,Preclinical,TRPV antagonist,Q8NER1
CHEMBL4858926,,A-803467,Preclinical,sodium channel blocker,Q9Y5Y9
CHEMBL4303253,CCCCOC1=C(C=C(C=C1)C2=CC(=CN=C2)C(=O)NCC3=C(N=CC=C3)N4CCOCC4)Cl,A-887826,Preclinical,sodium channel blocker,Q9Y5Y9
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q9Y5Y9
CHEMBL221753,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],benzethonium,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL278172,CCOC(=O)C1=CC=C(C=C1)N,benzocaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1200396,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,bupivacaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q9Y5Y9
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1086,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,cinchocaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1200478,CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2.Cl,dyclonine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q9Y5Y9
CHEMBL1200409,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.O.Cl,lidocaine,Launched,histamine receptor agonist,Q9Y5Y9
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1200,CCCCOC1=C(C=CC(=C1)C(=O)OCCN(CC)CC)N,oxybuprocaine,Launched,local anesthetic,Q9Y5Y9
CHEMBL4849712,,PF-04885614,Preclinical,voltage-gated sodium channel blocker,Q9Y5Y9
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q9Y5Y9
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q9Y5Y9
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q9Y5Y9
CHEMBL1196,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,proxymetacaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1526084,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O.Cl.Cl,ranolazine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL4857180,CC1=CC(=CC(=C1NC2=NC(=NC(=C2)N)NC3=CC=C(C=C3)C#N)C)/C=C/C#N,rilpivirine,Launched,non-nucleoside reverse transcriptase inhibitor,Q9Y5Y9
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9Y5Y9
CHEMBL1077896,CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,ropivacaine,Launched,sodium channel blocker,Q9Y5Y9
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q9Y5Y9
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,Q9Y5Y9
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q9Y5Y9
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q9Y5Y9
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q9Y5Y9
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9Y5Y9
CHEMBL4876916,,A-867744,Preclinical,acetylcholine receptor allosteric modulator,P32297
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,P32297
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P32297
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P32297
CHEMBL2106279,C[N+](C)(C)CCCCCC[N+](C)(C)C.[I-].[I-],hexamethonium,Preclinical,cholinergic receptor antagonist,P32297
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,P32297
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P32297
CHEMBL4303695,CN1C2CCC1C=C(C2)C3=C(C=CS3)Br,NS-3861,Preclinical,acetylcholine receptor agonist,P32297
CHEMBL1318287,C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,pentolinium,Launched,cholinergic receptor antagonist,P32297
CHEMBL1256295,C1CSC2=N[C@@H](CN21)C3=CC=CC=C3.Cl,tetramisole,Launched,immunostimulant,P32297
CHEMBL1405034,C1C[C@H]2CC[C@H](N2)C(=C1)C3=CN=C(C=C3)Cl,UB-165,Preclinical,acetylcholine receptor agonist,P32297
CHEMBL1396,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,varenicline,Launched,acetylcholine receptor agonist,P32297
CHEMBL4876916,,A-867744,Preclinical,acetylcholine receptor allosteric modulator,P43681
CHEMBL2146093,CN1CCC[C@H]1C2=CN=CC(=C2)C#C.C(=C/C(=O)O)\C(=O)O,altinicline,Phase 2,nicotinic receptor agonist,P43681
CHEMBL4848919,,AZD1446,Phase 2,acetylcholine receptor agonist,P43681
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P43681
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,P43681
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P43681
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P43681
CHEMBL2106279,C[N+](C)(C)CCCCCC[N+](C)(C)C.[I-].[I-],hexamethonium,Preclinical,cholinergic receptor antagonist,P43681
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,P43681
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P43681
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P43681
CHEMBL4871679,,NS-9283,Preclinical,acetylcholine receptor allosteric modulator,P43681
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-9965,Preclinical,acetylcholine receptor antagonist,P43681
CHEMBL1318287,C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,pentolinium,Launched,cholinergic receptor antagonist,P43681
CHEMBL4870941,,pozanicline,Phase 2,acetylcholine receptor antagonist,P43681
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P43681
CHEMBL4521451,C.CNCC/C=C/C1=CN=CC=C1,rivanicline,Phase 2,acetylcholine receptor agonist,P43681
CHEMBL4861818,,TC2559,Preclinical,acetylcholine receptor agonist,P43681
CHEMBL1405034,C1C[C@H]2CC[C@H](N2)C(=C1)C3=CN=C(C=C3)Cl,UB-165,Preclinical,acetylcholine receptor agonist,P43681
CHEMBL1396,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,varenicline,Launched,acetylcholine receptor agonist,P43681
CHEMBL4855367,,A-922500,Preclinical,diacylglycerol O acyltransferase inhibitor,O75907
CHEMBL4855925,,AZD3988,Preclinical,diacylglycerol kinase inhibitor,O75907
CHEMBL4853518,,AZD7687,Phase 1,diacylglycerol O acyltransferase inhibitor,O75907
CHEMBL430405,C1C[C@H]([C@@H](C1)C(=O)O)C(=O)C2=CC=C(C=C2)C3=CC=C(C=C3)NC(=O)NC4=CC=CC=C4,A922500,Preclinical,diacylglycerol O acyltransferase inhibitor,O75907
CHEMBL399121,COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O,hesperetin,Launched,ACAT inhibitor,O75907
CHEMBL2364624,C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F,LCQ908,Phase 3,diacylglycerol O acyltransferase inhibitor,O75907
CHEMBL4868616,,PF-04620110,Phase 1,diacylglycerol O acyltransferase inhibitor,O75907
CHEMBL4871006,,A-939572,Preclinical,stearoyl-CoA desaturase inhibitor,O00767
CHEMBL4854549,,MK-8245,Phase 2,stearoyl-CoA desaturase inhibitor,O00767
CHEMBL4303458,C1=CC=C(C=C1)NNC(=O)C2=CC=NC=C2,plurisin-1,Preclinical,stearoyl-CoA desaturase inhibitor,O00767
CHEMBL4845864,,A-967079,Preclinical,transient receptor potential channel antagonist,O75762
CHEMBL359965,C=CCSS(=O)CC=C,allicin,Phase 2,cytokine production inhibitor,O75762
CHEMBL4675867,,allylisothiocyanate,Preclinical,TRPV agonist,O75762
CHEMBL4869325,,AP-18,Preclinical,transient receptor potential channel antagonist,O75762
CHEMBL1366,,auranofin,Launched,NFkB pathway inhibitor,O75762
CHEMBL293492,C1=CC=C(C=C1)/C=C/C=O,cinnamaldehyde,Preclinical,aldose reductase inhibitor|TRPV agonist,O75762
CHEMBL1141634,,dibutyl-phthalate,Preclinical,,O75762
CHEMBL4870323,,HC-030031,Phase 1,TRPA1 channel blocker,O75762
CHEMBL258405,C1C=C(NC(=O)N1C2=CC=CC=C2O)C3=CC(=CC=C3)[N+](=O)[O-],icilin,Phase 1,TRPV agonist,O75762
CHEMBL4862828,,levomenthol,Launched,,O75762
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,O75762
CHEMBL4871860,,NPPB,Preclinical,chloride channel blocker,O75762
CHEMBL4868146,,salirasib,Phase 2,mTOR inhibitor,O75762
CHEMBL4857698,,TCS-5861528,Preclinical,transient receptor potential channel antagonist,O75762
CHEMBL29411,CC1=CC(=C(C=C1)C(C)C)O,thymol,Launched,GABA receptor positive allosteric modulator,O75762
CHEMBL4872470,,URB597,Phase 1,FAAH inhibitor,O75762
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P30542
CHEMBL2106660,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.C1CNCCN1,acefylline,Launched,adenosine receptor agonist,P30542
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,P30542
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,P30542
CHEMBL4202825,C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N,BAY-60-6583,Preclinical,adenosine receptor agonist,P30542
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P30542
CHEMBL3235279,C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO,capadenoson,Phase 2,adenosine receptor agonist,P30542
CHEMBL4857678,,CF102,Phase 2,adenosine receptor agonist,P30542
CHEMBL1551336,C1=CC(=C(C=C1C2=C(SC(=N2)N)C3=CC=NC=C3)Cl)Cl.Cl.Cl,CGH2466,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4879351,,CGS-15943,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4303688,CCNC(=O)[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O,CGS-21680,Preclinical,adenosine receptor agonist,P30542
CHEMBL4558169,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,cyproterone-acetate,Launched,androgen receptor antagonist,P30542
CHEMBL1527608,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,doxofylline,Launched,adenosine receptor antagonist,P30542
CHEMBL4870151,,DPCPX,Phase 1,adenosine receptor antagonist,P30542
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,P30542
CHEMBL4846193,,etofylline,Launched,adenosine receptor antagonist,P30542
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,P30542
CHEMBL4846786,,GR-79236,Phase 1,adenosine receptor agonist,P30542
CHEMBL4861828,,GS-6201,Phase 1,adenosine receptor antagonist,P30542
CHEMBL4871645,,HEMADO,Preclinical,adenosine receptor agonist,P30542
CHEMBL4754465,CNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O,IB-MECA,Phase 3,adenosine receptor agonist,P30542
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,P30542
CHEMBL3736368,CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)/C=C/C3=CC(=C(C=C3)OC)OC,istradefylline,Launched,adenosine receptor antagonist,P30542
CHEMBL4848909,,KW-3902,Phase 3,adenosine receptor antagonist,P30542
CHEMBL1321988,C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S,MRS-3777,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4868351,,NECA,Launched,adenosine receptor agonist,P30542
CHEMBL4863705,,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P30542
CHEMBL4878743,,PD-81723,Preclinical,adenosine receptor agonist,P30542
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P30542
CHEMBL4870232,,preladenant,Phase 3,adenosine receptor antagonist,P30542
CHEMBL1593850,CC[C@@H]1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1.Cl,PSB-11,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4871855,,PSB-1115,Preclinical,adenosine receptor antagonist,P30542
CHEMBL1316674,CCCCN1C(=O)C2=C(N=C(N2)C34CC5CC(C3)CC4C5)N(C1=O)CCCO,PSB-36,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4869798,,PSB-603,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4303537,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4C(C([C@H](O4)CO)O)O)N,regadenoson,Launched,adenosine receptor agonist,P30542
CHEMBL4853381,,SCH-58261,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4853680,,SDZ-WAG-994,Phase 2,adenosine receptor agonist,P30542
CHEMBL4874146,,SLV-320,Phase 2,adenosine receptor antagonist,P30542
CHEMBL400190,C[C@]1([C@@H]([C@H](O[C@H]1N2C=NC3=C(N=CN=C32)N[C@@H]4CCOC4)CO)O)O,tecadenoson,Phase 2,adenosine receptor agonist,P30542
CHEMBL1114,CN1C=NC2=C1C(=O)NC(=O)N2C,theobromine,Launched,phosphodiesterase inhibitor,P30542
CHEMBL447664,CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N,vipadenant,Phase 1,adenosine receptor antagonist,P30542
CHEMBL4846009,,ZM-241385,Preclinical,adenosine receptor antagonist,P30542
CHEMBL4852941,,2'-MeCCPA,Preclinical,adenosine receptor agonist,P30542
CHEMBL2168889,,2-chloro-N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P30542
CHEMBL4867466,,2-chloroadenosine,Preclinical,adenosine receptor agonist,P30542
CHEMBL1153422,,5'-chloro-5'-deoxy-ENBA-(+/-),Preclinical,adenosine receptor agonist,P30542
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P37288
CHEMBL378642,CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O,atosiban,Launched,oxytocin receptor antagonist,P37288
CHEMBL1755,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,conivaptan,Launched,vasopressin receptor antagonist,P37288
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,desmopressin-acetate,Launched,vasopressin receptor agonist,P37288
CHEMBL4858531,,L-368899,Phase 1,oxytocin receptor antagonist,P37288
CHEMBL1200690,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N,lypressin,Launched,vasopressin receptor agonist,P37288
CHEMBL5087555,CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C.Cl,mozavaptan,Launched,vasopressin receptor antagonist,P37288
CHEMBL1126531,,OPC-21268,Phase 1,vasopressin receptor antagonist,P37288
CHEMBL4846117,,OT-R-antagonist-1,Preclinical,oxytocin receptor antagonist,P37288
CHEMBL4303358,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,oxytocin,Launched,oxytocin receptor agonist,P37288
CHEMBL594828,COCC1=NN=C(N1C2=CN=C(C=C2)OC)N3CC(C3)OC4=C(C=C(C=C4)F)Cl,PF-3274167,Phase 2,oxytocin receptor antagonist,P37288
CHEMBL4862361,,relcovaptan,Phase 2,vasopressin receptor antagonist,P37288
CHEMBL4845918,,TC-OT-39,Preclinical,oxytocin receptor agonist|vasopressin receptor agonist,P37288
CHEMBL2135460,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N,terlipressin,Launched,vasopressin receptor agonist,P37288
CHEMBL344159,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,tolvaptan,Launched,vasopressin receptor antagonist,P37288
CHEMBL1201528,,vasopressin,Launched,vasopressin receptor agonist,P37288
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P32246
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-5844,Preclinical,CC chemokine receptor agonist,P32246
CHEMBL4869073,,ZK-811752,Phase 2,CC chemokine receptor antagonist,P32246
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P11229
CHEMBL4303558,CC(=O)OC1CN2CCC1CC2.Cl,aceclidine,Launched,acetylcholine receptor agonist,P11229
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P11229
CHEMBL551466,C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-],aclidinium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL3305985,C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\CO)/C1)CC2,alcuronium,Launched,muscle relaxant,P11229
CHEMBL3561133,CC(CC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)N(C)C.OS(=O)(=O)O,aminopentamide,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P11229
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P11229
CHEMBL1475038,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC=C(C1)C(=O)OCC#C,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,P11229
CHEMBL449209,CN1CCC=C(C1)C(=O)OC.Br,arecoline,Phase 1,acetylcholine receptor agonist,P11229
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P11229
CHEMBL4557433,CN1[C@H]2CCC1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,atropine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4865574,,atropine-oxide,Preclinical,acetylcholine receptor antagonist,P11229
CHEMBL1200383,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O,benztropine-mesylate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1768,CC(C[N+](C)(C)C)OC(=O)N.[Cl-],bethanechol,Launched,acetylcholine receptor agonist,P11229
CHEMBL1201067,CC(C(=O)O)O.C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,biperiden,Launched,acetylcholine receptor antagonist,P11229
CHEMBL3039186,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7C4N2C(=O)CC7OCC=C6C5)OC,brucine,Preclinical,glycine receptor antagonist,P11229
CHEMBL1598472,CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2.Cl,caramiphen,Launched,cholinergic receptor antagonist,P11229
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,P11229
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P11229
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P11229
CHEMBL2110773,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)CC5CC5,cimetropium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P11229
CHEMBL620,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,clidinium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P11229
CHEMBL1200935,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,darifenacin,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P11229
CHEMBL1123,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,dicycloverine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL936,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,diphenidol,Launched,acetylcholine receptor agonist,P11229
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,P11229
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P11229
CHEMBL1201765,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O,fesoterodine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1493,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,flavoxate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P11229
CHEMBL1201027,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1200851,C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-],homatropine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1331216,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,hyoscyamine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4858478,,imidafenacin,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P11229
CHEMBL1621597,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,ipratropium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4297319,CN1CC2CCCC(C1)C2OC(=O)C(C3CCCC3)(C4=CC=CC=C4)O.Cl,levo-phencynonate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P11229
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL1444844,CCN(CCCCOC(=O)C1=CC(=C(C=C1)OC)OC)[C@@H](C)CC2=CC=C(C=C2)OC,mebeverine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1200988,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13.[Br-],methantheline,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1354199,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],methscopolamine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1715737,C[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[N+](=O)([O-])[O-],methylatropine-nitrate,Preclinical,acetylcholine receptor antagonist,P11229
CHEMBL1200940,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P11229
CHEMBL2104682,C1C(CN(C1=O)CC2=CC=CC=C2)CN,nebracetam,Phase 3,acetylcholine receptor agonist,P11229
CHEMBL260829,CC1=C(C(=CC=C1)C)NC(=O)CN2CCCC2=O,nefiracetam,Phase 3,acetylcholine receptor agonist|benzodiazepine receptor agonist,P11229
CHEMBL4866592,,nitrocaramiphen,Preclinical,cholinergic receptor antagonist,P11229
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P11229
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL4867004,,otenzepad,Phase 3,acetylcholine receptor antagonist,P11229
CHEMBL4858825,,oxotremorine-M,Preclinical,acetylcholine receptor agonist,P11229
CHEMBL1551988,C1CN(CC1)CC#CCN2C(=O)CCC2.C1CN(CC1)CC#CCN2C(=O)CCC2.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,P11229
CHEMBL4874019,,oxybutynin,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1201286,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,oxyphenonium,Launched,cholinergic receptor antagonist,P11229
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P11229
CHEMBL1213136,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C.[N+](=O)(O)[O-],pilocarpine,Launched,acetylcholine receptor agonist,P11229
CHEMBL1619528,CC[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C,pipenzolate,Launched,cholinergic receptor antagonist,P11229
CHEMBL1623992,CCN1CCCC(C1)OC(=O)C(C2=CC=CC=C2)C3=CC=CC=C3,piperidolate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1531864,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,pirenzepine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1494883,CCN(CC)[C@@H](C)CN1C2=CC=CC=C2SC3=CC=CC=C31,profenamine,Launched,butyrylcholinesterase inhibitor|cholinergic receptor antagonist,P11229
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P11229
CHEMBL1180725,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,propantheline,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1078261,CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C,propiverine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL4846346,,SCH-202676,Preclinical,G protein-coupled receptor modulator,P11229
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1740879,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)[O-],scopolamine-N-oxide,Preclinical,acetylcholine receptor antagonist,P11229
CHEMBL1200803,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,solifenacin-succinate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL4846617,,SR-95639A,Preclinical,acetylcholine receptor agonist,P11229
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P11229
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,P11229
CHEMBL1257109,CC1=C2C(=CS1)C(=O)NC3=CC=CC=C3N2C(=O)CN4CCN(CC4)C.Cl.Cl,telenzepine,Phase 3,acetylcholine receptor antagonist,P11229
CHEMBL3545181,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.O.[Br-],tiotropium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1200871,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,tolterodine,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1725880,CCOC1=CC(=C(C=C1C(=O)CCC(=O)O)OCC)OCC,trepibutone,Launched,cholinergic receptor antagonist,P11229
CHEMBL1201102,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,triflupromazine,Launched,dopamine receptor antagonist,P11229
CHEMBL1490,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,trihexyphenidyl,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1888176,C1CC[N+]2(C1)[C@@H]3CC[C@H]2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O,trospium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1187833,C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5,umeclidinium,Launched,acetylcholine receptor antagonist,P11229
CHEMBL2107687,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],valethamate,Launched,acetylcholine receptor antagonist,P11229
CHEMBL1892145,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2,vinburnine,Launched,adrenergic receptor antagonist,P11229
CHEMBL1728279,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@@](C2)(C(=O)OC)O,vincamine,Withdrawn,adrenergic receptor antagonist,P11229
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P11229
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P11229
CHEMBL4854212,,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,P11229
CHEMBL4874798,,4-DAMP,Preclinical,cholinergic receptor antagonist,P11229
CHEMBL1316369,CC1=CC=C(O1)C[N+](C)(C)C.[I-],5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,P11229
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P08172
CHEMBL4303558,CC(=O)OC1CN2CCC1CC2.Cl,aceclidine,Launched,acetylcholine receptor agonist,P08172
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P08172
CHEMBL551466,C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-],aclidinium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL3305985,C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\CO)/C1)CC2,alcuronium,Launched,muscle relaxant,P08172
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08172
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P08172
CHEMBL4878863,,AQ-RA741,Preclinical,acetylcholine receptor antagonist,P08172
CHEMBL1395412,CC#CCOC(=O)C1=CCCN(C1)C,arecaidine-but-2-ynyl-ester,Preclinical,acetylcholine receptor agonist,P08172
CHEMBL1475038,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC=C(C1)C(=O)OCC#C,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,P08172
CHEMBL449209,CN1CCC=C(C1)C(=O)OC.Br,arecoline,Phase 1,acetylcholine receptor agonist,P08172
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08172
CHEMBL4557433,CN1[C@H]2CCC1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,atropine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL4865574,,atropine-oxide,Preclinical,acetylcholine receptor antagonist,P08172
CHEMBL1768,CC(C[N+](C)(C)C)OC(=O)N.[Cl-],bethanechol,Launched,acetylcholine receptor agonist,P08172
CHEMBL1201067,CC(C(=O)O)O.C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,biperiden,Launched,acetylcholine receptor antagonist,P08172
CHEMBL3039186,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7C4N2C(=O)CC7OCC=C6C5)OC,brucine,Preclinical,glycine receptor antagonist,P08172
CHEMBL1598472,CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2.Cl,caramiphen,Launched,cholinergic receptor antagonist,P08172
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,P08172
CHEMBL1256696,CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,carbetapentane,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P08172
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08172
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P08172
CHEMBL1200935,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,darifenacin,Launched,acetylcholine receptor antagonist,P08172
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08172
CHEMBL1123,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,dicycloverine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL936,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,diphenidol,Launched,acetylcholine receptor agonist,P08172
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,P08172
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P08172
CHEMBL1201765,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O,fesoterodine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1493,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,flavoxate,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1200993,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],gallamine-triethiodide,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1201027,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1331216,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,hyoscyamine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P08172
CHEMBL1621597,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,ipratropium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P08172
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08172
CHEMBL978,CC(C[N+](C)(C)C)OC(=O)C,methacholine,Launched,acetylcholine receptor agonist,P08172
CHEMBL1354199,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],methscopolamine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL2105841,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[Cl-].[Cl-],metocurine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08172
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08172
CHEMBL4867004,,otenzepad,Phase 3,acetylcholine receptor antagonist,P08172
CHEMBL4858825,,oxotremorine-M,Preclinical,acetylcholine receptor agonist,P08172
CHEMBL1551988,C1CN(CC1)CC#CCN2C(=O)CCC2.C1CN(CC1)CC#CCN2C(=O)CCC2.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,P08172
CHEMBL4874019,,oxybutynin,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-],pancuronium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P08172
CHEMBL1213136,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C.[N+](=O)(O)[O-],pilocarpine,Launched,acetylcholine receptor agonist,P08172
CHEMBL1200722,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C.[Br-].[Br-],pipecuronium,Launched,neuromuscular blocker,P08172
CHEMBL1531864,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,pirenzepine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P08172
CHEMBL1180725,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,propantheline,Launched,acetylcholine receptor antagonist,P08172
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08172
CHEMBL1200648,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],rocuronium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL4846346,,SCH-202676,Preclinical,G protein-coupled receptor modulator,P08172
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1740879,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)[O-],scopolamine-N-oxide,Preclinical,acetylcholine receptor antagonist,P08172
CHEMBL1200803,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,solifenacin-succinate,Launched,acetylcholine receptor antagonist,P08172
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P08172
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,P08172
CHEMBL3545181,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.O.[Br-],tiotropium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1200871,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,tolterodine,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1725880,CCOC1=CC(=C(C=C1C(=O)CCC(=O)O)OCC)OCC,trepibutone,Launched,cholinergic receptor antagonist,P08172
CHEMBL1201102,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,triflupromazine,Launched,dopamine receptor antagonist,P08172
CHEMBL1187833,C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5,umeclidinium,Launched,acetylcholine receptor antagonist,P08172
CHEMBL1892145,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2,vinburnine,Launched,adrenergic receptor antagonist,P08172
CHEMBL1728279,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@@](C2)(C(=O)OC)O,vincamine,Withdrawn,adrenergic receptor antagonist,P08172
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P08172
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08172
CHEMBL4874798,,4-DAMP,Preclinical,cholinergic receptor antagonist,P08172
CHEMBL1316369,CC1=CC=C(O1)C[N+](C)(C)C.[I-],5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,P08172
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P20309
CHEMBL4303558,CC(=O)OC1CN2CCC1CC2.Cl,aceclidine,Launched,acetylcholine receptor agonist,P20309
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P20309
CHEMBL551466,C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-],aclidinium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL3305985,C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\CO)/C1)CC2,alcuronium,Launched,muscle relaxant,P20309
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P20309
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P20309
CHEMBL1475038,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC=C(C1)C(=O)OCC#C,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,P20309
CHEMBL449209,CN1CCC=C(C1)C(=O)OC.Br,arecoline,Phase 1,acetylcholine receptor agonist,P20309
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P20309
CHEMBL4557433,CN1[C@H]2CCC1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,atropine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL4865574,,atropine-oxide,Preclinical,acetylcholine receptor antagonist,P20309
CHEMBL1768,CC(C[N+](C)(C)C)OC(=O)N.[Cl-],bethanechol,Launched,acetylcholine receptor agonist,P20309
CHEMBL1201067,CC(C(=O)O)O.C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,biperiden,Launched,acetylcholine receptor antagonist,P20309
CHEMBL3039186,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7C4N2C(=O)CC7OCC=C6C5)OC,brucine,Preclinical,glycine receptor antagonist,P20309
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,P20309
CHEMBL2218917,CC1OC2(CN3CCC2CC3)CS1.O.Cl,cevimeline,Launched,acetylcholine receptor agonist,P20309
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P20309
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P20309
CHEMBL620,C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,clidinium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P20309
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P20309
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P20309
CHEMBL1200935,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,darifenacin,Launched,acetylcholine receptor antagonist,P20309
CHEMBL4859335,,DAU-5884,Preclinical,acetylcholine receptor antagonist,P20309
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P20309
CHEMBL1123,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,dicycloverine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1200880,C[N+]1(CCC(=C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)C.COS(=O)(=O)[O-],diphemanil,Launched,acetylcholine receptor antagonist,P20309
CHEMBL936,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,diphenidol,Launched,acetylcholine receptor agonist,P20309
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,P20309
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P20309
CHEMBL1201765,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O,fesoterodine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1201027,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1331216,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,hyoscyamine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL4858478,,imidafenacin,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P20309
CHEMBL1621597,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,ipratropium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1200347,CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-],isopropamide-iodide,Launched,acetylcholine receptor antagonist,P20309
CHEMBL2107457,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,itopride,Launched,dopamine receptor antagonist,P20309
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P20309
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P20309
CHEMBL1354199,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],methscopolamine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P20309
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P20309
CHEMBL4867004,,otenzepad,Phase 3,acetylcholine receptor antagonist,P20309
CHEMBL4858825,,oxotremorine-M,Preclinical,acetylcholine receptor agonist,P20309
CHEMBL1551988,C1CN(CC1)CC#CCN2C(=O)CCC2.C1CN(CC1)CC#CCN2C(=O)CCC2.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,P20309
CHEMBL4874019,,oxybutynin,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1201286,CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,oxyphenonium,Launched,cholinergic receptor antagonist,P20309
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-],pancuronium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P20309
CHEMBL1213136,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C.[N+](=O)(O)[O-],pilocarpine,Launched,acetylcholine receptor agonist,P20309
CHEMBL1200722,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C.[Br-].[Br-],pipecuronium,Launched,neuromuscular blocker,P20309
CHEMBL1531864,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,pirenzepine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P20309
CHEMBL1180725,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,propantheline,Launched,acetylcholine receptor antagonist,P20309
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P20309
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1740879,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)[O-],scopolamine-N-oxide,Preclinical,acetylcholine receptor antagonist,P20309
CHEMBL1200803,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,solifenacin-succinate,Launched,acetylcholine receptor antagonist,P20309
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P20309
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,P20309
CHEMBL1779046,C1CN2CCC1[C@H](C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F,tarafenacin,Phase 2,acetylcholine receptor antagonist,P20309
CHEMBL3545181,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4=CC=CS4)(C5=CC=CS5)O)C.O.[Br-],tiotropium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1200871,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,tolterodine,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1725880,CCOC1=CC(=C(C=C1C(=O)CCC(=O)O)OCC)OCC,trepibutone,Launched,cholinergic receptor antagonist,P20309
CHEMBL1457550,CCN(CC1=CC=NC=C1)C(=O)[C@@H](CO)C2=CC=CC=C2,tropicamide,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1187833,C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5,umeclidinium,Launched,acetylcholine receptor antagonist,P20309
CHEMBL1892145,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2,vinburnine,Launched,adrenergic receptor antagonist,P20309
CHEMBL1728279,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@@](C2)(C(=O)OC)O,vincamine,Withdrawn,adrenergic receptor antagonist,P20309
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P20309
CHEMBL4858858,,zamifenacin,Phase 3,acetylcholine receptor antagonist,P20309
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P20309
CHEMBL4874798,,4-DAMP,Preclinical,cholinergic receptor antagonist,P20309
CHEMBL3348932,CC(C)N(CC[C@H](C1=CC=CC=C1)C2=C(C=CC(=C2)CO)O)C(C)C,5-hydroxymethyl-tolterodine,Phase 1,acetylcholine receptor antagonist,P20309
CHEMBL1316369,CC1=CC=C(O1)C[N+](C)(C)C.[I-],5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,P20309
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P08173
CHEMBL4303558,CC(=O)OC1CN2CCC1CC2.Cl,aceclidine,Launched,acetylcholine receptor agonist,P08173
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P08173
CHEMBL551466,C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-],aclidinium,Launched,acetylcholine receptor antagonist,P08173
,,VU152100,Preclinical,acetylcholine receptor allosteric modulator,P08173
CHEMBL3305985,C=CC[N@@+]12[C@@H]3[C@]4(C5=CC=CC=C5N/6[C@H]4/C(=C\N7[C@H]8/C(=C6)/[C@@H]9/C(=C\CO)/C[N@+]4([C@H]([C@]8(C5=CC=CC=C75)CC4)C9)CC=C)/[C@@H](C3)/C(=C\CO)/C1)CC2,alcuronium,Launched,muscle relaxant,P08173
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08173
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P08173
CHEMBL1475038,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC=C(C1)C(=O)OCC#C,arecaidine-propargyl-ester,Preclinical,acetylcholine receptor agonist,P08173
CHEMBL449209,CN1CCC=C(C1)C(=O)OC.Br,arecoline,Phase 1,acetylcholine receptor agonist,P08173
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08173
CHEMBL4865574,,atropine-oxide,Preclinical,acetylcholine receptor antagonist,P08173
CHEMBL1768,CC(C[N+](C)(C)C)OC(=O)N.[Cl-],bethanechol,Launched,acetylcholine receptor agonist,P08173
CHEMBL1201067,CC(C(=O)O)O.C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,biperiden,Launched,acetylcholine receptor antagonist,P08173
CHEMBL3039186,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7C4N2C(=O)CC7OCC=C6C5)OC,brucine,Preclinical,glycine receptor antagonist,P08173
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,P08173
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P08173
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08173
CHEMBL1200935,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,darifenacin,Launched,acetylcholine receptor antagonist,P08173
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08173
CHEMBL936,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,diphenidol,Launched,acetylcholine receptor agonist,P08173
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P08173
CHEMBL1201765,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O,fesoterodine,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1201027,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1331216,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)[C@H](CO)C3=CC=CC=C3,hyoscyamine,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P08173
CHEMBL1621597,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,ipratropium,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1200347,CC(C)[N+](C)(CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N)C(C)C.[I-],isopropamide-iodide,Launched,acetylcholine receptor antagonist,P08173
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P08173
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08173
CHEMBL978,CC(C[N+](C)(C)C)OC(=O)C,methacholine,Launched,acetylcholine receptor agonist,P08173
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08173
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08173
CHEMBL4867004,,otenzepad,Phase 3,acetylcholine receptor antagonist,P08173
CHEMBL4858825,,oxotremorine-M,Preclinical,acetylcholine receptor agonist,P08173
CHEMBL1551988,C1CN(CC1)CC#CCN2C(=O)CCC2.C1CN(CC1)CC#CCN2C(=O)CCC2.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O,oxotremorine-sesquifumarate,Preclinical,cholinergic receptor agonist,P08173
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P08173
CHEMBL4868577,,PD-102807,Preclinical,acetylcholine receptor antagonist,P08173
CHEMBL1213136,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C.[N+](=O)(O)[O-],pilocarpine,Launched,acetylcholine receptor agonist,P08173
CHEMBL1531864,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,pirenzepine,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P08173
CHEMBL1180725,CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C,propantheline,Launched,acetylcholine receptor antagonist,P08173
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08173
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1740879,C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)[O-],scopolamine-N-oxide,Preclinical,acetylcholine receptor antagonist,P08173
CHEMBL1200803,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,solifenacin-succinate,Launched,acetylcholine receptor antagonist,P08173
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P08173
CHEMBL1200871,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,tolterodine,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1725880,CCOC1=CC(=C(C=C1C(=O)CCC(=O)O)OCC)OCC,trepibutone,Launched,cholinergic receptor antagonist,P08173
CHEMBL1457550,CCN(CC1=CC=NC=C1)C(=O)[C@@H](CO)C2=CC=CC=C2,tropicamide,Launched,acetylcholine receptor antagonist,P08173
CHEMBL2107687,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],valethamate,Launched,acetylcholine receptor antagonist,P08173
CHEMBL1892145,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=O)C2,vinburnine,Launched,adrenergic receptor antagonist,P08173
CHEMBL1728279,CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4[C@@](C2)(C(=O)OC)O,vincamine,Withdrawn,adrenergic receptor antagonist,P08173
CHEMBL4869649,,VU10010,Preclinical,acetylcholine receptor allosteric modulator,P08173
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P08173
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08173
CHEMBL4874798,,4-DAMP,Preclinical,cholinergic receptor antagonist,P08173
CHEMBL1316369,CC1=CC=C(O1)C[N+](C)(C)C.[I-],5-methylfurmethiodide,Preclinical,acetylcholine receptor agonist,P08173
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P35462
CHEMBL4873519,,AJ76-(+),Preclinical,dopamine receptor antagonist,P35462
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P35462
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P35462
CHEMBL4873542,,azaperone,Launched,dopamine receptor antagonist,P35462
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P35462
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P35462
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P35462
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P35462
CHEMBL2024517,CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,cariprazine,Launched,dopamine receptor antagonist,P35462
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P35462
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P35462
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL1256832,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,dihydrexidine,Phase 2,dopamine receptor agonist,P35462
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P35462
CHEMBL4856009,,domperidone,Launched,dopamine receptor antagonist,P35462
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P35462
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P35462
CHEMBL1256917,CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl.Cl,eticlopride,Preclinical,dopamine receptor antagonist,P35462
CHEMBL1823681,CCOC(=O)[C@H](CC1=CC(=C(C=C1)O)O)N,etilevodopa,Phase 3,dopamine receptor agonist,P35462
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P35462
CHEMBL4874715,,GR-103691,Preclinical,dopamine receptor antagonist,P35462
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P35462
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol-decanoate,Launched,psychoactive drug,P35462
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL4872403,,L-741742,Preclinical,dopamine receptor antagonist,P35462
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P35462
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P35462
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P35462
CHEMBL4869247,,levosulpiride,Launched,dopamine receptor antagonist,P35462
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P35462
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL4848364,,NADPH,Preclinical,,P35462
CHEMBL1443376,CCCCN1CCC[C@@H]1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC,nafadotride,Preclinical,dopamine receptor antagonist,P35462
CHEMBL4846754,,nemonapride,Launched,dopamine receptor antagonist,P35462
CHEMBL4848080,,NGB-2904,Preclinical,dopamine receptor antagonist,P35462
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL2105649,CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,P35462
CHEMBL4859572,,PD-128907,Preclinical,dopamine receptor agonist,P35462
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P35462
CHEMBL1472975,C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54,perospirone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P35462
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P35462
CHEMBL1697690,CCCNCCC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)OC(F)(F)F,PNU-177864,Preclinical,dopamine receptor antagonist,P35462
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P35462
CHEMBL1201154,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(CS(=O)(=O)O)S(=O)(=O)O,prochlorperazine,Launched,dopamine receptor antagonist,P35462
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P35462
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL4743453,CCCN1CCCC2C1CC3=CN=C(N=C3C2)N,quinelorane,Phase 3,dopamine receptor agonist,P35462
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P35462
CHEMBL2104769,CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2O[11CH3])Cl)Cl)O,raclopride,Launched,dopamine receptor antagonist,P35462
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.O.Cl,remoxipride,Withdrawn,dopamine receptor antagonist,P35462
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P35462
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P35462
CHEMBL4846909,,rotundine,Launched,serotonin receptor agonist,P35462
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P35462
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P35462
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P35462
CHEMBL1256772,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC.Cl,tiapride,Launched,dopamine receptor antagonist,P35462
CHEMBL4874003,,U-99194,Preclinical,dopamine receptor antagonist,P35462
CHEMBL4865280,,UH-232-(+),Preclinical,dopamine receptor antagonist,P35462
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,P35462
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P35462
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35462
CHEMBL4855125,,7-hydroxy-DPAT,Preclinical,dopamine receptor agonist,P35462
CHEMBL4858600,,7-hydroxy-PIPAT,Preclinical,dopamine receptor ligand,P35462
CHEMBL4869260,,8-hydroxy-PIPAT,Preclinical,dopamine receptor ligand,P35462
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P08908
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P08908
CHEMBL2111138,C1CN(CCN1CCNC(=O)C23CC4CC(C2)CC(C4)C3)C5=NC=CC=N5,adatanserin,Phase 2,serotonin receptor agonist|serotonin receptor antagonist,P08908
CHEMBL4865274,,adoprazine,Phase 2,dopamine receptor antagonist|serotonin receptor agonist,P08908
CHEMBL1408594,CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,alverine,Launched,muscle relaxant,P08908
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08908
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P08908
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08908
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL4872423,,BMY-14802,Phase 2,sigma receptor antagonist,P08908
CHEMBL4846881,,BMY-7378,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1401324,C1CN(CCN1CCCOC2=CC3=C(C=C2)OCO3)C4=CC=CC=C4,BP-554,Preclinical,serotonin receptor agonist,P08908
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P08908
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P08908
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P08908
CHEMBL4857453,,buspirone,Launched,serotonin receptor agonist,P08908
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P08908
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P08908
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P08908
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL4848193,,CP-93129,Preclinical,serotonin receptor agonist,P08908
CHEMBL2104153,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C,cyamemazine,Launched,serotonin receptor antagonist,P08908
CHEMBL378501,CC(C)(C)NCC(COC1=CC=CC2=C1C=C(N2)C#N)O,cyanopindolol,Phase 2,adrenergic receptor antagonist,P08908
CHEMBL2110900,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P08908
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08908
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P08908
CHEMBL4303330,CC(C)N(CCC1=CNC2=CC=CC=C21)C(C)C,DIPT,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,P08908
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P08908
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P08908
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P08908
CHEMBL3187065,C1CN(CCN1)C2=C3C(=CC=C2)OCCO3.Cl,eltoprazine,Phase 2,serotonin receptor agonist,P08908
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P08908
CHEMBL3421613,,F-11440,Phase 2,serotonin receptor agonist,P08908
CHEMBL231068,C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F,flibanserin,Launched,serotonin receptor agonist,P08908
CHEMBL1605835,CCC(=O)C1=C(C=C(C=C1O)O)O,flopropione,Launched,serotonin receptor antagonist,P08908
CHEMBL2106753,C1CN(CCN1CCNC(=O)N)C2=CC=CC(=C2)C(F)(F)F,fluprazine,Phase 1,serotonin receptor agonist,P08908
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P08908
CHEMBL2138684,CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O.O,frovatriptan,Launched,serotonin receptor agonist,P08908
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P08908
CHEMBL4854471,,GSK163090,Phase 2,serotonin receptor antagonist,P08908
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P08908
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P08908
CHEMBL4878560,,ipsapirone,Phase 3,serotonin receptor agonist,P08908
CHEMBL4853238,,isamoltane,Phase 1,adrenergic receptor antagonist,P08908
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P08908
CHEMBL4855569,,L-694247,Preclinical,serotonin receptor agonist,P08908
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P08908
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P08908
CHEMBL2106638,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl.Cl,lofepramine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P08908
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P08908
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P08908
CHEMBL4863814,,MDL-72832,Preclinical,serotonin receptor agonist,P08908
CHEMBL1487115,C1CCC2(C1)CC(=O)N(C(=O)C2)CCNCC3COC4=CC=CC=C4O3,MDL-73005EF,Phase 1,serotonin receptor antagonist,P08908
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P08908
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P08908
CHEMBL4877034,,MM77,Preclinical,serotonin receptor antagonist,P08908
CHEMBL1443376,CCCCN1CCC[C@@H]1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC,nafadotride,Preclinical,dopamine receptor antagonist,P08908
CHEMBL4850949,,NAN-190,Preclinical,serotonin receptor agonist,P08908
CHEMBL1200601,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl,naratriptan,Launched,serotonin receptor agonist,P08908
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P08908
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08908
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1742408,C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4,osemozotan,Phase 2/Phase 3,serotonin receptor agonist,P08908
CHEMBL2105649,CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,P08908
CHEMBL1200363,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,penbutolol,Launched,adrenergic receptor antagonist,P08908
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P08908
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P08908
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol,Launched,adrenergic receptor antagonist,P08908
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol-(-),Phase 2,adrenergic receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P08908
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine,Launched,dopamine receptor antagonist,P08908
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine-palmitate,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P08908
CHEMBL294951,CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1,pizotifen,Launched,serotonin receptor antagonist,P08908
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P08908
CHEMBL545328,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(S),Preclinical,adrenergic receptor antagonist,P08908
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P08908
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P08908
CHEMBL2104769,CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2O[11CH3])Cl)Cl)O,raclopride,Launched,dopamine receptor antagonist,P08908
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P08908
CHEMBL1201032,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O,rizatriptan,Launched,serotonin receptor agonist,P08908
CHEMBL1628569,C1CC(C1)N([C@@H]2CC3=C(C=CC(=C3OC2)F)C(=O)N)C4CCC4,robalzotan,Phase 2,serotonin receptor antagonist,P08908
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P08908
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P08908
CHEMBL4846909,,rotundine,Launched,serotonin receptor agonist,P08908
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P08908
CHEMBL1590266,COC1=CC2=C(C=CC=C2N3CCN(CC3)CCNC(=O)C4=CC=C(C=C4)F)C=C1,S-14506,Preclinical,serotonin receptor agonist,P08908
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P08908
CHEMBL1433455,CC(C)OC(=O)C1=CC2=C(N1)C=CC=C2OC[C@H](CNC(C)(C)C)O,SDZ-21009,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P08908
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL4876227,,SLV-319-(+/-),Phase 2,cannabinoid receptor antagonist,P08908
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P08908
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P08908
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P08908
CHEMBL2103888,C1C[C@H]2C[C@@H]1[C@H]3[C@@H]2C(=O)N(C3=O)CCCCN4CCN(CC4)C5=NC=CC=N5.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,tandospirone,Launched,serotonin receptor agonist,P08908
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P08908
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P08908
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P08908
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P08908
CHEMBL4865280,,UH-232-(+),Preclinical,dopamine receptor antagonist,P08908
CHEMBL1256716,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC.Cl,urapidil,Launched,adrenergic receptor antagonist,P08908
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,P08908
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08908
CHEMBL4850975,,WAY-100635,Phase 1,serotonin receptor antagonist,P08908
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P08908
CHEMBL3183486,C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3.Cl,xaliproden,Phase 3,serotonin receptor agonist,P08908
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P08908
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P08908
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL120768,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,zolmitriptan,Launched,serotonin receptor agonist,P08908
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08908
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P08908
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P28222
CHEMBL1200521,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O,almotriptan,Launched,serotonin receptor agonist,P28222
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P28222
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P28222
CHEMBL1316374,C1CNCCC1SC2=NC(=CC=C2)Cl,anpirtoline,Phase 1,serotonin receptor agonist,P28222
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28222
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P28222
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P28222
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P28222
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1570196,CCCOC1=NC2=C(C=C1)NC=C2C3=CCNCC3,CP-94253,Preclinical,serotonin receptor agonist,P28222
CHEMBL2110900,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P28222
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P28222
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P28222
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P28222
CHEMBL3187065,C1CN(CCN1)C2=C3C(=CC=C2)OCCO3.Cl,eltoprazine,Phase 2,serotonin receptor agonist,P28222
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P28222
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine-decanoate,Launched,dopamine receptor antagonist,P28222
CHEMBL2106753,C1CN(CCN1CCNC(=O)N)C2=CC=CC(=C2)C(F)(F)F,fluprazine,Phase 1,serotonin receptor agonist,P28222
CHEMBL2138684,CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O.O,frovatriptan,Launched,serotonin receptor agonist,P28222
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P28222
CHEMBL4854471,,GSK163090,Phase 2,serotonin receptor antagonist,P28222
CHEMBL4853238,,isamoltane,Phase 1,adrenergic receptor antagonist,P28222
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P28222
CHEMBL4855569,,L-694247,Preclinical,serotonin receptor agonist,P28222
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P28222
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P28222
CHEMBL4303390,CC(C)N1CC2=C(C=CC(=C2)S(=O)(=O)C)N(S1(=O)=O)CCN3CCC(=CC3)C4=CNC5=C4C=CC(=C5)F,LY393558,Preclinical,serotonin receptor antagonist,P28222
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28222
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P28222
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P28222
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P28222
CHEMBL1200601,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl,naratriptan,Launched,serotonin receptor agonist,P28222
CHEMBL3645748,CC1([C@@]2(C13CCC3)C[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=CC(=NN5C)C(C)(C)C)C(=O)N[C@@]6(C[C@H]6C=C)C(=O)NS(=O)(=O)N7CCCC7)C,NAS-181,Preclinical,serotonin receptor antagonist,P28222
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P28222
CHEMBL1200363,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,penbutolol,Launched,adrenergic receptor antagonist,P28222
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P28222
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P28222
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P28222
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P28222
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P28222
CHEMBL1201032,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O,rizatriptan,Launched,serotonin receptor agonist,P28222
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P28222
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P28222
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P28222
CHEMBL1433455,CC(C)OC(=O)C1=CC2=C(N1)C=CC=C2OC[C@H](CNC(C)(C)C)O,SDZ-21009,Preclinical,adrenergic receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P28222
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P28222
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28222
CHEMBL3352722,,triptan,Phase 1,serotonin receptor agonist,P28222
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28222
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P28222
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P28222
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL120768,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,zolmitriptan,Launched,serotonin receptor agonist,P28222
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28222
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P28222
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P28223
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P28223
CHEMBL2111138,C1CN(CCN1CCNC(=O)C23CC4CC(C2)CC(C4)C3)C5=NC=CC=N5,adatanserin,Phase 2,serotonin receptor agonist|serotonin receptor antagonist,P28223
CHEMBL4848377,,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,P28223
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P28223
CHEMBL1371857,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=S.O.Cl,altanserin,Phase 2,serotonin receptor antagonist,P28223
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P28223
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P28223
CHEMBL1079935,CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,amperozide,Launched,dopamine receptor antagonist,P28223
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P28223
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28223
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL4303347,C1CN(CCC1C(=O)NCCN2CCC(=C3C4=CC=CC=C4C=CC5=CC=CC=C53)CC2)C=O,AT-1015,Preclinical,serotonin receptor antagonist,P28223
CHEMBL178803,CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F,blonanserin,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P28223
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P28223
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P28223
CHEMBL1600780,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl,BW-723C86,Preclinical,serotonin receptor agonist,P28223
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P28223
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P28223
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P28223
CHEMBL2104137,CN(C)CCCSC1=CC=CC=C1NC(=O)/C=C/C2=CC=CC=C2.Cl,cinanserin,Preclinical,serotonin receptor antagonist,P28223
CHEMBL1236602,C1=C(NC=N1)/C=C/C(=O)O,cis-urocanic-acid,Phase 2,serotonin receptor agonist,P28223
CHEMBL74656,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,cisapride,Withdrawn,serotonin receptor agonist,P28223
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P28223
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL2104153,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C,cyamemazine,Launched,serotonin receptor antagonist,P28223
CHEMBL1200636,CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31.Cl,cyclobenzaprine,Launched,adrenergic receptor agonist|serotonin receptor agonist,P28223
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P28223
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P28223
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P28223
CHEMBL4303330,CC(C)N(CCC1=CNC2=CC=CC=C21)C(C)C,DIPT,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,P28223
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P28223
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P28223
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P28223
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P28223
CHEMBL4857741,,fananserin,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL231068,C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F,flibanserin,Launched,serotonin receptor agonist,P28223
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P28223
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P28223
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P28223
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P28223
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P28223
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol-decanoate,Launched,psychoactive drug,P28223
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P28223
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P28223
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P28223
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P28223
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P28223
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL3306803,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,lumateperone,Launched,dopamine receptor modulator|serotonin receptor antagonist,P28223
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P28223
CHEMBL4303390,CC(C)N1CC2=C(C=CC(=C2)S(=O)(=O)C)N(S1(=O)=O)CCN3CCC(=CC3)C4=CNC5=C4C=CC(=C5)F,LY393558,Preclinical,serotonin receptor antagonist,P28223
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P28223
CHEMBL4873760,,MDL-11939,Phase 2,serotonin receptor antagonist,P28223
CHEMBL1531134,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,melperone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1201052,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C.C1=CC=C(C=C1)S(=O)(=O)O,mesoridazine,Launched,dopamine receptor antagonist,P28223
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P28223
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28223
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P28223
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P28223
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P28223
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P28223
CHEMBL4866128,,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1200419,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C.Cl,molindone,Launched,dopamine receptor antagonist,P28223
CHEMBL4848364,,NADPH,Preclinical,,P28223
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P28223
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P28223
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL506999,C1CN(CCN1)C2=NC(=C(C=C2)C(F)(F)F)Cl,ORG-12962,Phase 2,serotonin receptor agonist,P28223
CHEMBL2107360,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C,paliperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P28223
CHEMBL2110706,C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC=CC=C4,pelanserin,Phase 2,serotonin receptor antagonist,P28223
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P28223
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P28223
CHEMBL2111101,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,pimavanserin,Launched,serotonin receptor inverse agonist,P28223
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P28223
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol,Launched,adrenergic receptor antagonist,P28223
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P28223
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine,Launched,dopamine receptor antagonist,P28223
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine-palmitate,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL18331,CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F,pirenperone,Preclinical,serotonin receptor antagonist,P28223
CHEMBL1723412,CC1(C2CCC1(C(=O)N(C2=O)CCCCN3CCN(CC3)C4=CC=CC=N4)C)C,piricapiron,Phase 2,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL294951,CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1,pizotifen,Launched,serotonin receptor antagonist,P28223
CHEMBL1445061,CN1C2=C(CCNCC2)C3=CC=CC=C31.Cl,PNU-22394,Phase 2,serotonin receptor agonist,P28223
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P28223
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P28223
CHEMBL2104980,C1CN(CCN1CCC2=CC=C(C=C2)F)C(=O)C3=CC=CC4=C3NC=C4C#N.Cl,pruvanserin,Phase 2,serotonin receptor antagonist,P28223
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P28223
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P28223
CHEMBL1415927,CN1C[C@@H](C[C@H]1CCOC2=CC=CC=C2CCC3=CC(=CC=C3)OC)O.Cl,R-96544,Preclinical,serotonin receptor antagonist,P28223
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.O.Cl,remoxipride,Withdrawn,dopamine receptor antagonist,P28223
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P28223
CHEMBL4874837,,Ro-60-0175,Preclinical,serotonin receptor agonist,P28223
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P28223
CHEMBL4848167,,RS-102221,Preclinical,serotonin receptor antagonist,P28223
CHEMBL4867868,,RS-127445,Phase 1,serotonin receptor antagonist,P28223
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P28223
CHEMBL52939,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,sarpogrelate,Launched,serotonin receptor antagonist,P28223
CHEMBL4868931,,SB-206553,Preclinical,serotonin receptor antagonist,P28223
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P28223
CHEMBL4855890,,SB-221284,Preclinical,serotonin receptor antagonist,P28223
CHEMBL4875090,,SB-228357,Preclinical,serotonin receptor antagonist,P28223
CHEMBL4874156,,SB-243213,Phase 1,serotonin receptor inverse agonist,P28223
CHEMBL4865265,,SDZ-SER-082,Preclinical,serotonin receptor antagonist,P28223
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P28223
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL2104895,CN1CCC2=C(C1)C3=CC=CC=C3CC4=CC=CC=C24,setiptiline,Launched,adrenergic receptor antagonist,P28223
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P28223
CHEMBL1516474,CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC.C(=C\C(=O)O)\C(=O)O,tegaserod,Withdrawn,serotonin receptor partial agonist,P28223
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28223
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P28223
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P28223
CHEMBL1200902,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.Cl,thiothixene,Launched,dopamine receptor antagonist,P28223
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P28223
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P28223
CHEMBL4861017,,volinanserin,Phase 3,serotonin receptor antagonist,P28223
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28223
CHEMBL5079373,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F.Cl.Cl,WAY-208466,Preclinical,serotonin receptor agonist,P28223
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P28223
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P28223
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28223
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P28223
CHEMBL4868000,,4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine,Preclinical,serotonin receptor antagonist,P28223
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P28223
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P41595
CHEMBL4848377,,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,P41595
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P41595
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P41595
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P41595
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P41595
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P41595
CHEMBL1600780,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl,BW-723C86,Preclinical,serotonin receptor agonist,P41595
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P41595
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P41595
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P41595
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P41595
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P41595
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P41595
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P41595
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P41595
CHEMBL254832,CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3,fendiline,Preclinical,calcium channel blocker,P41595
CHEMBL1201082,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,fluoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P41595
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P41595
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P41595
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P41595
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P41595
CHEMBL4849443,,LY266097,Preclinical,serotonin receptor antagonist,P41595
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P41595
CHEMBL4303390,CC(C)N1CC2=C(C=CC(=C2)S(=O)(=O)C)N(S1(=O)=O)CCN3CCC(=CC3)C4=CNC5=C4C=CC(=C5)F,LY393558,Preclinical,serotonin receptor antagonist,P41595
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P41595
CHEMBL4873760,,MDL-11939,Phase 2,serotonin receptor antagonist,P41595
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P41595
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P41595
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P41595
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P41595
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P41595
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P41595
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P41595
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P41595
CHEMBL446084,C1=CC=C(C=C1)[C@@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,norfluoxetine,Phase 1,selective serotonin reuptake inhibitor (SSRI),P41595
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P41595
CHEMBL506999,C1CN(CCN1)C2=NC(=C(C=C2)C(F)(F)F)Cl,ORG-12962,Phase 2,serotonin receptor agonist,P41595
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P41595
CHEMBL2106927,CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42.Cl,piboserod,Phase 2,serotonin receptor antagonist,P41595
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol,Launched,adrenergic receptor antagonist,P41595
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P41595
CHEMBL1445061,CN1C2=C(CCNCC2)C3=CC=CC=C31.Cl,PNU-22394,Phase 2,serotonin receptor agonist,P41595
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P41595
CHEMBL4297322,C1CN(CCC1NC2=C3C=C(SC3=NC=N2)Cl)CC4=CC(=C(C=C4)F)C#N.C(=C/C(=O)O)\C(=O)O,PRX-08066,Phase 2,serotonin receptor antagonist,P41595
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P41595
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P41595
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P41595
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P41595
CHEMBL4874837,,Ro-60-0175,Preclinical,serotonin receptor agonist,P41595
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P41595
CHEMBL4848167,,RS-102221,Preclinical,serotonin receptor antagonist,P41595
CHEMBL4867868,,RS-127445,Phase 1,serotonin receptor antagonist,P41595
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P41595
CHEMBL52939,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,sarpogrelate,Launched,serotonin receptor antagonist,P41595
CHEMBL4853040,,SB-200646,Preclinical,serotonin receptor antagonist,P41595
CHEMBL4868931,,SB-206553,Preclinical,serotonin receptor antagonist,P41595
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P41595
CHEMBL4855890,,SB-221284,Preclinical,serotonin receptor antagonist,P41595
CHEMBL4875090,,SB-228357,Preclinical,serotonin receptor antagonist,P41595
CHEMBL4874156,,SB-243213,Phase 1,serotonin receptor inverse agonist,P41595
CHEMBL4865265,,SDZ-SER-082,Preclinical,serotonin receptor antagonist,P41595
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P41595
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P41595
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P41595
CHEMBL1516474,CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC.C(=C\C(=O)O)\C(=O)O,tegaserod,Withdrawn,serotonin receptor partial agonist,P41595
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P41595
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P41595
CHEMBL1201102,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,triflupromazine,Launched,dopamine receptor antagonist,P41595
CHEMBL4861017,,volinanserin,Phase 3,serotonin receptor antagonist,P41595
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P41595
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P41595
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P41595
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P46098
CHEMBL1200885,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C.Cl,alosetron,Withdrawn,serotonin receptor antagonist,P46098
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P46098
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P46098
CHEMBL1598608,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,azasetron,Launched,serotonin receptor antagonist,P46098
CHEMBL376379,CN1C2CCC1CC(C2)OC(=O)C3=CC(=CC(=C3)Cl)Cl,bemesetron,Phase 3,serotonin receptor antagonist,P46098
CHEMBL3348958,CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,bilobalide,Preclinical,GABA receptor modulator,P46098
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,P46098
CHEMBL128672,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3.C(=C\C(=O)O)\C(=O)O,ciproxifan,Preclinical,histamine receptor antagonist,P46098
CHEMBL74656,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,cisapride,Withdrawn,serotonin receptor agonist,P46098
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P46098
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,P46098
CHEMBL1237118,C1[C@H]2CC(CC3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54,dolasetron,Launched,serotonin receptor antagonist,P46098
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,P46098
CHEMBL1237080,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C.Cl,granisetron,Launched,serotonin receptor antagonist,P46098
CHEMBL406,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,indapamide,Launched,thiazide diuretic,P46098
CHEMBL4875585,,lerisetron,Phase 3,serotonin receptor antagonist,P46098
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL4864535,,m-chlorophenylbiguanide,Preclinical,serotonin receptor agonist,P46098
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P46098
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P46098
CHEMBL1200940,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL4138046,,ML10302,Preclinical,serotonin receptor partial agonist,P46098
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL3186492,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl,ondansetron,Launched,serotonin receptor antagonist,P46098
CHEMBL1189679,C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5,palonosetron,Launched,serotonin receptor antagonist,P46098
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,P46098
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,P46098
CHEMBL1643880,C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,pumosetrag,Phase 2,serotonin receptor agonist,P46098
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P46098
CHEMBL1643895,CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4,ramosetron,Launched,serotonin receptor antagonist,P46098
CHEMBL1200648,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],rocuronium,Launched,acetylcholine receptor antagonist,P46098
CHEMBL4856780,,RS-56812,Preclinical,serotonin receptor partial agonist,P46098
CHEMBL4861596,,SDZ-205-557,Preclinical,serotonin receptor antagonist,P46098
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P46098
CHEMBL4848282,,SR-57227A,Phase 2,serotonin receptor agonist,P46098
CHEMBL1504869,C=CCN1CCC2=C(CC1)SC(=N2)N.Cl,talipexole,Launched,adrenergic receptor agonist|dopamine receptor agonist,P46098
CHEMBL1742402,CC1=CC(=CC(=C1)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)C,"tropanyl-3,5-dimethylbenzoate",Preclinical,serotonin receptor antagonist,P46098
CHEMBL4303202,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl,tropisetron,Launched,serotonin receptor antagonist,P46098
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,P46098
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P46098
CHEMBL261010,CN1CCN(CC1)C2=NC3=CC=CC=C3N=C2Cl,VUF10166,Preclinical,serotonin receptor antagonist,P46098
CHEMBL1516756,COC1=CC(=C(C=C1C(=O)NC2CN3CCC2CC3)Cl)N.O.Cl,zacopride,Phase 2,serotonin receptor antagonist,P46098
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P46098
CHEMBL3039205,C1=CC=C(C=C1)N=C(N)N=C(N)N.Cl,1-phenylbiguanide,Preclinical,serotonin receptor agonist,P46098
CHEMBL4850773,,3-AQC,Preclinical,serotonin receptor agonist,P46098
CHEMBL4851486,,A-987306,Preclinical,histamine receptor antagonist,P21452
CHEMBL1416993,CN1C=C(C2=CC=CC=C21)C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N(C)CC6=CC=CC=C6)O,FK-888,Phase 2,tachykinin antagonist,P21452
CHEMBL4867795,,GR-159897,Preclinical,tachykinin antagonist,P21452
CHEMBL188166,CC(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,"L-732,138",Preclinical,tachykinin antagonist,P21452
CHEMBL414370,CC(C)C[C@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]3CCCN3C(=O)[C@@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N,substance-P,Phase 1,neurokinin receptor antagonist,P21452
CHEMBL4856283,,talnetant,Phase 2,tachykinin antagonist,P21452
CHEMBL4863034,,WAY-207024,Preclinical,gonadotropin releasing factor hormone receptor antagonist,P21452
CHEMBL4303215,CCOC(=O)NC1=C(C=C(C=C1)NCC2=C(C=C(C=C2C)C)C)N,AA-29504,Preclinical,GABA receptor positive allosteric modulator,P14867
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P14867
CHEMBL4865748,,alpidem,Withdrawn,benzodiazepine receptor agonist,P14867
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P14867
CHEMBL1214192,CCC1(CC(=O)NC(=O)C1)C,bemegride,Launched,chemoreceptor agonist,P14867
CHEMBL1394514,CCCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,beta-CCB,Launched,benzodiazepine receptor ligand,P14867
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,P14867
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,P14867
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P14867
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,P14867
CHEMBL507327,C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl,CGS-9896,Preclinical,GABA receptor antagonist,P14867
CHEMBL1200714,CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl,chlormezanone,Withdrawn,GABA receptor modulator,P14867
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P14867
CHEMBL315795,CC1=C(SC=N1)CCCl,clomethiazole,Launched,GABA receptor antagonist|GABA receptor modulator,P14867
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P14867
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P14867
CHEMBL4865535,,enciprazine,Phase 3,GABA receptor modulator,P14867
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P14867
CHEMBL2106227,CCN=C1NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3,etifoxine,Launched,GABA receptor modulator,P14867
CHEMBL1289779,CCC1=CC2=C(S1)N3C(=NN=C3CN=C2C4=CC=CC=C4Cl)C,etizolam,Launched,benzodiazepine receptor agonist,P14867
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P14867
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P14867
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P14867
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P14867
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P14867
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,P14867
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P14867
CHEMBL4851216,,indiplon,Phase 3,benzodiazepine receptor agonist,P14867
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P14867
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P14867
CHEMBL3054746,,"L-655,708",Preclinical,GABA receptor inverse agonist,P14867
CHEMBL4868978,,L-838417,Preclinical,GABA receptor partial agonist,P14867
CHEMBL4303403,CC(=O)N(C)C1=C(C=CC(=C1)C2=CC=NC3=C(C=NN23)C(=O)C4=CC=CS4)F,lorediplon,Phase 2,GABA receptor modulator,P14867
CHEMBL180920,C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O,magnolol,Preclinical,PPAR receptor agonist,P14867
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P14867
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P14867
CHEMBL4872812,,MRK-016,Phase 1,GABA receptor inverse agonist,P14867
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P14867
CHEMBL2105199,C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4,ocinaplon,Phase 3,GABA receptor modulator,P14867
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14867
CHEMBL4849017,,PHP-501,Preclinical,GABA receptor antagonist,P14867
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P14867
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P14867
CHEMBL4852123,,ripazepam,Phase 2,benzodiazepine receptor agonist,P14867
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P14867
CHEMBL4851136,,Ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,P14867
CHEMBL303062,C1CCN2[C@H](C1)[C@]34C[C@H]2C=CC3=CC(=O)O4,securinine,Preclinical,GABA receptor antagonist|TP53 activator,P14867
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P14867
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TP-003,Preclinical,GABA receptor inverse agonist,P14867
CHEMBL1201065,CCCC(C)C1(C(=O)NC(=S)[N-]C1=O)CC=C.[Na+],thiamylal,Launched,glutamate receptor antagonist,P14867
CHEMBL213907,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,thiocolchicoside,Launched,GABA receptor antagonist,P14867
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P14867
CHEMBL4864636,,tracazolate,Phase 2,GABA receptor modulator,P14867
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P14867
CHEMBL4877796,,ZK-93426,Phase 1,benzodiazepine receptor antagonist,P14867
CHEMBL4303215,CCOC(=O)NC1=C(C=C(C=C1)NCC2=C(C=C(C=C2C)C)C)N,AA-29504,Preclinical,GABA receptor positive allosteric modulator,P48169
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P48169
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P48169
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,P48169
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,P48169
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P48169
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,P48169
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P48169
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P48169
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P48169
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P48169
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P48169
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P48169
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P48169
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,P48169
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P48169
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P48169
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P48169
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P48169
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P48169
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P48169
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P48169
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P48169
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P48169
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P48169
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P48169
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P48169
CHEMBL4303215,CCOC(=O)NC1=C(C=C(C=C1)NCC2=C(C=C(C=C2C)C)C)N,AA-29504,Preclinical,GABA receptor positive allosteric modulator,P28472
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P28472
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P28472
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P28472
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P28472
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P28472
CHEMBL1256671,CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC.Cl,etazolate,Phase 2,phosphodiesterase inhibitor,P28472
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P28472
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P28472
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P28472
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P28472
CHEMBL2359260,C1=CC(=C(C=C1Cl)Cl)/C(=C/N2C=NC=N2)/Cl.Cl,loreclezole,Phase 2,benzodiazepine receptor agonist,P28472
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P28472
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P28472
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28472
CHEMBL3990694,C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,piperazine,Launched,benzodiazepine receptor agonist,P28472
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P28472
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P28472
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P28472
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P28472
CHEMBL3215298,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,abamectin,Launched,benzodiazepine receptor agonist,Q9UBS5
CHEMBL1897150,C1=CC(=CC=C1C(CC(=O)O)CN)Cl.Cl,baclofen,Launched,benzodiazepine receptor agonist,Q9UBS5
CHEMBL4303701,CC(C1=CC=NC2=NC=NN12)OC3=CC=C(C=C3)Cl,BTS-72664,Phase 1,GABA receptor antagonist,Q9UBS5
CHEMBL4867920,,CGP-13501,Preclinical,GABA receptor modulator,Q9UBS5
CHEMBL4860479,,CGP-54626,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL4848857,,CGP-55845,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL4869667,,CGP-7930,Preclinical,GABA receptor modulator,Q9UBS5
CHEMBL315818,C1=CC=C(C=C1)C(CC(=O)O)CN,fenigam,Launched,benzodiazepine receptor agonist,Q9UBS5
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,Q9UBS5
CHEMBL4861211,,GS-39783,Preclinical,GABA receptor modulator,Q9UBS5
CHEMBL4864839,,isoliquiritigenin,Preclinical,guanylate cyclase activator,Q9UBS5
CHEMBL4588354,C1CC2=CC=CC=C2C(/C(=C\C(=O)O)/C1)O,NCS-382,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL4866876,,PNU-89843,Preclinical,benzodiazepine receptor agonist,Q9UBS5
CHEMBL4857939,,rac-BHFF,Preclinical,GABA receptor positive allosteric modulator,Q9UBS5
CHEMBL4297526,CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4,remimazolam,Phase 3,benzodiazepine receptor agonist,Q9UBS5
CHEMBL4870362,,saclofen,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL3183495,CC1=C(C(CC=C1)(C)C)C=O,safranal,Phase 2,benzodiazepine receptor agonist,Q9UBS5
CHEMBL112797,CCCCP(=O)(CCCN)O,SGS-742,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL4859478,,suritozole,Phase 2,GABA receptor inverse agonist,Q9UBS5
CHEMBL1256573,C1=CC(=CC=C1C(CN)(CS(=O)(=O)O)O)Cl,2-hydroxysaclofen,Preclinical,GABA receptor antagonist,Q9UBS5
CHEMBL3215298,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,abamectin,Launched,benzodiazepine receptor agonist,O75899
CHEMBL1897150,C1=CC(=CC=C1C(CC(=O)O)CN)Cl.Cl,baclofen,Launched,benzodiazepine receptor agonist,O75899
CHEMBL4860479,,CGP-54626,Preclinical,GABA receptor antagonist,O75899
CHEMBL4848857,,CGP-55845,Preclinical,GABA receptor antagonist,O75899
CHEMBL315818,C1=CC=C(C=C1)C(CC(=O)O)CN,fenigam,Launched,benzodiazepine receptor agonist,O75899
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,O75899
CHEMBL4588354,C1CC2=CC=CC=C2C(/C(=C\C(=O)O)/C1)O,NCS-382,Preclinical,GABA receptor antagonist,O75899
CHEMBL4870362,,saclofen,Preclinical,GABA receptor antagonist,O75899
CHEMBL112797,CCCCP(=O)(CCCN)O,SGS-742,Preclinical,GABA receptor antagonist,O75899
CHEMBL1256573,C1=CC(=CC=C1C(CN)(CS(=O)(=O)O)O)Cl,2-hydroxysaclofen,Preclinical,GABA receptor antagonist,O75899
CHEMBL2205807,CC1=CN=C(C=C1)C2=NC=C(C=C2)C,abametapir,Phase 3,metalloproteinase inhibitor,P14780
CHEMBL3392650,CC1(C(N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C,apratastat,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,P14780
CHEMBL448502,CC(=C)[C@@H]1CC[C@@]([C@@H](C1)C(=C)C)(C)C=C,beta-elemene,Launched,apoptosis stimulant,P14780
CHEMBL4852091,,captopril,Launched,angiotensin converting enzyme inhibitor,P14780
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P14780
CHEMBL4869111,,CP-471474,Preclinical,matrix metalloprotease inhibitor,P14780
CHEMBL4869630,,CTS-1027,Phase 2,metalloproteinase inhibitor,P14780
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P14780
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P14780
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P14780
CHEMBL541265,C1=CC(=C(C=C1C[C@H](C(=O)O)OC([C@@H]2[C@H](OC3=CC(=CC(=C23)/C=C/C(=O)O[C@H](CC4=CC(=C(C=C4)O)O)C(=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O,salvianolic-acid-B,Phase 2,EGFR inhibitor|metalloproteinase inhibitor,P14780
CHEMBL4867936,,UK-356618,Preclinical,metalloproteinase inhibitor,P14780
CHEMBL1252,C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C,abarelix,Phase 3,gonadotropin releasing factor hormone receptor antagonist,P30968
CHEMBL2103735,C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C.CC(=O)O,cetrorelix,Launched,gonadotropin releasing factor hormone receptor antagonist,P30968
CHEMBL4871688,,CMPD-1,Preclinical,p38 MAPK inhibitor,P30968
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,P30968
CHEMBL415606,C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C,degarelix,Launched,gonadotropin releasing factor hormone receptor antagonist,P30968
CHEMBL1208155,CC1=C(C(=O)N(C(=O)N1CC2=C(C=CC=C2F)C(F)(F)F)C[C@@H](C3=CC=CC=C3)NCCCC(=O)O)C4=C(C(=CC=C4)OC)F,elagolix,Launched,gonadotropin releasing factor hormone receptor antagonist,P30968
CHEMBL1200511,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O,gonadorelin,Launched,gonadotropin releasing factor hormone receptor agonist,P30968
CHEMBL1200501,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O,goserelin-acetate,Launched,gonadotropin releasing factor hormone receptor agonist,P30968
CHEMBL1200775,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O,leuprolide,Launched,gonadotropin releasing factor hormone receptor agonist,P30968
CHEMBL1200554,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,triptorelin,Launched,gonadotropin releasing factor hormone receptor agonist,P30968
CHEMBL4863034,,WAY-207024,Preclinical,gonadotropin releasing factor hormone receptor antagonist,P30968
CHEMBL2158685,C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl,ABC-294640,Phase 2,sphingosine kinase inhibitor,Q9NRA0
CHEMBL4848513,,K145,Preclinical,sphingosine kinase inhibitor,Q9NRA0
CHEMBL3301610,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,abemaciclib,Launched,CDK inhibitor,P11802
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P11802
CHEMBL4876879,,AMG-925,Phase 1,CDK inhibitor|FLT3 inhibitor,P11802
CHEMBL4867423,,arcyriaflavin-a,Preclinical,CDK inhibitor,P11802
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,P11802
CHEMBL1331734,COC1=C2C(=C(C=C1)OC)NC3=CC=CC=C3C2=S,NSC-625987,Preclinical,CDK inhibitor,P11802
CHEMBL4853290,,ON123300,Preclinical,CDK inhibitor,P11802
CHEMBL2364621,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.C(CS(=O)(=O)O)O,palbociclib,Launched,CDK inhibitor,P11802
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,P11802
CHEMBL4862981,,PHA-848125,Phase 2,CDK inhibitor|growth factor receptor inhibitor,P11802
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,P11802
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,P11802
CHEMBL3991935,CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,P276-00,Phase 2,CDK inhibitor,P11802
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P11802
CHEMBL3545110,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,ribociclib,Launched,CDK inhibitor,P11802
CHEMBL4856364,,ryuvidine,Preclinical,histone lysine methyltransferase inhibitor,P11802
CHEMBL4852606,,R547,Phase 1,CDK inhibitor,P11802
CHEMBL4864204,,SU9516,Preclinical,CDK inhibitor,P11802
CHEMBL3301610,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,abemaciclib,Launched,CDK inhibitor,Q00534
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,Q00534
CHEMBL4876879,,AMG-925,Phase 1,CDK inhibitor|FLT3 inhibitor,Q00534
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,Q00534
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,Q00534
CHEMBL117,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,chrysin,Phase 1,breast cancer resistance protein inhibitor,Q00534
CHEMBL4847440,,fisetin,Preclinical,Aurora kinase inhibitor,Q00534
CHEMBL2364621,CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.C(CS(=O)(=O)O)O,palbociclib,Launched,CDK inhibitor,Q00534
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,Q00534
CHEMBL3545110,CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5,ribociclib,Launched,CDK inhibitor,Q00534
CHEMBL271227,CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,abiraterone,Launched,androgen biosynthesis inhibitor,P15538
CHEMBL9298,C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N,fadrozole,Launched,aromatase inhibitor,P15538
CHEMBL934,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,metyrapone,Launched,cytochrome P450 inhibitor,P15538
CHEMBL1572655,C1=CC=C(C(=C1)[C@H](C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,mitotane,Launched,antineoplastic agent,P15538
CHEMBL271227,CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,abiraterone,Launched,androgen biosynthesis inhibitor,P05093
CHEMBL271227,CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC=C4C5=CN=CC=C5)C)C,abiraterone-acetate,Launched,androgen biosynthesis inhibitor,P05093
CHEMBL4851780,,coenzyme-I,Phase 2,,P05093
CHEMBL2105738,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O,galeterone,Phase 3,androgen receptor modulator,P05093
CHEMBL1571863,C1=CC(=C(C(=C1)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,isoconazole,Launched,fungal lanosterol demethylase inhibitor,P05093
CHEMBL1921976,CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@]3(CCN4C3=CN=C4)O,orteronel,Phase 3,androgen biosynthesis inhibitor|androgen receptor antagonist|cytochrome P450 inhibitor,P05093
CHEMBL2105373,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCC(=O)O)C)C,pregnenolone-succinate,Preclinical,GABA receptor negative allosteric modulator,P05093
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,P05093
CHEMBL3264610,CC(C)[C@](C1=CC2=CC(=C(C=C2C=C1)OC(F)F)OC(F)F)(C3=NNN=C3)O,VT-464,Phase 2,cytochrome P450 inhibitor,P05093
CHEMBL4869430,,ABT-239,Phase 1,histamine receptor antagonist,P35367
CHEMBL4859977,,acrivastine,Launched,histamine receptor antagonist,P35367
CHEMBL1201747,CN1CCC(=C2C3=CC=CC=C3CCN4C2=NC=C4C=O)CC1,alcaftadine,Launched,histamine receptor antagonist,P35367
CHEMBL829,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C,alimemazine,Launched,histamine receptor agonist|histamine receptor antagonist,P35367
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P35367
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P35367
CHEMBL1200550,C1CN=C(N1)CN(CC2=CC=CC=C2)C3=CC=CC=C3.OP(=O)(O)O,antazoline,Launched,antihistamine,P35367
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P35367
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL296419,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,astemizole,Withdrawn,histamine receptor antagonist,P35367
CHEMBL4856414,,azacyclonol,Preclinical,histamine receptor antagonist,P35367
CHEMBL3544908,CN1CCC(=C2C3=C(C=CC=N3)CCC4=CC=CC=C24)CC1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,azatadine,Launched,histamine receptor antagonist,P35367
CHEMBL1200809,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl.Cl,azelastine,Launched,histamine receptor antagonist,P35367
CHEMBL1200383,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O,benztropine-mesylate,Launched,acetylcholine receptor antagonist,P35367
CHEMBL1201759,C1CN(CCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O.C1=CC=C(C=C1)S(=O)(=O)O,bepotastine,Launched,histamine receptor antagonist,P35367
CHEMBL1446813,CNCCC1=CC=CC=N1.Cl.Cl,betahistine,Launched,histamine receptor agonist|histamine receptor antagonist,P35367
CHEMBL1742423,CCOCCN1C2=CC=CC=C2N=C1C3CCN(CC3)CCC4=CC=C(C=C4)C(C)(C)C(=O)O,bilastine,Launched,histamine receptor antagonist,P35367
CHEMBL1200961,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,brompheniramine,Launched,histamine receptor antagonist,P35367
CHEMBL1201271,CC(C)(C)C1=CC=C(C=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,buclizine,Launched,histamine receptor antagonist,P35367
CHEMBL864,CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,carbinoxamine,Launched,histamine receptor antagonist,P35367
CHEMBL4847669,,carebastine,Phase 1,histamine receptor antagonist,P35367
CHEMBL1607273,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl,cetirizine,Launched,histamine receptor antagonist,P35367
CHEMBL1194287,CN(C)CCN(CC1=CC=C(C=C1)Cl)C2=CC=CC=N2,chloropyramine,Launched,histamine receptor antagonist,P35367
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P35367
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P35367
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P35367
CHEMBL1200795,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C.C(=C/C(=O)O)\C(=O)O,clemastine,Launched,histamine receptor antagonist,P35367
CHEMBL4869322,,clobenpropit,Preclinical,histamine receptor antagonist,P35367
CHEMBL1870961,CN(C)CC[C@@](C1=CC=CC=C1)(C2=CC=CC=C2Cl)O,clofedanol,Launched,histamine receptor antagonist,P35367
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P35367
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL648,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,cyclizine,Launched,histamine receptor modulator,P35367
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P35367
CHEMBL1475191,CN1[C@@H]2CC[C@H]1CC(C2)OC3C4=CC=CC=C4CCC5=CC=CC=C35.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,deptropine,Preclinical,histamine receptor antagonist,P35367
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P35367
CHEMBL1172,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,desloratadine,Launched,histamine receptor antagonist,P35367
CHEMBL1200406,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,dimenhydrinate,Launched,histamine receptor antagonist,P35367
CHEMBL2356801,C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C.C(=C\C(=O)O)\C(=O)O,dimethindene-(S)-(+),Preclinical,acetylcholine receptor antagonist,P35367
CHEMBL4853908,,dimetindene,Launched,cholinergic receptor antagonist|histamine receptor antagonist,P35367
CHEMBL1201089,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,diphenhydramine,Launched,histamine receptor antagonist,P35367
CHEMBL1564,CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3.Cl,diphenylpyraline,Launched,dopamine reuptake inhibitor,P35367
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P35367
CHEMBL1256774,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31.Cl,doxepin,Launched,histamine receptor antagonist,P35367
CHEMBL1004,CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C,doxylamine,Launched,histamine receptor antagonist,P35367
CHEMBL4862237,,DPPE,Phase 3,histamine receptor antagonist,P35367
CHEMBL4867302,,ebastine,Launched,histamine receptor antagonist,P35367
CHEMBL2103739,CCOCCN1C(=NC2=CC=CC=C12)N3CCN(CCC3)C.C(=C/C(=O)O)\C(=O)O.C(=C/C(=O)O)\C(=O)O,emedastine,Launched,histamine receptor antagonist,P35367
CHEMBL1200491,C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N.Cl,epinastine,Launched,histamine receptor antagonist,P35367
CHEMBL1200618,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O.Cl,fexofenadine,Launched,histamine receptor antagonist,P35367
CHEMBL552659,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,flunarizine,Launched,calcium channel blocker,P35367
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P35367
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P35367
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P35367
CHEMBL1533310,C1=C(NC=N1)CCN.Cl.Cl,histamine,Launched,histamine receptor agonist,P35367
CHEMBL1515447,CN1CCCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,homochlorcyclizine,Launched,antihistamine,P35367
CHEMBL1200467,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O,hydroxyzine,Launched,antihistamine,P35367
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P35367
CHEMBL1633,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1.C(=C/C(=O)O)\C(=O)O,ketotifen,Launched,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor,P35367
CHEMBL2105703,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C.Cl.Cl,latrepirdine,Phase 3,glutamate receptor antagonist,P35367
CHEMBL1615438,C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F,levocabastine,Launched,histamine receptor antagonist,P35367
CHEMBL1201191,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl,levocetirizine,Launched,histamine receptor antagonist,P35367
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P35367
CHEMBL1367006,C1CN2CCC1[C@H](C2)CN3C4=CC=CC=C4SC5=CC=CC=C53,levomequitazine,Phase 2,histamine receptor antagonist,P35367
CHEMBL4859181,,loratadine,Launched,histamine receptor antagonist,P35367
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL511,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,mepyramine,Launched,histamine receptor antagonist,P35367
CHEMBL1411979,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,methapyrilene,Withdrawn,histamine receptor antagonist,P35367
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P35367
CHEMBL4863323,,mizolastine,Launched,histamine receptor antagonist,P35367
CHEMBL1200419,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C.Cl,molindone,Launched,dopamine receptor antagonist,P35367
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P35367
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,P35367
CHEMBL4875902,,oxatomide,Launched,histamine receptor antagonist,P35367
CHEMBL1201050,CC1=CC=CN2C1=NC=C(C2=O)C3=NN=N[N-]3.[K+],pemirolast,Launched,mediator release inhibitor,P35367
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P35367
CHEMBL2107213,CN1CCC2=C(C1)C(C3=CC=CC=C23)C4=CC=CC=C4.C(C(C(=O)O)O)(C(=O)O)O,phenindamine,Launched,histamine receptor antagonist,P35367
CHEMBL1653,CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=N2.C(=C\C(=O)O)\C(=O)O,pheniramine,Launched,histamine receptor antagonist,P35367
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P35367
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P35367
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P35367
CHEMBL1200750,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C.Cl,promethazine,Launched,histamine receptor antagonist,P35367
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL4857900,,rupatadine,Launched,histamine receptor antagonist|platelet activating factor receptor antagonist,P35367
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL2104895,CN1CCC2=C(C1)C3=CC=CC=C3CC4=CC=CC=C24,setiptiline,Launched,adrenergic receptor antagonist,P35367
CHEMBL4858222,,terfenadine,Withdrawn,histamine receptor antagonist,P35367
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P35367
CHEMBL1200902,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.Cl,thiothixene,Launched,dopamine receptor antagonist,P35367
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P35367
CHEMBL415324,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,tranilast,Launched,angiogenesis inhibitor,P35367
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P35367
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P35367
CHEMBL1200446,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2.Cl,tripelennamine,Launched,histamine receptor antagonist,P35367
CHEMBL3188034,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3.O.Cl,triprolidine,Launched,histamine receptor antagonist,P35367
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,P35367
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P35367
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P35367
CHEMBL4855236,,2-pyridylethylamine,Preclinical,histamine receptor agonist,P35367
CHEMBL4869430,,ABT-239,Phase 1,histamine receptor antagonist,P25021
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P25021
CHEMBL293762,CC1=C(SC(=N1)N)CCN,amthamine,Preclinical,histamine receptor agonist,P25021
CHEMBL1200949,C1=C(NN=C1)CCN.Cl,betazole,Launched,histamine receptor agonist,P25021
CHEMBL4857013,,cimetidine,Launched,histamine receptor antagonist,P25021
CHEMBL4869322,,clobenpropit,Preclinical,histamine receptor antagonist,P25021
CHEMBL12344,CN(C)CCCSC(=N)N,dimaprit,Preclinical,histamine receptor agonist,P25021
CHEMBL1742471,C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br,ebrotidine,Withdrawn,histamine receptor antagonist,P25021
CHEMBL902,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,famotidine,Launched,histamine receptor antagonist,P25021
CHEMBL1533310,C1=C(NC=N1)CCN.Cl.Cl,histamine,Launched,histamine receptor agonist,P25021
CHEMBL4875713,,ICI-162846,Phase 1,histamine receptor antagonist,P25021
CHEMBL1742461,C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)CS(=O)CC3=CC=CO3,lafutidine,Launched,histamine receptor antagonist,P25021
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25021
CHEMBL1200988,CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13.[Br-],methantheline,Launched,acetylcholine receptor antagonist,P25021
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P25021
CHEMBL653,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,nizatidine,Launched,histamine receptor antagonist,P25021
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P25021
CHEMBL512,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,ranitidine,Launched,histamine receptor antagonist,P25021
CHEMBL2104871,CC(=O)OCC(=O)NCCCOC1=CC=CC(=C1)CN2CCCCC2.Cl,roxatidine-acetate,Launched,histamine receptor antagonist,P25021
CHEMBL4871754,,tiotidine,Phase 2,histamine receptor antagonist,P25021
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P25021
CHEMBL4863034,,WAY-207024,Preclinical,gonadotropin releasing factor hormone receptor antagonist,P25021
CHEMBL4872923,,zaltidine,Phase 3,histamine receptor antagonist,P25021
CHEMBL4869430,,ABT-239,Phase 1,histamine receptor antagonist,Q9Y5N1
CHEMBL4874703,,alpha-methylhistamine-dihydrobromide-(R)-(-),Preclinical,histamine receptor agonist,Q9Y5N1
CHEMBL4855683,,alpha-methylhistamine-dihydrobromide-(S)-(+),Preclinical,histamine receptor agonist,Q9Y5N1
CHEMBL2103862,C1CC1N2CCN(CC2)C(=O)C3=CC=C(C=C3)CN4CCOCC4,bavisant,Phase 2,histamine receptor antagonist,Q9Y5N1
CHEMBL1446813,CNCCC1=CC=CC=N1.Cl.Cl,betahistine,Launched,histamine receptor agonist|histamine receptor antagonist,Q9Y5N1
CHEMBL128672,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3.C(=C\C(=O)O)\C(=O)O,ciproxifan,Preclinical,histamine receptor antagonist,Q9Y5N1
CHEMBL4869322,,clobenpropit,Preclinical,histamine receptor antagonist,Q9Y5N1
CHEMBL12344,CN(C)CCCSC(=N)N,dimaprit,Preclinical,histamine receptor agonist,Q9Y5N1
CHEMBL1533310,C1=C(NC=N1)CCN.Cl.Cl,histamine,Launched,histamine receptor agonist,Q9Y5N1
CHEMBL1490875,C1=C(NC=N1)CCSC(=N)N.Br.Br,imetit,Preclinical,histamine receptor agonist,Q9Y5N1
CHEMBL5077041,C1CNCCC1CC2=CN=CN2.Br.Br,immepip,Preclinical,histamine receptor agonist,Q9Y5N1
CHEMBL82298,C1=CN=CC=C1CC2=CN=CN2,immethridine,Phase 1,histamine receptor agonist,Q9Y5N1
CHEMBL4869992,,impentamine,Preclinical,histamine receptor antagonist,Q9Y5N1
CHEMBL4854360,,iodophenpropit,Preclinical,histamine receptor antagonist,Q9Y5N1
CHEMBL4164059,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl.Cl,pitolisant,Launched,histamine receptor antagonist,Q9Y5N1
CHEMBL19173,C1=CC=C(C=C1)COCCCC2=CN=CN2,proxyfan,Preclinical,histamine receptor modulator,Q9Y5N1
CHEMBL1256702,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3.C(=C\C(=O)O)\C(=O)O,thioperamide,Preclinical,histamine receptor antagonist,Q9Y5N1
CHEMBL4854531,,ABT-491,Phase 1,platelet activating factor receptor antagonist,P25105
CHEMBL2074496,,apafant,Phase 3,platelet activating factor receptor antagonist,P25105
CHEMBL1628662,CC(C)C1=CC(=C(C(=C1)C(C)C)C2=CSC(=N2)N(CCN(C)C)CC3=CN=CC=C3)C(C)C,foropafant,Phase 3,platelet activating factor receptor antagonist,P25105
CHEMBL1590048,C[C@@H]1C(=C(NC(=C1C(=O)OCCSC2=CC=CC=C2)C)C)C(=O)OC,PCA-4248,Phase 1,platelet activating factor receptor antagonist,P25105
CHEMBL4857900,,rupatadine,Launched,histamine receptor antagonist|platelet activating factor receptor antagonist,P25105
CHEMBL3590674,C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F,ABT-639,Phase 2,calcium channel blocker,O43497
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,O43497
CHEMBL2105555,CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,benidipine,Launched,calcium channel blocker,O43497
CHEMBL696,CCC1(CC(=O)NC1=O)C,ethosuximide,Launched,succinimide antiepileptic,O43497
CHEMBL552659,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,flunarizine,Launched,calcium channel blocker,O43497
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O43497
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin-enacarbil,Launched,adrenergic receptor agonist,O43497
CHEMBL4854920,,methsuximide,Launched,T-type calcium channel blocker,O43497
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,O43497
CHEMBL4535646,CC(C)(C)CCN1CC2C(C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl,ML218,Preclinical,T-type calcium channel blocker,O43497
CHEMBL1100,CCC1(C(=O)N(C(=O)O1)C)C,paramethadione,Launched,anticonvulsant,O43497
CHEMBL4257579,,penfluridol,Launched,T-type calcium channel blocker,O43497
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,O43497
CHEMBL695,CC1(C(=O)N(C(=O)O1)C)C,trimethadione,Launched,oxazolidine antiepileptic,O43497
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,O43497
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,O43497
CHEMBL3590674,C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F,ABT-639,Phase 2,calcium channel blocker,O95180
CHEMBL1083993,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,amiodarone,Launched,potassium channel blocker,O95180
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,O95180
CHEMBL696,CCC1(CC(=O)NC1=O)C,ethosuximide,Launched,succinimide antiepileptic,O95180
CHEMBL552659,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,flunarizine,Launched,calcium channel blocker,O95180
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O95180
CHEMBL4854920,,methsuximide,Launched,T-type calcium channel blocker,O95180
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,O95180
CHEMBL4535646,CC(C)(C)CCN1CC2C(C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl,ML218,Preclinical,T-type calcium channel blocker,O95180
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,O95180
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,O95180
CHEMBL695,CC1(C(=O)N(C(=O)O1)C)C,trimethadione,Launched,oxazolidine antiepileptic,O95180
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,O95180
CHEMBL3590674,C1C[C@@H]2CN(CCN2C1)C(=O)C3=CC(=C(C=C3Cl)F)S(=O)(=O)NC4=CC=CC=C4F,ABT-639,Phase 2,calcium channel blocker,Q9P0X4
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q9P0X4
CHEMBL696,CCC1(CC(=O)NC1=O)C,ethosuximide,Launched,succinimide antiepileptic,Q9P0X4
CHEMBL552659,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,flunarizine,Launched,calcium channel blocker,Q9P0X4
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9P0X4
CHEMBL4854920,,methsuximide,Launched,T-type calcium channel blocker,Q9P0X4
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q9P0X4
CHEMBL4535646,CC(C)(C)CCN1CC2C(C1)C2CNC(=O)C3=CC(=CC(=C3)Cl)Cl,ML218,Preclinical,T-type calcium channel blocker,Q9P0X4
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,Q9P0X4
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q9P0X4
CHEMBL695,CC1(C(=O)N(C(=O)O1)C)C,trimethadione,Launched,oxazolidine antiepileptic,Q9P0X4
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q9P0X4
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9P0X4
CHEMBL4858753,,ABT-702,Preclinical,adenosine kinase inhibitor,P55263
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P55263
CHEMBL4851831,,ribavirin,Launched,antiviral,P55263
CHEMBL4870638,,ABT-737,Phase 1/Phase 2,BCL inhibitor,P10415
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P10415
CHEMBL4877105,,edaravone,Launched,nootropic agent,P10415
CHEMBL555017,CC(=CCC[C@@]1(C=CC2=C(C3=C(C(=C2O1)CC=C(C)C)O[C@@]45[C@H]6C[C@@H](C=C4C3=O)C(=O)[C@@]5(OC6(C)C)C/C=C(/C)\C(=O)O)O)C)C,gambogic-acid,Phase 2,caspase activator,P10415
CHEMBL4856269,,gossypol,Phase 2,BCL inhibitor|MCL1 inhibitor,P10415
CHEMBL4303144,CCOC(=O)C1=C(OC2=C([C@H]1[C@H](C#N)C(=O)OCC)C=C(C=C2)Br)N,HA14-1,Preclinical,BCL inhibitor,P10415
CHEMBL2105690,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C.Cl.Cl,navitoclax,Phase 2,BCL inhibitor,P10415
CHEMBL4525540,CC1=CC(=C(N1)/C=C\2/C(=C/C(=C/3\C=C4C=CC=CC4=N3)/N2)OC)C,obatoclax,Phase 3,BCL inhibitor,P10415
CHEMBL454570,CC1(CC[C@@H]([C@]23[C@@H]1[C@@H]([C@@]([C@]45[C@H]2CC[C@H]([C@H]4O)C(=C)C5=O)(OC3)O)O)O)C,oridonin,Preclinical,BCL inhibitor,P10415
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P10415
CHEMBL887,C#CCN[C@@H]1CCC2=CC=CC=C12,rasagiline,Launched,monoamine oxidase inhibitor,P10415
CHEMBL4865794,,TW-37,Preclinical,BCL inhibitor,P10415
CHEMBL3970001,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC(=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NCC5CCOCC5)[N+](=O)[O-])OC6=CN=C7C(=C6)C=CN7)C8=CC=C(C=C8)Cl)C,venetoclax,Launched,BCL inhibitor,P10415
CHEMBL4870638,,ABT-737,Phase 1/Phase 2,BCL inhibitor,Q07817
CHEMBL2105690,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C.Cl.Cl,navitoclax,Phase 2,BCL inhibitor,Q07817
CHEMBL4865794,,TW-37,Preclinical,BCL inhibitor,Q07817
CHEMBL1356094,C1=CC(=C(C(=C1)Cl)Cl)OCCCNCCO,"2,3-DCPE",Preclinical,BCL-XL downregulator,Q07817
CHEMBL4870638,,ABT-737,Phase 1/Phase 2,BCL inhibitor,Q92843
CHEMBL2105690,CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C.Cl.Cl,navitoclax,Phase 2,BCL inhibitor,Q92843
CHEMBL4869868,,ABT-751,Phase 2,tubulin polymerization inhibitor,P07437
CHEMBL1483,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,albendazole,Launched,tubulin polymerization inhibitor,P07437
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P07437
CHEMBL70971,COC(=O)NC1=NC2=CC=CC=C2N1,carbendazim,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P07437
CHEMBL4879257,,cevipabulin,Phase 1,microtubule stimulant|tubulin polymerization inhibitor,P07437
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P07437
CHEMBL552212,CCC[C@@H](C1=CN=CC=C1)NC2=NC(=NC=C2C)C3=CC(=C(C=C3)NC(=O)NCC)OC,CYT-997,Phase 2,tubulin polymerization inhibitor,P07437
CHEMBL4859004,,D-64131,Preclinical,microtubule inhibitor,P07437
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P07437
CHEMBL39541,CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@@H](CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C,dolastatin-10,Phase 2,tubulin polymerization inhibitor,P07437
CHEMBL4303268,C[C@H]1CCC[C@@]2([C@@H](O2)C[C@@H](OC(=O)C[C@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C,epothilone-B,Phase 3,microtubule stabilizing agent|tubulin polymerization inhibitor,P07437
CHEMBL96172,C[C@H]1CCC/C(=C\C[C@H](OC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C2=CSC(=N2)C)/C)/C,epothilone-D,Phase 2,microtubule stabilizing agent|tubulin polymerization inhibitor,P07437
CHEMBL37161,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,fenbendazole,Launched,tubulin polymerization inhibitor,P07437
CHEMBL1454946,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,flubendazole,Launched,tubulin polymerization inhibitor,P07437
CHEMBL1201752,C[C@H]1CCC[C@@]2([C@@H](O2)C[C@H](NC(=O)C[C@@H](C(C(=O)[C@@H]([C@H]1O)C)(C)C)O)/C(=C/C3=CSC(=N3)C)/C)C,ixabepilone,Launched,microtubule stabilizing agent,P07437
CHEMBL685,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,mebendazole,Launched,tubulin polymerization inhibitor,P07437
CHEMBL1087630,CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,oxibendazole,Launched,tubulin polymerization inhibitor,P07437
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P07437
CHEMBL528271,CCCCC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,parbendazole,Preclinical,tubulin polymerization inhibitor,P07437
CHEMBL61,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,podophyllotoxin,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P07437
CHEMBL2105697,CC1=NC2=CC=CC=C2C(=N1)N(C)C3=CC=C(C=C3)OC.Cl,verubulin,Phase 2,tubulin polymerization inhibitor,P07437
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P07437
CHEMBL499458,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vincristine,Launched,tubulin polymerization inhibitor,P07437
CHEMBL3989543,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O,vindesine,Launched,tubulin polymerization inhibitor,P07437
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P07437
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,P07437
CHEMBL4303689,C1CC(CCC1(C2=CC=C(C=C2)O)C3=CC=CC=C3F)(F)F,AC-186,Preclinical,estrogen receptor agonist,Q92731
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q92731
CHEMBL2106615,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O.CC(=O)O,bazedoxifene,Launched,selective estrogen receptor modulator (SERM),Q92731
CHEMBL418971,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,bisphenol-A,Phase 1,synthetic estrogen,Q92731
CHEMBL290106,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,bithionol,Withdrawn,autotaxin inhibitor,Q92731
CHEMBL1200761,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC,chlorotrianisene,Launched,estrogenic hormone,Q92731
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,Q92731
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q92731
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone-sulfate,Launched,androgen receptor agonist|estrogen receptor agonist,Q92731
CHEMBL4849831,,diarylpropionitrile,Preclinical,estrogen receptor agonist,Q92731
CHEMBL4857863,,diethylstilbestrol,Withdrawn,estrogen receptor agonist,Q92731
CHEMBL198877,C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O,equol,Launched,estrogen receptor agonist,Q92731
CHEMBL4853332,,erteberel,Phase 2,estrogen receptor agonist,Q92731
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol,Launched,estrogen receptor agonist,Q92731
CHEMBL1200721,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],estramustine,Launched,DNA alkylating agent,Q92731
CHEMBL1756,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,estramustine-phosphate,Launched,DNA synthesis inhibitor|microtubule inhibitor,Q92731
CHEMBL4867163,,estriol,Launched,estrogen receptor agonist,Q92731
CHEMBL494753,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,estrone,Launched,estrogen receptor agonist|estrogenic hormone,Q92731
CHEMBL1200980,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1,estropipate,Launched,estrogen receptor agonist,Q92731
CHEMBL4864802,,ethinyl-estradiol,Launched,estrogen receptor agonist|estrogenic hormone,Q92731
CHEMBL4742841,CC/C(=C(\CC)/C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O,fosfestrol,Launched,synthetic estrogen,Q92731
CHEMBL1712246,C[C@]12CC[C@H]3C([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,fulvestrant,Launched,estrogen receptor antagonist,Q92731
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,Q92731
CHEMBL9225,CC[C@H](C1=CC=C(C=C1)O)[C@@H](CC)C2=CC=C(C=C2)O,hexestrol,Launched,synthetic estrogen,Q92731
CHEMBL4873567,,lasofoxifene,Launched,selective estrogen receptor modulator (SERM),Q92731
CHEMBL28626,C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,morin,Preclinical,cytochrome P450 inhibitor,Q92731
CHEMBL9352,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,Q92731
CHEMBL2105395,C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCO)/CCCl,ospemifene,Launched,selective estrogen receptor modulator (SERM),Q92731
CHEMBL4847358,,PHTPP,Preclinical,estrogen receptor antagonist,Q92731
CHEMBL4849253,,prinaberel,Phase 2,estrogen receptor agonist,Q92731
CHEMBL1201165,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5,quinestrol,Launched,estrogen receptor agonist,Q92731
CHEMBL4865006,,raloxifene,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q92731
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q92731
CHEMBL4870392,,WAY-200070,Preclinical,estrogen receptor agonist,Q92731
CHEMBL4870794,,Y-134,Preclinical,estrogen receptor antagonist,Q92731
CHEMBL4869768,,ZK-164015,Preclinical,estrogen receptor antagonist,Q92731
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,Q92731
CHEMBL4874390,,AC-261066,Preclinical,retinoid receptor agonist,P10826
CHEMBL4859402,,AC-55649,Preclinical,retinoid receptor agonist,P10826
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P10826
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P10826
CHEMBL4878368,,adarotene,Phase 1,retinoid receptor agonist,P10826
CHEMBL4876829,,CH55,Preclinical,retinoid receptor binder,P10826
CHEMBL4853069,,EC-23,Preclinical,retinoid receptor agonist,P10826
CHEMBL3889357,,isotretinoin,Launched,retinoid receptor agonist,P10826
CHEMBL4856327,,LE-135,Preclinical,retinoid receptor agonist,P10826
CHEMBL4857794,,tamibarotene,Launched,retinoid receptor agonist,P10826
CHEMBL1657,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,tazarotene,Launched,retinoid receptor agonist,P10826
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P10826
CHEMBL4859841,,TTNPB,Phase 1,retinoid receptor agonist,P10826
CHEMBL4848090,,AC-264613,Preclinical,PAR agonist,P55085
CHEMBL4874615,,AC-55541,Preclinical,PARP inhibitor,Q9UGN5
CHEMBL4858072,,E7449,Phase 2,PARP inhibitor,Q9UGN5
CHEMBL521686,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,olaparib,Launched,PARP inhibitor,Q9UGN5
CHEMBL3833368,CC1([C@@H]2CC[C@]1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,rucaparib,Phase 3,PARP inhibitor,Q9UGN5
CHEMBL3137320,CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F,talazoparib,Launched,PARP inhibitor,Q9UGN5
CHEMBL4849034,,UPF-1069,Preclinical,PARP inhibitor,Q9UGN5
CHEMBL497608,C[C@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,veliparib,Phase 3,PARP inhibitor,Q9UGN5
CHEMBL4859402,,AC-55649,Preclinical,retinoid receptor agonist,P10276
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P10276
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P10276
CHEMBL4859721,,AGN-195183,Phase 1/Phase 2,retinoid receptor agonist,P10276
CHEMBL4862943,,AM-580,Preclinical,retinoid receptor agonist,P10276
CHEMBL4876829,,CH55,Preclinical,retinoid receptor binder,P10276
CHEMBL4853069,,EC-23,Preclinical,retinoid receptor agonist,P10276
CHEMBL4872863,,ER-50891,Preclinical,retinoid receptor antagonist,P10276
CHEMBL464,CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C,etretinate,Withdrawn,protein synthesis inhibitor,P10276
CHEMBL4864808,,fenretinide,Phase 3,apoptosis stimulant|retinoid receptor agonist,P10276
CHEMBL3889357,,isotretinoin,Launched,retinoid receptor agonist,P10276
CHEMBL4857794,,tamibarotene,Launched,retinoid receptor agonist,P10276
CHEMBL1657,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,tazarotene,Launched,retinoid receptor agonist,P10276
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P10276
CHEMBL4859841,,TTNPB,Phase 1,retinoid receptor agonist,P10276
CHEMBL4856322,,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P07333
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P07333
CHEMBL2105728,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,P07333
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P07333
CHEMBL4878661,,GTP-14564,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,P07333
CHEMBL3677988,C1CC(CCC1NC(=O)NC2=CC=C(C=C2)Cl)OC3=CC=C(C=C3)C#N,GW-2580,Preclinical,cFMS kinase inhibitor,P07333
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P07333
CHEMBL4874773,,KI-20227,Preclinical,c-Fms inhibitor,P07333
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P07333
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P07333
CHEMBL3989973,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F.Cl,pexidartinib,Launched,tyrosine kinase inhibitor,P07333
CHEMBL4226338,COC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CC=C(C=C4)C(F)(F)F)N=C1,PLX647,Preclinical,receptor tyrosine protein kinase inhibitor,P07333
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P07333
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P07333
CHEMBL4532415,CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C4C=C(C(=CC4=NC=C3)OCCCN5CCCCC5)OC,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P07333
CHEMBL4856322,,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P36888
CHEMBL4864488,,tyrphostin-AG-1296,Preclinical,FLT3 inhibitor,P36888
CHEMBL4876879,,AMG-925,Phase 1,CDK inhibitor|FLT3 inhibitor,P36888
CHEMBL4852054,,BMS-690514,Phase 2,EGFR inhibitor|VEGFR inhibitor,P36888
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P36888
CHEMBL2403108,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,P36888
CHEMBL2105728,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,P36888
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P36888
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P36888
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,P36888
CHEMBL3301622,CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5,gilteritinib,Launched,FLT3 inhibitor,P36888
CHEMBL4878661,,GTP-14564,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,P36888
CHEMBL3932957,CSC1=NC(=CC(=N1)OC2=CC=C(C=C2)C3=NC(=NN3)NC4=CC=CC(=C4)C(F)(F)F)N,KG-5,Preclinical,RAF inhibitor,P36888
CHEMBL4874165,,KW-2449,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,P36888
CHEMBL4469622,C[C@@]1(C[C@@H]2N3C4=CC=CC=C4C5=C6CNC(=O)C6=C7C8=CC=CC=C8N(C7=C53)[C@]1(O2)C)CO,lestaurtinib,Phase 3,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,P36888
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P36888
CHEMBL4790597,C[C@@]12C[C@@H](C[C@@](O1)(N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)C)N(C)C(=O)C9=CC=CC=C9,midostaurin,Launched,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,P36888
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P36888
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P36888
CHEMBL4868631,,NMS-1286937,Phase 2,PLK inhibitor,P36888
CHEMBL4778465,C1CCN(C1)CCOC2=C3COC/C=C\COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,pacritinib,Phase 3,FLT3 inhibitor|JAK inhibitor,P36888
CHEMBL3989973,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F.Cl,pexidartinib,Launched,tyrosine kinase inhibitor,P36888
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P36888
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P36888
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P36888
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P36888
CHEMBL4846077,,SGI-1776,Phase 1,Pim kinase inhibitor,P36888
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P36888
CHEMBL4532415,CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C4C=C(C(=CC4=NC=C3)OCCCN5CCCCC5)OC,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P36888
CHEMBL4864453,,TCS-359,Preclinical,FLT3 inhibitor,P36888
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,P36888
CHEMBL2103833,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O,toceranib,Launched,protein tyrosine kinase inhibitor,P36888
CHEMBL4868263,,UNC2025,Preclinical,FLT3 inhibitor|MER tyrosine kinase inhibitor,P36888
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,P36888
CHEMBL4856322,,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL4867230,,amuvatinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,P10721
CHEMBL3186534,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,apatinib,Phase 3,RET tyrosine kinase inhibitor,P10721
CHEMBL4303655,COC1=CC(=CC(=C1)C2=NC3=NNC(=C3C=C2)C4=CC=C(C=C4)F)OC,APcK-110,Preclinical,KIT inhibitor,P10721
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P10721
CHEMBL4303508,COCCOC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4N5CCC(CC5)N)C=C3,CP-673451,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL2105728,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P10721
CHEMBL4216467,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,DCC-2618,Phase 1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P10721
CHEMBL4878661,,GTP-14564,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,P10721
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL3932957,CSC1=NC(=CC(=N1)OC2=CC=C(C=C2)C3=NC(=NN3)NC4=CC=CC(=C4)C(F)(F)F)N,KG-5,Preclinical,RAF inhibitor,P10721
CHEMBL4874773,,KI-20227,Preclinical,c-Fms inhibitor,P10721
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P10721
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P10721
CHEMBL1908391,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,masitinib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,P10721
CHEMBL2107357,CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O,motesanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P10721
CHEMBL255863,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,nilotinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,P10721
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P10721
CHEMBL4847840,,OSI-930,Phase 1,KIT inhibitor|VEGFR inhibitor,P10721
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P10721
CHEMBL3989973,C1=CC(=NC=C1CC2=CNC3=C2C=C(C=N3)Cl)NCC4=CN=C(C=C4)C(F)(F)F.Cl,pexidartinib,Launched,tyrosine kinase inhibitor,P10721
CHEMBL4226338,COC1=CC2=C(NC=C2CC3=CN=C(C=C3)NCC4=CC=C(C=C4)C(F)(F)F)N=C1,PLX647,Preclinical,receptor tyrosine protein kinase inhibitor,P10721
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P10721
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P10721
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P10721
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P10721
CHEMBL4532415,CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C4C=C(C(=CC4=NC=C3)OCCCN5CCCCC5)OC,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P10721
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P10721
CHEMBL4856322,,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P16234
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P16234
CHEMBL4303508,COCCOC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4N5CCC(CC5)N)C=C3,CP-673451,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL2105728,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL4216467,CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC,DCC-2618,Phase 1,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P16234
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,P16234
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P16234
CHEMBL1908391,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,masitinib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,P16234
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P16234
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P16234
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P16234
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P16234
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P16234
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P16234
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P16234
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P16234
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P16234
CHEMBL4877939,,TAK-593,Phase 1,VEGFR inhibitor,P16234
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P16234
CHEMBL2103833,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O,toceranib,Launched,protein tyrosine kinase inhibitor,P16234
CHEMBL132767,CCN(CC)C1=CC(=NC2=NC=NN12)C,trapidil,Launched,PDGFR tyrosine kinase receptor inhibitor,P16234
CHEMBL4856322,,AC-710,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL4303201,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,anlotinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P09619
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P09619
CHEMBL4303508,COCCOC1=CC2=C(C=C1)N(C=N2)C3=NC4=C(C=CC=C4N5CCC(CC5)N)C=C3,CP-673451,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL2105728,CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4,crenolanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P09619
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL4865546,,flumatinib,Phase 3,Bcr-Abl kinase inhibitor,P09619
CHEMBL4878661,,GTP-14564,Preclinical,FLT3 inhibitor|tyrosine kinase inhibitor,P09619
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL3932957,CSC1=NC(=CC(=N1)OC2=CC=C(C=C2)C3=NC(=NN3)NC4=CC=CC(=C4)C(F)(F)F)N,KG-5,Preclinical,RAF inhibitor,P09619
CHEMBL4874773,,KI-20227,Preclinical,c-Fms inhibitor,P09619
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P09619
CHEMBL1908391,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,masitinib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,P09619
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P09619
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P09619
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL4853290,,ON123300,Preclinical,CDK inhibitor,P09619
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,P09619
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P09619
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P09619
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P09619
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P09619
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P09619
CHEMBL149201,CC1=C(NC(=C1CCC(=O)O)C)/C=C\2/C3=C(C=C(C=C3)C4=CC=CC=C4)NC2=O,SU16f,Preclinical,PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL2050148,,SU4312,Preclinical,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,P09619
CHEMBL4532415,CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C4C=C(C(=CC4=NC=C3)OCCCN5CCCCC5)OC,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P09619
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P09619
CHEMBL2103833,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O,toceranib,Launched,protein tyrosine kinase inhibitor,P09619
CHEMBL4848946,,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09619
CHEMBL4849103,,AC-7954-(+/-),Preclinical,urotensin receptor agonist,Q9UKP6
,,GSK1562590,Preclinical,urotensin receptor antagonist,Q9UKP6
CHEMBL4846156,,ICI-199441,Preclinical,opioid receptor agonist,Q9UKP6
CHEMBL567303,CC1=NC2=CC=CC=C2C(=C1)NC(=O)NCCN3CCC(CC3)(CC4=CC=CC=C4)O,palosuran,Phase 2,urotensin receptor antagonist,Q9UKP6
CHEMBL4863638,,SB-657510,Preclinical,urotensin receptor antagonist,Q9UKP6
CHEMBL4850710,,SB-706375,Preclinical,urotensin receptor antagonist,Q9UKP6
CHEMBL3707348,CC#CC(=O)N1CCC[C@H]1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5,acalabrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4851455,,AVL-292,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4872058,,CNX-774,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4861835,,GDC-0834,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4466205,C=CC(=O)N1CCC[C@H](C1)N2C3=CC=CC=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5,ibrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4872497,,LFM-A13,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4851203,,olmutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,Q06187
CHEMBL4303189,C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5)N,ONO-4059,Phase 1,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4865081,,PCI-29732,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL1455300,CC1=C(C(=O)[C@H]2[C@@H](C1=O)O2)O,terreic-acid-(-),Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,Q06187
CHEMBL4303323,C[C@@H](C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,acalisib,Phase 1,PI3K inhibitor,P42338
CHEMBL2396661,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,alpelisib,Launched,PI3K inhibitor,P42338
CHEMBL4874238,,AZD6482,Phase 1,PI3K inhibitor,P42338
CHEMBL4876154,,AZD8186,Phase 1,PI3K inhibitor,P42338
CHEMBL3545096,CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=C\C(=O)O)\C(=O)O,BGT226,Phase 1/Phase 2,PI3K inhibitor,P42338
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P42338
CHEMBL4867637,,CH5132799,Phase 1,PI3K inhibitor,P42338
CHEMBL3545068,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5.Cl.Cl,copanlisib,Launched,PI3K inhibitor,P42338
CHEMBL4538684,C[C@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,duvelisib,Launched,PI3K inhibitor,P42338
CHEMBL4303351,CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4,ETP-45658,Preclinical,PI3K inhibitor,P42338
CHEMBL4873525,,GDC-0941,Phase 2,PI3K inhibitor,P42338
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P42338
CHEMBL4859753,,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,P42338
CHEMBL4865728,,GSK2636771,Phase 2,PI3K inhibitor,P42338
CHEMBL4095008,CC[C@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,idelalisib,Launched,PI3K inhibitor,P42338
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P42338
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,P42338
CHEMBL3182327,CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=NC=NC(=C5C=N4)N,PIK-293,Preclinical,PI3K inhibitor,P42338
CHEMBL4878936,,PIK-294,Preclinical,PI3K inhibitor,P42338
CHEMBL4853500,,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,P42338
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P42338
CHEMBL578092,C=CCN1CCN(CC1)C(C2=CC=CC=C2F)C3=NN=NN3CC4=CC=CO4.Cl,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,P42338
CHEMBL3585342,,TGX-221,Preclinical,PI3K inhibitor,P42338
CHEMBL230011,C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N,TG100-115,Phase 1/Phase 2,PI3K inhibitor,P42338
CHEMBL586701,CC1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4C3=O)NC5=CC=CC=C5S2,ZSTK-474,Phase 1/Phase 2,PI3K inhibitor,P42338
CHEMBL4303323,C[C@@H](C1=NC2=C(C=C(C=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,acalisib,Phase 1,PI3K inhibitor,O00329
CHEMBL2396661,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,alpelisib,Launched,PI3K inhibitor,O00329
CHEMBL3545048,,AMG-319,Phase 2,PI3K inhibitor,O00329
CHEMBL4303302,CC(C1=C(N=C2C=C(C=CC2=C1)F)C3=CC=CC=N3)NC4=NC=NC5=C4NC=N5,AMG319,Phase 2,PI3K inhibitor,O00329
CHEMBL4874238,,AZD6482,Phase 1,PI3K inhibitor,O00329
CHEMBL4876154,,AZD8186,Phase 1,PI3K inhibitor,O00329
CHEMBL3894518,CCN1C(=NC(=N1)C2CCN(CC2)C(=O)CCO)C3=CN=C(C(=N3)C4=NN=C(O4)C(C)(C)C)N,AZD8835,Phase 1,PI3K inhibitor,O00329
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O00329
CHEMBL4867637,,CH5132799,Phase 1,PI3K inhibitor,O00329
CHEMBL3545068,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5.Cl.Cl,copanlisib,Launched,PI3K inhibitor,O00329
CHEMBL4538684,C[C@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,duvelisib,Launched,PI3K inhibitor,O00329
CHEMBL4303351,CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4,ETP-45658,Preclinical,PI3K inhibitor,O00329
CHEMBL4873525,,GDC-0941,Phase 2,PI3K inhibitor,O00329
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,O00329
CHEMBL4859753,,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,O00329
CHEMBL4095008,CC[C@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,idelalisib,Launched,PI3K inhibitor,O00329
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,O00329
CHEMBL4869629,,MLN0128,Phase 2,mTOR inhibitor,O00329
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,O00329
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,O00329
CHEMBL3182327,CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=NC=NC(=C5C=N4)N,PIK-293,Preclinical,PI3K inhibitor,O00329
CHEMBL4878936,,PIK-294,Preclinical,PI3K inhibitor,O00329
CHEMBL4853500,,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,O00329
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,O00329
CHEMBL578092,C=CCN1CCN(CC1)C(C2=CC=CC=C2F)C3=NN=NN3CC4=CC=CO4.Cl,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,O00329
CHEMBL3585342,,TGX-221,Preclinical,PI3K inhibitor,O00329
CHEMBL230011,C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N,TG100-115,Phase 1/Phase 2,PI3K inhibitor,O00329
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,O00329
CHEMBL4851334,,XL147,Phase 2,PI3K inhibitor,O00329
CHEMBL586701,CC1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4C3=O)NC5=CC=CC=C5S2,ZSTK-474,Phase 1/Phase 2,PI3K inhibitor,O00329
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P47869
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P47869
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,P47869
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,P47869
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P47869
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,P47869
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P47869
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P47869
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P47869
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P47869
CHEMBL2106227,CCN=C1NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3,etifoxine,Launched,GABA receptor modulator,P47869
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P47869
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P47869
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P47869
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P47869
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P47869
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,P47869
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P47869
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P47869
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P47869
CHEMBL3054746,,"L-655,708",Preclinical,GABA receptor inverse agonist,P47869
CHEMBL4868978,,L-838417,Preclinical,GABA receptor partial agonist,P47869
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P47869
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P47869
CHEMBL4872812,,MRK-016,Phase 1,GABA receptor inverse agonist,P47869
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P47869
CHEMBL2105199,C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4,ocinaplon,Phase 3,GABA receptor modulator,P47869
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P47869
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P47869
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P47869
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P47869
CHEMBL4851136,,Ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,P47869
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P47869
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TP-003,Preclinical,GABA receptor inverse agonist,P47869
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P47869
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P47869
CHEMBL4877796,,ZK-93426,Phase 1,benzodiazepine receptor antagonist,P47869
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P34903
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P34903
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,P34903
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,P34903
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P34903
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,P34903
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P34903
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P34903
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P34903
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P34903
CHEMBL2106227,CCN=C1NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3,etifoxine,Launched,GABA receptor modulator,P34903
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P34903
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P34903
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P34903
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P34903
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P34903
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,P34903
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P34903
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P34903
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P34903
CHEMBL3054746,,"L-655,708",Preclinical,GABA receptor inverse agonist,P34903
CHEMBL4868978,,L-838417,Preclinical,GABA receptor partial agonist,P34903
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P34903
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P34903
CHEMBL4872812,,MRK-016,Phase 1,GABA receptor inverse agonist,P34903
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P34903
CHEMBL2105199,C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4,ocinaplon,Phase 3,GABA receptor modulator,P34903
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34903
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P34903
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P34903
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P34903
CHEMBL4851136,,Ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,P34903
CHEMBL4877829,,SB-205384,Preclinical,GABA receptor modulator,P34903
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P34903
CHEMBL1983350,CC(C)(C)C(/C=C/C1=CC2=C(C=C1)OCO2)O,stiripentol,Launched,GABA uptake inhibitor,P34903
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TP-003,Preclinical,GABA receptor inverse agonist,P34903
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P34903
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P34903
CHEMBL4877796,,ZK-93426,Phase 1,benzodiazepine receptor antagonist,P34903
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P31644
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P31644
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,P31644
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,P31644
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P31644
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,P31644
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P31644
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P31644
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P31644
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P31644
CHEMBL2106227,CCN=C1NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3,etifoxine,Launched,GABA receptor modulator,P31644
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P31644
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P31644
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P31644
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P31644
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P31644
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,P31644
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P31644
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P31644
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P31644
CHEMBL3054746,,"L-655,708",Preclinical,GABA receptor inverse agonist,P31644
CHEMBL4868978,,L-838417,Preclinical,GABA receptor partial agonist,P31644
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P31644
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P31644
CHEMBL4872812,,MRK-016,Phase 1,GABA receptor inverse agonist,P31644
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P31644
CHEMBL2105199,C1=CC=NC(=C1)C(=O)C2=C3N=CC=C(N3N=C2)C4=CC=NC=C4,ocinaplon,Phase 3,GABA receptor modulator,P31644
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P31644
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P31644
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P31644
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P31644
CHEMBL4851136,,Ro-19-4605,Preclinical,GABA benzodiazepine site receptor inverse agonist,P31644
CHEMBL4877829,,SB-205384,Preclinical,GABA receptor modulator,P31644
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P31644
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TP-003,Preclinical,GABA receptor inverse agonist,P31644
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P31644
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P31644
CHEMBL4877796,,ZK-93426,Phase 1,benzodiazepine receptor antagonist,P31644
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q16445
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q16445
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,Q16445
CHEMBL4859585,,bretazenil,Phase 2,GABA benzodiazepine site receptor partial agonist,Q16445
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q16445
CHEMBL1395823,COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2,CGS-20625,Phase 1,benzodiazepine receptor agonist|GABA benzodiazepine site receptor partial agonist,Q16445
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q16445
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,Q16445
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q16445
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,Q16445
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,Q16445
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,Q16445
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,Q16445
CHEMBL1568698,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@@](C4)(C)O)C)C,ganaxolone,Phase 3,GABA receptor modulator,Q16445
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q16445
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q16445
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,Q16445
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q16445
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,Q16445
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,Q16445
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q16445
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q16445
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q16445
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,Q16445
CHEMBL4877829,,SB-205384,Preclinical,GABA receptor modulator,Q16445
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q16445
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q16445
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P18505
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P18505
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P18505
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P18505
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P18505
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P18505
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P18505
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P18505
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P18505
CHEMBL15891,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,lindane,Launched,,P18505
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P18505
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P18505
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18505
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P18505
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P18505
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P18505
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P18505
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P47870
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P47870
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P47870
CHEMBL507327,C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl,CGS-9896,Preclinical,GABA receptor antagonist,P47870
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P47870
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P47870
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P47870
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P47870
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P47870
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P47870
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P47870
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P47870
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P47870
CHEMBL2359260,C1=CC(=C(C=C1Cl)Cl)/C(=C/N2C=NC=N2)/Cl.Cl,loreclezole,Phase 2,benzodiazepine receptor agonist,P47870
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P47870
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P47870
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P47870
CHEMBL4849017,,PHP-501,Preclinical,GABA receptor antagonist,P47870
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P47870
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P47870
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P47870
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P47870
CHEMBL213907,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,thiocolchicoside,Launched,GABA receptor antagonist,P47870
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P47870
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P47870
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,O14764
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,O14764
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,O14764
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O14764
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,O14764
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,O14764
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,O14764
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,O14764
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,O14764
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,O14764
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,O14764
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,O14764
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,O14764
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,O14764
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,O14764
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,O14764
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,O14764
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P78334
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P78334
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P78334
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P78334
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P78334
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P78334
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P78334
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P78334
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P78334
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P78334
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P78334
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P78334
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P78334
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P78334
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P78334
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P78334
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q8N1C3
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q8N1C3
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q8N1C3
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q8N1C3
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q8N1C3
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,Q8N1C3
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,Q8N1C3
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q8N1C3
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q8N1C3
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q8N1C3
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,Q8N1C3
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q8N1C3
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q8N1C3
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q8N1C3
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q8N1C3
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q8N1C3
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P18507
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P18507
CHEMBL1394514,CCCCOC(=O)C1=NC=C2C(=C1)C3=CC=CC=C3N2,beta-CCB,Launched,benzodiazepine receptor ligand,P18507
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P18507
CHEMBL507327,C1=CC=C2C(=C1)C3=C(C=N2)C(=O)N(N3)C4=CC=C(C=C4)Cl,CGS-9896,Preclinical,GABA receptor antagonist,P18507
CHEMBL4877059,,CL-218872,Phase 1,benzodiazepine receptor agonist,P18507
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P18507
CHEMBL210952,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C,eltanolone,Phase 3,GABA receptor positive allosteric modulator,P18507
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P18507
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P18507
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,P18507
CHEMBL4872115,,gabazine,Preclinical,GABA receptor antagonist,P18507
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P18507
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P18507
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P18507
CHEMBL3054746,,"L-655,708",Preclinical,GABA receptor inverse agonist,P18507
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P18507
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P18507
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18507
CHEMBL4849017,,PHP-501,Preclinical,GABA receptor antagonist,P18507
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P18507
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P18507
CHEMBL4853906,,Ro-15-4513,Preclinical,GABA benzodiazepine site receptor inverse agonist,P18507
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P18507
CHEMBL213907,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,thiocolchicoside,Launched,GABA receptor antagonist,P18507
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P18507
CHEMBL4869073,,ZK-93423,Phase 3,benzodiazepine receptor agonist,P18507
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q99928
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q99928
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q99928
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q99928
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q99928
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,Q99928
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,Q99928
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q99928
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q99928
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q99928
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,Q99928
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q99928
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q99928
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q99928
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q99928
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q99928
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,O00591
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,O00591
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,O00591
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O00591
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,O00591
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,O00591
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,O00591
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,O00591
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,O00591
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,O00591
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,O00591
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,O00591
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,O00591
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,O00591
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,O00591
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,O00591
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q9UN88
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q9UN88
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q9UN88
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q9UN88
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q9UN88
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,Q9UN88
CHEMBL4863733,,flumazenil,Launched,benzodiazepine receptor antagonist,Q9UN88
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q9UN88
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q9UN88
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q9UN88
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,Q9UN88
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q9UN88
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q9UN88
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q9UN88
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q9UN88
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q9UN88
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q05586
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q05586
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,Q05586
CHEMBL43527,CN(CCC1=CC(=C(C=C1)Cl)Cl)CC(COC2=CC=C(C=C2)NS(=O)(=O)C)O,AM-92016,Preclinical,potassium channel blocker,Q05586
CHEMBL4860463,,AMPA-(RS),Preclinical,glutamate receptor agonist,Q05586
CHEMBL4861521,,AMPA-(S),Preclinical,glutamate receptor agonist,Q05586
CHEMBL554054,CCC1=CC(=CC=C1)N(C)C(=NC2=CC=CC3=CC=CC=C32)N.Cl,aptiganel,Phase 3,glutamate receptor antagonist,Q05586
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q05586
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q05586
CHEMBL467084,C1=CC=C(C=C1)[C@H](CC2=CC=CC=N2)N,AZD6765,Phase 2,glutamate receptor antagonist,Q05586
CHEMBL334491,CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3,budipine,Launched,glutamate receptor antagonist,Q05586
CHEMBL4874719,,CPP,Phase 2,glutamate receptor antagonist,Q05586
CHEMBL771,C1[C@H](C(=O)NO1)N,cycloserine-(D),Launched,bacterial cell wall synthesis inhibitor,Q05586
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,Q05586
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q05586
CHEMBL4873317,,ditolylguanidine,Preclinical,sigma receptor agonist,Q05586
CHEMBL465477,C[C@]12C3=CC=CC=C3C[C@H](N1)C4=CC=CC=C24.C(=C\C(=O)O)\C(=O)O,dizocilpine-(+),Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4865095,,eliprodil,Phase 3,glutamate receptor antagonist,Q05586
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,Q05586
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q05586
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,Q05586
CHEMBL280828,C1=CC(=C(N=C1)C(=O)O)CC(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,Q05586
CHEMBL4858134,,ibotenic-acid,Preclinical,glutamate receptor agonist,Q05586
CHEMBL4849655,,kynurenic-acid,Phase 1,glutamate receptor antagonist,Q05586
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q05586
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q05586
CHEMBL4872187,,L-689560,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4858871,,L-701252,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4879070,,L-701324,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4854519,,NMDA,Preclinical,glutamate receptor agonist,Q05586
CHEMBL4864635,,perzinfotel,Phase 2,glutamate receptor antagonist,Q05586
CHEMBL1552984,C[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN,remacemide,Phase 3,glutamate receptor antagonist,Q05586
CHEMBL4862222,,SDZ-220-040,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL1331280,C1=CC=C(C(=C1)C2=CC(=CC(=C2)CP(=O)(O)O)C[C@@H](C(=O)O)N)Cl,SDZ-220-581,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q05586
CHEMBL140784,C1(=NNN=N1)C(C(=O)O)N,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,Q05586
CHEMBL1513845,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(R),Preclinical,glutamate receptor antagonist,Q05586
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,Q05586
CHEMBL4852498,,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,Q05586
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q12879
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q12879
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,Q12879
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q12879
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q12879
CHEMBL189477,C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O,CGP-37849,Phase 1,glutamate receptor antagonist,Q12879
CHEMBL4874719,,CPP,Phase 2,glutamate receptor antagonist,Q12879
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,Q12879
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q12879
CHEMBL4873317,,ditolylguanidine,Preclinical,sigma receptor agonist,Q12879
CHEMBL465477,C[C@]12C3=CC=CC=C3C[C@H](N1)C4=CC=CC=C24.C(=C\C(=O)O)\C(=O)O,dizocilpine-(+),Preclinical,glutamate receptor antagonist,Q12879
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,Q12879
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q12879
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,Q12879
CHEMBL280828,C1=CC(=C(N=C1)C(=O)O)CC(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,Q12879
CHEMBL4849655,,kynurenic-acid,Phase 1,glutamate receptor antagonist,Q12879
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q12879
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q12879
CHEMBL4872187,,L-689560,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL4879070,,L-701324,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL4859673,,midafotel,Phase 3,glutamate receptor antagonist,Q12879
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL4854519,,NMDA,Preclinical,glutamate receptor agonist,Q12879
CHEMBL4864635,,perzinfotel,Phase 2,glutamate receptor antagonist,Q12879
CHEMBL39664,C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O,selfotel,Phase 3,glutamate receptor antagonist,Q12879
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q12879
CHEMBL4864891,,TCN201,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL140784,C1(=NNN=N1)C(C(=O)O)N,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,Q12879
CHEMBL1513845,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(R),Preclinical,glutamate receptor antagonist,Q12879
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,Q12879
CHEMBL4852498,,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,Q12879
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q13224
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q13224
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,Q13224
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q13224
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q13224
CHEMBL189477,C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O,CGP-37849,Phase 1,glutamate receptor antagonist,Q13224
CHEMBL4856964,,CO-101244,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4874719,,CPP,Phase 2,glutamate receptor antagonist,Q13224
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,Q13224
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q13224
CHEMBL4873317,,ditolylguanidine,Preclinical,sigma receptor agonist,Q13224
CHEMBL465477,C[C@]12C3=CC=CC=C3C[C@H](N1)C4=CC=CC=C24.C(=C\C(=O)O)\C(=O)O,dizocilpine-(+),Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4865095,,eliprodil,Phase 3,glutamate receptor antagonist,Q13224
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,Q13224
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q13224
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,Q13224
CHEMBL508320,C=C[C@H]1[C@@H](OC=C2C1=CCOC2=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,gentiopicrin,Phase 3,glutamate receptor downregulator,Q13224
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,Q13224
CHEMBL280828,C1=CC(=C(N=C1)C(=O)O)CC(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,Q13224
CHEMBL1256662,CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3.C(C(C(=O)O)O)(C(=O)O)O,ifenprodil,Launched,adrenergic receptor antagonist|glutamate receptor antagonist,Q13224
CHEMBL4849655,,kynurenic-acid,Phase 1,glutamate receptor antagonist,Q13224
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q13224
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q13224
CHEMBL4872187,,L-689560,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4879070,,L-701324,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4859673,,midafotel,Phase 3,glutamate receptor antagonist,Q13224
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4854519,,NMDA,Preclinical,glutamate receptor agonist,Q13224
CHEMBL4864635,,perzinfotel,Phase 2,glutamate receptor antagonist,Q13224
CHEMBL1624380,CN1CCC2=CC(=C(C=C2C1CCC3=CC=C(C=C3)Cl)O)OC,Ro-04-5595,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4859784,,Ro-25-6981,Preclinical,glutamate receptor antagonist|monamine transporter modulator,Q13224
CHEMBL39664,C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O,selfotel,Phase 3,glutamate receptor antagonist,Q13224
CHEMBL140784,C1(=NNN=N1)C(C(=O)O)N,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,Q13224
CHEMBL3989673,C[C@@H]([C@H](C1=CC=C(C=C1)O)O)N2CCC(CC2)(C3=CC=CC=C3)O.CS(=O)(=O)O.O.O.O,traxoprodil,Phase 2,glutamate receptor antagonist,Q13224
CHEMBL1513845,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(R),Preclinical,glutamate receptor antagonist,Q13224
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,Q13224
CHEMBL4852498,,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,Q13224
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q14957
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,Q14957
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q14957
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q14957
CHEMBL189477,C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O,CGP-37849,Phase 1,glutamate receptor antagonist,Q14957
CHEMBL4877584,,CIQ,Preclinical,glutamate receptor potentiator,Q14957
CHEMBL4874719,,CPP,Phase 2,glutamate receptor antagonist,Q14957
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,Q14957
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q14957
CHEMBL465477,C[C@]12C3=CC=CC=C3C[C@H](N1)C4=CC=CC=C24.C(=C\C(=O)O)\C(=O)O,dizocilpine-(+),Preclinical,glutamate receptor antagonist,Q14957
CHEMBL4860425,,DQP-1105,Preclinical,glutamate receptor antagonist,Q14957
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,Q14957
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q14957
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,Q14957
CHEMBL280828,C1=CC(=C(N=C1)C(=O)O)CC(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,Q14957
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q14957
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q14957
CHEMBL4872187,,L-689560,Preclinical,glutamate receptor antagonist,Q14957
CHEMBL4879070,,L-701324,Preclinical,glutamate receptor antagonist,Q14957
CHEMBL4859673,,midafotel,Phase 3,glutamate receptor antagonist,Q14957
CHEMBL4854519,,NMDA,Preclinical,glutamate receptor agonist,Q14957
CHEMBL39664,C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O,selfotel,Phase 3,glutamate receptor antagonist,Q14957
CHEMBL140784,C1(=NNN=N1)C(C(=O)O)N,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,Q14957
CHEMBL1513845,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(R),Preclinical,glutamate receptor antagonist,Q14957
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,Q14957
CHEMBL4852498,,7-chlorokynurenic-acid,Preclinical,glutamate receptor antagonist,Q14957
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,O15399
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,O15399
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,O15399
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,O15399
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,O15399
CHEMBL189477,C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O,CGP-37849,Phase 1,glutamate receptor antagonist,O15399
CHEMBL4877584,,CIQ,Preclinical,glutamate receptor potentiator,O15399
CHEMBL4874719,,CPP,Phase 2,glutamate receptor antagonist,O15399
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,O15399
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O15399
CHEMBL465477,C[C@]12C3=CC=CC=C3C[C@H](N1)C4=CC=CC=C24.C(=C\C(=O)O)\C(=O)O,dizocilpine-(+),Preclinical,glutamate receptor antagonist,O15399
CHEMBL4860425,,DQP-1105,Preclinical,glutamate receptor antagonist,O15399
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,O15399
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O15399
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,O15399
CHEMBL280828,C1=CC(=C(N=C1)C(=O)O)CC(=O)O,homoquinolinic-acid,Preclinical,glutamate receptor agonist,O15399
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,O15399
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O15399
CHEMBL4872187,,L-689560,Preclinical,glutamate receptor antagonist,O15399
CHEMBL4879070,,L-701324,Preclinical,glutamate receptor antagonist,O15399
CHEMBL4859673,,midafotel,Phase 3,glutamate receptor antagonist,O15399
CHEMBL4854519,,NMDA,Preclinical,glutamate receptor agonist,O15399
CHEMBL39664,C1CN[C@@H](C[C@@H]1CP(=O)(O)O)C(=O)O,selfotel,Phase 3,glutamate receptor antagonist,O15399
CHEMBL140784,C1(=NNN=N1)C(C(=O)O)N,tetrazol-5-yl-glycine-(RS),Preclinical,glutamate receptor agonist,O15399
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,O15399
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,Q8TCU5
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q8TCU5
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,Q8TCU5
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q8TCU5
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,Q8TCU5
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q8TCU5
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,Q8TCU5
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,Q8TCU5
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q8TCU5
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,Q8TCU5
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q8TCU5
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q8TCU5
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,O60391
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,O60391
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,O60391
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O60391
CHEMBL1094,C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N,felbamate,Launched,glutamate receptor antagonist,O60391
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O60391
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,O60391
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O60391
CHEMBL1201293,CC(=O)NCCCS(=O)(=O)O,acamprosate,Launched,glutamate receptor antagonist,P41594
CHEMBL1616372,CN(C)C1=NC(=C(N=C1Cl)C(=O)NC2=CN=CC=C2)N,ACDPP,Preclinical,glutamate receptor antagonist,P41594
CHEMBL4866836,,ADX-10059,Phase 2,glutamate receptor negative allosteric modulator,P41594
CHEMBL4867185,,ADX-47273,Preclinical,glutamate receptor modulator,P41594
CHEMBL4866489,,AZD9272,Preclinical,glutamate receptor antagonist,P41594
CHEMBL4861131,,basimglurant,Phase 2,glutamate receptor antagonist,P41594
CHEMBL4850998,,CDPPB,Preclinical,glutamate receptor positive allosteric modulator,P41594
CHEMBL1611192,C1=CC(=C(C=C1O)[C@H](C(=O)O)N)Cl,CHPG,Preclinical,glutamate receptor agonist,P41594
CHEMBL3410223,CC1=C(N=C(N1C2=CC=C(C=C2)OC(F)(F)F)C)C#CC3=CC(=NC=C3)Cl,CTEP,Preclinical,glutamate receptor antagonist,P41594
CHEMBL4849274,,DFB,Preclinical,glutamate receptor agonist,P41594
CHEMBL74987,C1=C(C=C(C=C1O)O)[C@H](C(=O)O)N,dihydroxyphenylglycine,Preclinical,glutamate receptor agonist,P41594
CHEMBL4871336,,dipraglurant,Phase 2,glutamate receptor negative allosteric modulator,P41594
CHEMBL3334989,COC1=CC=CC(=C1)/C=N/N=C/C2=CC(=CC=C2)OC,DMeOB,Preclinical,glutamate receptor modulator,P41594
CHEMBL2103779,CN\1CC(=O)N/C1=N/C(=O)NC2=CC(=CC=C2)Cl.O,fenobam,Phase 2,glutamate receptor antagonist,P41594
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,P41594
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,P41594
CHEMBL2431212,CC(C)NC(=O)C1=NC=C(C=C1)C#CC2=CC=NC=C2,LSN-2463359,Preclinical,glutamate receptor positive allosteric modulator,P41594
CHEMBL3087515,CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O,mavoglurant,Phase 2,glutamate receptor antagonist,P41594
CHEMBL4846859,,MPEP,Preclinical,glutamate receptor antagonist,P41594
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,P41594
CHEMBL4867473,,SIB-1757,Preclinical,glutamate receptor antagonist,P41594
CHEMBL4871653,,SIB-1893,Preclinical,glutamate receptor antagonist,P41594
CHEMBL2151790,CCCCOC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)F,VU0357121,Preclinical,glutamate receptor positive allosteric modulator,P41594
CHEMBL4870190,,VU0360172,Preclinical,glutamate receptor positive allosteric modulator,P41594
CHEMBL4873033,,VU1545,Preclinical,glutamate receptor positive allosteric modulator,P41594
CHEMBL4865465,,VU29,Preclinical,glutamate receptor potentiator,P41594
CHEMBL3334990,C1=CC(=CC(=C1)Cl)/C=N/N=C/C2=CC(=CC=C2)Cl,"3,3'-dichlorobenzaldazine",Preclinical,glutamate receptor modulator,P41594
CHEMBL128772,C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(S),Preclinical,glutamate receptor antagonist,P41594
CHEMBL404271,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,acarbose,Launched,glucosidase inhibitor,P04746
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P04746
CHEMBL404271,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](OC([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,acarbose,Launched,glucosidase inhibitor,O43451
CHEMBL1908365,C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O)CO)O)O)O)O,D-(+)-maltose,Preclinical,,O43451
CHEMBL1561,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,miglitol,Launched,glucosidase inhibitor,O43451
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,O43451
CHEMBL476960,C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO,voglibose,Launched,glucosidase inhibitor,O43451
CHEMBL642,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,acebutolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1256179,CC(C)NCC(COC1=CC=CC=C1CC=C)O.Cl,alprenolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1083993,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,amiodarone,Launched,potassium channel blocker,P08588
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08588
CHEMBL4851038,,atenolol-(+/-),Launched,adrenergic receptor antagonist,P08588
CHEMBL1691,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O.Cl,betaxolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1527815,CC(C)NC[C@H](COC1=CC=C(C=C1)COCCOC(C)C)O,bisoprolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL4864913,,BRL-37344,Phase 2,adrenergic receptor agonist,P08588
CHEMBL2106646,CCCCC1=CN=C(C=C1)C(=O)N,bupicomide,Phase 1,adrenergic receptor antagonist,P08588
CHEMBL305380,CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O,bupranolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P08588
CHEMBL4850111,,carazolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1201002,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl,carteolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1201167,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.OP(=O)(O)O,carvedilol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1742424,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,celiprolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL4873800,,CGP-12177,Phase 1,adrenergic receptor agonist,P08588
CHEMBL4870562,,CGP-20712A,Preclinical,adrenergic receptor antagonist,P08588
CHEMBL1374751,CC(C)NCC(C1=CC(=C(C=C1)N)C#N)O,cimaterol,Preclinical,adrenergic receptor agonist,P08588
CHEMBL156791,CC(C)(C)NCC(COC1=C(C=CC(=C1)Cl)Cl)O,cloranolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1902627,CC(C)NCC(C1=CC=CC=C1Cl)O,clorprenaline,Launched,adrenergic receptor agonist,P08588
CHEMBL378501,CC(C)(C)NCC(COC1=CC=CC2=C1C=C(N2)C#N)O,cyanopindolol,Phase 2,adrenergic receptor antagonist,P08588
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08588
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P08588
CHEMBL1200418,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O.Cl,dobutamine,Launched,adrenergic receptor agonist,P08588
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P08588
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P08588
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P08588
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P08588
CHEMBL1201115,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl,esmolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL3187408,CCNCC(C1=CC(=CC=C1)O)O.Cl,etilefrine,Launched,adrenergic receptor agonist,P08588
CHEMBL11268,C1=CC=C(C=C1)NC(=O)NCCNCC(COC2=CC=CC=C2C#N)O,ICI-89406,Phase 1,adrenergic receptor antagonist,P08588
CHEMBL1095777,CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,indacaterol,Launched,adrenergic receptor agonist,P08588
CHEMBL1160723,CC(C)NC[C@@H](C1=CC(=C(C=C1)O)O)O,isoprenaline,Launched,adrenergic receptor agonist,P08588
CHEMBL4845858,,L-755507,Preclinical,adrenergic receptor agonist,P08588
CHEMBL429,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,labetalol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1742466,CC1(OC[C@H](O1)COC(=O)CCC2=CC=C(C=C2)OC[C@H](CNCCNC(=O)N3CCOCC3)O)C,landiolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1200837,CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O.Cl,levobetaxolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1704116,CC(C)(C)NC[C@H](COC1=CC=CC2=C1CCCC2=O)O.Cl,levobunolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08588
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P08588
CHEMBL3989566,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(=C/C(=O)O)\C(=O)O,metoprolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL2095212,C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,mirabegron,Launched,adrenergic receptor agonist,P08588
CHEMBL521606,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,nadolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1201731,C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O.Cl,nebivolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL4853301,,nifenalol,Launched,adrenergic receptor antagonist,P08588
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P08588
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08588
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08588
CHEMBL1514683,CC(C)NC[C@H](COC1=CC=CC=C1OCC=C)O,oxprenolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1200363,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,penbutolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL4872837,,practolol,Withdrawn,adrenergic receptor antagonist,P08588
CHEMBL1201063,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.Cl,propafenone,Launched,antiarrhythmic,P08588
CHEMBL1358662,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL545328,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(S),Preclinical,adrenergic receptor antagonist,P08588
CHEMBL471,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,sotalol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1326499,CCC1=CC=CC=C1OC[C@H](CN[C@H]2CCCC3=CC=CC=C23)O,SR-59230A,Preclinical,adrenergic receptor antagonist,P08588
CHEMBL152067,CC(C)(C)NCC(COC1=CC=C(C=C1)NC(=O)NC2CCCCC2)O,talinolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL1200870,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O.C(=C\C(=O)O)\C(=O)O,timolol,Launched,adrenergic receptor antagonist,P08588
CHEMBL2111163,CC(C)NCC(COC1=CC=CC=C1SC)O,tiprenolol,Phase 2,adrenergic receptor antagonist,P08588
CHEMBL418192,CC1=CC=CC=C1OCC(CNCCOC2=CC=C(C=C2)C(=O)N)O,tolamolol,Phase 3,adrenergic receptor antagonist,P08588
CHEMBL1329567,C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C(=C/C(=O)O)\C(=O)O,xamoterol,Phase 3,adrenergic receptor agonist,P08588
CHEMBL1256805,CCN(CC)CCNC(=O)C1=CC=C(C=C1)NC(=O)C.Cl,acecainide,Phase 3,polarization inhibitor,Q14524
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q14524
CHEMBL2104501,CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3.Cl,aprindine,Launched,voltage-gated sodium channel blocker,Q14524
CHEMBL2105910,CC(COC1=CC=CC=C1CC2=CC=CC=C2)N3CCCCC3,benproperine,Launched,antitussive,Q14524
CHEMBL1374379,CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC,benzonatate,Launched,local anesthetic,Q14524
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q14524
CHEMBL1086,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,cinchocaine,Launched,sodium channel blocker,Q14524
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,Q14524
CHEMBL1200478,CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2.Cl,dyclonine,Launched,sodium channel blocker,Q14524
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q14524
CHEMBL1095,CCN1C(=O)C(NC1=O)C2=CC=CC=C2,ethotoin,Launched,hydantoin antiepileptic,Q14524
CHEMBL1200822,CC(=O)O.C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,flecainide,Launched,sodium channel blocker,Q14524
CHEMBL1201336,C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3,fosphenytoin,Launched,sodium channel blocker,Q14524
CHEMBL1604244,C[C@@H](CNC1CCCCC1)OC(=O)C2=CC=CC=C2,hexylcaine,Launched,sodium channel blocker,Q14524
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q14524
CHEMBL4852384,,licarbazepine,Phase 3,voltage-gated sodium channel blocker,Q14524
CHEMBL1200409,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.O.Cl,lidocaine,Launched,histamine receptor agonist,Q14524
CHEMBL1404407,COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC.Cl,lomerizine,Launched,calcium channel blocker,Q14524
CHEMBL1743264,CC[C@@]1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,mephenytoin,Launched,hydantoin antiepileptic,Q14524
CHEMBL558,CC1=C(C(=CC=C1)C)OCC(C)N,mexiletine,Launched,sodium channel blocker,Q14524
CHEMBL4878380,,moracizine,Withdrawn,sodium channel blocker,Q14524
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q14524
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q14524
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q14524
CHEMBL4859373,,pilsicainide,Launched,sodium channel blocker,Q14524
CHEMBL1200586,CCCNC(C)C(=O)NC1=CC=CC=C1C.Cl,prilocaine,Launched,local anesthetic,Q14524
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q14524
CHEMBL640,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,procainamide,Launched,sodium channel blocker,Q14524
CHEMBL1196,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,proxymetacaine,Launched,sodium channel blocker,Q14524
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q14524
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q14524
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q14524
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,Q14524
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q14524
CHEMBL1590144,CCOC(=O)NC1=CC2=C(CCC3=CC=CC=C3N2C(=O)CN(C)C)C=C1.Cl,tiracizine,Withdrawn,sodium channel blocker,Q14524
CHEMBL1762,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,tocainide,Launched,sodium channel blocker,Q14524
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q14524
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q14524
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q14524
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q14524
CHEMBL4303558,CC(=O)OC1CN2CCC1CC2.Cl,aceclidine,Launched,acetylcholine receptor agonist,P08912
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P08912
CHEMBL551466,C1C[N+]2(CCC1[C@H](C2)OC(=O)C(C3=CC=CS3)(C4=CC=CS4)O)CCCOC5=CC=CC=C5.[Br-],aclidinium,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08912
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P08912
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08912
CHEMBL4865574,,atropine-oxide,Preclinical,acetylcholine receptor antagonist,P08912
CHEMBL1201067,CC(C(=O)O)O.C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O,biperiden,Launched,acetylcholine receptor antagonist,P08912
CHEMBL3039186,COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7C4N2C(=O)CC7OCC=C6C5)OC,brucine,Preclinical,glycine receptor antagonist,P08912
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,P08912
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P08912
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08912
CHEMBL1200935,C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5.Br,darifenacin,Launched,acetylcholine receptor antagonist,P08912
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08912
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P08912
CHEMBL1201765,CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O,fesoterodine,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1201027,C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-],glycopyrrolate,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1200851,C[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O)C.[Br-],homatropine-methylbromide,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P08912
CHEMBL1621597,CC(C)[N+]1([C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C,ipratropium,Launched,acetylcholine receptor antagonist,P08912
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P08912
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08912
CHEMBL2359044,CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24.Cl,metixene,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08912
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08912
CHEMBL4867004,,otenzepad,Phase 3,acetylcholine receptor antagonist,P08912
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P08912
CHEMBL1213136,CC[C@H]1[C@H](COC1=O)CC2=CN=CN2C.[N+](=O)(O)[O-],pilocarpine,Launched,acetylcholine receptor agonist,P08912
CHEMBL1531864,CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4.Cl.Cl,pirenzepine,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P08912
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08912
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P08912
CHEMBL1200803,C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O,solifenacin-succinate,Launched,acetylcholine receptor antagonist,P08912
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P08912
CHEMBL1200871,CC1=CC(=C(C=C1)O)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O,tolterodine,Launched,acetylcholine receptor antagonist,P08912
CHEMBL2107687,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],valethamate,Launched,acetylcholine receptor antagonist,P08912
CHEMBL4847041,,VU0238429,Preclinical,acetylcholine receptor allosteric modulator,P08912
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P08912
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08912
CHEMBL4874798,,4-DAMP,Preclinical,cholinergic receptor antagonist,P08912
CHEMBL93645,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,aceclofenac,Launched,prostanoid receptor antagonist,P35354
CHEMBL189171,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,acemetacin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,P35354
CHEMBL25146,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)O,amfenac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL2096646,C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+],aminosalicylate,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1566249,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,ampiroxicam,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1766570,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC,amtolmetin-guacil,Launched,cyclooxygenase inhibitor,P35354
CHEMBL3187683,CCCCCC[C@@H](CCC)C(=O)O,arundic-acid,Phase 2/Phase 3,astrocyte modulating agent,P35354
CHEMBL4871092,,NO-ASA,Phase 2,cyclooxygenase inhibitor,P35354
CHEMBL1164301,COC1=CC(=C(C=C1C=O)OC)OC,asaraldehyde,Preclinical,cyclooxygenase inhibitor,P35354
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1483341,CCC[C@@H]1C(=O)N2C3=C(C=CC(=C3)C)N=C(N2C1=O)N(C)C,azapropazone,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL1200760,C1=CC(=CC=C1C(=O)NCCC(=O)[O-])N=NC2=CC(=C(C=C2)[O-])C(=O)O.[Na+].[Na+],balsalazide,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1089221,C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)O,bendazac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1077,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,bromfenac,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL4872563,,carprofen,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4869523,,celecoxib,Launched,cyclooxygenase inhibitor,P35354
CHEMBL2104122,CC(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)O,cicloprofen,Preclinical,cyclooxygenase inhibitor,P35354
CHEMBL1332971,CC1=C(C=CC=C1Cl)NC2=C(C=CC=N2)C(=O)O,clonixin,Preclinical,cyclooxygenase inhibitor,P35354
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P35354
CHEMBL4856703,,deracoxib,Launched,cyclooxygenase inhibitor,P35354
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4745456,[2H]C1=C(C(=C(C(=C1C2=C(C=C(C=C2)F)F)[2H])C(=O)O)O)[2H],diflunisal,Launched,prostanoid receptor antagonist,P35354
CHEMBL465183,CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O,dihomo-gamma-linolenic-acid,Phase 2,prostanoid receptor agonist,P35354
CHEMBL367149,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,doconexent,Launched,PPAR receptor agonist,P35354
CHEMBL4865944,,DUP-697,Phase 1,cyclooxygenase inhibitor,P35354
CHEMBL4855999,,epirizole,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1315939,CCC1=C2C(=CC=C1)C3=C(N2)[C@](OCC3)(CC)CC(=O)O,etodolac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1451633,C1=CC=C(C(=C1)C(=O)OCCOCCO)NC2=CC=CC(=C2)C(F)(F)F,etofenamate,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4871925,,etoricoxib,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1886408,CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,felbinac-ethyl,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4876516,,fenbufen,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4877535,,fentiazac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4851984,,firocoxib,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4303327,CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F,FK-3311,Phase 2,cyclooxygenase inhibitor,P35354
CHEMBL2105075,C1=CC=C(C(=C1)C(=O)OCC(CO)O)NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F,floctafenine,Launched,cyclooxygenase inhibitor,P35354
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P35354
CHEMBL563,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,flurbiprofen-(S)-(+),Launched,cyclooxygenase inhibitor,P35354
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,P35354
CHEMBL287275,C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O,fosfosal,Launched,phosphodiesterase inhibitor,P35354
CHEMBL4868962,,gamma-linolenic-acid,Phase 2,cyclooxygenase inhibitor|prostanoid receptor agonist,P35354
CHEMBL4868425,,ginsenoside-C-K,Phase 1,NFkB pathway inhibitor|nitric oxide synthase inhibitor,P35354
CHEMBL16901,C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C,honokiol,Phase 3,AKT inhibitor,P35354
CHEMBL3989408,CC(C)CC1=CC=C(C=C1)C(C)C(=O)[O-].O.O.[Na+],ibuprofen-(S),Launched,cyclooxygenase inhibitor,P35354
CHEMBL2106254,CC(C)CC1=CC=C(C=C1)C(C)C(=O)OCC2=CC=CC=N2,ibuprofen-piconol,Launched,cyclooxygenase inhibitor,P35354
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,P35354
CHEMBL4862464,,idazoxan,Phase 3,adrenergic receptor antagonist,P35354
CHEMBL2107455,CS(=O)(=O)NC1=C(C=C2C(=C1)OC=C(C2=O)NC=O)OC3=CC=CC=C3,iguratimod,Launched,cyclooxygenase inhibitor|NFkB pathway inhibitor,P35354
CHEMBL1765292,CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indobufen,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor,P35354
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL264931,C[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indoprofen,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL4878474,,isoxicam,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL571,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,ketoprofen,Launched,cyclooxygenase inhibitor,P35354
CHEMBL469,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,ketorolac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4876408,,licofelone,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,P35354
CHEMBL1569487,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,lornoxicam,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4875053,,loxoprofen,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL404108,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,lumiracoxib,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL686,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,mefenamic-acid,Launched,cyclooxygenase inhibitor,P35354
CHEMBL599,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,meloxicam,Launched,cyclooxygenase inhibitor,P35354
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL4795894,CC(C)CC1=CC=C(C=C1)C(C)C(=O)OC2=CC=CC=C2OC,metoxibutropate,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1070,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,nabumetone,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1618254,C[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,naproxen,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1021,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,nepafenac,Launched,cyclooxygenase inhibitor,P35354
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P35354
CHEMBL56367,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,nimesulide,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1200463,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)[O-])C3=CC=CC=C3.[K+],oxaprozin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL112,CC(=O)NC1=CC=C(C=C1)O,paracetamol,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1526434,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)O,phenazone,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4846367,,phenylbutazone,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL4846697,,piroxicam,Launched,cyclooxygenase inhibitor,P35354
CHEMBL2105825,CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CC1)CCOC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C)NC(=O)C5=CC=CC=C5,proglumetacin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1851805,CCN(CC)CC(=O)OC1=CC=C(C=C1)NC(=O)C,propacetamol,Launched,cyclooxygenase inhibitor,P35354
CHEMBL268501,CC1=CC2=C(C=C1)C(=NC(=O)N2C(C)C)C3=CC=CC=C3,proquazone,Launched,cyclooxygenase inhibitor,P35354
CHEMBL4303505,COC1=CC(=CC(=C1)C=CC2=CC=C(C=C2)O)OC,pterostilbene,Phase 2/Phase 3,cyclooxygenase inhibitor|PPAR receptor agonist,P35354
CHEMBL165,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,resveratrol,Launched,cytochrome P450 inhibitor|SIRT activator,P35354
CHEMBL4858819,,rofecoxib,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL85139,C1CN2C(=NC3=CC=CC=C3C2=O)C4=C1C5=CC=CC=C5N4,rutaecarpine,Preclinical,cyclooxygenase inhibitor,P35354
CHEMBL4847871,,RWJ-67657,Phase 1,MAP kinase inhibitor,P35354
CHEMBL424,C1=CC=C(C(=C1)C(=O)O)O,salicylic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P35354
CHEMBL154111,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,sasapyrine,Launched,NFkB pathway inhibitor,P35354
CHEMBL4858276,,SB-239063,Preclinical,p38 MAPK inhibitor,P35354
CHEMBL4854148,,SC-236,Preclinical,cyclooxygenase inhibitor,P35354
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P35354
CHEMBL956,CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,suprofen,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL4857686,,tenoxicam,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1234071,C1CSS[C@H]1CCCCC(=O)O,thioctic-acid,Launched,reducing agent,P35354
CHEMBL365795,CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O,tiaprofenic-acid,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1200613,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)[O-].[Na+],tolmetin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL1054,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,trichlormethiazide,Launched,chloride channel blocker,P35354
CHEMBL4303336,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(C4=CC=CC=C4)C(=O)O,tropesin,Launched,cyclooxygenase inhibitor,P35354
CHEMBL2105605,CCCCOC(=O)C1=CC=CC=C1NC2=CC=CC(=C2)C(F)(F)F,ufenamate,Launched,cyclooxygenase inhibitor,P35354
CHEMBL865,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,valdecoxib,Withdrawn,cyclooxygenase inhibitor,P35354
CHEMBL2104464,CC(C1=CC=C(C2=CC=CC=C21)C3CCCCC3)C(=O)O,vedaprofen,Launched,anti-inflammatory agent,P35354
CHEMBL189171,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,acemetacin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL94081,C=CCOC1=C(C=C(C=C1)CC(=O)O)Cl,alclofenac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL25146,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)O,amfenac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL2096646,C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+],aminosalicylate,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1566249,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,ampiroxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1766570,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)NCC(=O)OC3=CC=CC=C3OC,amtolmetin-guacil,Launched,cyclooxygenase inhibitor,P23219
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,P23219
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1200760,C1=CC(=CC=C1C(=O)NCCC(=O)[O-])N=NC2=CC(=C(C=C2)[O-])C(=O)O.[Na+].[Na+],balsalazide,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1089221,C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)O,bendazac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1077,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,bromfenac,Withdrawn,cyclooxygenase inhibitor,P23219
CHEMBL4868707,,cianidanol,Withdrawn,fatty acid synthase inhibitor,P23219
CHEMBL2104122,CC(C1=CC2=C(C=C1)C3=CC=CC=C3C2)C(=O)O,cicloprofen,Preclinical,cyclooxygenase inhibitor,P23219
CHEMBL1332971,CC1=C(C=CC=C1Cl)NC2=C(C=CC=N2)C(=O)O,clonixin,Preclinical,cyclooxygenase inhibitor,P23219
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P23219
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL4863188,,diethylcarbamazine,Launched,lipoxygenase inhibitor,P23219
CHEMBL4745456,[2H]C1=C(C(=C(C(=C1C2=C(C=C(C=C2)F)F)[2H])C(=O)O)O)[2H],diflunisal,Launched,prostanoid receptor antagonist,P23219
CHEMBL465183,CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O,dihomo-gamma-linolenic-acid,Phase 2,prostanoid receptor agonist,P23219
CHEMBL367149,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,doconexent,Launched,PPAR receptor agonist,P23219
CHEMBL1213420,CN1C2=C(C3=CC=CC=C3S1(=O)=O)OC(=O)N(C2=O)C4=CC=CC=N4,droxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL4855999,,epirizole,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1451633,C1=CC=C(C(=C1)C(=O)OCCOCCO)NC2=CC=CC(=C2)C(F)(F)F,etofenamate,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1886408,CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,felbinac-ethyl,Launched,cyclooxygenase inhibitor,P23219
CHEMBL4876516,,fenbufen,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1297,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,fenoprofen,Launched,prostaglandin inhibitor,P23219
CHEMBL4877535,,fentiazac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL2105075,C1=CC=C(C(=C1)C(=O)OCC(CO)O)NC2=C3C=CC=C(C3=NC=C2)C(F)(F)F,floctafenine,Launched,cyclooxygenase inhibitor,P23219
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P23219
CHEMBL563,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,flurbiprofen-(S)-(+),Launched,cyclooxygenase inhibitor,P23219
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,P23219
CHEMBL287275,C1=CC=C(C(=C1)C(=O)O)OP(=O)(O)O,fosfosal,Launched,phosphodiesterase inhibitor,P23219
CHEMBL4868962,,gamma-linolenic-acid,Phase 2,cyclooxygenase inhibitor|prostanoid receptor agonist,P23219
CHEMBL16901,C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C,honokiol,Phase 3,AKT inhibitor,P23219
CHEMBL3989408,CC(C)CC1=CC=C(C=C1)C(C)C(=O)[O-].O.O.[Na+],ibuprofen-(S),Launched,cyclooxygenase inhibitor,P23219
CHEMBL2106254,CC(C)CC1=CC=C(C=C1)C(C)C(=O)OCC2=CC=CC=N2,ibuprofen-piconol,Launched,cyclooxygenase inhibitor,P23219
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,P23219
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P23219
CHEMBL1765292,CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indobufen,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor,P23219
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL264931,C[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indoprofen,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P23219
CHEMBL4878474,,isoxicam,Withdrawn,cyclooxygenase inhibitor,P23219
CHEMBL571,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,ketoprofen,Launched,cyclooxygenase inhibitor,P23219
CHEMBL469,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,ketorolac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1569487,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,lornoxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL404108,CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O,lumiracoxib,Withdrawn,cyclooxygenase inhibitor,P23219
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P23219
CHEMBL686,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,mefenamic-acid,Launched,cyclooxygenase inhibitor,P23219
CHEMBL599,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,meloxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,P23219
CHEMBL461522,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O,metamizole,Withdrawn,cyclooxygenase inhibitor|opioid receptor agonist,P23219
CHEMBL4795894,CC(C)CC1=CC=C(C=C1)C(C)C(=O)OC2=CC=CC=C2OC,metoxibutropate,Launched,cyclooxygenase inhibitor,P23219
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,P23219
CHEMBL259972,COC1=CC=C(C=C1)C2=C(ON=C2C3=CC=C(C=C3)OC)CC(=O)O,mofezolac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1070,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,nabumetone,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1618254,C[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,naproxen,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1021,C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N,nepafenac,Launched,cyclooxygenase inhibitor,P23219
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P23219
CHEMBL56367,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,nimesulide,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1234916,CC(=O)OC[C@@H](C(=O)O)N,O-acetyl-L-serine,Preclinical,,P23219
CHEMBL1200463,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)[O-])C3=CC=CC=C3.[K+],oxaprozin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL112,CC(=O)NC1=CC=C(C=C1)O,paracetamol,Launched,cyclooxygenase inhibitor,P23219
CHEMBL16073,CCOC1=CC=C(C=C1)NC(=O)C,phenacetin,Withdrawn,cyclooxygenase inhibitor,P23219
CHEMBL1526434,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)O,phenazone,Launched,cyclooxygenase inhibitor,P23219
CHEMBL4846367,,phenylbutazone,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P23219
CHEMBL4846697,,piroxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL2105825,CCCN(CCC)C(=O)C(CCC(=O)OCCCN1CCN(CC1)CCOC(=O)CC2=C(N(C3=C2C=C(C=C3)OC)C(=O)C4=CC=C(C=C4)Cl)C)NC(=O)C5=CC=CC=C5,proglumetacin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL268501,CC1=CC2=C(C=C1)C(=NC(=O)N2C(C)C)C3=CC=CC=C3,proquazone,Launched,cyclooxygenase inhibitor,P23219
CHEMBL24147,C1=CC(=CC(=C1)O)O,resorcinol,Launched,phosphodiesterase inhibitor,P23219
CHEMBL165,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,resveratrol,Launched,cytochrome P450 inhibitor|SIRT activator,P23219
CHEMBL424,C1=CC=C(C(=C1)C(=O)O)O,salicylic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P23219
CHEMBL154111,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,sasapyrine,Launched,NFkB pathway inhibitor,P23219
CHEMBL4867463,,SC-560,Preclinical,cyclooxygenase inhibitor,P23219
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P23219
CHEMBL956,CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O,suprofen,Withdrawn,cyclooxygenase inhibitor,P23219
CHEMBL1908355,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,tenidap,Phase 3,cyclooxygenase inhibitor,P23219
CHEMBL4857686,,tenoxicam,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1200613,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)[O-].[Na+],tolmetin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL1054,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,trichlormethiazide,Launched,chloride channel blocker,P23219
CHEMBL1332032,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,P23219
CHEMBL4303336,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(C4=CC=CC=C4)C(=O)O,tropesin,Launched,cyclooxygenase inhibitor,P23219
CHEMBL2105605,CCCCOC(=O)C1=CC=CC=C1NC2=CC=CC(=C2)C(F)(F)F,ufenamate,Launched,cyclooxygenase inhibitor,P23219
CHEMBL638,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,voriconazole,Launched,cytochrome P450 inhibitor,P23219
CHEMBL2105945,CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O,aceneuramic-acid,Phase 3,,P02795
CHEMBL2105945,CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O,aceneuramic-acid,Phase 3,,P23141
CHEMBL4861533,,apoptosis-activator-II,Preclinical,carboxylesterase inhibitor,P02795
CHEMBL4861533,,apoptosis-activator-II,Preclinical,carboxylesterase inhibitor,P23141
CHEMBL4878433,,avasimibe,Phase 3,ACAT inhibitor,P02795
CHEMBL4878433,,avasimibe,Phase 3,ACAT inhibitor,P23141
CHEMBL4853793,,benzoin,Preclinical,,P02795
CHEMBL4853793,,benzoin,Preclinical,,P23141
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P02795
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P23141
CHEMBL4861492,,CI-976,Phase 1,ACAT inhibitor,P02795
CHEMBL4861492,,CI-976,Phase 1,ACAT inhibitor,P23141
CHEMBL1200340,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O,oseltamivir-phosphate,Launched,neuraminidase inhibitor,P02795
CHEMBL1200340,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O,oseltamivir-phosphate,Launched,neuraminidase inhibitor,P23141
CHEMBL4869371,,probucol,Launched,atherogenesis inhibitor,P02795
CHEMBL4869371,,probucol,Launched,atherogenesis inhibitor,P23141
CHEMBL2105945,CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O,aceneuramic-acid,Phase 3,,P16581
CHEMBL4874603,,A205804,Preclinical,ICAM1 expression inhibitor,P16581
CHEMBL2105945,CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O,aceneuramic-acid,Phase 3,,P16109
CHEMBL2105945,CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O,aceneuramic-acid,Phase 3,,P49908
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P16109
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P49908
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P16109
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P49908
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P16109
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P49908
CHEMBL4854862,,KF-38789,Preclinical,P selectin inhibitor,P16109
CHEMBL4854862,,KF-38789,Preclinical,P selectin inhibitor,P49908
CHEMBL397420,CC(=O)CC(C1=CC=C(C=C1)[N+](=O)[O-])C2=C(C3=CC=CC=C3OC2=O)O,acenocoumarol,Launched,vitamin K antagonist,Q9BQB6
CHEMBL1138328,,dicoumarol,Launched,NADPH inhibitor,Q9BQB6
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,Q9BQB6
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione-bisulfite,Phase 2,vitamin K,Q9BQB6
CHEMBL711,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,phenindione,Launched,vitamin K antagonist,Q9BQB6
CHEMBL3589649,CC[C@@H](C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,phenprocoumon,Launched,vitamin K antagonist,Q9BQB6
CHEMBL1200879,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)[O-].[Na+],warfarin,Launched,vitamin K antagonist,Q9BQB6
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P21728
CHEMBL2360079,CC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO)C=C1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,acetophenazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P21728
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P21728
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P21728
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P21728
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P21728
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P21728
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P21728
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL1122253,,deoxyepinephrine,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,P21728
CHEMBL4226242,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC(=C(C=C3)Cl)Cl,diclofensine,Phase 3,dopamine reuptake inhibitor,P21728
CHEMBL1256832,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,dihydrexidine,Phase 2,dopamine receptor agonist,P21728
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P21728
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P21728
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P21728
CHEMBL1256646,C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O.Br,fenoldopam,Launched,dopamine receptor agonist,P21728
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P21728
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P21728
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P21728
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P21728
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P21728
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P21728
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P21728
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P21728
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P21728
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P21728
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P21728
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P21728
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine,Launched,dopamine receptor antagonist,P21728
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine-palmitate,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P21728
CHEMBL1201154,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(CS(=O)(=O)O)S(=O)(=O)O,prochlorperazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P21728
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P21728
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P21728
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P21728
CHEMBL4846909,,rotundine,Launched,serotonin receptor agonist,P21728
CHEMBL4846346,,SCH-202676,Preclinical,G protein-coupled receptor modulator,P21728
CHEMBL4870993,,SCH-23390,Preclinical,dopamine receptor antagonist,P21728
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P21728
CHEMBL505308,C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3.Br,SKF-38393,Preclinical,dopamine receptor agonist,P21728
CHEMBL4857023,,SKF-77434,Preclinical,dopamine receptor agonist,P21728
CHEMBL4862451,,SKF-81297,Preclinical,dopamine receptor agonist,P21728
CHEMBL1473849,CN1CCC2=CC(=C(C=C2[C@@H](C1)C3=CC=CC=C3)O)Br,SKF-83566,Preclinical,dopamine receptor antagonist,P21728
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P21728
CHEMBL3989478,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(CC4)C)C=C1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,thiethylperazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P21728
CHEMBL1200902,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.Cl,thiothixene,Launched,dopamine receptor antagonist,P21728
CHEMBL1201102,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,triflupromazine,Launched,dopamine receptor antagonist,P21728
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21728
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P21728
CHEMBL4874380,,acepromazine,Launched,dopamine receptor antagonist,P14416
CHEMBL2360079,CC(=O)C1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(CC4)CCO)C=C1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,acetophenazine,Launched,dopamine receptor antagonist,P14416
CHEMBL4865274,,adoprazine,Phase 2,dopamine receptor antagonist|serotonin receptor agonist,P14416
CHEMBL4867222,,afalanine,Phase 3,dopamine receptor agonist,P14416
CHEMBL4873519,,AJ76-(+),Preclinical,dopamine receptor antagonist,P14416
CHEMBL660,C1C2CC3CC1CC(C2)(C3)N,amantadine,Launched,glutamate receptor antagonist,P14416
CHEMBL243712,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,amisulpride,Launched,dopamine receptor antagonist,P14416
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P14416
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P14416
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P14416
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL4873542,,azaperone,Launched,dopamine receptor antagonist,P14416
CHEMBL297302,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,benperidol,Launched,dopamine receptor antagonist,P14416
CHEMBL178803,CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F,blonanserin,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P14416
CHEMBL2105760,C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4,brexpiprazole,Launched,dopamine receptor partial agonist,P14416
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P14416
CHEMBL399510,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Br,bromopride,Launched,dopamine receptor antagonist,P14416
CHEMBL4875226,,bromperidol,Launched,dopamine receptor antagonist,P14416
CHEMBL4857453,,buspirone,Launched,serotonin receptor agonist,P14416
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P14416
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P14416
CHEMBL2024517,CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl,cariprazine,Launched,dopamine receptor antagonist,P14416
CHEMBL4854097,,carmoxirole,Phase 2,dopamine receptor agonist,P14416
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P14416
CHEMBL1599248,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N.C(=C\C(=O)O)\C(=O)O,clebopride,Launched,dopamine receptor antagonist,P14416
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P14416
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1122253,,deoxyepinephrine,Preclinical,adrenergic receptor agonist|dopamine receptor agonist,P14416
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P14416
CHEMBL1256832,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,dihydrexidine,Phase 2,dopamine receptor agonist,P14416
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P14416
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P14416
CHEMBL4856009,,domperidone,Launched,dopamine receptor antagonist,P14416
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P14416
CHEMBL4852826,,droperidol,Launched,dopamine receptor antagonist,P14416
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P14416
CHEMBL1256917,CCC1=CC(=C(C(=C1O)C(=O)NC[C@@H]2CCCN2CC)OC)Cl.Cl,eticlopride,Preclinical,dopamine receptor antagonist,P14416
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P14416
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine-decanoate,Launched,dopamine receptor antagonist,P14416
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P14416
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P14416
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol-decanoate,Launched,psychoactive drug,P14416
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P14416
CHEMBL2107457,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C=C2)OC)OC,itopride,Launched,dopamine receptor antagonist,P14416
CHEMBL3234237,C1CN(CCC1NC2=NN=C(C=C2)C(F)(F)F)CC3=CC(=C(C=C3)F)F,JNJ-37822681,Phase 2,dopamine receptor antagonist,P14416
CHEMBL292477,C1CC2(CCN(CC2)CC3=CC=CC=C3)C4=CC=CC=C41,L-693403,Preclinical,sigma receptor agonist|sigma receptor antagonist,P14416
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P14416
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P14416
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P14416
CHEMBL4869247,,levosulpiride,Launched,dopamine receptor antagonist,P14416
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P14416
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL3306803,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,lumateperone,Launched,dopamine receptor modulator|serotonin receptor antagonist,P14416
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1531134,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,melperone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1201052,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C.C1=CC=C(C=C1)S(=O)(=O)O,mesoridazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1200940,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P14416
CHEMBL1200419,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C.Cl,molindone,Launched,dopamine receptor antagonist,P14416
CHEMBL4848364,,NADPH,Preclinical,,P14416
CHEMBL1443376,CCCCN1CCC[C@@H]1CNC(=O)C2=C(C3=CC=CC=C3C(=C2)C#N)OC,nafadotride,Preclinical,dopamine receptor antagonist,P14416
CHEMBL4846754,,nemonapride,Launched,dopamine receptor antagonist,P14416
CHEMBL4864471,,nomifensine,Withdrawn,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,P14416
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P14416
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL2107360,CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C,paliperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL4861824,,PAOPA,Preclinical,dopamine receptor modulator,P14416
CHEMBL2105649,CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,P14416
CHEMBL4859572,,PD-128907,Preclinical,dopamine receptor agonist,P14416
CHEMBL4872498,,PD-168077,Preclinical,dopamine receptor agonist,P14416
CHEMBL4878444,,PD-168568,Preclinical,dopamine receptor antagonist,P14416
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P14416
CHEMBL1472975,C1CC[C@H]2[C@@H](C1)C(=O)N(C2=O)CCCCN3CCN(CC3)C4=NSC5=CC=CC=C54,perospirone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P14416
CHEMBL2111101,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,pimavanserin,Launched,serotonin receptor inverse agonist,P14416
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P14416
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P14416
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine,Launched,dopamine receptor antagonist,P14416
CHEMBL2106439,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,pipotiazine-palmitate,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P14416
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P14416
CHEMBL7549,CCCN1CCC[C@H](C1)C2=CC(=CC=C2)O,preclamol,Phase 2,dopamine receptor agonist,P14416
CHEMBL1201154,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(CS(=O)(=O)O)S(=O)(=O)O,prochlorperazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P14416
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL2218861,CCCN1CC(CC2C1CC3=C(C2)C(=CC=C3)O)NS(=O)(=O)N(CC)CC,quinagolide,Launched,dopamine receptor agonist,P14416
CHEMBL4743453,CCCN1CCCC2C1CC3=CN=C(N=C3C2)N,quinelorane,Phase 3,dopamine receptor agonist,P14416
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P14416
CHEMBL2104769,CCN1CCC[C@H]1CNC(=O)C2=C(C(=CC(=C2O[11CH3])Cl)Cl)O,raclopride,Launched,dopamine receptor antagonist,P14416
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.O.Cl,remoxipride,Withdrawn,dopamine receptor antagonist,P14416
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P14416
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P14416
CHEMBL4846909,,rotundine,Launched,serotonin receptor agonist,P14416
CHEMBL4846346,,SCH-202676,Preclinical,G protein-coupled receptor modulator,P14416
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL4876227,,SLV-319-(+/-),Phase 2,cannabinoid receptor antagonist,P14416
CHEMBL4866493,,SNAP-94847,Preclinical,,P14416
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P14416
CHEMBL5071215,CN[C@@H]1CC2=C3C(=CC=C2)NC(=O)N3C1.C(=C\C(=O)O)\C(=O)O,sumanirole,Phase 3,dopamine receptor agonist,P14416
CHEMBL1504869,C=CCN1CCC2=C(CC1)SC(=N2)N.Cl,talipexole,Launched,adrenergic receptor agonist|dopamine receptor agonist,P14416
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P14416
CHEMBL3989478,CCSC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCN(CC4)C)C=C1.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,thiethylperazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1481539,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,thioproperazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P14416
CHEMBL1200902,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C.Cl,thiothixene,Launched,dopamine receptor antagonist,P14416
CHEMBL1256772,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC.Cl,tiapride,Launched,dopamine receptor antagonist,P14416
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1201102,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F.Cl,triflupromazine,Launched,dopamine receptor antagonist,P14416
CHEMBL1201256,CN(C)CCOC1=CC=C(C=C1)CNC(=O)C2=CC(=C(C(=C2)OC)OC)OC,trimethobenzamide,Launched,histamine receptor antagonist,P14416
CHEMBL4865280,,UH-232-(+),Preclinical,dopamine receptor antagonist,P14416
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,P14416
CHEMBL5079373,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F.Cl.Cl,WAY-208466,Preclinical,serotonin receptor agonist,P14416
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P14416
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P14416
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P14416
CHEMBL4850555,,2-CMDO,Preclinical,dopamine receptor antagonist,P14416
CHEMBL4873045,,3'-fluorobenzylspiperone,Preclinical,dopamine receptor ligand,P14416
CHEMBL4855125,,7-hydroxy-DPAT,Preclinical,dopamine receptor agonist,P14416
CHEMBL4869260,,8-hydroxy-PIPAT,Preclinical,dopamine receptor ligand,P14416
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P29972
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL4849610,,carzenide,Preclinical,,P00915
CHEMBL1200616,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[Na+],chlorothiazide,Launched,diuretic,P00915
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,P00915
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P00915
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,P00915
CHEMBL4853468,,diclofenamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL4849647,,ditiocarb-sodium-trihydrate,Phase 3,immunostimulant,P00915
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P00915
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,P00915
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P00915
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,P00915
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P00915
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,P00915
CHEMBL4869247,,levosulpiride,Launched,dopamine receptor antagonist,P00915
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,P00915
CHEMBL1201117,COC1=CC=CC=C1OCC(COC(=O)N)O,methocarbamol,Launched,muscle relaxant,P00915
CHEMBL4852969,,phenol,Preclinical,,P00915
CHEMBL310671,C1=CC=C2C(=C1)C(=O)NS2(=O)=O,saccharin,Launched,DNA polymerase inhibitor,P00915
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P00915
CHEMBL4877943,,U-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,P00915
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P00915
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL4849610,,carzenide,Preclinical,,O43570
CHEMBL4869523,,celecoxib,Launched,cyclooxygenase inhibitor,O43570
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,O43570
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,O43570
CHEMBL4853468,,diclofenamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,O43570
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,O43570
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,O43570
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,O43570
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,O43570
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,O43570
CHEMBL4869247,,levosulpiride,Launched,dopamine receptor antagonist,O43570
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,O43570
CHEMBL4847779,,para-toluenesulfonamide,Phase 3,,O43570
CHEMBL4852969,,phenol,Preclinical,,O43570
CHEMBL24147,C1=CC(=CC(=C1)O)O,resorcinol,Launched,phosphodiesterase inhibitor,O43570
CHEMBL310671,C1=CC=C2C(=C1)C(=O)NS2(=O)=O,saccharin,Launched,DNA polymerase inhibitor,O43570
CHEMBL2022564,CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)O[C@@H](C[C@H](C[C@@H]([C@@H](C3=N[C@@H](CCC(=O)N[C@H](C(=O)N([C@H](C(=O)N1C)C)C)CC4=CC=C(C=C4)OC)CS3)C)O)C)C(C)(C)C,S4,Preclinical,carbonic anhydrase inhibitor,O43570
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,O43570
CHEMBL4877943,,U-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,O43570
CHEMBL865,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,valdecoxib,Withdrawn,cyclooxygenase inhibitor,O43570
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,O43570
CHEMBL6705,C1=CC=C(C(=C1)N)S(=O)(=O)N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,O43570
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL4849610,,carzenide,Preclinical,,Q9ULX7
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,Q9ULX7
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,Q9ULX7
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,Q9ULX7
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,Q9ULX7
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,Q9ULX7
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,Q9ULX7
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL4852969,,phenol,Preclinical,,Q9ULX7
CHEMBL24147,C1=CC(=CC(=C1)O)O,resorcinol,Launched,phosphodiesterase inhibitor,Q9ULX7
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q9ULX7
CHEMBL3989777,C(CNCCNCCN)N.Cl.Cl,trientine,Launched,chelating agent,Q9ULX7
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9ULX7
CHEMBL6705,C1=CC=C(C(=C1)N)S(=O)(=O)N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,Q9ULX7
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL1201039,C1=CC=C(C=C1)CSCC2=NS(=O)(=O)C3=CC(=C(C=C3N2)Cl)S(=O)(=O)N,benzthiazide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL4862480,,butylated-hydroxytoluene,Phase 1,carbonic anhydrase inhibitor,P00918
CHEMBL4849610,,carzenide,Preclinical,,P00918
CHEMBL1200616,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[Na+],chlorothiazide,Launched,diuretic,P00918
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,P00918
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P00918
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P00918
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P00918
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,P00918
CHEMBL4853468,,diclofenamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL4849647,,ditiocarb-sodium-trihydrate,Phase 3,immunostimulant,P00918
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P00918
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,P00918
CHEMBL4852901,,furosemide,Launched,diuretic,P00918
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P00918
CHEMBL13766,COC1=CC=CC=C1O,guaiacol,Launched,local anesthetic,P00918
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,P00918
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P00918
CHEMBL406,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,indapamide,Launched,thiazide diuretic,P00918
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,P00918
CHEMBL4102229,COC1=C(C=C2C(=C1)C3=C(CCCCC3)C(=O)O2)OS(=O)(=O)N,irosustat,Phase 2,steroid sulfatase inhibitor,P00918
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,P00918
CHEMBL4847779,,para-toluenesulfonamide,Phase 3,,P00918
CHEMBL4852969,,phenol,Preclinical,,P00918
CHEMBL24147,C1=CC(=CC(=C1)O)O,resorcinol,Launched,phosphodiesterase inhibitor,P00918
CHEMBL310671,C1=CC=C2C(=C1)C(=O)NS2(=O)=O,saccharin,Launched,DNA polymerase inhibitor,P00918
CHEMBL3989657,C(C(C(=O)O)NC(=O)CP(=O)([O-])[O-])C(=O)O.[Na+].[Na+],sparfosate,Phase 3,aspartate carbamoyltransferase inhibitor,P00918
CHEMBL328560,C1CCS(=O)(=O)N(C1)C2=CC=C(C=C2)S(=O)(=O)N,sultiame,Phase 3,carbonic anhydrase inhibitor,P00918
CHEMBL442687,C1=CC2=C(C=C1O)OC(=O)S2,tioxolone,Preclinical,carbonic anhydrase inhibitor,P00918
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P00918
CHEMBL4877943,,U-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,P00918
CHEMBL4852012,,urea,Launched,hydroxy radical formation stimulant,P00918
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P00918
CHEMBL6705,C1=CC=C(C(=C1)N)S(=O)(=O)N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,P00918
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P07451
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P07451
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P07451
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P07451
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL1200616,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[Na+],chlorothiazide,Launched,diuretic,P22748
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P22748
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,P22748
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P22748
CHEMBL4853468,,diclofenamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL4849647,,ditiocarb-sodium-trihydrate,Phase 3,immunostimulant,P22748
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P22748
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,P22748
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P22748
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,P22748
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P22748
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,P22748
CHEMBL4852969,,phenol,Preclinical,,P22748
CHEMBL3989657,C(C(C(=O)O)NC(=O)CP(=O)([O-])[O-])C(=O)O.[Na+].[Na+],sparfosate,Phase 3,aspartate carbamoyltransferase inhibitor,P22748
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P22748
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P22748
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P22748
CHEMBL1200814,CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+],acetazolamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4853468,,diclofenamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4867316,,dorzolamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P43166
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,P43166
CHEMBL4869247,,levosulpiride,Launched,dopamine receptor antagonist,P43166
CHEMBL1335656,CC(=O)N=C1N(N=C(S1)S(=O)(=O)N)C,methazolamide,Launched,carbonic anhydrase inhibitor,P43166
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P43166
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P43166
CHEMBL1589,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,acetohexamide,Launched,ATP channel blocker,Q09428
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q09428
CHEMBL498,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,chlorpropamide,Launched,ATP channel blocker,Q09428
CHEMBL1330729,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O.Cl,clenbuterol,Launched,adrenergic receptor agonist,Q09428
CHEMBL1481,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,glimepiride,Launched,insulin secretagogue,Q09428
CHEMBL1073,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,glipizide,Launched,sulfonylurea,Q09428
CHEMBL383634,CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C,gliquidone,Launched,sulfonylurea,Q09428
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,Q09428
CHEMBL471498,C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O,mitiglinide,Launched,insulin secretagogue,Q09428
CHEMBL783,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,nateglinide,Launched,insulin secretagogue,Q09428
CHEMBL1200338,CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1.O,pinacidil,Launched,ATP channel activator|potassium channel activator,Q09428
CHEMBL1272,CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,repaglinide,Launched,insulin secretagogue,Q09428
CHEMBL135191,CC1(CC1)N=C2NC3=C(SC(=C3)Cl)S(=O)(=O)N2,tifenazoxide,Phase 1,ATP-sensitive potassium channel agonist,Q09428
CHEMBL817,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,tolazamide,Launched,ATP channel blocker,Q09428
CHEMBL782,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,tolbutamide,Launched,ATP channel blocker,Q09428
CHEMBL1589,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,acetohexamide,Launched,ATP channel blocker,P48048
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,P48048
CHEMBL1481,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,glimepiride,Launched,insulin secretagogue,P48048
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,P48048
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,P48048
CHEMBL817,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,tolazamide,Launched,ATP channel blocker,P48048
CHEMBL782,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,tolbutamide,Launched,ATP channel blocker,P48048
CHEMBL4858456,,VU591,Preclinical,potassium channel blocker,P48048
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P48048
CHEMBL1589,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,acetohexamide,Launched,ATP channel blocker,P78508
CHEMBL498,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,chlorpropamide,Launched,ATP channel blocker,P78508
CHEMBL1073,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,glipizide,Launched,sulfonylurea,P78508
CHEMBL383634,CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C,gliquidone,Launched,sulfonylurea,P78508
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,P78508
CHEMBL471498,C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O,mitiglinide,Launched,insulin secretagogue,P78508
CHEMBL783,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,nateglinide,Launched,insulin secretagogue,P78508
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P78508
CHEMBL817,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,tolazamide,Launched,ATP channel blocker,P78508
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P78508
CHEMBL1589,CC(=O)C1=CC=C(C=C1)S(=O)(=O)NC(=O)NC2CCCCC2,acetohexamide,Launched,ATP channel blocker,Q14654
CHEMBL1330729,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O.Cl,clenbuterol,Launched,adrenergic receptor agonist,Q14654
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,Q14654
CHEMBL1481,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,glimepiride,Launched,insulin secretagogue,Q14654
CHEMBL1073,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,glipizide,Launched,sulfonylurea,Q14654
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,Q14654
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,levosimendan,Launched,calcium sensitizer,Q14654
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,Q14654
CHEMBL783,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,nateglinide,Launched,insulin secretagogue,Q14654
CHEMBL284906,C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-],nicorandil,Launched,nitric oxide donor|potassium channel activator,Q14654
CHEMBL1272,CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,repaglinide,Launched,insulin secretagogue,Q14654
CHEMBL135191,CC1(CC1)N=C2NC3=C(SC(=C3)Cl)S(=O)(=O)N2,tifenazoxide,Phase 1,ATP-sensitive potassium channel agonist,Q14654
CHEMBL817,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,tolazamide,Launched,ATP channel blocker,Q14654
CHEMBL782,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,tolbutamide,Launched,ATP channel blocker,Q14654
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q14654
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,Q14654
CHEMBL734,CC(=O)NO,acetohydroxamic-acid,Launched,urease inhibitor,P39900
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,P39900
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P39900
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P39900
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P39900
CHEMBL4303274,CC(=CCC/C(=C/CC/C(=C/CSCC(C(=O)O)NC(=O)C)/C)/C)C,acetyl-farnesyl-cysteine,Launched,methyltransferase inhibitor,P37231
CHEMBL258558,CC(C)(C1=CC=C(C=C1)OCC2CO2)C3=CC=C(C=C3)OCC4CO4,BADGE,Preclinical,PPAR receptor antagonist,P37231
CHEMBL2103991,CN1C(=NC2=CC=CC=C2C1=O)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4,balaglitazone,Phase 3,insulin sensitizer|PPAR receptor partial agonist,P37231
CHEMBL1200760,C1=CC(=CC=C1C(=O)NCCC(=O)[O-])N=NC2=CC(=C(C=C2)[O-])C(=O)O.[Na+].[Na+],balsalazide,Launched,cyclooxygenase inhibitor,P37231
CHEMBL4460360,C[C@@]12CC[C@@H]3[C@@]([C@H]1C(=O)C=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)C)(C=C(C(=O)C3(C)C)C#N)C,bardoxolone,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,P37231
CHEMBL4460360,C[C@@]12CC[C@@H]3[C@@]([C@H]1C(=O)C=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)C)(C=C(C(=O)C3(C)C)C#N)C,bardoxolone-methyl,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,P37231
CHEMBL4874807,,bezafibrate,Launched,PPAR receptor agonist,P37231
CHEMBL418971,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,bisphenol-A,Phase 1,synthetic estrogen,P37231
CHEMBL1398683,CC1(CCCCC1)COC2=CC=C(C=C2)C[C@@H]3C(=O)NC(=O)S3,ciglitazone,Phase 2,PPAR receptor agonist,P37231
CHEMBL4867639,,CINPA-1,Preclinical,CAR antagonist,P37231
CHEMBL2106162,CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)[N-]C(=O)S4.[Na+],darglitazone,Phase 2,PPAR receptor antagonist,P37231
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P37231
CHEMBL3990804,CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC5C(=O)NC(=O)S5,edaglitazone,Phase 2,PPAR receptor agonist,P37231
CHEMBL3545279,CC1=CC(=CC(=C1N)C)OC2=CC3=C(C=C2)N=C(N3C)COC4=CC=C(C=C4)CC5C(=O)NC(=O)S5.Cl.Cl,efatutazone,Phase 2,PPAR receptor agonist,P37231
CHEMBL4878630,,elafibranor,Phase 3,PPAR receptor agonist,P37231
CHEMBL4856134,,FH-535,Preclinical,PPAR receptor antagonist|WNT signaling inhibitor,P37231
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P37231
CHEMBL1073,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,glipizide,Launched,sulfonylurea,P37231
CHEMBL4861651,,GW-1929,Preclinical,PPAR receptor agonist,P37231
CHEMBL4868759,,GW-9662,Preclinical,PPAR receptor antagonist,P37231
CHEMBL4303690,,hemomex-s,Launched,,P37231
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,P37231
CHEMBL1232583,COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O,indeglitazar,Phase 2,PPAR receptor agonist,P37231
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,P37231
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,P37231
CHEMBL180920,C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O,magnolol,Preclinical,PPAR receptor agonist,P37231
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,P37231
CHEMBL4873706,,mifobate,Phase 2,PPAR receptor antagonist,P37231
CHEMBL471498,C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O,mitiglinide,Launched,insulin secretagogue,P37231
CHEMBL783,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,nateglinide,Launched,insulin secretagogue,P37231
CHEMBL4872362,,NPC-15199,Phase 2,ICAM1 antagonist,P37231
CHEMBL4853447,,nTZDpa,Preclinical,PPAR receptor agonist,P37231
CHEMBL595,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,pioglitazone,Launched,insulin sensitizer|PPAR receptor agonist,P37231
CHEMBL1272,CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O,repaglinide,Launched,insulin secretagogue,P37231
CHEMBL121,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,rosiglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,P37231
CHEMBL4297530,CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O,saroglitazar,Launched,PPAR receptor agonist,P37231
CHEMBL534243,CC(CNCC1=C(C=CC(=C1)C2=C(C=CC(=C2)OC)OC)O)C3=CC=CC=C3,SR-1664,Preclinical,PPAR receptor ligand,P37231
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P37231
CHEMBL4303501,COC(=O)C(CC1=CC=C(C=C1)OCCN2C3=C(C=C(C=C3)C(=O)C4=CC=CC=C4)SC2=O)C(=O)OC,S26948,Preclinical,PPAR receptor agonist,P37231
CHEMBL4860608,,T-0070907,Preclinical,PPAR receptor antagonist,P37231
CHEMBL1017,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,telmisartan,Launched,angiotensin receptor antagonist,P37231
CHEMBL4855291,,tesaglitazar,Phase 3,insulin sensitizer|PPAR receptor agonist,P37231
CHEMBL2074778,CC1=C(C(=C(C2=C1OC(CC2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)OS(=O)(=O)O)C,troglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,P37231
CHEMBL4303252,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)C4[C@]3(CCC5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C,acetyl-11-keto-beta-boswellic-acid,Phase 2,lipoxygenase inhibitor,P28845
CHEMBL485683,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CCC4=O)C,adrenosterone,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,P28845
CHEMBL4297742,,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,P28845
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P28845
CHEMBL680578,,chenodeoxycholic-acid,Launched,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,P28845
CHEMBL4851780,,coenzyme-I,Phase 2,,P28845
CHEMBL4043266,,corosolic-acid,Phase 2,PKC inhibitor|protein tyrosine kinase inhibitor,P28845
CHEMBL4847130,,corticosterone,Preclinical,mineralocorticoid receptor agonist,P28845
CHEMBL4870622,,enoxolone,Launched,gap junction modulator,P28845
CHEMBL4856614,,PF-915275,Phase 1,11-beta hydroxysteroid dehydrogenase inhibitor,P28845
CHEMBL15720,CC12CC(=O)C3C(C1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,prednisone,Launched,glucocorticoid receptor agonist,P28845
CHEMBL399491,C1CCN(C1)C(=S)S,pyrrolidine-dithiocarbamate,Preclinical,NFkB pathway inhibitor,P28845
CHEMBL169,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,P28845
CHEMBL4303252,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC(=O)C4[C@]3(CCC5[C@@]4(CC[C@H]([C@]5(C)C(=O)O)OC(=O)C)C)C)[C@@H]2[C@H]1C)C)C,acetyl-11-keto-beta-boswellic-acid,Phase 2,lipoxygenase inhibitor,P80365
CHEMBL485683,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CCC4=O)C,adrenosterone,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,P80365
CHEMBL4297742,,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,P80365
CHEMBL4851780,,coenzyme-I,Phase 2,,P80365
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,P22303
CHEMBL1200541,CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl)CC2=CC=CC=C2Cl.[Cl-].[Cl-],ambenonium,Launched,cholinesterase inhibitor,P22303
CHEMBL463210,CCOP(=S)(OCC)OC1=NC(=C(C=C1Cl)Cl)Cl,chlorpyrifos,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,P22303
CHEMBL1231700,C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,citicoline,Launched,glutathione transferase stimulant|membrane permeability enhancer,P22303
CHEMBL1599248,COC1=CC(=C(C=C1C(=O)NC2CCN(CC2)CC3=CC=CC=C3)Cl)N.C(=C\C(=O)O)\C(=O)O,clebopride,Launched,dopamine receptor antagonist,P22303
CHEMBL4860587,,decamethonium,Launched,acetylcholine receptor agonist,P22303
CHEMBL4128948,CC1=C2C=CC(=C(C2=C[N+]3=C1C4=CC(=C(C=C4CC3)OC)OC)OC)O,dehydrocorydaline,Phase 3,acetylcholinesterase inhibitor,P22303
CHEMBL1200514,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-],demecarium,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL2163792,C1CC2=NC3=CC=CC=C3CN2C1.O.Cl,desoxypeganine,Phase 1,acetylcholinesterase inhibitor|monoamine oxidase inhibitor,P22303
CHEMBL4872866,,dimpylate,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL502,COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC,donepezil,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL1104,CC[N+](C)(C)C1=CC(=CC=C1)O,edrophonium,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,P22303
CHEMBL485259,CC1(C2CCC(O1)(CC2)C)C,eucalyptol,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL445740,C/C/1=C\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C,g-caryophyllene,Preclinical,acetylcholinesterase inhibitor,P22303
CHEMBL395280,C/C=C/1\[C@@H]2CC3=C([C@]1(CC(=C2)C)N)C=CC(=O)N3,huperzine-A,Phase 2,acetylcholinesterase inhibitor,P22303
CHEMBL4865295,,"hydroxytacrine-maleate-(R,S)",Preclinical,cholinesterase inhibitor,P22303
CHEMBL4869911,,ipidacrine,Phase 3,acetylcholinesterase inhibitor,P22303
CHEMBL1025,CC(C)OP(=O)(OC(C)C)F,isoflurophate,Launched,cholinesterase inhibitor,P22303
CHEMBL1200468,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,malathion,Launched,cholinesterase inhibitor,P22303
CHEMBL4861767,,mestinon,Launched,cholinesterase inhibitor,P22303
CHEMBL4297433,CS(=O)(=O)F,methanesulfonyl-fluoride,Phase 2,acetylcholinesterase inhibitor,P22303
CHEMBL550495,CN(C)C1=CC2=C(C=C1)N=C3C=CC(=[N+](C)C)C=C3S2.O.O.O.[Cl-],methylene-blue,Launched,guanylyl cyclase inhibitor|nitric oxide production inhibitor,P22303
CHEMBL167150,COP(=O)(C(C(Cl)(Cl)Cl)O)OC,metrifonate,Phase 3,acetylcholinesterase inhibitor,P22303
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P22303
CHEMBL278020,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C,neostigmine,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL451635,C1=C[N+](=CC=C1/C=N/O)COC[N+]2=CC=C(C=C2)/C=N/O,obidoxime,Launched,cholinesterase reactivator,P22303
CHEMBL4095755,CC1CC[C@@]2([C@H]1C(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C,phenserine,Phase 3,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,P22303
CHEMBL4566020,CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C.C1=CC=C(C(=C1)C(=O)O)O,physostigmine,Launched,acetylcholinesterase inhibitor|cholinesterase inhibitor,P22303
CHEMBL2104739,C[N+]1=CC=CC=C1C=NO.CS(=O)(=O)[O-],pralidoxime,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL4303284,C[N+]1=CC=CC=C1CN=O,pralidoxime-chloride,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL4867786,,PRIMA1,Preclinical,TP53 inhibitor,P22303
CHEMBL345124,CC[N+](C)(CC)CCC[N+]1=C2C=C(C=CC2=C3C=CC(=CC3=C1C4=CC=CC=C4)N)N.[I-].[I-],propidium-iodide,Preclinical,,P22303
CHEMBL636,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,rivastigmine,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL95,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,tacrine,Launched,acetylcholinesterase inhibitor,P22303
CHEMBL1234071,C1CSS[C@H]1CCCCC(=O)O,thioctic-acid,Launched,reducing agent,P22303
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,P22303
CHEMBL1256415,COC1=CC2=C(C=C1)N=C3CCCCC3=C2N,7-methoxytacrine,Phase 2,acetylcholinesterase inhibitor,P22303
CHEMBL1184,CC(=O)OCC[N+](C)(C)C.[Cl-],acetylcholine,Launched,acetylcholine receptor agonist,Q15822
CHEMBL965,C[N+](C)(C)CCOC(=O)N,carbachol,Launched,cholinergic receptor agonist,Q15822
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,Q15822
CHEMBL1201248,C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C,cisatracurium,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,Q15822
CHEMBL4860587,,decamethonium,Launched,acetylcholine receptor agonist,Q15822
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,Q15822
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q15822
CHEMBL2106279,C[N+](C)(C)CCCCCC[N+](C)(C)C.[I-].[I-],hexamethonium,Preclinical,cholinergic receptor antagonist,Q15822
CHEMBL2062276,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O.C(C(C(=O)O)O)(C(=O)O)O,levallorphan,Launched,opioid receptor antagonist,Q15822
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL2105841,C[N+]1(CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.[Cl-].[Cl-],metocurine,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL1182833,C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C,mivacurium,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,Q15822
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-],pancuronium,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL1200722,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CC[N+](CC4)(C)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)N6CC[N+](CC6)(C)C)C.[Br-].[Br-],pipecuronium,Launched,neuromuscular blocker,Q15822
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q15822
CHEMBL1200648,CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C.[Br-],rocuronium,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL1200629,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],vecuronium,Launched,acetylcholine receptor antagonist,Q15822
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q03154
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q03154
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,O15111
CHEMBL2096646,C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+],aminosalicylate,Launched,cyclooxygenase inhibitor,O15111
CHEMBL435734,COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O)OC)OC,arctigenin,Preclinical,MEK inhibitor,O15111
CHEMBL4799297,CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O,BMS-345541,Preclinical,IKK inhibitor,O15111
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,O15111
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,O15111
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,P48637
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P48637
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P48637
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P48637
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,O14920
,,hypoestoxide,Phase 1,IKK inhibitor,O14920
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,O14920
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,O14920
CHEMBL1366,,auranofin,Launched,NFkB pathway inhibitor,O14920
CHEMBL4303437,CC1=C(C(=NO1)C)C2=CC(=C(C=C2)C3=CC(=C(S3)NC(=O)N)C(=O)N)O[C@H]4CCNC4,AZD3264,Preclinical,IKK inhibitor,O14920
CHEMBL4799297,CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O,BMS-345541,Preclinical,IKK inhibitor,O14920
CHEMBL4793424,C1CCN(C1)C2CCN(CC2)C(=O)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC6=CC=CC=C6S5.Cl,IKK-16,Preclinical,IKK inhibitor,O14920
CHEMBL4867292,,IKK-2-inhibitor,Preclinical,IKK inhibitor|SYK inhibitor,O14920
CHEMBL4878651,,IKK-2-inhibitor-V,Phase 1,IKK inhibitor|NFkB pathway inhibitor,O14920
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,O14920
CHEMBL388727,CC1=CCC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,parthenolide-(alternate-stereo),Preclinical,NFkB pathway inhibitor,O14920
CHEMBL4859598,,PF-573228,Preclinical,focal adhesion kinase inhibitor,O14920
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,O14920
CHEMBL4850303,,TPCA-1,Preclinical,IKK inhibitor,O14920
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q04206
CHEMBL4860228,,BAY-11-7082,Preclinical,NFkB pathway inhibitor,Q04206
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,Q04206
CHEMBL2400700,,caffeic-acid-phenethyl-ester,Preclinical,HIV integrase inhibitor,Q04206
CHEMBL621433,,NFKB-activation-inhibitor-II,Preclinical,NFkB pathway inhibitor,Q04206
CHEMBL388727,CC1=CCC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,parthenolide-(alternate-stereo),Preclinical,NFkB pathway inhibitor,Q04206
CHEMBL399491,C1CCN(C1)C(=S)S,pyrrolidine-dithiocarbamate,Preclinical,NFkB pathway inhibitor,Q04206
CHEMBL463763,CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C,triptolide,Phase 3,RNA polymerase inhibitor,Q04206
CHEMBL4863286,,acetylcysteine,Launched,mucolytic agent,Q9UPY5
CHEMBL4878884,,L-cystine,Launched,,Q9UPY5
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9UPY5
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9UPY5
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,Q9UPY5
CHEMBL2105922,CC(=O)NCCCCCC(=O)O,acexamic-acid,Launched,5 alpha reductase inhibitor,P01350
CHEMBL1414826,COC1=CC(=CC(=C1OC)OC)C(=S)N2CCOCC2,sulmetozine,Launched,gastrin inhibitor,P01350
CHEMBL4849860,,acifran,Phase 3,cholesterol inhibitor,Q8TDS4
CHEMBL345714,CC1=CN=C(C=[N+]1[O-])C(=O)O,acipimox,Launched,cholesterol inhibitor,Q8TDS4
CHEMBL1162496,CC(CC(=O)O)O,beta-hydroxybutyrate,Phase 1,,Q8TDS4
CHEMBL4875050,,MK-0354,Phase 2,niacin receptor agonist,Q8TDS4
CHEMBL4870477,,naringeninic-acid,Phase 1,,Q8TDS4
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,Q8TDS4
CHEMBL4849860,,acifran,Phase 3,cholesterol inhibitor,P49019
CHEMBL4303563,C1=CC=C(C=C1)C[C@H](C(=O)O)N.Cl,D-phenylalanine,Preclinical,enkephalinase inhibitor,P49019
CHEMBL4853868,,IBC-293,Preclinical,hydroxycarboxylic acid receptor agonist,P49019
CHEMBL4875050,,MK-0354,Phase 2,niacin receptor agonist,P49019
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,P49019
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P13631
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P13631
CHEMBL4878368,,adarotene,Phase 1,retinoid receptor agonist,P13631
CHEMBL1434137,C1C2CC3CC1CC(C2)(C3)C4=C(C=C5C=C(C=CC5=C4)C6=CC=C(C=C6)C(=O)O)O,CD-1530,Preclinical,retinoid receptor agonist,P13631
CHEMBL4862124,,CD-437,Preclinical,retinoid receptor agonist,P13631
CHEMBL4853069,,EC-23,Preclinical,retinoid receptor agonist,P13631
CHEMBL3889357,,isotretinoin,Launched,retinoid receptor agonist,P13631
CHEMBL4853406,,MM-11253,Preclinical,retinoid receptor antagonist,P13631
CHEMBL2105648,CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C,palovarotene,Phase 3,retinoid receptor agonist,P13631
CHEMBL1657,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,tazarotene,Launched,retinoid receptor agonist,P13631
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P13631
CHEMBL4859841,,TTNPB,Phase 1,retinoid receptor agonist,P13631
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,O95153
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P09455
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P29374
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,O95153
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P09455
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P29374
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P19793
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P19793
CHEMBL4303670,CCC1=CC=C(C=C1)C2=CC(SC3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C,AGN-194310,Phase 3,retinoid receptor antagonist,P19793
CHEMBL4848998,,bexarotene,Launched,retinoid receptor agonist,P19793
CHEMBL4852150,,BMS-649,Preclinical,retinoid receptor agonist,P19793
CHEMBL4868759,,GW-9662,Preclinical,PPAR receptor antagonist,P19793
CHEMBL4872818,,PA-452,Preclinical,retinoid receptor antagonist,P19793
CHEMBL4303228,CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C,peretinoin,Phase 3,retinoid receptor agonist,P19793
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P19793
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P28702
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P28702
CHEMBL4303670,CCC1=CC=C(C=C1)C2=CC(SC3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C,AGN-194310,Phase 3,retinoid receptor antagonist,P28702
CHEMBL4848998,,bexarotene,Launched,retinoid receptor agonist,P28702
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P28702
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,P28702
CHEMBL1657,CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C,tazarotene,Launched,retinoid receptor agonist,P28702
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P28702
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P48443
CHEMBL1265,COC1=C(C=C(C=C1)C2=CC3=C(C=C2)C=C(C=C3)C(=O)O)C45CC6CC(C4)CC(C6)C5,adapalene,Launched,retinoid receptor agonist,P48443
CHEMBL4303670,CCC1=CC=C(C=C1)C2=CC(SC3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C,AGN-194310,Phase 3,retinoid receptor antagonist,P48443
CHEMBL4848998,,bexarotene,Launched,retinoid receptor agonist,P48443
CHEMBL464,CCOC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C,etretinate,Withdrawn,protein synthesis inhibitor,P48443
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P48443
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P48443
CHEMBL1131,CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C)C)C)OC,acitretin,Launched,retinoid receptor agonist,P40763
CHEMBL4847301,,alantolactone,Preclinical,apoptosis stimulant|STAT inhibitor,P40763
CHEMBL4303655,COC1=CC(=CC(=C1)C2=NC3=NNC(=C3C=C2)C4=CC=C(C=C4)F)OC,APcK-110,Preclinical,KIT inhibitor,P40763
CHEMBL3215883,CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC.Cl.Cl,atiprimod,Phase 2,JAK inhibitor|STAT inhibitor,P40763
CHEMBL4460360,C[C@@]12CC[C@@H]3[C@@]([C@H]1C(=O)C=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)C)(C=C(C(=O)C3(C)C)C#N)C,bardoxolone-methyl,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,P40763
CHEMBL187460,C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,cryptotanshinone,Preclinical,acetylcholinesterase inhibitor|STAT inhibitor,P40763
CHEMBL607535,CN1C2=CC=CC=C2C(=C1O)C3=C4C=CC=CC4=NC3=O,meisoindigo,Phase 3,STAT inhibitor,P40763
CHEMBL4856862,,napabucasin,Phase 3,STAT inhibitor,P40763
CHEMBL1448,C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O,niclosamide,Launched,DNA replication inhibitor|STAT inhibitor,P40763
CHEMBL4861177,,ochromycinone,Phase 1,STAT inhibitor,P40763
CHEMBL4536936,CCCOC1=CC=C(C=C1)/C=C/2\C(=O)NC(=O)S2,STAT3-inhibitor-VI,Preclinical,STAT inhibitor,P40763
CHEMBL4854007,,WP1066,Phase 1,STAT inhibitor,P40763
CHEMBL1417849,C1[C@H](ON=C1Cl)[C@H](C(=O)O)N,acivicin,Phase 2,gamma glutamyltransferase inhibitor,P17812
CHEMBL3707366,C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N,L-glutamine,Launched,,P17812
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P17812
CHEMBL1697719,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O.Cl,aclarubicin,Launched,topoisomerase inhibitor,P11387
CHEMBL15192,CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C,beta-lapachone,Phase 2,topoisomerase inhibitor,P11387
CHEMBL65,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,camptothecin,Phase 3,topoisomerase inhibitor,P11387
CHEMBL3989759,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)N)O.CS(=O)(=O)O.O.O,exatecan-mesylate,Phase 3,topoisomerase inhibitor,P11387
CHEMBL4849525,,genz-644282,Phase 1,topoisomerase inhibitor,P11387
CHEMBL3989514,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl,irinotecan,Launched,topoisomerase inhibitor,P11387
CHEMBL1743260,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O,karenitecin,Phase 3,topoisomerase inhibitor,P11387
CHEMBL2007389,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O.Cl,lucanthone,Phase 2,endonuclease inhibitor,P11387
CHEMBL151,C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O,luteolin,Phase 2,glucosidase inhibitor,P11387
CHEMBL1232279,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N6CCO[C@@H](C6)OC)O,nemorubicin,Phase 2,topoisomerase inhibitor,P11387
CHEMBL4856620,,pyrazoloacridine,Phase 2,topoisomerase inhibitor,P11387
CHEMBL4862575,,rubitecan,Phase 3,topoisomerase inhibitor,P11387
CHEMBL1743143,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,SN-38,Launched,topoisomerase inhibitor,P11387
CHEMBL4852283,,TAS-103,Phase 1,topoisomerase inhibitor,P11387
CHEMBL4860438,,topotecan,Launched,topoisomerase inhibitor,P11387
CHEMBL4855453,,10-hydroxycamptothecin,Preclinical,topoisomerase inhibitor,P11387
CHEMBL4856286,,9-aminocamptothecin,Phase 2,topoisomerase inhibitor,P11387
CHEMBL1697719,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O.Cl,aclarubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL2107818,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O,aldoxorubicin,Phase 3,topoisomerase inhibitor,P11388
CHEMBL1910266,CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,amonafide,Phase 3,topoisomerase inhibitor,P11388
CHEMBL1186894,CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N,amrubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL1256655,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42.Cl,amsacrine,Launched,topoisomerase inhibitor,P11388
CHEMBL117391,C[N+](C)(CCNC1=C2C(=C(C=C1)NCC[N+](C)(C)[O-])C(=O)C3=C(C=CC(=C3C2=O)O)O)[O-],banoxantrone,Phase 1/Phase 2,topoisomerase inhibitor,P11388
CHEMBL1077975,CC(C(=O)O)O.C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,ciprofloxacin,Launched,bacterial DNA gyrase inhibitor,P11388
CHEMBL1200475,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,daunorubicin,Launched,RNA synthesis inhibitor|topoisomerase inhibitor,P11388
CHEMBL1738,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,dexrazoxane,Launched,chelating agent|topoisomerase inhibitor,P11388
CHEMBL4848288,,doxorubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL826,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,enoxacin,Launched,topoisomerase inhibitor,P11388
CHEMBL1200981,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,epirubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL1200645,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)O)O,etoposide,Launched,topoisomerase inhibitor,P11388
CHEMBL1200645,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)O)O,etoposide-phosphate,Launched,topoisomerase inhibitor,P11388
CHEMBL4854798,,fleroxacin,Launched,topoisomerase inhibitor,P11388
CHEMBL3183451,C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F.CS(=O)(=O)O.O,garenoxacin,Launched,topoisomerase inhibitor,P11388
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P11388
CHEMBL1200976,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl,idarubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL2237108,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O.Cl,levofloxacin,Launched,bacterial DNA gyrase inhibitor,P11388
CHEMBL2007389,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O.Cl,lucanthone,Phase 2,endonuclease inhibitor,P11388
CHEMBL1765797,C1=CC=C(C=C1)NC(=O)C2C(=O)NC(=S)NC2=O,merbarone,Phase 2,topoisomerase inhibitor,P11388
CHEMBL4869257,,mitoxantrone,Launched,topoisomerase inhibitor,P11388
CHEMBL1200735,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl,moxifloxacin,Launched,bacterial DNA gyrase inhibitor,P11388
CHEMBL1232279,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N6CCO[C@@H](C6)OC)O,nemorubicin,Phase 2,topoisomerase inhibitor,P11388
CHEMBL9,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,norfloxacin,Launched,bacterial DNA gyrase inhibitor,P11388
CHEMBL1428564,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O.CS(=O)(=O)O,pefloxacin,Launched,bacterial DNA gyrase inhibitor,P11388
CHEMBL4852224,,pirarubicin,Launched,topoisomerase inhibitor,P11388
CHEMBL4303533,,pixantrone,Launched,topoisomerase inhibitor,P11388
CHEMBL61,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,podophyllotoxin,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P11388
CHEMBL4856620,,pyrazoloacridine,Phase 2,topoisomerase inhibitor,P11388
CHEMBL4867803,,sparfloxacin,Withdrawn,bacterial DNA gyrase inhibitor,P11388
CHEMBL3039470,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H](C7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,teniposide,Launched,topoisomerase inhibitor,P11388
CHEMBL1200779,CS(=O)(=O)O.C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,trovafloxacin,Withdrawn,bacterial DNA gyrase inhibitor,P11388
CHEMBL1096885,CCCCC(=O)OCC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=C(C3=O)C=CC=C4OC)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC(=O)C(F)(F)F)O,valrubicin,Launched,DNA inhibitor|topoisomerase inhibitor,P11388
CHEMBL4858565,,voreloxin,Phase 3,topoisomerase inhibitor,P11388
CHEMBL1977761,C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.Cl.[Cl-],acriflavine,Launched,hypoxia inducible factor inhibitor,Q16665
CHEMBL4853348,,acriflavinium,Launched,hypoxia inducible factor inhibitor,Q16665
CHEMBL262344,CC(=CCC[C@@](C)(C=C)/C=C/C1=CC=C(C=C1)O)C,bakuchiol,Phase 2,DNA polymerase inhibitor,Q16665
CHEMBL4859280,,BAY-87-2243,Phase 1,hypoxia inducible factor inhibitor,Q16665
CHEMBL4858783,,FG-2216,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,Q16665
CHEMBL4297403,CCOC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)[C@H](CC2=CC=C(C=C2)N(CCCl)CCCl)N.Cl,melphalan-n-oxide,Phase 1,hypoxia inducible factor inhibitor,Q16665
CHEMBL2150882,,ML228,Preclinical,hypoxia inducible factor activator,Q16665
CHEMBL4857295,,YC-1,Preclinical,guanylyl cyclase activator,Q16665
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,Q16665
CHEMBL446452,C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43,"3,3'-diindolylmethane",Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",Q16665
CHEMBL2165326,C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br,ACT-132577,Launched,endothelin receptor antagonist,P25101
CHEMBL1111,CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,ambrisentan,Launched,endothelin receptor antagonist,P25101
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P25101
CHEMBL2106068,CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C2=CC=C(C=C2)OC)C(=O)O)C3=CC4=C(C=C3)OCO4.Cl,atrasentan,Phase 3,endothelin receptor antagonist,P25101
CHEMBL4879005,,BMS-182874,Phase 2,endothelin receptor antagonist,P25101
CHEMBL957,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,bosentan,Launched,endothelin receptor antagonist,P25101
CHEMBL1269102,CC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N1)C(C)C)CC(=O)O)CC3=CNC4=CC=CC=C43,BQ-123,Phase 2,endothelin receptor antagonist,P25101
CHEMBL4866891,,darusentan,Phase 3,endothelin receptor antagonist,P25101
CHEMBL4873885,,FR-139317,Phase 1,endothelin receptor antagonist,P25101
CHEMBL2103873,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,macitentan,Launched,endothelin receptor antagonist,P25101
CHEMBL4851428,,PD-156707,Preclinical,endothelin receptor antagonist,P25101
CHEMBL2105740,CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+],sitaxentan,Withdrawn,endothelin receptor antagonist,P25101
CHEMBL3989834,CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC,SPP301,Phase 3,endothelin receptor antagonist,P25101
CHEMBL1628688,CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4,zibotentan,Phase 3,endothelin receptor antagonist,P25101
CHEMBL2165326,C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br,ACT-132577,Launched,endothelin receptor antagonist,P24530
CHEMBL1111,CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C,ambrisentan,Launched,endothelin receptor antagonist,P24530
CHEMBL957,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC,bosentan,Launched,endothelin receptor antagonist,P24530
CHEMBL1741040,CCCC[C@H](C(=O)O)NC(=O)[C@@H](CC1=CN(C2=CC=CC=C21)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](CCC[C@@H]3C)C,BQ-788,Phase 1,endothelin receptor antagonist,P24530
CHEMBL4862120,,IRL-2500,Preclinical,endothelin receptor antagonist,P24530
CHEMBL2103873,CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br,macitentan,Launched,endothelin receptor antagonist,P24530
CHEMBL4851428,,PD-156707,Preclinical,endothelin receptor antagonist,P24530
CHEMBL2105740,CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)[N-]C4=C(C(=NO4)C)Cl)OCO2.[Na+],sitaxentan,Withdrawn,endothelin receptor antagonist,P24530
CHEMBL4857140,,ACT-462206,Phase 1,orexin receptor antagonist,O43613
CHEMBL455136,CNC(=O)[C@@H](C1=CC=CC=C1)N2CCC3=CC(=C(C=C3[C@@H]2CCC4=CC=C(C=C4)C(F)(F)F)OC)OC,almorexant,Phase 3,orexin receptor antagonist,O43613
CHEMBL4878859,,JNJ-10397049,Preclinical,orexin receptor antagonist,O43613
CHEMBL4866867,,lemborexant,Launched,orexin receptor antagonist,O43613
CHEMBL2107822,C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F,MK-6096,Phase 2,orexin receptor antagonist,O43613
CHEMBL4847214,,SB-334867,Preclinical,orexin receptor antagonist,O43613
CHEMBL4877255,,SB-408124,Preclinical,orexin receptor antagonist,O43613
CHEMBL4857140,,ACT-462206,Phase 1,orexin receptor antagonist,O43614
CHEMBL455136,CNC(=O)[C@@H](C1=CC=CC=C1)N2CCC3=CC(=C(C=C3[C@@H]2CCC4=CC=C(C=C4)C(F)(F)F)OC)OC,almorexant,Phase 3,orexin receptor antagonist,O43614
CHEMBL4878859,,JNJ-10397049,Preclinical,orexin receptor antagonist,O43614
CHEMBL4866867,,lemborexant,Launched,orexin receptor antagonist,O43614
CHEMBL4856016,,MK-3697,Phase 2,orexin receptor antagonist,O43614
CHEMBL2107822,C[C@@H]1CC[C@H](CN1C(=O)C2=C(C=CC(=C2)C)C3=NC=CC=N3)COC4=NC=C(C=C4)F,MK-6096,Phase 2,orexin receptor antagonist,O43614
CHEMBL4847214,,SB-334867,Preclinical,orexin receptor antagonist,O43614
CHEMBL4877255,,SB-408124,Preclinical,orexin receptor antagonist,O43614
CHEMBL4867956,,TCS-OX2-29,Preclinical,orexin receptor antagonist,O43614
CHEMBL3991934,COCC1=C(N2C(=C1C3=CC(=C(C=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F)F)C(=NC=N2)N)CN5CCOCC5,ACTB-1003,Phase 1,FGFR inhibitor|VEGFR inhibitor,P35968
,,SU014813,Phase 2,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL3545365,C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F,altiratinib,Phase 1,MET inhibitor|VEGFR inhibitor,P35968
CHEMBL4303201,CC1=CC2=C(N1)C=CC(=C2F)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,anlotinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL3186534,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,apatinib,Phase 3,RET tyrosine kinase inhibitor,P35968
CHEMBL1289926,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P35968
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P35968
CHEMBL4852054,,BMS-690514,Phase 2,EGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL3545050,,BMS-817378,Phase 1,c-Met inhibitor|VEGFR inhibitor,P35968
CHEMBL3526086,,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,P35968
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,P35968
CHEMBL2105717,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,cabozantinib,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P35968
CHEMBL4853670,,CYC116,Phase 1,Aurora kinase inhibitor,P35968
CHEMBL4859543,,DMH4,Preclinical,VEGFR inhibitor,P35968
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P35968
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,P35968
CHEMBL1230609,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,foretinib,Phase 2,VEGFR inhibitor,P35968
CHEMBL4303214,CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC,fruquintinib,Launched,VEGFR inhibitor,P35968
CHEMBL3039525,CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,golvatinib,Phase 2,VEGFR inhibitor,P35968
CHEMBL4874773,,KI-20227,Preclinical,c-Fms inhibitor,P35968
CHEMBL4850671,,KI-8751,Preclinical,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4874827,,KRN-633,Preclinical,VEGFR inhibitor,P35968
CHEMBL1289601,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,lenvatinib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL4796872,C[C@@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO,LY2874455,Phase 1,FGFR antagonist,P35968
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL2107357,CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O,motesanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL3989921,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\C(=O)O)\C(=O)O,neratinib,Launched,EGFR inhibitor,P35968
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4854312,,NVP-BGJ398,Phase 3,FGFR inhibitor,P35968
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4847840,,OSI-930,Phase 1,KIT inhibitor|VEGFR inhibitor,P35968
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL1112822,,PD-153035,Phase 1,EGFR inhibitor,P35968
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL3751850,,PLX4720,Preclinical,RAF inhibitor,P35968
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P35968
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P35968
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P35968
CHEMBL4852103,,SKLB1002,Preclinical,VEGFR inhibitor,P35968
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL2050148,,SU4312,Preclinical,PDGFR tyrosine kinase receptor inhibitor|tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL2079588,CNC(=O)C1=NC=CC(=C1)COC2=NN=C(C3=C2OC=C3)NC4=CC=C(C=C4)Cl,telatinib,Phase 2,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL4868350,,TG-100572,Preclinical,SRC inhibitor|VEGFR inhibitor,P35968
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P35968
CHEMBL4857538,,tie2-kinase-inhibitor,Preclinical,TIE tyrosine kinase inhibitor,P35968
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P35968
CHEMBL2103833,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O,toceranib,Launched,protein tyrosine kinase inhibitor,P35968
CHEMBL4877167,,tyrphostin-AG-879,Preclinical,tyrosine kinase inhibitor,P35968
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35968
CHEMBL4848946,,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35968
CHEMBL3544983,CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,P35968
CHEMBL4865501,,ZM-306416,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,P35968
CHEMBL4856486,,ZM-323881,Preclinical,VEGFR inhibitor,P35968
CHEMBL3991934,COCC1=C(N2C(=C1C3=CC(=C(C=C3)NC(=O)NC4=C(C=CC(=C4)C(F)(F)F)F)F)C(=NC=N2)N)CN5CCOCC5,ACTB-1003,Phase 1,FGFR inhibitor|VEGFR inhibitor,Q02763
CHEMBL3545365,C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F,altiratinib,Phase 1,MET inhibitor|VEGFR inhibitor,Q02763
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,Q02763
CHEMBL3991932,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NCC3=C(C=CC(=C3)F)OC4=CC5=C(C=C4)N(N=C5)CCO,pexmetinib,Phase 1,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,Q02763
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,Q02763
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q02763
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q02763
CHEMBL4875255,,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,Q13547
,,Merck60,Preclinical,HDAC inhibitor,Q13547
CHEMBL4861209,,AR-42,Phase 1,HDAC inhibitor,Q13547
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q13547
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q13547
CHEMBL27759,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,entinostat,Phase 3,HDAC inhibitor,Q13547
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q13547
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q13547
CHEMBL4862129,,mocetinostat,Phase 2,HDAC inhibitor,Q13547
CHEMBL2179618,CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2,nexturastat-A,Preclinical,HDAC inhibitor,Q13547
CHEMBL1479316,C1=CC2=C(C=CC(=C2N=C1)O)N=O,NSC-3852,Preclinical,HDAC inhibitor,Q13547
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q13547
CHEMBL388727,CC1=CCC[C@@]2([C@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,parthenolide-(-),Preclinical,NFkB pathway inhibitor,Q13547
CHEMBL2103863,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PCI-24781,Phase 3,HDAC inhibitor,Q13547
CHEMBL4868784,,PCI-34051,Preclinical,HDAC inhibitor,Q13547
CHEMBL1746,C1=CC=C(C=C1)CCCC(=O)[O-].[Na+],phenylbutyrate,Launched,HDAC inhibitor,Q13547
CHEMBL100014,CCCC(=O)OCOC(=O)C(C)(C)C,pivanex,Phase 2,HDAC inhibitor,Q13547
CHEMBL353581,C1=CC(=CN=C1)NC(=O)CCCCCCC(=O)NO,pyroxamide,Phase 1,HDAC inhibitor,Q13547
CHEMBL4296717,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO,resminostat,Phase 2,HDAC inhibitor,Q13547
CHEMBL4855332,,RG2833,Phase 1,HDAC inhibitor,Q13547
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q13547
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,Q13547
CHEMBL4848666,,SBHA,Preclinical,HDAC inhibitor,Q13547
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q13547
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,Q13547
CHEMBL4851996,,tacedinaline,Phase 3,HDAC inhibitor,Q13547
CHEMBL4859602,,TC-H-106,Preclinical,HDAC inhibitor,Q13547
CHEMBL4303643,CCCCNNC(=O)C1=CC=C(C=C1)Br,UF-010,Preclinical,HDAC inhibitor,Q13547
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q13547
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q13547
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q13547
CHEMBL4863305,,4SC-202,Phase 1,HDAC inhibitor,Q13547
CHEMBL4875255,,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,Q92769
,,Merck60,Preclinical,HDAC inhibitor,Q92769
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q92769
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q92769
CHEMBL4857479,,CUDC-907,Phase 2,PI3K inhibitor,Q92769
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q92769
CHEMBL27759,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,entinostat,Phase 3,HDAC inhibitor,Q92769
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q92769
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q92769
CHEMBL4848770,,lovastatin,Launched,HMGCR inhibitor,Q92769
CHEMBL4849772,,MC1568,Preclinical,HDAC inhibitor,Q92769
CHEMBL4862129,,mocetinostat,Phase 2,HDAC inhibitor,Q92769
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q92769
CHEMBL2103863,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PCI-24781,Phase 3,HDAC inhibitor,Q92769
CHEMBL100014,CCCC(=O)OCOC(=O)C(C)(C)C,pivanex,Phase 2,HDAC inhibitor,Q92769
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q92769
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,Q92769
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q92769
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,Q92769
CHEMBL4859602,,TC-H-106,Preclinical,HDAC inhibitor,Q92769
CHEMBL4303643,CCCCNNC(=O)C1=CC=C(C=C1)Br,UF-010,Preclinical,HDAC inhibitor,Q92769
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q92769
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q92769
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q92769
CHEMBL4875255,,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,O15379
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,O15379
CHEMBL4087968,C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=CC(=C3)F)N,chidamide,Launched,HDAC inhibitor,O15379
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,O15379
CHEMBL27759,C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC(=O)OCC3=CN=CC=C3,entinostat,Phase 3,HDAC inhibitor,O15379
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,O15379
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,O15379
CHEMBL4862129,,mocetinostat,Phase 2,HDAC inhibitor,O15379
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,O15379
CHEMBL2103863,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PCI-24781,Phase 3,HDAC inhibitor,O15379
CHEMBL100014,CCCC(=O)OCOC(=O)C(C)(C)C,pivanex,Phase 2,HDAC inhibitor,O15379
CHEMBL4296717,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO,resminostat,Phase 2,HDAC inhibitor,O15379
CHEMBL4851992,,RGFP966,Preclinical,HDAC inhibitor,O15379
CHEMBL4855332,,RG2833,Phase 1,HDAC inhibitor,O15379
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,O15379
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,O15379
CHEMBL4848666,,SBHA,Preclinical,HDAC inhibitor,O15379
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,O15379
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,O15379
CHEMBL4859602,,TC-H-106,Preclinical,HDAC inhibitor,O15379
CHEMBL4303643,CCCCNNC(=O)C1=CC=C(C=C1)Br,UF-010,Preclinical,HDAC inhibitor,O15379
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,O15379
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,O15379
CHEMBL4875255,,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,Q9UBN7
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q9UBN7
CHEMBL94394,CCCCOC1=CC=C(C=C1)CC(=O)NO,bufexamac,Withdrawn,cyclooxygenase inhibitor,Q9UBN7
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q9UBN7
CHEMBL1526649,CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO,droxinostat,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q9UBN7
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q9UBN7
CHEMBL2179618,CCCCN(CC1=CC=C(C=C1)C(=O)NO)C(=O)NC2=CC=CC=C2,nexturastat-A,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q9UBN7
CHEMBL2103863,CN(C)CC1=C(OC2=CC=CC=C21)C(=O)NCCOC3=CC=C(C=C3)C(=O)NO,PCI-24781,Phase 3,HDAC inhibitor,Q9UBN7
CHEMBL4868784,,PCI-34051,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL4296717,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO,resminostat,Phase 2,HDAC inhibitor,Q9UBN7
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q9UBN7
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,Q9UBN7
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL4870198,,TCS-HDAC6-20b,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q9UBN7
CHEMBL2018302,CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO,tubastatin-A,Preclinical,HDAC inhibitor,Q9UBN7
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q9UBN7
CHEMBL4875255,,ACY-1215,Phase 1/Phase 2,HDAC inhibitor,Q9BY41
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q9BY41
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q9BY41
CHEMBL1526649,CC1=C(C=CC(=C1)Cl)OCCCC(=O)NO,droxinostat,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q9BY41
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q9BY41
CHEMBL3654102,CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)OCC6COCCO6)[N+](=O)[O-])OC7=CC(=C(N=C7)N)Cl)C,M-344,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q9BY41
CHEMBL4868784,,PCI-34051,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL100014,CCCC(=O)OCOC(=O)C(C)(C)C,pivanex,Phase 2,HDAC inhibitor,Q9BY41
CHEMBL4296717,CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO,resminostat,Phase 2,HDAC inhibitor,Q9BY41
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q9BY41
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,Q9BY41
CHEMBL4859602,,TC-H-106,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL4303643,CCCCNNC(=O)C1=CC=C(C=C1)Br,UF-010,Preclinical,HDAC inhibitor,Q9BY41
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q9BY41
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q9BY41
CHEMBL1200380,C1=NC2=C(N1COCCO)N=C(N=C2[O-])N.[Na+],acyclovir,Launched,DNA polymerase inhibitor,P00491
CHEMBL1200380,C1=NC2=C(N1COCCO)N=C(N=C2[O-])N.[Na+],acyclovir,Launched,DNA polymerase inhibitor,P01298
CHEMBL374107,C12=NNN=C1N=C(NC2=O)N,azaguanine-8,Preclinical,purine antagonist,P00491
CHEMBL374107,C12=NNN=C1N=C(NC2=O)N,azaguanine-8,Preclinical,purine antagonist,P01298
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P00491
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P01298
CHEMBL4869806,,didanosine,Launched,nucleoside reverse transcriptase inhibitor,P00491
CHEMBL4869806,,didanosine,Launched,nucleoside reverse transcriptase inhibitor,P01298
CHEMBL550755,C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl,forodesine,Launched,purinergic receptor antagonist,P00491
CHEMBL550755,C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O.Cl,forodesine,Launched,purinergic receptor antagonist,P01298
CHEMBL4303152,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@@H](O3)CO)O)O)N=C(NC2=O)N,guanosine,Preclinical,,P00491
CHEMBL4303152,C1=NC2=C(N1[C@H]3[C@@H]([C@@H]([C@@H](O3)CO)O)O)N=C(NC2=O)N,guanosine,Preclinical,,P01298
CHEMBL1427,C1=NC2=C(N1)C(=O)NC=N2,hypoxanthine,Preclinical,PARP inhibitor,P00491
CHEMBL1427,C1=NC2=C(N1)C(=O)NC=N2,hypoxanthine,Preclinical,PARP inhibitor,P01298
CHEMBL3833327,CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,inosine,Launched,neurotrophic agent,P00491
CHEMBL3833327,CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,inosine,Launched,neurotrophic agent,P01298
CHEMBL579173,CC(C)C1=NC(=C(C2=C1COC(C2)(C)C)C#N)N3CCN(CC3)C(=O)NC4=CC=CC=C4,AD-5467,Phase 2,aldose reductase inhibitor,P15121
,,adaprev,Phase 3,TGF beta receptor inhibitor,P15121
CHEMBL2106598,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CC(=O)[O-].[Na+],alrestatin,Preclinical,aldose reductase inhibitor,P15121
CHEMBL225304,C(=NN)(N)N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,P15121
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,P15121
CHEMBL117,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,chrysin,Phase 1,breast cancer resistance protein inhibitor,P15121
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P15121
CHEMBL4851780,,coenzyme-I,Phase 2,,P15121
CHEMBL1892416,CCOC(=O)C1CN(C(=O)C1=O)CC2=CC=CC=C2,EBPC,Preclinical,aldose reductase inhibitor,P15121
CHEMBL56337,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,epalrestat,Launched,aldose reductase inhibitor,P15121
CHEMBL408742,C1C(OC2=C(C13C(=O)NC(=O)N3)C=C(C=C2)F)C(=O)N,fidarestat,Phase 3,aldose reductase inhibitor,P15121
CHEMBL251254,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O,hyperin,Preclinical,aldose reductase inhibitor,P15121
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,P15121
CHEMBL4876218,,ranirestat,Phase 3,aldose reductase inhibitor,P15121
CHEMBL4865620,,sorbinil,Phase 3,aldose reductase inhibitor,P15121
CHEMBL15770,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,sulindac,Launched,cyclooxygenase inhibitor,P15121
CHEMBL4868051,,tolrestat,Withdrawn,aldose reductase inhibitor,P15121
CHEMBL4303636,C1=CC=C2C(=C1)C(=CC(=O)O)NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F,zopolrestat,Phase 2,,P15121
,,adaprev,Phase 3,TGF beta receptor inhibitor,P06744
,,adaprev,Phase 3,TGF beta receptor inhibitor,P19367
,,adaprev,Phase 3,TGF beta receptor inhibitor,P20645
,,adaprev,Phase 3,TGF beta receptor inhibitor,P11217
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P11217
CHEMBL404313,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O,asiatic-acid,Preclinical,apoptosis stimulant,P11217
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P11217
CHEMBL515408,CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl,maribavir,Phase 3,cytomegalovirus inhibitor|protein kinase inhibitor,P11217
CHEMBL4872529,,MC-1,Phase 3,,P11217
CHEMBL579498,CC1=C(C=C(C=C1)NC2=CC(=NC3=NC(=NN23)C)C)C,NSC-4644,Phase 2,ACAT inhibitor|sterol regulatory element binding protein (SREBP) inhibitor,P11217
CHEMBL277150,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O,polyinosine,Preclinical,immunostimulant,P11217
CHEMBL1908359,[O-]P(=O)([O-])F.[Na+].[Na+],sodium-monofluorophosphate,Launched,,P11217
CHEMBL169,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,P11217
,,adaptavir,Phase 2,CC chemokine receptor antagonist,P51681
CHEMBL4203190,C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3.Cl,AMD11070,Phase 3,CC chemokine receptor antagonist,P51681
CHEMBL425618,CC1=NN=C(N1C2CC3CCC(C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C,maraviroc,Launched,CC chemokine receptor antagonist,P51681
CHEMBL4853888,,TAK-220,Phase 1,CC chemokine receptor antagonist,P51681
CHEMBL2107384,C[C@H]1CN(CCN1[C@@H](COC)C2=CC=C(C=C2)C(F)(F)F)C3(CCN(CC3)C(=O)C4=C(N=CN=C4C)C)C.C(=C\C(=O)O)\C(=O)O,vicriviroc,Phase 3,CC chemokine receptor antagonist,P51681
,,AZD5069,Phase 2,CC chemokine receptor antagonist,P25025
CHEMBL3039531,CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O,danirixin,Phase 2,CC chemokine receptor antagonist,P25025
CHEMBL264931,C[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indoprofen,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P25025
CHEMBL2103864,CC[C@H](C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C.O,navarixin,Phase 2,CC chemokine receptor antagonist,P25025
CHEMBL191413,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C,reparixin,Phase 3,CC chemokine receptor antagonist,P25025
CHEMBL4863435,,SB-225002,Preclinical,CC chemokine receptor antagonist,P25025
,,BRD7389,Preclinical,ribosomal protein inhibitor,Q15418
CHEMBL4877166,,BI-D1870,Preclinical,ribosomal protein inhibitor,Q15418
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,Q15418
CHEMBL4860561,,GSK1838705A,Preclinical,insulin growth factor receptor inhibitor,Q15418
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,Q15418
,,BRD7389,Preclinical,ribosomal protein inhibitor,Q15349
CHEMBL4877166,,BI-D1870,Preclinical,ribosomal protein inhibitor,Q15349
,,BRD7389,Preclinical,ribosomal protein inhibitor,P51812
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P51812
CHEMBL4877166,,BI-D1870,Preclinical,ribosomal protein inhibitor,P51812
,,BRD9876,Preclinical,kinesin inhibitor,P52732
CHEMBL4303449,C#CC[C@H](C1=NC2=C(C=CC(=C2)Cl)C(=O)N1NC3=CC=CC=C3)N(CCCN)C(=O)C4=C(C(=CC=C4)Cl)F,ARQ-621,Phase 1,kinesin-like spindle protein inhibitor,P52732
CHEMBL2347655,CN(C(=O)N1[C@](SC(=N1)C2=C(C=CC(=C2)F)F)(CCCN)C3=CC=CC=C3)OC,filanesib,Phase 3,kinesin inhibitor|kinesin-like spindle protein inhibitor,P52732
CHEMBL4869329,,ispinesib,Phase 2,kinesin inhibitor,P52732
CHEMBL4878129,,K-858,Preclinical,kinesin-like spindle protein inhibitor,P52732
CHEMBL2105661,CCNCCS(=O)(=O)NC[C@@]1(N(N=C(S1)NC(=O)C(C)(C)C)C(=O)C(C)(C)C)C2=CC=CC=C2,litronesib,Phase 2,kinesin-like spindle protein inhibitor,P52732
CHEMBL1213887,CCOC(=O)C1=C(NC(=S)N[C@@H]1C2=CC(=CC=C2)O)C,monastrol,Preclinical,kinesin inhibitor,P52732
CHEMBL4590257,CC1=CC=C(C=C1)C(=O)N(CCCN)C(C2=C(C(=O)C3=C(O2)C=C(C=C3)Cl)CC4=CC=CC=C4)C(C)C,SB-743921,Phase 1/Phase 2,kinesin-like spindle protein inhibitor,P52732
,,CTS21166,Phase 1,beta-secretase inhibitor,P56817
CHEMBL4303211,C1=CC(=CC(=C1)[C@@]2(C3=C(C(N2)N)C(=CC=C3)F)C4=CC(=NC=C4)C(F)F)C5=CN=CN=C5,AZD3839,Phase 1,beta-secretase inhibitor,P56817
CHEMBL1553155,C1=CC(=CC=C1[N+](=O)[O-])OC2=CC(=CC(=C2)C(=O)O)OC3=CC=C(C=C3)[N+](=O)[O-],compound-w,Preclinical,beta-secretase inhibitor,P56817
CHEMBL36327,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epicatechin-gallate-(-),Phase 2,bacterial DNA gyrase inhibitor,P56817
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,P56817
CHEMBL4861690,,LY2811376,Phase 1,beta-secretase inhibitor,P56817
CHEMBL4303286,C1[C@@H]2CSC(=N[C@]2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N,LY2886721,Phase 1/Phase 2,beta-secretase inhibitor,P56817
CHEMBL4848936,,TC1,Preclinical,beta-secretase inhibitor,P56817
,,elactocin,Phase 1,exportin antagonist,O14980
CHEMBL4863697,,KPT-185,Preclinical,exportin antagonist,O14980
CHEMBL4303237,C1C(CN1C(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)(F)F,KPT-276,Preclinical,exportin antagonist,O14980
CHEMBL4848646,,selinexor,Launched,exportin antagonist,O14980
,,GSK37647,Preclinical,free fatty acid receptor agonist,Q5NUL3
CHEMBL3311302,CC1=CC=C(C=C1)S(=O)(=O)NC2C3=CC=CC=C3OC4=CC=CC=C24,AH-7614,Preclinical,free fatty acid receptor antagonist,Q5NUL3
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,Q5NUL3
CHEMBL3989529,CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N,ethanolamine-oleate,Launched,immunostimulant,Q5NUL3
CHEMBL4303269,CC1=C(C=CC(=C1)OCC2=NC(=CS2)C3=CC=CC=C3Cl)OCC(=O)O,GPR120-modulator-1,Preclinical,G protein-coupled receptor modulator,Q5NUL3
CHEMBL4852429,,GW-9508,Preclinical,free fatty acid receptor agonist|G protein-coupled receptor agonist,Q5NUL3
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,Q5NUL3
CHEMBL4845897,,TUG-891,Preclinical,free fatty acid receptor agonist,Q5NUL3
,,hypoestoxide,Phase 1,IKK inhibitor,P01584
CHEMBL186141,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,P01584
CHEMBL273019,COC1=C(C=C2C(=C1O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC2=O)O,bergenin,Preclinical,interleukin inhibitor,P01584
CHEMBL41286,CC(=O)OC1=CC=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3OC(=O)C)C(=O)O,diacerein,Launched,interleukin inhibitor,P01584
CHEMBL234432,C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)N)O)O)O,glucosamine,Launched,glycosylated protein precursor,P01584
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,P01584
CHEMBL4303719,CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl,JTE-607,Phase 2,cytokine production inhibitor,P01584
CHEMBL4863553,,talmapimod,Phase 2,p38 MAPK inhibitor,P01584
CHEMBL187266,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,tanshinone-IIA,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,P01584
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,P01584
,,hypoestoxide,Phase 1,IKK inhibitor,P01375
CHEMBL12856,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,amrinone,Launched,phosphodiesterase inhibitor,P01375
CHEMBL186141,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,P01375
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P01375
CHEMBL273019,COC1=C(C=C2C(=C1O)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)OC2=O)O,bergenin,Preclinical,interleukin inhibitor,P01375
CHEMBL4297369,CC(=O)NC1=CC=C(C=C1)C(=O)NC(C)(C)C,CPI-1189,Phase 2,tumor necrosis factor release inhibitor,P01375
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P01375
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P01375
CHEMBL513024,COC1=C(C=C2C(=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O)O,glycitein,Phase 3,tumor necrosis factor release inhibitor,P01375
CHEMBL4303719,CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl,JTE-607,Phase 2,cytokine production inhibitor,P01375
CHEMBL848,C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N,lenalidomide,Launched,anticancer agent,P01375
CHEMBL481246,CCC/C=C\1/C2=C(C=CCC2)C(=O)O1,ligustilide,Preclinical,tumor necrosis factor production inhibitor,P01375
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P01375
CHEMBL1256391,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,pirfenidone,Launched,TGF beta receptor inhibitor,P01375
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,P01375
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P01375
CHEMBL4863553,,talmapimod,Phase 2,p38 MAPK inhibitor,P01375
CHEMBL187266,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,tanshinone-IIA,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,P01375
CHEMBL426123,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,thalidomide,Launched,tumor necrosis factor production inhibitor,P01375
CHEMBL4865042,,trofinetide,Phase 2,cytokine production inhibitor,P01375
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,P01375
,,IEM1754,Preclinical,glutamate receptor antagonist,P42261
,,LY215490,Phase 1,glutamate receptor antagonist,P42261
,,LY404187,Preclinical,glutamate receptor positive allosteric modulator,P42261
CHEMBL136800,C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2,ampalex,Phase 2,glutamate receptor agonist,P42261
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P42261
CHEMBL222418,C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N,CNQX,Phase 1,glutamate receptor antagonist,P42261
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P42261
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,P42261
CHEMBL1015,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O,evans-blue,Launched,glutamate receptor negative allosteric modulator,P42261
CHEMBL4866359,,GYKI-52466,Preclinical,glutamate receptor antagonist,P42261
CHEMBL4848649,,HA-966-(R)-(+),Preclinical,glutamate receptor agonist,P42261
CHEMBL1564377,C1CN(C(=O)[C@H]1N)O,HA-966-(S)-(-),Preclinical,glutamate receptor antagonist,P42261
CHEMBL4847737,,IDRA-21,Preclinical,glutamate receptor positive allosteric modulator,P42261
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,P42261
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P42261
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P42261
CHEMBL1277001,C[C@@H](CNS(=O)(=O)C(C)C)C1=CC=C(C=C1)C2=CC=C(C=C2)CCNS(=O)(=O)C,mibampator,Phase 2,glutamate receptor modulator,P42261
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,P42261
CHEMBL36715,C1CC(=O)N(C1)CC(=O)N,piracetam,Launched,acetylcholine receptor agonist,P42261
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P42261
CHEMBL4871617,,SYM-2206,Preclinical,glutamate receptor antagonist,P42261
CHEMBL320642,C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1,S18986,Phase 2,glutamate receptor modulator,P42261
CHEMBL4847635,,talampanel,Phase 2,glutamate receptor antagonist,P42261
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P42261
,,LX1031,Phase 2,tryptophan hydroxylase inhibitor,P17752
CHEMBL1256351,C1=CC(=CC=C1CC(C(=O)O)N)Cl,fenclonine-(+/-),Preclinical,tryptophan hydroxylase inhibitor,P17752
CHEMBL1201775,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,P17752
CHEMBL2105695,CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N,telotristat,Launched,tryptophan hydroxylase inhibitor,P17752
CHEMBL2105695,CCOC(=O)[C@H](CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)O[C@H](C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N,telotristat-ethyl,Launched,tryptophan hydroxylase inhibitor,P17752
,,LY215490,Phase 1,glutamate receptor antagonist,P42262
,,LY404187,Preclinical,glutamate receptor positive allosteric modulator,P42262
CHEMBL4861521,,AMPA-(S),Preclinical,glutamate receptor agonist,P42262
CHEMBL136800,C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2,ampalex,Phase 2,glutamate receptor agonist,P42262
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P42262
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,P42262
CHEMBL222418,C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N,CNQX,Phase 1,glutamate receptor antagonist,P42262
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P42262
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,P42262
CHEMBL4866359,,GYKI-52466,Preclinical,glutamate receptor antagonist,P42262
CHEMBL4847737,,IDRA-21,Preclinical,glutamate receptor positive allosteric modulator,P42262
CHEMBL1618199,C[N+](C)(C)CCCCCNCC12CC3CC(C1)CC(C3)C2,IEM1460,Preclinical,glutamate receptor antagonist,P42262
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P42262
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,P42262
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,P42262
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,P42262
CHEMBL36715,C1CC(=O)N(C1)CC(=O)N,piracetam,Launched,acetylcholine receptor agonist,P42262
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P42262
CHEMBL4871617,,SYM-2206,Preclinical,glutamate receptor antagonist,P42262
CHEMBL320642,C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1,S18986,Phase 2,glutamate receptor modulator,P42262
CHEMBL4847635,,talampanel,Phase 2,glutamate receptor antagonist,P42262
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P42262
,,LY215490,Phase 1,glutamate receptor antagonist,P42263
,,LY404187,Preclinical,glutamate receptor positive allosteric modulator,P42263
CHEMBL136800,C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2,ampalex,Phase 2,glutamate receptor agonist,P42263
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P42263
CHEMBL222418,C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N,CNQX,Phase 1,glutamate receptor antagonist,P42263
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P42263
CHEMBL4866359,,GYKI-52466,Preclinical,glutamate receptor antagonist,P42263
CHEMBL4847737,,IDRA-21,Preclinical,glutamate receptor positive allosteric modulator,P42263
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P42263
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,P42263
CHEMBL36715,C1CC(=O)N(C1)CC(=O)N,piracetam,Launched,acetylcholine receptor agonist,P42263
CHEMBL4871617,,SYM-2206,Preclinical,glutamate receptor antagonist,P42263
CHEMBL320642,C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1,S18986,Phase 2,glutamate receptor modulator,P42263
CHEMBL4847635,,talampanel,Phase 2,glutamate receptor antagonist,P42263
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P42263
,,LY215490,Phase 1,glutamate receptor antagonist,P48058
,,LY404187,Preclinical,glutamate receptor positive allosteric modulator,P48058
CHEMBL136800,C1CCN(CC1)C(=O)C2=CC3=NC=CN=C3C=C2,ampalex,Phase 2,glutamate receptor agonist,P48058
CHEMBL36994,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,aniracetam,Launched,glutamate receptor agonist,P48058
CHEMBL222418,C1=C(C(=CC2=C1NC(=O)C(=O)N2)[N+](=O)[O-])C#N,CNQX,Phase 1,glutamate receptor antagonist,P48058
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P48058
CHEMBL4866359,,GYKI-52466,Preclinical,glutamate receptor antagonist,P48058
CHEMBL4847737,,IDRA-21,Preclinical,glutamate receptor positive allosteric modulator,P48058
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P48058
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,P48058
CHEMBL36715,C1CC(=O)N(C1)CC(=O)N,piracetam,Launched,acetylcholine receptor agonist,P48058
CHEMBL4871617,,SYM-2206,Preclinical,glutamate receptor antagonist,P48058
CHEMBL320642,C1C[C@@H]2NS(=O)(=O)C3=CC=CC=C3N2C1,S18986,Phase 2,glutamate receptor modulator,P48058
CHEMBL4847635,,talampanel,Phase 2,glutamate receptor antagonist,P48058
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P48058
,,LY215490,Phase 1,glutamate receptor antagonist,P39086
CHEMBL4868347,,ATPA,Preclinical,glutamate receptor agonist,P39086
CHEMBL4872041,,DNQX,Preclinical,glutamate receptor antagonist,P39086
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,P39086
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P39086
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,P39086
CHEMBL4864860,,NBQX,Preclinical,glutamate receptor antagonist,P39086
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,P39086
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P39086
CHEMBL4863776,,UBP-296,Preclinical,glutamate receptor antagonist,P39086
CHEMBL4863776,,UBP-302,Preclinical,glutamate receptor antagonist,P39086
CHEMBL4859444,,UBP-310,Preclinical,glutamate receptor antagonist,P39086
,,metatinib,Phase 1,Bcr-Abl kinase inhibitor,P00519
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P00519
CHEMBL4303396,CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CN=C5,bafetinib,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,P00519
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P00519
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P00519
CHEMBL4865546,,flumatinib,Phase 3,Bcr-Abl kinase inhibitor,P00519
CHEMBL4425166,,GNF-2,Preclinical,Bcr-Abl kinase inhibitor,P00519
CHEMBL4425166,,GNF-5,Preclinical,Bcr-Abl kinase inhibitor,P00519
CHEMBL4868371,,GZD824,Preclinical,Bcr-Abl kinase inhibitor,P00519
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P00519
CHEMBL4874165,,KW-2449,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,P00519
CHEMBL4870084,,LDN-212854,Preclinical,bone morphogenic protein inhibitor,P00519
CHEMBL255863,CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,nilotinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor,P00519
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P00519
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P00519
CHEMBL4869189,,PP-2,Preclinical,SRC inhibitor,P00519
CHEMBL4849857,,PPY-A,Preclinical,Abl kinase inhibitor,P00519
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P00519
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P00519
CHEMBL4438584,CN1CCN(CC1)CCOC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6,saracatinib,Phase 2/Phase 3,SRC inhibitor,P00519
,,metatinib,Phase 1,Bcr-Abl kinase inhibitor,P11274
CHEMBL4303396,CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CN=C5,bafetinib,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,P11274
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P11274
CHEMBL4425166,,GNF-2,Preclinical,Bcr-Abl kinase inhibitor,P11274
CHEMBL4425166,,GNF-5,Preclinical,Bcr-Abl kinase inhibitor,P11274
CHEMBL4868371,,GZD824,Preclinical,Bcr-Abl kinase inhibitor,P11274
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P11274
CHEMBL4849857,,PPY-A,Preclinical,Abl kinase inhibitor,P11274
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P11274
,,metenkephalin,Phase 2,immunostimulant,P41143
CHEMBL4868900,,ADL5859,Phase 2,opioid receptor agonist,P41143
CHEMBL270190,C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O,alvimopan,Launched,opioid receptor antagonist,P41143
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P41143
CHEMBL4876136,,beta-funaltrexamine,Preclinical,opioid receptor antagonist,P41143
CHEMBL436031,C1CC1CN2CC[C@]34[C@@H]5C(=O)/C(=C/C6=CC=CC=C6)/C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O,BNTX,Preclinical,opioid receptor antagonist,P41143
CHEMBL1600780,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl,BW-180C,Phase 2,opioid receptor agonist,P41143
CHEMBL4857041,,BW-373U86,Preclinical,opioid receptor agonist,P41143
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P41143
CHEMBL4865923,,eluxadoline,Launched,opioid receptor agonist|opioid receptor antagonist,P41143
CHEMBL1256915,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C.C(=C/C(=O)O)\C(=O)O,eseroline-(-),Preclinical,acetylcholinesterase inhibitor,P41143
CHEMBL636031,,FIT,Preclinical,opioid receptor agonist,P41143
CHEMBL4846156,,ICI-199441,Preclinical,opioid receptor agonist,P41143
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,P41143
CHEMBL1186579,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,methylnaltrexone,Launched,opioid receptor antagonist,P41143
CHEMBL1201132,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl,nalbuphine,Launched,opioid receptor agonist|opioid receptor antagonist,P41143
CHEMBL982,C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O,nalmefene,Launched,opioid receptor antagonist,P41143
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,P41143
CHEMBL1201149,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O.Cl,naltrexone,Launched,opioid receptor antagonist,P41143
CHEMBL295413,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6,naltriben,Preclinical,opioid receptor antagonist,P41143
CHEMBL149,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8N6,naltrindole,Preclinical,opioid receptor antagonist,P41143
CHEMBL2374078,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl,nor-binaltorphimine,Preclinical,opioid receptor antagonist,P41143
CHEMBL4855108,,salvinorin-A,Phase 1,opioid receptor agonist,P41143
CHEMBL1324873,CC(=C)CN1CC[C@]23[C@@H]4C5=C(C[C@]2(C1CC6=C3C(=C(C=C6)O)O4)O)C7=CC=CC=C7N5.O.Cl,SDM25N,Preclinical,opioid receptor antagonist,P41143
CHEMBL4877511,,SNC-80,Preclinical,,P41143
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P41143
CHEMBL1289110,CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O,tianeptine,Launched,selective serotonin reuptake enhancer (SSRE),P41143
CHEMBL190044,CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C,trimebutine,Launched,opioid receptor agonist,P41143
,,ML141,Preclinical,GTPase inhibitor,P60953
CHEMBL4303199,C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)C4=CC=CC=C4)NCCO,casin,Preclinical,GTPase inhibitor,P60953
CHEMBL4303380,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)NC(=S)NC(=O)COC3=C(C=C(C=C3)Br)Cl)C,ZCL-278,Preclinical,CDC inhibitor,P60953
,,ML179,Preclinical,liver receptor homolog inverse agonist,O00482
,,PS178990,Phase 1,androgen receptor modulator,P10275
CHEMBL4857519,,andarine,Phase 1,androgen receptor modulator,P10275
CHEMBL4874508,,APC-100,Phase 1/Phase 2,androgen receptor antagonist|anti-inflammatory agent,P10275
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,P10275
CHEMBL4877543,,ASC-J9,Phase 2,androgen receptor enhancer,P10275
CHEMBL4857916,,AZD3514,Phase 1,androgen receptor modulator,P10275
CHEMBL4740742,C1=CC(=CC=C1F)S(=O)(=O)CC(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F,bicalutamide,Launched,androgen receptor antagonist,P10275
CHEMBL418971,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,bisphenol-A,Phase 1,synthetic estrogen,P10275
CHEMBL3590187,CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)CO,CB-03-01,Phase 3,androgen receptor antagonist,P10275
CHEMBL14058,CC12CCC(=O)C=C1CCC3C2CCC4(C3CC[C@@]4(C(=O)CO)O)C,cortodoxone,Phase 3,androgen receptor antagonist,P10275
CHEMBL4558169,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,cyproterone-acetate,Launched,androgen receptor antagonist,P10275
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,P10275
CHEMBL4297185,C[C@@H](CN1C=CC(=N1)C2=CC(=C(C=C2)C#N)Cl)NC(=O)C3=NNC(=C3)C(C)O,darolutamide,Launched,androgen receptor antagonist,P10275
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone-sulfate,Launched,androgen receptor agonist|estrogen receptor agonist,P10275
CHEMBL1201048,CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@H](C(=O)C4)C)C)C,dromostanolone-propionate,Launched,androgen receptor modulator,P10275
CHEMBL1509,C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C,drospirenone,Launched,mineralocorticoid receptor antagonist,P10275
CHEMBL1082407,CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C,enzalutamide,Launched,androgen receptor antagonist,P10275
CHEMBL2106161,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@@H]4[C@@]3(C[C@@H]5[C@H](C4)S5)C,epitiostanol,Launched,androgen receptor agonist,P10275
CHEMBL42710,COC1=C(C=CC(=C1)CC=C)O,eugenol,Launched,androgen receptor antagonist,P10275
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P10275
CHEMBL806,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,flutamide,Launched,androgen receptor antagonist,P10275
CHEMBL2105738,C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4N5C=NC6=CC=CC=C65)C)O,galeterone,Phase 3,androgen receptor modulator,P10275
CHEMBL4853354,,gestrinone,Launched,progesterone receptor antagonist,P10275
CHEMBL4876384,,GLPG0492,Phase 1,androgen receptor modulator,P10275
CHEMBL4863006,,GLPG0492-R-enantiomer,Phase 1,androgen receptor modulator,P10275
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,P10275
CHEMBL4875793,,LXR-623,Phase 1,LXR agonist,P10275
CHEMBL4867799,,LY2452473,Phase 2,androgen receptor modulator,P10275
CHEMBL4862709,,mifepristone,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,P10275
CHEMBL3545333,C[C@]12CCC3C(C1CC[C@@H]2C(=O)NCC4=NC5=C(N4)C=CC=N5)CCC6[C@@]3(C=C(C(=O)N6C)F)C,MK-0773,Phase 2,androgen receptor modulator,P10275
CHEMBL1274,CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C,nilutamide,Launched,androgen receptor antagonist,P10275
CHEMBL4873643,,norgestrel,Launched,progesterone receptor agonist,P10275
CHEMBL1738889,C[C@](COC1=CC=C(C=C1)C#N)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,ostarine,Phase 3,androgen receptor modulator,P10275
CHEMBL1908377,CC1=CC(=C(N1C2=CC=CC=C2)C)/C=C/C3=[N+](C4=C(C=C(C=C4)N(C)C)C=C3)C.CC1=CC(=C(N1C2=CC=CC=C2)C)/C=C/C3=[N+](C4=C(C=C(C=C4)N(C)C)C=C3)C.C1=CC=C2C(=C(C(=CC2=C1)C(=O)O)[O-])CC3=C(C(=CC4=CC=CC=C34)C(=O)O)[O-],pyrvinium-pamoate,Launched,androgen receptor antagonist,P10275
CHEMBL4852572,,RU-58841,Phase 2,androgen receptor antagonist,P10275
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P10275
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,P10275
CHEMBL4849372,,2-hydroxyflutamide,Phase 2,androgen receptor antagonist,P10275
CHEMBL446452,C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43,"3,3'-diindolylmethane",Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",P10275
,,RG1530,Phase 1,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P11362
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P11362
CHEMBL3526086,,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,P11362
CHEMBL4303231,CC1=NC(=NO1)CN2C=NC3=C2C(=O)N(C(=O)N3C)C,CH-5183284,Phase 2,fibroblast growth factor inhibitor,P11362
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,P11362
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P11362
CHEMBL3545376,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,erdafitinib,Launched,FGFR inhibitor,P11362
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P11362
CHEMBL4796872,C[C@@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO,LY2874455,Phase 1,FGFR antagonist,P11362
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P11362
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P11362
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P11362
CHEMBL4854312,,NVP-BGJ398,Phase 3,FGFR inhibitor,P11362
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P11362
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P11362
CHEMBL4861653,,PD-161570,Preclinical,FGFR inhibitor,P11362
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,P11362
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P11362
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P11362
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P11362
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P11362
CHEMBL4303490,CC1=C(C(=C(C(=C1N)C)C)NCC(=O)N(C)C2CCN(CC2)CC3=CC=C(C=C3)C(=O)N)C,SUN-11602,Preclinical,fibroblast growth factor mimetic,P11362
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P11362
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P11362
,,RG1530,Phase 1,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P21802
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,P21802
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P21802
CHEMBL4303231,CC1=NC(=NO1)CN2C=NC3=C2C(=O)N(C(=O)N3C)C,CH-5183284,Phase 2,fibroblast growth factor inhibitor,P21802
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P21802
CHEMBL3545376,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,erdafitinib,Launched,FGFR inhibitor,P21802
CHEMBL4796872,C[C@@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO,LY2874455,Phase 1,FGFR antagonist,P21802
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P21802
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P21802
CHEMBL4854312,,NVP-BGJ398,Phase 3,FGFR inhibitor,P21802
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P21802
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P21802
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P21802
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P21802
,,SPP86,Preclinical,receptor tyrosine protein kinase inhibitor,P07949
CHEMBL3186534,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,apatinib,Phase 3,RET tyrosine kinase inhibitor,P07949
CHEMBL2105717,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,cabozantinib,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,P07949
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,P07949
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P07949
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P07949
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P07949
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P07949
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P07949
CHEMBL4873107,,PP-1,Preclinical,SRC inhibitor,P07949
CHEMBL4877675,,quizartinib,Phase 3,FLT3 inhibitor,P07949
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P07949
CHEMBL4858394,,R406,Phase 1,SYK inhibitor,P07949
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P07949
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P07949
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P07949
,,TCN238,Preclinical,glutamate receptor positive allosteric modulator,Q14833
,,VU0364770,Preclinical,glutamate receptor positive allosteric modulator,Q14833
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q14833
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q14833
CHEMBL4846859,,MPEP,Preclinical,glutamate receptor antagonist,Q14833
CHEMBL4877959,,PHCCC,Preclinical,glutamate receptor agonist,Q14833
CHEMBL4871653,,SIB-1893,Preclinical,glutamate receptor antagonist,Q14833
CHEMBL4877081,,VU0361737,Preclinical,glutamate receptor positive allosteric modulator,Q14833
CHEMBL1221266,,VU0364439,Preclinical,glutamate receptor positive allosteric modulator,Q14833
,,UNC2327,Preclinical,protein arginine N-methyltransferase inhibitor,O60678
CHEMBL4848307,,SGC-707,Preclinical,protein arginine N-methyltransferase inhibitor,O60678
,,UNC3230,Preclinical,phosphatidyl-inositol activator,O60331
,,VU0240551,Preclinical,potassium/chloride cotransporter inhibitor,Q9H2X9
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,Q9H2X9
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,O00763
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,O00763
CHEMBL4854214,,CP-640186,Preclinical,acetyl-CoA carboxylase inhibitor,O00763
CHEMBL4875847,,KD-023,Phase 2,ACAT inhibitor,O00763
CHEMBL1431,CN(C)C(=N)N=C(N)N,metformin,Launched,insulin sensitizer,O00763
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,P24666
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,P07741
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P07741
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,Q13126
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,Q9BY49
CHEMBL226345,C1=NC2=NC=NC(=C2N1)N,adenine,Preclinical,protein synthesis stimulant,P78362
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,P78362
CHEMBL4867051,,SRPIN340,Preclinical,serine arginine protein kinase inhibitor,P78362
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,P78362
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,P29274
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,P29274
CHEMBL4303273,CCN1C2=NC=NC(=C2N=C1OCC)N,ANR-94,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4202825,C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N,BAY-60-6583,Preclinical,adenosine receptor agonist,P29274
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P29274
CHEMBL4857678,,CF102,Phase 2,adenosine receptor agonist,P29274
CHEMBL4879351,,CGS-15943,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4303688,CCNC(=O)[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O,CGS-21680,Preclinical,adenosine receptor agonist,P29274
CHEMBL4869900,,CV-1808,Preclinical,adenosine receptor agonist,P29274
CHEMBL4870151,,DPCPX,Phase 1,adenosine receptor antagonist,P29274
CHEMBL539313,CCC1(CC2=CC=CC=C2O1)C3=NCCN3.Cl,efaroxan,Phase 2,adrenergic receptor antagonist,P29274
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,P29274
CHEMBL4846786,,GR-79236,Phase 1,adenosine receptor agonist,P29274
CHEMBL4861828,,GS-6201,Phase 1,adenosine receptor antagonist,P29274
CHEMBL4871645,,HEMADO,Preclinical,adenosine receptor agonist,P29274
CHEMBL4754465,CNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O,IB-MECA,Phase 3,adenosine receptor agonist,P29274
CHEMBL3736368,CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)/C=C/C3=CC(=C(C=C3)OC)OC,istradefylline,Launched,adenosine receptor antagonist,P29274
CHEMBL4848909,,KW-3902,Phase 3,adenosine receptor antagonist,P29274
CHEMBL4858319,,Lu-AA-47070,Phase 2,adenosine receptor antagonist,P29274
CHEMBL4872120,,LUF-5834,Preclinical,adenosine receptor agonist,P29274
CHEMBL28626,C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,morin,Preclinical,cytochrome P450 inhibitor,P29274
CHEMBL1321988,C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S,MRS-3777,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4868351,,NECA,Launched,adenosine receptor agonist,P29274
CHEMBL4863705,,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P29274
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P29274
CHEMBL4870232,,preladenant,Phase 3,adenosine receptor antagonist,P29274
CHEMBL1593850,CC[C@@H]1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1.Cl,PSB-11,Preclinical,adenosine receptor antagonist,P29274
CHEMBL1316674,CCCCN1C(=O)C2=C(N=C(N2)C34CC5CC(C3)CC4C5)N(C1=O)CCCO,PSB-36,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4869798,,PSB-603,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4303537,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4C(C([C@H](O4)CO)O)O)N,regadenoson,Launched,adenosine receptor agonist,P29274
CHEMBL4853381,,SCH-58261,Preclinical,adenosine receptor antagonist,P29274
CHEMBL4874146,,SLV-320,Phase 2,adenosine receptor antagonist,P29274
CHEMBL4856815,,T-62,Phase 2,adenosine receptor modulator,P29274
CHEMBL4859620,,TC-G-1004,Preclinical,adenosine receptor antagonist,P29274
CHEMBL1114,CN1C=NC2=C1C(=O)NC(=O)N2C,theobromine,Launched,phosphodiesterase inhibitor,P29274
CHEMBL2105747,CC1(CCN(CC1)C(=O)NC2=NC3=C(C=CC(=C3S2)N4CCOCC4)OC)O,tozadenant,Phase 3,adenosine receptor antagonist,P29274
CHEMBL447664,CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N,vipadenant,Phase 1,adenosine receptor antagonist,P29274
CHEMBL4846009,,ZM-241385,Preclinical,adenosine receptor antagonist,P29274
CHEMBL2168889,,2-chloro-N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P29274
CHEMBL4867466,,2-chloroadenosine,Preclinical,adenosine receptor agonist,P29274
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,P29275
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,P29275
CHEMBL4202825,C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N,BAY-60-6583,Preclinical,adenosine receptor agonist,P29275
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P29275
CHEMBL4857678,,CF102,Phase 2,adenosine receptor agonist,P29275
CHEMBL1551336,C1=CC(=C(C=C1C2=C(SC(=N2)N)C3=CC=NC=C3)Cl)Cl.Cl.Cl,CGH2466,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4879351,,CGS-15943,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4303688,CCNC(=O)[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O,CGS-21680,Preclinical,adenosine receptor agonist,P29275
CHEMBL4870151,,DPCPX,Phase 1,adenosine receptor antagonist,P29275
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,P29275
CHEMBL4861828,,GS-6201,Phase 1,adenosine receptor antagonist,P29275
CHEMBL4871645,,HEMADO,Preclinical,adenosine receptor agonist,P29275
CHEMBL4754465,CNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O,IB-MECA,Phase 3,adenosine receptor agonist,P29275
CHEMBL3736368,CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)/C=C/C3=CC(=C(C=C3)OC)OC,istradefylline,Launched,adenosine receptor antagonist,P29275
CHEMBL4848909,,KW-3902,Phase 3,adenosine receptor antagonist,P29275
CHEMBL4872120,,LUF-5834,Preclinical,adenosine receptor agonist,P29275
CHEMBL4856523,,MRS-1220,Preclinical,adenosine receptor antagonist,P29275
CHEMBL1321988,C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S,MRS-3777,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4868351,,NECA,Launched,adenosine receptor agonist,P29275
CHEMBL4863705,,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P29275
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P29275
CHEMBL4870232,,preladenant,Phase 3,adenosine receptor antagonist,P29275
CHEMBL4871855,,PSB-1115,Preclinical,adenosine receptor antagonist,P29275
CHEMBL1316674,CCCCN1C(=O)C2=C(N=C(N2)C34CC5CC(C3)CC4C5)N(C1=O)CCCO,PSB-36,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4869798,,PSB-603,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4303537,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4C(C([C@H](O4)CO)O)O)N,regadenoson,Launched,adenosine receptor agonist,P29275
CHEMBL4853381,,SCH-58261,Preclinical,adenosine receptor antagonist,P29275
CHEMBL4874146,,SLV-320,Phase 2,adenosine receptor antagonist,P29275
CHEMBL447664,CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N,vipadenant,Phase 1,adenosine receptor antagonist,P29275
CHEMBL4846009,,ZM-241385,Preclinical,adenosine receptor antagonist,P29275
CHEMBL2168889,,2-chloro-N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P29275
CHEMBL4867466,,2-chloroadenosine,Preclinical,adenosine receptor agonist,P29275
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,P0DMS8
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,P0DMS8
CHEMBL4866863,,aminothiadiazole,Phase 2,inosine monophosphate dehydrogenase inhibitor,P0DMS8
CHEMBL4202825,C1CC1COC2=CC=C(C=C2)C3=C(C(=NC(=C3C#N)SCC(=O)N)N)C#N,BAY-60-6583,Preclinical,adenosine receptor agonist,P0DMS8
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P0DMS8
CHEMBL4857678,,CF102,Phase 2,adenosine receptor agonist,P0DMS8
CHEMBL1551336,C1=CC(=C(C=C1C2=C(SC(=N2)N)C3=CC=NC=C3)Cl)Cl.Cl.Cl,CGH2466,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4879351,,CGS-15943,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4303688,CCNC(=O)[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=C(N=C32)NCCC4=CC=C(C=C4)CCC(=O)O)N)O)O,CGS-21680,Preclinical,adenosine receptor agonist,P0DMS8
CHEMBL4875123,,dexniguldipine,Phase 2,calmodulin antagonist,P0DMS8
CHEMBL4870151,,DPCPX,Phase 1,adenosine receptor antagonist,P0DMS8
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,P0DMS8
CHEMBL4861828,,GS-6201,Phase 1,adenosine receptor antagonist,P0DMS8
CHEMBL4871645,,HEMADO,Preclinical,adenosine receptor agonist,P0DMS8
CHEMBL4754465,CNC(=O)[C@@H]1[C@@H]([C@@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)NCC4=CC(=CC=C4)I)O)O,IB-MECA,Phase 3,adenosine receptor agonist,P0DMS8
CHEMBL3736368,CCN1C2=C(C(=O)N(C1=O)CC)NC(=N2)/C=C/C3=CC(=C(C=C3)OC)OC,istradefylline,Launched,adenosine receptor antagonist,P0DMS8
CHEMBL4848909,,KW-3902,Phase 3,adenosine receptor antagonist,P0DMS8
CHEMBL4856523,,MRS-1220,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL265096,CCOC(=O)C1=C(NC(=C(C1C#CC2=CC=CC=C2)C(=O)OCC3=CC=C(C=C3)[N+](=O)[O-])C4=CC=CC=C4)C,MRS-1334,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL1321988,C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S,MRS-3777,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4868351,,NECA,Launched,adenosine receptor agonist,P0DMS8
CHEMBL1200326,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC.Cl,nicardipine,Launched,calcium channel blocker,P0DMS8
CHEMBL4863705,,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P0DMS8
CHEMBL4870232,,preladenant,Phase 3,adenosine receptor antagonist,P0DMS8
CHEMBL1593850,CC[C@@H]1CN2C(=C3C(=NC(=N3)C4=CC=CC=C4)N(C2=O)C)N1.Cl,PSB-11,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4871855,,PSB-1115,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL1316674,CCCCN1C(=O)C2=C(N=C(N2)C34CC5CC(C3)CC4C5)N(C1=O)CCCO,PSB-36,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4869798,,PSB-603,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4303537,CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4C(C([C@H](O4)CO)O)O)N,regadenoson,Launched,adenosine receptor agonist,P0DMS8
CHEMBL4853381,,SCH-58261,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL4874146,,SLV-320,Phase 2,adenosine receptor antagonist,P0DMS8
CHEMBL447664,CC1=C(C=CC(=C1)CN2C3=NC(=NC(=C3N=N2)C4=CC=CO4)N)N,vipadenant,Phase 1,adenosine receptor antagonist,P0DMS8
CHEMBL4846009,,ZM-241385,Preclinical,adenosine receptor antagonist,P0DMS8
CHEMBL2168889,,2-chloro-N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,P0DMS8
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,Q9BTU6
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,Q8TCG2
CHEMBL4303303,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)C4=CC=C(O4)CNCCS(=O)(=O)C)OC5=CC6=NC=NN6C=C5,PI4KIII-beta-inhibitor-1,Preclinical,PI4K inhibitor,Q8TCG2
CHEMBL606298,C1=NC(=C2C(=N1)N(C=N2)C3[C@@H]([C@@H]([C@H](O3)CO)O)O)N,adenosine,Launched,adenosine receptor agonist,Q8TD43
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q8TD43
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q8TD43
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,Q8TD43
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q8TD43
CHEMBL4874755,,YM-58483,Preclinical,calcium channel blocker,Q8TD43
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P33121
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P33121
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q9NUB1
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q9NUB1
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q9NR19
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q9NR19
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q08828
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q08828
CHEMBL4870146,,SQ-22536,Preclinical,adenylyl cyclase inhibitor,Q08828
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P16220
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,P16220
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P09467
CHEMBL601823,COC1=CC=C(C=C1)N(CCCNC(=O)CCl)C(=O)NC2=CC(=CC=C2)Cl,CS-917,Phase 2,fructose biphosphate inhibitor,P09467
CHEMBL4854905,,MDL-29951,Preclinical,glutamate receptor antagonist,P09467
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P49773
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q07343
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q07343
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,Q07343
CHEMBL12856,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,amrinone,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL514800,CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,apremilast,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL1229569,COC1=C(C=C(C=C1)C2CNC(=O)NC2)O[C@H]3C[C@@H]4CC[C@H]3C4,atizoram,Phase 2,phosphodiesterase inhibitor,Q07343
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q07343
CHEMBL32854,COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3,cilomilast,Phase 3,phosphodiesterase inhibitor,Q07343
CHEMBL484785,B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O,crisaborole,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL1527608,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,doxofylline,Launched,adenosine receptor antagonist,Q07343
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,Q07343
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,Q07343
CHEMBL19224,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,papaverine,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL4864511,,piclamilast,Phase 2,phosphodiesterase inhibitor,Q07343
CHEMBL4857497,,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,Q07343
CHEMBL193240,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,roflumilast,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL1114,CN1C=NC2=C1C(=O)NC(=O)N2C,theobromine,Launched,phosphodiesterase inhibitor,Q07343
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q08499
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q08499
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,Q08499
CHEMBL514800,CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,apremilast,Launched,phosphodiesterase inhibitor,Q08499
CHEMBL1229569,COC1=C(C=C(C=C1)C2CNC(=O)NC2)O[C@H]3C[C@@H]4CC[C@H]3C4,atizoram,Phase 2,phosphodiesterase inhibitor,Q08499
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q08499
CHEMBL32854,COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3,cilomilast,Phase 3,phosphodiesterase inhibitor,Q08499
CHEMBL484785,B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O,crisaborole,Launched,phosphodiesterase inhibitor,Q08499
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q08499
CHEMBL1527608,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,doxofylline,Launched,adenosine receptor antagonist,Q08499
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,Q08499
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,Q08499
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q08499
CHEMBL4864511,,piclamilast,Phase 2,phosphodiesterase inhibitor,Q08499
CHEMBL4857497,,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,Q08499
CHEMBL193240,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,roflumilast,Launched,phosphodiesterase inhibitor,Q08499
CHEMBL332750,CCOC1=C(C=C(C=C1)C2=NC(=CS2)C3=NC(=CC=C3)C(=O)O)OCC,tetomilast,Phase 2,phosphodiesterase inhibitor,Q08499
CHEMBL28079,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,zaprinast,Phase 2,phosphodiesterase inhibitor,Q08499
CHEMBL4853932,,zardaverine,Phase 2,phosphodiesterase inhibitor,Q08499
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P11309
CHEMBL1200939,N.Cl,ammonium-perfluorocaprylate,Phase 1,Pim kinase inhibitor,P11309
CHEMBL4879359,,AZD1208,Phase 1,Pim kinase inhibitor,P11309
CHEMBL3544943,C1CC(NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl.Cl,BMS-863233,Phase 1/Phase 2,CDC inhibitor,P11309
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P11309
CHEMBL4872220,,GF109203X,Preclinical,PKC inhibitor,P11309
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P11309
CHEMBL4856902,,PIM-1-Inhibitor-2,Preclinical,Pim kinase inhibitor,P11309
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P11309
CHEMBL4846077,,SGI-1776,Phase 1,Pim kinase inhibitor,P11309
CHEMBL4303289,C1=CC(=CC(=C1)C(F)(F)F)/C=C/2\C(=O)NC(=O)S2,SMI-4a,Preclinical,Pim kinase inhibitor,P11309
CHEMBL4850851,,TCS-PIM-1-1,Preclinical,Pim kinase inhibitor,P11309
CHEMBL4863760,,10-DEBC,Preclinical,AKT inhibitor,P11309
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q13131
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q13131
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q13131
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,Q13131
CHEMBL170988,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,phenformin,Withdrawn,AMPK activator,Q13131
CHEMBL4303623,CC1=CC(=C(C=C1)OCCSC2=NC=CC=N2)Br,ZLN024,Preclinical,AMPK activator,Q13131
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,Q9Y478
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q9Y478
CHEMBL1431,CN(C)C(=N)N=C(N)N,metformin,Launched,insulin sensitizer,Q9Y478
CHEMBL4303623,CC1=CC(=C(C=C1)OCCSC2=NC=CC=N2)Br,ZLN024,Preclinical,AMPK activator,Q9Y478
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,O43741
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,O43741
CHEMBL1775011,C1=CC=C(C=C1)C2=NC3=C(N=CN=C3N2[C@H]4[C@@H]([C@@H]([C@H](O4)COP(=O)(O)O)O)O)N,adenosine-phosphate,Launched,adenosine receptor agonist,P06737
CHEMBL4303657,CN(C(=O)[C@@H]([C@H](CC1=CC=CC=C1)NC(=O)C2=CC3=C(N2)C=CC(=C3)Cl)O)OC,CP-316819,Preclinical,glycogen phosphorylase inhibitor,P06737
CHEMBL4869279,,CP-91149,Preclinical,glycogen phosphorylase inhibitor,P06737
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P06737
CHEMBL4872529,,MC-1,Phase 3,,P06737
CHEMBL1236183,C([C@H]([C@@H]([C@@H](C(=O)CO)O)O)O)O,tagatose,Launched,phosphorylase inhibitor,P06737
CHEMBL4870046,,uric-acid,Phase 3,,P06737
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,O95477
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,O95477
CHEMBL4869371,,probucol,Launched,atherogenesis inhibitor,O95477
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P08183
CHEMBL4872429,,dofequidar,Phase 3,MRP inhibitor|P glycoprotein inhibitor,P08183
CHEMBL4862237,,DPPE,Phase 3,histamine receptor antagonist,P08183
CHEMBL4868171,,elacridar,Phase 1,P glycoprotein inhibitor,P08183
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,P08183
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,P08183
CHEMBL3745690,,Ko143,Preclinical,BCRP inhibitor,P08183
CHEMBL348475,COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC,tariquidar,Phase 3,P glycoprotein inhibitor,P08183
CHEMBL4878823,,valspodar,Phase 3,P glycoprotein inhibitor,P08183
CHEMBL444172,C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47,zosuquidar,Phase 3,P glycoprotein inhibitor,P08183
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,O95342
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,O95342
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,O95342
CHEMBL4869371,,probucol,Launched,atherogenesis inhibitor,O95342
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q92887
CHEMBL4870037,,MK-571,Phase 2,leukotriene receptor antagonist,Q92887
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,O60706
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,O60706
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,O60706
CHEMBL1200338,CC(C(C)(C)C)N=C(NC#N)NC1=CC=NC=C1.O,pinacidil,Launched,ATP channel activator|potassium channel activator,O60706
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P45844
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P42684
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P42684
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q04771
CHEMBL4874202,,DMH1,Preclinical,ALK tyrosine kinase receptor inhibitor,Q04771
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,Q04771
CHEMBL4870084,,LDN-212854,Preclinical,bone morphogenic protein inhibitor,Q04771
CHEMBL4869412,,LDN193189,Preclinical,bone morphogenic protein inhibitor,Q04771
CHEMBL4862402,,ML347,Preclinical,ALK tyrosine kinase receptor inhibitor,Q04771
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P36896
CHEMBL4871718,,EW-7197,Phase 2,TGF beta receptor inhibitor,P36896
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P37023
CHEMBL4862402,,ML347,Preclinical,ALK tyrosine kinase receptor inhibitor,P37023
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P25098
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P35626
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q9Y4W6
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q9UM73
CHEMBL1738797,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,alectinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL4858905,,AP26113,Phase 2,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL4858098,,ASP3026,Phase 1,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL4863743,,AZD3463,Preclinical,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,Q9UM73
CHEMBL3545311,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,brigatinib,Launched,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,Q9UM73
CHEMBL4872798,,CEP-37440,Phase 1,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL2403108,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL601719,C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,crizotinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL1983268,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,Q9UM73
CHEMBL4860561,,GSK1838705A,Preclinical,insulin growth factor receptor inhibitor,Q9UM73
CHEMBL3941724,CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC(=NC=C3Cl)NC4=C(C=C(C=C4)N5CCN(CC5)C(=O)C)OC)OC,KRCA-0008,Preclinical,ALK inihibitor,Q9UM73
CHEMBL3286830,C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,lorlatinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL4873176,,NVP-TAE684,Preclinical,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL4303155,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PF-06463922,Launched,ALK tyrosine kinase receptor inhibitor,Q9UM73
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q16671
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,O14727
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P10398
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,O43681
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P08243
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,P08243
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P08243
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P08243
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P00966
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P00966
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P00966
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P00966
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q96Q40
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q13304
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q14643
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q14643
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q13564
CHEMBL2364622,C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N.Cl,pevonedistat,Phase 3,nedd activating enzyme inhibitor,Q13564
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P49902
CHEMBL4851831,,ribavirin,Launched,antiviral,P49902
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P47900
CHEMBL1364808,CC1=CC=C(C=C1)S(=O)(=O)O.C1=CC=C2C(=C1)C(=O)C(=[N+]2[O-])C3=CC=CC=N3,PIT,Preclinical,purinergic receptor antagonist,P47900
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P47900
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q96G91
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,Q96G91
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,Q96G91
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine-5'-triphosphate,Launched,purinergic receptor activator,Q96G91
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q9BPV8
CHEMBL339385,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N,diadenosine-tetraphosphate,Phase 1,adenosine kinase inhibitor,Q9BPV8
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,Q9BPV8
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P41231
CHEMBL339385,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)N,diadenosine-tetraphosphate,Phase 1,adenosine kinase inhibitor,P41231
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P41231
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine-5'-triphosphate,Launched,purinergic receptor activator,P41231
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P51582
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine-5'-triphosphate,Launched,purinergic receptor activator,P51582
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P21817
CHEMBL102358,C1=CC=C(C=C1)/C=C/C(=O)NCCO,brolitene,Launched,muscle relaxant,P21817
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P21817
CHEMBL1201288,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],dantrolene,Launched,calcium channel blocker,P21817
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,P21817
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P21817
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q92736
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q92736
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q92736
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,Q92736
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q15413
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q15413
CHEMBL1201288,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-],dantrolene,Launched,calcium channel blocker,Q15413
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,P12235
CHEMBL12318,C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl,clodronic-acid,Launched,bone resorption inhibitor,P12235
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q07912
CHEMBL4874256,,AIM-100,Preclinical,tyrosine kinase inhibitor,Q07912
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q07912
CHEMBL4196175,,GNF-7,Preclinical,glucokinase inhibitor|protein kinase inhibitor,Q07912
CHEMBL2106579,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)([O-])OP(=O)(O)[O-])O)O)N.[Na+].[Na+],adenosine-triphosphate,Phase 2,adenosine receptor agonist,Q96QT4
CHEMBL1014671,,cyclic-AMP,Preclinical,,Q96QT4
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,Q96QT4
CHEMBL4847902,,adiphenine,Launched,acetylcholine receptor antagonist,P02708
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,P02708
CHEMBL1358790,CC[N+](CC)(CCCNC1=CC(=O)C(=CC1=O)NCCC[N+](CC)(CC)CC2=CC=CC=C2)CC3=CC=CC=C3,benzoquinonium-dibromide,Preclinical,cholinergic receptor antagonist,P02708
CHEMBL1398654,C[N+]1(CC2=C(C1)C(=C(C(=C2Cl)Cl)Cl)Cl)CC[N+](C)(C)C,chlorisondamine-diiodide,Preclinical,acetylcholine receptor antagonist,P02708
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P02708
CHEMBL1200993,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],gallamine-triethiodide,Launched,acetylcholine receptor antagonist,P02708
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,P02708
CHEMBL1200757,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-],pancuronium,Launched,acetylcholine receptor antagonist,P02708
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,P02708
CHEMBL1157,C(CCC(=O)O)CC(=O)O,adipic-acid,Preclinical,solute carrier family member inhibitor,Q4U2R8
CHEMBL2105950,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)[O-])C.[Na+],amoxicillin,Launched,penicillin binding protein inhibitor,Q4U2R8
CHEMBL1644,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,Q4U2R8
CHEMBL1057,C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O,fluorescein,Launched,,Q4U2R8
CHEMBL1200344,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[Na+],nafcillin,Launched,bacterial cell wall synthesis inhibitor,Q4U2R8
CHEMBL897,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,probenecid,Launched,uricosuric blocker,Q4U2R8
CHEMBL463,C1=CC(=CC=C1C(=O)NCC(=O)O)N,4-aminohippuric-acid,Launched,,Q4U2R8
CHEMBL3393145,C1CN(CCC1NC(=O)COC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CC4=CC=CC=C4,adiporon,Preclinical,adiponectin receptor agonist,Q96A54
CHEMBL3393145,C1CN(CCC1NC(=O)COC2=CC=C(C=C2)C(=O)C3=CC=CC=C3)CC4=CC=CC=C4,adiporon,Preclinical,adiponectin receptor agonist,Q86V24
CHEMBL66,C1=CC(=C(C=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,taxifolin,Phase 2,opioid receptor antagonist,Q86V24
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,P00533
CHEMBL2105712,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,afatinib,Launched,EGFR inhibitor,P00533
CHEMBL4866332,,AG-490,Preclinical,EGFR inhibitor|JAK inhibitor,P00533
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P00533
CHEMBL4858905,,AP26113,Phase 2,ALK tyrosine kinase receptor inhibitor,P00533
CHEMBL4779286,CC1=CC=C(C=C1)S(=O)(=O)O.C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl,AST-1306,Phase 1,EGFR inhibitor,P00533
CHEMBL4855523,,AV-412,Phase 1,protein tyrosine kinase inhibitor,P00533
CHEMBL4876253,,AZD3759,Phase 2/Phase 3,EGFR inhibitor,P00533
CHEMBL4860251,,AZD8931,Phase 2,EGFR inhibitor,P00533
CHEMBL4859125,,AZ5104,Preclinical,EGFR inhibitor,P00533
CHEMBL1358485,CCN(CC)CC1CCN(CC1)C2=NC=C3C(=N2)C(=NC=N3)NC4=CC(=C(C=C4)F)Cl,BIBU-1361,Preclinical,EGFR inhibitor,P00533
CHEMBL4868717,,BIBX-1382,Phase 1,EGFR inhibitor,P00533
CHEMBL4875880,,BMS-599626,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,P00533
CHEMBL4852054,,BMS-690514,Phase 2,EGFR inhibitor|VEGFR inhibitor,P00533
CHEMBL3545311,CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC,brigatinib,Launched,ALK tyrosine kinase receptor inhibitor|EGFR inhibitor,P00533
CHEMBL4867134,,canertinib,Phase 3,EGFR inhibitor,P00533
CHEMBL4863559,,CGP-52411,Preclinical,EGFR inhibitor,P00533
CHEMBL4853924,,CGP-53353,Preclinical,EGFR inhibitor|PKC inhibitor,P00533
CHEMBL3707295,,chrysophanic-acid,Preclinical,EGFR inhibitor,P00533
CHEMBL3985592,COC1=C(C=CC(=C1)NC2CN(C2)CCF)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F,CNX-2006,Preclinical,EGFR inhibitor,P00533
CHEMBL4855571,,CUDC-101,Phase 1,EGFR inhibitor,P00533
CHEMBL2105719,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4.O,dacomitinib,Launched,EGFR inhibitor,P00533
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P00533
CHEMBL3787344,CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)C(=CC=C3)Cl,EGF816,Phase 2,EGFR inhibitor,P00533
CHEMBL4848415,,erbstatin-analog,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,P00533
CHEMBL553,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,erlotinib,Launched,EGFR inhibitor,P00533
CHEMBL939,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4,gefitinib,Launched,EGFR inhibitor,P00533
CHEMBL1356199,CS(=O)(=O)CCNCC1=NC(=CS1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.Cl.Cl,GW-583340,Preclinical,EGFR inhibitor,P00533
CHEMBL178654,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl)C#N)NC(=O)/C=C/CN(C)C,HKI-357,Phase 1,EGFR inhibitor,P00533
CHEMBL2087361,C#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4,icotinib,Launched,EGFR inhibitor,P00533
CHEMBL554,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,lapatinib,Launched,EGFR inhibitor,P00533
CHEMBL1200409,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.O.Cl,lidocaine,Launched,histamine receptor agonist,P00533
CHEMBL1614707,C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)/C=C/C4=CC=C(C=C4)C(F)(F)F,mubritinib,Phase 1,protein tyrosine kinase inhibitor,P00533
CHEMBL3989921,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\C(=O)O)\C(=O)O,neratinib,Launched,EGFR inhibitor,P00533
CHEMBL4851203,,olmutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor|EGFR inhibitor,P00533
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P00533
CHEMBL3186743,COCCOC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCO,OSI-420,Preclinical,EGFR inhibitor,P00533
CHEMBL3545063,CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O,osimertinib,Launched,EGFR inhibitor,P00533
CHEMBL1112822,,PD-153035,Phase 1,EGFR inhibitor,P00533
CHEMBL4852986,,PD-158780,Preclinical,EGFR inhibitor,P00533
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,P00533
CHEMBL285063,C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br,PD-168393,Preclinical,EGFR inhibitor,P00533
CHEMBL4878110,,pelitinib,Phase 2,EGFR inhibitor,P00533
CHEMBL1963502,C[C@H](C1=CC=CC=C1)NC2=NC=NC3=C2C=C(N3)C4=CC=C(C=C4)O,PKI-166,Phase 1,EGFR inhibitor,P00533
CHEMBL3545154,COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C,poziotinib,Phase 2,EGFR inhibitor,P00533
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P00533
CHEMBL4527443,CC(=O)N1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC,rociletinib,Phase 3,EGFR inhibitor,P00533
CHEMBL4856995,,tyrphostin-AG-1478,Preclinical,EGFR inhibitor,P00533
CHEMBL4856141,,tyrphostin-AG-18,Preclinical,EGFR inhibitor|tyrosine kinase inhibitor,P00533
CHEMBL1255754,C1=CC=C(C=C1)/C=C(\C#N)/C(=O)NC2=CC=CC=C2,tyrphostin-AG-494,Preclinical,EGFR inhibitor,P00533
CHEMBL4848128,,tyrphostin-AG-835,Preclinical,protein tyrosine kinase inhibitor,P00533
CHEMBL4876379,,tyrphostin-AG-99,Preclinical,tyrosine kinase inhibitor,P00533
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P00533
CHEMBL4848946,,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P00533
CHEMBL4877936,,WHI-P154,Preclinical,JAK inhibitor,P00533
CHEMBL4526902,,WZ-3146,Preclinical,EGFR inhibitor,P00533
CHEMBL584671,CC1=C(N=C(S1)C)C(C)N(C)CC2=C(N=C3N2C=CS3)C(=O)N4CCCCCCC4,WZ-4002,Preclinical,EGFR inhibitor,P00533
CHEMBL1643989,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)SC4=CC=CC(=C4)NC(=O)C=C)Cl,WZ8040,Preclinical,EGFR inhibitor,P00533
CHEMBL3544983,CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,P00533
CHEMBL4865501,,ZM-306416,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,P00533
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,P04626
CHEMBL2105712,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,afatinib,Launched,EGFR inhibitor,P04626
CHEMBL2103842,C[C@@H]1COC(=N1)NC2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=NC=CS5)Cl,ARRY-334543,Phase 2/Phase 3,EGFR inhibitor,P04626
CHEMBL4779286,CC1=CC=C(C=C1)S(=O)(=O)O.C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=C(C=C3)OCC4=CC(=CC=C4)F)Cl,AST-1306,Phase 1,EGFR inhibitor,P04626
CHEMBL4855523,,AV-412,Phase 1,protein tyrosine kinase inhibitor,P04626
CHEMBL4860251,,AZD8931,Phase 2,EGFR inhibitor,P04626
CHEMBL4868717,,BIBX-1382,Phase 1,EGFR inhibitor,P04626
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P04626
CHEMBL4875880,,BMS-599626,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,P04626
CHEMBL4852054,,BMS-690514,Phase 2,EGFR inhibitor|VEGFR inhibitor,P04626
CHEMBL4867134,,canertinib,Phase 3,EGFR inhibitor,P04626
CHEMBL483321,CC1=NC=C(C=C1)OC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)/C=C/CNC(=O)COC)C,CP-724714,Phase 2,EGFR inhibitor|protein tyrosine kinase inhibitor,P04626
CHEMBL4855571,,CUDC-101,Phase 1,EGFR inhibitor,P04626
CHEMBL2105719,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4.O,dacomitinib,Launched,EGFR inhibitor,P04626
CHEMBL4871625,,FERb-033,Preclinical,EGFR inhibitor,P04626
CHEMBL1356199,CS(=O)(=O)CCNCC1=NC(=CS1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl.Cl.Cl,GW-583340,Preclinical,EGFR inhibitor,P04626
CHEMBL554,CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl,lapatinib,Launched,EGFR inhibitor,P04626
CHEMBL1614707,C1=CC(=CC=C1CCCCN2C=CN=N2)OCC3=COC(=N3)/C=C/C4=CC=C(C=C4)C(F)(F)F,mubritinib,Phase 1,protein tyrosine kinase inhibitor,P04626
CHEMBL3989921,CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C.C(=C\C(=O)O)\C(=O)O,neratinib,Launched,EGFR inhibitor,P04626
CHEMBL285063,C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br,PD-168393,Preclinical,EGFR inhibitor,P04626
CHEMBL3545154,COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C,poziotinib,Phase 2,EGFR inhibitor,P04626
CHEMBL4849513,,TAK-285,Phase 1,EGFR inhibitor,P04626
CHEMBL3989868,CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5,tucatinib,Phase 3,EGFR inhibitor,P04626
CHEMBL4871273,,tyrphostin-AG-825,Preclinical,protein tyrosine kinase inhibitor,P04626
CHEMBL4877167,,tyrphostin-AG-879,Preclinical,tyrosine kinase inhibitor,P04626
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P04626
CHEMBL4870392,,WAY-200070,Preclinical,estrogen receptor agonist,P04626
CHEMBL584671,CC1=C(N=C(S1)C)C(C)N(C)CC2=C(N=C3N2C=CS3)C(=O)N4CCCCCCC4,WZ-4002,Preclinical,EGFR inhibitor,P04626
CHEMBL3544983,CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,P04626
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,Q15303
CHEMBL2105712,CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,afatinib,Launched,EGFR inhibitor,Q15303
CHEMBL4875880,,BMS-599626,Phase 1,EGFR inhibitor|protein tyrosine kinase inhibitor,Q15303
CHEMBL4867134,,canertinib,Phase 3,EGFR inhibitor,Q15303
CHEMBL2105719,COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4.O,dacomitinib,Launched,EGFR inhibitor,Q15303
CHEMBL3545154,COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C,poziotinib,Phase 2,EGFR inhibitor,Q15303
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q15303
CHEMBL4870392,,WAY-200070,Preclinical,estrogen receptor agonist,Q15303
CHEMBL4853826,,AEE788,Phase 1/Phase 2,EGFR inhibitor|VEGFR inhibitor,P22607
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P22607
CHEMBL3526086,,brivanib-alaninate,Phase 3,FGFR inhibitor|VEGFR inhibitor,P22607
CHEMBL4303231,CC1=NC(=NO1)CN2C=NC3=C2C(=O)N(C(=O)N3C)C,CH-5183284,Phase 2,fibroblast growth factor inhibitor,P22607
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P22607
CHEMBL3545376,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,erdafitinib,Launched,FGFR inhibitor,P22607
CHEMBL4796872,C[C@@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO,LY2874455,Phase 1,FGFR antagonist,P22607
CHEMBL1908391,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5,masitinib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor,P22607
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P22607
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P22607
CHEMBL4854312,,NVP-BGJ398,Phase 3,FGFR inhibitor,P22607
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P22607
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P22607
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P22607
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,P03372
CHEMBL2105618,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCCC34,allylestrenol,Launched,steroidal progestin,P03372
CHEMBL4876489,,AZD9496,Phase 1,estrogen receptor agonist,P03372
CHEMBL2106615,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O.CC(=O)O,bazedoxifene,Launched,selective estrogen receptor modulator (SERM),P03372
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P03372
CHEMBL418971,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,bisphenol-A,Phase 1,synthetic estrogen,P03372
CHEMBL290106,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,bithionol,Withdrawn,autotaxin inhibitor,P03372
CHEMBL1200761,COC1=CC=C(C=C1)C(=C(C2=CC=C(C=C2)OC)Cl)C3=CC=C(C=C3)OC,chlorotrianisene,Launched,estrogenic hormone,P03372
CHEMBL2355051,CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3,clomifene,Launched,estrogen receptor antagonist,P03372
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,P03372
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P03372
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone-sulfate,Launched,androgen receptor agonist|estrogen receptor agonist,P03372
CHEMBL1533,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34,desogestrel,Launched,progesterone receptor agonist,P03372
CHEMBL1018,C/C=C(/C(=C/C)/C1=CC=C(C=C1)O)\C2=CC=C(C=C2)O,dienestrol,Launched,estrogen receptor agonist,P03372
CHEMBL4857863,,diethylstilbestrol,Withdrawn,estrogen receptor agonist,P03372
CHEMBL4758803,CC/C(=C(\C1=CC=C(C=C1)OCCN(C)C)/C2=CC(=CC=C2)O)/C3=CC=CC=C3,droloxifene,Phase 3,selective estrogen receptor modulator (SERM),P03372
CHEMBL1093458,CC/C(=C(\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)OCCNC)/C3=CC=CC=C3,endoxifen,Phase 2,estrogen receptor antagonist,P03372
CHEMBL198877,C1[C@H](COC2=C1C=CC(=C2)O)C3=CC=C(C=C3)O,equol,Launched,estrogen receptor agonist,P03372
CHEMBL4853332,,erteberel,Phase 2,estrogen receptor agonist,P03372
CHEMBL1230314,C[C@]12CC[C@H]3[C@H]([C@@H]1[C@H]([C@H]([C@@H]2O)O)O)CCC4=C3C=CC(=C4)O,estetrol,Phase 3,selective estrogen receptor modulator (SERM),P03372
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol,Launched,estrogen receptor agonist,P03372
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol-valerate,Launched,estrogen receptor agonist,P03372
CHEMBL1200430,CC(=O)OC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4O)C,estradiol-acetate,Launched,estrogen receptor agonist,P03372
CHEMBL430289,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,estradiol-benzoate,Preclinical,contraceptive agent,P03372
CHEMBL3039335,C[C@]12CCC3C(C1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O,estradiol-cypionate,Launched,estrogen receptor agonist,P03372
CHEMBL1200721,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],estramustine,Launched,DNA alkylating agent,P03372
CHEMBL1756,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,estramustine-phosphate,Launched,DNA synthesis inhibitor|microtubule inhibitor,P03372
CHEMBL4867163,,estriol,Launched,estrogen receptor agonist,P03372
CHEMBL494753,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O,estrone,Launched,estrogen receptor agonist|estrogenic hormone,P03372
CHEMBL1200980,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1,estropipate,Launched,estrogen receptor agonist,P03372
CHEMBL4864802,,ethinyl-estradiol,Launched,estrogen receptor agonist|estrogenic hormone,P03372
CHEMBL1200624,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,ethynodiol-diacetate,Launched,,P03372
CHEMBL1531,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,etonogestrel,Launched,progesterone receptor agonist,P03372
CHEMBL4742841,CC/C(=C(\CC)/C1=CC=C(C=C1)OP(=O)(O)O)/C2=CC=C(C=C2)OP(=O)(O)O,fosfestrol,Launched,synthetic estrogen,P03372
CHEMBL1712246,C[C@]12CC[C@H]3C([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,fulvestrant,Launched,estrogen receptor antagonist,P03372
CHEMBL3581693,CC/C(=C(/C1=CC=C(C=C1)/C=C/C(=O)O)\C2=CC3=C(C=C2)NN=C3)/C4=C(C=C(C=C4)F)Cl,GDC-0810,Phase 2,selective estrogen receptor destabilizer,P03372
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P03372
CHEMBL4853354,,gestrinone,Launched,progesterone receptor antagonist,P03372
CHEMBL9225,CC[C@H](C1=CC=C(C=C1)O)[C@@H](CC)C2=CC=C(C=C2)O,hexestrol,Launched,synthetic estrogen,P03372
CHEMBL4873567,,lasofoxifene,Launched,selective estrogen receptor modulator (SERM),P03372
CHEMBL305242,C[C@H]1CC2C(CC[C@]3(C2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,medroxyprogesterone-acetate,Launched,progesterone receptor agonist,P03372
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P03372
CHEMBL4750003,CC12CCC3C(C1CC[C@@]2(C#C)O)CCC4=C3C=CC(=C4)OC,mestranol,Launched,estrogen receptor agonist,P03372
CHEMBL1572655,C1=CC=C(C(=C1)[C@H](C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,mitotane,Launched,antineoplastic agent,P03372
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,P03372
CHEMBL1200934,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34,norgestimate,Launched,progesterone receptor agonist,P03372
CHEMBL4873643,,norgestrel,Launched,progesterone receptor agonist,P03372
CHEMBL2105395,C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C3=CC=C(C=C3)OCCO)/CCCl,ospemifene,Launched,selective estrogen receptor modulator (SERM),P03372
CHEMBL4851890,,PPT,Preclinical,estrogen receptor agonist,P03372
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,P03372
CHEMBL2105394,CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C,promestriene,Launched,estrogen receptor agonist,P03372
CHEMBL1201165,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC5CCCC5,quinestrol,Launched,estrogen receptor agonist,P03372
CHEMBL4865006,,raloxifene,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P03372
CHEMBL4303319,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)C(F)(F)F)O)C,SNG-1153,Preclinical,selective estrogen receptor modulator (SERM),P03372
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P03372
CHEMBL2103774,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,tibolone,Launched,androgen receptor agonist|estrogen receptor agonist|progesterone receptor agonist,P03372
CHEMBL4752424,CN(C)CCOC1=CC=C(C=C1)/C(=C(\CCCl)/C2=CC=CC=C2)/C3=CC=CC=C3,toremifene,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P03372
CHEMBL4870794,,Y-134,Preclinical,estrogen receptor antagonist,P03372
CHEMBL4869768,,ZK-164015,Preclinical,estrogen receptor antagonist,P03372
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,P03372
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,P62508
CHEMBL418971,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,bisphenol-A,Phase 1,synthetic estrogen,P62508
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P62508
CHEMBL8145,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,daidzein,Phase 2,estrogen receptor agonist,P62508
CHEMBL4857863,,diethylstilbestrol,Withdrawn,estrogen receptor agonist,P62508
CHEMBL192509,CCN(CC)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O,DY131,Preclinical,estrogen-related receptor agonist,P62508
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P62508
CHEMBL564769,CC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,P62508
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q13393
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,Q13393
CHEMBL4870577,,FIPI,Preclinical,phospholipase inhibitor,Q13393
CHEMBL245621,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F,halopemide,Phase 2,phospholipase inhibitor,Q13393
CHEMBL4867694,,VU0155069,Preclinical,phospholipase inhibitor,Q13393
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q05655
CHEMBL2107337,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7.Cl,enzastaurin,Phase 3,PKC inhibitor,Q05655
CHEMBL4847929,,go-6983,Preclinical,protein kinase inhibitor,Q05655
CHEMBL2165402,C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4O)C)O)O)CO,ingenol,Launched,PKC activator,Q05655
CHEMBL1863513,C/C=C(/C)\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C,ingenol-mebutate,Launched,PKC activator,Q05655
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,Q05655
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q05655
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,Q05655
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q02156
CHEMBL2165402,C[C@@H]1C[C@@H]2[C@@H](C2(C)C)[C@@H]3C=C([C@H]([C@]4([C@@]1(C3=O)C=C([C@@H]4O)C)O)O)CO,ingenol,Launched,PKC activator,Q02156
CHEMBL1863513,C/C=C(/C)\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C,ingenol-mebutate,Launched,PKC activator,Q02156
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,Q02156
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q02156
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,Q02156
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,Q02156
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q04759
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q04759
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,Q04759
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,Q04759
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q04759
CHEMBL4865156,,afimoxifene,Phase 2,estrogen receptor antagonist,Q05513
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,Q05513
CHEMBL4872220,,GF109203X,Preclinical,PKC inhibitor,Q05513
CHEMBL4847929,,go-6983,Preclinical,protein kinase inhibitor,Q05513
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q05513
CHEMBL4864418,,AF38469,Preclinical,sortilin inhibitor,Q99523
CHEMBL4857081,,AG-1024,Preclinical,insulin growth factor receptor inhibitor,P08069
CHEMBL4863743,,AZD3463,Preclinical,ALK tyrosine kinase receptor inhibitor|insulin growth factor receptor inhibitor,P08069
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P08069
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P08069
CHEMBL1154171,,BMS-754807,Phase 2,IGF-1 inhibitor,P08069
CHEMBL2403108,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,P08069
CHEMBL4860561,,GSK1838705A,Preclinical,insulin growth factor receptor inhibitor,P08069
CHEMBL466397,CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F,GSK1904529A,Preclinical,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,P08069
CHEMBL1091644,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,linsitinib,Phase 3,IGF-1 inhibitor,P08069
CHEMBL4303361,C1=C(C=C(C(=C1O)O)O)CNC(=S)/C=C/C2=CC(=C(C(=C2)Br)O)O,NT157,Preclinical,IGF-1 inhibitor,P08069
CHEMBL4866959,,NVP-ADW742,Preclinical,insulin growth factor receptor inhibitor,P08069
CHEMBL4797365,C1CN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6.Cl.Cl,NVP-AEW541,Preclinical,IGF-1 inhibitor,P08069
CHEMBL61,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,podophyllotoxin,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P08069
CHEMBL4845996,,PQ-401,Preclinical,IGF-1 inhibitor,P08069
CHEMBL4853537,,XL228,Phase 1,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,P08069
CHEMBL4864488,,AG-14361,Preclinical,PARP inhibitor,P09874
CHEMBL4866767,,BYK-204165,Preclinical,PARP inhibitor,P09874
CHEMBL4870054,,DR-2313,Preclinical,PARP inhibitor,P09874
CHEMBL4303238,C1CN(CCN1CC(=O)NC2=CC=CC3=C2CNC3=O)C(=O)[C@H]4[C@@H]([C@@H]([C@H](O4)N5C=NC6=C(N=CN=C65)N)O)O,EB-47,Preclinical,PARP inhibitor,P09874
CHEMBL4858072,,E7449,Phase 2,PARP inhibitor,P09874
CHEMBL1170047,C1=CC(=C(C=C1C(=O)N)[N+](=O)[O-])I,iniparib,Phase 3,PARP inhibitor,P09874
CHEMBL3833327,CC(CN(C)C)O.CC(CN(C)C)O.CC(CN(C)C)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.CC(=O)NC1=CC=C(C=C1)C(=O)O.C1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O,inosine,Launched,neurotrophic agent,P09874
CHEMBL1805766,,nicotinamide,Launched,protein synthesis stimulant,P09874
CHEMBL1094636,C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N,niraparib,Launched,PARP inhibitor,P09874
CHEMBL4866224,,NU-1025,Preclinical,PARP inhibitor,P09874
CHEMBL521686,C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F,olaparib,Launched,PARP inhibitor,P09874
CHEMBL1821568,,PJ-34,Preclinical,PARP inhibitor,P09874
CHEMBL3833368,CC1([C@@H]2CC[C@]1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2,rucaparib,Phase 3,PARP inhibitor,P09874
CHEMBL3832885,CC1=CC(=C(N1C2=CC=C(C=C2)OC)C)/C=C\3/C(=O)NC(=NC4=CC=CC=C4)S3,S-111,Phase 2,PARP inhibitor,P09874
CHEMBL497608,C[C@]1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N,veliparib,Phase 3,PARP inhibitor,P09874
CHEMBL4859437,,3-amino-benzamide,Phase 2,PARP inhibitor,P09874
CHEMBL4864677,,4-HQN,Preclinical,PARP inhibitor,P09874
CHEMBL4866332,,AG-490,Preclinical,EGFR inhibitor|JAK inhibitor,O60674
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,O60674
CHEMBL3215883,CCCC1(CCC2(CC1)CCN(C2)CCCN(CC)CC)CCC.Cl.Cl,atiprimod,Phase 2,JAK inhibitor|STAT inhibitor,O60674
CHEMBL3112447,,AZD1480,Phase 1,JAK inhibitor,O60674
CHEMBL4428064,,AZ960,Preclinical,JAK inhibitor,O60674
CHEMBL2105759,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,baricitinib,Launched,JAK inhibitor,O60674
CHEMBL2062804,CN1CCN(CC1)C2=CC=CC(=C2)NC3=NN4C=CC=C(C4=N3)C5=CC=C(C=C5)S(=O)(=O)C,CEP-33779,Preclinical,JAK inhibitor,O60674
CHEMBL3936137,CC1=C(C=CC=C1Cl)C2=CC(=C(C=C2F)N3C4=C(C=CC3=O)C=C(C=C4)S(=O)(=O)NC5=NOC=C5)OC,CKD-712,Phase 1,NFkB pathway inhibitor,O60674
CHEMBL4303567,C[C@H]1CC[C@@H]2[C@]13C[C@H]([C@](O3)(CC2=C)O)C(C)C,curcumol,Phase 1,JAK inhibitor,O60674
CHEMBL4863704,,cyt387,Phase 3,JAK inhibitor,O60674
CHEMBL4297216,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,O60674
CHEMBL3301607,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,filgotinib,Phase 3,JAK inhibitor,O60674
CHEMBL4872219,,LY2784544,Phase 2,JAK inhibitor,O60674
CHEMBL3545217,,NS-018,Phase 1/Phase 2,JAK inhibitor,O60674
CHEMBL4873353,,NVP-BSK805,Preclinical,JAK inhibitor,O60674
CHEMBL4778465,C1CCN(C1)CCOC2=C3COC/C=C\COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,pacritinib,Phase 3,FLT3 inhibitor|JAK inhibitor,O60674
CHEMBL4536840,C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O,peficitinib,Launched,JAK inhibitor,O60674
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,O60674
CHEMBL1789941,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib,Launched,JAK inhibitor,O60674
CHEMBL1287854,C1CCC(C1)[C@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib-(S),Preclinical,JAK inhibitor,O60674
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,O60674
CHEMBL4869526,,TG-101209,Preclinical,JAK inhibitor,O60674
CHEMBL120563,CN(C)C(=S)SSC(=S)N(C)C,thiram,Launched,,O60674
CHEMBL2103743,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,tofacitinib,Launched,JAK inhibitor,O60674
CHEMBL4877936,,WHI-P154,Preclinical,JAK inhibitor,O60674
CHEMBL4862486,,WP1130,Preclinical,deubiquitinase inhibitor,O60674
CHEMBL4871051,,XL019,Phase 1,JAK inhibitor,O60674
CHEMBL444236,C1(C(C(C(C(C1Br)Br)Br)Br)Br)Br,"1,2,3,4,5,6-hexabromocyclohexane",Preclinical,JAK inhibitor,O60674
CHEMBL4866332,,AG-490,Preclinical,EGFR inhibitor|JAK inhibitor,P52333
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,P52333
CHEMBL3112447,,AZD1480,Phase 1,JAK inhibitor,P52333
CHEMBL4303567,C[C@H]1CC[C@@H]2[C@]13C[C@H]([C@](O3)(CC2=C)O)C(C)C,curcumol,Phase 1,JAK inhibitor,P52333
CHEMBL4863704,,cyt387,Phase 3,JAK inhibitor,P52333
CHEMBL3039513,CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3,decernotinib,Phase 2/Phase 3,JAK inhibitor,P52333
CHEMBL4297216,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,P52333
CHEMBL3301607,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,filgotinib,Phase 3,JAK inhibitor,P52333
CHEMBL4851770,,JAK3-inhibitor-V,Preclinical,JAK inhibitor,P52333
CHEMBL4872219,,LY2784544,Phase 2,JAK inhibitor,P52333
CHEMBL3545217,,NS-018,Phase 1/Phase 2,JAK inhibitor,P52333
CHEMBL4778465,C1CCN(C1)CCOC2=C3COC/C=C\COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,pacritinib,Phase 3,FLT3 inhibitor|JAK inhibitor,P52333
CHEMBL4536840,C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O,peficitinib,Launched,JAK inhibitor,P52333
CHEMBL1789941,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib,Launched,JAK inhibitor,P52333
CHEMBL4865175,,TCS-21311,Preclinical,JAK inhibitor,P52333
CHEMBL4869526,,TG-101209,Preclinical,JAK inhibitor,P52333
CHEMBL2103743,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,tofacitinib,Launched,JAK inhibitor,P52333
CHEMBL4877936,,WHI-P154,Preclinical,JAK inhibitor,P52333
CHEMBL4871051,,XL019,Phase 1,JAK inhibitor,P52333
CHEMBL4849222,,ZM-39923,Preclinical,JAK inhibitor,P52333
CHEMBL4854324,,AG-555,Preclinical,tyrosine kinase inhibitor,P24941
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P24941
CHEMBL4878491,,aminopurvalanol-a,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,P24941
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,P24941
CHEMBL4877789,,BMS-265246,Preclinical,CDK inhibitor,P24941
CHEMBL2074409,,BMS-387032,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,P24941
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P24941
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P24941
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,P24941
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,P24941
CHEMBL4860897,,CGP-60474,Preclinical,CDK inhibitor,P24941
CHEMBL2103840,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO,dinaciclib,Phase 3,CDK inhibitor,P24941
CHEMBL1496098,C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P24941
CHEMBL4857627,,JNJ-7706621,Preclinical,CDK inhibitor,P24941
CHEMBL1331734,COC1=C2C(=C(C=C1)OC)NC3=CC=CC=C3C2=S,NSC-625987,Preclinical,CDK inhibitor,P24941
CHEMBL4868423,,NU-2058,Preclinical,cyclin D inhibitor,P24941
CHEMBL303958,C1CCC(CC1)COC2=NC(=NC(=C2N=O)N)N,NU-6027,Preclinical,CDK inhibitor,P24941
CHEMBL4865572,,olomoucine,Preclinical,CDK inhibitor,P24941
CHEMBL4859598,,PF-573228,Preclinical,focal adhesion kinase inhibitor,P24941
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,P24941
CHEMBL4862981,,PHA-848125,Phase 2,CDK inhibitor|growth factor receptor inhibitor,P24941
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,P24941
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,P24941
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P24941
CHEMBL14762,CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3,roscovitine,Phase 2,CDK inhibitor,P24941
CHEMBL4877589,,RX-3117,Phase 1/Phase 2,CDK inhibitor|DNA synthesis inhibitor,P24941
CHEMBL4856364,,ryuvidine,Preclinical,histone lysine methyltransferase inhibitor,P24941
CHEMBL4852606,,R547,Phase 1,CDK inhibitor,P24941
CHEMBL4858767,,SB-216763,Preclinical,glycogen synthase kinase inhibitor,P24941
CHEMBL4877269,,SCH-900776,Phase 2,CHK inhibitor,P24941
CHEMBL4864204,,SU9516,Preclinical,CDK inhibitor,P24941
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,P24941
CHEMBL4850044,,AGI-5198,Preclinical,isocitrate dehydrogenase inhibitor,O75874
CHEMBL3989931,CC(C)(CNC1=NC(=NC(=N1)C2=NC(=CC=C2)C(F)(F)F)NC3=CC(=NC=C3)C(F)(F)F)O.CS(=O)(=O)O,enasidenib,Launched,isocitrate dehydrogenase inhibitor,O75874
CHEMBL4853219,,ivosidenib,Launched,isocitrate dehydrogenase inhibitor,O75874
CHEMBL4877212,,AGI-6780,Preclinical,isocitrate dehydrogenase inhibitor,P48735
CHEMBL582669,CCCCCCN(C(CC)C1=NC2=CC=CC=C2C(=O)N1C3=CC(=CC=C3)Cl)C(=O)C4=CC=C(C=C4)CC,AGM-1470,Phase 2,cell cycle inhibitor,P50579
CHEMBL1522710,CC(=CC[C@@H]1[C@@](O1)(C)C2[C@@H]([C@@H](CC[C@]23CO3)OC(=O)/C=C/C=C/C=C/C=C/C(=O)O)OC)C,fumagillin,Launched,methionine aminopeptidase inhibitor,P50579
CHEMBL4851692,,L-methionine,Launched,voltage-gated calcium channel ligand,P50579
CHEMBL1234268,CSCC[C@H](C(=O)O)N,methionine,Launched,,P50579
CHEMBL1454910,C1=CC2=C(C=CC(=C2N=C1)O)[N+](=O)[O-],nitroxoline,Launched,cathepsin inhibitor,P50579
CHEMBL1697698,C1=CC2=C(C(=C1)O)N=CC=C2.C1=CC2=C(C(=C1)O)N=CC=C2.OS(=O)(=O)O,oxyquinoline,Launched,chelating agent,P50579
CHEMBL4874171,,TNP-470,Phase 2,methionine aminopeptidase inhibitor,P50579
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,P18825
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P18825
CHEMBL1200379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,apraclonidine,Launched,adrenergic receptor agonist,P18825
CHEMBL4858847,,ARC-239,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P18825
CHEMBL2062257,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O,brimonidine,Launched,adrenergic receptor agonist,P18825
CHEMBL4856906,,BRL-44408,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P18825
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P18825
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P18825
CHEMBL128672,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3.C(=C\C(=O)O)\C(=O)O,ciproxifan,Preclinical,histamine receptor antagonist,P18825
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P18825
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P18825
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,guanaben-acetate,Launched,adrenergic receptor agonist,P18825
CHEMBL2106195,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl,dexmedetomidine,Launched,adrenergic receptor agonist,P18825
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P18825
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P18825
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P18825
CHEMBL862,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,guanfacine,Launched,adrenergic receptor agonist,P18825
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL2104941,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,indoramin,Launched,adrenergic receptor antagonist,P18825
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P18825
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P18825
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P18825
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P18825
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P18825
CHEMBL4867828,,methyldopa,Launched,adrenergic receptor agonist,P18825
CHEMBL4866128,,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL1256287,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC.Cl,moxonidine,Launched,imidazoline receptor agonist,P18825
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P18825
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P18825
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P18825
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P18825
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P18825
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P18825
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P18825
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P18825
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P18825
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P18825
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P18825
CHEMBL4870922,,TC-G-1000,Preclinical,adrenergic receptor agonist,P18825
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P18825
CHEMBL1200329,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl,tizanidine,Launched,adrenergic receptor agonist,P18825
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P18825
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P18825
CHEMBL1256022,CC1=C(C(=CC=C1)C)NC2=NCCCS2.Cl,xylazine,Launched,adrenergic receptor agonist,P18825
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P18825
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P18825
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18825
CHEMBL4873019,,2-BFI,Preclinical,imidazoline receptor ligand,P18825
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,Q9UHC3
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q9UHC3
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q9UHC3
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,Q9UHC3
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,Q9UHC3
CHEMBL424,C1=CC=C(C(=C1)C(=O)O)O,salicylic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,Q9UHC3
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,Q00975
CHEMBL449317,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,hesperidin,Launched,flavanone glycoside,Q00975
CHEMBL452076,CC1=C(C(C(=C(N1)C)C(=O)OC/C=C/C2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OCCOC,cilnidipine,Launched,calcium channel blocker,Q00975
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q00975
CHEMBL1286,CC[C@@H](C(=O)N)N1CCCC1=O,levetiracetam,Launched,calcium channel blocker,Q00975
CHEMBL1404407,COC1=C(C(=C(C=C1)CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)OC)OC.Cl,lomerizine,Launched,calcium channel blocker,Q00975
CHEMBL4863453,,PD-173212,Preclinical,calcium channel blocker,Q00975
CHEMBL4859693,,priralfinamide,Phase 3,sodium channel blocker,Q00975
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q00975
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q00975
CHEMBL1256618,C(CCN=C(N)N)CN.OS(=O)(=O)O,agmatine,Phase 3,nitric oxide synthase inhibitor,Q9Y2I1
CHEMBL430112,CC(C)C1C2CCC(C2)C1N,AGN-192403,Preclinical,imidazoline receptor ligand,Q9Y2I1
CHEMBL1200329,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl,tizanidine,Launched,adrenergic receptor agonist,Q9Y2I1
CHEMBL4848377,,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,P28335
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P28335
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P28335
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P28335
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28335
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P28335
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P28335
CHEMBL1600780,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl,BW-723C86,Preclinical,serotonin receptor agonist,P28335
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P28335
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P28335
CHEMBL1256658,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.Cl,chlorprothixene,Launched,dopamine receptor antagonist,P28335
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P28335
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P28335
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL2104153,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C,cyamemazine,Launched,serotonin receptor antagonist,P28335
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P28335
CHEMBL2110900,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P28335
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P28335
CHEMBL4854128,,desmethylclozapine,Phase 2,acetylcholine receptor agonist,P28335
CHEMBL4303330,CC(C)N(CCC1=CNC2=CC=CC=C21)C(C)C,DIPT,Launched,dopamine reuptake inhibitor|serotonin reuptake inhibitor,P28335
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P28335
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P28335
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P28335
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P28335
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P28335
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P28335
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P28335
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P28335
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P28335
CHEMBL4873760,,MDL-11939,Phase 2,serotonin receptor antagonist,P28335
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P28335
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28335
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P28335
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P28335
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P28335
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P28335
CHEMBL4866128,,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL4848364,,NADPH,Preclinical,,P28335
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P28335
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P28335
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL506999,C1CN(CCN1)C2=NC(=C(C=C2)C(F)(F)F)Cl,ORG-12962,Phase 2,serotonin receptor agonist,P28335
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P28335
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P28335
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P28335
CHEMBL294951,CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1,pizotifen,Launched,serotonin receptor antagonist,P28335
CHEMBL1445061,CN1C2=C(CCNCC2)C3=CC=CC=C31.Cl,PNU-22394,Phase 2,serotonin receptor agonist,P28335
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P28335
CHEMBL1200469,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31.Cl,promazine,Launched,dopamine receptor antagonist,P28335
CHEMBL2104980,C1CN(CCN1CCC2=CC=C(C=C2)F)C(=O)C3=CC=CC4=C3NC=C4C#N.Cl,pruvanserin,Phase 2,serotonin receptor antagonist,P28335
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL4861539,,quinpirol-(-),Phase 2,dopamine receptor agonist,P28335
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P28335
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P28335
CHEMBL4874837,,Ro-60-0175,Preclinical,serotonin receptor agonist,P28335
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P28335
CHEMBL4848167,,RS-102221,Preclinical,serotonin receptor antagonist,P28335
CHEMBL4867868,,RS-127445,Phase 1,serotonin receptor antagonist,P28335
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P28335
CHEMBL52939,CN(C)CC(COC1=CC=CC=C1CCC2=CC(=CC=C2)OC)OC(=O)CCC(=O)O,sarpogrelate,Launched,serotonin receptor antagonist,P28335
CHEMBL4853040,,SB-200646,Preclinical,serotonin receptor antagonist,P28335
CHEMBL4868931,,SB-206553,Preclinical,serotonin receptor antagonist,P28335
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P28335
CHEMBL4855890,,SB-221284,Preclinical,serotonin receptor antagonist,P28335
CHEMBL4875090,,SB-228357,Preclinical,serotonin receptor antagonist,P28335
CHEMBL4874156,,SB-243213,Phase 1,serotonin receptor inverse agonist,P28335
CHEMBL4870993,,SCH-23390,Preclinical,dopamine receptor antagonist,P28335
CHEMBL4865265,,SDZ-SER-082,Preclinical,serotonin receptor antagonist,P28335
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P28335
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL2104895,CN1CCC2=C(C1)C3=CC=CC=C3CC4=CC=CC=C24,setiptiline,Launched,adrenergic receptor antagonist,P28335
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P28335
CHEMBL1516474,CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC.C(=C\C(=O)O)\C(=O)O,tegaserod,Withdrawn,serotonin receptor partial agonist,P28335
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28335
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P28335
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P28335
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P28335
CHEMBL4861017,,volinanserin,Phase 3,serotonin receptor antagonist,P28335
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28335
CHEMBL4879209,,WAY-161503,Preclinical,serotonin receptor agonist,P28335
CHEMBL5079373,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F.Cl.Cl,WAY-208466,Preclinical,serotonin receptor agonist,P28335
CHEMBL4878403,,WAY-629,Preclinical,serotonin receptor agonist,P28335
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P28335
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P28335
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28335
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P28335
CHEMBL4848377,,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,P48039
CHEMBL286615,CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3,luzindole,Preclinical,melatonin receptor antagonist,P48039
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P48039
CHEMBL1218,CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3,ramelteon,Launched,melatonin receptor agonist,P48039
CHEMBL2103822,CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2,tasimelteon,Launched,melatonin receptor agonist,P48039
CHEMBL4878581,,2-iodomelatonin,Preclinical,melatonin receptor agonist,P48039
CHEMBL4853218,,2-phenylmelatonin,Preclinical,melatonin receptor agonist,P48039
CHEMBL4876621,,4-P-PDOT,Preclinical,melatonin receptor antagonist,P48039
CHEMBL4866838,,6-chloromelatonin,Preclinical,melatonin receptor agonist,P48039
CHEMBL4848179,,8-M-PDOT,Preclinical,melatonin receptor agonist,P48039
CHEMBL4848377,,agomelatine,Launched,melatonin receptor agonist|serotonin receptor antagonist,P49286
CHEMBL1327247,CCCCC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3,DH-97,Preclinical,melatonin receptor antagonist,P49286
CHEMBL286615,CC(=O)NCCC1=C(NC2=CC=CC=C21)CC3=CC=CC=C3,luzindole,Preclinical,melatonin receptor antagonist,P49286
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P49286
CHEMBL1218,CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3,ramelteon,Launched,melatonin receptor agonist,P49286
CHEMBL2103822,CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2,tasimelteon,Launched,melatonin receptor agonist,P49286
CHEMBL4878581,,2-iodomelatonin,Preclinical,melatonin receptor agonist,P49286
CHEMBL4853218,,2-phenylmelatonin,Preclinical,melatonin receptor agonist,P49286
CHEMBL4876621,,4-P-PDOT,Preclinical,melatonin receptor antagonist,P49286
CHEMBL4866838,,6-chloromelatonin,Preclinical,melatonin receptor agonist,P49286
CHEMBL4848179,,8-M-PDOT,Preclinical,melatonin receptor agonist,P49286
CHEMBL4864786,,AH6809,Preclinical,prostanoid receptor antagonist,Q13258
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,Q13258
CHEMBL1520583,C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+],cloprostenol-(+/-),Launched,prostaglandin receptor agonist,Q13258
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,Q13258
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q13258
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,Q13258
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,Q13258
CHEMBL4877379,,nedocromil,Launched,histamine receptor antagonist,Q13258
CHEMBL4864786,,AH6809,Preclinical,prostanoid receptor antagonist,P34995
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,P34995
CHEMBL4303730,CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(CCC2=CC=CC=C2)O)O)O,bimatoprost,Launched,prostanoid receptor agonist,P34995
CHEMBL1520583,C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+],cloprostenol-(+/-),Launched,prostaglandin receptor agonist,P34995
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P34995
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P34995
CHEMBL962,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+],epoprostenol,Launched,prostacyclin analog,P34995
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P34995
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P34995
CHEMBL2107456,CCCC[C@H](C)C[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCC/C=C/C(=O)O)O)O,limaprost-alfadex,Launched,prostanoid receptor agonist,P34995
CHEMBL3939289,CC1=CSC(=N1)S(=O)(=O)N(CC(C)C)C2=C(C=C3CCCC3=C2)OCC4=CC=C(C=C4)C(=O)O,ONO-8130,Preclinical,prostanoid receptor antagonist,P34995
CHEMBL4859413,,SC-19220,Preclinical,prostanoid receptor antagonist,P34995
CHEMBL4860388,,SC-51089,Preclinical,prostanoid receptor antagonist,P34995
CHEMBL4864786,,AH6809,Preclinical,prostanoid receptor antagonist,P35408
CHEMBL4864786,,AH6809,Preclinical,prostanoid receptor antagonist,P43116
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,P35408
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,P43116
CHEMBL4211107,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC3=CC=C(C=C3)C(=S)N,ATB-346,Phase 2,cyclooxygenase inhibitor,P35408
CHEMBL4211107,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC3=CC=C(C=C3)C(=S)N,ATB-346,Phase 2,cyclooxygenase inhibitor,P43116
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P35408
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P43116
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P35408
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P43116
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P35408
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P43116
CHEMBL4858874,,evatanepag,Phase 2,prostaglandin inhibitor,P35408
CHEMBL4858874,,evatanepag,Phase 2,prostaglandin inhibitor,P43116
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P35408
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P43116
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P35408
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P43116
CHEMBL4064157,CCCC[C@@](C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,misoprostol,Launched,prostanoid receptor agonist,P35408
CHEMBL4064157,CCCC[C@@](C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,misoprostol,Launched,prostanoid receptor agonist,P43116
CHEMBL4507298,,PF-04418948,Phase 1,prostaglandin inhibitor,P35408
CHEMBL4507298,,PF-04418948,Phase 1,prostaglandin inhibitor,P43116
CHEMBL2107783,C1=CC(=CC(=C1)OCC(=O)O)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4,taprenepag,Phase 2,prostaglandin receptor agonist,P35408
CHEMBL2107783,C1=CC(=CC(=C1)OCC(=O)O)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4,taprenepag,Phase 2,prostaglandin receptor agonist,P43116
CHEMBL4864786,,AH6809,Preclinical,prostanoid receptor antagonist,P43115
CHEMBL4303730,CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(CCC2=CC=CC=C2)O)O)O,bimatoprost,Launched,prostanoid receptor agonist,P43115
CHEMBL1520583,C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+],cloprostenol-(+/-),Launched,prostaglandin receptor agonist,P43115
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P43115
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P43115
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P43115
CHEMBL218071,COC1=C(C=C(C=C1)Br)S(=O)(=O)NC(=O)/C=C/C2=CC=CC=C2CC3=CC4=CC=CC=C4C=C3,L-798106,Preclinical,prostanoid receptor antagonist,P43115
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P43115
CHEMBL4064157,CCCC[C@@](C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,misoprostol,Launched,prostanoid receptor agonist,P43115
CHEMBL1235634,CCCCCC[C@H](C/C=C/CCCCCCCC(=O)O)O,ricinoleic-acid,Launched,prostanoid receptor agonist,P43115
CHEMBL4303677,C1=CC2=C(C=C1OC(F)(F)F)NC(=N2)C3=NC=C(C=C3)OCCOCCOC4=CN=C(C=C4)C5=NC6=C(N5)C=C(C=C6)OC(F)(F)F,AI-10-49,Preclinical,core binding factor inhibitor,Q13951
CHEMBL4868647,,AK-7,Preclinical,SIRT inhibitor,Q8IXJ6
CHEMBL4869061,,SirReal-2,Preclinical,SIRT inhibitor,Q8IXJ6
CHEMBL198582,C[C@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O,sirtinol,Preclinical,SIRT inhibitor,Q8IXJ6
CHEMBL595354,CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C,tenovin-6,Preclinical,SIRT inhibitor,Q8IXJ6
CHEMBL4866234,,AKBA,Phase 3,lipoxygenase inhibitor,P09917
CHEMBL4856423,,AM-24,Phase 2,lipoxygenase inhibitor,P09917
CHEMBL2096646,C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+],aminosalicylate,Launched,cyclooxygenase inhibitor,P09917
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P09917
CHEMBL1200760,C1=CC(=CC=C1C(=O)NCCC(=O)[O-])N=NC2=CC(=C(C=C2)[O-])C(=O)O.[Na+].[Na+],balsalazide,Launched,cyclooxygenase inhibitor,P09917
CHEMBL4856130,,BW-A4C,Phase 1,lipoxygenase inhibitor,P09917
CHEMBL86676,CC(/C=C/C1=CC(=CC=C1)OC2=CC=C(C=C2)F)N(C(=O)N)O,BW-B70C,Preclinical,lipoxygenase inhibitor,P09917
CHEMBL145,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,caffeic-acid,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,P09917
CHEMBL601539,COC1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C=N3)N,CBS-1114,Phase 1,lipoxygenase inhibitor,P09917
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P09917
CHEMBL4863188,,diethylcarbamazine,Launched,lipoxygenase inhibitor,P09917
CHEMBL304818,CC1=C(C(=O)C(=C(C1=O)C)CCCCC#CCCCC#CCO)C,docebenone,Phase 2,lipoxygenase inhibitor,P09917
CHEMBL16901,C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C,honokiol,Phase 3,AKT inhibitor,P09917
CHEMBL190266,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NO,ibuproxam,Launched,cyclooxygenase inhibitor|prostaglandin inhibitor,P09917
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,P09917
CHEMBL4876408,,licofelone,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,P09917
CHEMBL313972,C[C@H](CC1=CC(=C(C=C1)O)O)[C@@H](C)CC2=CC(=C(C=C2)O)O,masoprocol,Launched,lipoxygenase inhibitor,P09917
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P09917
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,P09917
CHEMBL1200681,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+],montelukast,Launched,leukotriene receptor antagonist,P09917
CHEMBL313489,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+],quiflapon,Phase 2,leukotriene synthesis inhibitor,P09917
CHEMBL4849094,,REV-5901,Phase 2,leukotriene receptor antagonist|lipoxygenase inhibitor,P09917
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P09917
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P09917
CHEMBL3739556,COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=C(C=C3)[C@@H]4[C@H](C(=O)C5=CC(=C(C=C5O4)O)O)O)CO)O,silibinin,Launched,cytochrome P450 inhibitor,P09917
CHEMBL1594610,C1CSC2=NC(=C(N21)C3=CC=NC=C3)C4=CC=C(C=C4)F.Cl.Cl,SKF-86002,Preclinical,p38 MAPK inhibitor,P09917
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P09917
CHEMBL4874490,,tepoxalin,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor,P09917
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,P09917
CHEMBL1743359,C[C@H](C1=CC2=CC=CC=C2S1)N(C(=O)N)O,zileuton,Launched,leukotriene synthesis inhibitor|lipoxygenase inhibitor,P09917
CHEMBL4875274,,AL-8697,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4857315,,AMG-548,Phase 1,MAP kinase inhibitor,Q16539
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,Q16539
CHEMBL4871688,,CMPD-1,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4878041,,doramapimod,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4850711,,EO-1428,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL202887,C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5,GW-788388,Preclinical,ALK tyrosine kinase receptor inhibitor,Q16539
CHEMBL1450144,COC1=C(C=CC(=C1)SC)C(=O)N2CCC(CC2)CC3=CC=CC=C3,JX-401,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,Q16539
CHEMBL1088752,CC1=C(C=C(C=C1F)C(=O)NC2CC2)C3=NC=C(C=C3)C(=O)NCC(C)(C)C,losmapimod,Phase 3,p38 MAPK inhibitor,Q16539
CHEMBL2364627,CC(C)(C)CN1C2=C(C=CC(=N2)C3=C(N=C(N3)C(C)(C)C)C4=CC=C(C=C4)F)N=C1N.CS(=O)(=O)O.CS(=O)(=O)O,LY2228820,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,Q16539
CHEMBL111364,CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F,ML3403,Preclinical,MAP kinase inhibitor,Q16539
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,Q16539
CHEMBL3991932,CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NCC3=C(C=CC(=C3)F)OC4=CC5=C(C=C4)N(N=C5)CCO,pexmetinib,Phase 1,MAP kinase inhibitor|TIE tyrosine kinase inhibitor,Q16539
CHEMBL4859416,,PH-797804,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4861955,,QX-314,Preclinical,sodium channel blocker,Q16539
CHEMBL4847871,,RWJ-67657,Phase 1,MAP kinase inhibitor,Q16539
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4858276,,SB-239063,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4870939,,SB-242235,Phase 1,p38 MAPK inhibitor,Q16539
CHEMBL1435541,C1=CC2=C(C=CN2)C=C1C(=O)N,SD-169,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL2107779,C/C(=N\N=C(N)N)/C1=CC(=CC(=C1)NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C)/C(=N/N=C(N)N)/C,semapimod,Phase 2,cytokine production inhibitor|p38 MAPK inhibitor,Q16539
CHEMBL4872085,,skepinone-L,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL1594610,C1CSC2=NC(=C(N21)C3=CC=NC=C3)C4=CC=C(C=C4)F.Cl.Cl,SKF-86002,Preclinical,p38 MAPK inhibitor,Q16539
CHEMBL4867472,,SX-011,Preclinical,MAP kinase inhibitor,Q16539
CHEMBL4303658,C1=CC(=C(C(=C1)F)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)F,TA-01,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,Q16539
CHEMBL4860056,,TAK-715,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4863553,,talmapimod,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4857538,,tie2-kinase-inhibitor,Preclinical,TIE tyrosine kinase inhibitor,Q16539
CHEMBL4856995,,tyrphostin-AG-1478,Preclinical,EGFR inhibitor,Q16539
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,Q16539
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4860551,,VX-745,Phase 2,p38 MAPK inhibitor,Q16539
CHEMBL4851744,,ZM-336372,Preclinical,RAF inhibitor,Q16539
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,Q16539
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,Q16539
CHEMBL4859366,,alacepril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL838,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,benazepril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL4870557,,butein,Preclinical,EGFR inhibitor|SRC inhibitor,P12821
CHEMBL4852091,,captopril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL515606,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCCN3CCC[C@H](N3C2=O)C(=O)O,cilazapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P12821
CHEMBL2106126,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N(CC(=O)O)C2CC3=CC=CC=C3C2.Cl,delapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL1200515,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,deserpidine,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL1200659,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O.C(=C\C(=O)O)\C(=O)O,enalapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL3989406,C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O.O.O,enalaprilat,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL3306578,CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3,fosinopril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL581,C1CCC(CC1)[C@@H]2C[C@H](N(C2)C(=O)CP(=O)(CCCCC3=CC=CC=C3)O)C(=O)O,fosinoprilat,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL251254,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@H]([C@H](O4)CO)O)O)O)O)O,hyperin,Preclinical,aldose reductase inhibitor,P12821
CHEMBL4303516,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H](CN(C2=O)C)C(=O)O,imidapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL419213,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O.O.O,lisinopril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL4542250,C[C@H]1CCC[C@H](N1C(=O)CCSC(=O)C)C(=O)O,methiopril,Phase 2,angiotensin converting enzyme inhibitor,P12821
CHEMBL1200534,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC.Cl,moexipril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL4266030,,omapatrilat,Preclinical,metalloproteinase inhibitor,P12821
CHEMBL1200343,CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O.CC(C)(C)N,perindopril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL1201368,CCC[C@@H](C(=O)O)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,perindoprilat,Phase 2,angiotensin converting enzyme inhibitor,P12821
CHEMBL1162799,CCCC[P+](CCCC)(CCCC)CC1=CC=C(C=C1)NC(=O)C2CC3=CC=CC=C3CN2C(=O)[C@H](CCC4=CC=CC=C4)NC(=NC5CCCCC5)NC6CCCCC6.Cl.Cl,quinapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL4856940,,quinaprilat,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL1168,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,ramipril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL2110627,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CS[C@@H](CN(C2=O)CC(=O)O)C3=CC=CS3,temocapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL3039089,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H](C)C(=O)N2[C@@H](CC3C2CCCC3)C(=O)O,trandolapril,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL2105776,C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3=CC=CC=C3.C[C@H](CSC(=O)C1=CC=CC=C1)C(=O)N2C[C@H](C[C@H]2C(=O)[O-])SC3=CC=CC=C3.[Ca+2],zofenopril-calcium,Launched,angiotensin converting enzyme inhibitor,P12821
CHEMBL1256359,CC(C(=O)OC(C)(C)CC1=CC=C(C=C1)Cl)N.Cl,alaproclate,Phase 2,serotonin receptor antagonist,P31645
CHEMBL1697712,C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O.Cl,amineptine,Withdrawn,dopamine receptor agonist,P31645
CHEMBL4227511,C1C2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,amitifadine,Phase 3,serotonin transporter (SERT) inhibitor,P31645
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P31645
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,P31645
CHEMBL1625728,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N,BTS-54505,Withdrawn,dopamine reuptake inhibitor,P31645
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P31645
CHEMBL2110900,CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C21)C3=CC=CC=C3,dapoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P31645
CHEMBL1201728,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O,desvenlafaxine,Launched,serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P31645
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P31645
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P31645
CHEMBL1256774,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31.Cl,doxepin,Launched,histamine receptor antagonist,P31645
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P31645
CHEMBL1200322,CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.C(=O)(C(=O)O)O,escitalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1201082,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,fluoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL814,COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F,fluvoxamine,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P31645
CHEMBL276520,C1CNCCC1CCC2=CNC3=CC=CC=C32,indalpine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL2106638,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl.Cl,lofepramine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P31645
CHEMBL4297064,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2.Cl,milnacipran,Launched,serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P31645
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P31645
CHEMBL1256695,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC.Cl,nisoxetine,Phase 1,norepinephrine reuptake inhibitor,P31645
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P31645
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P31645
CHEMBL1200332,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.Cl,protriptyline,Launched,tricyclic antidepressant,P31645
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P31645
CHEMBL809,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,sertraline,Launched,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P31645
CHEMBL1200948,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C.C(=C\C(=O)O)\C(=O)O,trimipramine,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,P31645
CHEMBL1201066,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O.Cl,venlafaxine,Launched,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P31645
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,P31645
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,P31645
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P31645
CHEMBL2355333,CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2.O.Cl.Cl,zimelidine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),P31645
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P31645
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P31645
CHEMBL4854212,,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,P31645
CHEMBL4875197,,alarelin,Launched,gonadotropin releasing factor hormone receptor antagonist,P01148
CHEMBL1483,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,albendazole,Launched,tubulin polymerization inhibitor,Q71U36
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q71U36
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q71U36
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q71U36
CHEMBL685,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,mebendazole,Launched,tubulin polymerization inhibitor,Q71U36
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q71U36
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,Q71U36
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q71U36
CHEMBL1483,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,albendazole,Launched,tubulin polymerization inhibitor,P68371
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P68371
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P68371
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P68371
CHEMBL685,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,mebendazole,Launched,tubulin polymerization inhibitor,P68371
CHEMBL1087630,CCCOC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,oxibendazole,Launched,tubulin polymerization inhibitor,P68371
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P68371
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P68371
CHEMBL1441059,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.OS(=O)(=O)O,albuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1256179,CC(C)NCC(COC1=CC=CC=C1CC=C)O.Cl,alprenolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL2106667,COC1=[N+](N=CC(=C1)N)C2=CC=CC=C2.COS(=O)(=O)[O-],amezinium,Launched,adrenergic receptor agonist,P07550
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P07550
CHEMBL4851038,,atenolol-(+/-),Launched,adrenergic receptor antagonist,P07550
CHEMBL521589,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,bambuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1691,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O.Cl,betaxolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL4864913,,BRL-37344,Phase 2,adrenergic receptor agonist,P07550
CHEMBL2105475,CC(C)(C)NCC(C1=CC(=NO1)Br)O,broxaterol,Phase 3,adrenergic receptor agonist,P07550
CHEMBL114655,CC(CCC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,buphenine,Launched,adrenergic receptor agonist,P07550
CHEMBL305380,CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O,bupranolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P07550
CHEMBL4850111,,carazolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1094785,C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O,carmoterol,Phase 2,adrenergic receptor agonist,P07550
CHEMBL1201002,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl,carteolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1201167,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.OP(=O)(O)O,carvedilol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1742424,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,celiprolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL4873800,,CGP-12177,Phase 1,adrenergic receptor agonist,P07550
CHEMBL1374751,CC(C)NCC(C1=CC(=C(C=C1)N)C#N)O,cimaterol,Preclinical,adrenergic receptor agonist,P07550
CHEMBL1330729,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O.Cl,clenbuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL156791,CC(C)(C)NCC(COC1=C(C=CC(=C1)Cl)Cl)O,cloranolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1902627,CC(C)NCC(C1=CC=CC=C1Cl)O,clorprenaline,Launched,adrenergic receptor agonist,P07550
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P07550
CHEMBL1200418,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O.Cl,dobutamine,Launched,adrenergic receptor agonist,P07550
CHEMBL1126098,,DPI-201106,Phase 2,sodium channel activator,P07550
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P07550
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,P07550
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P07550
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P07550
CHEMBL32800,CC(CC1=CC=C(C=C1)O)NCC(C2=CC(=CC(=C2)O)O)O,fenoterol,Withdrawn,adrenergic receptor agonist,P07550
CHEMBL3989798,CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O.C(=C/C(=O)O)\C(=O)O.O.O,formoterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1589896,C1=CC(=C(C=C1C(CNCCCCCCNCC(C2=CC(=C(C=C2)O)O)O)O)O)O,hexoprenaline,Launched,adrenergic receptor agonist,P07550
CHEMBL4177625,,higenamine,Phase 1,adrenergic receptor agonist,P07550
CHEMBL1233766,CC1=C2CCCC2=C(C=C1)OC[C@H]([C@H](C)NC(C)C)O,"ICI-118,551",Phase 2,adrenergic receptor antagonist,P07550
CHEMBL11268,C1=CC=C(C=C1)NC(=O)NCCNCC(COC2=CC=CC=C2C#N)O,ICI-89406,Phase 1,adrenergic receptor antagonist,P07550
CHEMBL1095777,CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC,indacaterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1160723,CC(C)NC[C@@H](C1=CC(=C(C=C1)O)O)O,isoprenaline,Launched,adrenergic receptor agonist,P07550
CHEMBL1197051,CC(COC1=CC=CC=C1)NC(C)C(C2=CC=C(C=C2)O)O,isoxsuprine,Launched,adrenergic receptor agonist,P07550
CHEMBL4845858,,L-755507,Preclinical,adrenergic receptor agonist,P07550
CHEMBL429,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,labetalol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1201061,CC(C)(C)NC[C@@H](C1=CC(=C(C=C1)O)CO)O.Cl,levalbuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1200837,CC(C)NC[C@@H](COC1=CC=C(C=C1)CCOCC2CC2)O.Cl,levobetaxolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1704116,CC(C)(C)NC[C@H](COC1=CC=CC2=C1CCCC2=O)O.Cl,levobunolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL86749,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)C(F)(F)F)O,mabuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P07550
CHEMBL1568057,CC(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O,metaproterenol,Launched,adrenergic receptor agonist,P07550
CHEMBL3989566,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(=C/C(=O)O)\C(=O)O,metoprolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL2095212,C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,mirabegron,Launched,adrenergic receptor agonist,P07550
CHEMBL521606,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,nadolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL4853301,,nifenalol,Launched,adrenergic receptor antagonist,P07550
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P07550
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P07550
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P07550
CHEMBL1200363,CC(C)(C)NC[C@@H](COC1=CC=CC=C1C2CCCC2)O.OS(=O)(=O)O,penbutolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1530633,CC(C)NC[C@H](COC1=CC=CC2=C1C=CN2)O,pindolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1478530,CC[C@@H]([C@@H](C1=C2C=CC(=O)NC2=C(C=C1)O)O)NC(C)C,procaterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1201063,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.Cl,propafenone,Launched,antiarrhythmic,P07550
CHEMBL1358662,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1358662,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(R),Preclinical,adrenergic receptor antagonist,P07550
CHEMBL2218907,CC(C)NC1CCN2C3=C(C1O)C=CC=C3NC2=O,RU-42173,Phase 2,adrenergic receptor agonist,P07550
CHEMBL1263,C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O,salmeterol,Launched,adrenergic receptor agonist,P07550
CHEMBL471,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,sotalol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1326499,CCC1=CC=CC=C1OC[C@H](CN[C@H]2CCCC3=CC=CC=C23)O,SR-59230A,Preclinical,adrenergic receptor antagonist,P07550
CHEMBL1315867,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O.OS(=O)(=O)O,terbutaline,Launched,adrenergic receptor agonist,P07550
CHEMBL1200870,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O.C(=C\C(=O)O)\C(=O)O,timolol,Launched,adrenergic receptor antagonist,P07550
CHEMBL2111163,CC(C)NCC(COC1=CC=CC=C1SC)O,tiprenolol,Phase 2,adrenergic receptor antagonist,P07550
CHEMBL418192,CC1=CC=CC=C1OCC(CNCCOC2=CC=C(C=C2)C(=O)N)O,tolamolol,Phase 3,adrenergic receptor antagonist,P07550
CHEMBL2093109,COC1=CC(=CC(=C1OC)OC)C[C@@H]2C3=CC(=C(C=C3CCN2)O)O.Cl,trimethoquinol,Launched,adrenergic receptor antagonist,P07550
CHEMBL1256478,CC(C)(C)NCC(C1=CC=CC=C1Cl)O.Cl,tulobuterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1198857,C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNC[C@@H](C2=CC(=C(C=C2)O)CO)O)Cl,vilanterol,Launched,adrenergic receptor agonist,P07550
CHEMBL4859286,,zilpaterol,Launched,adrenergic receptor agonist,P07550
CHEMBL1200989,CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)C=C[C@]34C)Cl)O)C)C)OC(=O)CC,alclometasone-dipropionate,Launched,glucocorticoid receptor agonist,P08684
CHEMBL153479,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,ambroxol,Launched,sodium channel blocker,P08684
CHEMBL1214598,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,arbidol,Launched,cytochrome P450 inhibitor,P08684
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P08684
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P08684
CHEMBL3526086,,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,P08684
CHEMBL4856033,,cefradine,Launched,bacterial cell wall synthesis inhibitor,P08684
CHEMBL3937847,CC[C@H]1[C@]([C@H]([C@@H](C(=O)[C@H](C[C@]([C@H](C([C@H]([C@@H](C(=O)O1)C)O[C@@H]2C[C@]([C@@H]([C@H](O2)C)O)(C)OC)C)O[C@@H]3[C@H]([C@@H](C[C@@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,clarithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,P08684
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,P08684
CHEMBL2095208,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,cobicistat,Launched,cytochrome P450 inhibitor,P08684
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P08684
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P08684
CHEMBL70663,CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C,dapivirine,Phase 3,non-nucleoside reverse transcriptase inhibitor,P08684
CHEMBL1201127,CCO.CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,darunavir,Launched,HIV protease inhibitor,P08684
CHEMBL550348,C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O,deferasirox,Launched,chelating agent,P08684
CHEMBL270515,B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,delanzomib,Phase 1/Phase 2,proteasome inhibitor,P08684
CHEMBL4846223,,delavirdine,Launched,non-nucleoside reverse transcriptase inhibitor,P08684
CHEMBL4303416,C[C@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,dolutegravir,Launched,HIV integrase inhibitor,P08684
CHEMBL4867302,,ebastine,Launched,histamine receptor antagonist,P08684
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P08684
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P08684
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,P08684
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,P08684
CHEMBL308954,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,etravirine,Launched,non-nucleoside reverse transcriptase inhibitor,P08684
CHEMBL4870522,,GSK1070916,Phase 1,Aurora kinase inhibitor,P08684
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P08684
CHEMBL1735,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O,indinavir,Launched,HIV protease inhibitor,P08684
CHEMBL409153,C[C@@H](C1=NC(=CS1)C2=CC=C(C=C2)C#N)[C@](CN3C=NC=N3)(C4=C(C=CC(=C4)F)F)O,isavuconazole,Phase 3,cytochrome P450 inhibitor,P08684
CHEMBL64,C1=CN=CC=C1C(=O)NN,isoniazid,Launched,FABI inhibitor,P08684
CHEMBL4869448,,methoxsalen,Launched,DNA synthesis inhibitor,P08684
CHEMBL1200869,CC1=NC=C(N1CCO)[N+](=O)[O-].Cl,metronidazole,Launched,DNA inhibitor,P08684
CHEMBL111364,CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F,ML3403,Preclinical,MAP kinase inhibitor,P08684
CHEMBL1200344,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[Na+],nafcillin,Launched,bacterial cell wall synthesis inhibitor,P08684
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P08684
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P08684
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P08684
CHEMBL206106,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC(=C(C=C4CC3)OC)OC)OC,palmatine-chloride,Preclinical,dopamine synthesis inhibitor,P08684
CHEMBL4860844,,PF-4981517,Preclinical,cytochrome P450 inhibitor,P08684
CHEMBL1397,CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F,posaconazole,Launched,sterol demethylase inhibitor,P08684
CHEMBL1660,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,rifapentine,Launched,RNA polymerase inhibitor,P08684
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P08684
CHEMBL296480,CC(C)(C)NC(=O)[C@@H]1CC2CCCCC2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,saquinavir,Launched,HIV protease inhibitor,P08684
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P08684
CHEMBL4303318,CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4C(C3)C(=O)N(CCCC/C=C\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,simeprevir,Launched,HCV inhibitor,P08684
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,P08684
CHEMBL3038236,C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.Cl.Cl.[Zn+2],sulfanilamide,Launched,carbonic anhydrase inhibitor,P08684
CHEMBL1136,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,P08684
CHEMBL671,C1CN1P(=S)(N2CC2)N3CC3,thiotepa,Launched,cytochrome P450 inhibitor,P08684
CHEMBL404216,CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C,tofisopam,Launched,cytochrome P450 inhibitor|phosphodiesterase inhibitor,P08684
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,P08684
CHEMBL638,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,voriconazole,Launched,cytochrome P450 inhibitor,P08684
CHEMBL1200989,CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)C=C[C@]34C)Cl)O)C)C)OC(=O)CC,alclometasone-dipropionate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL3039466,CC(=O)OCC(=O)[C@@]12[C@@H](CC3[C@@]1(C[C@@H]([C@]4(C3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC6(O2)CCCC6,amcinonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1586,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,beclomethasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4846930,,beclomethasone-dipropionate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1610678,C[C@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,betamethasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4875211,,betamethasone-acetate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4853025,,betamethasone-dipropionate,Launched,anti-inflammatory agent,P04150
CHEMBL10858,CCCCC(=O)O[C@@]1(C(CC2C1(CC([C@]3(C2CCC4=CC(=O)C=CC43C)F)O)C)C)C(=O)CO,betamethasone-valerate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1370,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,budesonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL2040682,CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6,ciclesonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4851304,,clobetasol-propionate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL2308885,CCCC(=O)O[C@@]1([C@@H](C[C@H]2[C@@]1(CC(=O)[C@@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)C)C)C(=O)CCl,clobetasone-butyrate,Launched,corticosteroid agonist,P04150
CHEMBL1200975,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)Cl)C)F,clocortolone-pivalate,Launched,steroid,P04150
CHEMBL68363,C[C@]12CCC(=O)C=C1CCC3C2C(=O)C[C@]4(C3CC[C@@]4(C(=O)CO)O)C,cortisone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4862162,,cortisone-acetate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201891,CC1=N[C@@]2([C@H](O1)C[C@@H]3[C@@]2(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)C(=O)COC(=O)C,deflazacort,Launched,glucocorticoid receptor agonist,P04150
CHEMBL5090905,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O,desonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1766,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,desoximetasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4855808,,desoxycortone,Preclinical,mineralocorticoid receptor agonist,P04150
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4303696,C[C@H]1CC2C3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,diflorasone-diacetate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4303220,CCCC(=O)O[C@]1(CC[C@@H]2[C@@]1(C[C@H]([C@@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C(=O)COC(=O)C,difluprednate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201012,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,fludroxycortide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201392,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F,flumethasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200877,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F,flumethasone-pivalate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1322608,CC1(O[C@@H]2CC3C4C[C@@H](C5=CC(=O)C=CC5(C4C(CC3([C@@]2(O1)C(=O)CO)C)O)C)F)C,flunisolide,Launched,cytochrome P450 inhibitor,P04150
CHEMBL989,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,fluocinolone-acetonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL3039305,CC(=O)OCC(=O)[C@@]12[C@@H](CC3[C@@]1(C[C@@H]([C@]4(C3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,fluocinonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200600,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,fluorometholone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201064,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)OC(=O)C,fluorometholone-acetate,Launched,,P04150
CHEMBL1473,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,fluticasone-propionate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4859329,,GSK9027,Preclinical,glucocorticoid receptor agonist,P04150
CHEMBL3039407,CC1(O[C@@H]2CC3C4CCC5=CC(=O)CCC5(C4(C(CC3([C@@]2(O1)C(=O)CCl)C)O)F)C)C,halcinonide,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200908,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl,halobetasol-propionate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone-valerate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL790958,,hydrocortisone-acetate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1434261,CCCC(=O)OC1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)C(=O)CO,hydrocortisone-butyrate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1608183,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)O,isoflupredone-acetate,Preclinical,,P04150
CHEMBL1200865,CCOC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)OCCl,loteprednol,Launched,glucocorticoid receptor agonist|phospholipase inhibitor,P04150
CHEMBL4875793,,LXR-623,Phase 1,LXR agonist,P04150
CHEMBL1201173,C[C@H]1C[C@H]2[C@@H]3CC[C@@H]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)CC4)C)O)C)C(=O)C,medrysone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201139,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,megestrol-acetate,Launched,progesterone receptor agonist,P04150
CHEMBL4303282,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)CO)O)C)C,meprednisone,Launched,,P04150
CHEMBL4849419,,methylprednisolone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1697782,CCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)C)O)C)C(=O)COC(=O)C,methylprednisolone-aceponate,Launched,anti-inflammatory agent|glucocorticoid receptor agonist,P04150
CHEMBL4862709,,mifepristone,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,P04150
CHEMBL1201404,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)Cl)C,mometasone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1161,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C,mometasone-furoate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201014,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+].[Na+],prednisolone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1201014,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+].[Na+],prednisolone-sodium-phosphate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1697848,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C(=O)COC(=O)C,prednisolone-acetate,Launched,glucocorticoid receptor agonist,P04150
CHEMBL4847089,,prednisolone-hemisuccinate,Preclinical,glucocorticoid receptor agonist,P04150
CHEMBL15720,CC12CC(=O)C3C(C1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=CC34C,prednisone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1200617,CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C,rimexolone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P04150
CHEMBL1200449,CC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)OC(=O)C)O,triamcinolone,Launched,glucocorticoid receptor agonist,P04150
CHEMBL275338,C[C@]12C[C@@H]([C@]3(C(C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,triamcinolone-acetonide,Launched,glucocorticoid receptor agonist|immunosuppressant,P04150
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,P04150
CHEMBL1200989,CCC(=O)OCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2[C@@H](CC4=CC(=O)C=C[C@]34C)Cl)O)C)C)OC(=O)CC,alclometasone-dipropionate,Launched,glucocorticoid receptor agonist,P08185
CHEMBL1586,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,beclomethasone,Launched,glucocorticoid receptor agonist,P08185
CHEMBL2040682,CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6,ciclesonide,Launched,glucocorticoid receptor agonist,P08185
CHEMBL1201012,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,fludroxycortide,Launched,glucocorticoid receptor agonist,P08185
CHEMBL1200877,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C)F,flumethasone-pivalate,Launched,glucocorticoid receptor agonist,P08185
CHEMBL989,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,fluocinolone-acetonide,Launched,glucocorticoid receptor agonist,P08185
CHEMBL3039305,CC(=O)OCC(=O)[C@@]12[C@@H](CC3[C@@]1(C[C@@H]([C@]4(C3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,fluocinonide,Launched,glucocorticoid receptor agonist,P08185
CHEMBL1201014,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+].[Na+],prednisolone,Launched,glucocorticoid receptor agonist,P08185
CHEMBL1200617,CCC(=O)[C@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)C)C,rimexolone,Launched,glucocorticoid receptor agonist,P08185
CHEMBL275338,C[C@]12C[C@@H]([C@]3(C(C1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,triamcinolone-acetonide,Launched,glucocorticoid receptor agonist|immunosuppressant,P08185
CHEMBL4863627,,alda-1,Preclinical,aldehyde dehydrogenase activator,P05091
CHEMBL4851780,,coenzyme-I,Phase 2,,P05091
CHEMBL4303226,CS(=O)(=O)NC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C(=O)O,CVT-10216,Phase 1,aldehyde dehydrogenase inhibitor,P05091
CHEMBL486422,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,daidzin,Phase 1,antioxidant,P05091
CHEMBL964,CCN(CC)C(=S)SSC(=S)N(CC)CC,disulfiram,Launched,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,P05091
CHEMBL2078034,,guanidine,Launched,HSP inhibitor,P05091
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P05091
CHEMBL1738797,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,alectinib,Launched,ALK tyrosine kinase receptor inhibitor,P08581
CHEMBL1738797,CCC1=CC2=C(C=C1N3CCC(CC3)N4CCOCC4)C(C5=C(C2=O)C6=C(N5)C=C(C=C6)C#N)(C)C,alectinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9NWH9
CHEMBL3545365,C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F,altiratinib,Phase 1,MET inhibitor|VEGFR inhibitor,P08581
CHEMBL3545365,C1CC1C(=O)NC2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F)F,altiratinib,Phase 1,MET inhibitor|VEGFR inhibitor,Q9NWH9
CHEMBL4864242,,AMG-208,Phase 1,tyrosine kinase inhibitor,P08581
CHEMBL4864242,,AMG-208,Phase 1,tyrosine kinase inhibitor,Q9NWH9
CHEMBL4869750,,AMG-337,Phase 2,MET inhibitor,P08581
CHEMBL4869750,,AMG-337,Phase 2,MET inhibitor,Q9NWH9
CHEMBL4865577,,AMG458,Preclinical,MET inhibitor,P08581
CHEMBL4865577,,AMG458,Preclinical,MET inhibitor,Q9NWH9
CHEMBL4867230,,amuvatinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,P08581
CHEMBL4867230,,amuvatinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAD51 inhibitor|RET tyrosine kinase inhibitor,Q9NWH9
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P08581
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,Q9NWH9
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,P08581
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,Q9NWH9
CHEMBL3545050,,BMS-817378,Phase 1,c-Met inhibitor|VEGFR inhibitor,P08581
CHEMBL3545050,,BMS-817378,Phase 1,c-Met inhibitor|VEGFR inhibitor,Q9NWH9
CHEMBL2105717,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,cabozantinib,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,P08581
CHEMBL2105717,COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F,cabozantinib,Launched,RET tyrosine kinase inhibitor|VEGFR inhibitor,Q9NWH9
CHEMBL601719,C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,crizotinib,Launched,ALK tyrosine kinase receptor inhibitor,P08581
CHEMBL601719,C[C@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,crizotinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9NWH9
CHEMBL5085086,CC(C)C[C@H](COC)N=C1N/C(=C\C2=CC3=C(C=C2)N=CS3)/C(=O)N1C,EMD-1214063,Phase 2,hepatocyte growth factor receptor inhibitor,P08581
CHEMBL5085086,CC(C)C[C@H](COC)N=C1N/C(=C\C2=CC3=C(C=C2)N=CS3)/C(=O)N1C,EMD-1214063,Phase 2,hepatocyte growth factor receptor inhibitor,Q9NWH9
CHEMBL1230609,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,foretinib,Phase 2,VEGFR inhibitor,P08581
CHEMBL1230609,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,foretinib,Phase 2,VEGFR inhibitor,Q9NWH9
CHEMBL3039525,CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,golvatinib,Phase 2,VEGFR inhibitor,P08581
CHEMBL3039525,CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(=C3)OC4=CC(=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,golvatinib,Phase 2,VEGFR inhibitor,Q9NWH9
CHEMBL3582305,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=NN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,INC-280,Phase 3,c-Met inhibitor,P08581
CHEMBL3582305,CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=NN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F,INC-280,Phase 3,c-Met inhibitor,Q9NWH9
CHEMBL4871881,,JNJ-38877605,Phase 1,tyrosine kinase inhibitor,P08581
CHEMBL4871881,,JNJ-38877605,Phase 1,tyrosine kinase inhibitor,Q9NWH9
CHEMBL3545307,CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F,LY2801653,Phase 2,MET inhibitor,P08581
CHEMBL3545307,CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F,LY2801653,Phase 2,MET inhibitor,Q9NWH9
CHEMBL4848151,,MGCD-265,Preclinical,VEGFR inhibitor,P08581
CHEMBL4848151,,MGCD-265,Preclinical,VEGFR inhibitor,Q9NWH9
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P08581
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,Q9NWH9
CHEMBL4867124,,MK-8033,Phase 1,c-Met inhibitor,P08581
CHEMBL4867124,,MK-8033,Phase 1,c-Met inhibitor,Q9NWH9
CHEMBL4866398,,NVP-BVU972,Preclinical,MET inhibitor,P08581
CHEMBL4866398,,NVP-BVU972,Preclinical,MET inhibitor,Q9NWH9
CHEMBL4862688,,PF-04217903,Phase 1,c-Met inhibitor,P08581
CHEMBL4862688,,PF-04217903,Phase 1,c-Met inhibitor,Q9NWH9
CHEMBL4872316,,PHA-665752,Preclinical,c-Met inhibitor,P08581
CHEMBL4872316,,PHA-665752,Preclinical,c-Met inhibitor,Q9NWH9
CHEMBL4847640,,savolitinib,Phase 3,c-Met inhibitor,P08581
CHEMBL4847640,,savolitinib,Phase 3,c-Met inhibitor,Q9NWH9
CHEMBL1236107,CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2,SGX523,Phase 1,hepatocyte growth factor receptor inhibitor,P08581
CHEMBL1236107,CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=C(C=C4)N=CC=C5)C=C2,SGX523,Phase 1,hepatocyte growth factor receptor inhibitor,Q9NWH9
CHEMBL4873746,,SU11274,Preclinical,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,P08581
CHEMBL4873746,,SU11274,Preclinical,hepatocyte growth factor receptor inhibitor|tyrosine kinase inhibitor,Q9NWH9
CHEMBL2103882,C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65,tivantinib,Phase 3,tyrosine kinase inhibitor,P08581
CHEMBL2103882,C1CC2=C3C(=CC=C2)C(=CN3C1)[C@H]4[C@@H](C(=O)NC4=O)C5=CNC6=CC=CC=C65,tivantinib,Phase 3,tyrosine kinase inhibitor,Q9NWH9
CHEMBL675,C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+],alendronate,Launched,bone resorption inhibitor,P38606
CHEMBL871,CC(O)(P(=O)(O)O)P(=O)(O)O,etidronic-acid,Launched,bone resorption inhibitor,P38606
CHEMBL1200448,C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+],tiludronate,Launched,bone resorption inhibitor|osteoclast inhibitor,P38606
CHEMBL675,C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+],alendronate,Launched,bone resorption inhibitor,P14324
CHEMBL3989569,CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)[O-].O.[Na+],ibandronate,Launched,bone resorption inhibitor,P14324
CHEMBL319144,C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,minodronic-acid,Launched,bone resorption inhibitor,P14324
CHEMBL55214,C(CCC(O)(P(=O)(O)O)P(=O)(O)O)CCN,neridronic-acid,Launched,bone resorption inhibitor,P14324
CHEMBL3989401,C(CN)C(O)(P(=O)(O)[O-])P(=O)(O)[O-].O.O.O.O.O.[Na+].[Na+],pamidronate,Launched,bone resorption inhibitor,P14324
CHEMBL1654,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)[O-].[Na+],risedronate,Launched,osteoclast inhibitor,P14324
CHEMBL4303669,C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O.O,zoledronic-acid,Launched,bone resorption inhibitor,P14324
CHEMBL675,C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+],alendronate,Launched,bone resorption inhibitor,P29074
CHEMBL675,C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+],alendronate,Launched,bone resorption inhibitor,P23469
CHEMBL675,C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.[Na+],alendronate,Launched,bone resorption inhibitor,Q13332
CHEMBL871,CC(O)(P(=O)(O)O)P(=O)(O)O,etidronic-acid,Launched,bone resorption inhibitor,Q13332
CHEMBL1195210,CCCCC(CC)CN=C(N)NC(=NCCCCCCN=C(N)NC(=NCC(CC)CCCC)N)N,alexidine,Preclinical,phosphatidylglycerophosphatase inhibitor,Q8WUK0
CHEMBL4866503,,alfacalcidol,Launched,vitamin D receptor agonist,O15528
CHEMBL4866503,,alfacalcidol,Launched,vitamin D receptor agonist,P11473
CHEMBL4877215,,calcifediol,Launched,vitamin D receptor agonist,P11473
CHEMBL4563773,C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C\4/C[C@@H](C[C@@H](C4=C)O)O)C,calcipotriol,Launched,vitamin D receptor agonist,P11473
CHEMBL4848426,,calcitriol,Launched,vitamin D receptor agonist,P11473
CHEMBL4875761,,cholecalciferol,Launched,,P11473
CHEMBL1435687,CC\1CCC(C/C1=C\C=C\2/CCCC3(C2CCC3C(C)/C=C/C(C)C(C)C)C)O,dihydrotachysterol,Launched,vitamin analog,P11473
CHEMBL1200810,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,doxercalciferol,Launched,vitamin D receptor agonist,P11473
CHEMBL4297608,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H]([C@H]([C@@H](C3=C)O)OCCCO)O)C,eldecalcitol,Phase 3,bone formation stimulant,P11473
CHEMBL4303615,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,ercalcitriol,Phase 1,vitamin D receptor agonist,P11473
CHEMBL1536,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,ergocalciferol,Launched,vitamin analog,P11473
CHEMBL2106158,C[C@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,falecalcitriol,Launched,vitamin D receptor agonist,P11473
CHEMBL4794162,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC[C@H](C4)O)C)C,lithocholic-acid,Preclinical,FXR antagonist|vitamin D receptor agonist,P11473
CHEMBL4303452,[2H]C([2H])([2H])C(CCO[C@@H](C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)(C([2H])([2H])[2H])O,maxacalcitol,Launched,vitamin D receptor agonist,P11473
CHEMBL1200622,C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C,paricalcitol,Launched,vitamin D receptor agonist,P11473
CHEMBL1590076,C[C@H](CC[C@H](C(C)(C)O)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,secalciferol,Launched,vitamin D receptor agonist,P11473
CHEMBL4859792,,seocalcitol,Phase 3,vitamin D receptor agonist,P11473
CHEMBL4873762,,tacalcitol,Launched,vitamin D receptor agonist,P11473
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q9UI33
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q9UI33
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q9UI33
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q9UI33
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q9UI33
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q9UI33
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q9UI33
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q9UI33
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9UI33
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q9UI33
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q9UI33
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q9UI33
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q9UI33
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9UI33
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,P35498
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,P35498
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P35498
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,P35498
CHEMBL4870996,,ICA-121431,Preclinical,sodium channel blocker,P35498
CHEMBL4872403,,L-741742,Preclinical,dopamine receptor antagonist,P35498
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,P35498
CHEMBL1286,CC[C@@H](C(=O)N)N1CCCC1=O,levetiracetam,Launched,calcium channel blocker,P35498
CHEMBL4867623,,lidoflazine,Launched,calcium channel blocker,P35498
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,P35498
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,P35498
CHEMBL1201022,C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl,phenazopyridine,Launched,local anesthetic,P35498
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,P35498
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P35498
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,P35498
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,P35498
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,P35498
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,P35498
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P35498
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,P35498
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P35498
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q99250
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q99250
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q99250
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q99250
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q99250
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q99250
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q99250
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q99250
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q99250
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q99250
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q99250
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q99250
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q99250
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q99250
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q99250
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q9NY46
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q9NY46
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q9NY46
CHEMBL4870996,,ICA-121431,Preclinical,sodium channel blocker,Q9NY46
CHEMBL4872403,,L-741742,Preclinical,dopamine receptor antagonist,Q9NY46
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q9NY46
CHEMBL4867623,,lidoflazine,Launched,calcium channel blocker,Q9NY46
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q9NY46
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q9NY46
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q9NY46
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q9NY46
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9NY46
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q9NY46
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,Q9NY46
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q9NY46
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q9NY46
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q9NY46
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9NY46
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,P35499
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,P35499
CHEMBL4862070,,CO-102862,Phase 1,sodium channel blocker,P35499
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P35499
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,P35499
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,P35499
CHEMBL558,CC1=C(C(=CC=C1)C)OCC(C)N,mexiletine,Launched,sodium channel blocker,P35499
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,P35499
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,P35499
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,P35499
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,P35499
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,P35499
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,P35499
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,P35499
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,P35499
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,P35499
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,P35499
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,P35499
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P35499
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q01118
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q01118
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q01118
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q01118
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q01118
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q01118
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q01118
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q01118
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q01118
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q01118
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q01118
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q01118
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q01118
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q01118
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q9UQD0
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q9UQD0
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q9UQD0
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q9UQD0
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q9UQD0
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q9UQD0
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q9UQD0
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q9UQD0
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9UQD0
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q9UQD0
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q9UQD0
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q9UQD0
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q9UQD0
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9UQD0
CHEMBL1723,CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC.Cl,alfuzosin,Launched,adrenergic receptor antagonist,Q15858
CHEMBL108,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,carbamazepine,Launched,carboxamide antiepileptic,Q15858
CHEMBL4862070,,CO-102862,Phase 1,sodium channel blocker,Q15858
CHEMBL87992,CC(=O)O[C@H]1CC2=CC=CC=C2N(C3=CC=CC=C13)C(=O)N,eslicarbazepine-acetate,Launched,sodium channel blocker,Q15858
CHEMBL4851255,,lamotrigine,Launched,serotonin receptor antagonist|sodium channel blocker,Q15858
CHEMBL1200409,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C.O.Cl,lidocaine,Launched,histamine receptor agonist,Q15858
CHEMBL4879344,,NAV-26,Preclinical,voltage-gated sodium channel blocker,Q15858
CHEMBL1068,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,oxcarbazepine,Launched,sodium channel blocker,Q15858
CHEMBL918,C1=CC=C(C=C1)CC(=O)NC(=O)N,phenacemide,Launched,sodium channel blocker,Q15858
CHEMBL1611,C1=CC=C(C=C1)C2(C(=O)NC(=N2)[O-])C3=CC=CC=C3.[Na+],phenytoin,Launched,hydantoin antiepileptic,Q15858
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q15858
CHEMBL1526084,CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O.Cl.Cl,ranolazine,Launched,sodium channel blocker,Q15858
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q15858
CHEMBL1201754,C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F,rufinamide,Launched,voltage-gated sodium channel blocker,Q15858
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,Q15858
CHEMBL4854912,,TC-N-1752,Preclinical,sodium channel blocker,Q15858
CHEMBL1255654,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C.Cl,tetracaine,Launched,membrane integrity inhibitor,Q15858
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q15858
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q15858
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q15858
CHEMBL2103871,COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)[O-])OC.O.[Na+],alisertib,Phase 3,Aurora kinase inhibitor,O14965
CHEMBL2140408,CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N,AMG900,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,O14965
CHEMBL4859056,,aurora-a-inhibitor-i,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL4858356,,barasertib,Phase 2/Phase 3,Aurora kinase inhibitor,O14965
CHEMBL4303500,CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,O14965
CHEMBL4858688,,CCT129202,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL4868270,,CCT137690,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL4853670,,CYC116,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,O14965
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,O14965
CHEMBL4870522,,GSK1070916,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4879292,,GSK2334470,Preclinical,phosphoinositide dependent kinase inhibitor,O14965
CHEMBL4857627,,JNJ-7706621,Preclinical,CDK inhibitor,O14965
CHEMBL4874165,,KW-2449,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,O14965
CHEMBL4591460,C1CC2(CCC1C(=O)NC3=NN(C=C3)C4=CC=CC=C4F)C5=C(C=CN=C5)C(=O)O2,MK-8745,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL3182444,C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O,MK-5108,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4863943,,MLN8054,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,O14965
CHEMBL4857821,,PF-03814735,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4861873,,PHA-680632,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL482767,C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4,SNS-314,Phase 1,Aurora kinase inhibitor,O14965
CHEMBL4872369,,TC-A-2317,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL4744548,CC1=C(C=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C,tozasertib,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,O14965
CHEMBL4874577,,ZM-447439,Preclinical,Aurora kinase inhibitor,O14965
CHEMBL3508698,CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC([14CH3])([14CH3])C(=O)N)O)N.C(=C/C(=O)O)\C(=O)O,aliskiren-hemifumarate,Launched,renin inhibitor,P00797
CHEMBL3508698,CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC([14CH3])([14CH3])C(=O)N)O)N.C(=C/C(=O)O)\C(=O)O,aliskiren-hemifumarate,Launched,renin inhibitor,Q693B1
CHEMBL3314610,CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)O,pepstatin,Preclinical,aspartic protease inhibitor,P00797
CHEMBL3314610,CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)O,pepstatin,Preclinical,aspartic protease inhibitor,Q693B1
CHEMBL4877555,,VTP-27999,Phase 1,renin inhibitor,P00797
CHEMBL4877555,,VTP-27999,Phase 1,renin inhibitor,Q693B1
CHEMBL1213178,C1=NN(C2=C1C(=O)NC=N2)[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O,allopurinol,Launched,xanthine oxidase inhibitor,P47989
CHEMBL2106558,C1=CC(=CC(=C1)C(F)(F)F)C2=NSC(=C2N)C(=O)O,amflutizole,Phase 2,xanthine oxidase inhibitor,P47989
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P47989
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P47989
CHEMBL355200,C#CC1=CNC(=O)NC1=O,eniluracil,Phase 3,dihydropyrimidine dehydrogenase inhibitor,P47989
CHEMBL1164729,CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O,febuxostat,Launched,xanthine oxidase inhibitor,P47989
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P47989
CHEMBL3321989,CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N,MF-101,Phase 3,estrogen receptor agonist,P47989
CHEMBL859,C1=NNC2=C1C(=O)NC(=O)N2,oxypurinol,Phase 2/Phase 3,xanthine oxidase inhibitor,P47989
CHEMBL4848968,,topiroxostat,Launched,xanthine oxidase inhibitor,P47989
CHEMBL2105618,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCCC34,allylestrenol,Launched,steroidal progestin,P06401
CHEMBL1315492,C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC=C)O,altrenogest,Launched,progestogen hormone,P06401
CHEMBL4553748,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3C2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,chlormadinone-acetate,Launched,5 alpha reductase inhibitor,P06401
CHEMBL4874228,,cridanimod,Launched,progesterone receptor agonist,P06401
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,P06401
CHEMBL1533,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CCCC[C@H]34,desogestrel,Launched,progesterone receptor agonist,P06401
CHEMBL1201864,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@]2(CC#N)O,dienogest,Launched,progesterone receptor agonist,P06401
CHEMBL1509,C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C,drospirenone,Launched,mineralocorticoid receptor antagonist,P06401
CHEMBL1200853,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3[C@H]2C=CC4=CC(=O)CC[C@@]34C)C,dydrogesterone,Launched,progesterone receptor agonist,P06401
CHEMBL1200624,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,ethynodiol-diacetate,Launched,,P06401
CHEMBL1531,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,etonogestrel,Launched,progesterone receptor agonist,P06401
CHEMBL1473,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,fluticasone-propionate,Launched,glucocorticoid receptor agonist,P06401
CHEMBL4853354,,gestrinone,Launched,progesterone receptor antagonist,P06401
CHEMBL302529,CC(=O)[C@]1(CCC2[C@@]1(CCC3C2CCC4=CC(=O)CC[C@]34C)C)O,hydroxyprogesterone,Launched,progesterone receptor agonist,P06401
CHEMBL4865900,,hydroxyprogesterone-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL4571597,CC[C@]12CCC3[C@H]4CCC(=O)C=C4CCC3C1CC[C@]2(C#C)O,levonorgestrel,Launched,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist,P06401
CHEMBL1390,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C,medroxyprogesterone,Launched,progesterone receptor agonist,P06401
CHEMBL305242,C[C@H]1CC2C(CC[C@]3(C2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,medroxyprogesterone-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL1201139,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,megestrol-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL4862709,,mifepristone,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,P06401
CHEMBL1476022,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4,nomegestrol-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL1200807,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C/C(=N/O)/CC[C@H]34,norelgestromin,Launched,,P06401
CHEMBL4082273,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,norethindrone,Launched,progesterone receptor agonist,P06401
CHEMBL1201146,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,norethindrone-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL1387,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3CCC(=O)C4,noretynodrel,Launched,progestogen hormone,P06401
CHEMBL1200934,CC[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)OC(=O)C)CCC4=C/C(=N/O)/CC[C@H]34,norgestimate,Launched,progesterone receptor agonist,P06401
CHEMBL4873643,,norgestrel,Launched,progesterone receptor agonist,P06401
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,P06401
CHEMBL3707377,CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C,segesterone-acetate,Launched,progesterone receptor agonist,P06401
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P06401
CHEMBL4861829,,tanaproget,Phase 2,progesterone receptor agonist,P06401
CHEMBL573043,[2H][C@](CCC)(C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5,telaprevir,Launched,HCV inhibitor,P06401
CHEMBL2103846,CC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,ulipristal,Launched,progesterone receptor antagonist,P06401
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,P06401
CHEMBL2105618,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(CC=C)O)CCC4=CCCCC34,allylestrenol,Launched,steroidal progestin,P48067
CHEMBL4868382,,ALX-5407,Phase 1,glycine transporter inhibitor,P48067
CHEMBL4303475,CC(C)C1=NN=C(N1C2=CC=CC3=NON=C32)C4=CN=C(C=C4)C5=CC=CC=C5,ASP-2535,Phase 1,glycine transporter inhibitor,P48067
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P48067
CHEMBL4858256,,bitopertin,Phase 3,glycine transporter inhibitor,P48067
CHEMBL1628564,CC(C)(C)C1=C(C=CC(=C1)C2=CC3=C(C=C2)OCO3)OCCN(C)CC(=O)O,LY2365109,Preclinical,glycine transporter inhibitor,P48067
CHEMBL304383,CNCC(=O)O,sarcosine,Phase 2,glycine transporter inhibitor,P48067
CHEMBL1183717,C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C,almitrine,Launched,neurotransmitter agonist,P05023
CHEMBL4740236,C[C@@H]1CCC2[C@H](C(O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C,artemether,Launched,antimalarial agent,P05023
CHEMBL1095292,CC[N+](C)(C)CC1=CC=CC=C1Br.CC1=CC=C(C=C1)S(=O)(=O)[O-],bretylium,Launched,norepinephrine inhibitor,P05023
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,P05023
CHEMBL1413,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,ciclopirox,Launched,membrane integrity inhibitor,P05023
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P05023
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,P05023
CHEMBL1908061,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@H](C2)CC[C@@H]4[C@@H]3CC[C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)C)O)O,digitoxigenin,Preclinical,ATPase inhibitor,P05023
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P05023
CHEMBL3039191,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CCC6C5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,digoxin,Launched,ATPase inhibitor,P05023
CHEMBL456,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,etacrynic-acid,Launched,sodium/potassium/chloride transporter inhibitor,P05023
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P05023
CHEMBL469045,C[C@]12CC/C(=N\OCCN)/C[C@@H]1C(=O)C[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,istaroxime,Phase 2,ATPase inhibitor,P05023
CHEMBL4532565,C[C@]12CCC3[C@H]([C@]1(CC[C@@H]2C4=CC(=O)OC4)O)CC[C@]5([C@@]3(CC[C@@H](C5)O)C=O)O,K-strophanthidin,Phase 2,ATPase inhibitor,P05023
CHEMBL4873382,,lumefantrine,Launched,antimalarial agent,P05023
CHEMBL1720907,CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,ouabain,Launched,ATPase inhibitor,P05023
CHEMBL4862060,,rostafuroxine,Phase 2,ATPase inhibitor,P05023
CHEMBL1200521,CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3.C(C(C(=O)O)O)C(=O)O,almotriptan,Launched,serotonin receptor agonist,P28221
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P28221
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P28221
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28221
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P28221
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P28221
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P28221
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL378501,CC(C)(C)NCC(COC1=CC=CC2=C1C=C(N2)C#N)O,cyanopindolol,Phase 2,adrenergic receptor antagonist,P28221
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P28221
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P28221
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P28221
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P28221
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P28221
CHEMBL2138684,CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N.C(CC(=O)O)C(=O)O.O,frovatriptan,Launched,serotonin receptor agonist,P28221
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P28221
CHEMBL4857420,,GR46611,Preclinical,serotonin receptor agonist,P28221
CHEMBL4854471,,GSK163090,Phase 2,serotonin receptor antagonist,P28221
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P28221
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P28221
CHEMBL4855569,,L-694247,Preclinical,serotonin receptor agonist,P28221
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P28221
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL4849900,,LY310762,Preclinical,serotonin receptor antagonist,P28221
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P28221
CHEMBL4303390,CC(C)N1CC2=C(C=CC(=C2)S(=O)(=O)C)N(S1(=O)=O)CCN3CCC(=CC3)C4=CNC5=C4C=CC(=C5)F,LY393558,Preclinical,serotonin receptor antagonist,P28221
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P28221
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28221
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P28221
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P28221
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P28221
CHEMBL1200601,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl,naratriptan,Launched,serotonin receptor agonist,P28221
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P28221
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P28221
CHEMBL440294,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,pipamperone,Launched,dopamine receptor antagonist,P28221
CHEMBL4856095,,PNU-142633,Phase 2,serotonin receptor agonist,P28221
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P28221
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P28221
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P28221
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P28221
CHEMBL1201032,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O,rizatriptan,Launched,serotonin receptor agonist,P28221
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P28221
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P28221
CHEMBL5089005,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)OCCN(C)C.Cl,SB-216641,Preclinical,serotonin receptor antagonist,P28221
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P28221
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P28221
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P28221
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28221
CHEMBL3352722,,triptan,Phase 1,serotonin receptor agonist,P28221
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P28221
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P28221
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL120768,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,zolmitriptan,Launched,serotonin receptor agonist,P28221
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28221
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P28221
CHEMBL4870886,,aloe-emodin,Preclinical,anticancer agent,Q14790
CHEMBL376359,CN1C(=O)C=C(N(C1=O)CC2=CC=CC=C2C#N)N3CCC[C@H](C3)N,alogliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4859403,,anagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4587343,,atorvastatin,Launched,HMGCR inhibitor,P27487
CHEMBL4874357,,DBPR108,Phase 1,dipeptidyl peptidase inhibitor,P27487
CHEMBL4747683,CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5C=CC=CC5C(=N4)C)C,linagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4854968,,NVP-DPP728,Phase 2,dipeptidyl peptidase inhibitor,P27487
CHEMBL4857912,,omarigliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4303603,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=C4C=CC(=C(C4=NN3)F)F)N,PK-44,Preclinical,dipeptidyl peptidase inhibitor,P27487
CHEMBL2103745,C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N.O,saxagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL1201174,C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N.O.OP(=O)(O)O,sitagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL3545064,B([C@@H]1CCCN1C(=O)[C@H](C(C)C)N)(O)O.CS(=O)(=O)O,talabostat,Phase 3,dipeptidyl peptidase inhibitor|fibroblast activation protein inhibitor,P27487
CHEMBL2147777,CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5,teneligliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4303381,CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N,trelagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL4878152,,UAMC-00039,Preclinical,dipeptidyl peptidase inhibitor,P27487
CHEMBL142703,C1C[C@H](N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N,vildagliptin,Launched,dipeptidyl peptidase inhibitor,P27487
CHEMBL1233638,C1=CC(=CC=C1C[C@H](C(=O)O)N)I,4-iodo-L-phenylalanine,Preclinical,,P27487
CHEMBL4458593,CCOC(=O)[C@H]1C[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,aloxistatin,Phase 3,protease inhibitor,P08311
CHEMBL270515,B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,delanzomib,Phase 1/Phase 2,proteasome inhibitor,P08311
CHEMBL2396661,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,alpelisib,Launched,PI3K inhibitor,P42336
CHEMBL1231533,C1=CC2=C(C=C1/C=C\3/C(=O)NC(=O)S3)OC(O2)(F)F,AS-604850,Preclinical,PI3K inhibitor,P42336
CHEMBL4874238,,AZD6482,Phase 1,PI3K inhibitor,P42336
CHEMBL3894518,CCN1C(=NC(=N1)C2CCN(CC2)C(=O)CCO)C3=CN=C(C(=N3)C4=NN=C(O4)C(C)(C)C)N,AZD8835,Phase 1,PI3K inhibitor,P42336
CHEMBL4847710,,A66,Preclinical,PI3K inhibitor,P42336
CHEMBL3545096,CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=C\C(=O)O)\C(=O)O,BGT226,Phase 1/Phase 2,PI3K inhibitor,P42336
CHEMBL2364604,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4.Cl,buparlisib,Phase 3,PI3K inhibitor,P42336
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P42336
CHEMBL4867637,,CH5132799,Phase 1,PI3K inhibitor,P42336
CHEMBL3545068,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5.Cl.Cl,copanlisib,Launched,PI3K inhibitor,P42336
CHEMBL4538684,C[C@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,duvelisib,Launched,PI3K inhibitor,P42336
CHEMBL4303351,CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4,ETP-45658,Preclinical,PI3K inhibitor,P42336
CHEMBL4871416,,GDC-0349,Phase 1,Pim kinase inhibitor,P42336
CHEMBL4873525,,GDC-0941,Phase 2,PI3K inhibitor,P42336
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4859753,,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4095008,CC[C@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,idelalisib,Launched,PI3K inhibitor,P42336
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P42336
CHEMBL4869629,,MLN0128,Phase 2,mTOR inhibitor,P42336
CHEMBL3935857,C1COCCN1C(=O)C2=CN=C3N2C=C(C=C3)C4=CC5=C(C=C4)OC(=N5)N,MLN1117,Phase 2,PI3K inhibitor,P42336
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4878605,,PF-04691502,Phase 2,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4874638,,PF-05212384,Phase 2,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL3182327,CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=NC=NC(=C5C=N4)N,PIK-293,Preclinical,PI3K inhibitor,P42336
CHEMBL4853500,,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,P42336
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P42336
CHEMBL578092,C=CCN1CCN(CC1)C(C2=CC=CC=C2F)C3=NN=NN3CC4=CC=CO4.Cl,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4865088,,taselisib,Phase 3,PI3K inhibitor,P42336
CHEMBL230011,C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N,TG100-115,Phase 1/Phase 2,PI3K inhibitor,P42336
CHEMBL3545366,CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N,voxtalisib,Phase 2,mTOR inhibitor|PI3K inhibitor,P42336
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P42336
CHEMBL4851334,,XL147,Phase 2,PI3K inhibitor,P42336
CHEMBL2396661,CC1=C(SC(=N1)NC(=O)N2CCC[C@H]2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F,alpelisib,Launched,PI3K inhibitor,P48736
CHEMBL4877830,,AS-252424,Preclinical,PI3K inhibitor,P48736
CHEMBL1231533,C1=CC2=C(C=C1/C=C\3/C(=O)NC(=O)S3)OC(O2)(F)F,AS-604850,Preclinical,PI3K inhibitor,P48736
CHEMBL4874238,,AZD6482,Phase 1,PI3K inhibitor,P48736
CHEMBL2134545,CC1=NC2=CN=C3C=CC(=CC3=C2N1C4=CC=C(C=C4)C(C)(C)C#N)C#CC5=CN=CC=C5,BAG-956,Preclinical,phosphoinositide dependent kinase inhibitor,P48736
CHEMBL3545096,CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=C\C(=O)O)\C(=O)O,BGT226,Phase 1/Phase 2,PI3K inhibitor,P48736
CHEMBL2364604,C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4.Cl,buparlisib,Phase 3,PI3K inhibitor,P48736
CHEMBL4863625,,CAY10505,Preclinical,PI3K inhibitor,P48736
CHEMBL4867637,,CH5132799,Phase 1,PI3K inhibitor,P48736
CHEMBL3545068,COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5.Cl.Cl,copanlisib,Launched,PI3K inhibitor,P48736
CHEMBL4860848,,CZC24832,Preclinical,PI3K inhibitor,P48736
CHEMBL4538684,C[C@H](C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,duvelisib,Launched,PI3K inhibitor,P48736
CHEMBL4303351,CN1C2=C(C=N1)C(=NC(=N2)C3=CC(=CC=C3)O)N4CCOCC4,ETP-45658,Preclinical,PI3K inhibitor,P48736
CHEMBL4873525,,GDC-0941,Phase 2,PI3K inhibitor,P48736
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P48736
CHEMBL4876295,,GSK1059615,Phase 1,PI3K inhibitor,P48736
CHEMBL4859753,,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,P48736
CHEMBL4095008,CC[C@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5,idelalisib,Launched,PI3K inhibitor,P48736
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P48736
CHEMBL4869629,,MLN0128,Phase 2,mTOR inhibitor,P48736
CHEMBL164,C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,myricetin,Preclinical,androgen receptor agonist|cytochrome P450 inhibitor,P48736
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,P48736
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,P48736
CHEMBL3182327,CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)CN4C5=NC=NC(=C5C=N4)N,PIK-293,Preclinical,PI3K inhibitor,P48736
CHEMBL4878936,,PIK-294,Preclinical,PI3K inhibitor,P48736
CHEMBL4853500,,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,P48736
CHEMBL4857460,,PIK-93,Preclinical,PI3K inhibitor,P48736
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P48736
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P48736
CHEMBL2109635,,SAR-245409,Phase 1/Phase 2,PI3K inhibitor,P48736
CHEMBL578092,C=CCN1CCN(CC1)C(C2=CC=CC=C2F)C3=NN=NN3CC4=CC=CO4.Cl,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,P48736
CHEMBL230011,C1=CC(=CC(=C1)O)C2=NC3=C(N=C(N=C3N=C2C4=CC(=CC=C4)O)N)N,TG100-115,Phase 1/Phase 2,PI3K inhibitor,P48736
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,P48736
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P48736
CHEMBL4851334,,XL147,Phase 2,PI3K inhibitor,P48736
CHEMBL586701,CC1=CC=C(C=C1)C2C3=C(C4=CC=CC=C4C3=O)NC5=CC=CC=C5S2,ZSTK-474,Phase 1/Phase 2,PI3K inhibitor,P48736
CHEMBL333306,C/C=C/C1=CC(=C(C=C1OC)OC)OC,alpha-asarone,Preclinical,cytochrome P450 inhibitor|HMGCR inhibitor,P04035
CHEMBL4587343,,atorvastatin,Launched,HMGCR inhibitor,P04035
CHEMBL1412305,CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC=C2.Cl,benfluorex,Withdrawn,gluconeogenesis inhibitor,P04035
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,P04035
CHEMBL4851780,,coenzyme-I,Phase 2,,P04035
CHEMBL121305,CC1=CC(=CC2=C1O[C@](CC2)(C)CC/C=C(\C)/CC/C=C(\C)/CCC=C(C)C)O,delta-tocotrienol,Phase 1,HMGCR inhibitor,P04035
CHEMBL1078,CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F,fluvastatin,Launched,HMGCR inhibitor,P04035
CHEMBL4848770,,lovastatin,Launched,HMGCR inhibitor,P04035
CHEMBL50444,CC(CC(=O)O)(CC(=O)O)O,meglutol,Launched,HMGCR inhibitor,P04035
CHEMBL4873726,,mevastatin,Preclinical,HMGCR inhibitor,P04035
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P04035
CHEMBL1201753,C1CC1C2=NC3=CC=CC=C3C(=C2/C=C/[C@H](C[C@H](CC(=O)O)O)O)C4=CC=C(C=C4)F,pitavastatin,Launched,HMGCR inhibitor,P04035
CHEMBL1144,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,pravastatin,Launched,HMGCR inhibitor,P04035
CHEMBL1744447,CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.[Ca+2],rosuvastatin,Launched,HMGCR inhibitor,P04035
CHEMBL1201391,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)C,simvastatin,Launched,HMGCR inhibitor,P04035
CHEMBL449317,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,hesperidin,Launched,flavanone glycoside,Q96GD4
CHEMBL2140408,CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N,AMG900,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,Q96GD4
CHEMBL4858356,,barasertib,Phase 2/Phase 3,Aurora kinase inhibitor,Q96GD4
CHEMBL4858356,,barasertib-HQPA,Phase 2/Phase 3,Aurora kinase inhibitor,Q96GD4
CHEMBL4303500,CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,Q96GD4
CHEMBL4858688,,CCT129202,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL4868270,,CCT137690,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL576817,C1=CC(=CC=C1NC2C3=C(N=CN=C3N=N2)N)F,CGP-57380,Preclinical,MAP kinase inhibitor,Q96GD4
CHEMBL4853670,,CYC116,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,Q96GD4
CHEMBL4870522,,GSK1070916,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4879292,,GSK2334470,Preclinical,phosphoinositide dependent kinase inhibitor,Q96GD4
CHEMBL514409,CCS(=O)(=O)NC1=CC2=C(C=C1)NC(=C2C(=NC3=CC=C(C=C3)CN4CCCCC4)C5=CC=CC=C5)O,hesperadin,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL4857627,,JNJ-7706621,Preclinical,CDK inhibitor,Q96GD4
CHEMBL4874165,,KW-2449,Phase 1,Abl kinase inhibitor|Aurora kinase inhibitor|FLT3 inhibitor,Q96GD4
CHEMBL3182444,C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O,MK-5108,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4850230,,orantinib,Phase 3,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,Q96GD4
CHEMBL4857821,,PF-03814735,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4861873,,PHA-680632,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL4862978,,reversine,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL482767,C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4,SNS-314,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4856756,,TAK-901,Phase 1,Aurora kinase inhibitor,Q96GD4
CHEMBL4744548,CC1=C(C=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C,tozasertib,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,Q96GD4
CHEMBL4874577,,ZM-447439,Preclinical,Aurora kinase inhibitor,Q96GD4
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,Q9GZR5
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,O60427
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,O60427
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,O95864
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,O14842
CHEMBL4873101,,AMG-837,Phase 1,free fatty acid receptor agonist,O14842
CHEMBL4303234,C1CC2=C(C=CC=C2N(C1)CCOC3=CC=CC=C3)CNC4=CC(=C(C=C4)CCC(=O)O)F,AS-2034178,Preclinical,free fatty acid receptor agonist,O14842
CHEMBL3931570,CCCCC1=CC=C(C=C1)NS(=O)(=O)C2=CC=C(C=C2)F,DC-260126,Preclinical,free fatty acid receptor antagonist,O14842
CHEMBL367149,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,doconexent,Launched,PPAR receptor agonist,O14842
CHEMBL3989529,CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N,ethanolamine-oleate,Launched,immunostimulant,O14842
CHEMBL4303679,CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC,GW-1100,Preclinical,G protein-coupled receptor agonist,O14842
CHEMBL4852429,,GW-9508,Preclinical,free fatty acid receptor agonist|G protein-coupled receptor agonist,O14842
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,O14842
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,O14842
CHEMBL4860481,,medica-16,Phase 2,ATP citrase lyase inhibitor,O14842
CHEMBL121,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,rosiglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,O14842
CHEMBL4865302,,TAK-875,Phase 3,insulin secretagogue,O14842
CHEMBL4854598,,TUG-770,Preclinical,free fatty acid receptor agonist,O14842
CHEMBL8739,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,alpha-linolenic-acid,Phase 3,omega 3 fatty acid stimulant,P32418
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P32418
CHEMBL1447233,C1C(=O)NC2=C(C=C(C=C2)Cl)[C@@H](S1)C3=CC=CC=C3Cl,CGP-37157,Preclinical,mitochondrial Na+/Ca2+ exchanger antagonist|sodium/calcium exchange inhibitor,P32418
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,P32418
CHEMBL1433489,C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-],KB-R7943,Preclinical,sodium/calcium exchange inhibitor,P32418
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P28566
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P28566
CHEMBL3187365,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,asenapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P28566
CHEMBL1371156,CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O,BRL-54443,Preclinical,serotonin receptor agonist,P28566
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P28566
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P28566
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P28566
CHEMBL1213135,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C.C(=C\C(=O)O)\C(=O)O,ergonovine,Launched,adrenergic receptor agonist|serotonin receptor agonist,P28566
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P28566
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,P28566
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P28566
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P28566
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P28566
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P28566
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P28566
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P28566
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P28566
CHEMBL1200601,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl,naratriptan,Launched,serotonin receptor agonist,P28566
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P28566
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1201032,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O,rizatriptan,Launched,serotonin receptor agonist,P28566
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P28566
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P28566
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P28566
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P28566
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL120768,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,zolmitriptan,Launched,serotonin receptor agonist,P28566
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P28566
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P28566
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,P30939
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P30939
CHEMBL1371156,CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)O,BRL-54443,Preclinical,serotonin receptor agonist,P30939
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P30939
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P30939
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P30939
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P30939
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P30939
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P30939
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P30939
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P30939
CHEMBL4860152,,methylergometrine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P30939
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P30939
CHEMBL4850949,,NAN-190,Preclinical,serotonin receptor agonist,P30939
CHEMBL1200601,CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.Cl,naratriptan,Launched,serotonin receptor agonist,P30939
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL1201032,CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O,rizatriptan,Launched,serotonin receptor agonist,P30939
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P30939
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P30939
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P30939
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P30939
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P30939
CHEMBL120768,CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3,zolmitriptan,Launched,serotonin receptor agonist,P30939
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P30939
CHEMBL4874858,,alpha-methylserotonin,Preclinical,serotonin receptor agonist,Q13639
CHEMBL324057,CC(C)N1C2=CC=CC=C2N(C1=O)C(=O)NC3CC4CCCC(C3)N4C,BIMU-8,Preclinical,serotonin receptor agonist,Q13639
CHEMBL74656,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,cisapride,Withdrawn,serotonin receptor agonist,Q13639
CHEMBL4875715,,CJ-033466,Preclinical,serotonin receptor agonist,Q13639
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,Q13639
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine-decanoate,Launched,dopamine receptor antagonist,Q13639
CHEMBL4874008,,GR-113808,Preclinical,serotonin receptor antagonist,Q13639
CHEMBL4851855,,GR125487,Preclinical,serotonin receptor antagonist,Q13639
CHEMBL1200940,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q13639
CHEMBL4138046,,ML10302,Preclinical,serotonin receptor partial agonist,Q13639
CHEMBL4865104,,mosapride,Launched,serotonin receptor agonist,Q13639
CHEMBL2106927,CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42.Cl,piboserod,Phase 2,serotonin receptor antagonist,Q13639
CHEMBL2105748,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl.C(CC(=O)O)C(=O)O,prucalopride,Launched,serotonin receptor agonist,Q13639
CHEMBL1643880,C1CN2CCC1[C@H](C2)NC(=O)C3=CNC4=C(C3=O)SC=C4,pumosetrag,Phase 2,serotonin receptor agonist,Q13639
CHEMBL4873697,,RS-23597-190,Preclinical,serotonin receptor antagonist,Q13639
CHEMBL4866680,,RS-39604,Preclinical,serotonin receptor antagonist,Q13639
CHEMBL4867457,,RS-67333,Preclinical,serotonin receptor partial agonist,Q13639
CHEMBL4853396,,RS-67506,Preclinical,serotonin receptor partial agonist,Q13639
CHEMBL4877226,,SB-203186,Preclinical,serotonin receptor antagonist,Q13639
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,Q13639
CHEMBL1516474,CCCCCN=C(N)N/N=C/C1=CNC2=C1C=C(C=C2)OC.C(=C\C(=O)O)\C(=O)O,tegaserod,Withdrawn,serotonin receptor partial agonist,Q13639
CHEMBL4303202,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl,tropisetron,Launched,serotonin receptor antagonist,Q13639
CHEMBL1615374,C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N.Cl,vilazodone,Launched,serotonin reuptake inhibitor,Q13639
CHEMBL1516756,COC1=CC(=C(C=C1C(=O)NC2CN3CCC2CC3)Cl)N.O.Cl,zacopride,Phase 2,serotonin receptor antagonist,Q13639
CHEMBL4850376,,2-[1-(4-piperonyl)piperazinyl]benzothiazole,Preclinical,serotonin receptor agonist,Q13639
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,Q8NEC5
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q8NEC5
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q8NEC5
CHEMBL4875620,,NNC-55-0396,Preclinical,T-type calcium channel blocker,Q8NEC5
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,Q8NEC5
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,Q96P56
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q96P56
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q96P56
CHEMBL4875620,,NNC-55-0396,Preclinical,T-type calcium channel blocker,Q96P56
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,Q96P56
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,Q86XQ3
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q86XQ3
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q86XQ3
CHEMBL4875620,,NNC-55-0396,Preclinical,T-type calcium channel blocker,Q86XQ3
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,Q86XQ3
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,Q7RTX7
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q7RTX7
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q7RTX7
CHEMBL4875620,,NNC-55-0396,Preclinical,T-type calcium channel blocker,Q7RTX7
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,Q7RTX7
CHEMBL4852715,,alprostadil,Launched,prostanoid receptor agonist,P43119
CHEMBL125569,C1=CC=C(C=C1)C2=C(OC(=N2)C3=C(OC=N3)C4=CC(=CC=C4)OCC(=O)O)C5=CC=CC=C5,BMY-45778,Preclinical,IP1 prostacyclin receptor agonist,P43119
CHEMBL962,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+],epoprostenol,Launched,prostacyclin analog,P43119
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P43119
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P43119
CHEMBL4064157,CCCC[C@@](C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O,misoprostol,Launched,prostanoid receptor agonist,P43119
CHEMBL4859315,,Ro-1138452,Preclinical,prostanoid receptor antagonist,P43119
CHEMBL238804,CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3,selexipag,Launched,IP1 prostacyclin receptor agonist|platelet aggregation inhibitor,P43119
CHEMBL1237119,CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,treprostinil,Launched,prostanoid receptor agonist,P43119
CHEMBL2146093,CN1CCC[C@H]1C2=CN=CC(=C2)C#C.C(=C/C(=O)O)\C(=O)O,altinicline,Phase 2,nicotinic receptor agonist,P17787
CHEMBL4848919,,AZD1446,Phase 2,acetylcholine receptor agonist,P17787
CHEMBL4303499,C1[C@H]2CN(C[C@@H]1C3=CC=CC(=O)N3C2)CCN4C[C@@H]5C[C@H](C4)C6=CC=CC(=O)N6C5,CC4,Preclinical,nicotinic receptor agonist,P17787
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,P17787
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P17787
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P17787
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P17787
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-9965,Preclinical,acetylcholine receptor antagonist,P17787
CHEMBL4870941,,pozanicline,Phase 2,acetylcholine receptor antagonist,P17787
CHEMBL4521451,C.CNCC/C=C/C1=CN=CC=C1,rivanicline,Phase 2,acetylcholine receptor agonist,P17787
CHEMBL1405034,C1C[C@H]2CC[C@H](N2)C(=C1)C3=CN=C(C=C3)Cl,UB-165,Preclinical,acetylcholine receptor agonist,P17787
CHEMBL4748565,C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(\[C@@H]([C@H](/C=C\C=C(/C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)\C)OC)OC(=O)N)/C)C)O)OC,alvespimycin,Phase 2,HSP inhibitor,P07900
CHEMBL4870300,,AT13387,Phase 2,HSP inhibitor,P07900
CHEMBL4868940,,BIIB021,Phase 2,HSP inhibitor,P07900
CHEMBL4870654,,CCT018159,Preclinical,HSP inhibitor,P07900
CHEMBL4850247,,EC-144,Preclinical,HSP inhibitor,P07900
CHEMBL2103879,CC(C)C1=C(C=C(C(=C1)C2=NNC(=O)N2C3=CC4=C(C=C3)N(C=C4)C)O)O,ganetespib,Phase 3,HSP inhibitor,P07900
CHEMBL465226,CC(=O)O[C@@H]1C[C@@H]2[C@](C=CC(=O)C2(C)C)([C@@H]3[C@@]1([C@]45[C@H](O4)C(=O)O[C@H]([C@@]5(CC3)C)C6=COC=C6)C)C,gedunin,Preclinical,HSP inhibitor,P07900
CHEMBL4303630,C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C/C=C(/C(=O)NC2=CC(=O)C(=C(C1)C2=O)OC)\C)OC)OC(=O)N)\C)C)O)OC,geldanamycin,Preclinical,HSP inhibitor,P07900
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P07900
CHEMBL4877379,,nedocromil,Launched,histamine receptor antagonist,P07900
CHEMBL4012591,,NVP-AUY922,Phase 2,HSP inhibitor,P07900
CHEMBL4857467,,NVP-HSP990,Phase 1,HSP inhibitor,P07900
CHEMBL4850673,,PU-H71,Phase 1,HSP inhibitor,P07900
CHEMBL1184904,C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=C(C(=C2O)C1)NCC=C)O)/C)OC)OC(=O)N)\C)C)O)OC,retaspimycin,Phase 3,HSP inhibitor,P07900
CHEMBL497000,COC(=O)C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O,rhein,Phase 1,,P07900
CHEMBL4856355,,SNX-5422,Phase 1/Phase 2,HSP inhibitor,P07900
CHEMBL4786163,C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(\[C@@H]([C@H](/C=C\C=C(/C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)\C)OC)OC(=O)N)/C)C)O)OC,tanespimycin,Phase 3,HSP inhibitor,P07900
CHEMBL4875373,,VER-49009,Preclinical,HSP inhibitor,P07900
CHEMBL270190,C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O,alvimopan,Launched,opioid receptor antagonist,P41145
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P41145
CHEMBL2074513,,asimadoline,Phase 3,opioid receptor agonist,P41145
CHEMBL4876136,,beta-funaltrexamine,Preclinical,opioid receptor antagonist,P41145
CHEMBL436031,C1CC1CN2CC[C@]34[C@@H]5C(=O)/C(=C/C6=CC=CC=C6)/C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O,BNTX,Preclinical,opioid receptor antagonist,P41145
CHEMBL4750757,C1CCN([C@@H](C1)CN2CCCC2)C(=O)CC3=CC(=C(C=C3)Cl)Cl.Cl,BRL-52537,Preclinical,opioid receptor agonist,P41145
CHEMBL1200596,C1=CC2=C(C(=C(C=C2Cl)Cl)O)N=C1,chloroxine,Launched,opioid receptor antagonist,P41145
CHEMBL497,C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1,clioquinol,Withdrawn,chelating agent,P41145
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P41145
CHEMBL4865923,,eluxadoline,Launched,opioid receptor agonist|opioid receptor antagonist,P41145
CHEMBL3391755,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)C=CC(=C8)N=C(N)N.Cl,GNTI,Preclinical,opioid receptor antagonist,P41145
CHEMBL4846156,,ICI-199441,Preclinical,opioid receptor agonist,P41145
CHEMBL4862217,,JDTic,Phase 1,opioid receptor antagonist,P41145
CHEMBL4862828,,levomenthol,Launched,,P41145
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,P41145
CHEMBL204860,C1C[C@@H]2[C@H]3CCCN4[C@H]3[C@@H](CCC4)CN2C(=O)C1,matrine,Phase 2,opioid receptor agonist,P41145
CHEMBL1186579,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,methylnaltrexone,Launched,opioid receptor antagonist,P41145
CHEMBL1201132,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl,nalbuphine,Launched,opioid receptor agonist|opioid receptor antagonist,P41145
CHEMBL4879316,,nalfurafine,Launched,opioid receptor agonist,P41145
CHEMBL982,C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O,nalmefene,Launched,opioid receptor antagonist,P41145
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,P41145
CHEMBL1256836,C=CCN1CC[C@]23[C@@H]4/C(=N/NC(=O)C5=CC=CC=C5)/CC[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O,naloxone-benzoylhydrazone,Preclinical,opioid receptor antagonist,P41145
CHEMBL1201149,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O.Cl,naltrexone,Launched,opioid receptor antagonist,P41145
CHEMBL295413,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6,naltriben,Preclinical,opioid receptor antagonist,P41145
CHEMBL149,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8N6,naltrindole,Preclinical,opioid receptor antagonist,P41145
CHEMBL2374078,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl,nor-binaltorphimine,Preclinical,opioid receptor antagonist,P41145
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,P41145
CHEMBL4855108,,salvinorin-A,Phase 1,opioid receptor agonist,P41145
CHEMBL118865,CN(C1CCC2(CCCO2)CC1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,spiradoline,Phase 2,opioid receptor agonist,P41145
CHEMBL1289110,CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O,tianeptine,Launched,selective serotonin reuptake enhancer (SSRE),P41145
CHEMBL190044,CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C,trimebutine,Launched,opioid receptor agonist,P41145
CHEMBL4859222,,U-50488-(-),Preclinical,opioid receptor agonist,P41145
CHEMBL1711959,CN([C@@H]1CCCC[C@@H]1N2CCCC2)C(=O)C3=CC(=C(C=C3)Cl)Cl,U-54494A,Preclinical,opioid receptor agonist,P41145
CHEMBL270190,C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O,alvimopan,Launched,opioid receptor antagonist,P35372
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P35372
CHEMBL4876136,,beta-funaltrexamine,Preclinical,opioid receptor antagonist,P35372
CHEMBL436031,C1CC1CN2CC[C@]34[C@@H]5C(=O)/C(=C/C6=CC=CC=C6)/C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O,BNTX,Preclinical,opioid receptor antagonist,P35372
CHEMBL1600780,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N.Cl,BW-180C,Phase 2,opioid receptor agonist,P35372
CHEMBL2364605,CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5,cebranopadol,Phase 3,opioid receptor agonist,P35372
CHEMBL4777766,C[C@@H](C(=O)NCC(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)N[C@H](CCCN=C(N)N)C(=O)O)NC(=O)C(CC2=CC=C(C=C2)O)N,dalargin,Phase 2,opioid receptor agonist,P35372
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P35372
CHEMBL4865923,,eluxadoline,Launched,opioid receptor agonist|opioid receptor antagonist,P35372
CHEMBL1256915,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C.C(=C/C(=O)O)\C(=O)O,eseroline-(-),Preclinical,acetylcholinesterase inhibitor,P35372
CHEMBL4303387,CC(=O)N1CCC(CC1)NC(=O)C2=CC=C(C=C2)F,FK-33-824,Phase 2,opioid receptor agonist,P35372
CHEMBL3391755,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)C=CC(=C8)N=C(N)N.Cl,GNTI,Preclinical,opioid receptor antagonist,P35372
CHEMBL4846156,,ICI-199441,Preclinical,opioid receptor agonist,P35372
CHEMBL2062276,C=CCN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O.C(C(C(=O)O)O)(C(=O)O)O,levallorphan,Launched,opioid receptor antagonist,P35372
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,P35372
CHEMBL1186579,C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6,methylnaltrexone,Launched,opioid receptor antagonist,P35372
CHEMBL1201132,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O.Cl,nalbuphine,Launched,opioid receptor agonist|opioid receptor antagonist,P35372
CHEMBL4879316,,nalfurafine,Launched,opioid receptor agonist,P35372
CHEMBL982,C=C1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC6CC6)O,nalmefene,Launched,opioid receptor antagonist,P35372
CHEMBL2219418,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@]2([C@H]3CC4=C5[C@]2([C@H]1OC5=C(C=C4)O)CCN3CC=C)O,naloxegol,Launched,opioid receptor antagonist,P35372
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,P35372
CHEMBL1256836,C=CCN1CC[C@]23[C@@H]4/C(=N/NC(=O)C5=CC=CC=C5)/CC[C@]2([C@H]1CC6=C3C(=C(C=C6)O)O4)O,naloxone-benzoylhydrazone,Preclinical,opioid receptor antagonist,P35372
CHEMBL1201149,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O.Cl,naltrexone,Launched,opioid receptor antagonist,P35372
CHEMBL295413,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8O6,naltriben,Preclinical,opioid receptor antagonist,P35372
CHEMBL149,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3(C2CC7=C4C(=C(C=C7)O)O5)O)C8=CC=CC=C8N6,naltrindole,Preclinical,opioid receptor antagonist,P35372
CHEMBL2374078,C1CC1CN2CC[C@]34[C@@H]5C6=C(C[C@]3([C@H]2CC7=C4C(=C(C=C7)O)O5)O)C8=C(N6)[C@H]9[C@@]12CCN([C@@H]([C@@]1(C8)O)CC1=C2C(=C(C=C1)O)O9)CC1CC1.Cl.Cl,nor-binaltorphimine,Preclinical,opioid receptor antagonist,P35372
CHEMBL264846,C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O,orphanin-fq,Phase 1,opioid receptor agonist,P35372
CHEMBL4855108,,salvinorin-A,Phase 1,opioid receptor agonist,P35372
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P35372
CHEMBL1289110,CN1C2=CC=CC=C2C(C3=C(S1(=O)=O)C=C(C=C3)Cl)NCCCCCCC(=O)O,tianeptine,Launched,selective serotonin reuptake enhancer (SSRE),P35372
CHEMBL190044,CCC(COC(=O)C1=CC(=C(C(=C1)OC)OC)OC)(C2=CC=CC=C2)N(C)C,trimebutine,Launched,opioid receptor agonist,P35372
CHEMBL5042488,,TRV130,Phase 3,opioid receptor agonist,P35372
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P06493
CHEMBL4878491,,aminopurvalanol-a,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,P06493
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,P06493
CHEMBL4877789,,BMS-265246,Preclinical,CDK inhibitor,P06493
CHEMBL4877650,,CDK1-5-inhibitor,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P06493
CHEMBL4860897,,CGP-60474,Preclinical,CDK inhibitor,P06493
CHEMBL4867295,,CGP-74514,Preclinical,CDK inhibitor,P06493
CHEMBL4863895,,CHIR-99021,Preclinical,glycogen synthase kinase inhibitor,P06493
CHEMBL2103840,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO,dinaciclib,Phase 3,CDK inhibitor,P06493
CHEMBL1276127,C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O,indirubin,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,P06493
CHEMBL1496098,C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P06493
CHEMBL4857627,,JNJ-7706621,Preclinical,CDK inhibitor,P06493
CHEMBL4867858,,kenpaullone,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P06493
CHEMBL4865572,,olomoucine,Preclinical,CDK inhibitor,P06493
CHEMBL4859598,,PF-573228,Preclinical,focal adhesion kinase inhibitor,P06493
CHEMBL4872476,,PHA-767491,Preclinical,CDC inhibitor,P06493
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,P06493
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,P06493
CHEMBL3991935,CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,P276-00,Phase 2,CDK inhibitor,P06493
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P06493
CHEMBL4877504,,Ro-3306,Preclinical,CDK inhibitor,P06493
CHEMBL4852606,,R547,Phase 1,CDK inhibitor,P06493
CHEMBL4864204,,SU9516,Preclinical,CDK inhibitor,P06493
CHEMBL4858264,,terameprocol,Phase 1/Phase 2,lipoxygenase inhibitor,P06493
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,P06493
CHEMBL4874931,,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,P06493
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P06493
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,Q00535
CHEMBL4878491,,aminopurvalanol-a,Preclinical,CDK inhibitor|tyrosine kinase inhibitor,Q00535
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,Q00535
CHEMBL4877650,,CDK1-5-inhibitor,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,Q00535
CHEMBL2103840,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO,dinaciclib,Phase 3,CDK inhibitor,Q00535
CHEMBL1276127,C1=CC=C2C(=C1)C(=C(N2)O)C3=NC4=CC=CC=C4C3=O,indirubin,Phase 2/Phase 3,CDK inhibitor|glycogen synthase kinase inhibitor,Q00535
CHEMBL1496098,C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,Q00535
CHEMBL4867858,,kenpaullone,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,Q00535
CHEMBL4865572,,olomoucine,Preclinical,CDK inhibitor,Q00535
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,Q00535
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,Q00535
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,Q00535
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,Q00535
CHEMBL4864204,,SU9516,Preclinical,CDK inhibitor,Q00535
CHEMBL4874931,,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,Q00535
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P50613
CHEMBL2074409,,BMS-387032,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,P50613
CHEMBL4867461,,BS-181,Preclinical,CDK inhibitor,P50613
CHEMBL4859598,,PF-573228,Preclinical,focal adhesion kinase inhibitor,P50613
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,P50613
CHEMBL4862981,,PHA-848125,Phase 2,CDK inhibitor|growth factor receptor inhibitor,P50613
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P50613
CHEMBL4852606,,R547,Phase 1,CDK inhibitor,P50613
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,P50613
CHEMBL4874355,,THZ1,Preclinical,CDK inhibitor,P50613
CHEMBL4862390,,THZ1-R,Preclinical,CDK inhibitor,P50613
CHEMBL4874108,,THZ2,Preclinical,CDK inhibitor,P50613
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P49336
CHEMBL2105698,CN1CC[C@@H]([C@@H](C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,alvocidib,Phase 2,CDK inhibitor,P50750
CHEMBL445813,C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl,AT-7519,Phase 2,CDK inhibitor,P50750
CHEMBL2074409,,BMS-387032,Phase 1,CDK inhibitor|cell cycle inhibitor|MCL1 inhibitor,P50750
CHEMBL4525049,C1CC(CCC1N)NC2=NC=C(C(=C2)C3=NC(=CC=C3)NCC4=CC(=CC=C4)F)Cl,CDK9-IN-6,Preclinical,CDK inhibitor,P50750
CHEMBL2103840,CCC1=C2N=C(C=C(N2N=C1)NCC3=C[N+](=CC=C3)[O-])N4CCCC[C@H]4CCO,dinaciclib,Phase 3,CDK inhibitor,P50750
CHEMBL4859956,,LY2857785,Preclinical,CDK inhibitor,P50750
CHEMBL1230607,CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C,PHA-793887,Phase 1,CDK inhibitor,P50750
CHEMBL3991935,CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl,P276-00,Phase 2,CDK inhibitor,P50750
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P50750
CHEMBL14762,CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=CC=C3,roscovitine,Phase 2,CDK inhibitor,P50750
CHEMBL4869526,,TG-02,Phase 1/Phase 2,CDK inhibitor|FLT3 inhibitor|JAK inhibitor,P50750
CHEMBL4873241,,AM-1241,Preclinical,cannabinoid receptor agonist,P21554
CHEMBL4851395,,AM-251,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL4849314,,AM-281,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL4875214,,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,P21554
CHEMBL4847446,,AM-630,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL4851202,,AM679,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,P21554
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,P21554
CHEMBL3526047,,"CP-945,598",Phase 3,cannabinoid receptor antagonist,P21554
CHEMBL1552895,CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@]([C@@H]3CC2)(C)CN)C.Cl,lylamine,Preclinical,cannabinoid receptor agonist,P21554
CHEMBL4853188,,LY320135,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,P21554
CHEMBL4303333,CC1=C(N(N=C1C(=O)NCC2=CN=CC=C2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Cl,MJ-15,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL4854329,,NIDA-41020,Preclinical,cannabinoid receptor antagonist,P21554
CHEMBL4872662,,oleoylethanolamide,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,P21554
CHEMBL4866771,,olvanil,Preclinical,TRPV agonist,P21554
CHEMBL4858045,,ORG-27569,Preclinical,cannabinoid receptor modulator,P21554
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,P21554
CHEMBL4847027,,pravadoline,Preclinical,cyclooxygenase inhibitor,P21554
CHEMBL4871663,,PSNCBAM-1,Preclinical,cannabinoid receptor modulator,P21554
CHEMBL4860585,,PX-12,Phase 2,thioredoxin inhibitor,P21554
CHEMBL4865288,,rimonabant,Withdrawn,cannabinoid receptor antagonist,P21554
CHEMBL4876227,,SLV-319-(+/-),Phase 2,cannabinoid receptor antagonist,P21554
CHEMBL4876973,,taranabant,Phase 3,cannabinoid receptor inverse agonist,P21554
CHEMBL576981,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O,tebipenem,Launched,bacterial cell wall synthesis inhibitor,P21554
CHEMBL4873241,,AM-1241,Preclinical,cannabinoid receptor agonist,P34972
CHEMBL4849314,,AM-281,Preclinical,cannabinoid receptor antagonist,P34972
CHEMBL4875214,,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,P34972
CHEMBL4847446,,AM-630,Preclinical,cannabinoid receptor antagonist,P34972
CHEMBL4851202,,AM679,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,P34972
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,P34972
CHEMBL4869902,,BML-190,Preclinical,cannabinoid receptor inverse agonist,P34972
CHEMBL4866744,,COR-170,Preclinical,cannabinoid receptor inverse agonist,P34972
CHEMBL4869744,,GP1a,Preclinical,cannabinoid receptor agonist,P34972
CHEMBL4868215,,GP2a,Preclinical,cannabinoid receptor agonist,P34972
CHEMBL1252563,,GW-405833,Preclinical,cannabinoid receptor agonist,P34972
CHEMBL225411,C1COCCC1CNC(=O)C2=CN=C(N=C2C(F)(F)F)NC3=C(C=C(C=C3)Cl)Cl,GW-842166,Phase 2,cannabinoid receptor agonist,P34972
CHEMBL4870511,,JTE-907,Phase 1,cannabinoid receptor inverse agonist,P34972
CHEMBL417675,CCCCCCCCCCCCCCCC(=O)NCCO,palmitoylethanolamide,Launched,cannabinoid receptor agonist,P34972
CHEMBL4847027,,pravadoline,Preclinical,cyclooxygenase inhibitor,P34972
CHEMBL4851395,,AM-251,Preclinical,cannabinoid receptor antagonist,Q14330
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q14330
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q14330
CHEMBL4851395,,AM-251,Preclinical,cannabinoid receptor antagonist,Q9Y2T6
CHEMBL4849314,,AM-281,Preclinical,cannabinoid receptor antagonist,Q9Y2T6
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q9Y2T6
CHEMBL1341792,CC1=CC=C(C=C1)C2=NNC3=C2C(N(C3=O)C4=CC=C(C=C4)C(=O)O)C5=CC(=CC=C5)O,CID-16020046,Preclinical,G protein-coupled receptor antagonist,Q9Y2T6
CHEMBL1310336,CC1=CC(=C2C(=C1)C(=CC(=N2)C3=CC=CC=N3)C(=O)NC4=CC=C(C=C4)S(=O)(=O)NC5=C(C(=NO5)C)C)C,ML193,Preclinical,G protein-coupled receptor antagonist,Q9Y2T6
CHEMBL4872662,,oleoylethanolamide,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,Q9Y2T6
CHEMBL417675,CCCCCCCCCCCCCCCC(=O)NCCO,palmitoylethanolamide,Launched,cannabinoid receptor agonist,Q9Y2T6
CHEMBL4865288,,rimonabant,Withdrawn,cannabinoid receptor antagonist,Q9Y2T6
CHEMBL4875214,,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,O00519
CHEMBL4875214,,AM-404,Preclinical,cyclooxygenase inhibitor|FAAH inhibitor|TRPV antagonist,Q7L5A8
CHEMBL1079935,CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,amperozide,Launched,dopamine receptor antagonist,O00519
CHEMBL1079935,CCNC(=O)N1CCN(CC1)CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F,amperozide,Launched,dopamine receptor antagonist,Q7L5A8
CHEMBL4860461,,JNJ-1661010,Preclinical,FAAH inhibitor,O00519
CHEMBL4860461,,JNJ-1661010,Preclinical,FAAH inhibitor,Q7L5A8
CHEMBL4297294,C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl,JNJ-42165279,Phase 2,FAAH inhibitor,O00519
CHEMBL4297294,C1CN(CCN1CC2=CC3=C(C=C2)OC(O3)(F)F)C(=O)NC4=C(C=CN=C4)Cl,JNJ-42165279,Phase 2,FAAH inhibitor,Q7L5A8
CHEMBL4859034,,JZL-195,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,O00519
CHEMBL4859034,,JZL-195,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,Q7L5A8
CHEMBL4862366,,LY2183240,Preclinical,FAAH inhibitor|FAAH reuptake inhibitor,O00519
CHEMBL4862366,,LY2183240,Preclinical,FAAH inhibitor|FAAH reuptake inhibitor,Q7L5A8
CHEMBL112,CC(=O)NC1=CC=C(C=C1)O,paracetamol,Launched,cyclooxygenase inhibitor,O00519
CHEMBL112,CC(=O)NC1=CC=C(C=C1)O,paracetamol,Launched,cyclooxygenase inhibitor,Q7L5A8
CHEMBL4303222,CCCCCCCCCCCCCCCC1=CC(=CC=C1)OCC(=O)NCCO,PDP-EA,Preclinical,FAAH activator,O00519
CHEMBL4303222,CCCCCCCCCCCCCCCC1=CC(=CC=C1)OCC(=O)NCCO,PDP-EA,Preclinical,FAAH activator,Q7L5A8
CHEMBL4869679,,PF-04457845,Phase 2,FAAH inhibitor,O00519
CHEMBL4869679,,PF-04457845,Phase 2,FAAH inhibitor,Q7L5A8
CHEMBL4858545,,PF-3845,Preclinical,FAAH inhibitor,O00519
CHEMBL4858545,,PF-3845,Preclinical,FAAH inhibitor,Q7L5A8
CHEMBL585085,COC1=CC=C(C=C1)N/C=C/C2=C(C(=NO2)C3=C(C=CC=C3Cl)F)C(=O)OC,PF-750,Preclinical,FAAH inhibitor,O00519
CHEMBL585085,COC1=CC=C(C=C1)N/C=C/C2=C(C(=NO2)C3=C(C=CC=C3Cl)F)C(=O)OC,PF-750,Preclinical,FAAH inhibitor,Q7L5A8
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,O00519
CHEMBL526,CC(C)C1=C(C(=CC=C1)C(C)C)O,propofol,Launched,benzodiazepine receptor agonist,Q7L5A8
CHEMBL4303659,CC1=NC(=CC=C1)N2CCC(CC2)CCNC(=O)OCC(=O)NC,SA-47,Preclinical,FAAH inhibitor,O00519
CHEMBL4303659,CC1=NC(=CC=C1)N2CCC(CC2)CCNC(=O)OCC(=O)NC,SA-47,Preclinical,FAAH inhibitor,Q7L5A8
CHEMBL1738872,CCN1C2=CC=CC=C2N(C1=O)[C@H]3CCCN(C3)C4=NC=CC(=N4)C5=CC6=CC=CC=C6O5,TC-F-2,Preclinical,FAAH inhibitor,O00519
CHEMBL1738872,CCN1C2=CC=CC=C2N(C1=O)[C@H]3CCCN(C3)C4=NC=CC(=N4)C5=CC6=CC=CC=C6O5,TC-F-2,Preclinical,FAAH inhibitor,Q7L5A8
CHEMBL441,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,thiopental,Launched,GABA receptor antagonist,O00519
CHEMBL441,CCCC(C)C1(C(=O)NC(=S)NC1=O)CC,thiopental,Launched,GABA receptor antagonist,Q7L5A8
CHEMBL4872470,,URB597,Phase 1,FAAH inhibitor,O00519
CHEMBL4872470,,URB597,Phase 1,FAAH inhibitor,Q7L5A8
CHEMBL4874687,,AMD-3465,Preclinical,CC chemokine receptor antagonist,P61073
CHEMBL4203190,C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3.Cl,AMD11070,Phase 3,CC chemokine receptor antagonist,P61073
CHEMBL4866047,,IT1t,Preclinical,CC chemokine receptor antagonist,P61073
CHEMBL3545330,C1=CN=C(N=C1)NCC2=CC=C(C=C2)CNC3=NC=CC=N3,MSX-122,Phase 2,CC chemokine receptor antagonist,P61073
CHEMBL3754093,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H](C(O4)CN)O)O)N)O)O)N,neomycin,Launched,bacterial 30S ribosomal subunit inhibitor,P61073
CHEMBL554014,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl,plerixafor,Launched,CC chemokine receptor antagonist,P61073
CHEMBL3861984,,WZ811,Preclinical,CC chemokine receptor antagonist,P61073
CHEMBL4849242,,AMG-PERK-44,Preclinical,PERK inhibitor,Q9P2K8
CHEMBL4854900,,AMG-232,Phase 2,MDM inhibitor,Q00987
CHEMBL4852461,,CGM097,Phase 1,MDM inhibitor,Q00987
CHEMBL4851126,,idasanutlin,Phase 3,MDM inhibitor,Q00987
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q00987
CHEMBL211045,CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl,nutlin-3,Preclinical,MDM inhibitor,Q00987
CHEMBL4303528,CCOC1=C(C=CC(=C1)C(C)(C)C)C2=NC(C(N2C(=O)N3CCN(CC3)CCCS(=O)(=O)C)(C)C4=CC=C(C=C4)Cl)(C)C5=CC=C(C=C5)Cl,RG7112,Phase 1,MDM inhibitor,Q00987
CHEMBL4004890,,RITA,Preclinical,MDM inhibitor,Q00987
CHEMBL4303150,CC(C)(C)CC1C2(C(C(N1)C(=O)NC3CCC(CC3)O)C4=C(C(=CC=C4)Cl)F)C5=C(C=C(C=C5)Cl)NC2=O,SAR405838,Phase 1,MDM inhibitor,Q00987
CHEMBL2137530,C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4,serdemetan,Phase 1,MDM inhibitor,Q00987
CHEMBL4303369,COC1=CC2=C(C=C1)NC3=C2C=CN=C3C4=CC=CC5=CC=CC=C54,SP-141,Preclinical,ubiquitin ligase inhibitor,Q00987
CHEMBL4876144,,AMG-487-(+/-),Phase 2,CC chemokine receptor antagonist,P49682
CHEMBL507001,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1,dioscin,Preclinical,apoptosis stimulant,P49682
CHEMBL4859078,,NBI-74330-(+/-),Preclinical,CC chemokine receptor antagonist,P49682
CHEMBL4857315,,AMG-548,Phase 1,MAP kinase inhibitor,Q15759
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,Q15759
CHEMBL4878041,,doramapimod,Phase 2,p38 MAPK inhibitor,Q15759
CHEMBL4850711,,EO-1428,Preclinical,p38 MAPK inhibitor,Q15759
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,Q15759
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,Q15759
CHEMBL111364,CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F,ML3403,Preclinical,MAP kinase inhibitor,Q15759
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,Q15759
CHEMBL4859416,,PH-797804,Phase 2,p38 MAPK inhibitor,Q15759
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q15759
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,Q15759
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,Q15759
CHEMBL4858276,,SB-239063,Preclinical,p38 MAPK inhibitor,Q15759
CHEMBL4863553,,talmapimod,Phase 2,p38 MAPK inhibitor,Q15759
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,Q15759
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,Q15759
CHEMBL4860551,,VX-745,Phase 2,p38 MAPK inhibitor,Q15759
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,Q15759
CHEMBL4857315,,AMG-548,Phase 1,MAP kinase inhibitor,P53778
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P53778
CHEMBL4878041,,doramapimod,Phase 2,p38 MAPK inhibitor,P53778
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P53778
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P53778
CHEMBL111364,CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C3=C(NC(=N3)SC)C4=CC=C(C=C4)F,ML3403,Preclinical,MAP kinase inhibitor,P53778
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P53778
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P53778
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P53778
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P53778
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,P53778
CHEMBL4860551,,VX-745,Phase 2,p38 MAPK inhibitor,P53778
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P53778
CHEMBL4857315,,AMG-548,Phase 1,MAP kinase inhibitor,O15264
CHEMBL4878041,,doramapimod,Phase 2,p38 MAPK inhibitor,O15264
CHEMBL2140408,CC1=CSC(=C1)C2=NN=C(C3=CC=CC=C32)NC4=CC=C(C=C4)OC5=C(C=CC=N5)C6=NC(=NC=C6)N,AMG900,Phase 1,Aurora kinase inhibitor,Q9UQB9
CHEMBL4303500,CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,Q9UQB9
CHEMBL4858688,,CCT129202,Preclinical,Aurora kinase inhibitor,Q9UQB9
CHEMBL4868270,,CCT137690,Preclinical,Aurora kinase inhibitor,Q9UQB9
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,Q9UQB9
CHEMBL4870522,,GSK1070916,Phase 1,Aurora kinase inhibitor,Q9UQB9
CHEMBL3182444,C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O,MK-5108,Phase 1,Aurora kinase inhibitor,Q9UQB9
CHEMBL4861873,,PHA-680632,Preclinical,Aurora kinase inhibitor,Q9UQB9
CHEMBL482767,C1=CC(=CC(=C1)Cl)NC(=O)NC2=NC=C(S2)CCNC3=NC=NC4=C3SC=C4,SNS-314,Phase 1,Aurora kinase inhibitor,Q9UQB9
CHEMBL4744548,CC1=C(C=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C,tozasertib,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,Q9UQB9
CHEMBL3636206,,AMI-1,Preclinical,protein arginine N-methyltransferase inhibitor,Q99873
CHEMBL1964991,C1=CC(=CC=C1C2=CC=C(O2)C3=CC=C(C=C3)C(=N)N)C(=N)N.Cl,furamidine,Preclinical,protein arginine N-methyltransferase inhibitor,Q99873
CHEMBL1193948,CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@@H](C3=CC(=CC=C3)Cl)O)C=C1,amibegron,Phase 3,adrenergic receptor agonist,P13945
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P13945
CHEMBL3185966,CC(C)(C)NCC(CSC1=NC(=CS1)C2=CC=C(S2)C(=O)N)O.Cl,arotinolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL4864913,,BRL-37344,Phase 2,adrenergic receptor agonist,P13945
CHEMBL305380,CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O,bupranolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL4850111,,carazolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL1201002,CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl,carteolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL1201167,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.OP(=O)(O)O,carvedilol,Launched,adrenergic receptor antagonist,P13945
CHEMBL4873800,,CGP-12177,Phase 1,adrenergic receptor agonist,P13945
CHEMBL4870562,,CGP-20712A,Preclinical,adrenergic receptor antagonist,P13945
CHEMBL1374751,CC(C)NCC(C1=CC(=C(C=C1)N)C#N)O,cimaterol,Preclinical,adrenergic receptor agonist,P13945
CHEMBL156791,CC(C)(C)NCC(COC1=C(C=CC(=C1)Cl)Cl)O,cloranolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL4846290,,CL316243,Phase 2,adrenergic receptor agonist,P13945
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P13945
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P13945
CHEMBL1233766,CC1=C2CCCC2=C(C=C1)OC[C@H]([C@H](C)NC(C)C)O,"ICI-118,551",Phase 2,adrenergic receptor antagonist,P13945
CHEMBL11268,C1=CC=C(C=C1)NC(=O)NCCNCC(COC2=CC=CC=C2C#N)O,"ICI-215,001",Preclinical,adrenergic receptor agonist,P13945
CHEMBL1160723,CC(C)NC[C@@H](C1=CC(=C(C=C1)O)O)O,isoprenaline,Launched,adrenergic receptor agonist,P13945
CHEMBL4845858,,L-755507,Preclinical,adrenergic receptor agonist,P13945
CHEMBL1704116,CC(C)(C)NC[C@H](COC1=CC=CC2=C1CCCC2=O)O.Cl,levobunolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P13945
CHEMBL2095212,C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O,mirabegron,Launched,adrenergic receptor agonist,P13945
CHEMBL521606,CC(C)(C)NCC(COC1=CC=CC2=C1CC(C(C2)O)O)O,nadolol,Launched,adrenergic receptor antagonist,P13945
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P13945
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P13945
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P13945
CHEMBL1358662,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(R),Preclinical,adrenergic receptor antagonist,P13945
CHEMBL1326499,CCC1=CC=CC=C1OC[C@H](CN[C@H]2CCCC3=CC=CC=C23)O,SR-59230A,Preclinical,adrenergic receptor antagonist,P13945
CHEMBL2111163,CC(C)NCC(COC1=CC=CC=C1SC)O,tiprenolol,Phase 2,adrenergic receptor antagonist,P13945
CHEMBL418192,CC1=CC=CC=C1OCC(CNCCOC2=CC=C(C=C2)C(=O)N)O,tolamolol,Phase 3,adrenergic receptor antagonist,P13945
CHEMBL2093109,COC1=CC(=CC(=C1OC)OC)C[C@@H]2C3=CC(=C(C=C3CCN2)O)O.Cl,trimethoquinol,Launched,adrenergic receptor antagonist,P13945
CHEMBL1354284,C1=CC=C(C=C1)[C@H](CNCCOC2=CC=C(C=C2)CC(=O)O)O.Cl,ZD-2079,Phase 2,adrenergic receptor agonist,P13945
CHEMBL4853514,,ZD-7114,Phase 1,adrenergic receptor agonist,P13945
CHEMBL3989773,CC1=C(C=CC(=C1)N(C)C)C[C@H](C)N,amiflamine,Phase 1,monoamine oxidase inhibitor,P21397
CHEMBL4868689,,bifemelane,Launched,acetylcholine release enhancer,P21397
CHEMBL4877864,,BU-224,Preclinical,imidazoline receptor ligand,P21397
CHEMBL4877671,,BW-616U,Preclinical,monoamine oxidase inhibitor,P21397
CHEMBL2104164,C1C2=CC=CC=C2OC(=O)N1CC(=O)N,caroxazone,Withdrawn,monoamine oxidase inhibitor,P21397
CHEMBL8706,CN(CCCOC1=C(C=C(C=C1)Cl)Cl)CC#C,clorgiline,Phase 2,monoamine oxidase inhibitor,P21397
CHEMBL4226242,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC(=C(C=C3)Cl)Cl,diclofensine,Phase 3,dopamine reuptake inhibitor,P21397
CHEMBL2104298,C1COCCN1CCCNC(=O)C2=CC=C(C=C2)Cl,eprobemide,Launched,monoamine oxidase inhibitor,P21397
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P21397
CHEMBL510348,CC1=NC=CC2=C1NC3=CC=CC=C23.Cl,harmane,Preclinical,monoamine oxidase inhibitor,P21397
CHEMBL12208,CC1=CC(=O)OC2=C1C=CC(=C2)O,hymecromone,Phase 2,monoamine oxidase inhibitor,P21397
CHEMBL1256749,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.Cl,indatraline,Preclinical,norepinephrine transporter inhibitor,P21397
CHEMBL92401,CC(C)NNC(=O)C1=CC=NC=C1,iproniazid,Withdrawn,monoamine oxidase inhibitor,P21397
CHEMBL1201168,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,isocarboxazid,Launched,monoamine oxidase inhibitor,P21397
CHEMBL126,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,linezolid,Launched,bacterial 50S ribosomal subunit inhibitor,P21397
CHEMBL1364551,CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl,minaprine,Withdrawn,serotonin reuptake inhibitor,P21397
CHEMBL86304,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,moclobemide,Launched,monoamine oxidase inhibitor,P21397
CHEMBL489079,C1=CC(=CC=C1CC/C(=C\F)/CN)F,mofegiline,Phase 1,monoamine oxidase inhibitor,P21397
CHEMBL1256841,C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=NC=C2,nialamide,Withdrawn,monoamine oxidase inhibitor,P21397
CHEMBL673,CN(CC#C)CC1=CC=CC=C1,pargyline,Launched,monoamine oxidase inhibitor,P21397
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P21397
CHEMBL3889591,CCCN(CC)C(=O)/C=C/C=C/C1=CC2=C(C=C1)OCO2,piperine,Phase 1,monoamine oxidase inhibitor,P21397
CHEMBL1713992,CC1=CC2=C(C=C1)N3CCNC4C3=C2CCC4.CS(=O)(=O)O,pirlindole,Launched,monoamine oxidase inhibitor,P21397
CHEMBL1445061,CN1C2=C(CCNCC2)C3=CC=CC=C31.Cl,PNU-22394,Phase 2,serotonin receptor agonist,P21397
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,P21397
CHEMBL164660,C1=CC(=O)OC2=CC3=C(C=CO3)C=C21,psoralen,Launched,,P21397
CHEMBL1200904,C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl,selegiline,Launched,monoamine oxidase inhibitor,P21397
CHEMBL4303571,C1CCC(CC1)C2=CC3=C(C=C2)N4CCNC5C4=C3CCC5,tetrindole,Phase 3,monoamine oxidase inhibitor,P21397
CHEMBL18116,CC1=CC(=CC=C1)N2CC(OC2=O)CO,toloxatone,Launched,monoamine oxidase inhibitor,P21397
CHEMBL1255743,C1[C@H]([C@@H]1N)C2=CC=CC=C2.Cl,tranylcypromine,Launched,monoamine oxidase inhibitor,P21397
CHEMBL2355333,CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2.O.Cl.Cl,zimelidine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),P21397
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P21397
CHEMBL4873019,,2-BFI,Preclinical,imidazoline receptor ligand,P21397
CHEMBL3989773,CC1=C(C=CC(=C1)N(C)C)C[C@H](C)N,amiflamine,Phase 1,monoamine oxidase inhibitor,P23975
CHEMBL1697712,C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O.Cl,amineptine,Withdrawn,dopamine receptor agonist,P23975
CHEMBL4227511,C1C2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,amitifadine,Phase 3,serotonin transporter (SERT) inhibitor,P23975
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P23975
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,P23975
CHEMBL1625728,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N,BTS-54505,Withdrawn,dopamine reuptake inhibitor,P23975
CHEMBL1201735,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.Br,bupropion,Launched,dopamine reuptake inhibitor,P23975
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),P23975
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P23975
CHEMBL1593558,C1CN(CC2=CC=CC=C21)C(=N)N.C1CN(CC2=CC=CC=C21)C(=N)N.OS(=O)(=O)O,debrisoquin,Launched,adrenergic neuron blocker,P23975
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P23975
CHEMBL1201728,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O,desvenlafaxine,Launched,serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P23975
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P23975
CHEMBL1711280,CN(C)CC/C=C/1\C2=CC=CC=C2CSC3=CC=CC=C31.Cl,dosulepin,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI)|tricyclic antidepressant,P23975
CHEMBL1256774,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31.Cl,doxepin,Launched,histamine receptor antagonist,P23975
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,P23975
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P23975
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P23975
CHEMBL1345,C1CCCN(CCC1)CCN=C(N)N.OS(=O)(=O)O,guanethidine,Launched,adrenergic inhibitor,P23975
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P23975
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P23975
CHEMBL2106638,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl.Cl,lofepramine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P23975
CHEMBL21731,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,maprotiline,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,P23975
CHEMBL4297064,CCN(CC)C(=O)C1(CC1CN)C2=CC=CC=C2.Cl,milnacipran,Launched,serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P23975
CHEMBL1256695,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC.Cl,nisoxetine,Phase 1,norepinephrine reuptake inhibitor,P23975
CHEMBL4864471,,nomifensine,Withdrawn,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,P23975
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P23975
CHEMBL1200609,CS(=O)(=O)O.C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,paroxetine,Launched,selective serotonin reuptake inhibitor (SSRI),P23975
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P23975
CHEMBL1200332,CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13.Cl,protriptyline,Launched,tricyclic antidepressant,P23975
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P23975
CHEMBL383921,CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,reboxetine,Launched,adrenergic receptor antagonist,P23975
CHEMBL4874342,,talopram,Phase 2,adrenergic inhibitor,P23975
CHEMBL1200948,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C.C(=C\C(=O)O)\C(=O)O,trimipramine,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,P23975
CHEMBL1201066,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O.Cl,venlafaxine,Launched,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P23975
CHEMBL2106483,CCOC1=CC=CC=C1OCC2CNCCO2.Cl,viloxazine,Launched,norepinephrine reuptake inhibitor,P23975
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P23975
CHEMBL4854212,,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,P23975
CHEMBL4853728,,amifostine,Launched,reducing agent,P10696
CHEMBL1256295,C1CSC2=N[C@@H](CN21)C3=CC=CC=C3.Cl,tetramisole,Launched,immunostimulant,P10696
CHEMBL4853728,,amifostine,Launched,reducing agent,P22413
CHEMBL4851831,,ribavirin,Launched,antiviral,P22413
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P19801
CHEMBL380216,CC(=O)NCC(=O)O.CC(=O)NCC(=O)O.C1=CC(=CC=C1C(=N)N)NN=NC2=CC=C(C=C2)C(=N)N,diminazene-aceturate,Phase 3,angiotensin converting enzyme activator,P19801
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P78348
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P78348
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P78348
CHEMBL4860236,,EIPA,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,P78348
CHEMBL3989408,CC(C)CC1=CC=C(C=C1)C(C)C(=O)[O-].O.O.[Na+],ibuprofen-(S),Launched,cyclooxygenase inhibitor,P78348
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,P78348
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q16515
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,Q16515
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q13563
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q9BZL6
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q13563
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q9BZL6
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q9P0L9
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,Q9P0L9
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9P0L9
CHEMBL4860236,,EIPA,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,Q9P0L9
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9P0L9
CHEMBL1455497,C(C(C(=O)O)O)C(=O)O,malic-acid,Launched,,Q9P0L9
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P00749
CHEMBL4303420,B(C1=CC=C(C=C1)CSC(=N)N)(O)O,BC-11,Preclinical,urokinase inhibitor,P00749
CHEMBL558,CC1=C(C(=CC=C1)C)OCC(C)N,mexiletine,Launched,sodium channel blocker,P00749
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P37088
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P37088
CHEMBL585,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,triamterene,Launched,sodium channel blocker,P37088
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P51168
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P51168
CHEMBL585,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,triamterene,Launched,sodium channel blocker,P51168
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P51172
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P51172
CHEMBL585,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,triamterene,Launched,sodium channel blocker,P51172
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P51170
CHEMBL1256878,C1=CC=C(C=C1)CN=C(N)NC(=O)C2=C(N=C(C(=N2)Cl)N)N.Cl,benzamil,Phase 2,sodium channel blocker,P51170
CHEMBL585,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,triamterene,Launched,sodium channel blocker,P51170
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,P19634
CHEMBL462831,CC(C)C1=C(C=C(C=C1)C(=O)N=C(N)N)S(=O)(=O)C.CS(=O)(=O)O,cariporide,Phase 3,sodium/hydrogen exchanger inhibitor,P19634
CHEMBL355862,C1CC1C2=C(C=NN2C3=CC=CC4=C3C=CC=N4)C(=O)N=C(N)N,zoniporide,Phase 3,sodium/hydrogen exchanger inhibitor,P19634
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,O94759
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q9HCX4
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",O94759
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9HCX4
CHEMBL1398126,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N.O.O.Cl,amiloride,Launched,sodium channel blocker,Q9Y5S1
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q9Y5S1
CHEMBL1046,C(CCC(=O)O)CCN,aminocaproic-acid,Launched,plasminogen activator inhibitor,P08519
CHEMBL4303365,CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)CSCCC(=O)OC,ki16198,Preclinical,lipoprotein antagonist,P08519
CHEMBL1046,C(CCC(=O)O)CCN,aminocaproic-acid,Launched,plasminogen activator inhibitor,P00750
CHEMBL1046,C(CCC(=O)O)CCN,aminocaproic-acid,Launched,plasminogen activator inhibitor,P00747
CHEMBL877,C1CC(CCC1CN)C(=O)O,tranexamic-acid,Launched,antifibrinolytic|plasminogen activator inhibitor,P00747
CHEMBL1256323,CCC1(CCC(=O)CC1=O)C2=CC=C(C=C2)N,aminoglutethimide,Launched,glucocorticoid receptor antagonist,P05108
CHEMBL1572655,C1=CC=C(C(=C1)[C@H](C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,mitotane,Launched,antineoplastic agent,P05108
CHEMBL1256323,CCC1(CCC(=O)CC1=O)C2=CC=C(C=C2)N,aminoglutethimide,Launched,glucocorticoid receptor antagonist,P11511
CHEMBL1399,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,anastrozole,Launched,aromatase inhibitor,P11511
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,P11511
CHEMBL117,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,chrysin,Phase 1,breast cancer resistance protein inhibitor,P11511
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P11511
CHEMBL1200374,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C,exemestane,Launched,aromatase inhibitor,P11511
CHEMBL9298,C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N,fadrozole,Launched,aromatase inhibitor,P11511
CHEMBL1871851,C[C@]12CCC(=O)C(=O)C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C,formestane,Launched,aromatase inhibitor,P11511
CHEMBL1444,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,letrozole,Launched,aromatase inhibitor,P11511
CHEMBL2105595,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4.C(=C/C(=O)O)\C(=O)O,liarozole,Phase 2/Phase 3,cytochrome P450 inhibitor,P11511
CHEMBL3321989,CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N,MF-101,Phase 3,estrogen receptor agonist,P11511
CHEMBL9352,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,P11511
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P11511
CHEMBL4851137,,YM-511,Phase 2,aromatase inhibitor,P11511
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,P11511
CHEMBL564769,CC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,P11511
CHEMBL225304,C(=NN)(N)N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,P35228
CHEMBL225304,C(=NN)(N)N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,P60321
CHEMBL4852853,,aminomethyltransferase,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL4852853,,aminomethyltransferase,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL344760,C1=CSC(=N1)N,aminothiazole,Preclinical,cyclin D inhibitor,P35228
CHEMBL344760,C1=CSC(=N1)N,aminothiazole,Preclinical,cyclin D inhibitor,P60321
CHEMBL457530,CN(C)C(=NCCC[C@@H](C(=O)O)N)N,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,P35228
CHEMBL457530,CN(C)C(=NCCC[C@@H](C(=O)O)N)N,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,P60321
CHEMBL4460360,C[C@@]12CC[C@@H]3[C@@]([C@H]1C(=O)C=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)C)(C=C(C(=O)C3(C)C)C#N)C,bardoxolone,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,P35228
CHEMBL4460360,C[C@@]12CC[C@@H]3[C@@]([C@H]1C(=O)C=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)OC)C)(C=C(C(=O)C3(C)C)C#N)C,bardoxolone,Phase 1,nuclear factor erythroid derived|like (NRF2) activator,P60321
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P35228
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P60321
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P35228
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P60321
CHEMBL365739,C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL365739,C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,EIT-hydrobromide,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,EIT-hydrobromide,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL4859770,,guanidinoethyldisulfide-bicarbonate,Phase 2,nitric oxide synthase inhibitor,P35228
CHEMBL4859770,,guanidinoethyldisulfide-bicarbonate,Phase 2,nitric oxide synthase inhibitor,P60321
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,P35228
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,P60321
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P35228
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P60321
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P35228
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P60321
CHEMBL4849447,,L-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,P35228
CHEMBL4849447,,L-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,P60321
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,P35228
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,P60321
CHEMBL1332032,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,P35228
CHEMBL1332032,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,P60321
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL1233598,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)N=C(N2)N,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,P35228
CHEMBL1233598,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)N=C(N2)N,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,P60321
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P35228
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P60321
CHEMBL225304,C(=NN)(N)N,aminoguanidine,Phase 3,nitric oxide synthase inhibitor,P35625
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q14432
CHEMBL12856,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,amrinone,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL1200759,C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3.Cl,anagrelide,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q14432
CHEMBL4845914,,cilostamide,Preclinical,phosphodiesterase inhibitor,Q14432
CHEMBL799,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,cilostazol,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL4874431,,enoximone,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,Q14432
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,levosimendan,Launched,calcium sensitizer,Q14432
CHEMBL4856647,,milrinone,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL1436121,CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2.Cl,olprinone,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL4763174,C[C@@H]1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC,pimobendan,Launched,calcium sensitizer|phosphodiesterase inhibitor,Q14432
CHEMBL4855643,,piroximone,Phase 2,phosphodiesterase inhibitor,Q14432
CHEMBL320341,C[C@@H]1C(=O)NC2=NC3=C(CN12)C(=CC=C3)Cl,quazinone,Phase 2,phosphodiesterase inhibitor,Q14432
CHEMBL4857497,,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,Q14432
CHEMBL1334817,C[C@H]1CC(=O)NN=C1C2=CC=C(C=C2)NC(=NC)NC#N,siguazodan,Phase 1,phosphodiesterase inhibitor,Q14432
CHEMBL4871628,,vesnarinone,Launched,phosphodiesterase inhibitor,Q14432
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q13370
CHEMBL12856,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,amrinone,Launched,phosphodiesterase inhibitor,Q13370
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q13370
CHEMBL4845914,,cilostamide,Preclinical,phosphodiesterase inhibitor,Q13370
CHEMBL799,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,cilostazol,Launched,phosphodiesterase inhibitor,Q13370
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q13370
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,Q13370
CHEMBL4856647,,milrinone,Launched,phosphodiesterase inhibitor,Q13370
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q13370
CHEMBL320341,C[C@@H]1C(=O)NC2=NC3=C(CN12)C(=CC=C3)Cl,quazinone,Phase 2,phosphodiesterase inhibitor,Q13370
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,P27815
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,P27815
CHEMBL514800,CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,apremilast,Launched,phosphodiesterase inhibitor,P27815
CHEMBL1598450,CCCN1C(=O)C2=C(N=CN2)N(C1=O)C3=CC=C(C=C3)Cl,arofylline,Phase 3,phosphodiesterase inhibitor,P27815
CHEMBL1229569,COC1=C(C=C(C=C1)C2CNC(=O)NC2)O[C@H]3C[C@@H]4CC[C@H]3C4,atizoram,Phase 2,phosphodiesterase inhibitor,P27815
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P27815
CHEMBL32854,COC1=C(C=C(C=C1)C2(CCC(CC2)C(=O)O)C#N)OC3CCCC3,cilomilast,Phase 3,phosphodiesterase inhibitor,P27815
CHEMBL484785,B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O,crisaborole,Launched,phosphodiesterase inhibitor,P27815
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P27815
CHEMBL1527608,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,doxofylline,Launched,adenosine receptor antagonist,P27815
CHEMBL1488819,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)C[C@H](CO)O,dyphylline,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P27815
CHEMBL279898,CCCN1C2=C(C(=O)NC1=O)NC=N2,enprofylline,Phase 3,phosphodiesterase inhibitor,P27815
CHEMBL1256671,CCN1C2=NC=C(C(=C2C=N1)NN=C(C)C)C(=O)OCC.Cl,etazolate,Phase 2,phosphodiesterase inhibitor,P27815
CHEMBL4859003,,GSK256066,Phase 2,phosphodiesterase inhibitor,P27815
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,P27815
CHEMBL1712923,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,irsogladine,Launched,phosphodiesterase inhibitor,P27815
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P27815
CHEMBL4864511,,piclamilast,Phase 2,phosphodiesterase inhibitor,P27815
CHEMBL4857497,,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,P27815
CHEMBL193240,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,roflumilast,Launched,phosphodiesterase inhibitor,P27815
CHEMBL1358525,CCC1=NC2=C(C=C1)C(=NC(=O)N2CC)C3=CC(=CC=C3)Cl,YM-976,Phase 1,phosphodiesterase inhibitor,P27815
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,Q08493
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,Q08493
CHEMBL514800,CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC,apremilast,Launched,phosphodiesterase inhibitor,Q08493
CHEMBL1229569,COC1=C(C=C(C=C1)C2CNC(=O)NC2)O[C@H]3C[C@@H]4CC[C@H]3C4,atizoram,Phase 2,phosphodiesterase inhibitor,Q08493
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q08493
CHEMBL484785,B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O,crisaborole,Launched,phosphodiesterase inhibitor,Q08493
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q08493
CHEMBL1527608,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,doxofylline,Launched,adenosine receptor antagonist,Q08493
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,Q08493
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q08493
CHEMBL4864511,,piclamilast,Phase 2,phosphodiesterase inhibitor,Q08493
CHEMBL4857497,,Ro-20-1724,Preclinical,phosphodiesterase inhibitor,Q08493
CHEMBL193240,C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F,roflumilast,Launched,phosphodiesterase inhibitor,Q08493
CHEMBL1370561,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,aminophylline,Launched,adenosine receptor antagonist,O76074
CHEMBL3770899,COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NC3=NC=CC=N3)N4CCC[C@H]4CO)Cl,avanafil,Launched,phosphodiesterase inhibitor,O76074
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O76074
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,O76074
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4846141,,exisulind,Phase 3,phosphodiesterase inhibitor,O76074
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,O76074
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,O76074
CHEMBL553204,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O,icariin,Phase 3,phosphodiesterase inhibitor,O76074
CHEMBL498485,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=CC=C(C=C3)OC)O)C,icaritin,Phase 3,PPAR receptor antagonist,O76074
CHEMBL4856647,,milrinone,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4297518,CCCC1=CN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CCO)OCCC)CC,mirodenafil,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4858488,,MY-5445,Preclinical,phosphodiesterase inhibitor|platelet aggregation inhibitor,O76074
CHEMBL19224,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,papaverine,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4865422,,PF-03049423,Phase 2,phosphodiesterase inhibitor,O76074
CHEMBL4792718,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.CC(=O)CC(CC(=O)C)(C(=O)C)O,sildenafil,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4854725,,T-0156,Preclinical,phosphodiesterase inhibitor,O76074
CHEMBL177542,CN1CC(=O)N2[C@@H](C1=O)CC3C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,tadalafil,Launched,phosphodiesterase inhibitor,O76074
CHEMBL4850125,,trequinsin,Phase 1,phosphodiesterase inhibitor,O76074
CHEMBL3889385,,vardenafil,Launched,phosphodiesterase inhibitor,O76074
CHEMBL28079,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,zaprinast,Phase 2,phosphodiesterase inhibitor,O76074
CHEMBL2104643,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])NCC2=CN=C3C(=N2)C(=NC(=N3)N)N.[Na+].[Na+],aminopterin,Phase 3,dihydrofolate reductase inhibitor,P00374
CHEMBL1213553,CC(C)N=C(N)/N=C(\N)/NC1=CC(=C(C=C1)Cl)Cl,chlorproguanil,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL4851780,,coenzyme-I,Phase 2,,P00374
CHEMBL1043,C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N,dapsone,Launched,bacterial antifolate,P00374
CHEMBL2074970,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O,methotrexate,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL2360464,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],pemetrexed,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,P00374
CHEMBL1201746,C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,pralatrexate,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL1377,CC(C)N=C(N)/N=C(\N)/NC1=CC=C(C=C1)Cl,proguanil,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL4876069,,pyrimethamine,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL1484857,C1=CC(=CC=C1NC(=O)CCC(=O)O)S(=O)(=O)NC2=NC=CS2,succinylsulfathiazole,Phase 2,dihydrofolate reductase inhibitor,P00374
CHEMBL1200359,COC1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,sulfameter,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL2110367,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.OS(=O)(=O)O,trimethoprim,Launched,dihydrofolate reductase inhibitor,P00374
CHEMBL2218878,CC1=C(C=CC2=C1C(=NC(=N2)N)N)CNC3=CC(=C(C(=C3)OC)OC)OC.[C@@H]1([C@@H]([C@H](O[C@@H]([C@@H]1O)O)C(=O)O)O)O,trimetrexate,Phase 3,dihydrofolate reductase inhibitor,P00374
CHEMBL2104643,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])NCC2=CN=C3C(=N2)C(=NC(=N3)N)N.[Na+].[Na+],aminopterin,Phase 3,dihydrofolate reductase inhibitor,Q96NT5
CHEMBL2161355,,folic-acid,Launched,folate receptor ligand,Q96NT5
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,Q96NT5
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,Q96NT5
CHEMBL2096646,C1=CC(=C(C=C1N)O)C(=O)[O-].O.O.[Na+],aminosalicylate,Launched,cyclooxygenase inhibitor,Q9NZK7
CHEMBL4851038,,atenolol-(+/-),Launched,adrenergic receptor antagonist,Q9NZK7
CHEMBL4876408,,licofelone,Phase 3,cyclooxygenase inhibitor|lipoxygenase inhibitor,Q9NZK7
CHEMBL56367,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,nimesulide,Launched,cyclooxygenase inhibitor,Q9NZK7
CHEMBL4297402,CC1=NN=NN1N=CC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)O)C4=C(C=CC(=C4)C=NN5C(=NN=N5)C)O,VP-20629,Phase 1,beta amyloid antagonist,Q9NZK7
CHEMBL171623,C(CCO)CO,"1,4-butanediol",Phase 1,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,Q9NZK7
CHEMBL4866863,,aminothiadiazole,Phase 2,inosine monophosphate dehydrogenase inhibitor,P20839
CHEMBL3349001,CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C3=CN=CO3)OC,AVN-944,Phase 2,inosine monophosphate dehydrogenase inhibitor,P20839
CHEMBL1200400,CN1C=NC(=C1SC2=NC=NC3=C2N=C[N-]3)[N+](=O)[O-].[Na+],azathioprine,Launched,dehydrogenase inhibitor,P20839
CHEMBL4860028,,BMS-566419,Preclinical,inosine monophosphate dehydrogenase inhibitor,P20839
CHEMBL4851780,,coenzyme-I,Phase 2,,P20839
CHEMBL1425,C1=NC2=C(N1)C(=S)N=CN2,mercaptopurine,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,P20839
CHEMBL4850854,,merimepodib,Phase 2,inosine monophosphate dehydrogenase inhibitor,P20839
CHEMBL4870789,,mizoribine,Launched,immunosuppressant|inosine monophosphate dehydrogenase inhibitor,P20839
CHEMBL1456,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,mycophenolate-mofetil,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,P20839
CHEMBL1908143,,mycophenolic-acid,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,P20839
CHEMBL4851831,,ribavirin,Launched,antiviral,P20839
CHEMBL727,C1=NC2=C(N1)C(=S)N=C(N2)N,thioguanine,Launched,purine antagonist,P20839
CHEMBL1083993,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,amiodarone,Launched,potassium channel blocker,Q9NY47
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9NY47
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q9NY47
CHEMBL1083993,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,amiodarone,Launched,potassium channel blocker,Q96RP8
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q96RP8
CHEMBL1200822,CC(=O)O.C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,flecainide,Launched,sodium channel blocker,Q96RP8
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q96RP8
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q96RP8
CHEMBL1083993,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I.Cl,amiodarone,Launched,potassium channel blocker,Q12809
CHEMBL1256655,COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42.Cl,amsacrine,Launched,topoisomerase inhibitor,Q12809
CHEMBL296419,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,astemizole,Withdrawn,histamine receptor antagonist,Q12809
CHEMBL4865314,,AZD5438,Phase 1,CDK inhibitor,Q12809
CHEMBL512351,CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl,betrixaban,Launched,coagulation factor inhibitor,Q12809
CHEMBL3526086,,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,Q12809
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,Q12809
CHEMBL74656,CO[C@@H]1CN(CC[C@@H]1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,cisapride,Withdrawn,serotonin receptor agonist,Q12809
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q12809
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,Q12809
CHEMBL4851326,,dofetilide,Withdrawn,potassium channel blocker,Q12809
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q12809
CHEMBL4858730,,E-4031,Phase 1,potassium channel blocker,Q12809
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,Q12809
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,Q12809
CHEMBL583152,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@@H]6[C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)C,ginsenoside-RE3,Launched,angiogenesis inhibitor|apoptosis stimulant,Q12809
CHEMBL4871823,,GW-803430,Phase 1,melanin inhibitor,Q12809
CHEMBL2355456,CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.C(=C/C(=O)O)\C(=O)O,ibutilide,Launched,potassium channel blocker,Q12809
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,Q12809
CHEMBL1514181,C1=CC(=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)O)O,NS-1643,Preclinical,voltage-gated potassium channel activator,Q12809
CHEMBL4303572,C1=CC(=CC(=C1)NC(=O)NC2=C(C=C(C=C2)Br)C3=NNN=N3)C(F)(F)F,NS-3623,Preclinical,voltage-gated potassium channel activator,Q12809
CHEMBL4861365,,PD-118057,Preclinical,potassium channel activator,Q12809
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,Q12809
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,Q12809
CHEMBL1201063,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.Cl,propafenone,Launched,antiarrhythmic,Q12809
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q12809
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,Q12809
CHEMBL471,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,sotalol,Launched,adrenergic receptor antagonist,Q12809
CHEMBL4867963,,tecastemizole,Phase 3,histamine receptor antagonist,Q12809
CHEMBL4858222,,terfenadine,Withdrawn,histamine receptor antagonist,Q12809
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q12809
CHEMBL4871628,,vesnarinone,Launched,phosphodiesterase inhibitor,Q12809
CHEMBL4861017,,volinanserin,Phase 3,serotonin receptor antagonist,Q12809
CHEMBL4227511,C1C2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,amitifadine,Phase 3,serotonin transporter (SERT) inhibitor,Q01959
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q01959
CHEMBL1702,CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2.Cl,atomoxetine,Launched,norepinephrine transporter inhibitor,Q01959
CHEMBL1200383,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.CS(=O)(=O)O,benztropine-mesylate,Launched,acetylcholine receptor antagonist,Q01959
CHEMBL1625728,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N,BTS-54505,Withdrawn,dopamine reuptake inhibitor,Q01959
CHEMBL1201735,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C.Br,bupropion,Launched,dopamine reuptake inhibitor,Q01959
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,Q01959
CHEMBL1200781,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F.Br,citalopram,Launched,selective serotonin reuptake inhibitor (SSRI),Q01959
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,Q01959
CHEMBL1950108,CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2C(=O)O)O[C@@H]3[C@H]([C@@H](O[C@@H]([C@@H]3OS(=O)(=O)[O-])CO)O[C@H]4[C@@H]([C@H]([C@@H](O[C@@H]4C(=O)O)OCCNC(=O)CCOCCOCCOCCOCCNC(=O)CCCC[C@H]5[C@@H]6[C@H](CS5)NC(=O)N6)O)O)NC(=O)C)O)O)COS(=O)(=O)[O-])OS(=O)(=O)[O-])O.[Na+].[Na+].[Na+],CS-110266,Preclinical,dopamine receptor agonist,Q01959
CHEMBL1201728,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O,desvenlafaxine,Launched,serotonin–norepinephrine reuptake inhibitor (SNRI),Q01959
CHEMBL1564,CN1CCC(CC1)OC(C2=CC=CC=C2)C3=CC=CC=C3.Cl,diphenylpyraline,Launched,dopamine reuptake inhibitor,Q01959
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,Q01959
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),Q01959
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,Q01959
CHEMBL4850556,,GBR-12935,Preclinical,dopamine reuptake inhibitor,Q01959
CHEMBL4864192,,GBR-13069,Preclinical,dopamine reuptake inhibitor,Q01959
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,Q01959
CHEMBL4855622,,JHW-007,Preclinical,dopamine reuptake inhibitor,Q01959
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q01959
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,Q01959
CHEMBL1256695,CNCCC(C1=CC=CC=C1)OC2=CC=CC=C2OC.Cl,nisoxetine,Phase 1,norepinephrine reuptake inhibitor,Q01959
CHEMBL4864471,,nomifensine,Withdrawn,dopamine reuptake inhibitor|noradrenaline uptake inhibitor,Q01959
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,Q01959
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q01959
CHEMBL2107365,C[C@H]1[C@@](OCC(N1)(C)C)(C2=CC(=CC=C2)Cl)O.Cl,radafaxine,Phase 2,dopamine-norepinephrine reuptake inhibitor,Q01959
CHEMBL809,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,sertraline,Launched,selective serotonin reuptake inhibitor (SSRI),Q01959
CHEMBL176045,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,tetrandrine,Preclinical,calcium channel blocker,Q01959
CHEMBL1200948,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C.C(=C\C(=O)O)\C(=O)O,trimipramine,Launched,norepinephrine reputake inhibitor|tricyclic antidepressant,Q01959
CHEMBL4532742,C.C1CN(CCN1CCCC2=CC=CC=C2)CCOC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,vanoxerine,Phase 3,dopamine reuptake inhibitor,Q01959
CHEMBL4854212,,3-alpha-bis-(4-fluorophenyl)-methoxytropane,Preclinical,dopamine uptake inhibitor,Q01959
CHEMBL1365675,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,amitraz,Launched,adrenergic receptor agonist,P08913
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P08913
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P08913
CHEMBL1200379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,apraclonidine,Launched,adrenergic receptor agonist,P08913
CHEMBL4858847,,ARC-239,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P08913
CHEMBL4851709,,BP-897,Phase 2,dopamine receptor agonist,P08913
CHEMBL2062257,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O,brimonidine,Launched,adrenergic receptor agonist,P08913
CHEMBL4856906,,BRL-44408,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P08913
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P08913
CHEMBL1742424,CCN(CC)C(=O)NC1=CC(=C(C=C1)OCC(CNC(C)(C)C)O)C(=O)C.Cl,celiprolol,Launched,adrenergic receptor antagonist,P08913
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P08913
CHEMBL128672,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3.C(=C\C(=O)O)\C(=O)O,ciproxifan,Preclinical,histamine receptor antagonist,P08913
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P08913
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P08913
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,guanaben-acetate,Launched,adrenergic receptor agonist,P08913
CHEMBL2106210,CC1=C(C(=CC=C1)CC2=CN=CN2)C.Cl,detomidine,Launched,adrenergic receptor agonist,P08913
CHEMBL2106195,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl,dexmedetomidine,Launched,adrenergic receptor agonist,P08913
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P08913
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P08913
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P08913
CHEMBL4860236,,EIPA,Preclinical,sodium/hydrogen exchanger inhibitor|transient receptor potential polycystic inhibitor,P08913
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P08913
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P08913
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P08913
CHEMBL255044,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,flupirtine,Launched,glutamate receptor antagonist,P08913
CHEMBL862,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,guanfacine,Launched,adrenergic receptor agonist,P08913
CHEMBL4862464,,idazoxan,Phase 3,adrenergic receptor antagonist,P08913
CHEMBL4847393,,imiloxan,Phase 1,adrenergic receptor antagonist,P08913
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P08913
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P08913
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P08913
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P08913
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P08913
CHEMBL4867828,,methyldopa,Launched,adrenergic receptor agonist,P08913
CHEMBL4866128,,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL1256287,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC.Cl,moxonidine,Launched,imidazoline receptor agonist,P08913
CHEMBL1706,C1CN=C(N1)CC2=CC=CC3=CC=CC=C32.Cl,naphazoline,Launched,adrenergic receptor agonist,P08913
CHEMBL1200492,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl.Cl,nefazodone,Withdrawn,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor,P08913
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P08913
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P08913
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL4303509,CC1(CC2=CC=CC=C2C1)CN,ORG-9768,Phase 1,adrenergic receptor antagonist,P08913
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P08913
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P08913
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P08913
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P08913
CHEMBL1865834,C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C4=NC=CC=N4.Cl,piribedil,Launched,dopamine receptor agonist,P08913
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P08913
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P08913
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL1256674,C1CC1C(C2CC2)NC3=NCCO3.C(=C/C(=O)O)\C(=O)O,rilmenidine,Launched,adrenergic receptor agonist|imidazoline receptor agonist,P08913
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P08913
CHEMBL4303564,CCS(=O)(=O)N1CCC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C=C(C=C4)OC,RS-79948,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P08913
CHEMBL1504869,C=CCN1CCC2=C(CC1)SC(=N2)N.Cl,talipexole,Launched,adrenergic receptor agonist|dopamine receptor agonist,P08913
CHEMBL4870922,,TC-G-1000,Preclinical,adrenergic receptor agonist,P08913
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P08913
CHEMBL1200329,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl,tizanidine,Launched,adrenergic receptor agonist,P08913
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P08913
CHEMBL4868718,,tolonidine,Launched,adrenergic receptor antagonist,P08913
CHEMBL1200798,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl,trazodone,Launched,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor,P08913
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P08913
CHEMBL1256022,CC1=C(C(=CC=C1)C)NC2=NCCCS2.Cl,xylazine,Launched,adrenergic receptor agonist,P08913
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P08913
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P08913
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P08913
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P08913
CHEMBL4873019,,2-BFI,Preclinical,imidazoline receptor ligand,P08913
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q9H3N8
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,Q9H3N8
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,Q9H3N8
CHEMBL128672,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3.C(=C\C(=O)O)\C(=O)O,ciproxifan,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL4869322,,clobenpropit,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q9H3N8
CHEMBL12344,CN(C)CCCSC(=N)N,dimaprit,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL1533310,C1=C(NC=N1)CCN.Cl.Cl,histamine,Launched,histamine receptor agonist,Q9H3N8
CHEMBL4856411,,HTMT,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL1490875,C1=C(NC=N1)CCSC(=N)N.Br.Br,imetit,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL5077041,C1CNCCC1CC2=CN=CN2.Br.Br,immepip,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL4854360,,iodophenpropit,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL1403509,CN1CCN(CC1)C(=O)C2=NC3=C(N2)C=C(C=C3)Cl.C(=C\C(=O)O)\C(=O)O,JNJ-10191584,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL4865387,,JNJ-7777120,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q9H3N8
CHEMBL268490,CNCCC1=CN=CN1,N-alpha-methylhistamine-dihydrochloride,Phase 3,histamine receptor agonist,Q9H3N8
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q9H3N8
CHEMBL1256702,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3.C(=C\C(=O)O)\C(=O)O,thioperamide,Preclinical,histamine receptor antagonist,Q9H3N8
CHEMBL4877873,,VUF10460,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL3272580,CC1=C(N=CN1)CCN.Cl,4-methylhistamine,Preclinical,histamine receptor agonist,Q9H3N8
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P50406
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P50406
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P50406
CHEMBL4850096,,BRL-15572,Preclinical,serotonin receptor antagonist,P50406
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P50406
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P50406
CHEMBL64249,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,clorotepine,Launched,adrenergic receptor antagonist|dopamine receptor antagonist,P50406
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P50406
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P50406
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P50406
CHEMBL1200328,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32.Cl,duloxetine,Launched,norepinephrine reuptake inhibitor|serotonin–norepinephrine reuptake inhibitor (SNRI),P50406
CHEMBL4873502,,EMD-386088,Preclinical,serotonin receptor agonist,P50406
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P50406
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P50406
CHEMBL4857814,,GR-127935,Preclinical,serotonin receptor antagonist,P50406
CHEMBL4857904,,idalopirdine,Phase 3,serotonin receptor antagonist,P50406
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P50406
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P50406
CHEMBL2105703,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C.Cl.Cl,latrepirdine,Phase 3,glutamate receptor antagonist,P50406
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P50406
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL732586,,mCPP,Phase 2,serotonin receptor agonist,P50406
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P50406
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P50406
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,P50406
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P50406
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P50406
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P50406
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P50406
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P50406
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,P50406
CHEMBL4850778,,R-1485,Phase 1,serotonin receptor antagonist,P50406
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P50406
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P50406
CHEMBL4874156,,SB-243213,Phase 1,serotonin receptor inverse agonist,P50406
CHEMBL4853276,,SB-258585,Preclinical,serotonin receptor antagonist,P50406
CHEMBL4871825,,SB-271046,Phase 1,serotonin receptor antagonist,P50406
CHEMBL4879135,,SB-399885,Preclinical,serotonin receptor antagonist,P50406
CHEMBL4875993,,SB-742457,Phase 3,serotonin receptor antagonist,P50406
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P50406
CHEMBL4851845,,sertindole,Withdrawn,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P50406
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P50406
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P50406
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P50406
CHEMBL5079373,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F.Cl.Cl,WAY-208466,Preclinical,serotonin receptor agonist,P50406
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P50406
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P50406
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P50406
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P34969
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P34969
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P34969
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P34969
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P34969
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P34969
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL2104153,CC(CN1C2=CC=CC=C2SC3=C1C=C(C=C3)C#N)CN(C)C,cyamemazine,Launched,serotonin receptor antagonist,P34969
CHEMBL1716,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1.Cl,cyproheptadine,Launched,histamine receptor antagonist,P34969
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P34969
CHEMBL1200517,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergotamine,Launched,serotonin receptor agonist,P34969
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P34969
CHEMBL4846963,,DR-4485,Preclinical,serotonin receptor antagonist,P34969
CHEMBL1510,CN1CCC[C@@H]1CC2=CNC3=C2C=C(C=C3)CCS(=O)(=O)C4=CC=CC=C4,eletriptan,Launched,serotonin receptor agonist,P34969
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P34969
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P34969
CHEMBL14376,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,iloperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P34969
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P34969
CHEMBL4854617,,L-745870,Preclinical,dopamine receptor antagonist,P34969
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL1237021,C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O,lurasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL1628565,CN(C)[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)NC(=O)C4=CC=C(C=C4)F,LY344864,Preclinical,serotonin receptor agonist,P34969
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,P34969
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P34969
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P34969
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P34969
CHEMBL544428,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl,mianserin,Launched,serotonin receptor antagonist,P34969
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL4850031,,oleamide,Preclinical,cannabinoid receptor agonist,P34969
CHEMBL2105649,CN1CCN(CC1)C2=CC=CC3=C2OC(=O)N3.Cl,pardoprunox,Phase 3,dopamine receptor agonist|serotonin receptor agonist,P34969
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P34969
CHEMBL18331,CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F,pirenperone,Preclinical,serotonin receptor antagonist,P34969
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P34969
CHEMBL4859514,,SB-269970,Preclinical,serotonin receptor antagonist,P34969
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P34969
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P34969
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P34969
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P34969
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P34969
CHEMBL5079373,CN(C)CCN1C=C(C2=C1N=CC=C2)S(=O)(=O)C3=CC=CC(=C3)F.Cl.Cl,WAY-208466,Preclinical,serotonin receptor agonist,P34969
CHEMBL2336050,CCCCCCOC1=NSN=C1C2=CCCN(C2)C.C(C(C(=O)O)O)(C(=O)O)O,xanomeline,Phase 3,acetylcholine receptor agonist,P34969
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P34969
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P34969
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P34969
CHEMBL4863540,,8-hydroxy-DPAT,Preclinical,serotonin receptor agonist,P34969
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q09470
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q09470
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,Q09470
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q09470
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q09470
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q9NZV8
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9NZV8
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,Q9NZV8
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,Q9NZV8
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q9UK17
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9UK17
CHEMBL1201020,CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C.OP(=O)(O)O,disopyramide,Launched,sodium channel blocker,Q9UK17
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,Q9UK17
CHEMBL4303239,C1=C(C=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=C(C=C2Br)Br)C3=NNN=N3)C(F)(F)F,NS-5806,Preclinical,voltage-gated potassium channel activator,Q9UK17
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),O43526
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,O43526
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,O43526
CHEMBL4858501,,flindokalner,Phase 3,potassium channel agonist,O43526
CHEMBL255044,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,flupirtine,Launched,glutamate receptor antagonist,O43526
CHEMBL4853368,,ICA-069673,Preclinical,voltage-gated potassium channel activator,O43526
CHEMBL4860322,,ICA-110381,Preclinical,voltage-gated potassium channel activator,O43526
CHEMBL4877777,,linopirdine,Phase 3,potassium channel blocker,O43526
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,O43526
CHEMBL3392049,C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2],pyrithione-zinc,Launched,ATP synthase inhibitor,O43526
CHEMBL4855722,,XE-991,Preclinical,potassium channel blocker,O43526
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),O43525
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,O43525
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,O43525
CHEMBL4853368,,ICA-069673,Preclinical,voltage-gated potassium channel activator,O43525
CHEMBL4877777,,linopirdine,Phase 3,potassium channel blocker,O43525
CHEMBL509,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,meclofenamic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,O43525
CHEMBL4855722,,XE-991,Preclinical,potassium channel blocker,O43525
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),P04629
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,P04629
CHEMBL1983268,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,P04629
CHEMBL2037226,CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4,GNF-5837,Preclinical,growth factor receptor inhibitor,P04629
CHEMBL4847276,,GW-441756,Preclinical,growth factor receptor inhibitor,P04629
CHEMBL4858976,,GW-5074,Phase 1/Phase 2,leucine rich repeat kinase inhibitor|RAF inhibitor,P04629
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,P04629
CHEMBL4856292,C1C[C@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@H](C4)O)C5=C(C=CC(=C5)F)F,larotrectinib,Launched,tropomyosin receptor kinase inhibitor,P04629
CHEMBL4469622,C[C@@]1(C[C@@H]2N3C4=CC=CC=C4C5=C6CNC(=O)C6=C7C8=CC=CC=C8N(C7=C53)[C@]1(O2)C)CO,lestaurtinib,Phase 3,FLT3 inhibitor|growth factor receptor inhibitor|JAK inhibitor,P04629
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P04629
CHEMBL4862981,,PHA-848125,Phase 2,CDK inhibitor|growth factor receptor inhibitor,P04629
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P04629
CHEMBL4877167,,tyrphostin-AG-879,Preclinical,tyrosine kinase inhibitor,P04629
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q16620
CHEMBL4303548,C1CCNC(=O)C(C1)NC(=O)C2=CC=CC=C2NC(=O)C3=CC4=CC=CC=C4S3,ANA-12,Preclinical,tropomyosin receptor kinase inhibitor,Q16620
CHEMBL1983268,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,Q16620
CHEMBL2037226,CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4,GNF-5837,Preclinical,growth factor receptor inhibitor,Q16620
CHEMBL4856292,C1C[C@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@H](C4)O)C5=C(C=CC(=C5)F)F,larotrectinib,Launched,tropomyosin receptor kinase inhibitor,Q16620
CHEMBL4303415,C1=C(C=C(C=C1C(=O)NCCO)C(=O)NCCO)C(=O)NCCO,LM-22A4,Preclinical,tropomyosin receptor kinase inhibitor,Q16620
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,Q16620
CHEMBL1200964,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,amitriptyline,Launched,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin–norepinephrine reuptake inhibitor (SNRI),Q99720
CHEMBL4303566,C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N,API-001,Phase 2,sigma receptor antagonist,Q99720
CHEMBL143360,CN(C)CCN(C)CCC1=CC(=C(C=C1)Cl)Cl,BD-1047,Preclinical,adrenergic receptor antagonist,Q99720
CHEMBL4066998,CN1CCN(CC1)CCC2=CC(=C(C=C2)Cl)Cl.Cl.Cl,BD-1063,Preclinical,sigma receptor antagonist,Q99720
CHEMBL4858995,,cutamesine,Phase 2,sigma receptor agonist,Q99720
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q99720
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,Q99720
CHEMBL3188434,CC1=CC2=C(C[C@H]3[C@@H]4[C@]2(CCCC4)CCN3C)C=C1.OP(=O)(O)O,dimemorfan,Launched,sigma receptor agonist,Q99720
CHEMBL4873317,,ditolylguanidine,Preclinical,sigma receptor agonist,Q99720
CHEMBL2104866,CCC(C/C=C/C1=CC=CC=C1)(C2=CC=CC=C2)N(C)CC3CC3.Cl,igmesine,Phase 2,sigma receptor agonist,Q99720
CHEMBL292477,C1CC2(CCN(CC2)CC3=CC=CC=C3)C4=CC=CC=C41,L-693403,Preclinical,sigma receptor agonist|sigma receptor antagonist,Q99720
CHEMBL1201149,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O.Cl,naltrexone,Launched,opioid receptor antagonist,Q99720
CHEMBL4857360,,NE-100,Phase 2,sigma receptor antagonist,Q99720
CHEMBL4871940,,NNC-711,Preclinical,GABA uptake inhibitor,Q99720
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,Q99720
CHEMBL2106732,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3.Cl,noscapine,Launched,bradykinin receptor antagonist|tubulin polymerization inhibitor,Q99720
CHEMBL4868725,,PRE-084,Preclinical,sigma receptor agonist,Q99720
CHEMBL3989556,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2OC)Br)OC.O.Cl,remoxipride,Withdrawn,dopamine receptor antagonist,Q99720
CHEMBL2362766,C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42.Cl.Cl,rimcazole,Phase 1,sigma receptor antagonist,Q99720
CHEMBL451146,CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N,SK&F-10047-(+),Phase 1,sigma receptor agonist,Q99720
CHEMBL4876893,,4-IBP,Preclinical,sigma receptor agonist,Q99720
CHEMBL4855270,,4-PPBP,Preclinical,sigma receptor ligand,Q99720
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,P05230
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P05230
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,P08700
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,P80511
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,P80511
CHEMBL1096,CC(C)C1=CC2=C(C=C1)OC3=NC(=C(C=C3C2=O)C(=O)O)N,amlexanox,Launched,histamine receptor modulator,Q99584
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,Q99584
CHEMBL1200402,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O,amlodipine,Launched,calcium channel blocker,Q13936
CHEMBL1275868,CC1=C(C(C(=C(N1)N)C(=O)OC2CN(C2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC(C)C,azelnidipine,Launched,calcium channel blocker,Q13936
CHEMBL513599,CC1=C([C@@H](C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)OC,BAY-K-8644-(s)-(-),Preclinical,L-type calcium channel activator,Q13936
CHEMBL2105555,CC1=C([C@H](C(=C(N1)C)C(=O)O[C@@H]2CCCN(C2)CC3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,benidipine,Launched,calcium channel blocker,Q13936
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,cleviprex,Launched,calcium channel blocker,Q13936
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,Q13936
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q13936
CHEMBL4860660,,FPL-64176,Preclinical,calcium channel activator,Q13936
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q13936
CHEMBL2355456,CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.C(=C/C(=O)O)\C(=O)O,ibutilide,Launched,potassium channel blocker,Q13936
CHEMBL460291,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,lacidipine,Launched,calcium channel blocker,Q13936
CHEMBL1085699,CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,manidipine,Launched,calcium channel blocker,Q13936
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q13936
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q13936
CHEMBL517427,CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C,nilvadipine,Launched,calcium channel blocker,Q13936
CHEMBL1726,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,nisoldipine,Launched,calcium channel blocker,Q13936
CHEMBL2103773,CCCCCCCCOC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)OCC[N+](C)(CC)CC.[Br-],otilonium,Launched,acetylcholine receptor antagonist,Q13936
CHEMBL4303628,CC1([C@H]2CCC([C@@H]1C2)CCOCC[N+]3(CCOCC3)CC4=CC(=C(C=C4Br)OC)OC)C,pinaverium,Launched,T-type calcium channel blocker,Q13936
CHEMBL4847368,,pranidipine,Phase 2,calcium channel blocker,Q13936
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,Q13936
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q13936
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q13936
CHEMBL1200402,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O,amlodipine,Launched,calcium channel blocker,Q01668
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,cleviprex,Launched,calcium channel blocker,Q01668
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q01668
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q01668
CHEMBL1648,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,isradipine,Launched,calcium channel blocker,Q01668
CHEMBL1085699,CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=CC=C4)C5=CC(=CC=C5)[N+](=O)[O-])C(=O)OC,manidipine,Launched,calcium channel blocker,Q01668
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q01668
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q01668
CHEMBL517427,CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C,nilvadipine,Launched,calcium channel blocker,Q01668
CHEMBL1726,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,nisoldipine,Launched,calcium channel blocker,Q01668
CHEMBL4856187,,nitrendipine,Launched,calcium channel blocker,Q01668
CHEMBL4847951,,sipatrigine,Phase 2,voltage-gated sodium channel blocker,Q01668
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,Q01668
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q01668
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q01668
CHEMBL1200402,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O,amlodipine,Launched,calcium channel blocker,O60840
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,cleviprex,Launched,calcium channel blocker,O60840
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,O60840
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O60840
CHEMBL1648,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,isradipine,Launched,calcium channel blocker,O60840
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,O60840
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,O60840
CHEMBL1726,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,nisoldipine,Launched,calcium channel blocker,O60840
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,O60840
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,O60840
CHEMBL1200402,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O,amlodipine,Launched,calcium channel blocker,Q13698
CHEMBL1237132,CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,cleviprex,Launched,calcium channel blocker,Q13698
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,Q13698
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q13698
CHEMBL4860660,,FPL-64176,Preclinical,calcium channel activator,Q13698
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q13698
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q13698
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q13698
CHEMBL1726,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,nisoldipine,Launched,calcium channel blocker,Q13698
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q13698
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q13698
CHEMBL1200402,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN.C1=CC=C(C=C1)S(=O)(=O)O,amlodipine,Launched,calcium channel blocker,P54289
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,P54289
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,P54289
CHEMBL1648,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC,isradipine,Launched,calcium channel blocker,P54289
CHEMBL250270,CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,lercanidipine,Launched,calcium channel blocker,P54289
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,P54289
CHEMBL4856187,,nitrendipine,Launched,calcium channel blocker,P54289
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P54289
CHEMBL931831,,Z160,Phase 2,N-type calcium channel blocker,P54289
CHEMBL4297742,,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,Q9Y6L6
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,Q9Y6L6
CHEMBL457,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,gemfibrozil,Launched,lipoprotein lipase activator,Q9Y6L6
CHEMBL1201304,CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)O)/C=C\C=C\C=C\C=C/4\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C,indocyanine-green,Launched,contrast agent,Q9Y6L6
CHEMBL1144,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,pravastatin,Launched,HMGCR inhibitor,Q9Y6L6
CHEMBL1909658,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C=N/N5CCN(CC5)C)/C,rifampin,Launched,RNA polymerase inhibitor,Q9Y6L6
CHEMBL236921,C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C,rifamycin,Launched,DNA directed RNA polymerase inhibitor,Q9Y6L6
CHEMBL4792718,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.CC(=O)CC(CC(=O)C)(C(=O)C)O,sildenafil,Launched,phosphodiesterase inhibitor,Q9Y6L6
CHEMBL4297742,,ammonium-glycyrrhizinate,Launched,thrombin inhibitor,Q9NPD5
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,Q9NPD5
CHEMBL457,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,gemfibrozil,Launched,lipoprotein lipase activator,Q9NPD5
CHEMBL1909658,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C=N/N5CCN(CC5)C)/C,rifampin,Launched,RNA polymerase inhibitor,Q9NPD5
CHEMBL236921,C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C,rifamycin,Launched,DNA directed RNA polymerase inhibitor,Q9NPD5
CHEMBL4792718,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.CC(=O)CC(CC(=O)C)(C(=O)C)O,sildenafil,Launched,phosphodiesterase inhibitor,Q9NPD5
CHEMBL1200747,CC(C(=O)O)O.N,ammonium-lactate,Launched,,Q9BXC0
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,Q9BXC0
CHEMBL1613220,C1=CC=C(C=C1)C(C2=CC=CC=C2)NCCNC(C3=CC=CC=C3)C4=CC=CC=C4.Cl.Cl,AMN-082,Preclinical,glutamate receptor modulator,Q14831
CHEMBL1435977,C1C[C@@](C[C@@H]1C(=O)O)(C(=O)O)N.C1C[C@](C[C@H]1C(=O)O)(C(=O)O)N,cis-ACPD,Preclinical,glutamate receptor agonist,Q14831
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q14831
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q14831
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q14831
CHEMBL682,CCN(CC)CC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O,amodiaquine,Launched,histamine receptor agonist,P50135
CHEMBL1398213,CN(C)CCCCSC(=N)N.Cl.Cl,SKF-91488,Preclinical,histamine N-methyltransferase inhibitor,P50135
CHEMBL1910266,CN(C)CCN1C(=O)C2=CC=CC3=CC(=CC(=C32)C1=O)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,amonafide,Phase 3,topoisomerase inhibitor,Q02880
CHEMBL1186894,CC(=O)[C@]1(C[C@@H](C2=C(C1)C(=C3C(=C2O)C(=O)C4=CC=CC=C4C3=O)O)O[C@H]5C[C@@H]([C@@H](CO5)O)O)N,amrubicin,Launched,topoisomerase inhibitor,Q02880
CHEMBL1200475,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,daunorubicin,Launched,RNA synthesis inhibitor|topoisomerase inhibitor,Q02880
CHEMBL1738,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,dexrazoxane,Launched,chelating agent|topoisomerase inhibitor,Q02880
CHEMBL1200645,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)O)O,etoposide,Launched,topoisomerase inhibitor,Q02880
CHEMBL3039470,COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H](C7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O,teniposide,Launched,topoisomerase inhibitor,Q02880
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P18089
CHEMBL1200379,C1CN=C(N1)NC2=C(C=C(C=C2Cl)N)Cl.Cl,apraclonidine,Launched,adrenergic receptor agonist,P18089
CHEMBL4858847,,ARC-239,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P18089
CHEMBL2062257,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O,brimonidine,Launched,adrenergic receptor agonist,P18089
CHEMBL4856906,,BRL-44408,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P18089
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P18089
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P18089
CHEMBL1705,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl.Cl,clonidine,Launched,adrenergic receptor agonist,P18089
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P18089
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,guanaben-acetate,Launched,adrenergic receptor agonist,P18089
CHEMBL2106195,CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl,dexmedetomidine,Launched,adrenergic receptor agonist,P18089
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P18089
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P18089
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P18089
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P18089
CHEMBL4862782,,etomidate,Launched,GABA receptor modulator,P18089
CHEMBL862,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,guanfacine,Launched,adrenergic receptor agonist,P18089
CHEMBL4847393,,imiloxan,Phase 1,adrenergic receptor antagonist,P18089
CHEMBL2104941,C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43.Cl,indoramin,Launched,adrenergic receptor antagonist,P18089
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P18089
CHEMBL4854864,,levonordefrin,Launched,vasodilator,P18089
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P18089
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL537161,CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl,medetomidine,Launched,adrenergic receptor agonist,P18089
CHEMBL3184799,CC(C)(CC1=CC=CC=C1)NC.CC(C)(CC1=CC=CC=C1)NC.OS(=O)(=O)O,mephentermine,Launched,adrenergic receptor agonist,P18089
CHEMBL4867828,,methyldopa,Launched,adrenergic receptor agonist,P18089
CHEMBL4866128,,mirtazapine,Launched,adrenergic receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL1256287,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC.Cl,moxonidine,Launched,imidazoline receptor agonist,P18089
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P18089
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,P18089
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL1200791,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl,oxymetazoline,Launched,adrenergic receptor agonist,P18089
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P18089
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P18089
CHEMBL1200787,CC(COC1=CC=CC=C1)N(CCCl)CC2=CC=CC=C2.Cl,phenoxybenzamine,Launched,adrenergic receptor antagonist,P18089
CHEMBL1200873,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O.CS(=O)(=O)O,phentolamine,Launched,adrenergic receptor antagonist,P18089
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P18089
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,P18089
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL1257131,COC(=O)[C@@H]1[C@H](CC[C@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,rauwolscine,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL4850212,,risperidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P18089
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P18089
CHEMBL4847920,,RX-821002,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL4865112,,SNAP-5089,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL1358012,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)C[C@H]4COC5=CC=CC=C5O4,spiroxatrine,Preclinical,serotonin receptor antagonist,P18089
CHEMBL4870922,,TC-G-1000,Preclinical,adrenergic receptor agonist,P18089
CHEMBL1480516,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C,terguride,Launched,dopamine receptor agonist|serotonin receptor antagonist,P18089
CHEMBL1200329,C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl.Cl,tizanidine,Launched,adrenergic receptor agonist,P18089
CHEMBL1689,C1CN=C(N1)CC2=CC=CC=C2.Cl,tolazoline,Launched,adrenergic receptor antagonist,P18089
CHEMBL4874429,,WB-4101,Preclinical,adrenergic receptor antagonist,P18089
CHEMBL1256022,CC1=C(C(=CC=C1)C)NC2=NCCCS2.Cl,xylazine,Launched,adrenergic receptor agonist,P18089
CHEMBL1256400,CC1=CC(=CC(=C1CC2=NCCN2)C)C(C)(C)C.Cl,xylometazoline,Launched,adrenergic receptor agonist,P18089
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P18089
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL285802,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,zotepine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P18089
CHEMBL4873019,,2-BFI,Preclinical,imidazoline receptor ligand,P18089
CHEMBL1113,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,amoxapine,Launched,norepinephrine reputake inhibitor,P21918
CHEMBL2219425,CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,aripiprazole,Launched,serotonin receptor agonist|serotonin receptor antagonist,P21918
CHEMBL1255752,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O.Cl,bromocriptine,Launched,dopamine receptor agonist,P21918
CHEMBL1256790,CC(C)(C)C1(CCN2CC3C4=CC=CC=C4CCC5=C3C(=CC=C5)C2C1)O.Cl,butaclamol,Phase 2,dopamine receptor antagonist,P21918
CHEMBL1201087,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C,cabergoline,Launched,dopamine receptor agonist,P21918
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P21918
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21918
CHEMBL1256832,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,dihydrexidine,Phase 2,dopamine receptor agonist,P21918
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P21918
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P21918
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P21918
CHEMBL4857163,,flupentixol,Launched,dopamine receptor antagonist,P21918
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P21918
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,P21918
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,P21918
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P21918
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P21918
CHEMBL2104973,C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C.Cl,levomepromazine,Launched,dopamine receptor antagonist,P21918
CHEMBL57059,CCN(CC)C(=O)NC1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C,lisuride,Launched,dopamine receptor agonist,P21918
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21918
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21918
CHEMBL1275,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O,pergolide,Withdrawn,dopamine receptor agonist,P21918
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P21918
CHEMBL3182733,CCCN[C@H]1CCC2=C(C1)SC(=N2)N.O.Cl.Cl,pramipexole,Launched,dopamine receptor agonist,P21918
CHEMBL3188993,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42.C(=C/C(=O)O)\C(=O)O,quetiapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21918
CHEMBL1200411,CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl,ropinirole,Launched,dopamine receptor agonist,P21918
CHEMBL104383,CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O,rotigotine,Launched,dopamine receptor agonist,P21918
CHEMBL4870993,,SCH-23390,Preclinical,dopamine receptor antagonist,P21918
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P21918
CHEMBL505308,C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3.Br,SKF-38393,Preclinical,dopamine receptor agonist,P21918
CHEMBL4862451,,SKF-81297,Preclinical,dopamine receptor agonist,P21918
CHEMBL1473849,CN1CCC2=CC(=C(C=C2[C@@H](C1)C3=CC=CC=C3)O)Br,SKF-83566,Preclinical,dopamine receptor antagonist,P21918
CHEMBL1256875,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F.Cl,spiperone,Launched,dopamine receptor antagonist,P21918
CHEMBL1200916,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl,thioridazine,Withdrawn,dopamine receptor antagonist,P21918
CHEMBL1375743,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54.O.Cl,ziprasidone,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P21918
CHEMBL2360084,C1CN(CCN1CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO.Cl.Cl,zuclopenthixol,Launched,dopamine receptor antagonist,P21918
CHEMBL2105950,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)[O-])C.[Na+],amoxicillin,Launched,penicillin binding protein inhibitor,P33261
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P33261
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P33261
CHEMBL308954,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,etravirine,Launched,non-nucleoside reverse transcriptase inhibitor,P33261
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P33261
CHEMBL64,C1=CN=CC=C1C(=O)NN,isoniazid,Launched,FABI inhibitor,P33261
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P33261
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P33261
CHEMBL3038236,C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.Cl.Cl.[Zn+2],sulfanilamide,Launched,carbonic anhydrase inhibitor,P33261
CHEMBL1076211,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,tolperisone,Launched,voltage-gated sodium channel blocker,P33261
CHEMBL638,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,voriconazole,Launched,cytochrome P450 inhibitor,P33261
CHEMBL2105950,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)[O-])C.[Na+],amoxicillin,Launched,penicillin binding protein inhibitor,P46059
CHEMBL1644,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,P46059
CHEMBL2105950,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)[O-])C.[Na+],amoxicillin,Launched,penicillin binding protein inhibitor,Q16348
CHEMBL1644,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,Q16348
CHEMBL461727,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,amygdalin,Phase 2,caspase activator,P42574
CHEMBL4870753,,AZ-10417808,Preclinical,caspase inhibitor,P42574
CHEMBL4868481,,DBeQ,Preclinical,ATPase inhibitor,P42574
CHEMBL197672,C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C,emricasan,Phase 2,caspase inhibitor,P42574
CHEMBL4860545,,NQDI-1,Preclinical,caspase inhibitor,P42574
CHEMBL4848518,,PAC-1,Phase 1,caspase activator,P42574
CHEMBL1416055,C1=CN=CC=C1C[C@@H](C(Cl)(Cl)Cl)O,PETCM,Preclinical,caspase activator,P42574
CHEMBL4856448,,sanguinarium-chloride,Phase 1,apoptosis stimulant,P42574
CHEMBL4851202,,AM679,Preclinical,cannabinoid receptor agonist|lipoxygenase inhibitor,P20292
CHEMBL1921749,,GSK2190915,Phase 2,lipoxygenase inhibitor,P20292
CHEMBL313489,CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+],quiflapon,Phase 2,leukotriene synthesis inhibitor,P20292
CHEMBL4858103,,veliflapon,Phase 3,leukotriene synthesis inhibitor,P20292
CHEMBL1800807,C[C@H]1[C@H](OC(=O)N1CC2=C(C=CC(=C2)C(F)(F)F)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F,anacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,P11597
CHEMBL4877435,,CP-532623,Phase 1,cholesteryl ester transfer protein inhibitor,P11597
CHEMBL4855874,,dalcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,P11597
CHEMBL2017179,CC1=CC(=C2C(=C1)[C@H](CCCN2CC3CCC(CC3)C(=O)O)N(CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=NN(N=N5)C)C,evacetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,P11597
CHEMBL479527,CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC,torcetrapib,Phase 3,cholesteryl ester transfer protein inhibitor,P11597
CHEMBL2110579,CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N,anamorelin,Phase 3,growth hormone secretagogue receptor agonist,Q92847
CHEMBL4861098,,examorelin,Phase 2,growth hormone releasing factor agonist,Q92847
CHEMBL2105872,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O,ibutamoren,Phase 2,growth hormone secretagogue receptor agonist,Q92847
CHEMBL4848364,,NADPH,Preclinical,,Q92847
CHEMBL4857092,,PF-05190457,Phase 2,growth hormone secretagogue receptor inverse agonist,Q92847
CHEMBL4848765,,tabimorelin,Phase 2,growth hormone secretagogue receptor agonist,Q92847
CHEMBL4877570,,U-75799E,Phase 1,growth hormone releasing factor agonist,Q92847
CHEMBL5093160,CC1=NC2=C(C=C(C=C2)OC3=CC=C(C=C3)F)C(=O)N1C[C@H]4CCCN(C4)C(C)C.Cl,YIL-781,Preclinical,ghrelin receptor antagonist,Q92847
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,P23415
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P23415
CHEMBL3348958,CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,bilobalide,Preclinical,GABA receptor modulator,P23415
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P23415
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,P23415
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P23415
CHEMBL465161,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3(C2)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-A,Preclinical,GABA receptor antagonist,P23415
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,P23415
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P23415
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P23415
CHEMBL15891,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,lindane,Launched,,P23415
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P23415
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,P23415
CHEMBL478523,C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O,picrotin,Phase 2,GABA receptor antagonist,P23415
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,P23415
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P23415
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P23415
CHEMBL213907,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,thiocolchicoside,Launched,GABA receptor antagonist,P23415
CHEMBL4303202,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl,tropisetron,Launched,serotonin receptor antagonist,P23415
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,P16389
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P16389
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,O14649
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,O14649
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,O14649
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,O14649
CHEMBL1081188,CC1=CC(=CC=C1)C(=O)NC2=CC(=CC=C2)NC(=O)C3=CC=CC=C3OC,ML365,Preclinical,potassium channel blocker,O14649
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,O14649
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q9NPC2
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q9NPC2
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q9NPC2
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q9NPC2
CHEMBL1081188,CC1=CC(=CC=C1)C(=O)NC2=CC(=CC=C2)NC(=O)C3=CC=CC=C3OC,ML365,Preclinical,potassium channel blocker,Q9NPC2
CHEMBL4876073,,PK-THPP,Preclinical,potassium channel blocker,Q9NPC2
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q9NPC2
CHEMBL3638052,CCCCC/C=C\C/C=C\C/C=C/C/C=C\CCCC(=O)NCCO,anandamide,Phase 2,cannabinoid receptor agonist,Q7Z2W7
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,Q7Z2W7
CHEMBL258405,C1C=C(NC(=O)N1C2=CC=CC=C2O)C3=CC(=CC=C3)[N+](=O)[O-],icilin,Phase 1,TRPV agonist,Q7Z2W7
CHEMBL4862828,,levomenthol,Launched,,Q7Z2W7
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,Q7Z2W7
CHEMBL4860943,,M8-B,Preclinical,transient receptor potential channel antagonist,Q7Z2W7
CHEMBL4846083,,RQ-00203078,Preclinical,transient receptor potential channel antagonist,Q7Z2W7
CHEMBL4846854,,TC-I-2000,Preclinical,transient receptor potential channel antagonist,Q7Z2W7
CHEMBL4848373,,TC-I-2014,Preclinical,transient receptor potential channel antagonist,Q7Z2W7
CHEMBL186141,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,P05231
CHEMBL4204890,CC(C)CC(=O)C1=C2C=CC=CN2N=C1C(C)C,ibudilast,Launched,leukotriene receptor antagonist|phosphodiesterase inhibitor,P05231
CHEMBL4303719,CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl,JTE-607,Phase 2,cytokine production inhibitor,P05231
CHEMBL4865042,,trofinetide,Phase 2,cytokine production inhibitor,P05231
CHEMBL1090090,C1=CC(=C(C(=C1)F)N(C2=NC(=C(C=C2)C(=O)N)C3=C(C=C(C=C3)F)F)C(=O)N)F,VX-702,Phase 2,p38 MAPK inhibitor,P05231
CHEMBL186141,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,P19838
CHEMBL2206431,CC1=CC[C@@]23[C@H]1[C@@H]4[C@@H](CC[C@@]2(O3)C)C(=C)C(=O)O4,arglabin,Launched,farnesyltransferase inhibitor,P19838
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P19838
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,P19838
CHEMBL4864934,,SP-100030,Preclinical,NFkB pathway inhibitor,P19838
CHEMBL1332032,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,P19838
CHEMBL186141,C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O,andrographolide,Phase 2,tumor necrosis factor production inhibitor,Q00653
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q00653
CHEMBL1151615,,anguidine,Phase 2,protein synthesis inhibitor,P13866
CHEMBL4594217,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,canagliflozin,Launched,sodium/glucose cotransporter inhibitor,P13866
CHEMBL429910,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl,dapagliflozin,Launched,sodium/glucose cotransporter inhibitor,P13866
CHEMBL2107830,C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl,empagliflozin,Launched,sodium/glucose cotransporter inhibitor,P13866
CHEMBL4303464,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,P13866
CHEMBL3039507,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl,sotagliflozin,Phase 3,sodium/glucose cotransporter inhibitor,P13866
CHEMBL4878918,,anisindione,Launched,vitamin K antagonist,P38435
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P38435
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P38435
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione-bisulfite,Phase 2,vitamin K,P38435
CHEMBL1550,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C,phytonadione,Launched,,P38435
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P55769
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P55769
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,Q96L21
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,Q96L21
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P62913
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P62913
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P40429
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P40429
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P61313
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P61313
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P84098
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P84098
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P62829
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P62829
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P62750
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P62750
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,Q9UNX3
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,Q9UNX3
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P39023
CHEMBL123292,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,cycloheximide,Preclinical,protein synthesis inhibitor,P39023
CHEMBL4852491,,homoharringtonine,Launched,protein synthesis inhibitor,P39023
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P39023
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P61927
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P61927
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,P62917
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,P62917
CHEMBL423192,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,anisomycin,Preclinical,DNA synthesis inhibitor,Q9UHA3
CHEMBL1233071,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)N)O,puromycin,Preclinical,protein synthesis inhibitor,Q9UHA3
CHEMBL4303227,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)N(C)C(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCN=C(N)N)N,antagonist-g,Phase 1,neuropeptide receptor antagonist,P45983
CHEMBL4853404,,BI-78D3,Preclinical,JNK inhibitor,P45983
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P45983
CHEMBL4854309,,CC-401,Phase 1,JNK inhibitor,P45983
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P45983
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P45983
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P45983
CHEMBL3545213,C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4,PGL5001,Phase 2,JNK inhibitor,P45983
CHEMBL4872164,,pyrazolanthrone,Preclinical,JNK inhibitor,P45983
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P45983
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P45983
CHEMBL4850171,,SR-3306,Preclinical,JNK inhibitor,P45983
CHEMBL4856354,,SU3327,Preclinical,JNK inhibitor,P45983
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P45983
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P45983
CHEMBL4303227,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)N(C)C(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCN=C(N)N)N,integrin-antagonist-1,Phase 1,integrin antagonist,P06756
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N,ATN-161,Phase 2,integrin antagonist,P06756
CHEMBL4853715,,cilengitide,Phase 3,integrin antagonist,P06756
CHEMBL1257246,CC(=CCC[C@]1([C@@H]2CC[C@H]3CC4=C([C@@]3([C@]2(CC[C@@H]1O)C)C)NC5=CC=CC=C45)C)C,SB-683698,Phase 1,integrin antagonist,P06756
CHEMBL4303227,CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=CC=C3)N(C)C(=O)[C@@H](CC4=CNC5=CC=CC=C54)NC(=O)[C@H](CCCN=C(N)N)N,integrin-antagonist-1,Phase 1,integrin antagonist,P18564
CHEMBL4866815,,antalarmin,Preclinical,corticotropin releasing factor receptor antagonist,P34998
CHEMBL4876065,,CP-376395,Phase 1,corticotropin releasing factor receptor antagonist,P34998
CHEMBL4848841,,NBI-27914,Preclinical,corticotropin releasing factor receptor antagonist,P34998
CHEMBL4873625,,NGD-98-2,Preclinical,corticotropin releasing factor receptor antagonist,P34998
CHEMBL1870796,CC(C)(C)C(=O)NCCCC(=O)O,pivagabine,Launched,corticotropin releasing factor receptor antagonist,P34998
CHEMBL55659,C1=CC=C2C(=C1)C(=O)C3=CC=CC=C3C2=O,anthraquinone,Preclinical,CDC inhibitor,P30305
CHEMBL4849723,,NSC-663284,Preclinical,CDC inhibitor,P30305
CHEMBL1139895,,NSC-95397,Preclinical,CDC inhibitor,P30305
CHEMBL211501,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,antimycin-A,Preclinical,ATP synthase inhibitor,P99999
CHEMBL2393130,CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2,apabetalone,Phase 3,apolipoprotein expression enhancer,Q15059
CHEMBL4868233,,I-BET-762,Phase 2,bromodomain inhibitor,Q15059
CHEMBL4862900,,I-BET151,Preclinical,bromodomain inhibitor,Q15059
CHEMBL4849190,,LY303511,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,Q15059
CHEMBL4852290,,OTX015,Phase 1/Phase 2,bromodomain inhibitor,Q15059
CHEMBL4867977,,XD-14,Preclinical,bromodomain inhibitor,Q15059
CHEMBL3186534,C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4,apatinib,Phase 3,RET tyrosine kinase inhibitor,P41240
CHEMBL4859038,,SRC-kinase-inhibitor-I,Preclinical,SRC inhibitor,P41240
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P41240
CHEMBL4871924,,APD597,Phase 1,glucose dependent insulinotropic receptor agonist,Q8TDV5
CHEMBL4862862,,APD668,Phase 1,glucose dependent insulinotropic receptor agonist,Q8TDV5
CHEMBL4846879,,AS-1269574,Preclinical,glucose dependent insulinotropic receptor agonist,Q8TDV5
CHEMBL4864614,,MBX-2982,Phase 2,glucose dependent insulinotropic receptor agonist,Q8TDV5
CHEMBL4868088,,OLDA,Preclinical,TRPV agonist,Q8TDV5
CHEMBL4872662,,oleoylethanolamide,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,Q8TDV5
CHEMBL4866771,,olvanil,Preclinical,TRPV agonist,Q8TDV5
CHEMBL4850871,,OMDM-2,Preclinical,FAAH inhibitor,Q8TDV5
CHEMBL417675,CCCCCCCCCCCCCCCC(=O)NCCO,palmitoylethanolamide,Launched,cannabinoid receptor agonist,Q8TDV5
CHEMBL4303425,CCCCC1CCC(CC1)C2=NC(=NO2)C3=CC=NC=C3,PSN-375963,Preclinical,glucose dependent insulinotropic receptor agonist,Q8TDV5
CHEMBL3182200,CCCCCCCC/C=C\CCCCCCCC(=O)OC(CO)CO,2-oleoylglycerol,Phase 1,glucose dependent insulinotropic receptor ligand,Q8TDV5
CHEMBL4303566,C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N,API-1,Preclinical,AKT inhibitor,P31751
CHEMBL4297188,C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N,ARQ-092,Phase 1,AKT inhibitor,P31751
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,P31751
CHEMBL4865739,,AT7867,Preclinical,AKT inhibitor,P31751
CHEMBL4874127,,AZD5363,Phase 3,AKT inhibitor,P31751
CHEMBL4847961,,GDC-0068,Phase 3,AKT inhibitor,P31751
CHEMBL2219422,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl,GSK2110183,Phase 2,AKT inhibitor,P31751
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,P31751
CHEMBL4863899,,MK-2206,Phase 2,AKT inhibitor,P31751
CHEMBL4871320,,PHT-427,Preclinical,AKT inhibitor|pyruvate dehydrogenase inhibitor,P31751
CHEMBL4873723,,triciribine,Phase 1/Phase 2,AKT inhibitor,P31751
CHEMBL4879093,,uprosertib,Phase 2,AKT inhibitor,P31751
CHEMBL4303566,C1=C(C(=O)C2=C(N=CN=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)N)C(=O)N,API-1,Preclinical,AKT inhibitor,Q9Y243
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,Q9Y243
CHEMBL4874127,,AZD5363,Phase 3,AKT inhibitor,Q9Y243
CHEMBL4847961,,GDC-0068,Phase 3,AKT inhibitor,Q9Y243
CHEMBL2219422,CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=CC=C3)F)CN)Cl,GSK2110183,Phase 2,AKT inhibitor,Q9Y243
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,Q9Y243
CHEMBL4863899,,MK-2206,Phase 2,AKT inhibitor,Q9Y243
CHEMBL4863031,,SB-747651A,Preclinical,kinase inhibitor,Q9Y243
CHEMBL4873723,,triciribine,Phase 1/Phase 2,AKT inhibitor,Q9Y243
CHEMBL4879093,,uprosertib,Phase 2,AKT inhibitor,Q9Y243
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,P13569
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,P13569
CHEMBL294199,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,capsaicin,Launched,TRPV agonist,P13569
CHEMBL4846100,,CFTRinh-172,Preclinical,chloride channel blocker,P13569
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P13569
CHEMBL4852378,,felodipine,Launched,calcium channel blocker,P13569
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P13569
CHEMBL146095,C1=CC=C(C(=C1)C(=O)OCC(CO)O)NC2=C3C=CC(=CC3=NC=C2)Cl,glafenine,Withdrawn,DeltaF508-CFTR Correctors,P13569
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,P13569
CHEMBL4297392,C1=CC=C(C=C1)OC2=CC=C(C=C2)CNC(=O)C3=NC(=NO3)C4=CC(=C(C(=C4)Br)O)Br,IOWH032,Phase 2,CFTR channel antagonist,P13569
CHEMBL2010601,CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C,ivacaftor,Launched,CFTR channel potentiator,P13569
CHEMBL2103870,CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O,lumacaftor,Launched,CFTR channel agonist,P13569
CHEMBL1514440,CC1=C([C@H](C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,nimodipine,Launched,calcium channel blocker,P13569
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,Q16678
CHEMBL117,C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O,chrysin,Phase 1,breast cancer resistance protein inhibitor,Q16678
CHEMBL90568,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,diosmetin,Launched,aryl hydrocarbon receptor agonist,Q16678
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,Q16678
CHEMBL9352,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,Q16678
CHEMBL399910,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=CC=C3,pinocembrin,Phase 2,cytochrome P450 inhibitor,Q16678
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,Q16678
CHEMBL28,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,apigenin,Preclinical,casein kinase inhibitor|cell proliferation inhibitor,P14061
CHEMBL4874840,,BVT-2733,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,P14061
CHEMBL4851780,,coenzyme-I,Phase 2,,P14061
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P14061
CHEMBL1474552,CC12CCC3C(=CCC4=C3C=CC(=C4)O)C1CCC2=O,equilin,Preclinical,estrogen receptor agonist,P14061
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,P14061
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P14061
CHEMBL9352,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,P14061
CHEMBL231779,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,apixaban,Launched,coagulation factor inhibitor,P00742
CHEMBL231779,COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N,apixaban,Launched,coagulation factor inhibitor,Q9BQ89
CHEMBL4303203,CN1CCC2=C(C1)SC(=N2)C(=O)N[C@H]3C[C@@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,edoxaban,Launched,coagulation factor inhibitor,P00742
CHEMBL4303203,CN1CCC2=C(C1)SC(=N2)C(=O)N[C@H]3C[C@@H](CC[C@@H]3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C,edoxaban,Launched,coagulation factor inhibitor,Q9BQ89
CHEMBL1276258,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])COC[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])COC[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],fondaparinux,Launched,coagulation factor inhibitor,P00742
CHEMBL1276258,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])COC[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])COC[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],fondaparinux,Launched,coagulation factor inhibitor,Q9BQ89
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P00742
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,Q9BQ89
CHEMBL1367565,C1=CC(=CC=C1C(CN)O)O.Cl,octopamine,Preclinical,trace amine associated receptor agonist,P00742
CHEMBL1367565,C1=CC(=CC=C1C(CN)O)O.Cl,octopamine,Preclinical,trace amine associated receptor agonist,Q9BQ89
CHEMBL4846679,,otamixaban,Phase 3,coagulation factor inhibitor,P00742
CHEMBL4846679,,otamixaban,Phase 3,coagulation factor inhibitor,Q9BQ89
CHEMBL198362,C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl,rivaroxaban,Launched,coagulation factor inhibitor,P00742
CHEMBL198362,C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl,rivaroxaban,Launched,coagulation factor inhibitor,Q9BQ89
CHEMBL346919,CC(=O)C1=CC(=C(C=C1)O)OC,apocynin,Phase 1,NADPH oxidase inhibitor,Q9NPH5
CHEMBL4303187,CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl,GKT137831,Phase 2,NADPH oxidase inhibitor,Q9NPH5
CHEMBL4861533,,apoptosis-activator-II,Preclinical,carboxylesterase inhibitor,P06276
CHEMBL521589,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,bambuterol,Launched,adrenergic receptor agonist,P06276
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,P06276
CHEMBL1200514,CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C.[Br-].[Br-],demecarium,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL1104,CC[N+](C)(C)C1=CC(=CC=C1)O,edrophonium,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL1025,CC(C)OP(=O)(OC(C)C)F,isoflurophate,Launched,cholinesterase inhibitor,P06276
CHEMBL1477274,CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O.Cl,meptazinol,Launched,opioid receptor agonist,P06276
CHEMBL4861767,,mestinon,Launched,cholinesterase inhibitor,P06276
CHEMBL4095755,CC1CC[C@@]2([C@H]1C(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C,phenserine,Phase 3,acetylcholinesterase inhibitor|beta amyloid synthesis inhibitor,P06276
CHEMBL4566020,CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC)C)C.C1=CC=C(C(=C1)C(=O)O)O,physostigmine,Launched,acetylcholinesterase inhibitor|cholinesterase inhibitor,P06276
CHEMBL2104739,C[N+]1=CC=CC=C1C=NO.CS(=O)(=O)[O-],pralidoxime,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL4303284,C[N+]1=CC=CC=C1CN=O,pralidoxime-chloride,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL636,CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,rivastigmine,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,P06276
CHEMBL95,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,tacrine,Launched,acetylcholinesterase inhibitor,P06276
CHEMBL4869332,,APR-246,Phase 3,p53 activator,P04637
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P04637
CHEMBL70971,COC(=O)NC1=NC2=CC=CC=C2N1,carbendazim,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P04637
CHEMBL4851126,,idasanutlin,Phase 3,MDM inhibitor,P04637
CHEMBL211045,CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl,nutlin-3,Preclinical,MDM inhibitor,P04637
CHEMBL4864409,,PhiKan-083,Preclinical,p53 stabilizing agent,P04637
CHEMBL4877130,,pifithrin-alpha,Preclinical,TP53 inhibitor,P04637
CHEMBL4855942,,pifithrin-cyclic,Preclinical,TP53 inhibitor,P04637
CHEMBL1241268,C1=CC=C(C=C1)C#CS(=O)(=O)N,pifithrin-mu,Preclinical,HSP inhibitor,P04637
CHEMBL4862075,,VLX600,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,P04637
CHEMBL3392650,CC1(C(N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C,apratastat,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,P78536
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P78536
CHEMBL3392650,CC1(C(N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C,apratastat,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,P03956
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P03956
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P03956
CHEMBL4869111,,CP-471474,Preclinical,matrix metalloprotease inhibitor,P03956
CHEMBL4869630,,CTS-1027,Phase 2,metalloproteinase inhibitor,P03956
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P03956
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P03956
CHEMBL4303335,CCCC(C)NC(=O)C1=CC(=C(C=C1)Cl)Cl,NSC-405020,Preclinical,matrix metalloprotease inhibitor,P03956
CHEMBL4860542,,SD-2590,Preclinical,matrix metalloprotease inhibitor,P03956
CHEMBL3392650,CC1(C(N(CCS1)S(=O)(=O)C2=CC=C(C=C2)OCC#CCO)C(=O)NO)C,apratastat,Phase 2,matrix metalloprotease inhibitor|tumor necrosis factor production inhibitor,P45452
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P45452
CHEMBL4869111,,CP-471474,Preclinical,matrix metalloprotease inhibitor,P45452
CHEMBL4869630,,CTS-1027,Phase 2,metalloproteinase inhibitor,P45452
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P45452
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P45452
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P45452
CHEMBL4866449,,PD-166793,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,P45452
CHEMBL4860542,,SD-2590,Preclinical,matrix metalloprotease inhibitor,P45452
CHEMBL4867936,,UK-356618,Preclinical,metalloproteinase inhibitor,P45452
CHEMBL4850927,,WAY-170523,Preclinical,metalloproteinase inhibitor,P45452
CHEMBL4303169,C[C@@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNC(=O)N3)C4=CC=C(C=C4)F,aprepitant,Launched,tachykinin antagonist,P25103
CHEMBL527237,CCNC(=O)NS(=O)(=O)C1=C(C=CN=C1)SC2=CC=CC(=C2)C,AV-608,Phase 2,tachykinin antagonist,P25103
CHEMBL4863395,,CP-99994,Phase 2,tachykinin antagonist,P25103
CHEMBL1416993,CN1C=C(C2=CC=CC=C21)C(=O)N3C[C@@H](C[C@H]3C(=O)N[C@@H](CC4=CC5=CC=CC=C5C=C4)C(=O)N(C)CC6=CC=CC=C6)O,FK-888,Phase 2,tachykinin antagonist,P25103
CHEMBL1201782,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C(C=C4)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O,fosaprepitant-dimeglumine,Launched,tachykinin antagonist,P25103
CHEMBL188166,CC(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)OCC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,"L-732,138",Preclinical,tachykinin antagonist,P25103
CHEMBL4877955,,L-733060,Preclinical,tachykinin antagonist,P25103
CHEMBL4303434,C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@@H]2[C@@H](N(CCO2)CC3=NNN=C3CN(C)C)C4=CC=C(C=C4)F,L-760735,Preclinical,tachykinin antagonist,P25103
CHEMBL2111099,CC(C)(C)C1=CC(=C(C=C1)OC)CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5,maropitant,Launched,neurokinin receptor antagonist,P25103
CHEMBL206253,CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C,netupitant,Launched,tachykinin antagonist,P25103
CHEMBL4852254,,SDZ-NKT-343,Phase 1,tachykinin antagonist,P25103
CHEMBL4866801,,SR-140333,Phase 2,neurokinin receptor antagonist,P25103
CHEMBL414370,CC(C)C[C@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]3CCCN3C(=O)[C@@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N,substance-P,Phase 1,neurokinin receptor antagonist,P25103
CHEMBL2104501,CCN(CC)CCCN(C1CC2=CC=CC=C2C1)C3=CC=CC=C3.Cl,aprindine,Launched,voltage-gated sodium channel blocker,P0DP23
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P0DP23
CHEMBL1086,CCCCOC1=NC2=CC=CC=C2C(=C1)C(=O)NCCN(CC)CC,cinchocaine,Launched,sodium channel blocker,P0DP23
CHEMBL552659,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F.Cl.Cl,flunarizine,Launched,calcium channel blocker,P0DP23
CHEMBL1200854,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,fluphenazine,Launched,dopamine receptor antagonist,P0DP23
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,P0DP23
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P0DP23
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,P0DP23
CHEMBL567,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,perphenazine,Launched,dopamine receptor antagonist,P0DP23
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,P0DP23
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P0DP23
CHEMBL1474352,CC1(C2=CC=CN2C3=CC=CC=C3CO1)CN4CCC(CC4)N5C6=CC=CC=C6NC5=O,zaldaride,Phase 3,calmodulin antagonist,P0DP23
CHEMBL4297261,CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6,APTO-253,Phase 1,krüppel-like factor expression enhancer,O43474
CHEMBL1231018,C1CC1C2=CC(=NN2)NC3=NC(=NC=C3)NC4=CC5=C(C=C4)N=CN5,APY-29,Preclinical,serine/threonine kinase inhibitor,O75460
CHEMBL4847250,,STF-083010,Preclinical,serine/threonine kinase inhibitor,O75460
CHEMBL4864776,,toyocamycin,Phase 1,serine/threonine kinase inhibitor,O75460
CHEMBL4864881,,4-mu-8C,Preclinical,IRE1 inhibitor,O75460
CHEMBL4303292,CC1=CC(=CC=C1)/C=N/NC2=NC3=CC(=NN3C(=C2)N4CCOCC4)C5=CC=NC=C5,APY0201,Preclinical,phosphoinositide dependent kinase inhibitor,P29459
CHEMBL4297643,CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4,STA-5326,Phase 2,interleukin synthesis inhibitor,P29459
CHEMBL4303292,CC1=CC(=CC=C1)/C=N/NC2=NC3=CC(=NN3C(=C2)N4CCOCC4)C5=CC=NC=C5,APY0201,Preclinical,phosphoinositide dependent kinase inhibitor,P29460
CHEMBL4303292,CC1=CC(=CC=C1)/C=N/NC2=NC3=CC(=NN3C(=C2)N4CCOCC4)C5=CC=NC=C5,APY0201,Preclinical,phosphoinositide dependent kinase inhibitor,Q9Y2I7
CHEMBL1136227,,AP1903,Phase 1/Phase 2,,P42345
CHEMBL4870689,,AZD2014,Phase 2,mTOR inhibitor,P42345
CHEMBL4850479,,AZD8055,Phase 1,mTOR inhibitor,P42345
CHEMBL4859631,,AZ20,Preclinical,ATR kinase inhibitor,P42345
CHEMBL4303673,CC(C)(CC(=O)O)O.CC(C)(CC(=O)O)O,beta-hydroxy-beta-methylbutyrate,Launched,protein synthesis stimulant,P42345
CHEMBL3545096,CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=C\C(=O)O)\C(=O)O,BGT226,Phase 1/Phase 2,PI3K inhibitor,P42345
CHEMBL3586573,CCN1C(=O)CNC2=NC=C(N=C21)C3=C(N=C(C=C3)C4=NC=NN4)C,CC-115,Phase 2,DNA protein kinase inhibitor|mTOR inhibitor,P42345
CHEMBL4867015,,CC-223,Phase 2,mTOR inhibitor,P42345
CHEMBL3707295,,chrysophanic-acid,Preclinical,EGFR inhibitor,P42345
CHEMBL4867637,,CH5132799,Phase 1,PI3K inhibitor,P42345
CHEMBL4852963,,compound-401,Preclinical,DNA dependent protein kinase inhibitor,P42345
CHEMBL4741795,C[C@@H]1CC[C@H]2C[C@@H](/C(=C\C=C/C=C\[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C\[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OP(=O)(C)C)C)/C)O)OC)C)C)/C)OC,deforolimus,Phase 3,mTOR inhibitor,P42345
CHEMBL1908360,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC,everolimus,Launched,mTOR inhibitor,P42345
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4859753,,GSK2126458,Phase 1,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4858705,,KU-0063794,Preclinical,mTOR inhibitor,P42345
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P42345
CHEMBL4297181,C[C@@H](CN1C2=C3C=C(C=CC3=NC=C2N(C1=O)C)C4=CC(=CN=C4)C(C)(C)O)OC,LY3023414,Phase 2,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4869629,,MLN0128,Phase 2,mTOR inhibitor,P42345
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4864277,,OSI-027,Phase 1,mTOR inhibitor,P42345
CHEMBL2141712,CC(C1=CC2=C(C=C1)C3=CC(=C(C=C3OC2=O)OCC4=CC=C(C=C4)OC)OC)O,palomid-529,Phase 1,AKT inhibitor|mTOR inhibitor,P42345
CHEMBL4878605,,PF-04691502,Phase 2,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4874638,,PF-05212384,Phase 2,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL1258517,C1CC2COCC1N2C3=NC(=NC(=N3)N4CCOCC4)C5=CC=C(C=C5)NC(=O)NC6=CC=NC=C6,PKI-179,Phase 1,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P42345
CHEMBL4870077,,PP242,Preclinical,mTOR inhibitor,P42345
CHEMBL2109635,,SAR-245409,Phase 1/Phase 2,PI3K inhibitor,P42345
CHEMBL578092,C=CCN1CCN(CC1)C(C2=CC=CC=C2F)C3=NN=NN3CC4=CC=CO4.Cl,SB-2343,Phase 1,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL2074450,,sirolimus,Launched,mTOR inhibitor,P42345
CHEMBL1201182,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC,temsirolimus,Launched,mTOR inhibitor,P42345
CHEMBL4859256,,torin-1,Preclinical,mTOR inhibitor,P42345
CHEMBL4869319,,torin-2,Preclinical,mTOR inhibitor,P42345
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,P42345
CHEMBL3545366,CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N,voxtalisib,Phase 2,mTOR inhibitor|PI3K inhibitor,P42345
CHEMBL4867865,,WAY-600,Preclinical,mTOR inhibitor,P42345
CHEMBL4870018,,WYE-125132,Preclinical,mTOR inhibitor,P42345
CHEMBL4875658,,WYE-354,Preclinical,mTOR inhibitor,P42345
CHEMBL4868640,,WYE-687,Preclinical,mTOR inhibitor,P42345
CHEMBL4876172,,XL388,Preclinical,mTOR inhibitor,P42345
CHEMBL4869251,,AR-C155858,Preclinical,monocarboxylate transporter inhibitor,P53985
CHEMBL4867875,,AZD3965,Phase 1,monocarboxylate transporter inhibitor,P53985
CHEMBL4868466,,CHC,Preclinical,monocarboxylate transporter inhibitor,P53985
CHEMBL4864270,,UK-5099,Preclinical,monocarboxylate transporter inhibitor,P53985
CHEMBL4869251,,AR-C155858,Preclinical,monocarboxylate transporter inhibitor,O60669
CHEMBL4858736,,AR-12,Phase 1,phosphoinositide dependent kinase inhibitor,O15530
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,O15530
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,O15530
CHEMBL4869523,,celecoxib,Launched,cyclooxygenase inhibitor,O15530
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,O15530
CHEMBL4872220,,GF109203X,Preclinical,PKC inhibitor,O15530
CHEMBL4879292,,GSK2334470,Preclinical,phosphoinositide dependent kinase inhibitor,O15530
CHEMBL4871320,,PHT-427,Preclinical,AKT inhibitor|pyruvate dehydrogenase inhibitor,O15530
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,O15530
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,P51788
CHEMBL1201134,CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@@H]2CCCCCCC(=O)O)O)(F)F,lubiprostone,Launched,chloride channel activator,P51788
CHEMBL4871860,,NPPB,Preclinical,chloride channel blocker,P51788
CHEMBL1567328,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2],omeprazole,Launched,ATPase inhibitor,P51788
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,P48050
CHEMBL1528028,C(CCN)CN.Cl.Cl,putrescine,Phase 2,tissue transglutaminase inhibitor,P48050
CHEMBL4870993,,SCH-23390,Preclinical,dopamine receptor antagonist,P48050
CHEMBL448065,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)NCCCCC(=O)N(CCCCN)CCCN)C)C(=C3C)CCC(=O)NCCCCC(=O)N(CCCCN)CCCN)C=C,spermidine,Preclinical,glutamate receptor modulator,P48050
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P48050
CHEMBL1908355,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,tenidap,Phase 3,cyclooxygenase inhibitor,P48050
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,P57789
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P57789
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P57789
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P57789
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,P57789
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P57789
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,Q7Z418
CHEMBL4849454,,cloxyquin,Preclinical,potassium channel activator,Q7Z418
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q7Z418
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q7Z418
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q7Z418
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q7Z418
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,O95069
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,Q13303
CHEMBL249818,CCCC[C@@H]1C2=CC=CC=C2C(=O)O1,butylphthalide,Launched,potassium channel antagonist,O95069
CHEMBL249818,CCCC[C@@H]1C2=CC=CC=C2C(=O)O1,butylphthalide,Launched,potassium channel antagonist,Q13303
CHEMBL4851326,,dofetilide,Withdrawn,potassium channel blocker,O95069
CHEMBL4851326,,dofetilide,Withdrawn,potassium channel blocker,Q13303
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,O95069
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q13303
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,O95069
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,Q13303
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,O95069
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q13303
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,O95069
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,Q13303
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,O95069
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q13303
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,O95069
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,Q13303
CHEMBL15594,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,arachidonic-acid,Phase 1,cytochrome P450 inhibitor,Q9Y210
CHEMBL1433489,C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-],KB-R7943,Preclinical,sodium/calcium exchange inhibitor,Q9Y210
CHEMBL4755617,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CCC6=C5C=CC(=C6)OC(=O)NC7CCCCC7)C)C)OC1,ML9,Preclinical,myosin light chain kinase inhibitor,Q9Y210
CHEMBL2157999,,SAG,Preclinical,smoothened receptor agonist,Q9Y210
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9Y210
CHEMBL4848925,,arbutin,Phase 2/Phase 3,melanin inhibitor,P14679
CHEMBL1238,C(CCCC(=O)O)CCCC(=O)O,azelaic-acid,Launched,tyrosinase inhibitor,P14679
CHEMBL4851780,,coenzyme-I,Phase 2,,P14679
CHEMBL1445833,CC12CCC(=O)C=C1CCC3C2CCC4(C3CCC4(C#C)O)C,ethisterone,Launched,progestogen hormone,P14679
CHEMBL329522,C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O,exifone,Withdrawn,nootropic agent,P14679
CHEMBL443605,CCCCCCC1=C(C=C(C=C1)O)O,hexylresorcinol,Launched,local anesthetic,P14679
CHEMBL537,C1=CC(=CC=C1O)O,hydroquinone,Launched,melanin inhibitor,P14679
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,mimosine,Preclinical,DNA replication inhibitor,P14679
CHEMBL4879306,,mequinol,Launched,,P14679
CHEMBL1388,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,monobenzone,Launched,melanin inhibitor,P14679
CHEMBL324842,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O,rosmarinic-acid,Launched,GABA transaminase inhibitor,P14679
CHEMBL4872131,,rucinol,Phase 1,tyrosinase inhibitor,P14679
CHEMBL435734,COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O)OC)OC,arctigenin,Preclinical,MEK inhibitor,Q02750
CHEMBL4852085,,AS-703026,Phase 2,MEK inhibitor,Q02750
CHEMBL4303500,CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,Q02750
CHEMBL3187723,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,binimetinib,Launched,MEK inhibitor,Q02750
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q02750
CHEMBL4538425,C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O,cobimetinib,Launched,MEK inhibitor,Q02750
CHEMBL76447,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC,nobiletin,Preclinical,MEK inhibitor,Q02750
CHEMBL540501,C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@@H](CO)O.C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@H](CO)O,PD-0325901,Phase 2,MEK inhibitor,Q02750
CHEMBL1240295,,PD-184352,Phase 2,MEK inhibitor,Q02750
CHEMBL1474985,CC1=C(C=CC(=C1)I)NC2=C(C(=C(C=C2C(=O)NOCC3CC3)F)F)F,PD-198306,Preclinical,MAP kinase inhibitor|MEK inhibitor,Q02750
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,Q02750
CHEMBL1236682,COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F,refametinib,Phase 2,MEK inhibitor,Q02750
CHEMBL4862978,,reversine,Preclinical,Aurora kinase inhibitor,Q02750
CHEMBL1614766,C1CC(=O)N(OC1)CC2=CC(=C(C(=C2F)F)NC3=C(C=C(C=C3)I)F)C(=O)NOCCO,Ro-4987655,Phase 1,MEK inhibitor,Q02750
CHEMBL4303496,CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C3=CC=C(C=C3)F,Ro-5126766,Phase 1,MEK inhibitor|RAF inhibitor,Q02750
CHEMBL2105684,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO.OS(=O)(=O)O,selumetinib,Phase 3,MEK inhibitor,Q02750
CHEMBL4856007,,TAK-733,Phase 1,MEK inhibitor,Q02750
CHEMBL2103875,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,trametinib,Launched,MEK inhibitor,Q02750
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,Q02750
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,Q02750
CHEMBL4867423,,arcyriaflavin-a,Preclinical,CDK inhibitor,P24385
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,P24385
CHEMBL1206245,COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)OP(=O)(O)O,briciclib,Phase 1,cyclin D inhibitor,P24385
CHEMBL1201448,,ardeparin,Withdrawn,thrombin inhibitor,P05546
CHEMBL59461,C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NC[C@@H](C3)C,argatroban,Launched,thrombin inhibitor,P00734
CHEMBL2103749,CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N,bivalirudin,Launched,thrombin inhibitor,P00734
CHEMBL539697,CCCCCCOC(=O)/N=C(\C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)/N,dabigatran,Launched,thrombin inhibitor,P00734
CHEMBL539697,CCCCCCOC(=O)/N=C(\C1=CC=C(C=C1)NCC2=NC3=C(N2C)C=CC(=C3)C(=O)N(CCC(=O)OCC)C4=CC=CC=N4)/N,dabigatran-etexilate,Launched,thrombin inhibitor,P00734
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P00734
CHEMBL465704,C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.OS(=O)(=O)O,proflavine-hemisulfate,Phase 2,topical anesthetic,P00734
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P00734
CHEMBL2206431,CC1=CC[C@@]23[C@H]1[C@@H]4[C@@H](CC[C@@]2(O3)C)C(=C)C(=O)O4,arglabin,Launched,farnesyltransferase inhibitor,P49354
CHEMBL4297396,C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl.Cl,L-778123,Phase 1,farnesyltransferase inhibitor,P49354
CHEMBL4862540,,lonafarnib,Phase 3,farnesyltransferase inhibitor,P49354
CHEMBL444711,CC(=C)C1CCC(=CC1)CO,perillyl-alcohol,Phase 2,apoptosis stimulant|farnesyltransferase inhibitor,P49354
CHEMBL4857005,,tipifarnib,Phase 3,farnesyltransferase inhibitor,P49354
CHEMBL351769,C1=CC(=CC=C1N)[As](=O)(O)O,arsanilic-acid,Phase 1,,P61626
CHEMBL1204779,CCCCCCCCCCCCOS(=O)(=O)O,dodecyl-sulfate,Preclinical,,P61626
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P61626
CHEMBL1200823,,sucrose,Launched,,P61626
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,P05412
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P05412
CHEMBL4863545,,irbesartan,Launched,angiotensin receptor antagonist,P05412
CHEMBL4864934,,SP-100030,Preclinical,NFkB pathway inhibitor,P05412
CHEMBL4861125,,T-5224,Phase 2,AP inhibitor,P05412
CHEMBL4872912,,TWS-119,Preclinical,glycogen synthase kinase inhibitor,P05412
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P05412
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,P28482
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P28482
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P28482
CHEMBL4863895,,CHIR-99021,Preclinical,glycogen synthase kinase inhibitor,P28482
CHEMBL4847356,,FR-180204,Preclinical,MAP kinase inhibitor,P28482
CHEMBL4303236,CN1C(=CC=N1)NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)C(CO)C4=CC(=C(C=C4)Cl)F,GDC-0994,Phase 1,MAP kinase inhibitor,P28482
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P28482
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P28482
CHEMBL4865572,,olomoucine,Preclinical,CDK inhibitor,P28482
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P28482
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,P28482
CHEMBL4859878,,ravoxertinib,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,P28482
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P28482
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P28482
CHEMBL3392223,CC1=CC=CC=C1CN2CC3=C(CCN(C3=O)CC4=CC=CC=C4)N5C2=NCC5,TIC10,Phase 2,AKT inhibitor|TRAIL modulator,P28482
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P28482
CHEMBL583042,CC1=CN=C(N=C1C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)NC4=C(C=C(C=C4)F)Cl,VX-11e,Preclinical,MAP kinase inhibitor,P28482
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P28482
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,P27361
CHEMBL4850884,,CID-5458317,Preclinical,MAP kinase phosphatase inhibitor,P27361
CHEMBL4847356,,FR-180204,Preclinical,MAP kinase inhibitor,P27361
CHEMBL4303236,CN1C(=CC=N1)NC2=NC=CC(=N2)C3=CC(=O)N(C=C3)C(CO)C4=CC(=C(C=C4)Cl)F,GDC-0994,Phase 1,MAP kinase inhibitor,P27361
CHEMBL4861946,,purvalanol-B,Preclinical,tyrosine kinase inhibitor,P27361
CHEMBL4859878,,ravoxertinib,Phase 1,ERK1 and ERK2 phosphorylation inhibitor,P27361
CHEMBL2362016,O1[As]2O[As]3O[As]1O[As](O2)O3,arsenic-trioxide,Launched,apoptosis stimulant,Q16881
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q16881
CHEMBL448065,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)NCCCCC(=O)N(CCCCN)CCCN)C)C(=C3C)CCC(=O)NCCCCC(=O)N(CCCCN)CCCN)C=C,spermidine,Preclinical,glutamate receptor modulator,Q16881
CHEMBL269671,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)C,artemisinin,Launched,DNA synthesis inhibitor,P20813
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P20813
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P20813
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P20813
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P20813
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P20813
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P20813
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P20813
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P20813
CHEMBL671,C1CN1P(=S)(N2CC2)N3CC3,thiotepa,Launched,cytochrome P450 inhibitor,P20813
CHEMBL3187683,CCCCCC[C@@H](CCC)C(=O)O,arundic-acid,Phase 2/Phase 3,astrocyte modulating agent,P04271
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,P04271
CHEMBL4848967,,ARV-825,Preclinical,bromodomain inhibitor,O60885
CHEMBL4863508,,BI-2536,Phase 2,PLK inhibitor,O60885
CHEMBL4847833,,CPI-0610,Phase 2,bromodomain inhibitor,O60885
CHEMBL4866316,,CPI-203,Preclinical,bromodomain inhibitor,O60885
CHEMBL4297216,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,O60885
CHEMBL4868233,,I-BET-762,Phase 2,bromodomain inhibitor,O60885
CHEMBL4862900,,I-BET151,Preclinical,bromodomain inhibitor,O60885
CHEMBL4869769,,JQ1-(+),Preclinical,bromodomain inhibitor,O60885
CHEMBL4849190,,LY303511,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,O60885
CHEMBL4852290,,OTX015,Phase 1/Phase 2,bromodomain inhibitor,O60885
CHEMBL4852260,,OXF-BD-02,Preclinical,bromodomain inhibitor,O60885
CHEMBL4752253,CN(C)C(=O)C1=C(C=C(C=C1)C2=CC(=NO2)C(=O)N[C@@H]3CCC4=CC=CC=C34)O,PFI-1,Preclinical,bromodomain inhibitor,O60885
CHEMBL4867977,,XD-14,Preclinical,bromodomain inhibitor,O60885
CHEMBL4878709,,AS-1892802,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,Q13464
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,Q13464
CHEMBL541388,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl,fasudil,Launched,rho associated kinase inhibitor,Q13464
CHEMBL4878360,,GSK269962,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL375312,CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F,GSK429286A,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL4873908,,hydroxyfasudil,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,Q13464
CHEMBL4866305,,LX7101,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,Q13464
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,Q13464
CHEMBL4303164,C1=CC=C(C(=C1)CNCC2=CC=C(C=C2)C3=C4C=CNC4=NC=C3)F,OXA-06,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,Q13464
CHEMBL3426621,C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)F,ripasudil,Launched,rho associated kinase inhibitor,Q13464
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL3545341,C1CNCCC1OC2=CC3=C(C=C2)C(=O)NC=C3.Cl,SAR407899,Phase 2,rho associated kinase inhibitor,Q13464
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,Q13464
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,Q13464
CHEMBL4863031,,SB-747651A,Preclinical,kinase inhibitor,Q13464
CHEMBL4860229,,SB-772077B,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,Q13464
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,Q13464
CHEMBL571948,C[C@H](C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N,Y-39983,Phase 2,rho associated kinase inhibitor,Q13464
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,Q13464
CHEMBL4874208,,AS-1949490,Preclinical,SHIP2 phosphatase inhibitor,Q92835
CHEMBL4867989,,AS-2444697,Preclinical,interleukin inhibitor,Q9NWZ3
CHEMBL4852085,,AS-703026,Phase 2,MEK inhibitor,P36507
CHEMBL4303500,CCNC(=O)C#CC1=CC2=C(C=C1)C(=C(N2)O)C(=NC3=CC=C(C=C3)CN(C)C)C4=CC=CC=C4,BI-847325,Phase 1,Aurora kinase inhibitor|MEK inhibitor,P36507
CHEMBL3187723,CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO,binimetinib,Launched,MEK inhibitor,P36507
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P36507
CHEMBL4861769,,MEK1-2-inhibitor,Preclinical,MEK inhibitor,P36507
CHEMBL1474985,CC1=C(C=CC(=C1)I)NC2=C(C(=C(C=C2C(=O)NOCC3CC3)F)F)F,PD-198306,Preclinical,MAP kinase inhibitor|MEK inhibitor,P36507
CHEMBL1236682,COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)NC3=C(C=C(C=C3)I)F)F)F,refametinib,Phase 2,MEK inhibitor,P36507
CHEMBL4303496,CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C3=CC=C(C=C3)F,Ro-5126766,Phase 1,MEK inhibitor|RAF inhibitor,P36507
CHEMBL2103875,CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5,trametinib,Launched,MEK inhibitor,P36507
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P36507
CHEMBL3650559,C1COCCC1CNC2=CC=C(C=C2)S(=O)(=O)NC(=O)C3=C(C=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)OC7=CC=CC(=C7)[N+](=O)[O-],AS-77,Phase 1,potassium channel blocker,P22001
CHEMBL4856603,,CP-339818,Preclinical,potassium channel blocker,P22001
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P22001
CHEMBL3650559,C1COCCC1CNC2=CC=C(C=C2)S(=O)(=O)NC(=O)C3=C(C=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)OC7=CC=CC(=C7)[N+](=O)[O-],AS-77,Phase 1,potassium channel blocker,P22460
CHEMBL3140370,CN1CCN(CC1)CCCCN2C(=O)CN(C2=O)/N=C/C3=CC=C(O3)C4=CC=C(C=C4)Cl.Cl.Cl,azimilide,Phase 3,potassium channel blocker,P22460
CHEMBL1200396,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,bupivacaine,Launched,sodium channel blocker,P22460
CHEMBL598270,CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(C=C1)Cl.CC1=CC=C(C=C1)S(=O)(=O)[O-],clofilium,Phase 2,potassium channel blocker,P22460
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P22460
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,P22460
CHEMBL4866025,,DPO-1,Preclinical,potassium channel blocker,P22460
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P22460
CHEMBL1200822,CC(=O)O.C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F,flecainide,Launched,sodium channel blocker,P22460
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,P22460
CHEMBL1201063,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O.Cl,propafenone,Launched,antiarrhythmic,P22460
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,P22460
CHEMBL2111112,COC1=C(C=C(C=C1)CCO[C@@H]2CCCC[C@H]2N3CC[C@H](C3)O)OC,vernakalant,Launched,potassium channel blocker,P22460
CHEMBL3650559,C1COCCC1CNC2=CC=C(C=C2)S(=O)(=O)NC(=O)C3=C(C=C(C=C3)N4CCN(CC4)CC5=CC=CC=C5C6=CC=C(C=C6)Cl)OC7=CC=CC(=C7)[N+](=O)[O-],AS-77,Phase 1,potassium channel blocker,O15554
CHEMBL1371,C1=CC2=C(C=C1Cl)NC(=O)O2,chlorzoxazone,Launched,bacterial 30S ribosomal subunit inhibitor,O15554
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,O15554
CHEMBL4866109,,DCEBIO,Preclinical,potassium channel activator,O15554
CHEMBL4858501,,flindokalner,Phase 3,potassium channel agonist,O15554
CHEMBL1200901,CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O.Cl,halofantrine,Launched,antimalarial agent,O15554
CHEMBL4856187,,nitrendipine,Launched,calcium channel blocker,O15554
CHEMBL4877048,,NS-309,Preclinical,calcium-activated potassium channel activator,O15554
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,O15554
CHEMBL2359966,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.O.O.OS(=O)(=O)O,quinine,Launched,hemozoin biocrystallization inhibitor,O15554
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,O15554
CHEMBL405821,C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N,senicapoc,Phase 3,intermediate conductance potassium channel blocker,O15554
CHEMBL1709719,C1=CC=C2C(=C1)C=CC3=C2N=C(S3)N,SKA-31,Preclinical,potassium channel activator,O15554
CHEMBL498270,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4,TRAM-34,Preclinical,potassium channel antagonist,O15554
CHEMBL118687,C1=CC=C(C=C1)C(C#N)(C2=CC=CC=C2)C3=CC=CC=C3Cl,TRAM-39,Preclinical,calcium-activated potassium channel activator,O15554
CHEMBL4870795,,1-EBIO,Preclinical,potassium channel activator,O15554
CHEMBL4549735,CC[C@@H]1/C=C(/C[C@H](C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC)C)\C,ascomycin,Preclinical,calcineurin inhibitor,P62942
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P62942
CHEMBL409571,C[C@@H]1CC2=C(C(=O)C(=C(C2=O)NC(=O)/C(=C/C=C\[C@@H]([C@H](/C(=C/[C@@H]([C@H]([C@H](C1)OC)O)C)/C)OC(=O)N)OC)/C)NCCCCCCCCCNC3=C4NC(=O)/C(=C/C=C\[C@@H]([C@H](/C(=C/[C@@H]([C@H]([C@H](C[C@@H](CC(=C(C3=O)OC)C4=O)C)OC)O)C)/C)OC(=O)N)OC)/C)OC,GM-1485,Preclinical,immunophilin ligand,P62942
CHEMBL4852985,,GPI-1046,Preclinical,FKBP inhibitor,P62942
CHEMBL2074450,,sirolimus,Launched,mTOR inhibitor,P62942
CHEMBL3989887,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC.O,tacrolimus,Launched,calcineurin inhibitor,P62942
CHEMBL4303246,C[C@@H]1CC[C@H]2CC(/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)N5C=NN=N5)C)/C)O)OC)C)C)/C)OC,zotarolimus,Launched,mTOR inhibitor,P62942
CHEMBL196,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,ascorbic-acid,Launched,antioxidant,Q9UGH3
CHEMBL196,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,ascorbic-acid,Launched,antioxidant,Q9UHI7
CHEMBL45068,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O,phloretin,Launched,sodium/glucose cotransporter inhibitor,Q9UGH3
CHEMBL45068,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O,phloretin,Launched,sodium/glucose cotransporter inhibitor,Q9UHI7
CHEMBL4875727,,aspartame,Launched,,Q8TE23
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q04828
CHEMBL4851780,,coenzyme-I,Phase 2,,Q04828
CHEMBL9225,CC[C@H](C1=CC=C(C=C1)O)[C@@H](CC)C2=CC=C(C=C2)O,hexestrol,Launched,synthetic estrogen,Q04828
CHEMBL424,C1=CC=C(C(=C1)C(=O)O)O,salicylic-acid,Launched,cyclooxygenase inhibitor|prostanoid receptor antagonist,Q04828
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P11021
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P25963
CHEMBL4863694,,BAY-11-7085,Preclinical,NFkB pathway inhibitor,P25963
CHEMBL4303714,C1=CC=C(C=C1)CC\2=NN(C(=O)/C2=C/C3=CC=C(O3)C4=CC=CC=C4F)C5=CC=C(C=C5)C(=O)O,GS-143,Preclinical,ubiquitin ligase inhibitor,P25963
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P54646
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,P54619
CHEMBL4303623,CC1=CC(=C(C=C1)OCCSC2=NC=CC=N2)Br,ZLN024,Preclinical,AMPK activator,P54619
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q9UGJ0
CHEMBL25,CC(=O)OC1=CC=CC=C1C(=O)O,aspirin,Launched,cyclooxygenase inhibitor,Q9UGI9
CHEMBL296419,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,astemizole,Withdrawn,histamine receptor antagonist,O95259
CHEMBL598270,CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(C=C1)Cl.CC1=CC=C(C=C1)S(=O)(=O)[O-],clofilium,Phase 2,potassium channel blocker,O95259
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,O95259
CHEMBL4851326,,dofetilide,Withdrawn,potassium channel blocker,O95259
CHEMBL4858730,,E-4031,Phase 1,potassium channel blocker,O95259
CHEMBL1200986,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,haloperidol,Launched,dopamine receptor antagonist,O95259
CHEMBL1692,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,imipramine,Launched,norepinephrine reputake inhibitor|serotonin reuptake inhibitor,O95259
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,O95259
CHEMBL4858222,,terfenadine,Withdrawn,histamine receptor antagonist,O95259
CHEMBL457530,CN(C)C(=NCCC[C@@H](C(=O)O)N)N,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,P29474
CHEMBL457530,CN(C)C(=NCCC[C@@H](C(=O)O)N)N,asymmetrical-dimethylarginine,Phase 1,nitric oxide synthase inhibitor,P60323
CHEMBL4303575,C[C@]12CC[C@H](C1(C)C)[C@@H]([C@@H]2O)O,"cis-exo-camphanediol-2,3",Phase 1,nitric oxide stimulant,P29474
CHEMBL4303575,C[C@]12CC[C@H](C1(C)C)[C@@H]([C@@H]2O)O,"cis-exo-camphanediol-2,3",Phase 1,nitric oxide stimulant,P60323
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P29474
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P60323
CHEMBL365739,C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL365739,C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2,diphenyleneiodonium,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,EIT-hydrobromide,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,EIT-hydrobromide,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL2251729,CCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,fenoxaprop-p-ethyl,Preclinical,,P29474
CHEMBL2251729,CCOC(=O)[C@@H](C)OC1=CC=C(C=C1)OC2=NC3=C(O2)C=C(C=C3)Cl,fenoxaprop-p-ethyl,Preclinical,,P60323
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P29474
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P60323
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P29474
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P60323
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P29474
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P60323
CHEMBL4852530,,L-NAME,Phase 2/Phase 3,nitric oxide synthase inhibitor,P29474
CHEMBL4852530,,L-NAME,Phase 2/Phase 3,nitric oxide synthase inhibitor,P60323
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,P29474
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,P60323
CHEMBL4866537,,S-isopropylisothiourea,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL4866537,,S-isopropylisothiourea,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL1201775,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,P29474
CHEMBL1201775,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,P60323
CHEMBL4855295,,targinine,Phase 3,nitric oxide synthase inhibitor,P29474
CHEMBL4855295,,targinine,Phase 3,nitric oxide synthase inhibitor,P60323
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P29474
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P60323
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,Q9UK32
CHEMBL4877166,,BI-D1870,Preclinical,ribosomal protein inhibitor,Q9UK32
CHEMBL495727,C1CC1NC(=O)NC2=C(NN=C2)C3=NC4=C(N3)C=C(C=C4)CN5CCOCC5,AT-9283,Phase 2,Aurora kinase inhibitor|JAK inhibitor,Q9UEE5
CHEMBL256997,C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F,ataluren,Launched,CFTR channel agonist|dystrophin stimulant,P11532
CHEMBL4851038,,atenolol-(+/-),Launched,adrenergic receptor antagonist,P02788
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,P02788
CHEMBL56367,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,nimesulide,Launched,cyclooxygenase inhibitor,P02788
CHEMBL1206690,CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C,parecoxib,Launched,cyclooxygenase inhibitor,P02788
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N,ATN-161,Phase 2,integrin antagonist,P08648
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N,ATN-161,Phase 2,integrin antagonist,P05556
CHEMBL88478,CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O,BIO-1211,Phase 2,integrin antagonist,P05556
CHEMBL4303683,CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N(C)[C@@H](CC(C)C)C(=O)NCC[C@@H](C(=O)O)NC(=O)[C@@H]3CCCN3S(=O)(=O)C4=CC(=CC(=C4)Cl)Cl,BIO-5192,Preclinical,integrin inhibitor,P05556
CHEMBL4847770,,BTT-3033,Preclinical,integrin inhibitor,P05556
CHEMBL1257246,CC(=CCC[C@]1([C@@H]2CC[C@H]3CC4=C([C@@]3([C@]2(CC[C@@H]1O)C)C)NC5=CC=CC=C45)C)C,SB-683698,Phase 1,integrin antagonist,P05556
CHEMBL4846854,,TC-I-15,Preclinical,integrin inhibitor,P05556
CHEMBL4870452,,TCS-2314,Preclinical,integrin inhibitor,P05556
CHEMBL4297456,CC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)N,ATN-161,Phase 2,integrin antagonist,P05106
CHEMBL4853715,,cilengitide,Phase 3,integrin antagonist,P05106
CHEMBL3678938,C1[C@H]2[C@@H]1N([C@@H](C2)C(=O)NC3=NC(=CC=C3)Br)C(=O)CN4C5=C(C=CN=C5)C(=N4)C(=O)N,DU-728,Phase 1,structural glycoprotein antagonist,P05106
CHEMBL4303580,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,eptifibatide,Launched,platelet aggregation inhibitor,P05106
CHEMBL4854244,,GR-144053,Preclinical,integrin antagonist,P05106
CHEMBL3189072,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O.O.Cl,tirofiban,Launched,platelet aggregation inhibitor|structural glycoprotein antagonist,P05106
CHEMBL4587343,,atorvastatin,Launched,HMGCR inhibitor,P35869
CHEMBL4875140,,CH223191,Preclinical,aryl hydrocarbon receptor antagonist,P35869
CHEMBL231884,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,diosmin,Launched,aryl hydrocarbon receptor agonist|capillary stabilizing agent,P35869
CHEMBL806,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,flutamide,Launched,androgen receptor antagonist,P35869
CHEMBL155625,C1=CC=C2C(=C1)C(=CN2)CO,indole-3-carbinol,Phase 2/Phase 3,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor",P35869
CHEMBL4848280,,ITE,Preclinical,aryl hydrocarbon receptor agonist,P35869
CHEMBL960,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,leflunomide,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,P35869
CHEMBL4855713,,phortress,Phase 1,aryl hydrocarbon receptor ligand,P35869
CHEMBL4303221,CC(C)N1C=NC2=C(N=C(N=C21)C3=CSC4=CC=CC=C43)NCCC5=CC=C(C=C5)O,stemregenin-1,Preclinical,aryl hydrocarbon receptor antagonist,P35869
CHEMBL378642,CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O,atosiban,Launched,oxytocin receptor antagonist,P47901
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,desmopressin-acetate,Launched,vasopressin receptor agonist,P47901
CHEMBL1200690,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N,lypressin,Launched,vasopressin receptor agonist,P47901
CHEMBL5087555,CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C.Cl,mozavaptan,Launched,vasopressin receptor antagonist,P47901
CHEMBL4303358,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,oxytocin,Launched,oxytocin receptor agonist,P47901
CHEMBL4862361,,relcovaptan,Phase 2,vasopressin receptor antagonist,P47901
CHEMBL1201528,,vasopressin,Launched,vasopressin receptor agonist,P47901
CHEMBL378642,CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O,atosiban,Launched,oxytocin receptor antagonist,P30518
CHEMBL1755,CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6,conivaptan,Launched,vasopressin receptor antagonist,P30518
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,desmopressin-acetate,Launched,vasopressin receptor agonist,P30518
CHEMBL4858531,,L-368899,Phase 1,oxytocin receptor antagonist,P30518
CHEMBL4861448,,lixivaptan,Phase 3,vasopressin receptor antagonist,P30518
CHEMBL1200690,C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N,lypressin,Launched,vasopressin receptor agonist,P30518
CHEMBL5087555,CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C.Cl,mozavaptan,Launched,vasopressin receptor antagonist,P30518
CHEMBL1126531,,OPC-21268,Phase 1,vasopressin receptor antagonist,P30518
CHEMBL4303358,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,oxytocin,Launched,oxytocin receptor agonist,P30518
CHEMBL4862361,,relcovaptan,Phase 2,vasopressin receptor antagonist,P30518
CHEMBL344159,CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C,tolvaptan,Launched,vasopressin receptor antagonist,P30518
CHEMBL1201528,,vasopressin,Launched,vasopressin receptor agonist,P30518
CHEMBL378642,CC[C@H](C)[C@H]1C(=O)NC(C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O,atosiban,Launched,oxytocin receptor antagonist,P30559
CHEMBL3301668,CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)OC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,carbetocin,Launched,oxytocin receptor agonist,P30559
CHEMBL1200556,CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N,desmopressin-acetate,Launched,vasopressin receptor agonist,P30559
CHEMBL4858531,,L-368899,Phase 1,oxytocin receptor antagonist,P30559
CHEMBL1126531,,OPC-21268,Phase 1,vasopressin receptor antagonist,P30559
CHEMBL4846117,,OT-R-antagonist-1,Preclinical,oxytocin receptor antagonist,P30559
CHEMBL4303358,CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N,oxytocin,Launched,oxytocin receptor agonist,P30559
CHEMBL594828,COCC1=NN=C(N1C2=CN=C(C=C2)OC)N3CC(C3)OC4=C(C=C(C=C4)F)Cl,PF-3274167,Phase 2,oxytocin receptor antagonist,P30559
CHEMBL4862361,,relcovaptan,Phase 2,vasopressin receptor antagonist,P30559
CHEMBL1201528,,vasopressin,Launched,vasopressin receptor agonist,P30559
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,O75116
CHEMBL541388,C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl,fasudil,Launched,rho associated kinase inhibitor,O75116
CHEMBL4878360,,GSK269962,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL2005186,CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5,KD025,Phase 2,rho associated kinase inhibitor,O75116
CHEMBL4866305,,LX7101,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,O75116
CHEMBL4303164,C1=CC=C(C(=C1)CNCC2=CC=C(C=C2)C3=C4C=CNC4=NC=C3)F,OXA-06,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL3426621,C[C@H]1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)F,ripasudil,Launched,rho associated kinase inhibitor,O75116
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL4860229,,SB-772077B,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL4876169,,SR-3677,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,O75116
CHEMBL571948,C[C@H](C1=CC=C(C=C1)C(=O)NC2=C3C=CNC3=NC=C2)N,Y-39983,Phase 2,rho associated kinase inhibitor,O75116
CHEMBL4850392,,AT13148,Phase 1,protein kinase inhibitor,Q96BR1
CHEMBL1366,,auranofin,Launched,NFkB pathway inhibitor,P30044
CHEMBL887937,,benzoic-acid,Launched,food preservative,P30044
CHEMBL380216,CC(=O)NCC(=O)O.CC(=O)NCC(=O)O.C1=CC(=CC=C1C(=N)N)NN=NC2=CC=C(C=C2)C(=N)N,diminazene-aceturate,Phase 3,angiotensin converting enzyme activator,P30044
CHEMBL2354773,,aurothioglucose,Launched,PKC inhibitor,P41743
CHEMBL4872220,,GF109203X,Preclinical,PKC inhibitor,P41743
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P41743
CHEMBL4303662,C[C@H](C1=CC2=C(C=C1)C=CC(=C2C(F)(F)F)OC3CCC(CC3)C(F)(F)F)N4C5CCC4CC(C5)C(=O)O,autotaxin-modulator-1,Preclinical,autotaxin inhibitor,Q13822
CHEMBL4857687,,HA-130,Preclinical,autotaxin inhibitor,Q13822
CHEMBL4878704,,PF-8380,Preclinical,autotaxin inhibitor,Q13822
CHEMBL4861130,,avagacestat,Phase 2,gamma secretase inhibitor,P49768
CHEMBL4848668,,begacestat,Phase 1,gamma secretase inhibitor,P49768
CHEMBL4536273,C[C@H](C1=CC(=C(C=C1)C2=CC(=C(C=C2)Cl)Cl)F)C(=O)O,CHF5074,Phase 2,gamma secretase modulator,P49768
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,P49768
CHEMBL4857190,,JLK-6,Preclinical,gamma secretase inhibitor,P49768
CHEMBL4297422,CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3NC1=O,RG4733,Phase 2,gamma secretase inhibitor,P49768
CHEMBL4303339,C[C@@H](C(=O)N[C@@H]1C2=CC=CC=C2CCN(C1=O)C)NC(=O)[C@H](C(C)C)O,semagacestat,Phase 3,gamma secretase inhibitor,P49768
CHEMBL2103883,C1CCC(CC1)N2CCN(CC2)C3=C(N=C(S3)NC(=O)C4=CC(=C(N=C4)N5CCC(CC5)C(=O)O)Cl)C6=CC(=CS6)Cl,avatrombopag,Launched,thrombopoietin receptor agonist,P40238
CHEMBL3989691,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N,eltrombopag,Launched,thrombopoietin receptor agonist,P40238
CHEMBL4862253,,AVE-0991,Preclinical,angiotensin receptor agonist,Q96LB2
CHEMBL4297165,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.Cl.Cl,chloroquine,Launched,antimalarial agent,Q96LB2
CHEMBL4851455,,AVL-292,Phase 2,Bruton's tyrosine kinase (BTK) inhibitor,P07947
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P07947
CHEMBL4438584,CN1CCN(CC1)CCOC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6,saracatinib,Phase 2/Phase 3,SRC inhibitor,P07947
CHEMBL3349001,CC[C@H](CC#N)OC(=O)N[C@@H](C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C3=CN=CO3)OC,AVN-944,Phase 2,inosine monophosphate dehydrogenase inhibitor,P12268
CHEMBL4860028,,BMS-566419,Preclinical,inosine monophosphate dehydrogenase inhibitor,P12268
CHEMBL4851780,,coenzyme-I,Phase 2,,P12268
CHEMBL1425,C1=NC2=C(N1)C(=S)N=CN2,mercaptopurine,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,P12268
CHEMBL1456,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,mycophenolate-mofetil,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,P12268
CHEMBL1908143,,mycophenolic-acid,Launched,dehydrogenase inhibitor|inositol monophosphatase inhibitor,P12268
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P12268
CHEMBL277150,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O,polyinosine,Preclinical,immunostimulant,P12268
CHEMBL4851831,,ribavirin,Launched,antiviral,P12268
CHEMBL727,C1=NC2=C(N1)C(=S)N=C(N2)N,thioguanine,Launched,purine antagonist,P12268
CHEMBL1289926,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09603
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P09603
CHEMBL1289926,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL3526086,,brivanib,Phase 3,FGFR inhibitor|VEGFR inhibitor,P17948
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P17948
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P17948
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL1230609,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,foretinib,Phase 2,VEGFR inhibitor,P17948
CHEMBL4874827,,KRN-633,Preclinical,VEGFR inhibitor,P17948
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL2220486,CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC,lucitanib,Phase 2,FGFR inhibitor|VEGFR inhibitor,P17948
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P17948
CHEMBL2107357,CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O,motesanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P17948
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL4847840,,OSI-930,Phase 1,KIT inhibitor|VEGFR inhibitor,P17948
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P17948
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P17948
CHEMBL4856468,,semaxanib,Phase 3,VEGFR inhibitor,P17948
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P17948
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P17948
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P17948
CHEMBL2103833,CC1=C(NC(=C1C(=O)NCCN2CCCC2)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O.OP(=O)(O)O,toceranib,Launched,protein tyrosine kinase inhibitor,P17948
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P17948
CHEMBL4848946,,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P17948
CHEMBL4865501,,ZM-306416,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,P17948
CHEMBL1289926,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL491473,CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5,cediranib,Phase 3,KIT inhibitor|VEGFR inhibitor,P35916
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL1230609,COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F,foretinib,Phase 2,VEGFR inhibitor,P35916
CHEMBL4874827,,KRN-633,Preclinical,VEGFR inhibitor,P35916
CHEMBL1289601,COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl,lenvatinib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL4871668,,linifanib,Phase 3,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,P35916
CHEMBL2107357,CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O,motesanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35916
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P35916
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35916
CHEMBL4861179,,SAR131675,Preclinical,VEGFR inhibitor,P35916
CHEMBL535,CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C,sunitinib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35916
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P35916
CHEMBL1289494,CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl,tivozanib,Launched,VEGFR inhibitor,P35916
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P35916
CHEMBL4848946,,vatalanib,Phase 3,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P35916
CHEMBL3544983,CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,P35916
CHEMBL4865501,,ZM-306416,Preclinical,Abl kinase inhibitor|SRC inhibitor|VEGFR inhibitor,P35916
CHEMBL1289926,CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4,axitinib,Launched,PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,O00444
CHEMBL4857157,,XMD8-92,Preclinical,MAP kinase inhibitor,O00444
CHEMBL4870419,,AZ-12080282,Preclinical,hedgehog pathway inhibitor,O43323
CHEMBL4861844,,CUR-61414,Phase 1,smoothened receptor antagonist,O43323
CHEMBL4857465,,M-25,Preclinical,smoothened receptor antagonist,O43323
CHEMBL2142592,CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F,taladegib,Phase 2,smoothened receptor antagonist,O43323
CHEMBL4848028,,AZ-628,Preclinical,RAF inhibitor,P15056
CHEMBL4848396,,CEP-32496,Phase 1/Phase 2,RAF inhibitor,P15056
CHEMBL2105729,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O,dabrafenib,Launched,RAF inhibitor,P15056
CHEMBL4303479,CC(C)N1C=C(C(=N1)C2=C(C(=CC(=C2)Cl)NS(=O)(=O)C)F)C3=NC(=NC=C3)NCC(C)NC(=O)OC,encorafenib,Launched,RAF inhibitor,P15056
CHEMBL2139930,C1CC(=NO)C2=C1C=C(C=C2)C3=CN(N=C3C4=CC=NC=C4)CCO,GDC-0879,Preclinical,RAF inhibitor,P15056
CHEMBL3932957,CSC1=NC(=CC(=N1)OC2=CC=C(C=C2)C3=NC(=NN3)NC4=CC=CC(=C4)C(F)(F)F)N,KG-5,Preclinical,RAF inhibitor,P15056
CHEMBL4866069,,LY3009120,Phase 1,RAF inhibitor,P15056
CHEMBL1688861,CC(C)(C1=CC(=CC(=C1)C(=O)N[C@@H]2CCC3=C(C2)C=C(C=C3)OC4=C5CCC(=O)NC5=NC=C4)C(F)(F)F)N,ML786,Preclinical,RAF inhibitor,P15056
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P15056
CHEMBL3751850,,PLX4720,Preclinical,RAF inhibitor,P15056
CHEMBL4303729,C1CN(C[C@@H]1F)S(=O)(=O)NC2=C(C(=C(C=C2)F)C(=O)C3=CNC4=C3C=C(C=N4)C5=CN=C(N=C5)C6CC6)F,PLX8394,Phase 1/Phase 2,serine/threonine kinase inhibitor,P15056
CHEMBL4873496,,RAF265,Phase 2,RAF inhibitor|VEGFR inhibitor,P15056
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P15056
CHEMBL4303496,CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C3=CC=C(C=C3)F,Ro-5126766,Phase 1,MEK inhibitor|RAF inhibitor,P15056
CHEMBL1909414,CN(C)CCOC1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC5=C(C=C4)/C(=N/O)/CC5.O.Cl,SB-590885,Preclinical,RAF inhibitor,P15056
CHEMBL4863757,,TAK-632,Preclinical,RAF inhibitor,P15056
CHEMBL1229517,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,vemurafenib,Launched,RAF inhibitor,P15056
CHEMBL4851744,,ZM-336372,Preclinical,RAF inhibitor,P15056
CHEMBL4848028,,AZ-628,Preclinical,RAF inhibitor,P04049
CHEMBL4848396,,CEP-32496,Phase 1/Phase 2,RAF inhibitor,P04049
CHEMBL2105729,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O,dabrafenib,Launched,RAF inhibitor,P04049
CHEMBL4858976,,GW-5074,Phase 1/Phase 2,leucine rich repeat kinase inhibitor|RAF inhibitor,P04049
CHEMBL4866069,,LY3009120,Phase 1,RAF inhibitor,P04049
CHEMBL1688861,CC(C)(C1=CC(=CC(=C1)C(=O)N[C@@H]2CCC3=C(C2)C=C(C=C3)OC4=C5CCC(=O)NC5=NC=C4)C(F)(F)F)N,ML786,Preclinical,RAF inhibitor,P04049
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P04049
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P04049
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P04049
CHEMBL4303496,CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C3=CC=C(C=C3)F,Ro-5126766,Phase 1,MEK inhibitor|RAF inhibitor,P04049
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P04049
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P04049
CHEMBL1229517,CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F,vemurafenib,Launched,RAF inhibitor,P04049
CHEMBL4851744,,ZM-336372,Preclinical,RAF inhibitor,P04049
CHEMBL4866555,,azacitidine,Launched,DNA methyltransferase inhibitor,P26358
CHEMBL4874650,,decitabine,Launched,DNA methyltransferase inhibitor,P26358
CHEMBL1201073,[C@@H]([C@@H](C(=O)O)S)(C(=O)O)S,dimercaptosuccinic-acid,Launched,chelating agent,P26358
CHEMBL4859503,,flucytosine,Launched,other antifungal,P26358
CHEMBL640,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,procainamide,Launched,sodium channel blocker,P26358
CHEMBL4871024,,RG108,Preclinical,DNA methyltransferase inhibitor,P26358
CHEMBL4877589,,RX-3117,Phase 1/Phase 2,CDK inhibitor|DNA synthesis inhibitor,P26358
CHEMBL4875941,,SGI-1027,Preclinical,DNA methyltransferase inhibitor,P26358
CHEMBL1086440,CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl,triclabendazole,Launched,microtubule inhibitor,P26358
CHEMBL849,C1=CC(=C(C=C1Cl)O)OC2=C(C=C(C=C2)Cl)Cl,triclosan,Launched,antibacterial agent,P26358
CHEMBL4856673,,zebularine,Preclinical,DNA methyltransferase inhibitor,P26358
CHEMBL4866555,,azacitidine,Launched,DNA methyltransferase inhibitor,Q9Y6K1
CHEMBL4874650,,decitabine,Launched,DNA methyltransferase inhibitor,Q9Y6K1
CHEMBL4875941,,SGI-1027,Preclinical,DNA methyltransferase inhibitor,Q9Y6K1
CHEMBL1598608,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,azasetron,Launched,serotonin receptor antagonist,O95264
CHEMBL376379,CN1C2CCC1CC(C2)OC(=O)C3=CC(=CC(=C3)Cl)Cl,bemesetron,Phase 3,serotonin receptor antagonist,O95264
CHEMBL3348958,CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,bilobalide,Preclinical,GABA receptor modulator,O95264
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,O95264
CHEMBL4864535,,m-chlorophenylbiguanide,Preclinical,serotonin receptor agonist,O95264
CHEMBL2303628,CN1C[C@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)NS(=O)(=O)N(C)C.Cl,mesulergine,Phase 2,dopamine receptor agonist,O95264
CHEMBL4849292,,2-methyl-5-hydroxytryptamine,Preclinical,serotonin receptor agonist,O95264
CHEMBL1200940,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl.O.Cl,metoclopramide,Launched,dopamine receptor antagonist|serotonin receptor antagonist,O95264
CHEMBL4138046,,ML10302,Preclinical,serotonin receptor partial agonist,O95264
CHEMBL3186492,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl,ondansetron,Launched,serotonin receptor antagonist,O95264
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,O95264
CHEMBL1315073,C1NCCN(C1)C2=NC3=CC=CC=C3C=C2.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,quipazine,Preclinical,serotonin receptor agonist,O95264
CHEMBL4861596,,SDZ-205-557,Preclinical,serotonin receptor antagonist,O95264
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,O95264
CHEMBL1742402,CC1=CC(=CC(=C1)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)C,"tropanyl-3,5-dimethylbenzoate",Preclinical,serotonin receptor antagonist,O95264
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,O95264
CHEMBL261010,CN1CCN(CC1)C2=NC3=CC=CC=C3N=C2Cl,VUF10166,Preclinical,serotonin receptor antagonist,O95264
CHEMBL1516756,COC1=CC(=C(C=C1C(=O)NC2CN3CCC2CC3)Cl)N.O.Cl,zacopride,Phase 2,serotonin receptor antagonist,O95264
CHEMBL3039205,C1=CC=C(C=C1)N=C(N)N=C(N)N.Cl,1-phenylbiguanide,Preclinical,serotonin receptor agonist,O95264
CHEMBL1200400,CN1C=NC(=C1SC2=NC=NC3=C2N=C[N-]3)[N+](=O)[O-].[Na+],azathioprine,Launched,dehydrogenase inhibitor,P00492
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P00492
CHEMBL1425,C1=NC2=C(N1)C(=S)N=CN2,mercaptopurine,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,P00492
CHEMBL277150,C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)O)O)O,polyinosine,Preclinical,immunostimulant,P00492
CHEMBL1200400,CN1C=NC(=C1SC2=NC=NC3=C2N=C[N-]3)[N+](=O)[O-].[Na+],azathioprine,Launched,dehydrogenase inhibitor,Q06203
CHEMBL3707366,C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N,L-glutamine,Launched,,Q06203
CHEMBL1425,C1=NC2=C(N1)C(=S)N=CN2,mercaptopurine,Launched,immunosuppressant|protein synthesis inhibitor|purine antagonist,Q06203
CHEMBL4879359,,AZD1208,Phase 1,Pim kinase inhibitor,Q9P1W9
CHEMBL4846077,,SGI-1776,Phase 1,Pim kinase inhibitor,Q9P1W9
CHEMBL4879359,,AZD1208,Phase 1,Pim kinase inhibitor,Q86V86
CHEMBL4846077,,SGI-1776,Phase 1,Pim kinase inhibitor,Q86V86
CHEMBL4849176,,AZD1283,Preclinical,purinergic receptor antagonist,Q9H244
CHEMBL1771,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,clopidogrel,Launched,purinergic receptor antagonist,Q9H244
CHEMBL2103828,CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F,elinogrel,Phase 2,purinergic receptor antagonist,Q9H244
CHEMBL962,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+],epoprostenol,Launched,prostacyclin analog,Q9H244
CHEMBL1201772,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,prasugrel,Launched,purinergic receptor antagonist,Q9H244
CHEMBL4303245,CCCSC1=NC(=C2C(=N1)N(N=N2)[C@@H]3C[C@@H]([C@@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@@H]4C5=CC(=C(C=C5)F)F,ticagrelor,Launched,purinergic receptor antagonist,Q9H244
CHEMBL833,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,ticlopidine,Launched,purinergic receptor antagonist,Q9H244
CHEMBL1237119,CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,treprostinil,Launched,prostanoid receptor agonist,Q9H244
CHEMBL3112447,,AZD1480,Phase 1,JAK inhibitor,P23458
CHEMBL2105759,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,baricitinib,Launched,JAK inhibitor,P23458
CHEMBL4303567,C[C@H]1CC[C@@H]2[C@]13C[C@H]([C@](O3)(CC2=C)O)C(C)C,curcumol,Phase 1,JAK inhibitor,P23458
CHEMBL4863704,,cyt387,Phase 3,JAK inhibitor,P23458
CHEMBL4297216,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,P23458
CHEMBL3301607,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,filgotinib,Phase 3,JAK inhibitor,P23458
CHEMBL4862271,,itacitinib,Phase 3,JAK inhibitor,P23458
CHEMBL3545217,,NS-018,Phase 1/Phase 2,JAK inhibitor,P23458
CHEMBL4778465,C1CCN(C1)CCOC2=C3COC/C=C\COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2,pacritinib,Phase 3,FLT3 inhibitor|JAK inhibitor,P23458
CHEMBL4536840,C1[C@@H]2CC3(C[C@@H](C2NC4=C5C=CNC5=NC=C4C(=O)N)CC1C3)O,peficitinib,Launched,JAK inhibitor,P23458
CHEMBL1789941,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib,Launched,JAK inhibitor,P23458
CHEMBL1287854,C1CCC(C1)[C@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib-(S),Preclinical,JAK inhibitor,P23458
CHEMBL3301606,CC1(CN(C1)C(=O)C2=CC=C(C=C2)C3=CC=CC4=NC(=NN43)NC(=O)C5CC5)C,solcitinib,Phase 1,JAK inhibitor,P23458
CHEMBL2103743,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O,tofacitinib,Launched,JAK inhibitor,P23458
CHEMBL4877936,,WHI-P154,Preclinical,JAK inhibitor,P23458
CHEMBL4871051,,XL019,Phase 1,JAK inhibitor,P23458
CHEMBL4849222,,ZM-39923,Preclinical,JAK inhibitor,P23458
CHEMBL4866402,,AZD1981,Phase 2,CRTH receptor antagonist,Q9Y5Y4
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,Q9Y5Y4
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,Q9Y5Y4
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,Q9Y5Y4
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,Q9Y5Y4
CHEMBL4864186,,OC000459,Phase 2,CRTH receptor antagonist,Q9Y5Y4
CHEMBL4852673,,ramatroban,Launched,prostanoid receptor antagonist,Q9Y5Y4
CHEMBL2386081,C1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54,setipiprant,Phase 3,prostaglandin inhibitor,Q9Y5Y4
CHEMBL3989403,CC1=C(N(C(=C1)CC(=O)[O-])C)C(=O)C2=CC=C(C=C2)Cl.O.O.[Na+],zomepirac,Withdrawn,prostaglandin synthesis inhibitor,Q9Y5Y4
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P21549
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,P21549
CHEMBL4872529,,MC-1,Phase 3,,P21549
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q9BYV1
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q9BYV1
CHEMBL4872529,,MC-1,Phase 3,,Q9BYV1
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P13196
CHEMBL4872529,,MC-1,Phase 3,,P13196
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P22557
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q14032
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P41250
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P50440
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P50440
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,O75600
CHEMBL4872529,,MC-1,Phase 3,,O75600
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P23434
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P23378
CHEMBL4872529,,MC-1,Phase 3,,P23378
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P23416
CHEMBL3348958,CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,bilobalide,Preclinical,GABA receptor modulator,P23416
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P23416
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,P23416
CHEMBL15891,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,lindane,Launched,,P23416
CHEMBL478523,C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O,picrotin,Phase 2,GABA receptor antagonist,P23416
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,P23416
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P23416
CHEMBL4303202,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl,tropisetron,Launched,serotonin receptor antagonist,P23416
CHEMBL749368,,"5,7-dichlorokynurenic-acid",Preclinical,glutamate receptor antagonist,P23416
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,O75311
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,O75311
CHEMBL15891,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,lindane,Launched,,O75311
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,O75311
CHEMBL478523,C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O,picrotin,Phase 2,GABA receptor antagonist,O75311
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,O75311
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,O75311
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P48167
CHEMBL3348958,CC(C)(C)[C@@]1(C[C@H]2[C@@]3(C14[C@H](C(=O)O[C@H]4OC3=O)O)CC(=O)O2)O,bilobalide,Preclinical,GABA receptor modulator,P48167
CHEMBL1257,C(C(OC(F)F)(F)F)(F)Cl,enflurane,Launched,membrane permeability inhibitor,P48167
CHEMBL4847684,,gavestinel,Phase 3,glutamate receptor antagonist,P48167
CHEMBL465161,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3(C2)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-A,Preclinical,GABA receptor antagonist,P48167
CHEMBL549485,C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5C3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O,ginkgolide-B,Phase 3,platelet activating factor receptor antagonist,P48167
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,P48167
CHEMBL1256,C(C(F)(F)F)(OC(F)F)Cl,isoflurane,Launched,inhaled anaesthetic,P48167
CHEMBL15891,C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl,lindane,Launched,,P48167
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P48167
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,P48167
CHEMBL4868603,,ORG-25543,Preclinical,glycine transporter inhibitor,P48167
CHEMBL478523,C[C@@]12[C@H]3[C@H]4[C@H]([C@@H]([C@@]1(C[C@@H]5[C@]2(O5)C(=O)O3)O)C(=O)O4)C(C)(C)O,picrotin,Phase 2,GABA receptor antagonist,P48167
CHEMBL2135566,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,picrotoxinin,Preclinical,GABA receptor antagonist,P48167
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P48167
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,P48167
CHEMBL213907,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)SC)OC)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,thiocolchicoside,Launched,GABA receptor antagonist,P48167
CHEMBL4303202,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl,tropisetron,Launched,serotonin receptor antagonist,P48167
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q6IB77
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q969I3
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q8WU03
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q14749
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q14749
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q5T6X5
CHEMBL3707366,C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N,L-glutamine,Launched,,Q5T6X5
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q5T6X5
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,Q5T6X5
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q5T6X5
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,Q5T6X5
CHEMBL446143,C(C[C@@H](C(=O)O)N)CN,ornithine,Launched,NFkB pathway modulator,Q5T6X5
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q9P0Z9
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P34896
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,mimosine,Preclinical,DNA replication inhibitor,P34896
CHEMBL4872529,,MC-1,Phase 3,,P34896
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,P34897
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,mimosine,Preclinical,DNA replication inhibitor,P34897
CHEMBL4872529,,MC-1,Phase 3,,P34897
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q9H598
CHEMBL4303352,C=CC(CCC(=O)O)N.Cl,vigabatrin,Launched,GABA aminotransferase inhibitor,Q9H598
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q7Z2H8
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q7Z2H8
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,Q7Z2H8
CHEMBL4853317,,tryptophan,Launched,serotonin receptor partial agonist,Q7Z2H8
CHEMBL4297402,CC1=NN=NN1N=CC2=CC(=C(C=C2)O)C(C3=CC=C(C=C3)O)C4=C(C=CC(=C4)C=NN5C(=NN=N5)C)O,VP-20629,Phase 1,beta amyloid antagonist,Q7Z2H8
CHEMBL4870839,,5-hydroxytryptophan,Launched,neurotransmitter,Q7Z2H8
CHEMBL773,C(C(=O)O)N,AZD4282,Phase 1,glutamate receptor antagonist,Q9Y345
CHEMBL4858256,,bitopertin,Phase 3,glycine transporter inhibitor,Q9Y345
CHEMBL4868603,,ORG-25543,Preclinical,glycine transporter inhibitor,Q9Y345
CHEMBL4872204,,AZD4547,Phase 2/Phase 3,FGFR inhibitor,P22455
CHEMBL4860389,,BLU9931,Preclinical,FGFR inhibitor,P22455
CHEMBL3545376,CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC,erdafitinib,Launched,FGFR inhibitor,P22455
CHEMBL4796872,C[C@@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO,LY2874455,Phase 1,FGFR antagonist,P22455
CHEMBL3039504,CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O,nintedanib,Launched,FGFR inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P22455
CHEMBL4854312,,NVP-BGJ398,Phase 3,FGFR inhibitor,P22455
CHEMBL189584,CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C,PD-173074,Preclinical,FGFR inhibitor|VEGFR inhibitor,P22455
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P22455
CHEMBL4856999,,AZD5582,Preclinical,XIAP inhibitor,Q13490
CHEMBL3804787,,birinapant,Phase 2,XIAP inhibitor,Q13490
CHEMBL4847101,,GDC-0152,Phase 1,XIAP inhibitor,Q13490
CHEMBL2431768,C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC,LCL-161,Phase 2,XIAP inhibitor,Q13490
CHEMBL4877609,,SM-164,Preclinical,XIAP inhibitor,Q13490
CHEMBL4856999,,AZD5582,Preclinical,XIAP inhibitor,Q13489
CHEMBL4847101,,GDC-0152,Phase 1,XIAP inhibitor,Q13489
CHEMBL4877609,,SM-164,Preclinical,XIAP inhibitor,Q13489
CHEMBL4856999,,AZD5582,Preclinical,XIAP inhibitor,P98170
CHEMBL3804787,,birinapant,Phase 2,XIAP inhibitor,P98170
CHEMBL197201,,cisplatin,Launched,DNA alkylating agent|DNA synthesis inhibitor,P98170
CHEMBL4863516,,CUDC-427,Phase 1,apoptosis inhibitor,P98170
CHEMBL221137,CCCCCCCCCCCC1=C(C(=O)C=C(C1=O)O)O,embelin,Preclinical,HCV inhibitor|XIAP inhibitor,P98170
CHEMBL4847101,,GDC-0152,Phase 1,XIAP inhibitor,P98170
CHEMBL2431768,C[C@@H](C(=O)N[C@@H](C1CCCCC1)C(=O)N2CCC[C@H]2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC,LCL-161,Phase 2,XIAP inhibitor,P98170
CHEMBL4877609,,SM-164,Preclinical,XIAP inhibitor,P98170
CHEMBL1527537,C1CCN(C1)CC2=CC(=C3C=CC=NC3=C2O)COCC4=CC=CC=C4,UC-112,Preclinical,XIAP inhibitor,P98170
CHEMBL4864823,,AZD6738,Phase 2,ATR kinase inhibitor,P20848
CHEMBL4864823,,AZD6738,Phase 2,ATR kinase inhibitor,Q13535
CHEMBL4864823,,AZD6738,Phase 2,ATR kinase inhibitor,Q9H6X2
CHEMBL4859631,,AZ20,Preclinical,ATR kinase inhibitor,P20848
CHEMBL4859631,,AZ20,Preclinical,ATR kinase inhibitor,Q13535
CHEMBL4859631,,AZ20,Preclinical,ATR kinase inhibitor,Q9H6X2
CHEMBL4866540,,CGK-733,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,P20848
CHEMBL4866540,,CGK-733,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,Q13535
CHEMBL4866540,,CGK-733,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,Q9H6X2
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,P20848
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,Q13535
CHEMBL4857602,,NVP-BEZ235,Phase 3,mTOR inhibitor|PI3K inhibitor,Q9H6X2
CHEMBL4303410,C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@@H]1C)OC)OC)OC)OC)OCO3,schisandrin-B,Preclinical,antioxidant,P20848
CHEMBL4303410,C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@@H]1C)OC)OC)OC)OC)OCO3,schisandrin-B,Preclinical,antioxidant,Q13535
CHEMBL4303410,C[C@H]1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4C[C@@H]1C)OC)OC)OC)OC)OCO3,schisandrin-B,Preclinical,antioxidant,Q9H6X2
CHEMBL4854004,,VE-821,Preclinical,ATR kinase inhibitor,P20848
CHEMBL4854004,,VE-821,Preclinical,ATR kinase inhibitor,Q13535
CHEMBL4854004,,VE-821,Preclinical,ATR kinase inhibitor,Q9H6X2
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,P20848
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,Q13535
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,Q9H6X2
CHEMBL3392645,CC(C(=O)NC1=C(C=C(C=C1)S(=O)(=O)C2=CC=C(C=C2)C(=O)N(C)C)Cl)(C(F)(F)F)O,AZD7545,Phase 1,pyruvate dehydrogenase kinase inhibitor,Q15118
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,Q15118
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,Q15118
CHEMBL4864372,,AZD7762,Phase 1,CHK inhibitor,O14757
CHEMBL4867116,,BX-795,Preclinical,IKK inhibitor,O14757
CHEMBL3916849,C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br,BX-912,Preclinical,pyruvate dehydrogenase kinase inhibitor,O14757
CHEMBL4855987,,CHIR-124,Preclinical,CHK inhibitor,O14757
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,O14757
CHEMBL4878525,,LY2603618,Phase 2,CHK inhibitor,O14757
CHEMBL3544911,COC1=C(C(=CC=C1)OCCCN)C2=CC(=NN2)NC3=NC=C(N=C3)C#N,LY2606368,Phase 2,CHK inhibitor,O14757
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,O14757
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,O14757
CHEMBL4860355,,PF-477736,Phase 1,CHK inhibitor,O14757
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,O14757
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,O14757
CHEMBL4856801,,SB-218078,Preclinical,CHK inhibitor,O14757
CHEMBL4877269,,SCH-900776,Phase 2,CHK inhibitor,O14757
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,O14757
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,O14757
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,O14757
CHEMBL4864372,,AZD7762,Phase 1,CHK inhibitor,O96017
CHEMBL4860355,,PF-477736,Phase 1,CHK inhibitor,O96017
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,O96017
CHEMBL4871171,,AZD8330,Phase 1,MEK inhibitor,Q13233
CHEMBL1240295,,PD-184352,Phase 2,MEK inhibitor,Q13233
CHEMBL4860251,,AZD8931,Phase 2,EGFR inhibitor,P21860
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P21860
CHEMBL4870392,,WAY-200070,Preclinical,estrogen receptor agonist,P21860
CHEMBL3617964,CC1=C(C=C(C(=O)N1C2=CC=CC(=C2)C(F)(F)F)C(=O)NCC3=NC=C(C=C3)S(=O)(=O)C)C4=CC=NN4C,AZD9668,Phase 2,elastase inhibitor,P08246
CHEMBL270515,B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,delanzomib,Phase 1/Phase 2,proteasome inhibitor,P08246
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,P08246
CHEMBL25892,CC(C)C(C(=O)C1=NN=C(O1)C(C)(C)C)NC(=O)CN2C(=NC=C(C2=O)N)C3=CC=CC=C3,freselestat,Preclinical,elastase inhibitor,P08246
CHEMBL4303679,CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC,GW-311616,Phase 1,elastase inhibitor|leukocyte elastase inhibitor,P08246
CHEMBL76688,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O,sivelestat,Launched,elastase inhibitor,P08246
CHEMBL1238,C(CCCC(=O)O)CCCC(=O)O,azelaic-acid,Launched,tyrosinase inhibitor,P51857
CHEMBL4777013,C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,finasteride,Launched,5 alpha reductase inhibitor,P51857
CHEMBL1238,C(CCCC(=O)O)CCCC(=O)O,azelaic-acid,Launched,tyrosinase inhibitor,P31213
CHEMBL1200969,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C,dutasteride,Launched,5 alpha reductase inhibitor,P31213
CHEMBL4777013,C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,finasteride,Launched,5 alpha reductase inhibitor,P31213
CHEMBL3989929,CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC,azeliragon,Phase 3,RAGE receptor antagonist,Q15109
CHEMBL1491875,CC1=NC=C(C(=N1)N)CN(C=O)/C(=C(\CCOP(=O)(O)O)/SC(=O)C2=CC=CC=C2)/C,benfotiamine,Launched,antioxidant,Q15109
CHEMBL4075936,C1CCC(CC1)N(CC2=CC=CC=C2)C(=O)C3=CC=C(C=C3)Cl,FPS-ZM1,Preclinical,RAGE receptor antagonist,Q15109
CHEMBL2028661,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C,azilsartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL2028661,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C,azilsartan-medoxomil,Launched,angiotensin receptor antagonist,P30556
CHEMBL4852359,,candesartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL4861126,,carboxylosartan,Phase 1,angiotensin antagonist,P30556
CHEMBL408403,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,delivert,Launched,angiotensin receptor agonist,P30556
CHEMBL4867782,,EMD-66684,Preclinical,angiotensin receptor antagonist,P30556
CHEMBL1200987,CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\CC3=CC=CS3)/C(=O)O.CS(=O)(=O)O,eprosartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL1951143,CCCCC1=NC(=C(C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CC(=S)N(C)C)C,fimasartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL4850556,,GBR-12935,Preclinical,dopamine reuptake inhibitor,P30556
CHEMBL4863545,,irbesartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL4865249,,losartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL1200692,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O,olmesartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL1200692,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O,olmesartan-medoxomil,Launched,angiotensin receptor antagonist,P30556
CHEMBL1017,CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C,telmisartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL1069,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,valsartan,Launched,angiotensin receptor antagonist,P30556
CHEMBL4879277,,ZD-7155,Preclinical,angiotensin receptor antagonist,P30556
CHEMBL2028661,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C,azilsartan,Launched,angiotensin receptor antagonist,P50052
CHEMBL2028661,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C,azilsartan-medoxomil,Launched,angiotensin receptor antagonist,P50052
CHEMBL408403,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,delivert,Launched,angiotensin receptor agonist,P50052
CHEMBL4874904,,PD-123319,Phase 1,angiotensin antagonist,P50052
CHEMBL4299381,CC[C@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@@H]([C@@H]([C@H](C(=O)O1)C)O[C@@H]2C[C@]([C@@H]([C@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,azithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,O43193
CHEMBL4860204,,camicinal,Phase 2,motilin receptor agonist,O43193
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin,Launched,NFkB pathway inhibitor,O43193
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,O43193
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,O43193
CHEMBL1214185,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,roxithromycin,Launched,bacterial 50S ribosomal subunit inhibitor,O43193
CHEMBL3545150,,AZM-475271,Preclinical,SRC inhibitor,P12931
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P12931
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P12931
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P12931
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P12931
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,P12931
CHEMBL4854556,,KB-SRC-4,Preclinical,SRC inhibitor,P12931
CHEMBL4861571,,KX2-391,Phase 3,SRC inhibitor|tubulin polymerization inhibitor,P12931
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,P12931
CHEMBL285063,C=CC(=O)NC1=CC2=C(C=C1)N=CN=C2NC3=CC(=CC=C3)Br,PD-168393,Preclinical,EGFR inhibitor,P12931
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P12931
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P12931
CHEMBL4869189,,PP-2,Preclinical,SRC inhibitor,P12931
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,P12931
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P12931
CHEMBL4438584,CN1CCN(CC1)CCOC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6,saracatinib,Phase 2/Phase 3,SRC inhibitor,P12931
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P12931
CHEMBL4868350,,TG-100572,Preclinical,SRC inhibitor|VEGFR inhibitor,P12931
CHEMBL4864888,,TG-100801,Phase 2,SRC inhibitor|VEGFR inhibitor,P12931
CHEMBL8030,CC1=CC(=CC=C1)OC2=CNC(=O)N=C2,tolimidone,Phase 2,SRC activator,P12931
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P12931
CHEMBL213100,CC1=C(C(=CC=C1)C)OC(=O)N(C2=C(C=C(C=C2)OC)OC)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(CC5)C,WH-4-023,Preclinical,SRC inhibitor,P12931
CHEMBL4853537,,XL228,Phase 1,Abl kinase inhibitor|insulin growth factor receptor inhibitor|SRC inhibitor,P12931
CHEMBL4878927,,1-naphthyl-PP1,Preclinical,SRC inhibitor,P12931
CHEMBL596380,C1OC2=C(O1)C=C(C=C2)/C=C/[N+](=O)[O-],"3,4-methylenedioxy-beta-nitrostyrene",Preclinical,SRC inhibitor|SYK inhibitor,P12931
CHEMBL1097235,C1=CSC(=C1)CNC2=CC(=C(C=C2C3=NNN=N3)S(=O)(=O)N)Cl,azosemide,Launched,electrolyte reabsorption inhibitor,Q13621
CHEMBL1684,C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2,bendroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,Q13621
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,Q13621
CHEMBL4863260,,chlorthalidone,Launched,carbonic anhydrase inhibitor,Q13621
CHEMBL456,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,etacrynic-acid,Launched,sodium/potassium/chloride transporter inhibitor,Q13621
CHEMBL4852901,,furosemide,Launched,diuretic,Q13621
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,Q13621
CHEMBL1577,CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl,methyclothiazide,Launched,chloride reabsorption inhibitor,Q13621
CHEMBL349803,C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3,piretanide,Launched,glucocorticoid receptor agonist,Q13621
CHEMBL4857718,,tienilic-acid,Withdrawn,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,Q13621
CHEMBL1148,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,torasemide,Launched,electrolyte reabsorption inhibitor|thromboxane receptor antagonist,Q13621
CHEMBL1054,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,trichlormethiazide,Launched,chloride channel blocker,Q13621
CHEMBL1097235,C1=CSC(=C1)CNC2=CC(=C(C=C2C3=NNN=N3)S(=O)(=O)N)Cl,azosemide,Launched,electrolyte reabsorption inhibitor,P55011
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,P55011
CHEMBL4852901,,furosemide,Launched,diuretic,P55011
CHEMBL349803,C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3,piretanide,Launched,glucocorticoid receptor agonist,P55011
CHEMBL3421968,CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=CC(=N3)C4=CN(C5=C4C=CN=C5)C)OC,AZ191,Preclinical,DYRK inhibitor,Q9Y463
CHEMBL4853060,,ML167,Preclinical,CLK inhibitor|DYRK inhibitor,Q9Y463
CHEMBL4871073,,TC-S-7004,Preclinical,DYRK inhibitor,Q9Y463
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TG-003,Preclinical,CLK inhibitor,Q9Y463
CHEMBL4863063,,AZ505,Preclinical,histone lysine methyltransferase inhibitor,Q9NRG4
CHEMBL4848084,,A12B4C3,Preclinical,polynucleotide kinase/phosphatase inhibitor,Q96T60
CHEMBL4874603,,A205804,Preclinical,ICAM1 expression inhibitor,P05362
CHEMBL4852016,,BIRT-377,Preclinical,lymphocyte function-associated antigen negative modulator,P05362
CHEMBL4857980,,BMS-688521,Preclinical,ICAM1 antagonist|leukocyte function-associated antigen receptor antagonist,P05362
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,P05362
CHEMBL4870639,,polydatin,Phase 2,ICAM1 expression inhibitor,P05362
CHEMBL4860954,,RWJ-50271,Preclinical,integrin inhibitor,P05362
CHEMBL4879090,,A77636,Preclinical,dopamine receptor agonist,Q9NYX4
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,Q9NYX4
CHEMBL4864041,,CY208-243,Phase 2,dopamine receptor agonist,Q9NYX4
CHEMBL505308,C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3.Br,SKF-38393,Preclinical,dopamine receptor agonist,Q9NYX4
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,Q9NYX4
CHEMBL1200558,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,bacitracin,Launched,bacterial cell wall synthesis inhibitor,P14735
CHEMBL1897150,C1=CC(=CC=C1C(CC(=O)O)CN)Cl.Cl,baclofen,Launched,benzodiazepine receptor agonist,Q96CX2
CHEMBL4860479,,CGP-54626,Preclinical,GABA receptor antagonist,Q96CX2
CHEMBL4848857,,CGP-55845,Preclinical,GABA receptor antagonist,Q96CX2
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,Q96CX2
CHEMBL4870362,,saclofen,Preclinical,GABA receptor antagonist,Q96CX2
CHEMBL1897150,C1=CC(=CC=C1C(CC(=O)O)CN)Cl.Cl,baclofen,Launched,benzodiazepine receptor agonist,Q68DU8
CHEMBL4860479,,CGP-54626,Preclinical,GABA receptor antagonist,Q68DU8
CHEMBL4848857,,CGP-55845,Preclinical,GABA receptor antagonist,Q68DU8
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,Q68DU8
CHEMBL4870362,,saclofen,Preclinical,GABA receptor antagonist,Q68DU8
CHEMBL1897150,C1=CC(=CC=C1C(CC(=O)O)CN)Cl.Cl,baclofen,Launched,benzodiazepine receptor agonist,Q6ZWB6
CHEMBL4860479,,CGP-54626,Preclinical,GABA receptor antagonist,Q6ZWB6
CHEMBL4848857,,CGP-55845,Preclinical,GABA receptor antagonist,Q6ZWB6
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,Q6ZWB6
CHEMBL4870362,,saclofen,Preclinical,GABA receptor antagonist,Q6ZWB6
CHEMBL4303396,CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=C(C=N4)C5=CN=CN=C5,bafetinib,Phase 2,Bcr-Abl kinase inhibitor|LYN tyrosine kinase inhibitor,P07948
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P07948
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P07948
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P07948
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P07948
CHEMBL8030,CC1=CC(=CC=C1)OC2=CNC(=O)N=C2,tolimidone,Phase 2,SRC activator,P07948
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,Q04760
CHEMBL590878,C1=C(C=C(C(=C1O)O)O)C2=[O+]C3=CC(=CC(=C3C=C2O)O)O.[Cl-],delphinidin,Phase 2,membrane permeability inhibitor,Q04760
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q04760
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,Q04760
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,Q04760
CHEMBL9352,C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O,naringenin,Phase 1,aromatase inhibitor|TRPV antagonist,Q04760
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P48147
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,Q5JRX3
CHEMBL485818,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O,baicalin,Launched,beta glucuronidase inhibitor,P48147
CHEMBL485818,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O,baicalin,Launched,beta glucuronidase inhibitor,Q5JRX3
CHEMBL4853595,,Y-29794,Preclinical,prolyl endopeptidase inhibitor,P48147
CHEMBL4853595,,Y-29794,Preclinical,prolyl endopeptidase inhibitor,Q5JRX3
CHEMBL8260,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,baicalein,Preclinical,lipoxygenase inhibitor,P14151
CHEMBL4873954,,balicatib,Phase 2,cathepsin inhibitor,P43235
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,P43235
CHEMBL4214483,CC(C)(C[C@H](C[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(=O)(=O)C)C(F)(F)F)C(=O)NC3(CC3)C#N)F,odanacatib,Phase 3,cathepsin inhibitor,P43235
CHEMBL4847448,,BAM7,Preclinical,BAX activator,Q07812
CHEMBL4873074,,BAX-channel-blocker,Preclinical,cytochrome C release inhibitor,Q07812
CHEMBL4869243,,BAN-ORL-24,Preclinical,nociceptin/orphanin FQ receptor antagonist,P41146
CHEMBL2364605,CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5,cebranopadol,Phase 3,opioid receptor agonist,P41146
CHEMBL531742,CCC1=CC=C(C=C1)OCC2=CC=CC=C2C(=O)NC3=CC4=C(C=C(N=C4C=C3)C)N.Cl,JTC-801,Phase 2,opioid receptor antagonist,P41146
CHEMBL4877049,,MCOPPB,Preclinical,nociceptin/orphanin FQ receptor agonist,P41146
CHEMBL4875235,,NNC-63-0532,Preclinical,opioid receptor agonist,P41146
CHEMBL264846,C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)F)NC(=O)CNC(=O)CNC(=O)[C@H](CC2=CC=CC=C2)N)O,orphanin-fq,Phase 1,opioid receptor agonist,P41146
CHEMBL4864236,,SB-612111,Preclinical,nociceptin/orphanin FQ receptor antagonist,P41146
CHEMBL513136,CC1=CC=CC=C1C(C2=CC=CC=C2C)N3C4CCC3CC(C4)(C5=CC=CC=C5)O,SCH-221510,Preclinical,nociceptin/orphanin FQ receptor agonist,P41146
CHEMBL3182208,CCN1C2=CC=CC=C2N(C1=O)C3=C(CN(CC3)CC4CCCCCCC4)CO,trap-101,Preclinical,nociceptin/orphanin FQ receptor antagonist|opioid receptor antagonist,P41146
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,Q9UKQ2
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,Q9UKQ2
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,Q9UKQ2
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,Q9UNA0
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,P51512
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P51512
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,P08253
CHEMBL448502,CC(=C)[C@@H]1CC[C@@]([C@@H](C1)C(=C)C)(C)C=C,beta-elemene,Launched,apoptosis stimulant,P08253
CHEMBL4852091,,captopril,Launched,angiotensin converting enzyme inhibitor,P08253
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P08253
CHEMBL4869111,,CP-471474,Preclinical,matrix metalloprotease inhibitor,P08253
CHEMBL4869630,,CTS-1027,Phase 2,metalloproteinase inhibitor,P08253
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,P08253
CHEMBL1199540,C1C[C@@H]([C@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O,halofuginone,Launched,collagenase inhibitor,P08253
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P08253
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P08253
CHEMBL4866449,,PD-166793,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,P08253
CHEMBL4860542,,SD-2590,Preclinical,matrix metalloprotease inhibitor,P08253
CHEMBL1200448,C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+],tiludronate,Launched,bone resorption inhibitor|osteoclast inhibitor,P08253
CHEMBL4867936,,UK-356618,Preclinical,metalloproteinase inhibitor,P08253
CHEMBL4861322,,batimastat,Phase 3,matrix metalloprotease inhibitor,P22894
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P22894
CHEMBL1200699,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O,doxycycline,Launched,bacterial 30S ribosomal subunit inhibitor|metalloproteinase inhibitor,P22894
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P22894
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P22894
CHEMBL4303601,CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)C1=CC=C(C=C1)OC2=CC=CC=C2,ONO-4817,Phase 1,matrix metalloprotease inhibitor,P22894
CHEMBL4849807,,BAY-41-2272,Preclinical,guanylyl cyclase activator,Q02108
CHEMBL1236936,C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O,cinaciguat,Phase 2,guanylate cyclase activator,Q02108
CHEMBL250009,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,Q02108
CHEMBL1311,C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O,isosorbide-mononitrate,Launched,nitric oxide stimulant,Q02108
CHEMBL1329455,CCO/C(=N/C1=C[N+](=NO1)N2CCOCC2)/[O-],molsidomine,Launched,guanylate cyclase stimulant,Q02108
CHEMBL4855884,,ODQ,Preclinical,guanylyl cyclase inhibitor,Q02108
CHEMBL2107834,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,riociguat,Launched,guanylate cyclase stimulant,Q02108
CHEMBL4857295,,YC-1,Preclinical,guanylyl cyclase activator,Q02108
CHEMBL4849807,,BAY-41-2272,Preclinical,guanylyl cyclase activator,Q02153
CHEMBL1236936,C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O,cinaciguat,Phase 2,guanylate cyclase activator,Q02153
CHEMBL250009,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,Q02153
CHEMBL1311,C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O,isosorbide-mononitrate,Launched,nitric oxide stimulant,Q02153
CHEMBL4855884,,ODQ,Preclinical,guanylyl cyclase inhibitor,Q02153
CHEMBL2107834,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,riociguat,Launched,guanylate cyclase stimulant,Q02153
CHEMBL4857295,,YC-1,Preclinical,guanylyl cyclase activator,Q02153
CHEMBL4861585,,BAY-60-7550,Preclinical,phosphodiesterase inhibitor,O00408
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O00408
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O00408
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,O00408
CHEMBL4856647,,milrinone,Launched,phosphodiesterase inhibitor,O00408
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O00408
CHEMBL4847816,,BAY-61-3606,Preclinical,SYK inhibitor,P43405
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P43405
CHEMBL1375018,CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3N2CCCN)C,ER-27319,Preclinical,mediator release inhibitor|SYK inhibitor,P43405
CHEMBL2103830,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,fostamatinib,Launched,SYK inhibitor,P43405
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P43405
CHEMBL4852757,,GS-9973,Phase 2,SYK inhibitor,P43405
CHEMBL4116008,CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N,PRT062070,Phase 2/Phase 3,JAK inhibitor|SYK inhibitor,P43405
CHEMBL4865660,,PRT062607,Phase 2,SYK inhibitor,P43405
CHEMBL4846116,,R112,Phase 1,SYK inhibitor,P43405
CHEMBL4858394,,R406,Phase 1,SYK inhibitor,P43405
CHEMBL596380,C1OC2=C(O1)C=C(C=C2)/C=C/[N+](=O)[O-],"3,4-methylenedioxy-beta-nitrostyrene",Preclinical,SRC inhibitor|SYK inhibitor,P43405
CHEMBL4296718,CN1C=C(C=N1)CCN2C=NC(=C2C3=CC=C(C=C3)C#N)C4=CN(N=C4)C,BAZ2-ICR,Preclinical,bromodomain inhibitor,Q9UL58
CHEMBL4867073,,BCX-1470,Phase 1,complement inhibitor|serine protease inhibitor,P00746
CHEMBL4846930,,beclomethasone-dipropionate,Launched,glucocorticoid receptor agonist,Q86Y34
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q969S8
CHEMBL94394,CCCCOC1=CC=C(C=C1)CC(=O)NO,bufexamac,Withdrawn,cyclooxygenase inhibitor,Q969S8
CHEMBL4087968,C1=CC(=CN=C1)/C=C/C(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=CC(=C3)F)N,chidamide,Launched,HDAC inhibitor,Q969S8
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q969S8
CHEMBL4868784,,PCI-34051,Preclinical,HDAC inhibitor,Q969S8
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,Q969S8
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q969S8
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q969S8
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q96DB2
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q96DB2
CHEMBL4862129,,mocetinostat,Phase 2,HDAC inhibitor,Q96DB2
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q96DB2
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,P56524
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,P56524
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,P56524
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,P56524
CHEMBL4871005,,LMK-235,Preclinical,HDAC inhibitor,P56524
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,P56524
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,P56524
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,P56524
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,P56524
CHEMBL2107784,CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O,tasquinimod,Phase 3,angiogenesis inhibitor|S100A9 inhibitor,P56524
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,P56524
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q9UQL6
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q9UQL6
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q9UQL6
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q9UQL6
CHEMBL4871005,,LMK-235,Preclinical,HDAC inhibitor,Q9UQL6
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q9UQL6
CHEMBL600959,C1C[C@@]23[C@@H](C[C@H](N2C1)C4=CC5=NON=C5C=C4)CN(C3=O)C6=CC=CC=C6,SB-939,Phase 3,HDAC inhibitor,Q9UQL6
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q9UQL6
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q9UQL6
CHEMBL98,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,vorinostat,Launched,HDAC inhibitor,Q9UQL6
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q8WUI4
CHEMBL408513,C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO,belinostat,Launched,HDAC inhibitor,Q9UKV0
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q8WUI4
CHEMBL4846572,,dacinostat,Phase 1,HDAC inhibitor,Q9UKV0
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q8WUI4
CHEMBL1213492,CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO,givinostat,Phase 3,HDAC inhibitor,Q9UKV0
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q8WUI4
CHEMBL4253692,,JNJ-26481585,Phase 2,HDAC inhibitor,Q9UKV0
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q8WUI4
CHEMBL3545368,CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O,panobinostat,Launched,HDAC inhibitor,Q9UKV0
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q8WUI4
CHEMBL3310505,C/C=C\1/C(=O)N[C@H](C(=O)O[C@@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C,romidepsin,Launched,HDAC inhibitor,Q9UKV0
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q8WUI4
CHEMBL96051,C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO,scriptaid,Preclinical,HDAC inhibitor,Q9UKV0
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q8WUI4
CHEMBL4873222,,trichostatin-a,Phase 1,HDAC inhibitor,Q9UKV0
CHEMBL3545313,CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O,bempedoic-acid,Launched,AMPK inhibitor,P53396
CHEMBL1684,C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2,bendroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P55017
CHEMBL1200616,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)[N-]C=N2.[Na+],chlorothiazide,Launched,diuretic,P55017
CHEMBL4870184,,cyclothiazide,Launched,glutamate receptor modulator,P55017
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,P55017
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,P55017
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,P55017
CHEMBL1577,CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl,methyclothiazide,Launched,chloride reabsorption inhibitor,P55017
CHEMBL4853298,,metolazone,Launched,carbonic anhydrase inhibitor,P55017
CHEMBL1587,CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CSCC(F)(F)F,polythiazide,Launched,sodium/chloride cotransporter inhibitor,P55017
CHEMBL517199,CC1=C(C(=CC=C1)C)NC(=O)C2=CC(=C(C=C2O)Cl)S(=O)(=O)N,xipamide,Launched,carbonic anhydrase inhibitor,P55017
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P04798
CHEMBL4869448,,methoxsalen,Launched,DNA synthesis inhibitor,P04798
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,P04798
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P05177
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P05177
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P05177
CHEMBL64,C1=CN=CC=C1C(=O)NN,isoniazid,Launched,FABI inhibitor,P05177
CHEMBL4869448,,methoxsalen,Launched,DNA synthesis inhibitor,P05177
CHEMBL1200344,CCOC1=C(C2=CC=CC=C2C=C1)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[Na+],nafcillin,Launched,bacterial cell wall synthesis inhibitor,P05177
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P05177
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P05177
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P05177
CHEMBL4303318,CC1=C(C=CC2=C1N=C(C=C2O[C@@H]3C[C@@H]4C(C3)C(=O)N(CCCC/C=C\[C@@H]5C[C@]5(NC4=O)C(=O)NS(=O)(=O)C6CC6)C)C7=NC(=CS7)C(C)C)OC,simeprevir,Launched,HCV inhibitor,P05177
CHEMBL1136,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,P05177
CHEMBL1486,C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\C(=O)O,tenofovir-disoproxil,Launched,nucleoside reverse transcriptase inhibitor,P05177
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,Q06520
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q06520
CHEMBL4858001,,3-alpha-hydroxy-5-beta-androstan-17-one,Preclinical,,Q06520
CHEMBL1256668,CCCCN(CC)C1=C(C=C(C=C1[N+](=O)[O-])C(F)(F)F)[N+](=O)[O-],benfluralin,Phase 3,,P22309
CHEMBL4303416,C[C@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,dolutegravir,Launched,HIV integrase inhibitor,P22309
CHEMBL1255778,C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O.Cl,benserazide,Launched,DOPA decarboxylase inhibitor,P20711
CHEMBL1200748,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,carbidopa,Launched,aromatic L-amino acid decarboxylase inhibitor,P20711
CHEMBL4872529,,MC-1,Phase 3,,P20711
CHEMBL4851833,,melevodopa,Launched,dopamine precursor|dopamine receptor agonist,P20711
CHEMBL4867828,,methyldopa,Launched,adrenergic receptor agonist,P20711
CHEMBL1200756,CC1=NC=C(C(=C1O)CO)CO.Cl,pyridoxine,Launched,vitamin B,P20711
CHEMBL1200368,C1=CC=C(C=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)NC3=CC=C(C=C3)C(=O)O,bentiromide,Launched,,P05981
CHEMBL388590,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,benzbromarone,Launched,chloride channel blocker,P33527
CHEMBL3745690,,Ko143,Preclinical,BCRP inhibitor,P33527
CHEMBL1506885,C1COCCN1CCCNC(=O)C2=C3N=C(C=C(N3N=C2)C4=CC=CC=C4)C5=CC=CC=C5,reversan,Preclinical,MRP inhibitor,P33527
CHEMBL4847000,,sulfinpyrazone,Launched,uricosuric blocker,P33527
CHEMBL887937,,benzoic-acid,Launched,food preservative,P14920
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P14920
CHEMBL4873572,,SEP-227900,Phase 1,D-amino acid oxidase Inhibitor,P14920
CHEMBL887937,,benzoic-acid,Launched,food preservative,P52758
CHEMBL887937,,benzoic-acid,Launched,food preservative,P51151
CHEMBL96074,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,benzotript,Phase 1,CCK receptor antagonist,P32238
CHEMBL1201355,C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]5CCC(=O)N5)O,ceruletide,Preclinical,CCK receptor agonist,P32238
CHEMBL550781,CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl,dexloxiglumide,Phase 3,CCK receptor antagonist,P32238
CHEMBL4877417,,L-365260,Phase 2,CCK receptor antagonist,P32238
CHEMBL1255589,CCCCCN(CCCCC)C(=O)C(CCC(=O)[O-])NC(=O)C1=CC(=C(C=C1)Cl)Cl.[Na+],lorglumide,Phase 1,CCK receptor antagonist,P32238
CHEMBL316561,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,proglumide,Withdrawn,CCK receptor antagonist,P32238
CHEMBL249973,C1=CC=C2C(=C1)C=C(N2CC(=O)O)C(=O)NC3=NC(=CS3)C4=CC=CC=C4Cl,SR-27897,Phase 2,CCK receptor antagonist,P32238
CHEMBL96074,C1=CC=C2C(=C1)C(=CN2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,benzotript,Phase 1,CCK receptor antagonist,P32239
CHEMBL4877417,,L-365260,Phase 2,CCK receptor antagonist,P32239
CHEMBL1255589,CCCCCN(CCCCC)C(=O)C(CCC(=O)[O-])NC(=O)C1=CC(=C(C=C1)Cl)Cl.[Na+],lorglumide,Phase 1,CCK receptor antagonist,P32239
CHEMBL4859479,,LY225910,Preclinical,CCK receptor antagonist,P32239
CHEMBL4849812,,LY288513,Preclinical,CCK receptor antagonist,P32239
CHEMBL4303633,CC(C)(C)C(=O)CN1C2=CC=CC=C2N(C[C@H](C1=O)NC(=O)NC3=CC=CC(=C3)C(=O)O)C4CCCCC4,nastorazepide,Phase 2,CCK receptor antagonist,P32239
CHEMBL1328,CC(C)(C)OC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N,pentagastrin,Launched,CCK receptor agonist,P32239
CHEMBL316561,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,proglumide,Withdrawn,CCK receptor antagonist,P32239
CHEMBL4303529,CC1=CC(=C(C(=C1)C)NC(=O)N(CC2=CC3=C(C=C2)C4=CC=CC=C4C3)C5CCCCCC5)C,YM-022,Phase 2,CCK receptor antagonist,P32239
CHEMBL635041,,benzyl-benzoate,Launched,lipase inhibitor,Q05469
CHEMBL1625,COC1=CC(=C(C=C1)C(=O)C2=CC=CC=C2)O,oxybenzone,Launched,lipase inhibitor,Q05469
CHEMBL1200382,CC(C)COCC(CN(CC1=CC=CC=C1)C2=CC=CC=C2)N3CCCC3.O.Cl,bepridil,Launched,calcium channel blocker,P56696
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P56696
CHEMBL4858501,,flindokalner,Phase 3,potassium channel agonist,P56696
CHEMBL4877777,,linopirdine,Phase 3,potassium channel blocker,P56696
CHEMBL1703636,CC1=CC(=C(C(=C1)C)NC(=O)C2CC3CCC2C3)C,ML213,Preclinical,potassium channel activator,P56696
CHEMBL3392049,C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2],pyrithione-zinc,Launched,ATP synthase inhibitor,P56696
CHEMBL4855722,,XE-991,Preclinical,potassium channel blocker,P56696
CHEMBL295124,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC,berberine,Launched,LDL receptor activator,P01130
CHEMBL3293247,,beta-amyloid-synthesis-inhibitor,Preclinical,beta amyloid synthesis inhibitor,P05067
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P05067
CHEMBL4303172,,EUK-134,Preclinical,catalase stimulant,P05067
CHEMBL4854408,,MRK-560,Preclinical,gamma secretase inhibitor,P05067
CHEMBL4846053,,Ro-90-7501,Preclinical,beta amyloid protein neurotoxicity inhibitor,P05067
CHEMBL465208,C1=CC(=CC=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O,salidroside,Preclinical,beta amyloid protein neurotoxicity inhibitor,P05067
CHEMBL4868680,,SEN-1269,Preclinical,beta amyloid inhibitor,P05067
CHEMBL4873452,,TC-E-5006,Preclinical,gamma secretase modulator,P05067
CHEMBL149082,C(CN)CS(=O)(=O)O,tramiprosate,Phase 3,beta amyloid protein neurotoxicity inhibitor,P05067
CHEMBL273386,C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])O,"2,4-dinitrophenol",Preclinical,ATP synthase inhibitor,P05067
CHEMBL4303527,CCS(=O)C1=NC(=CC(=N1)C(F)(F)F)C2=CC(=CC=C2)OCC3=CC=CC=C3,BETP,Preclinical,GLP receptor positive allosteric modulator,P43220
CHEMBL4396956,,exenatide,Launched,GLP receptor agonist,P43220
CHEMBL462894,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1CC=C2CO)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,geniposide,Preclinical,GLP receptor agonist,P43220
CHEMBL4084119,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O,liraglutide,Launched,GLP receptor agonist,P43220
CHEMBL1166363,,betulinic-acid,Phase 1/Phase 2,apoptosis stimulant|NFkB pathway inhibitor,Q8TDU6
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,Q8TDU6
CHEMBL514674,C[C@H](CCC(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@]2(CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C)O)C.[Na+],deoxycholic-acid,Launched,biliverdin reductase A activator|G protein-coupled receptor agonist,Q8TDU6
CHEMBL4869315,,GPBAR-A,Preclinical,G protein-coupled receptor agonist,Q8TDU6
CHEMBL3306873,CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCOS(=O)(=O)O)C)C)O,INT-767,Phase 1,FXR agonist,Q8TDU6
CHEMBL4794162,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC[C@H](C4)O)C)C,lithocholic-acid,Preclinical,FXR antagonist|vitamin D receptor agonist,Q8TDU6
CHEMBL168,C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O,oleanolic-acid,Preclinical,G protein-coupled receptor agonist,Q8TDU6
CHEMBL4303545,COC1=C(C=C(C=C1)S(=O)(=O)N2CCCN(CC2)S(=O)(=O)C3=CC(=C(C=C3)OC)OC)OC,SB-756050,Phase 1,G protein-coupled receptor agonist,Q8TDU6
CHEMBL2181226,CC1=CC(=C(C=C1)C)OC2=C(C=NC=C2)C(=O)N3CCN(C4=CC=CC=C43)C5CC5,TC-G-1005,Preclinical,G protein-coupled receptor agonist,Q8TDU6
CHEMBL4874807,,bezafibrate,Launched,PPAR receptor agonist,Q07869
CHEMBL4873043,,cetaben,Phase 2,ACAT inhibitor|cholesterol inhibitor,Q07869
CHEMBL557555,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,ciprofibrate,Launched,PPAR receptor agonist,Q07869
CHEMBL3833336,CC(C)(C(=O)[O-])OC1=CC=C(C=C1)Cl.CC(C)(C(=O)[O-])OC1=CC=C(C=C1)Cl.[OH-].[Al+3],clofibrate,Launched,PPAR receptor agonist,Q07869
CHEMBL683,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,clofibric-acid,Launched,PPAR receptor agonist,Q07869
CHEMBL4303229,CC(C)C1=CC=C(C=C1)CC(=O)N2CCC[C@H](C2)C3=CC(=CC=C3)OC(C)(C)C(=O)O,CP-775146,Preclinical,PPAR receptor agonist,Q07869
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q07869
CHEMBL4878630,,elafibranor,Phase 3,PPAR receptor agonist,Q07869
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,Q07869
CHEMBL358150,CC(C)(C(=O)OCCOC(=O)C1=CN=CC=C1)OC2=CC=C(C=C2)Cl,etofibrate,Launched,PPAR receptor agonist,Q07869
CHEMBL4846193,,etofylline-clofibrate,Launched,platelet aggregation inhibitor,Q07869
CHEMBL1201745,CC(C)(C(=O)[O-])OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl.C[N+](C)(C)CCO,fenofibrate,Launched,PPAR receptor agonist,Q07869
CHEMBL1785463,,fenofibric-acid,Launched,cytochrome P450 inhibitor,Q07869
CHEMBL457,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,gemfibrozil,Launched,lipoprotein lipase activator,Q07869
CHEMBL4868019,,GW-501516,Phase 2,PPAR receptor agonist,Q07869
CHEMBL4864445,,GW-6471,Preclinical,PPAR receptor antagonist,Q07869
CHEMBL4877593,,GW-7647,Preclinical,PPAR receptor agonist,Q07869
CHEMBL1232583,COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O,indeglitazar,Phase 2,PPAR receptor agonist,Q07869
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,Q07869
CHEMBL4872662,,oleoylethanolamide,Preclinical,cannabinoid receptor agonist|glucose dependent insulinotropic receptor agonist|potassium channel blocker|PPAR receptor agonist,Q07869
CHEMBL4867458,,pirinixic-acid,Preclinical,PPAR receptor agonist,Q07869
CHEMBL4297530,CCO[C@@H](CC1=CC=C(C=C1)OCCN2C(=CC=C2C3=CC=C(C=C3)SC)C)C(=O)O,saroglitazar,Launched,PPAR receptor agonist,Q07869
CHEMBL4855291,,tesaglitazar,Phase 3,insulin sensitizer|PPAR receptor agonist,Q07869
CHEMBL4874807,,bezafibrate,Launched,PPAR receptor agonist,Q03181
CHEMBL4875405,,DG-172,Preclinical,PPAR receptor inverse agonist,Q03181
CHEMBL4878630,,elafibranor,Phase 3,PPAR receptor agonist,Q03181
CHEMBL4856134,,FH-535,Preclinical,PPAR receptor antagonist|WNT signaling inhibitor,Q03181
CHEMBL592652,COC1=C(C=CC(=C1)NC2=CC=CC=C2)NS(=O)(=O)C3=C(SC=C3)C(=O)OC,GSK0660,Preclinical,PPAR receptor antagonist,Q03181
CHEMBL4869205,,GSK3787,Preclinical,PPAR receptor antagonist,Q03181
CHEMBL4864563,,GW-0742,Preclinical,PPAR receptor agonist,Q03181
CHEMBL4868019,,GW-501516,Phase 2,PPAR receptor agonist,Q03181
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,Q03181
CHEMBL1232583,COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O,indeglitazar,Phase 2,PPAR receptor agonist,Q03181
CHEMBL4868191,,L-165041,Preclinical,PPAR receptor agonist,Q03181
CHEMBL1237119,CCCCC[C@@H](CC[C@H]1[C@@H](C[C@H]2[C@@H]1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O,treprostinil,Launched,prostanoid receptor agonist,Q03181
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,Q03181
CHEMBL4855932,,BHQ,Preclinical,ATPase inhibitor,O14983
CHEMBL480627,C/C(=C/1\C(=O)[C@@H]2[C@@H]3[C@@H](CC4=C5C3=CNC5=CC=C4)C(N2C1=O)(C)C)/O,cyclopiazonic-acid,Preclinical,ATPase inhibitor,O14983
CHEMBL4863508,,BI-2536,Phase 2,PLK inhibitor,P53350
CHEMBL4872417,,GSK461364,Phase 1,PLK inhibitor,P53350
CHEMBL4861697,,GW-843682X,Preclinical,PLK inhibitor,P53350
CHEMBL3991927,CC(=O)N(C1=CC=CC=C1/C=C/C2=CC=[N+](C=C2)[O-])S(=O)(=O)C3=CC=C(C=C3)OC,HMN-214,Phase 1,PLK inhibitor,P53350
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P53350
CHEMBL4868631,,NMS-1286937,Phase 2,PLK inhibitor,P53350
CHEMBL1241855,COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O,rigosertib,Phase 3,cell cycle inhibitor|PLK inhibitor,P53350
CHEMBL1584055,COC1=C(C=C(C=C1)CCNCC2=CC(=C(C=C2)OCC3=CN=C(C=C3)Cl)OC)OC.Cl,SBE-13,Preclinical,PLK inhibitor,P53350
CHEMBL4860702,,TAK-960,Phase 1,PLK inhibitor,P53350
CHEMBL4284151,CC[C@@H]1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C,volasertib,Phase 3,PLK inhibitor,P53350
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P53350
CHEMBL4863508,,BI-2536,Phase 2,PLK inhibitor,Q9NYY3
CHEMBL4868631,,NMS-1286937,Phase 2,PLK inhibitor,Q9NYY3
CHEMBL4848348,,TC-S-7005,Preclinical,PLK inhibitor,Q9NYY3
CHEMBL4863508,,BI-2536,Phase 2,PLK inhibitor,Q9H4B4
CHEMBL4861697,,GW-843682X,Preclinical,PLK inhibitor,Q9H4B4
CHEMBL4868631,,NMS-1286937,Phase 2,PLK inhibitor,Q9H4B4
CHEMBL1141083,,BIBN4096,Phase 2,calcitonin antagonist,P01258
CHEMBL1141083,,BIBN4096,Phase 2,calcitonin antagonist,P06881
CHEMBL4867133,,MK-3207,Phase 2,calcitonin antagonist,P01258
CHEMBL4867133,,MK-3207,Phase 2,calcitonin antagonist,P06881
CHEMBL2364629,C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6.C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6.O.O.O.OS(=O)(=O)O,rimegepant,Launched,calcitonin antagonist,P01258
CHEMBL2364629,C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6.C1C[C@H](C2=C(C=CC=N2)[C@H]([C@@H]1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6.O.O.O.OS(=O)(=O)O,rimegepant,Launched,calcitonin antagonist,P06881
CHEMBL4303376,CC1=CC=CC=C1N(C)C(=O)C2=CC(=C(C=C2)S(=O)C3=NC=CS3)[N+](=O)[O-],SB-268262,Preclinical,calcitonin antagonist,P01258
CHEMBL4303376,CC1=CC=CC=C1N(C)C(=O)C2=CC(=C(C=C2)S(=O)C3=NC=CS3)[N+](=O)[O-],SB-268262,Preclinical,calcitonin antagonist,P06881
CHEMBL1141083,,BIBN4096,Phase 2,calcitonin antagonist,Q16602
CHEMBL2105656,CCO.C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(N=CC=C5)N=C4[O-].[K+],telcagepant,Phase 3,calcitonin antagonist,Q16602
CHEMBL1141083,,BIBN4096,Phase 2,calcitonin antagonist,O60894
CHEMBL2105656,CCO.C1C[C@H](C(=O)N(C[C@@H]1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(N=CC=C5)N=C4[O-].[K+],telcagepant,Phase 3,calcitonin antagonist,O60894
CHEMBL1136689,,BIBR-1532,Preclinical,telomerase inhibitor,O14746
CHEMBL26318,CC1=CN(C(=O)NC1=O)[C@H]2C[C@H]([C@H](O2)CO)N=[N+]=[N-],zidovudine,Launched,nucleoside reverse transcriptase inhibitor,O14746
CHEMBL4303663,CN1CCC2=CC3=C(C=C2C1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,bicuculline-(+),Preclinical,GABA receptor antagonist,Q92952
CHEMBL333826,CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C,dequalinium,Launched,PKC inhibitor,Q92952
CHEMBL4303385,CC(C)(C)OC(=O)N1CCC(CC1)COC(=O)NC2=CC=CC=C2OC,GW-542573X,Preclinical,calcium channel activator,Q92952
CHEMBL4877048,,NS-309,Preclinical,calcium-activated potassium channel activator,Q92952
CHEMBL4855912,,NS-8593,Preclinical,calcium-activated potassium channel modulator,Q92952
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q92952
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,Q92952
CHEMBL4870795,,1-EBIO,Preclinical,potassium channel activator,Q92952
CHEMBL482035,COC1=C2C(=C(C(=C1)CO)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2,bicyclol,Launched,NFkB pathway inhibitor,P0DMV8
CHEMBL1972860,CN(C(=S)C1=CC=CC=C1)NC(=O)CC(=O)NN(C)C(=S)C2=CC=CC=C2,elesclomol,Phase 3,oxidative stress inducer,P0DMV8
CHEMBL1241268,C1=CC=C(C=C1)C#CS(=O)(=O)N,pifithrin-mu,Preclinical,HSP inhibitor,P0DMV8
CHEMBL4849592,,VER-155008,Preclinical,HSP inhibitor,P0DMV8
CHEMBL482035,COC1=C2C(=C(C(=C1)CO)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2,bicyclol,Launched,NFkB pathway inhibitor,P04792
CHEMBL4870939,,SB-242235,Phase 1,p38 MAPK inhibitor,P04792
CHEMBL4868689,,bifemelane,Launched,acetylcholine release enhancer,P27338
CHEMBL4877864,,BU-224,Preclinical,imidazoline receptor ligand,P27338
CHEMBL2104164,C1C2=CC=CC=C2OC(=O)N1CC(=O)N,caroxazone,Withdrawn,monoamine oxidase inhibitor,P27338
CHEMBL4226242,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC(=C(C=C3)Cl)Cl,diclofensine,Phase 3,dopamine reuptake inhibitor,P27338
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P27338
CHEMBL510348,CC1=NC=CC2=C1NC3=CC=CC=C23.Cl,harmane,Preclinical,monoamine oxidase inhibitor,P27338
CHEMBL12208,CC1=CC(=O)OC2=C1C=CC(=C2)O,hymecromone,Phase 2,monoamine oxidase inhibitor,P27338
CHEMBL1256749,CN[C@@H]1C[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl.Cl,indatraline,Preclinical,norepinephrine transporter inhibitor,P27338
CHEMBL92401,CC(C)NNC(=O)C1=CC=NC=C1,iproniazid,Withdrawn,monoamine oxidase inhibitor,P27338
CHEMBL1201168,CC1=CC(=NO1)C(=O)NNCC2=CC=CC=C2,isocarboxazid,Launched,monoamine oxidase inhibitor,P27338
CHEMBL2105029,C1=CC(=NC=C1Cl)C(=O)NCCN.Cl,lazabemide,Phase 3,monoamine oxidase inhibitor,P27338
CHEMBL126,CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F,linezolid,Launched,bacterial 50S ribosomal subunit inhibitor,P27338
CHEMBL4849434,,milacemide,Phase 3,monoamine oxidase inhibitor,P27338
CHEMBL86304,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,moclobemide,Launched,monoamine oxidase inhibitor,P27338
CHEMBL489079,C1=CC(=CC=C1CC/C(=C\F)/CN)F,mofegiline,Phase 1,monoamine oxidase inhibitor,P27338
CHEMBL1256841,C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=NC=C2,nialamide,Withdrawn,monoamine oxidase inhibitor,P27338
CHEMBL673,CN(CC#C)CC1=CC=CC=C1,pargyline,Launched,monoamine oxidase inhibitor,P27338
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P27338
CHEMBL3889591,CCCN(CC)C(=O)/C=C/C=C/C1=CC2=C(C=C1)OCO2,piperine,Phase 1,monoamine oxidase inhibitor,P27338
CHEMBL1445061,CN1C2=C(CCNCC2)C3=CC=CC=C31.Cl,PNU-22394,Phase 2,serotonin receptor agonist,P27338
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,P27338
CHEMBL164660,C1=CC(=O)OC2=CC3=C(C=CO3)C=C21,psoralen,Launched,,P27338
CHEMBL887,C#CCN[C@@H]1CCC2=CC=CC=C12,rasagiline,Launched,monoamine oxidase inhibitor,P27338
CHEMBL396778,C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCC2=CC(=CC=C2)F,safinamide,Launched,dopamine reuptake inhibitor|glutamate inhibitor|monoamine oxidase inhibitor,P27338
CHEMBL1200904,C[C@H](CC1=CC=CC=C1)N(C)CC#C.Cl,selegiline,Launched,monoamine oxidase inhibitor,P27338
CHEMBL18116,CC1=CC(=CC=C1)N2CC(OC2=O)CO,toloxatone,Launched,monoamine oxidase inhibitor,P27338
CHEMBL1255743,C1[C@H]([C@@H]1N)C2=CC=CC=C2.Cl,tranylcypromine,Launched,monoamine oxidase inhibitor,P27338
CHEMBL2355333,CN(C)C/C=C(/C1=CC=C(C=C1)Br)\C2=CN=CC=C2.O.Cl.Cl,zimelidine,Withdrawn,selective serotonin reuptake inhibitor (SSRI),P27338
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P27338
CHEMBL4873019,,2-BFI,Preclinical,imidazoline receptor ligand,P27338
CHEMBL4303730,CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(CCC2=CC=CC=C2)O)O)O,bimatoprost,Launched,prostanoid receptor agonist,P42330
CHEMBL4851780,,coenzyme-I,Phase 2,,P42330
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P42330
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P42330
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P42330
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P42330
CHEMBL55153,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=C(C3=O)C(=CC(=C4)OC(=O)C)OC(=O)C)C5=CC(=C(C=C5)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C)OC(=O)C,rutin,Launched,antioxidant|capillary stabilizing agent|nitric oxide scavenger,P42330
CHEMBL4303730,CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(CCC2=CC=CC=C2)O)O)O,bimatoprost,Launched,prostanoid receptor agonist,P43088
CHEMBL1520583,C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+],cloprostenol-(+/-),Launched,prostaglandin receptor agonist,P43088
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P43088
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P43088
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P43088
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P43088
CHEMBL1051,CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1CC[C@H](CCC2=CC=CC=C2)O)O)O,latanoprost,Launched,prostanoid receptor agonist,P43088
CHEMBL1963683,CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O,tafluprost,Launched,prostaglandin inhibitor,P43088
CHEMBL1200799,CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](COC2=CC=CC(=C2)C(F)(F)F)O)O)O,travoprost,Launched,prostanoid receptor agonist,P43088
CHEMBL4859516,,BINA,Preclinical,glutamate receptor positive allosteric modulator,Q14416
CHEMBL4303163,CCS(=O)(=O)N(CC1=CN=CC=C1)C2=CC=CC(=C2)C3=CC=C(C=C3)C#N,CBiPES,Preclinical,glutamate receptor positive allosteric modulator,Q14416
CHEMBL1435977,C1C[C@@](C[C@@H]1C(=O)O)(C(=O)O)N.C1C[C@](C[C@H]1C(=O)O)(C(=O)O)N,cis-ACPD,Preclinical,glutamate receptor agonist,Q14416
CHEMBL8759,C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N,eglumetad,Phase 2,glutamate receptor agonist,Q14416
CHEMBL4756635,COC1=CC=C(C=C1)C2=CN(C(=O)C=C2)CC3=C(C=C(C=C3)Cl)F,JNJ-40411813,Phase 2,glutamate receptor positive allosteric modulator,Q14416
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q14416
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q14416
CHEMBL3544939,,LY2979165,Phase 1,glutamate receptor agonist,Q14416
CHEMBL1594103,CC(C1=CC=C(C=C1)C2=NNN=N2)(C(=O)O)N,MTPG,Preclinical,glutamate receptor antagonist,Q14416
CHEMBL128772,C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)O,4-carboxy-3-hydroxyphenylglycine-(S),Preclinical,glutamate receptor agonist|glutamate receptor antagonist,Q14416
CHEMBL2107549,CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,bindarit,Phase 2,NFkB pathway inhibitor,P13500
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,P13500
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,mimosine,Preclinical,DNA replication inhibitor,P13500
CHEMBL4846268,,RS-504393,Preclinical,CC chemokine receptor antagonist,P13500
CHEMBL2107549,CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,bindarit,Phase 2,NFkB pathway inhibitor,P80098
CHEMBL2107549,CC(C)(C(=O)O)OCC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3,bindarit,Phase 2,NFkB pathway inhibitor,P80075
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P80075
CHEMBL88478,CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)O,BIO-1211,Phase 2,integrin antagonist,P13612
CHEMBL4303683,CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)N(C)[C@@H](CC(C)C)C(=O)NCC[C@@H](C(=O)O)NC(=O)[C@@H]3CCCN3S(=O)(=O)C4=CC(=CC(=C4)Cl)Cl,BIO-5192,Preclinical,integrin inhibitor,P13612
CHEMBL4303708,C1CCC2(CC1)C(=C(C2=O)Br)N[C@@H](CC3=CC=C(C=C3)NC4=NC=CC5=C4C=NC=C5)C(=O)O,CT-7758,Phase 2,integrin antagonist,P13612
CHEMBL2104967,CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)C[C@@H](C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC,firategrast,Phase 2,integrin antagonist,P13612
CHEMBL1257246,CC(=CCC[C@]1([C@@H]2CC[C@H]3CC4=C([C@@]3([C@]2(CC[C@@H]1O)C)C)NC5=CC=CC=C45)C)C,SB-683698,Phase 1,integrin antagonist,P13612
CHEMBL4870452,,TCS-2314,Preclinical,integrin inhibitor,P13612
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,Q13085
CHEMBL4854214,,CP-640186,Preclinical,acetyl-CoA carboxylase inhibitor,Q13085
CHEMBL4875847,,KD-023,Phase 2,ACAT inhibitor,Q13085
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,P50747
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,Q96RQ3
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,Q9HCC0
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,P11498
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,P05165
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,P05166
CHEMBL857,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)NC(=O)N2,biotin,Launched,vitamin B,Q9Y289
CHEMBL4871472,,bipenamol,Phase 2,dipeptidyl peptidase inhibitor,P53634
CHEMBL286447,,bis(maltolato)oxovanadium(IV),Phase 2,tyrosine phosphatase inhibitor,P18031
CHEMBL4859488,,BVT-948,Preclinical,tyrosine phosphatase inhibitor,P18031
CHEMBL4043266,,corosolic-acid,Phase 2,PKC inhibitor|protein tyrosine kinase inhibitor,P18031
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P18031
CHEMBL1015,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)C)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O,evans-blue,Launched,glutamate receptor negative allosteric modulator,P18031
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P18031
CHEMBL4303304,CC(C)(C=C)C1=C(C=C(C(=C1)C=CC(=O)C2=CC=C(C=C2)O)OC)O,licochalcone-A,Phase 3,topoisomerase inhibitor,P18031
CHEMBL4857478,,rheochrysidin,Preclinical,protein tyrosine kinase inhibitor,P18031
CHEMBL4869266,,S-nitrosoglutathione,Phase 1,nitric oxide stimulant,P18031
CHEMBL27308,CC(=O)NC(C(=O)O)C(C)(C)SN=O,SNAP,Phase 2,nitric oxide donor,P18031
CHEMBL1200448,C1=CC(=CC=C1SC(P(=O)(O)[O-])P(=O)(O)[O-])Cl.[Na+].[Na+],tiludronate,Launched,bone resorption inhibitor|osteoclast inhibitor,P18031
CHEMBL169,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,P18031
CHEMBL1450004,CC1=C(C(=C2C(=C1O)[C@@]3(C(=CC(=O)C(C3=O)C(=O)C)O2)C)C(=O)C)O,usniacin-(+),Preclinical,MAP kinase activator,P18031
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P06239
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P06239
CHEMBL576817,C1=CC(=CC=C1NC2C3=C(N=CN=C3N=N2)N)F,CGP-57380,Preclinical,MAP kinase inhibitor,P06239
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P06239
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P06239
CHEMBL202887,C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5,GW-788388,Preclinical,ALK tyrosine kinase receptor inhibitor,P06239
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P06239
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P06239
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P06239
CHEMBL2105708,CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5.Cl,ponatinib,Launched,Bcr-Abl kinase inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor,P06239
CHEMBL4869189,,PP-2,Preclinical,SRC inhibitor,P06239
CHEMBL4438584,CN1CCN(CC1)CCOC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6,saracatinib,Phase 2/Phase 3,SRC inhibitor,P06239
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P06239
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P06239
CHEMBL4859038,,SRC-kinase-inhibitor-I,Preclinical,SRC inhibitor,P06239
CHEMBL4851935,,TC-S-7003,Preclinical,SRC inhibitor,P06239
CHEMBL4744548,CC1=C(C=NN1)NC2=CC(=NC(=N2)SC3=CC=C(C=C3)NC(=O)C4CC4)N5CCN(CC5)C,tozasertib,Phase 2,Aurora kinase inhibitor|Bcr-Abl kinase inhibitor|FLT3 inhibitor|JAK inhibitor,P06239
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P06239
CHEMBL213100,CC1=C(C(=CC=C1)C)OC(=O)N(C2=C(C=C(C=C2)OC)OC)C3=NC(=NC=C3)NC4=CC=C(C=C4)N5CCN(CC5)C,WH-4-023,Preclinical,SRC inhibitor,P06239
CHEMBL4851744,,ZM-336372,Preclinical,RAF inhibitor,P06239
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P06239
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P06239
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,P23443
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,P23443
CHEMBL4857989,,LY2584702,Phase 1,ribosomal protein inhibitor,P23443
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P23443
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,P23443
CHEMBL2134202,CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F,PF-4708671,Preclinical,ribosomal protein inhibitor,P23443
CHEMBL4872476,,PHA-767491,Preclinical,CDC inhibitor,P23443
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,P23443
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P23443
CHEMBL4856562,,SB-415286,Preclinical,glycogen synthase kinase inhibitor,P23443
CHEMBL4863031,,SB-747651A,Preclinical,kinase inhibitor,P23443
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,P23443
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P23443
CHEMBL4847515,,bisindolylmaleimide-IX,Preclinical,PKC inhibitor,Q96EB6
CHEMBL4857249,,EX-527,Phase 2,SIRT inhibitor,Q96EB6
CHEMBL198582,C[C@H](C1=CC=CC=C1)NC(=O)C2=CC=CC=C2N=CC3=C(C=CC4=CC=CC=C43)O,sirtinol,Preclinical,SIRT inhibitor,Q96EB6
CHEMBL86537,C1CC(=O)OC2=C1C3=CC=CC=C3C=C2,splitomycin,Preclinical,SIRT inhibitor,Q96EB6
CHEMBL4847599,,SRT1720,Preclinical,SIRT activator,Q96EB6
CHEMBL4297436,CC1=C(SC(=N1)C2=CN=CC=C2)C(=O)NC3=CC=CC=C3C4=CN5C(=CSC5=N4)CN6CCOCC6,SRT2104,Phase 2,SIRT activator,Q96EB6
CHEMBL4853318,,tenovin-1,Preclinical,SIRT inhibitor|TP53 activator,Q96EB6
CHEMBL595354,CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C,tenovin-6,Preclinical,SIRT inhibitor,Q96EB6
CHEMBL1592101,,bismuth-subgallate,Launched,nitric oxide synthase inhibitor,P29475
CHEMBL1592101,,bismuth-subgallate,Launched,nitric oxide synthase inhibitor,Q8WY41
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P29475
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,Q8WY41
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P29475
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q8WY41
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P29475
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q8WY41
CHEMBL4849447,,L-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,P29475
CHEMBL4849447,,L-monomethylarginine,Phase 3,nitric oxide synthase inhibitor,Q8WY41
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,P29475
CHEMBL1744034,CC(=NCCCC[C@@H](C(=O)O)N)N.Cl.Cl,L-NIL,Preclinical,nitric oxide synthase inhibitor,Q8WY41
CHEMBL454576,C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O,myricitrin,Preclinical,PKC inhibitor,P29475
CHEMBL454576,C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O,myricitrin,Preclinical,PKC inhibitor,Q8WY41
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,P29475
CHEMBL4878204,,NG-nitro-arginine,Phase 1,nitric oxide synthase inhibitor,Q8WY41
CHEMBL4876959,,proadifen,Preclinical,nitric oxide synthase inhibitor,P29475
CHEMBL4876959,,proadifen,Preclinical,nitric oxide synthase inhibitor,Q8WY41
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,P29475
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q8WY41
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,P29475
CHEMBL4853120,,1400W,Preclinical,nitric oxide synthase inhibitor,Q8WY41
CHEMBL1233598,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)N=C(N2)N,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,P29475
CHEMBL1233598,C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)O)N=C(N2)N,2-iminobiotin,Phase 2,nitric oxide synthase inhibitor,Q8WY41
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P29475
CHEMBL479014,C1=CC2=C(NN=C2C(=C1)[N+](=O)[O-])Br,3-bromo-7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,Q8WY41
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,P29475
CHEMBL247378,C1=CC2=C(C(=C1)[N+](=O)[O-])NN=C2,7-nitroindazole,Preclinical,nitric oxide synthase inhibitor,Q8WY41
CHEMBL290106,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,bithionol,Withdrawn,autotaxin inhibitor,Q07820
CHEMBL28626,C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,morin,Preclinical,cytochrome P450 inhibitor,Q07820
CHEMBL324842,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O,rosmarinic-acid,Launched,GABA transaminase inhibitor,Q07820
CHEMBL4865794,,TW-37,Preclinical,BCL inhibitor,Q07820
CHEMBL4859803,,BIX-02188,Preclinical,MEK inhibitor,Q13163
CHEMBL4861550,,BIX-02189,Preclinical,MEK inhibitor,Q13163
CHEMBL4861550,,BIX-02189,Preclinical,MEK inhibitor,Q13164
CHEMBL4856461,,ERK5-IN-1,Preclinical,MAP kinase inhibitor,Q13164
CHEMBL4875524,,XMD17-109,Preclinical,MAP kinase inhibitor,Q13164
CHEMBL4857157,,XMD8-92,Preclinical,MAP kinase inhibitor,Q13164
CHEMBL1231358,CC1=CC2=C(C=C1)N=C3[C@](C2=O)(CCN3C4=CC=CC=C4)O,blebbistatin-(+/-),Preclinical,ATPase inhibitor,Q7Z406
CHEMBL1231358,CC1=CC2=C(C=C1)N=C3[C@](C2=O)(CCN3C4=CC=CC=C4)O,blebbistatin-(+/-),Preclinical,ATPase inhibitor,Q9UKX2
CHEMBL4867330,,BMS-CCR2-22,Preclinical,CC chemokine receptor antagonist,P41597
CHEMBL4866698,,INCB-3284,Phase 2,CC chemokine receptor antagonist,P41597
CHEMBL4862441,,JNJ-27141491,Preclinical,CC chemokine receptor antagonist,P41597
CHEMBL4862236,,meglitinide,Phase 2,potassium channel blocker,P41597
CHEMBL3188657,CC(C)[C@@]1(CC[C@H](C1)N[C@H]2CCOC[C@H]2OC)C(=O)N3CCC4=C(C3)C=C(C=N4)C(F)(F)F.C(CC(=O)O)C(=O)O,MK-0812,Phase 2,CC chemokine receptor antagonist,P41597
CHEMBL1095301,,propagermanium,Launched,CCR agonist|interferon receptor agonist,P41597
CHEMBL1317124,C1CN(CCC12C3=CC=CC=C3NC(=O)O2)CCC4=CC=C(C=C4)C(F)(F)F.Cl,RS-102895,Preclinical,CCR antagonist,P41597
CHEMBL4846268,,RS-504393,Preclinical,CC chemokine receptor antagonist,P41597
CHEMBL4853630,,teijin-compound-1,Preclinical,CC chemokine receptor antagonist,P41597
CHEMBL4845940,,BMS-191011,Preclinical,potassium channel activator,Q12791
CHEMBL1371,C1=CC2=C(C=C1Cl)NC(=O)O2,chlorzoxazone,Launched,bacterial 30S ribosomal subunit inhibitor,Q12791
CHEMBL428880,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,cromoglicic-acid,Launched,immunosuppressant,Q12791
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,Q12791
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol,Launched,estrogen receptor agonist,Q12791
CHEMBL4858501,,flindokalner,Phase 3,potassium channel agonist,Q12791
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,Q12791
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,Q12791
CHEMBL4303589,C1=CC(=C(C=C1Br)C2=NNN=N2)NC(=S)NC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,NS-11021,Preclinical,calcium-activated potassium channel activator,Q12791
CHEMBL1514181,C1=CC(=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)O)O,NS-1643,Preclinical,voltage-gated potassium channel activator,Q12791
CHEMBL4853439,,NS-19504,Preclinical,calcium-activated potassium channel activator,Q12791
CHEMBL4878818,,NS-8,Phase 2,potassium channel agonist,Q12791
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q12791
CHEMBL4873852,,BMS-309403,Preclinical,fatty acid binding protein inhibitor,P15090
CHEMBL3989529,CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N,ethanolamine-oleate,Launched,immunostimulant,P15090
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,P15090
CHEMBL4876275,,BMS-470539,Preclinical,melanocortin receptor agonist,Q01726
CHEMBL4297533,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C.CC(=O)O,bremelanotide,Launched,melanocortin receptor agonist,Q01726
CHEMBL4866174,,BMS-536924,Preclinical,IGF-1 inhibitor,P24864
CHEMBL4861554,,BMS-587101,Phase 2,integrin antagonist,P20701
CHEMBL4848770,,lovastatin,Launched,HMGCR inhibitor,P20701
CHEMBL4861554,,BMS-587101,Phase 2,integrin antagonist,P05107
CHEMBL1201391,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)C,simvastatin,Launched,HMGCR inhibitor,P05107
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,P30530
CHEMBL3808844,CCOC1=CN(N=C1C(=O)NC2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)F)C5=C(C=C(C=C5)F)C,LDC1267,Preclinical,protein tyrosine kinase inhibitor,P30530
CHEMBL4848151,,MGCD-265,Preclinical,VEGFR inhibitor,P30530
CHEMBL3641986,CNC1CCN(CC1)C2=NN=C(C=C2)NC3=NC=C4C5=C(C=NC=C5)N(C4=N3)[C@@H]6CCOC6,R-428,Phase 2,AXL kinase inhibitor,P30530
CHEMBL2022968,CN1CCN(CC1)CC2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)N(C)C)Cl,TP-0903,Phase 1/Phase 2,AXL kinase inhibitor,P30530
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,Q12866
CHEMBL3808844,CCOC1=CN(N=C1C(=O)NC2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)F)C5=C(C=C(C=C5)F)C,LDC1267,Preclinical,protein tyrosine kinase inhibitor,Q12866
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,Q12866
CHEMBL4868263,,UNC2025,Preclinical,FLT3 inhibitor|MER tyrosine kinase inhibitor,Q12866
CHEMBL3092807,CCCCNC1=NC=C(C(=N1)NC2CCC(CC2)O)C3=NC=C(C=C3)CN4CCOCC4,UNC2250,Preclinical,MER tyrosine kinase inhibitor,Q12866
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,Q04912
CHEMBL4876939,,MK-2461,Phase 1/Phase 2,FGFR inhibitor|VEGFR inhibitor,Q04912
CHEMBL4869081,,BMS-777607,Phase 1/Phase 2,AXL kinase inhibitor|c-Met inhibitor|FLT3 inhibitor|hepatocyte growth factor receptor inhibitor|macrophage migration inhibiting factor inhibitor|tyrosine kinase inhibitor,Q06418
CHEMBL3808844,CCOC1=CN(N=C1C(=O)NC2=CC(=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)F)C5=C(C=C(C=C5)F)C,LDC1267,Preclinical,protein tyrosine kinase inhibitor,Q06418
CHEMBL4877521,,BMS-833923,Phase 2,smoothened receptor antagonist,Q99835
CHEMBL4877521,,BMS-833923,Phase 2,smoothened receptor antagonist,Q9NWM0
CHEMBL4861844,,CUR-61414,Phase 1,smoothened receptor antagonist,Q99835
CHEMBL4861844,,CUR-61414,Phase 1,smoothened receptor antagonist,Q9NWM0
CHEMBL3039305,CC(=O)OCC(=O)[C@@]12[C@@H](CC3[C@@]1(C[C@@H]([C@]4(C3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,fluocinonide,Launched,glucocorticoid receptor agonist,Q99835
CHEMBL3039305,CC(=O)OCC(=O)[C@@]12[C@@H](CC3[C@@]1(C[C@@H]([C@]4(C3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,fluocinonide,Launched,glucocorticoid receptor agonist,Q9NWM0
CHEMBL4297534,CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N.C(=C\C(=O)O)\C(=O)O,glasdegib,Launched,hedgehog pathway inhibitor,Q99835
CHEMBL4297534,CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N.C(=C\C(=O)O)\C(=O)O,glasdegib,Launched,hedgehog pathway inhibitor,Q9NWM0
CHEMBL4857465,,M-25,Preclinical,smoothened receptor antagonist,Q99835
CHEMBL4857465,,M-25,Preclinical,smoothened receptor antagonist,Q9NWM0
CHEMBL3186656,CC1=CC(=C(N=C1)C2=CC(=NC=C2Cl)N3CCN(CC3)C(=O)CCS(=O)(=O)C)C,PF-5274857,Preclinical,smoothened receptor antagonist,Q99835
CHEMBL3186656,CC1=CC(=C(N=C1)C2=CC(=NC=C2Cl)N3CCN(CC3)C(=O)CCS(=O)(=O)C)C,PF-5274857,Preclinical,smoothened receptor antagonist,Q9NWM0
CHEMBL1221984,C1CCC(CC1)N2C=NC3=C(N=C(N=C32)OC4=CC=CC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCOCC7,purmorphamine,Preclinical,smoothened receptor agonist,Q99835
CHEMBL1221984,C1CCC(CC1)N2C=NC3=C(N=C(N=C32)OC4=CC=CC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCOCC7,purmorphamine,Preclinical,smoothened receptor agonist,Q9NWM0
CHEMBL2157999,,SAG,Preclinical,smoothened receptor agonist,Q99835
CHEMBL2157999,,SAG,Preclinical,smoothened receptor agonist,Q9NWM0
CHEMBL4848410,,SANT-1,Preclinical,smoothened receptor antagonist,Q99835
CHEMBL4848410,,SANT-1,Preclinical,smoothened receptor antagonist,Q9NWM0
CHEMBL4878387,,SANT-2,Preclinical,smoothened receptor antagonist,Q99835
CHEMBL4878387,,SANT-2,Preclinical,smoothened receptor antagonist,Q9NWM0
CHEMBL3137317,C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O,sonidegib,Launched,smoothened receptor antagonist,Q99835
CHEMBL3137317,C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O,sonidegib,Launched,smoothened receptor antagonist,Q9NWM0
CHEMBL2142592,CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F,taladegib,Phase 2,smoothened receptor antagonist,Q99835
CHEMBL2142592,CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F,taladegib,Phase 2,smoothened receptor antagonist,Q9NWM0
CHEMBL473417,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,vismodegib,Launched,hedgehog pathway inhibitor|smoothened receptor antagonist,Q99835
CHEMBL473417,CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl,vismodegib,Launched,hedgehog pathway inhibitor|smoothened receptor antagonist,Q9NWM0
CHEMBL3544943,C1CC(NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl.Cl,BMS-863233,Phase 1/Phase 2,CDC inhibitor,O00311
CHEMBL4784083,CC1=NOC(=C1NC(=O)O[C@@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)O,BMS-986020,Phase 2,lysophosphatidic acid receptor antagonist,Q92633
CHEMBL604677,C1=CC(=CC(=C1)OC2=CC=C(C=C2)[N+](=O)[O-])N3C(=O)C4=C(C3=O)C=C(C=C4)C(=O)O,H2L-5765834,Preclinical,lysophosphatidic acid receptor antagonist,Q92633
CHEMBL403504,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)C3(CC(CC(C3)(C)C(=O)NC)(C)C=O)C,KI-16425,Preclinical,lysophosphatidic acid receptor antagonist,Q92633
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,P23946
CHEMBL270515,B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O,delanzomib,Phase 1/Phase 2,proteasome inhibitor,P23946
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,P10619
CHEMBL573043,[2H][C@](CCC)(C(=O)C(=O)NC1CC1)NC(=O)[C@@H]2[C@H]3CCC[C@H]3CN2C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C4CCCCC4)NC(=O)C5=NC=CN=C5,telaprevir,Launched,HCV inhibitor,P10619
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,Q9UBX1
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,P07711
CHEMBL4871268,,cathepsin-inhibitor-1,Preclinical,cathepsin inhibitor,P07711
CHEMBL1886408,CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,felbinac,Launched,cyclooxygenase inhibitor,P07711
CHEMBL3314610,CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)O,pepstatin,Preclinical,aspartic protease inhibitor,P07711
CHEMBL4303448,CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](C3=CC=C(C=C3)F)C(F)(F)F,VBY-825,Preclinical,cathepsin inhibitor,P07711
CHEMBL4868590,CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,boceprevir,Launched,HCV inhibitor,P25774
CHEMBL3702722,CN1CCC(CC1)N2CCN(CC2)C(=O)C3=CN(C4=C(C=CC=C34)CN5C[C@H]6N([C@H](C5=O)CC7=CC=C(C=C7)O)C(=O)CN(N6C(=O)NCC8=CC=CC=C8)CC=C)C,E-64,Preclinical,calpain inhibitor|cysteine protease inhibitor,P25774
CHEMBL3351795,,LY3000328,Phase 1,cathepsin inhibitor,P25774
CHEMBL4303448,CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](C3=CC=C(C=C3)F)C(F)(F)F,VBY-825,Preclinical,cathepsin inhibitor,P25774
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P25786
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P25786
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P25787
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P25787
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P25788
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P25788
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P25789
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P25789
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28066
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28066
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P60900
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P60900
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,O14818
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,O14818
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,Q8TAA3
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,Q8TAA3
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P20618
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P20618
CHEMBL4851750,,MG-132,Preclinical,proteasome inhibitor,P20618
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P40306
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P40306
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,A5LHX3
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,A5LHX3
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P49721
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P49721
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P49720
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P49720
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28070
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28070
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28074
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28074
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28072
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28072
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,Q99436
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,Q99436
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28062
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28062
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,P28065
CHEMBL451887,CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4,carfilzomib,Launched,proteasome inhibitor,P28065
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,Q99460
CHEMBL325041,B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O,bortezomib,Launched,NFkB pathway inhibitor|proteasome inhibitor,Q13200
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q8IU85
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q13555
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P42685
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P42685
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P42685
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P06241
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P06241
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P08631
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P08631
CHEMBL4873107,,PP-1,Preclinical,SRC inhibitor,P08631
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P08631
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P08631
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P08631
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q9Y2U5
CHEMBL1240295,,PD-184352,Phase 2,MEK inhibitor,Q9Y2U5
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,Q9Y2U5
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q9Y4K4
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,O94804
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q9Y6E0
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,Q13043
CHEMBL4867724,,bosutinib,Launched,Abl kinase inhibitor|Bcr-Abl kinase inhibitor|SRC inhibitor,P42681
CHEMBL4857776,,BQU57,Preclinical,Ras GTPase inhibitor,P11233
CHEMBL4850519,,RBC8,Preclinical,Ral GTPase inhibitor,P11233
CHEMBL4857776,,BQU57,Preclinical,Ras GTPase inhibitor,P11234
CHEMBL4850519,,RBC8,Preclinical,Ral GTPase inhibitor,P11234
CHEMBL4867139,,brefeldin-A,Preclinical,protein synthesis inhibitor,P84077
CHEMBL4867139,,brefeldin-A,Preclinical,protein synthesis inhibitor,Q99418
CHEMBL4297533,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C.CC(=O)O,bremelanotide,Launched,melanocortin receptor agonist,Q01718
CHEMBL4297533,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C.CC(=O)O,bremelanotide,Launched,melanocortin receptor agonist,P41968
CHEMBL4297533,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C.CC(=O)O,bremelanotide,Launched,melanocortin receptor agonist,P32245
CHEMBL4297533,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C.CC(=O)O,bremelanotide,Launched,melanocortin receptor agonist,P33032
CHEMBL38434,CC1=C(C2=C(C=CC(=C2)F)N=C1C3=CC=C(C=C3)C4=CC=CC=C4F)C(=O)O,brequinar,Phase 2,dihydroorotate dehydrogenase inhibitor,Q02127
CHEMBL960,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,leflunomide,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,Q02127
CHEMBL1235017,C1=C(NC(=O)NC1=O)C(=O)O,orotic-acid,Phase 2,,Q02127
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q02127
CHEMBL4877329,,teriflunomide,Launched,dihydroorotate dehydrogenase inhibitor,Q02127
CHEMBL4871229,,brinzolamide,Launched,carbonic anhydrase inhibitor,P35218
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P35218
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P35218
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P35218
CHEMBL4303469,C1=CC=C(C=C1)CC(C(=O)O)NCC2=CC=C(C=C2)Cl,BRL-26314,Phase 1,cholesterol inhibitor,P06858
CHEMBL1897738,CCC(C)(C(=O)O)OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(C=C3)OC(C)(CC)C(=O)O,clinofibrate,Launched,lipase clearing factor inhibitor,P06858
CHEMBL3833336,CC(C)(C(=O)[O-])OC1=CC=C(C=C1)Cl.CC(C)(C(=O)[O-])OC1=CC=C(C=C1)Cl.[OH-].[Al+3],clofibrate,Launched,PPAR receptor agonist,P06858
CHEMBL457,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,gemfibrozil,Launched,lipoprotein lipase activator,P06858
CHEMBL34234,CCOP(=O)(CC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)Br)C#N)OCC,ibrolipim,Phase 2,lipoprotein lipase activator,P06858
CHEMBL2106730,CC(C)(C(=O)N1CSCC1C(=O)O)OC2=CC=C(C=C2)Cl,timofibrate,Phase 2,cholesterol inhibitor|lipase clearing factor inhibitor,P06858
CHEMBL4878284,,BRL-50481,Preclinical,phosphodiesterase inhibitor,Q13946
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q13946
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q13946
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,Q13946
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q13946
CHEMBL4878284,,BRL-50481,Preclinical,phosphodiesterase inhibitor,Q9NP56
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q9NP56
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q9NP56
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q9NP56
CHEMBL4303674,C1=CC=C(C=C1)S(=O)(=O)C2=CC(=C(C=C2)[N+](=O)[O-])OC(=O)C3=CC=C(C=C3)Cl,BTB06584,Preclinical,ATPase inhibitor,P24539
CHEMBL1990168,C1=CC=C(C=C1)S(=O)(=O)C2=C(C=C(C=C2)Cl)[N+](=O)[O-],BTB1,Preclinical,mitotic kinesin inhibitor,Q8NI77
CHEMBL4847770,,BTT-3033,Preclinical,integrin inhibitor,P17301
CHEMBL4846854,,TC-I-15,Preclinical,integrin inhibitor,P17301
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,Q9HC97
CHEMBL4858143,,CID-2745687,Preclinical,G protein-coupled receptor antagonist,Q9HC97
CHEMBL4852901,,furosemide,Launched,diuretic,Q9HC97
CHEMBL4849655,,kynurenic-acid,Phase 1,glutamate receptor antagonist,Q9HC97
CHEMBL4869582,,TCS-3035,Preclinical,G protein-coupled receptor agonist,Q9HC97
CHEMBL28079,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,zaprinast,Phase 2,phosphodiesterase inhibitor,Q9HC97
CHEMBL1072,CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2,bumetanide,Launched,solute carrier family member inhibitor,Q9UP95
CHEMBL4873089,,butabindide,Preclinical,tripeptidyl peptidase inhibitor,P29144
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q13002
CHEMBL454,CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C,butalbital,Launched,GABA receptor antagonist,Q16478
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,Q13002
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,Q16478
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q13002
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q16478
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q13002
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q16478
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q13002
CHEMBL450,CCC1(C(=O)NC(=O)N(C1=O)C)CC,metharbital,Launched,GABA receptor modulator,Q16478
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q13002
CHEMBL856,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,primidone,Launched,GABA receptor antagonist,Q16478
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,Q13002
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,Q16478
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q13002
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q16478
CHEMBL1200397,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32.Cl,butenafine,Launched,fungal squalene epoxidase inhibitor,Q14534
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,Q14534
CHEMBL1200832,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21.Cl,terbinafine,Launched,fungal squalene epoxidase inhibitor,Q14534
CHEMBL1256575,CCCCS(=N)(=O)CCC(C(=O)O)N,buthionine-sulfoximine,Phase 1,glutathione transferase inhibitor,P48507
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P48507
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P48507
CHEMBL4859488,,BVT-948,Preclinical,tyrosine phosphatase inhibitor,Q06124
CHEMBL4857708,,SHP099,Preclinical,protein tyrosine kinase inhibitor,Q06124
CHEMBL4859488,,BVT-948,Preclinical,tyrosine phosphatase inhibitor,P17706
CHEMBL4857080,,C-021,Preclinical,CC chemokine receptor antagonist,P51679
CHEMBL4857080,,C-021,Preclinical,CC chemokine receptor antagonist,Q9UK39
CHEMBL4857080,,C-021,Preclinical,CC chemokine receptor antagonist,Q9ULM6
CHEMBL554014,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl,plerixafor,Launched,CC chemokine receptor antagonist,P51679
CHEMBL554014,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl,plerixafor,Launched,CC chemokine receptor antagonist,Q9UK39
CHEMBL554014,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl,plerixafor,Launched,CC chemokine receptor antagonist,Q9ULM6
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P68363
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P68363
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P68363
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P68363
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P68363
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q9BQE3
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q9BQE3
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q9BQE3
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q9BQE3
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q9BQE3
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P0DPH7
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P0DPH7
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P0DPH7
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P0DPH7
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P0DPH7
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P0DPH8
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P0DPH8
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P0DPH8
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P0DPH8
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P0DPH8
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q6PEY2
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q6PEY2
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q6PEY2
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q6PEY2
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q6PEY2
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P68366
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P68366
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P68366
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P68366
CHEMBL61,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,podophyllotoxin,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P68366
CHEMBL499458,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vincristine,Launched,tubulin polymerization inhibitor,P68366
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P68366
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q9H4B7
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q9H4B7
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q9H4B7
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q9H4B7
CHEMBL3989543,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O.OS(=O)(=O)O,vindesine,Launched,tubulin polymerization inhibitor,Q9H4B7
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q9H4B7
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q13885
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q13885
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q13885
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q13885
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q13885
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q9BVA1
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q9BVA1
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q9BVA1
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q9BVA1
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q9BVA1
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q13509
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q13509
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q13509
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q13509
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q13509
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,P04350
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,P04350
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P04350
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P04350
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,P04350
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q9BUF5
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q9BUF5
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q9BUF5
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q9BUF5
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q9BUF5
CHEMBL4823266,,cabazitaxel,Launched,microtubule inhibitor,Q3ZCM7
CHEMBL107,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,colchicine,Launched,microtubule inhibitor,Q3ZCM7
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,Q3ZCM7
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,Q3ZCM7
CHEMBL553025,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,vinorelbine,Launched,tubulin polymerization inhibitor,Q3ZCM7
CHEMBL4871735,,CaCCinh-A01,Preclinical,calcium-activated chloride channel inhibitor,A8K7I4
CHEMBL1081506,C1=CC=C2C(=C1)C(OC2=O)OC(=O)C3=C(N=CC=C3)NC4=CC=CC(=C4)C(F)(F)F,talniflumate,Launched,cyclooxygenase inhibitor,A8K7I4
CHEMBL145,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,caffeic-acid,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,P03971
CHEMBL145,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,caffeic-acid,Preclinical,HIV integrase inhibitor|lipoxygenase inhibitor|nitric oxide production inhibitor|tumor necrosis factor production inhibitor,P14174
CHEMBL311909,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)OC)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O,chicago-sky-blue-6b,Preclinical,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,P03971
CHEMBL311909,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C3)C(=CC(=C4N)S(=O)(=O)O)S(=O)(=O)O)O)OC)N=NC5=C(C6=C(C=C5)C(=CC(=C6N)S(=O)(=O)O)S(=O)(=O)O)O,chicago-sky-blue-6b,Preclinical,glutamate inhibitor|macrophage migration inhibiting factor inhibitor,P14174
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P03971
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P14174
CHEMBL4303715,C1COCCN1C(=O)CC2CC(=NO2)C3=C(C=C(C=C3)F)F,CPSI-1306-(+/-),Preclinical,macrophage migration inhibiting factor inhibitor,P03971
CHEMBL4303715,C1COCCN1C(=O)CC2CC(=NO2)C3=C(C=C(C=C3)F)F,CPSI-1306-(+/-),Preclinical,macrophage migration inhibiting factor inhibitor,P14174
CHEMBL4874030,,ISO-1,Preclinical,macrophage migration inhibiting factor inhibitor,P03971
CHEMBL4874030,,ISO-1,Preclinical,macrophage migration inhibiting factor inhibitor,P14174
CHEMBL4853106,,YZ9,Preclinical,phosphofructokinase inhibitor,P03971
CHEMBL4853106,,YZ9,Preclinical,phosphofructokinase inhibitor,P14174
CHEMBL497802,C1=CC=C(C=C1)C2=CC(=NC=N2)I,4-iodo-6-phenylpyrimidine,Preclinical,macrophage migration inhibiting factor inhibitor,P03971
CHEMBL497802,C1=CC=C(C=C1)C2=CC(=NC=N2)I,4-iodo-6-phenylpyrimidine,Preclinical,macrophage migration inhibiting factor inhibitor,P14174
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q13315
CHEMBL4866540,,CGK-733,Preclinical,ATM kinase inhibitor|ATR kinase inhibitor,Q13315
CHEMBL4870943,,KU-55933,Preclinical,ATM kinase inhibitor,Q13315
CHEMBL4867818,,KU-60019,Preclinical,ATM kinase inhibitor,Q13315
CHEMBL4879030,,VE-822,Phase 2,ATR kinase inhibitor,Q13315
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q14571
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q14573
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q9Y233
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q9Y233
CHEMBL4303586,CC1=CN=C(C2=NC(=NN12)[C@@H]3C[C@H]3C4=C(N5C=CC6=C(C5=N4)C=CC=N6)C)C,PDE10-IN-1,Preclinical,phosphodiesterase inhibitor,Q9Y233
CHEMBL19224,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,papaverine,Launched,phosphodiesterase inhibitor,Q9Y233
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q9Y233
CHEMBL562318,CN1C=C(C(=N1)C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C5=CC=NC=C5,PF-02545920,Phase 2,phosphodiesterase inhibitor,Q9Y233
CHEMBL4445635,COC1=CN(N=C(C1O)C2=CC=NN2C3=CC=CC=C3)C4=C(C=C(C=C4)N5C=CC=N5)F,TAK-063,Phase 2,phosphodiesterase inhibitor,Q9Y233
CHEMBL1332032,CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O,triflusal,Launched,cyclooxygenase inhibitor|platelet aggregation inhibitor|thromboxane synthase inhibitor,Q9Y233
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q9HCR9
CHEMBL177542,CN1CC(=O)N2[C@@H](C1=O)CC3C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36,tadalafil,Launched,phosphodiesterase inhibitor,Q9HCR9
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P54750
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P54750
CHEMBL4856202,,ITI214,Phase 1/Phase 2,phosphodiesterase inhibitor,P54750
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P54750
CHEMBL1079905,CCCN1C=NC2=C1C(=O)N(C(=O)N2C)CCCCC(=O)C,propentofylline,Launched,adenosine reuptake inhibitor|phosphodiesterase inhibitor,P54750
CHEMBL4869491,,vinpocetine,Launched,phosphodiesterase inhibitor|sodium channel blocker,P54750
CHEMBL28079,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,zaprinast,Phase 2,phosphodiesterase inhibitor,P54750
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q01064
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q01064
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q01064
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,Q14123
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q14123
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q14123
CHEMBL4869491,,vinpocetine,Launched,phosphodiesterase inhibitor|sodium channel blocker,Q14123
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P16499
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P16499
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P16499
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P35913
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P35913
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P35913
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P51160
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P51160
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P51160
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O60658
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O60658
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,O60658
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O60658
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O95263
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O95263
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O95263
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,O76083
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O76083
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,O76083
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O76083
CHEMBL4854165,,PF-04447943,Phase 2,phosphodiesterase inhibitor,O76083
CHEMBL28079,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,zaprinast,Phase 2,phosphodiesterase inhibitor,O76083
CHEMBL113,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,caffeine,Launched,adenosine receptor antagonist|phosphodiesterase inhibitor,P78527
CHEMBL4852963,,compound-401,Preclinical,DNA dependent protein kinase inhibitor,P78527
CHEMBL4870943,,KU-55933,Preclinical,ATM kinase inhibitor,P78527
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,P78527
CHEMBL4857542,,NU-7026,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,P78527
CHEMBL188678,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56,NU-7441,Preclinical,DNA dependent protein kinase inhibitor,P78527
CHEMBL4867587,,PI-103,Preclinical,mTOR inhibitor|PI3K inhibitor,P78527
CHEMBL4853500,,PIK-75,Preclinical,DNA protein kinase inhibitor|PI3K inhibitor,P78527
CHEMBL4857575,,PP-121,Preclinical,protein tyrosine kinase inhibitor,P78527
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P78527
CHEMBL4303565,C[C@H](C1=CC=CC2=CC=CC=C21)N[C@H]3CCCC[C@@H]3NC(=O)C4=CC=C(C=C4)Cl,Calhex-231,Preclinical,calcium sensing receptor negative allosteric modulator,P41180
CHEMBL1200776,C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F.Cl,cinacalcet,Launched,calcium channel activator,P41180
CHEMBL4857555,,NPS-2143,Preclinical,calcium receptor antagonist,P41180
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P41180
CHEMBL3707306,C(C1=C(SC(=C1C#N)N(CC(=O)[O-])CC(=O)[O-])C(=O)[O-])C(=O)[O-].[Sr+2].[Sr+2],strontium-ranelate,Launched,bone formation stimulant|bone resorption inhibitor,P41180
CHEMBL2107572,C[C@H](C1=CC(=CC=C1)OC)NCCCC2=CC=CC=C2Cl.Cl,tecalcet,Phase 2,calcium-sensing receptor agonist,P41180
CHEMBL4853317,,tryptophan,Launched,serotonin receptor partial agonist,P41180
CHEMBL4863026,,CaMKII-IN-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,Q9UQM7
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,Q9UQM7
CHEMBL4798656,[HH].CN(C/C=C/C1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC.OOP(=O)=O,KN-93,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,Q9UQM7
CHEMBL4863026,,CaMKII-IN-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,Q16566
CHEMBL4863026,,CaMKII-IN-1,Preclinical,calcium/calmodulin dependent protein kinase inhibitor,Q15746
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q15746
CHEMBL85164,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O,camostat-mesilate,Launched,protease inhibitor,P07477
CHEMBL380216,CC(=O)NCC(=O)O.CC(=O)NCC(=O)O.C1=CC(=CC=C1C(=N)N)NN=NC2=CC=C(C=C2)C(=N)N,diminazene-aceturate,Phase 3,angiotensin converting enzyme activator,P07477
CHEMBL1398351,CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N.CS(=O)(=O)O,gabexate,Launched,serine protease inhibitor,P07477
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,P07477
CHEMBL4594217,CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F.O,canagliflozin,Launched,sodium/glucose cotransporter inhibitor,P31639
CHEMBL429910,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl,dapagliflozin,Launched,sodium/glucose cotransporter inhibitor,P31639
CHEMBL2107830,C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl,empagliflozin,Launched,sodium/glucose cotransporter inhibitor,P31639
CHEMBL4874337,,ertugliflozin,Launched,sodium/glucose cotransporter inhibitor,P31639
CHEMBL242341,COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O,formononetin,Preclinical,alcohol dehydrogenase inhibitor,P31639
CHEMBL4297658,C1C[C@H](NC1)C(=O)O.C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F,ipragliflozin-L-proline,Launched,sodium/glucose cotransporter inhibitor,P31639
CHEMBL4303464,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,P31639
CHEMBL3039507,CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)SC)O)O)O)Cl,sotagliflozin,Phase 3,sodium/glucose cotransporter inhibitor,P31639
CHEMBL2140203,C[C@]12CCC(=O)C=C1C=CC3C2CC[C@]4(C3CC[C@@]45CCC(=O)O5)C,canrenone,Withdrawn,mineralocorticoid receptor antagonist,P08235
CHEMBL4847130,,corticosterone,Preclinical,mineralocorticoid receptor agonist,P08235
CHEMBL1200542,CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,deoxycorticosterone-acetate,Preclinical,progestogen hormone,P08235
CHEMBL1200592,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)COC(=O)C(C)(C)C)CCC4=CC(=O)CC[C@]34C,desoxycorticosterone-pivalate,Launched,corticosteroid agonist,P08235
CHEMBL4855808,,desoxycortone,Preclinical,mineralocorticoid receptor agonist,P08235
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P08235
CHEMBL1509,C[C@]12CCC(=O)C=C1[C@@H]3C[C@@H]3[C@@H]4[C@@H]2CC[C@]5([C@H]4[C@@H]6C[C@@H]6[C@@]57CCC(=O)O7)C,drospirenone,Launched,mineralocorticoid receptor antagonist,P08235
CHEMBL1095097,C[C@]12CCC(=O)C=C1C[C@H]([C@@H]3[C@]24[C@H](O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC,eplerenone,Launched,cytochrome P450 inhibitor,P08235
CHEMBL4303446,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H](C3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,fludrocortisone-acetate,Launched,,P08235
CHEMBL1473,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,fluticasone-propionate,Launched,glucocorticoid receptor agonist,P08235
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,P08235
CHEMBL1514440,CC1=C([C@H](C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,nimodipine,Launched,calcium channel blocker,P08235
CHEMBL1371200,C[C@]12CCC(=O)C=C1C=C[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(CCC(=O)[O-])O)C.[K+],potassium-canrenoate,Launched,mineralocorticoid receptor antagonist,P08235
CHEMBL1201014,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=C[C@]34C)O.[Na+].[Na+],prednisolone,Launched,glucocorticoid receptor agonist,P08235
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,P08235
CHEMBL2107003,CCC[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(CCC(=O)O)O)C,RU-28318,Phase 2,cytochrome P450 inhibitor,P08235
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P08235
CHEMBL1773,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O,capecitabine,Launched,DNA synthesis inhibitor|thymidylate synthase inhibitor,P04818
CHEMBL460499,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,carmofur,Launched,thymidylate synthase inhibitor,P04818
CHEMBL4861933,,doxifluridine,Launched,thymidylate synthase inhibitor,P04818
CHEMBL2106589,CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,enocitabine,Launched,DNA synthesis inhibitor,P04818
CHEMBL4878481,,floxuridine,Launched,DNA synthesis inhibitor,P04818
CHEMBL3244426,,ftorafur,Launched,thymidylate synthase inhibitor,P04818
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine,Launched,ribonucleotide reductase inhibitor,P04818
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine-elaidate,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,P04818
CHEMBL2356692,CC1=C(C2=C(C=C1)N=C(NC2=O)N)SC3=CC=NC=C3.Cl.Cl,nolatrexed,Phase 3,thymidylate synthase inhibitor,P04818
CHEMBL2360464,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],pemetrexed,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,P04818
CHEMBL140144,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,raltitrexed,Launched,thymidylate synthase inhibitor,P04818
CHEMBL4857126,,trifluridine,Launched,DNA directed DNA polymerase inhibitor|thymidylate synthase inhibitor,P04818
CHEMBL2110367,COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N.OS(=O)(=O)O,trimethoprim,Launched,dihydrofolate reductase inhibitor,P04818
CHEMBL4874454,,WR99210,Preclinical,dihydrofolate reductase inhibitor,P04818
CHEMBL4854670,C1=C(NC(=O)NC1=O)F,5-fluorouracil,Launched,thymidylate synthase inhibitor,P04818
CHEMBL4303165,C1=C(C=NC(=O)N1)F,5-FP,Phase 1,thymidylate synthase inhibitor,P04818
CHEMBL4875326,,capsazepine,Preclinical,TRPV agonist,Q9HBA0
CHEMBL3994677,,GSK2193874,Preclinical,transient receptor potential channel antagonist,Q9HBA0
CHEMBL2133556,CC1=C(C=C(N1CCCN2CCOCC2)C3=CC=CC=C3)C(=O)NC4=CC=CC(=C4)C(F)(F)F,HC-067047,Preclinical,transient receptor potential channel antagonist,Q9HBA0
CHEMBL4303584,C1CN(CCN1CC2=CC=CC=C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)[N+](=O)[O-],RN-1747,Preclinical,TRPV agonist,Q9HBA0
CHEMBL4876571,,RN-1734,Preclinical,TRPV antagonist,Q9HBA0
CHEMBL3598020,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H]([C@@]2([C@@H]3CC(C(=O)[C@]3(CC(=C[C@H]2[C@H]4[C@@]1(C4(C)C)OC(=O)C)CO)O)C)O)C,12-O-tetradecanoylphorbol-13-acetate,Phase 2,PKC activator,Q9HBA0
CHEMBL4852091,,captopril,Launched,angiotensin converting enzyme inhibitor,P09960
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P09960
CHEMBL4849355,,ubenimex,Launched,leukotriene synthesis inhibitor,P09960
CHEMBL9116,CC(=O)N(C(=O)NC)OC(=O)NC,caracemide,Phase 2,ribonucleotide reductase inhibitor,P23921
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P23921
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL367788,C1=CC(=C(C=C1C(=O)NO)O)O,didox,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL2106589,CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,enocitabine,Launched,DNA synthesis inhibitor,P23921
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine-elaidate,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,P23921
CHEMBL467,C(=O)(N)NO,hydroxyurea,Launched,ribonucleotide reductase inhibitor,P23921
CHEMBL4848331,,triapine,Phase 2,ribonucleotide reductase inhibitor,P23921
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P17302
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P17302
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P17302
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P57773
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q969M2
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P57773
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q969M2
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P57773
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q969M2
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q9Y6H8
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9Y6H8
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q9Y6H8
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P35212
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P35212
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P35212
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P36382
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P36382
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P36382
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P48165
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P48165
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P48165
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q9UKL4
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9UKL4
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q9UKL4
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P08034
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P08034
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P08034
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P29033
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P29033
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P29033
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,O75712
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,O75712
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,O75712
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q9NTQ9
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9NTQ9
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q9NTQ9
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,O95377
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,O95377
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,O95377
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,O95452
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,O95452
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,O95452
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q6PEY0
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q6PEY0
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q6PEY0
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,P36383
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q8N144
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,P36383
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q8N144
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,P36383
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q8N144
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q5T442
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q5T442
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q5T442
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q8NFK1
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q8NFK1
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q8NFK1
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q96KN9
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q96KN9
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,Q96KN9
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,A6NN92
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,A6NN92
CHEMBL26215,CCCCCCCCO,1-octanol,Phase 2,,A6NN92
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q96RD7
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q96RD7
CHEMBL897,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,probenecid,Launched,uricosuric blocker,Q96RD7
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q96RD6
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q96RD6
CHEMBL1697717,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CCC(=O)[O-])C)(C)C(=O)[O-].[Na+].[Na+],carbenoxolone,Launched,11-beta hydroxysteroid dehydrogenase inhibitor,Q96QZ0
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q96QZ0
CHEMBL508102,CCOC(=O)N1C=CN(C1=S)C,carbimazole,Launched,antithyroid agent,P07202
CHEMBL1515,CN1C=CNC1=S,methimazole,Launched,antithyroid agent,P07202
CHEMBL1518,CCCC1=CC(=O)NC(=S)N1,propylthiouracil,Launched,thyroid peroxidase inhibitor,P07202
CHEMBL4848898,,carboxyamidotriazole,Phase 3,calcium channel blocker,P10145
CHEMBL4521451,C.CNCC/C=C/C1=CN=CC=C1,rivanicline,Phase 2,acetylcholine receptor agonist,P10145
CHEMBL1382901,C1CCC(CC1)C2=NN3C(=NN=C3S2)C4=CC=CO4,cardionogen-1,Preclinical,WNT signaling inhibitor,P35222
CHEMBL4303205,C1CN2C3=CC=CC=C3N(C2=N1)CC(=O)C4=CC=C(C=C4)C5=CC=CC=C5,CCT-031374,Preclinical,WNT signaling inhibitor,P35222
CHEMBL4303484,C1CN([C@H]2CN(C(=O)[C@H](N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6,ICG-001,Preclinical,beta-catenin inhibitor,P35222
CHEMBL4878208,,iCRT-14,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,P35222
CHEMBL4873440,,PNU-74654,Preclinical,beta-catenin inhibitor,P35222
CHEMBL4852012,,urea,Launched,hydroxy radical formation stimulant,P35222
CHEMBL1201780,C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N,carglumic-acid,Launched,carbamoyl phosphate synthase activator,P31327
CHEMBL2000716,C1C=CN(C=C1C(=O)N)CC(=O)N,caricotamide,Phase 2,NADPH quinone oxidoreductase inhibitor,P16083
CHEMBL4851780,,coenzyme-I,Phase 2,,P16083
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P16083
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P16083
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P16083
CHEMBL165,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,resveratrol,Launched,cytochrome P450 inhibitor|SIRT activator,P16083
CHEMBL4851524,,tretazicar,Phase 2,DNA replication inhibitor,P16083
CHEMBL4878581,,2-iodomelatonin,Preclinical,melatonin receptor agonist,P16083
CHEMBL513,C(CCl)NC(=O)N(CCCl)N=O,carmustine,Launched,DNA alkylating agent|DNA inhibitor,P00390
CHEMBL4851780,,coenzyme-I,Phase 2,,P00390
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P00390
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P00390
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,P00390
CHEMBL4303334,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@H](C(=O)O)N,NOV-002,Phase 3,,P00390
CHEMBL4849610,,carzenide,Preclinical,,P23280
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,P23280
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,P23280
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P23280
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,P23280
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,P23280
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,P23280
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,P23280
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,P23280
CHEMBL4847779,,para-toluenesulfonamide,Phase 3,,P23280
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P23280
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P23280
CHEMBL6705,C1=CC=C(C(=C1)N)S(=O)(=O)N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,P23280
CHEMBL4849610,,carzenide,Preclinical,,Q16790
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,Q16790
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,Q16790
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,Q16790
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,Q16790
CHEMBL32749,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,ferulic-acid,Phase 2,antioxidant,Q16790
CHEMBL288114,C1=C(C=C(C(=C1O)O)O)C(=O)O,gallic-acid,Preclinical,beta amyloid protein neurotoxicity inhibitor|PPAR receptor agonist,Q16790
CHEMBL4851218,,hydrochlorothiazide,Launched,thiazide diuretic,Q16790
CHEMBL1763,C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,hydroflumethiazide,Launched,sodium/potassium/chloride transporter inhibitor,Q16790
CHEMBL4859083,,indisulam,Phase 2,CDK inhibitor,Q16790
CHEMBL1201161,CC(=O)O.C1=CC(=CC=C1CN)S(=O)(=O)N,mafenide,Launched,carbonic anhydrase inhibitor,Q16790
CHEMBL4847779,,para-toluenesulfonamide,Phase 3,,Q16790
CHEMBL4852969,,phenol,Preclinical,,Q16790
CHEMBL310671,C1=CC=C2C(=C1)C(=O)NS2(=O)=O,saccharin,Launched,DNA polymerase inhibitor,Q16790
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q16790
CHEMBL2022564,CC[C@H](C)[C@H]1C(=O)N2CCC[C@H]2C(=O)O[C@@H](C[C@H](C[C@@H]([C@@H](C3=N[C@@H](CCC(=O)N[C@H](C(=O)N([C@H](C(=O)N1C)C)C)CC4=CC=C(C=C4)OC)CS3)C)O)C)C(C)(C)C,S4,Preclinical,carbonic anhydrase inhibitor,Q16790
CHEMBL4877943,,U-104,Phase 1/Phase 2,carbonic anhydrase inhibitor,Q16790
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q16790
CHEMBL6705,C1=CC=C(C(=C1)N)S(=O)(=O)N,2-aminobenzenesulfonamide,Preclinical,carbonic anhydrase inhibitor,Q16790
CHEMBL311226,C1CN2C[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)O,castanospermine,Phase 2,glucosidase inhibitor,P10253
CHEMBL1561,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,miglitol,Launched,glucosidase inhibitor,P10253
CHEMBL311226,C1CN2C[C@@H]([C@H]([C@@H]([C@H]2[C@H]1O)O)O)O,castanospermine,Phase 2,glucosidase inhibitor,P04062
CHEMBL4112645,C[C@@H]1CN(CCN1C)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6,NN-DNJ,Preclinical,glucosidase inhibitor,P04062
CHEMBL4871268,,cathepsin-inhibitor-1,Preclinical,cathepsin inhibitor,P07858
CHEMBL63440,CCOC(=O)[C@@H]1[C@H](O1)C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,loxistatin-acid,Preclinical,cysteine peptidase inhibitor,P07858
CHEMBL3314610,CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)O,pepstatin,Preclinical,aspartic protease inhibitor,P07858
CHEMBL4303448,CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CS(=O)(=O)CC2CC2)N[C@@H](C3=CC=C(C=C3)F)C(F)(F)F,VBY-825,Preclinical,cathepsin inhibitor,P07858
CHEMBL4871268,,cathepsin-inhibitor-1,Preclinical,cathepsin inhibitor,O60911
CHEMBL4866613,,CB-5083,Phase 1,valosin-containing protein inhibitor,P55072
CHEMBL4866547,,NMS-873,Preclinical,ATPase inhibitor,P55072
CHEMBL3813656,,CB-839,Phase 2,glutaminase inhibitor,O94925
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O94925
CHEMBL4872505,,CCG-1423,Preclinical,apoptosis stimulant,P08134
CHEMBL4872505,,CCG-1423,Preclinical,apoptosis stimulant,P11831
CHEMBL4870373,,CCG-50014,Preclinical,G protein signaling inhibitor,P49798
CHEMBL4846835,,CCG-63802,Preclinical,G protein signaling inhibitor,P49798
CHEMBL4857442,,CCG-63808,Preclinical,G protein signaling inhibitor,P49798
CHEMBL4870373,,CCG-50014,Preclinical,G protein signaling inhibitor,P57771
CHEMBL4870654,,CCT018159,Preclinical,HSP inhibitor,P08238
CHEMBL4850247,,EC-144,Preclinical,HSP inhibitor,P08238
CHEMBL4012591,,NVP-AUY922,Phase 2,HSP inhibitor,P08238
CHEMBL4857467,,NVP-HSP990,Phase 1,HSP inhibitor,P08238
CHEMBL4856355,,SNX-5422,Phase 1/Phase 2,HSP inhibitor,P08238
CHEMBL1644,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O,cefadroxil,Launched,bacterial cell wall synthesis inhibitor,Q8TCC7
CHEMBL897,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,probenecid,Launched,uricosuric blocker,Q8TCC7
CHEMBL1200523,CC1=NN=C(S1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+],cefazolin,Launched,bacterial cell wall synthesis inhibitor,P27169
CHEMBL4853442,,cefdinir,Launched,bacterial cell wall synthesis inhibitor,P05164
CHEMBL4866696,,DMP-777,Phase 2,elastase inhibitor,P05164
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P05164
CHEMBL3525949,,mesalazine,Launched,cyclooxygenase inhibitor|lipoxygenase inhibitor|prostanoid receptor antagonist,P05164
CHEMBL2403108,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,P06213
CHEMBL4578973,CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N,dovitinib,Phase 3,EGFR inhibitor|FGFR inhibitor|FLT3 inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,P06213
CHEMBL4860561,,GSK1838705A,Preclinical,insulin growth factor receptor inhibitor,P06213
CHEMBL466397,CCC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)S(=O)(=O)C)OC)NC4=NC=CC(=N4)C5=C(N=C6N5C=CC=C6)C7=CC(=C(C=C7)OC)C(=O)NC8=C(C=CC=C8F)F,GSK1904529A,Preclinical,IGF-1 inhibitor|insulin growth factor receptor inhibitor|insulin receptor ligand,P06213
CHEMBL1091644,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,linsitinib,Phase 3,IGF-1 inhibitor,P06213
CHEMBL4797365,C1CN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6.Cl.Cl,NVP-AEW541,Preclinical,IGF-1 inhibitor,P06213
CHEMBL4873176,,NVP-TAE684,Preclinical,ALK tyrosine kinase receptor inhibitor,P06213
CHEMBL2403108,CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,ceritinib,Launched,ALK tyrosine kinase receptor inhibitor,Q9BXA7
CHEMBL4874543,,cerulenin,Launched,fatty acid synthase inhibitor,P49327
CHEMBL36327,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epicatechin-gallate-(-),Phase 2,bacterial DNA gyrase inhibitor,P49327
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,P49327
CHEMBL4847440,,fisetin,Preclinical,Aurora kinase inhibitor,P49327
CHEMBL3646801,C1CN(C[C@@H]1CC2=NNC(=O)N2C3=CC=C(C=C3)C4=CC5=C(C=C4)OC=C5)C(=O)C6CC6,GSK2194069,Preclinical,fatty acid synthase inhibitor,P49327
CHEMBL28626,C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,morin,Preclinical,cytochrome P450 inhibitor,P49327
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,P49327
CHEMBL4746300,C1[C@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)C(F)(F)F,pretomanid,Launched,nitric oxide donor,P49327
CHEMBL614,C1=CN=C(C=N1)C(=O)N,pyrazinamide,Launched,fatty acid synthase inhibitor,P49327
CHEMBL564769,CC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,P49327
CHEMBL2103825,CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C=C2)C)C(=O)O1,cetilistat,Phase 3,triacylglycerol lipase inhibitor,P16233
CHEMBL3301669,CC(C)CCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)O[C@@H]8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=C(C(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC=C(O3)C=C2)C(=O)N1)NC)O)O)Cl)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O,dalbavancin,Launched,bacterial cell wall synthesis inhibitor,P16233
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,P16233
CHEMBL2103735,C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C.CC(=O)O,cetrorelix,Launched,gonadotropin releasing factor hormone receptor antagonist,P22888
CHEMBL1200501,CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.CC(=O)O,goserelin-acetate,Launched,gonadotropin releasing factor hormone receptor agonist,P22888
CHEMBL4876518,,CE3F4,Preclinical,rap guanine nucleotide exchange factor inhibitor,O95398
CHEMBL4871102,,ESI-09,Preclinical,EPAC inhibitor,O95398
CHEMBL576817,C1=CC(=CC=C1NC2C3=C(N=CN=C3N=N2)N)F,CGP-57380,Preclinical,MAP kinase inhibitor,Q9BUB5
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,Q9BUB5
CHEMBL576817,C1=CC(=CC=C1NC2C3=C(N=CN=C3N=N2)N)F,CGP-57380,Preclinical,MAP kinase inhibitor,Q9HBH9
CHEMBL576817,C1=CC(=CC=C1NC2C3=C(N=CN=C3N=N2)N)F,CGP-57380,Preclinical,MAP kinase inhibitor,O00141
CHEMBL4848147,,GSK650394,Preclinical,serum/glucocorticoid regulated kinase inhibitor,O00141
CHEMBL4868076,,KN-62,Preclinical,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist,O00141
CHEMBL4847722,,LY294002,Preclinical,DNA dependent protein kinase inhibitor|mTOR inhibitor|phosphodiesterase inhibitor|PI3K inhibitor|PLK inhibitor,O00141
CHEMBL4858681,,PD-98059,Preclinical,MEK inhibitor,O00141
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,O00141
CHEMBL4846403,,SB-202190,Preclinical,p38 MAPK inhibitor,O00141
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,O00141
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,O00141
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,O00141
CHEMBL4853924,,CGP-53353,Preclinical,EGFR inhibitor|PKC inhibitor,P05771
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P05771
CHEMBL2107337,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7.Cl,enzastaurin,Phase 3,PKC inhibitor,P05771
CHEMBL4847929,,go-6983,Preclinical,protein kinase inhibitor,P05771
CHEMBL1863513,C/C=C(/C)\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C,ingenol-mebutate,Launched,PKC activator,P05771
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,P05771
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P05771
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,P05771
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P05771
CHEMBL4865113,,CGP-71683,Preclinical,neuropeptide receptor antagonist,Q15761
CHEMBL4303679,CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC,GW-438014A,Preclinical,neuropeptide receptor antagonist,Q15761
CHEMBL1421016,CC1(CC(=O)C(C(=O)C1)C2C3=CC=CC=C3OC4=C2C(=O)CC(C4)(C)C)C,L-152804,Preclinical,neuropeptide receptor antagonist,Q15761
CHEMBL4875311,,NPY-5RA972,Preclinical,neuropeptide receptor antagonist,Q15761
CHEMBL4868874,,NTNCB,Preclinical,neuropeptide receptor antagonist,Q15761
CHEMBL2016681,CC(C)(C)S(=O)(=O)NC1CCC(CC1)C(=O)NC2=NC=C(C=C2)C(F)(F)F,velneperit,Phase 2,neuropeptide receptor antagonist,Q15761
CHEMBL680578,,chenodeoxycholic-acid,Launched,11-beta hydroxysteroid dehydrogenase inhibitor|FXR agonist,Q96RI1
CHEMBL4867639,,CINPA-1,Preclinical,CAR antagonist,Q96RI1
CHEMBL4876493,,fexaramine,Preclinical,FXR agonist,Q96RI1
CHEMBL4861676,,GR-235,Launched,estrogen receptor agonist|FXR antagonist|progesterone receptor agonist,Q96RI1
CHEMBL4851513,,GW-4064,Preclinical,FXR agonist,Q96RI1
CHEMBL4794162,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC[C@H](C4)O)C)C,lithocholic-acid,Preclinical,FXR antagonist|vitamin D receptor agonist,Q96RI1
CHEMBL266340,CC[C@H]1[C@H]([C@H]2[C@@H]3CC[C@@H]([C@]3(CC[C@@H]2[C@@]4(C1C[C@@H](CC4)O)C)C)[C@H](C)CCC(=O)O)O,obeticholic-acid,Launched,FXR agonist,Q96RI1
CHEMBL4870567,,ursodiol,Launched,nuclear factor erythroid derived|like (NRF2) activator,Q96RI1
CHEMBL1155995,,WAY-362450,Phase 1,FXR agonist,Q96RI1
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,Q96RI1
CHEMBL1200729,C1=CC(=CC=C1[C@H]([C@@H](COC(=O)CCC(=O)[O-])NC(=O)C(Cl)Cl)O)[N+](=O)[O-].[Na+],chloramphenicol,Launched,bacterial 50S ribosomal subunit inhibitor,P08174
CHEMBL284616,C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O,chlorogenic-acid,Launched,antioxidant,O43826
CHEMBL944,CCN(CC)CCOC(=O)C1=C(C=C(C=C1)N)Cl.Cl,chloroprocaine,Launched,sodium channel blocker,Q9GZZ6
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q9GZZ6
CHEMBL1257005,CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O.Cl,lobeline,Launched,acetylcholine receptor antagonist,Q9GZZ6
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,Q9GZZ6
CHEMBL1318287,C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,pentolinium,Launched,cholinergic receptor antagonist,Q9GZZ6
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,Q9GZZ6
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,Q9GZZ6
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P02763
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P19652
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,P17405
CHEMBL4878344,,desipramine,Launched,tricyclic antidepressant,P17405
CHEMBL3220941,C[N+](C)(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)[O-],chlorpromazine,Launched,dopamine receptor antagonist,Q9UL62
CHEMBL8145,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,daidzein,Phase 2,estrogen receptor agonist,Q9UL62
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9UL62
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,Q9UL62
CHEMBL1433489,C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-],KB-R7943,Preclinical,sodium/calcium exchange inhibitor,Q9UL62
CHEMBL4845844,,ML204,Preclinical,transient receptor potential channel antagonist,Q9UL62
CHEMBL4855940,,progesterone,Launched,progesterone receptor agonist,Q9UL62
CHEMBL121,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,rosiglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,Q9UL62
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q9UL62
CHEMBL4874755,,YM-58483,Preclinical,calcium channel blocker,Q9UL62
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9UL62
CHEMBL3039057,CC(C)CCCC(C)[C@H]1CCC2[C@@]1(CCC3C2CC=C4[C@@]3(CC[C@@H](C4)O)C)C,cholesterol,Preclinical,,P35398
CHEMBL4871845,,SR-1078,Preclinical,retinoid receptor agonist,P35398
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P00326
CHEMBL4851780,,coenzyme-I,Phase 2,,P00326
CHEMBL1308,CC1=CNN=C1,fomepizole,Launched,alcohol dehydrogenase inhibitor,P00326
CHEMBL242341,COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O,formononetin,Preclinical,alcohol dehydrogenase inhibitor,P00326
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P13073
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P20674
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P10606
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,Q02221
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P14854
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P09669
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P24310
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P24311
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P15954
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P10176
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P51161
CHEMBL224867,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,taurocholate,Phase 1,G protein-coupled receptor agonist,P51161
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P22830
CHEMBL1096562,COC(=O)CCC(=O)CN,methyl-aminolevulinate,Launched,oxidizing agent,P22830
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P00395
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P00403
CHEMBL4863553,,talmapimod,Phase 2,p38 MAPK inhibitor,P00403
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P00414
CHEMBL205596,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,cholic-acid,Launched,bile acid,P04054
CHEMBL4851304,,clobetasol-propionate,Launched,glucocorticoid receptor agonist,P04054
CHEMBL1200975,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)COC(=O)C(C)(C)C)C)O)Cl)C)F,clocortolone-pivalate,Launched,steroid,P04054
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P04054
CHEMBL5090905,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@]35C)O,desonide,Launched,glucocorticoid receptor agonist,P04054
CHEMBL1766,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,desoximetasone,Launched,glucocorticoid receptor agonist,P04054
CHEMBL1201392,C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F,flumethasone,Launched,glucocorticoid receptor agonist,P04054
CHEMBL1200908,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)CCl,halobetasol-propionate,Launched,glucocorticoid receptor agonist,P04054
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P04054
CHEMBL3277743,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.CS(=O)(=O)C,mepacrine,Launched,cytokine production inhibitor|NFkB pathway inhibitor|TP53 activator,P04054
CHEMBL125,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,miltefosine,Launched,membrane integrity inhibitor,P04054
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P04054
CHEMBL1200386,CCC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)C=C[C@]34C)O)C)OC(=O)OCC,prednicarbate,Launched,phospholipase activator,P04054
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P04054
CHEMBL169,C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O,ursolic-acid,Phase 2/Phase 3,ATPase inhibitor|NFkB pathway inhibitor|STAT inhibitor,P04054
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,P49585
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,Q9Y5K3
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,Q8TCT1
CHEMBL920,C[N+](C)(C)CCO,choline,Phase 3,acetylcholine precursor,O14939
CHEMBL3989529,CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N,ethanolamine-oleate,Launched,immunostimulant,O14939
CHEMBL4870577,,FIPI,Preclinical,phospholipase inhibitor,O14939
CHEMBL245621,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F,halopemide,Phase 2,phospholipase inhibitor,O14939
CHEMBL2321744,,ML298,Preclinical,phospholipase inhibitor,O14939
CHEMBL1254577,C1CN(CCC12C(=O)NCN2C3=CC(=CC=C3)F)CCNC(=O)C4=CC5=CC=CC=C5C=C4,VU0364739,Preclinical,phospholipase inhibitor,O14939
CHEMBL4876112,,CHR-6494,Preclinical,serine/threonine kinase inhibitor,Q8TF76
CHEMBL4866884,,H-89,Preclinical,PKA inhibitor,Q8TF76
CHEMBL4303455,COC1=CC2=C(C=C1)N=C3C=CC(=CC3=C2SCCCN)Cl,LDN-209929,Preclinical,haspin kinase inhibitor,Q8TF76
CHEMBL4846126,,CI-966,Phase 1,GAT inhibitor,P30531
CHEMBL96,C(CC(=O)O)CN,gamma-aminobutyric-acid,Preclinical,benzodiazepine receptor agonist,P30531
CHEMBL1256362,C1CNCC(=C1)C(=O)O.Cl,guvacine,Preclinical,GABA uptake inhibitor,P30531
CHEMBL4871940,,NNC-711,Preclinical,GABA uptake inhibitor,P30531
CHEMBL4860104,,SKF-89976A,Preclinical,GABA uptake inhibitor,P30531
CHEMBL1027,CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C,tiagabine,Launched,GABA uptake inhibitor,P30531
CHEMBL4861492,,CI-976,Phase 1,ACAT inhibitor,P24752
CHEMBL4861492,,CI-976,Phase 1,ACAT inhibitor,P35610
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P24752
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P35610
CHEMBL1504776,C1COCCN1CC2=CC=C(C=C2)NC(=O)C3=CC=C(O3)C4=CC(=CC=C4)Cl,CID-2011756,Preclinical,protein kinase inhibitor,P98161
CHEMBL1504776,C1COCCN1CC2=CC=C(C=C2)NC(=O)C3=CC=C(O3)C4=CC(=CC=C4)Cl,CID-2011756,Preclinical,protein kinase inhibitor,Q15139
CHEMBL1201057,CC1(C[C@@H]1C(=O)N/C(=C\CCCCSC[C@@H](C(=O)O)N)/C(=O)[O-])C.[Na+],cilastatin,Launched,dehydropeptidase inhibitor,P16444
CHEMBL491571,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O,doripenem,Launched,bacterial cell wall synthesis inhibitor,P16444
CHEMBL4303225,CC1=CC(=NO1)NC(=O)C(C2=CC=CC=C2)N3CCCC4=CC=CC=C43,CIM-0216,Preclinical,transient receptor potential channel agonist,Q9HCF6
CHEMBL686,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,mefenamic-acid,Launched,cyclooxygenase inhibitor,Q9HCF6
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q9HCF6
CHEMBL595,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,pioglitazone,Launched,insulin sensitizer|PPAR receptor agonist,Q9HCF6
CHEMBL121,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,rosiglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,Q9HCF6
CHEMBL1442934,CCCCCCCCCCCCCCC[C@@H]([C@H](CO)N)O,safingol,Phase 1,PKC inhibitor,Q9HCF6
CHEMBL2074778,CC1=C(C(=C(C2=C1OC(CC2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)OS(=O)(=O)O)C,troglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,Q9HCF6
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9HCF6
CHEMBL4857013,,cimetidine,Launched,histamine receptor antagonist,Q7RTT9
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q7RTT9
CHEMBL2359966,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.O.O.OS(=O)(=O)O,quinine,Launched,hemozoin biocrystallization inhibitor,Q7RTT9
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q7RTT9
CHEMBL4857013,,cimetidine,Launched,histamine receptor antagonist,Q96FL8
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,Q96FL8
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,Q96FL8
CHEMBL4876069,,pyrimethamine,Launched,dihydrofolate reductase inhibitor,Q96FL8
CHEMBL4857013,,cimetidine,Launched,histamine receptor antagonist,Q86VL8
CHEMBL4856350,,cinalukast,Phase 2,leukotriene receptor antagonist,Q9Y271
CHEMBL4870037,,MK-571,Phase 2,leukotriene receptor antagonist,Q9Y271
CHEMBL1200681,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+],montelukast,Launched,leukotriene receptor antagonist,Q9Y271
CHEMBL4877379,,nedocromil,Launched,histamine receptor antagonist,Q9Y271
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,Q9Y271
CHEMBL4875059,,SR-2640,Phase 2,leukotriene receptor antagonist,Q9Y271
CHEMBL162358,CCCC1=C(C=CC(=C1O)C(=O)C)OCCCCC2=NNN=N2,tomelukast,Phase 3,leukotriene receptor antagonist,Q9Y271
CHEMBL4848353,,zafirlukast,Launched,leukotriene receptor antagonist,Q9Y271
CHEMBL3039381,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](C3=CC=NC4=CC=CC=C34)O,cinchonine,Preclinical,P glycoprotein inhibitor,P10635
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P10635
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P10635
CHEMBL4870522,,GSK1070916,Phase 1,Aurora kinase inhibitor,P10635
CHEMBL4846156,,ICI-199441,Preclinical,opioid receptor agonist,P10635
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P10635
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P10635
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P10635
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P10635
CHEMBL3038236,C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.Cl.Cl.[Zn+2],sulfanilamide,Launched,carbonic anhydrase inhibitor,P10635
CHEMBL1136,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,P10635
CHEMBL1076211,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,tolperisone,Launched,voltage-gated sodium channel blocker,P10635
CHEMBL4867639,,CINPA-1,Preclinical,CAR antagonist,Q14994
CHEMBL4869245,,CITCO,Preclinical,constitutive androstane receptor (CAR) agonist,Q14994
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,Q14994
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,Q14994
CHEMBL1623,CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl,meclizine,Launched,constitutive androstane receptor (CAR) agonist,Q14994
CHEMBL4303710,CC1=C(C2=CC=CC=C2O1)CNC(=O)NCC3=CC=CS3,S-07662,Preclinical,CAR antagonist,Q14994
CHEMBL115653,CC1(C(=O)N(C(=O)N1C)C[C@@H]([C@@H](CC2CCCC2)C(=O)N3CCCCC3)C(=O)NO)C,cipemastat,Phase 3,metalloproteinase inhibitor,P08254
CHEMBL4869111,,CP-471474,Preclinical,matrix metalloprotease inhibitor,P08254
CHEMBL4869630,,CTS-1027,Phase 2,metalloproteinase inhibitor,P08254
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P08254
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P08254
CHEMBL4866449,,PD-166793,Preclinical,collagenase inhibitor|metalloproteinase inhibitor,P08254
CHEMBL4867936,,UK-356618,Preclinical,metalloproteinase inhibitor,P08254
CHEMBL4870036,,cis-aconitic-acid,Preclinical,,Q99798
CHEMBL1435977,C1C[C@@](C[C@@H]1C(=O)O)(C(=O)O)N.C1C[C@](C[C@H]1C(=O)O)(C(=O)O)N,cis-ACPD,Preclinical,glutamate receptor agonist,Q14832
CHEMBL8759,C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N,eglumetad,Phase 2,glutamate receptor agonist,Q14832
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q14832
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q14832
CHEMBL4877103,,LY2140023,Phase 3,glutamate receptor agonist,Q14832
CHEMBL1594103,CC(C1=CC=C(C=C1)C2=NNN=N2)(C(=O)O)N,MTPG,Preclinical,glutamate receptor antagonist,Q14832
CHEMBL2105616,CC(=O)N[C@@H](CC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O,spaglumic-acid,Launched,glutamate receptor antagonist,Q14832
CHEMBL4162576,C1=CC=NC(=C1)C(=O)NC2=CC(=C(C=C2)OC3=NC=C(C=C3)Cl)Cl,VU0422288,Preclinical,glutamate receptor positive allosteric modulator,Q14832
CHEMBL1435977,C1C[C@@](C[C@@H]1C(=O)O)(C(=O)O)N.C1C[C@](C[C@H]1C(=O)O)(C(=O)O)N,cis-ACPD,Preclinical,glutamate receptor agonist,O15303
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,O15303
CHEMBL8759,C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N,eglumetad,Phase 2,glutamate receptor agonist,O15303
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O15303
CHEMBL1435977,C1C[C@@](C[C@@H]1C(=O)O)(C(=O)O)N.C1C[C@](C[C@H]1C(=O)O)(C(=O)O)N,cis-ACPD,Preclinical,glutamate receptor agonist,O00222
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,O00222
CHEMBL8759,C1C[C@]([C@H]2[C@@H]1[C@@H]2C(=O)O)(C(=O)O)N,eglumetad,Phase 2,glutamate receptor agonist,O00222
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O00222
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,O00222
CHEMBL1331443,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)C(=O)O,"3,4-DCPG-(+/-)",Preclinical,glutamate receptor agonist,O00222
CHEMBL1331443,C1=CC(=C(C=C1[C@H](C(=O)O)N)C(=O)O)C(=O)O,"3,4-DCPG-(S)",Preclinical,glutamate receptor agonist,O00222
CHEMBL1231700,C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,citicoline,Launched,glutathione transferase stimulant|membrane permeability enhancer,P43004
CHEMBL4850405,,DCPIB,Preclinical,chloride channel blocker|gap junction modulator|glutamate inhibitor,P43004
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P43004
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,P43004
CHEMBL4303337,C1=CC=C(C=C1)CO[C@H]([C@H](C(=O)O)N)C(=O)O.C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,P43004
CHEMBL4850279,,WAY-213613,Preclinical,glutamate inhibitor,P43004
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P03950
CHEMBL178459,CC1=C(SSC1=S)C2=NC=CN=C2,oltipraz,Phase 3,nuclear factor erythroid derived|like (NRF2) activator,P03950
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P03950
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q93088
CHEMBL4851692,,L-methionine,Launched,voltage-gated calcium channel ligand,Q93088
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P07360
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P15086
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,O75390
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,O75390
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9GZU7
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,O14964
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9Y663
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q96RQ9
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q96RQ9
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9BY32
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P62312
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine,Phase 2,dopamine receptor agonist,P62312
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P40926
CHEMBL4851780,,coenzyme-I,Phase 2,,P40926
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9HB21
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P07998
CHEMBL2078034,,guanidine,Launched,HSP inhibitor,P07998
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P07998
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,P12724
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,P12724
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9Y275
CHEMBL1261,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,citric-acid,Preclinical,coagulation factor inhibitor,Q9BZX2
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine-5'-triphosphate,Launched,purinergic receptor activator,Q9BZX2
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,P61160
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,P61158
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,O15143
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,O15144
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,O15145
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,P59998
CHEMBL1234574,CC1=C(C2=CC=CC=C2N1)CCNC(=O)C3=CC=CS3,CK-636,Preclinical,actin related protein inhibitor,O15511
CHEMBL3936137,CC1=C(C=CC=C1Cl)C2=CC(=C(C=C2F)N3C4=C(C=CC3=O)C=C(C=C4)S(=O)(=O)NC5=NOC=C5)OC,CKD-712,Phase 1,NFkB pathway inhibitor,P42224
CHEMBL4854102,,CKI-7,Preclinical,casein kinase inhibitor,P78368
CHEMBL4851872,,IC261,Preclinical,casein kinase inhibitor,P78368
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P00813
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P00813
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine,Launched,ribonucleotide reductase inhibitor,P00813
CHEMBL4864479,,pentostatin,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P00813
CHEMBL4845796,,vidarabine,Launched,antiviral,P00813
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P09884
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,P09884
CHEMBL605037,C1=CN(C(=O)N=C1N)C2[C@H]([C@@H]([C@H](O2)CO)O)O,cytarabine,Launched,ribonucleotide reductase inhibitor,P09884
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine,Launched,ribonucleotide reductase inhibitor,P09884
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,P09884
CHEMBL1201112,COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N,nelarabine,Launched,DNA synthesis inhibitor|T cell inhibitor,P09884
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,Q07864
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,Q07864
CHEMBL605037,C1=CN(C(=O)N=C1N)C2[C@H]([C@@H]([C@H](O2)CO)O)O,cytarabine,Launched,ribonucleotide reductase inhibitor,Q07864
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,Q07864
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P56282
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,Q9NRF9
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,Q9NR33
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,P31350
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,P31350
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine,Launched,ribonucleotide reductase inhibitor,P31350
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,P31350
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine,Launched,ribonucleotide reductase inhibitor,P31350
CHEMBL467,C(=O)(N)NO,hydroxyurea,Launched,ribonucleotide reductase inhibitor,P31350
CHEMBL4848331,,triapine,Phase 2,ribonucleotide reductase inhibitor,P31350
CHEMBL4776881,C1[C@@H]([C@H](O[C@@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,cladribine,Launched,adenosine deaminase inhibitor|ribonucleotide reductase inhibitor,Q7LG56
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,Q7LG56
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,Q7LG56
CHEMBL467,C(=O)(N)NO,hydroxyurea,Launched,ribonucleotide reductase inhibitor,Q7LG56
CHEMBL12318,C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl,clodronic-acid,Launched,bone resorption inhibitor,P05141
CHEMBL12318,C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl,clodronic-acid,Launched,bone resorption inhibitor,P12236
CHEMBL1750,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N,clofarabine,Launched,ribonucleotide reductase inhibitor,P28340
CHEMBL605037,C1=CN(C(=O)N=C1N)C2[C@H]([C@@H]([C@H](O2)CO)O)O,cytarabine,Launched,ribonucleotide reductase inhibitor,P28340
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine-phosphate,Launched,ribonucleotide reductase inhibitor,P28340
CHEMBL1200710,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl,clomipramine,Launched,serotonin transporter (SERT) inhibitor,P09211
CHEMBL2110585,CCOC(=O)[C@H](CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@H](C2=CC=CC=C2)C(=O)OCC)N,ezatiostat,Phase 2,glutathione transferase inhibitor,P09211
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P09211
CHEMBL4303635,C(CCN)C[C@@H](C(=O)O)N.C([C@@H](C(=O)O)N)SCC(=O)O.O,SCMC-Lys,Launched,mucolytic agent,P09211
CHEMBL1520583,C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+],cloprostenol-(+/-),Launched,prostaglandin receptor agonist,P21731
CHEMBL4850162,,daltroban,Phase 3,thromboxane receptor antagonist,P21731
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,dinoprost,Launched,prostacyclin analog,P21731
CHEMBL4846229,,dinoprostone,Withdrawn,prostanoid receptor agonist,P21731
CHEMBL4853373,,ICI-192605,Phase 2,thromboxane receptor antagonist,P21731
CHEMBL4864501,,iloprost,Launched,platelet aggregation inhibitor|prostanoid receptor agonist,P21731
CHEMBL426559,CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F,laropiprant,Launched,prostanoid receptor antagonist,P21731
CHEMBL1257015,COC1=C(C=C(C=C1)C(=O)NCC2=CN=CC=C2)C(=O)NCC3=CN=CC=C3,picotamide,Launched,thromboxane receptor antagonist|thromboxane synthase inhibitor,P21731
CHEMBL4852673,,ramatroban,Launched,prostanoid receptor antagonist,P21731
CHEMBL70972,CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C,seratrodast,Launched,prostanoid receptor antagonist,P21731
CHEMBL2107786,CC1=C(C2=C(C[C@@H](CC2)NS(=O)(=O)C3=CC=C(C=C3)Cl)C=C1)CCC(=O)O,terutroban,Phase 3,prostanoid receptor antagonist,P21731
CHEMBL104,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,clotrimazole,Launched,cytochrome P450 inhibitor|imidazoline receptor ligand,O75469
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O75469
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,O75469
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,O75469
CHEMBL553,COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC,erlotinib,Launched,EGFR inhibitor,O75469
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol,Launched,estrogen receptor agonist,O75469
CHEMBL4864802,,ethinyl-estradiol,Launched,estrogen receptor agonist|estrogenic hormone,O75469
CHEMBL4794162,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4[C@@]3(CC[C@H](C4)O)C)C,lithocholic-acid,Preclinical,FXR antagonist|vitamin D receptor agonist,O75469
CHEMBL4848770,,lovastatin,Launched,HMGCR inhibitor,O75469
CHEMBL4875793,,LXR-623,Phase 1,LXR agonist,O75469
CHEMBL4862709,,mifepristone,Launched,glucocorticoid receptor antagonist|progesterone receptor antagonist,O75469
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,O75469
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,O75469
CHEMBL1909658,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C=N/N5CCN(CC5)C)/C,rifampin,Launched,RNA polymerase inhibitor,O75469
CHEMBL4857180,CC1=CC(=CC(=C1NC2=NC(=NC(=C2)N)NC3=CC=C(C=C3)C#N)C)/C=C/C#N,rilpivirine,Launched,non-nucleoside reverse transcriptase inhibitor,O75469
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,O75469
CHEMBL187266,CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C,tanshinone-IIA,Phase 2/Phase 3,anti-inflammatory agent|interleukin inhibitor,O75469
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,O75469
CHEMBL1200848,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)C(=O)C,17-hydroxyprogesterone-caproate,Launched,progesterone receptor agonist,O75469
CHEMBL1688,C[N+]1(CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42)[O-],clozapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P47898
CHEMBL1255837,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,dihydroergocristine,Launched,adrenergic receptor antagonist|prolactin inhibitor,P47898
CHEMBL1742428,C1CN(CCN1C2=CC=C(C=C2)C#N)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,donitriptan,Phase 2,serotonin receptor agonist,P47898
CHEMBL2448612,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C.C(C(C(=O)O)O)(C(=O)O)O,ergotamine,Launched,adrenergic receptor antagonist,P47898
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P47898
CHEMBL1201155,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O,loxapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P47898
CHEMBL1526242,CN1CC(C[C@@H]2C1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,metergoline,Launched,dopamine receptor agonist|serotonin receptor antagonist,P47898
CHEMBL1065,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,methysergide,Launched,serotonin receptor antagonist,P47898
CHEMBL4864177,,metitepine,Preclinical,anti-HCVE2,P47898
CHEMBL3989694,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O)O.O,olanzapine,Launched,dopamine receptor antagonist|serotonin receptor antagonist,P47898
CHEMBL545328,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(S),Preclinical,adrenergic receptor antagonist,P47898
CHEMBL267777,CC1=C(C(=O)N2C=CSC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3,ritanserin,Phase 3,serotonin receptor antagonist,P47898
CHEMBL4876141,,RU-24969,Phase 1,serotonin receptor agonist,P47898
CHEMBL535832,C1=CC2=C(C=C1O)C(=CN2)CCN.Cl,serotonin,Launched,growth factor receptor activator,P47898
CHEMBL1201150,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C.C(CC(=O)O)C(=O)O,sumatriptan,Launched,serotonin receptor agonist,P47898
CHEMBL2104993,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C,vortioxetine,Launched,serotonin receptor agonist|serotonin receptor antagonist,P47898
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,P47898
CHEMBL1516756,COC1=CC(=C(C=C1C(=O)NC2CN3CCC2CC3)Cl)N.O.Cl,zacopride,Phase 2,serotonin receptor antagonist,P47898
CHEMBL1256863,C1=CC2=C(C=C1C(=O)N)C(=CN2)CCN.C(=C\C(=O)O)\C(=O)O,5-carboxamidotryptamine,Preclinical,serotonin receptor agonist,P47898
CHEMBL4863540,,8-hydroxy-DPAT,Preclinical,serotonin receptor agonist,P47898
CHEMBL4846290,,CL316243,Phase 2,adrenergic receptor agonist,P25874
CHEMBL4846290,,CL316243,Phase 2,adrenergic receptor agonist,P55851
CHEMBL4846290,,CL316243,Phase 2,adrenergic receptor agonist,P55916
CHEMBL2095208,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,cobicistat,Launched,cytochrome P450 inhibitor,Q9HB55
CHEMBL2095208,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,cobicistat,Launched,cytochrome P450 inhibitor,P20815
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P20815
CHEMBL70663,CC1=CC(=C(C(=C1)C)NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C,dapivirine,Phase 3,non-nucleoside reverse transcriptase inhibitor,P20815
CHEMBL4303416,C[C@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,dolutegravir,Launched,HIV integrase inhibitor,P20815
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P20815
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P20815
CHEMBL1735,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O,indinavir,Launched,HIV protease inhibitor,P20815
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P20815
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P20815
CHEMBL1136,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,P20815
CHEMBL638,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,voriconazole,Launched,cytochrome P450 inhibitor,P20815
CHEMBL2095208,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,cobicistat,Launched,cytochrome P450 inhibitor,P24462
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P24462
CHEMBL4303416,C[C@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,dolutegravir,Launched,HIV integrase inhibitor,P24462
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P24462
CHEMBL1735,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O,indinavir,Launched,HIV protease inhibitor,P24462
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P24462
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P24462
CHEMBL1136,CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=C4)C5=CN=CC=C5)C,telithromycin,Launched,bacterial 30S ribosomal subunit inhibitor|bacterial 50S ribosomal subunit inhibitor,P24462
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,O75908
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,Q9BWD1
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,P43155
CHEMBL1149,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,levocarnitine,Launched,,P43155
CHEMBL2107420,CCC(=O)O[C@H](CC(=O)O)C[N+](C)(C)C.[Cl-],levocarnitine-propionate,Launched,carnitine palmitoyltransferase inhibitor,P43155
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,P07108
CHEMBL1235338,CCCCCCCCCCCCCCCC=O,1-hexadecanal,Preclinical,sphingosine 1-phosphate receptor substrate,P07108
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,Q92830
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,Q92831
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,Q92831
CHEMBL4756598,CC(C)(COP(=O)(O)OP(=O)(O)OC[C@H]1[C@@H]([C@@H]([C@H](O1)N2C=NC3=C(N=CN=C32)N)O)OP(=O)(O)O)[C@@H](C(=O)NCCC(=O)NCCS)O,coenzyme-A,Launched,,Q92993
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9UDR5
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9UDR5
CHEMBL4851780,,coenzyme-I,Phase 2,,P16219
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P16219
CHEMBL4851780,,coenzyme-I,Phase 2,,P07327
CHEMBL1308,CC1=CNN=C1,fomepizole,Launched,alcohol dehydrogenase inhibitor,P07327
CHEMBL4851780,,coenzyme-I,Phase 2,,P00325
CHEMBL1308,CC1=CNN=C1,fomepizole,Launched,alcohol dehydrogenase inhibitor,P00325
CHEMBL4851780,,coenzyme-I,Phase 2,,P08319
CHEMBL4851780,,coenzyme-I,Phase 2,,P11766
CHEMBL4861466,,N6022,Phase 1/Phase 2,alcohol dehydrogenase inhibitor,P11766
CHEMBL4851780,,coenzyme-I,Phase 2,,P40394
CHEMBL4851780,,coenzyme-I,Phase 2,,P52895
CHEMBL4870567,,ursodiol,Launched,nuclear factor erythroid derived|like (NRF2) activator,P52895
CHEMBL4851780,,coenzyme-I,Phase 2,,P17516
CHEMBL4851780,,coenzyme-I,Phase 2,,P00352
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P00352
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P00352
CHEMBL4851780,,coenzyme-I,Phase 2,,O94788
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,O94788
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,O94788
CHEMBL294453,CCCC[P+](CCCC)(CCCC)CC1=CC=C(C=C1)NC(=O)[C@H](CC2=CC3=CC=CC=C3C=C2)NC(=NC4CCCCC4)NC5CCCCC5,WIN-18446,Preclinical,aldehyde dehydrogenase inhibitor,O94788
CHEMBL4851780,,coenzyme-I,Phase 2,,P47895
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P47895
CHEMBL4851780,,coenzyme-I,Phase 2,,P30837
CHEMBL4851780,,coenzyme-I,Phase 2,,P30838
CHEMBL4851780,,coenzyme-I,Phase 2,,P51648
CHEMBL4851780,,coenzyme-I,Phase 2,,P43353
CHEMBL4851780,,coenzyme-I,Phase 2,,P48448
CHEMBL4851780,,coenzyme-I,Phase 2,,P30038
CHEMBL4851780,,coenzyme-I,Phase 2,,P51649
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P51649
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,P51649
CHEMBL13883,COC1=C(C=CC(=C1)C=O)O,vanillin,Preclinical,,P51649
CHEMBL4851780,,coenzyme-I,Phase 2,,Q02252
CHEMBL4851780,,coenzyme-I,Phase 2,,P49419
CHEMBL4851780,,coenzyme-I,Phase 2,,P49189
CHEMBL4851780,,coenzyme-I,Phase 2,,P48728
CHEMBL4851780,,coenzyme-I,Phase 2,,Q02338
CHEMBL4851780,,coenzyme-I,Phase 2,,P53004
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P53004
CHEMBL4851780,,coenzyme-I,Phase 2,,P30043
CHEMBL1534,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,riboflavin,Launched,vitamin B,P30043
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,P30043
CHEMBL4851780,,coenzyme-I,Phase 2,,Q16878
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q16878
CHEMBL4851780,,coenzyme-I,Phase 2,,P00387
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P00387
CHEMBL4851780,,coenzyme-I,Phase 2,,Q02928
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9UBM7
CHEMBL4851780,,coenzyme-I,Phase 2,,P10515
CHEMBL4851780,,coenzyme-I,Phase 2,,P09622
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P09622
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P09622
CHEMBL4851780,,coenzyme-I,Phase 2,,Q08426
CHEMBL4851780,,coenzyme-I,Phase 2,,P04406
CHEMBL4851780,,coenzyme-I,Phase 2,,O14556
CHEMBL4851780,,coenzyme-I,Phase 2,,P00367
CHEMBL496,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,hexachlorophene,Launched,potassium channel activator,P00367
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P00367
CHEMBL4851780,,coenzyme-I,Phase 2,,P49448
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P49448
CHEMBL4851780,,coenzyme-I,Phase 2,,P21695
CHEMBL4851780,,coenzyme-I,Phase 2,,O95479
CHEMBL4851780,,coenzyme-I,Phase 2,,P40939
CHEMBL4851780,,coenzyme-I,Phase 2,,Q16836
CHEMBL4851780,,coenzyme-I,Phase 2,,P31937
CHEMBL4851780,,coenzyme-I,Phase 2,,P09601
CHEMBL1325592,CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C=C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C=C,protoporphyrin-IX,Preclinical,heme oxygenase inhibitor,P09601
CHEMBL4851780,,coenzyme-I,Phase 2,,P30519
CHEMBL4851780,,coenzyme-I,Phase 2,,P15428
CHEMBL1122224,,"16,16-dimethylprostaglandin-e2",Phase 2,prostanoid receptor agonist,P15428
CHEMBL4851780,,coenzyme-I,Phase 2,,Q99714
CHEMBL4851780,,coenzyme-I,Phase 2,,P37059
CHEMBL4851780,,coenzyme-I,Phase 2,,P37058
CHEMBL4851780,,coenzyme-I,Phase 2,,P51659
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P51659
CHEMBL4851780,,coenzyme-I,Phase 2,,P56937
CHEMBL4851780,,coenzyme-I,Phase 2,,Q92506
CHEMBL4851780,,coenzyme-I,Phase 2,,P14060
CHEMBL4851780,,coenzyme-I,Phase 2,,P26439
CHEMBL4851780,,coenzyme-I,Phase 2,,P50213
CHEMBL4851780,,coenzyme-I,Phase 2,,O43837
CHEMBL4851780,,coenzyme-I,Phase 2,,P51553
CHEMBL4851780,,coenzyme-I,Phase 2,,P00338
CHEMBL3335794,COC1=NC(=NC=C1C2=CC3=NC=C(C(=C3C=C2)NC4=CC(=CC(=C4)C(=O)O)OC5=CC(=CC(=C5)F)F)S(=O)(=O)NC6CC6)OC,GSK2837808A,Preclinical,lactate dehydrogenase inhibitor,P00338
CHEMBL4855338,,NHI-2,Preclinical,lactate dehydrogenase inhibitor,P00338
CHEMBL1805766,,nicotinamide,Launched,protein synthesis stimulant,P00338
CHEMBL4851780,,coenzyme-I,Phase 2,,Q6ZMR3
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9BYZ2
CHEMBL4851780,,coenzyme-I,Phase 2,,P07195
CHEMBL4851780,,coenzyme-I,Phase 2,,P07864
CHEMBL4851780,,coenzyme-I,Phase 2,,P40925
CHEMBL4851780,,coenzyme-I,Phase 2,,P48163
CHEMBL4851780,,coenzyme-I,Phase 2,,P23368
CHEMBL4851780,,coenzyme-I,Phase 2,,Q16798
CHEMBL4851780,,coenzyme-I,Phase 2,,Q15800
CHEMBL4851780,,coenzyme-I,Phase 2,,P03886
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P03886
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,P03886
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P03886
CHEMBL4851780,,coenzyme-I,Phase 2,,P03891
CHEMBL4851780,,coenzyme-I,Phase 2,,P03897
CHEMBL4851780,,coenzyme-I,Phase 2,,P03905
CHEMBL4851780,,coenzyme-I,Phase 2,,P03901
CHEMBL4851780,,coenzyme-I,Phase 2,,P03915
CHEMBL4851780,,coenzyme-I,Phase 2,,P03923
CHEMBL4851780,,coenzyme-I,Phase 2,,P11586
CHEMBL4851780,,coenzyme-I,Phase 2,,P13995
CHEMBL4851780,,coenzyme-I,Phase 2,,O15239
CHEMBL4851780,,coenzyme-I,Phase 2,,O95299
CHEMBL4851780,,coenzyme-I,Phase 2,,Q86Y39
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9UI09
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9P0J0
CHEMBL4851780,,coenzyme-I,Phase 2,,O43678
CHEMBL4851780,,coenzyme-I,Phase 2,,O95167
CHEMBL4851780,,coenzyme-I,Phase 2,,O00483
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9NRX3
CHEMBL4851780,,coenzyme-I,Phase 2,,Q16718
CHEMBL4851780,,coenzyme-I,Phase 2,,P56556
CHEMBL4851780,,coenzyme-I,Phase 2,,O95182
CHEMBL4851780,,coenzyme-I,Phase 2,,P51970
CHEMBL4851780,,coenzyme-I,Phase 2,,Q16795
CHEMBL4851780,,coenzyme-I,Phase 2,,O14561
CHEMBL4851780,,coenzyme-I,Phase 2,,O75438
CHEMBL4851780,,coenzyme-I,Phase 2,,O96000
CHEMBL4851780,,coenzyme-I,Phase 2,,O95178
CHEMBL4851780,,coenzyme-I,Phase 2,,O43676
CHEMBL4851780,,coenzyme-I,Phase 2,,O95168
CHEMBL4851780,,coenzyme-I,Phase 2,,O43674
CHEMBL4851780,,coenzyme-I,Phase 2,,O95139
CHEMBL4851780,,coenzyme-I,Phase 2,,P17568
CHEMBL4851780,,coenzyme-I,Phase 2,,O95169
CHEMBL4851780,,coenzyme-I,Phase 2,,Q9Y6M9
CHEMBL4851780,,coenzyme-I,Phase 2,,O43677
CHEMBL4851780,,coenzyme-I,Phase 2,,O95298
CHEMBL4851780,,coenzyme-I,Phase 2,,P28331
CHEMBL4851780,,coenzyme-I,Phase 2,,O75306
CHEMBL4851780,,coenzyme-I,Phase 2,,O75489
CHEMBL4851780,,coenzyme-I,Phase 2,,O43181
CHEMBL4851780,,coenzyme-I,Phase 2,,O43920
CHEMBL4851780,,coenzyme-I,Phase 2,,O75380
CHEMBL4851780,,coenzyme-I,Phase 2,,O75251
CHEMBL4851780,,coenzyme-I,Phase 2,,O00217
CHEMBL4851780,,coenzyme-I,Phase 2,,P49821
CHEMBL4851780,,coenzyme-I,Phase 2,,P19404
CHEMBL4851780,,coenzyme-I,Phase 2,,P56181
CHEMBL4851780,,coenzyme-I,Phase 2,,Q13423
CHEMBL4851780,,coenzyme-I,Phase 2,,Q15738
CHEMBL4851780,,coenzyme-I,Phase 2,,Q02218
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q02218
CHEMBL4851780,,coenzyme-I,Phase 2,,P08559
CHEMBL3186849,C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2,CPI-613,Phase 3,pyruvate dehydrogenase inhibitor,P08559
CHEMBL4851780,,coenzyme-I,Phase 2,,P29803
CHEMBL4851780,,coenzyme-I,Phase 2,,P11177
CHEMBL4851780,,coenzyme-I,Phase 2,,O43175
CHEMBL4851780,,coenzyme-I,Phase 2,,P32322
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P32322
CHEMBL4851780,,coenzyme-I,Phase 2,,Q96C36
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q96C36
CHEMBL4851780,,coenzyme-I,Phase 2,,P09417
CHEMBL4851780,,coenzyme-I,Phase 2,,Q92781
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q92781
CHEMBL4851780,,coenzyme-I,Phase 2,,Q00796
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,Q00796
CHEMBL4851780,,coenzyme-I,Phase 2,,Q13630
CHEMBL4851780,,coenzyme-I,Phase 2,,O60701
CHEMBL4303178,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C,colforsin,Phase 2,adenylyl cyclase activator,Q08462
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,Q08462
CHEMBL4303178,CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)OC(=O)CCN(C)C,colforsin,Phase 2,adenylyl cyclase activator,O95622
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,O95622
CHEMBL1456284,C1C(CC(=O)C2=CN=C(N=C21)N)C3=CC=CO3,NKY-80,Preclinical,adenylyl cyclase inhibitor,O95622
CHEMBL4297731,,copper-histidine,Phase 3,,Q8IY34
CHEMBL4297731,,copper-histidine,Phase 3,,Q8N697
CHEMBL4297731,,copper-histidine,Phase 3,,Q8WUX1
CHEMBL4847130,,corticosterone,Preclinical,mineralocorticoid receptor agonist,Q15788
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,Q15788
CHEMBL1232583,COC1=CC=C(C=C1)S(=O)(=O)N2C=C(C3=C2C=CC(=C3)OC)CCC(=O)O,indeglitazar,Phase 2,PPAR receptor agonist,Q15788
CHEMBL4849253,,prinaberel,Phase 2,estrogen receptor agonist,Q15788
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,Q15788
CHEMBL4849639,,cot-inhibitor-1,Preclinical,MAPK-interacting kinase inhibitor,P41279
CHEMBL4870582,,cot-inhibitor-2,Preclinical,MAPK-interacting kinase inhibitor,P41279
CHEMBL4873322,,TC-S-7006,Preclinical,MAP kinase inhibitor,P41279
CHEMBL6466,C1=CC=C2C(=C1)C=CC(=O)O2,coumarin,Launched,vitamin K antagonist,P11509
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P11509
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P11509
CHEMBL4869448,,methoxsalen,Launched,DNA synthesis inhibitor,P11509
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P11509
CHEMBL161702,C1=CC=C(C=C1)CC(CN(C(=O)CC2=CC=CC=C2)O)C(=O)O,CPA-inhibitor,Preclinical,carboxypeptidase inhibitor,P15085
CHEMBL161702,C1=CC=C(C=C1)CC(CN(C(=O)CC2=CC=CC=C2)O)C(=O)O,CPA-inhibitor,Preclinical,carboxypeptidase inhibitor,P48052
CHEMBL4854532,,CPCCOEt,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL74987,C1=C(C=C(C=C1O)O)[C@H](C(=O)O)N,dihydroxyphenylglycine,Preclinical,glutamate receptor agonist,Q13255
CHEMBL4867574,,JNJ-16259685,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,Q13255
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q13255
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q13255
CHEMBL4865789,,LY456236,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL4846859,,MPEP,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL4877959,,PHCCC,Preclinical,glutamate receptor agonist,Q13255
CHEMBL4303496,CC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C3=CC=C(C=C3)F,Ro-67-7476,Preclinical,glutamate receptor positive allosteric modulator,Q13255
CHEMBL1436386,CC1=C(SC2=NC3=C(N12)C=C(C=C3)N)C(=O)NC4CCCCC4.Cl,YM-298198,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL1436386,CC1=C(SC2=NC3=C(N12)C=C(C=C3)N)C(=O)NC4CCCCC4.Cl,YM-298198-desmethyl,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL1032432,,"3,5-DHPG-(S)",Preclinical,glutamate receptor agonist,Q13255
CHEMBL128772,C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)O,3-carboxy-4-hydroxyphenylglycine-(S),Preclinical,glutamate receptor antagonist,Q13255
CHEMBL128772,C1=CC(=C(C=C1[C@@H](C(=O)O)N)C(=O)O)O,4-carboxy-3-hydroxyphenylglycine-(S),Preclinical,glutamate receptor agonist|glutamate receptor antagonist,Q13255
CHEMBL1322301,CC1=C(SC(=C1)C(=O)O)C(C(=O)O)N,3-MATIDA,Preclinical,glutamate receptor antagonist,Q13255
CHEMBL1357932,C1=CC(=C(C=C1[C@H](C(=O)O)N)O)C(=O)O,4-carboxy-3-hydroxyphenylglycine-(RS),Preclinical,glutamate receptor agonist|glutamate receptor antagonist,Q13255
CHEMBL4576375,CCS(=O)(=O)N1CCC(CC1)C(C)N2C(=C(C3=CC=CC=C32)C(=O)NCC4=C(C=C(NC4=O)C)OC)C,CPI-169,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4854401,,CPI-360,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4864783,,EI1,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4860482,,EPZ005687,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL3672841,CCN(C1CCC(CC1)N(C)CCOC)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C#CCN4CCOCC4,EPZ011989,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL3287735,CC[C@H](C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C,GSK2816126,Phase 1,histone lysine methyltransferase inhibitor,Q15910
CHEMBL3909511,CC1=CC(=C(C(=O)N1)CNC(=O)C2=C3C(=CN(C3=CC(=C2)C4=CN=C(C=C4)N5CCN(CC5)C)C(C)C)C)C,GSK503,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4594260,CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5.Br,tazemetostat,Launched,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4870863,,UNC1999,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL4870724,,3-deazaneplanocin-A,Preclinical,histone lysine methyltransferase inhibitor,Q15910
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,P12277
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,P06732
CHEMBL4869471,,guanidinopropionic-acid,Phase 2,creatine kinase inhibitor,P06732
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,P12532
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,P17540
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,Q14353
CHEMBL2078034,,guanidine,Launched,HSP inhibitor,Q14353
CHEMBL283800,CN(CC(=O)O)C(=N)N,creatine,Launched,,P48029
CHEMBL1825141,C[C@@H](C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N,crizotinib-(S),Preclinical,MTH1 inhibitor,P36639
CHEMBL4878606,,SCH-51344,Preclinical,MTH1 inhibitor,P36639
CHEMBL4790618,CCCCN(CC1=CC=CC=C1)C(=O)C2=CC=C(C=C2)S(=O)(=O)NC3=CC=CC=C3,TH-588,Preclinical,MTH1 inhibitor,P36639
CHEMBL3259788,,cromakalim,Phase 2,,Q15842
CHEMBL4297276,CC1=NC2=C(C=C(C=C2)Cl)S(=O)(=O)[N-]1.C[N+](C)(C)CCO,diazoxide,Launched,potassium channel activator,Q15842
CHEMBL383634,CC1(C2=C(C=C(C=C2)OC)C(=O)N(C1=O)CCC3=CC=C(C=C3)S(=O)(=O)NC(=O)NC4CCCCC4)C,gliquidone,Launched,sulfonylurea,Q15842
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,Q15842
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,levosimendan,Launched,calcium sensitizer,Q15842
CHEMBL802,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,minoxidil,Launched,KATP activator|Kir6 channel (KATP) activator|vasodilator,Q15842
CHEMBL4870113,,PCO-400,Phase 1,potassium channel activator,Q15842
CHEMBL170988,C1=CC=C(C=C1)CCN=C(N)N=C(N)N,phenformin,Withdrawn,AMPK activator,Q15842
CHEMBL782,CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C,tolbutamide,Launched,ATP channel blocker,Q15842
CHEMBL1402866,CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)O,Y-26763,Phase 1,potassium channel activator,Q15842
CHEMBL1476996,CC(=O)N([C@H]1[C@@H](C(OC2=C1C=C(C=C2)C#N)(C)C)O)OCC3=CC=CC=C3,Y-27152,Phase 1,potassium channel activator,Q15842
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,Q15842
CHEMBL428880,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,cromoglicic-acid,Launched,immunosuppressant,P25815
CHEMBL4855457,,CR8-(R),Preclinical,CDK inhibitor,P20248
CHEMBL4868423,,NU-2058,Preclinical,cyclin D inhibitor,P20248
CHEMBL303958,C1CCC(CC1)COC2=NC(=NC(=C2N=O)N)N,NU-6027,Preclinical,CDK inhibitor,P20248
CHEMBL4858767,,SB-216763,Preclinical,glycogen synthase kinase inhibitor,P20248
CHEMBL4303728,C1=CC=C(C=C1)C[C@H](C(=O)O)NC(=O)C2=C(C3=C(S2)C=C(C=C3)F)Cl,CU-CPT-4a,Preclinical,toll-like receptor inhibitor,O15455
CHEMBL4856881,,CU-T12-9,Preclinical,toll-like receptor agonist,Q15399
CHEMBL4856881,,CU-T12-9,Preclinical,toll-like receptor agonist,O60603
CHEMBL4857479,,CUDC-907,Phase 2,PI3K inhibitor,P27986
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P27986
CHEMBL4861844,,CUR-61414,Phase 1,smoothened receptor antagonist,Q14623
CHEMBL4857465,,M-25,Preclinical,smoothened receptor antagonist,Q14623
CHEMBL2142592,CN1C(=CC=N1)C2=NN=C(C3=CC=CC=C32)N4CCC(CC4)N(C)C(=O)C5=C(C=C(C=C5)F)C(F)(F)F,taladegib,Phase 2,smoothened receptor antagonist,Q14623
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,Q9UBC3
CHEMBL4871024,,RG108,Preclinical,DNA methyltransferase inhibitor,Q9UBC3
CHEMBL4875941,,SGI-1027,Preclinical,DNA methyltransferase inhibitor,Q9UBC3
CHEMBL140,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,curcumin,Launched,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|NFkB pathway inhibitor,Q09472
CHEMBL4861022,,C646,Preclinical,histone acetyltransferase inhibitor,Q09472
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,Q09472
CHEMBL4846801,,I-CBP-112,Preclinical,bromodomain inhibitor,Q09472
CHEMBL4870447,,SGC-CBP30,Preclinical,bromodomain inhibitor,Q09472
CHEMBL4860881,,CX-4945,Phase 1/Phase 2,casein kinase inhibitor,P68400
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,P68400
CHEMBL289277,CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O,emodin,Preclinical,11-beta hydroxysteroid dehydrogenase inhibitor,P68400
CHEMBL165,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,resveratrol,Launched,cytochrome P450 inhibitor|SIRT activator,P68400
CHEMBL4862648,,TTP-22,Preclinical,casein kinase inhibitor,P68400
CHEMBL177820,C1(=C(C2=NNN=C2C(=C1Br)Br)Br)Br,"4,5,6,7-tetrabromobenzotriazole",Preclinical,casein kinase inhibitor,P68400
CHEMBL4860881,,CX-4945,Phase 1/Phase 2,casein kinase inhibitor,P19784
CHEMBL4860881,,CX-4945,Phase 1/Phase 2,casein kinase inhibitor,O43293
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,O43293
CHEMBL4860881,,CX-4945,Phase 1/Phase 2,casein kinase inhibitor,Q9H422
CHEMBL2110563,,cyanocobalamin,Launched,methylmalonyl CoA mutase stimulant|vitamin B,P22033
CHEMBL1014671,,cyclic-AMP,Preclinical,,Q16281
CHEMBL648,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,cyclizine,Launched,histamine receptor modulator,P49888
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P33260
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P33260
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P10632
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P10632
CHEMBL64,C1=CN=CC=C1C(=O)NN,isoniazid,Launched,FABI inhibitor,P10632
CHEMBL1660,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,rifapentine,Launched,RNA polymerase inhibitor,P10632
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P10632
CHEMBL2074778,CC1=C(C(=C(C2=C1OC(CC2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)OS(=O)(=O)O)C,troglitazone,Withdrawn,insulin sensitizer|PPAR receptor agonist,P10632
CHEMBL1200796,C1CNP(=O)(OC1)N(CCCl)CCCl.O,cyclophosphamide,Launched,DNA alkylating agent,P11712
CHEMBL223228,C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F,efavirenz,Launched,HIV protease inhibitor,P11712
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P11712
CHEMBL308954,CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N,etravirine,Launched,non-nucleoside reverse transcriptase inhibitor,P11712
CHEMBL4861992,,ifosfamide,Launched,DNA alkylating agent,P11712
CHEMBL1200869,CC1=NC=C(N1CCO)[N+](=O)[O-].Cl,metronidazole,Launched,DNA inhibitor,P11712
CHEMBL365442,CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O,nelfinavir,Launched,HIV protease inhibitor,P11712
CHEMBL4853926,,nevirapine,Launched,non-nucleoside reverse transcriptase inhibitor,P11712
CHEMBL1660,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,rifapentine,Launched,RNA polymerase inhibitor,P11712
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P11712
CHEMBL3038236,C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.Cl.Cl.[Zn+2],sulfanilamide,Launched,carbonic anhydrase inhibitor,P11712
CHEMBL4857718,,tienilic-acid,Withdrawn,cytochrome P450 inhibitor|sodium/potassium/chloride transporter inhibitor,P11712
CHEMBL638,C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O,voriconazole,Launched,cytochrome P450 inhibitor,P11712
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,P49069
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,P21462
CHEMBL514674,C[C@H](CCC(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@]2(CC[C@H]4[C@@]3(CC[C@H](C4)O)C)C)O)C.[Na+],deoxycholic-acid,Launched,biliverdin reductase A activator|G protein-coupled receptor agonist,P21462
CHEMBL4877379,,nedocromil,Launched,histamine receptor antagonist,P21462
CHEMBL1697771,C1=CC=C2C(=C1)C(=CC(=O)N2)CC(C(=O)O)NC(=O)C3=CC=C(C=C3)Cl,rebamipide,Launched,free radical scavenger,P21462
CHEMBL4847000,,sulfinpyrazone,Launched,uricosuric blocker,P21462
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,P62937
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P62937
CHEMBL4866217,,TMN-355,Preclinical,cyclophilin inhibitor,P62937
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,P30405
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P30405
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,Q08209
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,Q96LZ3
CHEMBL2371438,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@@H](C(=O)N(CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N1)[C@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C)C(C)C)CC(C)C)C)C,cyclosporin-A,Launched,calcineurin inhibitor,Q14973
CHEMBL4863545,,irbesartan,Launched,angiotensin receptor antagonist,Q14973
CHEMBL545328,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O.Cl,propranolol-(S),Preclinical,adrenergic receptor antagonist,Q14973
CHEMBL2362372,COC1=C(C=CC(=C1)C=C2CCCC(=CC3=CC(=C(C=C3)O)OC)C2=O)O,cyclovalone,Launched,breast cancer resistance protein inhibitor,Q9UNQ0
CHEMBL4303487,C1=CC=C(C(=C1)C(=O)NC2=CC=C(C=C2)CCO)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-],KS-176,Preclinical,BCRP inhibitor,Q9UNQ0
CHEMBL4877011,,CYM-50260,Preclinical,sphingosine 1-phosphate receptor agonist,O95977
CHEMBL4877304,,CYM-50358,Preclinical,sphingosine 1-phosphate receptor antagonist,O95977
CHEMBL4872404,,CYM-50769,Preclinical,neuropeptide receptor antagonist,P48145
CHEMBL4853646,,CYM-5442,Preclinical,sphingosine 1-phosphate receptor agonist,P21453
CHEMBL4855249,,fingolimod,Launched,immunosuppressant|sphingosine 1-phosphate receptor agonist,P21453
CHEMBL3707247,CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N,ozanimod,Phase 3,sphingosine 1-phosphate receptor agonist,P21453
CHEMBL1096146,CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C,ponesimod,Phase 3,sphingosine 1-phosphate receptor agonist,P21453
CHEMBL4872388,,RP-001,Preclinical,sphingosine 1-phosphate receptor agonist,P21453
CHEMBL4868129,,SEW-2871,Preclinical,lysophospholipid receptor agonist,P21453
CHEMBL4298150,CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O.CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O.C(=C/C(=O)O)\C(=O)O,siponimod,Launched,sphingosine 1-phosphate receptor modulator,P21453
CHEMBL4853921,,S1P1-agonist-III,Preclinical,sphingosine kinase inhibitor,P21453
CHEMBL4865142,,TC-SP-14,Preclinical,sphingosine 1-phosphate receptor agonist,P21453
CHEMBL1970071,C1CCC(CC1)N(C2CCCCC2)C(=O)C3=NOC(=C3)C4CC4,CYM-5520,Preclinical,sphingosine 1-phosphate receptor agonist,O95136
CHEMBL4862627,,JTE-013,Preclinical,lysophospholipid receptor antagonist,O95136
CHEMBL1970071,C1CCC(CC1)N(C2CCCCC2)C(=O)C3=NOC(=C3)C4CC4,CYM-5541,Preclinical,sphingosine 1-phosphate receptor agonist,Q99500
CHEMBL4303550,CC(C)(C)C(=O)C(=NC1=CC=C(C=C1)Cl)NNC2=CC=C(C=C2)Cl,TY-52156,Preclinical,sphingosine 1-phosphate receptor antagonist,Q99500
CHEMBL1256137,C(CS)N.Cl,cysteamine,Launched,tissue transglutaminase inhibitor,P49146
CHEMBL808,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,econazole,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,P49146
CHEMBL4871195,,SF-11,Preclinical,neuropeptide receptor antagonist,P49146
CHEMBL1256137,C(CS)N.Cl,cysteamine,Launched,tissue transglutaminase inhibitor,P61278
CHEMBL605037,C1=CN(C(=O)N=C1N)C2[C@H]([C@@H]([C@H](O2)CO)O)O,cytarabine,Launched,ribonucleotide reductase inhibitor,P06746
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,Q15825
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q15825
CHEMBL2106279,C[N+](C)(C)CCCCCC[N+](C)(C)C.[I-].[I-],hexamethonium,Preclinical,cholinergic receptor antagonist,Q15825
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,Q15825
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,Q15825
CHEMBL1396,C1C2CNCC1C3=CC4=NC=CN=C4C=C23,varenicline,Launched,acetylcholine receptor agonist,Q15825
CHEMBL4856087,,cytisine,Launched,acetylcholine receptor agonist,P30926
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P30926
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P30926
CHEMBL1237082,CC1(C2CCC(C2)C1(C)NC)C.Cl,mecamylamine,Launched,acetylcholine receptor antagonist,P30926
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P30926
CHEMBL4303695,CN1C2CCC1C=C(C2)C3=C(C=CS3)Br,NS-3861,Preclinical,acetylcholine receptor agonist,P30926
CHEMBL1318287,C[N+]1(CCCC1)CCCCC[N+]2(CCCC2)C.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O.[C@@H]([C@H](C(=O)[O-])O)(C(=O)O)O,pentolinium,Launched,cholinergic receptor antagonist,P30926
CHEMBL4853966,,SIB-1553A,Phase 2,acetylcholine receptor agonist,P30926
CHEMBL411729,C[C@@H]1CCC[C@H](/C=C/C(=O)O[C@]23[C@@H](/C=C/C1)[C@@H](C(=C)[C@H]([C@H]2[C@@H](NC3=O)CC4=CC=CC=C4)C)O)O,cytochalasin-B,Phase 2,microtubule inhibitor,P60709
CHEMBL4303382,COC1=C(C=CC(=C1)N2CCOCC2)NC3=NC=C(C(=N3)NC4=CC=CC=C4NS(=O)(=O)C)Cl,CZC-54252,Preclinical,leucine rich repeat kinase inhibitor,Q5S007
CHEMBL4869313,,GSK2578215A,Preclinical,leucine rich repeat kinase inhibitor,Q5S007
CHEMBL4867347,,LRRK2-IN-1,Preclinical,leucine rich repeat kinase inhibitor,Q5S007
CHEMBL4857323,,PF-06447475,Preclinical,serine/threonine kinase inhibitor,Q5S007
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,Q5S007
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P80404
CHEMBL1162144,CC(=O)C(=O)O,2-oxopropanoate,Preclinical,pyruvate dehydrogenase kinase inhibitor,P80404
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,P80404
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P80404
CHEMBL4872529,,MC-1,Phase 3,,P80404
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P80404
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,P80404
CHEMBL13883,COC1=C(C=CC(=C1)C=O)O,vanillin,Preclinical,,P80404
CHEMBL4303352,C=CC(CCC(=O)O)N.Cl,vigabatrin,Launched,GABA aminotransferase inhibitor,P80404
CHEMBL275655,CC(CC(=O)O)CN,3-methyl-GABA,Preclinical,GABA aminotransferase activator,P80404
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,Q9UNI1
CHEMBL25892,CC(C)C(C(=O)C1=NN=C(O1)C(C)(C)C)NC(=O)CN2C(=NC=C(C2=O)N)C3=CC=CC=C3,freselestat,Preclinical,elastase inhibitor,Q9UNI1
CHEMBL76688,CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC2=CC=CC=C2C(=O)NCC(=O)O,sivelestat,Launched,elastase inhibitor,Q9UNI1
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,O15552
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,O15552
CHEMBL4877759,,4-CMTB,Preclinical,free fatty acid receptor agonist,O15552
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,O14843
CHEMBL62381,CCCC(=O)[O-].[Na+],sodium-butyrate,Phase 2,HDAC inhibitor,O14843
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P00441
CHEMBL4303631,C(CNCCNCCNCCN)N.Cl.Cl.Cl.Cl.Cl,tetraethylenepentamine,Phase 2/Phase 3,superoxide dismutase inhibitor,P00441
CHEMBL3103190,C[C@H]1/C=C/C[C@H](CCCC[C@H](OC(=O)[C@H]([C@@]2([C@@H]([C@H]([C@@H]([C@H]1O2)C)O)OC)O)C)C3=CC=CC=C3)OC,C11-Acetate,Phase 3,,P10599
CHEMBL4860585,,PX-12,Phase 2,thioredoxin inhibitor,P10599
CHEMBL292687,C1=CC(=C(C=C1[N+](=O)[O-])[N+](=O)[O-])Cl,"2,4-dinitrochlorobenzene",Phase 2,thioredoxin inhibitor,P10599
CHEMBL4303607,CC(C)O[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COC(=O)C)OC(=O)C)OC(=O)C)NC(=O)C,C34,Preclinical,toll-like receptor inhibitor,O00206
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,O00206
CHEMBL3249799,C=CCN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1CC5=C3C(=C(C=C5)O)O4)O,naloxone,Launched,opioid receptor antagonist,O00206
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,O00206
CHEMBL4848585,,resatorvid,Phase 3,toll-like receptor inhibitor,O00206
CHEMBL1320667,C1C(ON=C1C2=CC=CC=C2)CC(=O)O,VGX-1027,Phase 1,tumor necrosis factor receptor antagonist,O00206
CHEMBL4303563,C1=CC=C(C=C1)C[C@H](C(=O)O)N.Cl,D-phenylalanine,Preclinical,enkephalinase inhibitor,Q16773
CHEMBL4872529,,MC-1,Phase 3,,Q16773
CHEMBL4303563,C1=CC=C(C=C1)C[C@H](C(=O)O)N.Cl,D-phenylalanine,Preclinical,enkephalinase inhibitor,P06850
CHEMBL285123,C([C@H](C(=O)O)N)O,D-serine,Launched,glutamate receptor agonist,P29508
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P29508
CHEMBL4858502,,D-4476,Preclinical,TGF beta receptor inhibitor,P48729
CHEMBL4863027,,DRF053-(R),Preclinical,CDK inhibitor,P48729
CHEMBL4851872,,IC261,Preclinical,casein kinase inhibitor,P48729
CHEMBL4858502,,D-4476,Preclinical,TGF beta receptor inhibitor,P48730
CHEMBL4851872,,IC261,Preclinical,casein kinase inhibitor,P48730
CHEMBL4303305,CC1=CC2=C(C=C1Cl)N=C(S2)NC(=O)CC3=CC=CC=C3,LH846,Preclinical,casein kinase inhibitor,P48730
CHEMBL4866343,,PF-4800567,Preclinical,casein kinase inhibitor,P48730
CHEMBL4878681,,PF-670462,Preclinical,casein kinase inhibitor,P48730
CHEMBL4303658,C1=CC(=C(C(=C1)F)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)F,TA-01,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,P48730
CHEMBL4858502,,D-4476,Preclinical,TGF beta receptor inhibitor,P01137
CHEMBL4297288,CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O,F351,Phase 2,TGF beta receptor inhibitor,P01137
CHEMBL4854002,,DAA-1106,Preclinical,benzodiazepine receptor agonist,B1AH88
CHEMBL4854002,,DAA-1106,Preclinical,benzodiazepine receptor agonist,P30536
CHEMBL4863046,,FGIN-1-27,Preclinical,inositol monophosphatase inhibitor,B1AH88
CHEMBL4863046,,FGIN-1-27,Preclinical,inositol monophosphatase inhibitor,P30536
CHEMBL4855025,,FGIN-1-43,Preclinical,benzodiazepine receptor agonist,B1AH88
CHEMBL4855025,,FGIN-1-43,Preclinical,benzodiazepine receptor agonist,P30536
CHEMBL4875537,,PK-11195,Phase 1,benzodiazepine receptor antagonist,B1AH88
CHEMBL4875537,,PK-11195,Phase 1,benzodiazepine receptor antagonist,P30536
CHEMBL513922,CCN(CC1=CC=CC=C1)C(=O)CN2C3=NC(=NC=C3N(C2=O)C)C4=CC=CC=C4,XBD173,Phase 2,benzodiazepine receptor ligand,B1AH88
CHEMBL513922,CCN(CC1=CC=CC=C1)C(=O)CN2C3=NC(=NC=C3N(C2=O)C)C4=CC=CC=C4,XBD173,Phase 2,benzodiazepine receptor ligand,P30536
CHEMBL2105729,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O,dabrafenib,Launched,RAF inhibitor,P53667
CHEMBL4863377,,LIMKi-3,Preclinical,LIM kinase inhibitor,P53667
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,P53667
CHEMBL2105729,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O,dabrafenib,Launched,RAF inhibitor,Q8NG66
CHEMBL2105729,CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O,dabrafenib,Launched,RAF inhibitor,P57059
CHEMBL4864496,,dacarbazine,Launched,DNA alkylating agent,P52209
CHEMBL4853208,,gadopentetic-acid,Launched,contrast agent,P52209
CHEMBL4864496,,dacarbazine,Launched,DNA alkylating agent,Q14181
CHEMBL4748391,C[C@@H]1[C@@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,dactinomycin,Launched,RNA polymerase inhibitor,P24928
CHEMBL8145,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,daidzein,Phase 2,estrogen receptor agonist,P11474
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,P11474
CHEMBL564769,CC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,P11474
CHEMBL8145,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,daidzein,Phase 2,estrogen receptor agonist,O95718
CHEMBL4857863,,diethylstilbestrol,Withdrawn,estrogen receptor agonist,O95718
CHEMBL192509,CCN(CC)C1=CC=C(C=C1)/C=N/NC(=O)C2=CC=C(C=C2)O,DY131,Preclinical,estrogen-related receptor agonist,O95718
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,O95718
CHEMBL564769,CC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O,4-methylgenistein,Preclinical,protein tyrosine kinase inhibitor,O95718
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q16322
CHEMBL75,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,ketoconazole,Launched,sterol demethylase inhibitor,Q16322
CHEMBL4864779,,pimozide,Launched,dopamine receptor antagonist,Q16322
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q16322
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P22459
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P17658
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q14721
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,Q14721
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q92953
CHEMBL2359966,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.O.O.OS(=O)(=O)O,quinine,Launched,hemozoin biocrystallization inhibitor,Q92953
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P48547
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q96PR1
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q14003
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q03721
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q03721
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9NSA2
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9H3M0
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9UIX4
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9UJ96
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q8TAE7
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q8TDN1
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9ULD8
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9UQ05
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q8NCM2
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q8NCM2
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9H252
CHEMBL1514181,C1=CC(=C(C=C1C(F)(F)F)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)O)O,NS-1643,Preclinical,voltage-gated potassium channel activator,Q9H252
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,Q9H252
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9NS40
CHEMBL1558,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC.Cl,prazosin,Launched,adrenergic receptor antagonist,Q9NS40
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q96L42
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,O60928
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P48544
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,P48544
CHEMBL4852247,,levcromakalim,Phase 3,potassium channel activator,P48544
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,P51787
CHEMBL255044,CCOC(=O)NC1=C(N=C(C=C1)NCC2=CC=C(C=C2)F)N,flupirtine,Launched,glutamate receptor antagonist,P51787
CHEMBL406,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,indapamide,Launched,thiazide diuretic,P51787
CHEMBL4877417,,L-365260,Phase 2,CCK receptor antagonist,P51787
CHEMBL451147,C/C=C(/C)\C(=O)OC[C@H]1C2=C(C[C@@H]3N1[C@H]([C@@H]4CC5=C([C@H]3N4C)C(=O)C(=C(C5=O)C)OC)C#N)C(=O)C(=C(C2=O)OC)C,M-14157,Phase 2,ATP-sensitive potassium channel antagonist,P51787
CHEMBL686,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,mefenamic-acid,Launched,cyclooxygenase inhibitor,P51787
CHEMBL2069205,,ML277,Preclinical,potassium channel activator,P51787
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P51787
CHEMBL3392049,C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2],pyrithione-zinc,Launched,ATP synthase inhibitor,P51787
CHEMBL4855722,,XE-991,Preclinical,potassium channel blocker,P51787
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9NR82
CHEMBL4858501,,flindokalner,Phase 3,potassium channel agonist,Q9NR82
CHEMBL4877777,,linopirdine,Phase 3,potassium channel blocker,Q9NR82
CHEMBL3392049,C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2],pyrithione-zinc,Launched,ATP synthase inhibitor,Q9NR82
CHEMBL4855722,,XE-991,Preclinical,potassium channel blocker,Q9NR82
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q96KK3
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9ULS6
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q9BQ31
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q6PIU1
CHEMBL284348,C1=CN=CC=C1N,dalfampridine,Launched,potassium channel blocker,Q8TDN2
CHEMBL2164243,CN(C)NC(=O)CCC(=O)O,daminozide,Preclinical,KDM2A inhibitor,Q9Y2K7
CHEMBL4864302,,IOX2,Preclinical,hypoxia inducible factor inhibitor,Q9Y2K7
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,Q9Y2K7
CHEMBL2164243,CN(C)NC(=O)CCC(=O)O,daminozide,Preclinical,KDM2A inhibitor,Q6ZMT4
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,Q6ZMT4
CHEMBL2164243,CN(C)NC(=O)CCC(=O)O,daminozide,Preclinical,KDM2A inhibitor,Q9UPP1
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,Q9UPP1
CHEMBL3039355,C[C@]12CCC3C(C1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,danazol,Launched,estrogen receptor antagonist|progesterone receptor agonist,Q96P88
CHEMBL4875044,,danusertib,Phase 2,Aurora kinase inhibitor|growth factor receptor inhibitor,Q9H2G2
CHEMBL3544988,C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O,daprodustat,Phase 3,hypoxia inducible factor inhibitor,Q9GZT9
CHEMBL4858783,,FG-2216,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,Q9GZT9
CHEMBL4124446,,FG-4592,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,Q9GZT9
CHEMBL4879132,,IOX1,Preclinical,histone demethylase inhibitor,Q9GZT9
CHEMBL4864302,,IOX2,Preclinical,hypoxia inducible factor inhibitor,Q9GZT9
CHEMBL204021,CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F,darapladib,Phase 3,phospholipase inhibitor,Q13093
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P51451
CHEMBL4466205,C=CC(=O)N1CCC[C@H](C1)N2C3=CC=CC=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5,ibrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,P51451
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P29317
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P29317
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P29317
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P29317
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P09769
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P09769
CHEMBL4865660,,PRT062607,Phase 2,SYK inhibitor,P09769
CHEMBL2107833,CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C)C1=NN(C(=C1)NC(=O)NC2=C(C=C(C=C2)OC3=CC(=NC=C3)C(=O)NC)F)C4=CC5=C(C=C4)N=CC=C5,rebastinib,Phase 1/Phase 2,Bcr-Abl kinase inhibitor|TIE tyrosine kinase inhibitor|VEGFR inhibitor,P09769
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,Q9H3Y6
CHEMBL1421,CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO,dasatinib,Launched,Bcr-Abl kinase inhibitor|ephrin inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|SRC inhibitor|tyrosine kinase inhibitor,P51692
CHEMBL283656,CC1=C(C2=CC=CC=C2N1CCC(=O)O)CN3C=CN=C3,dazmegrel,Phase 2,thromboxane synthase inhibitor,P24557
CHEMBL4875569,,dazoxiben,Phase 2,thromboxane synthase inhibitor,P24557
CHEMBL4875143,,furegrelate,Phase 1,thromboxane synthase inhibitor,P24557
CHEMBL4303640,C1=CC(=CC=C1CCO)OCCN2C=CN=C2,MR-948,Phase 1,thromboxane synthase inhibitor,P24557
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P24557
CHEMBL1715705,C1=CC(=CC=C1CN2C=CN=C2)/C=C/C(=O)O.O.Cl,ozagrel,Launched,thromboxane synthase inhibitor,P24557
CHEMBL421,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,sulfasalazine,Launched,cyclooxygenase inhibitor,P24557
CHEMBL4866109,,DCEBIO,Preclinical,potassium channel activator,Q9H2S1
CHEMBL4877048,,NS-309,Preclinical,calcium-activated potassium channel activator,Q9H2S1
CHEMBL4855912,,NS-8593,Preclinical,calcium-activated potassium channel modulator,Q9H2S1
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q9H2S1
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,Q9H2S1
CHEMBL4870795,,1-EBIO,Preclinical,potassium channel activator,Q9H2S1
CHEMBL4866109,,DCEBIO,Preclinical,potassium channel activator,Q9UGI6
CHEMBL333826,CC1=[N+](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC[N+]3=C(C=C(C4=CC=CC=C43)N)C,dequalinium,Launched,PKC inhibitor,Q9UGI6
CHEMBL4877048,,NS-309,Preclinical,calcium-activated potassium channel activator,Q9UGI6
CHEMBL4855912,,NS-8593,Preclinical,calcium-activated potassium channel modulator,Q9UGI6
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q9UGI6
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,Q9UGI6
CHEMBL4870795,,1-EBIO,Preclinical,potassium channel activator,Q9UGI6
CHEMBL4853609,,DDR1-IN-1,Preclinical,discoidin domain receptor inhibitor,Q08345
CHEMBL1642,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O,imatinib,Launched,Bcr-Abl kinase inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,Q08345
CHEMBL4853609,,DDR1-IN-1,Preclinical,discoidin domain receptor inhibitor,Q16832
CHEMBL1200485,CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F,sorafenib,Launched,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q16832
CHEMBL1946170,CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F,regorafenib,Launched,FGFR inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|RAF inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q16832
CHEMBL3137331,CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F,defactinib,Phase 2,focal adhesion kinase inhibitor,Q05397
CHEMBL482968,CC1=CC(=NN1)NC2=CC(=NC(=N2)/C=C/C3=CC=CC=C3)N4CCN(CC4)C,ENMD-2076,Phase 2,Aurora kinase inhibitor|FLT3 inhibitor|VEGFR inhibitor,Q05397
CHEMBL4870694,,NVP-TAE226,Preclinical,protein tyrosine kinase inhibitor,Q05397
CHEMBL4860698,,PF-431396,Preclinical,focal adhesion kinase inhibitor,Q05397
CHEMBL1084546,CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C,PF-562271,Phase 1,focal adhesion kinase inhibitor,Q05397
CHEMBL4303724,C1N2CN3CN1C[N+](C2)(C3)CCO,Y-11,Preclinical,focal adhesion kinase inhibitor,Q05397
CHEMBL4859946,,deferiprone,Launched,chelating agent,P19224
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,P11413
CHEMBL4303157,C[C@]12CC[C@@H](C[C@@H]1CC[C@@H]3[C@H]2CC[C@]4([C@H]3CCC4=O)C)O,epiandrosterone,Preclinical,steroid,P11413
CHEMBL5036323,,RRx-001,Phase 3,glucose 6-phosphate dehydrogenase inhibitor,P11413
CHEMBL259898,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C,dehydroepiandrosterone,Launched,protein synthesis stimulant,O00204
CHEMBL2262817,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)OC(=O)CCC(=O)O[C@@]5(CC[C@@H]6[C@@]5(CC[C@H]7[C@H]6CCC8=CC9=C(C[C@]78C)C=NO9)C)C#C)C)C,pregnenolone,Launched,glutamate receptor modulator,O00204
CHEMBL3286929,C1CNCCC1[C@@H](COC2=CC=C(C=C2)C3=NC4=CC=CC=C4N3CC5=CC=CC=C5)N6C7=CC=CC=C7N=C6C8=CC=CC=C8,deltarasin,Preclinical,phosphodiesterase inhibitor,P01116
CHEMBL4852829,,K-Ras(G12C)-inhibitor-12,Preclinical,K-Ras inhibitor,P01116
CHEMBL4862540,,lonafarnib,Phase 3,farnesyltransferase inhibitor,P01116
CHEMBL1200515,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=CC=CC=C45)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,deserpidine,Launched,angiotensin converting enzyme inhibitor,Q05940
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine,Launched,adrenergic receptor agonist,Q05940
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,Q05940
CHEMBL1257005,CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O.Cl,lobeline,Launched,acetylcholine receptor antagonist,Q05940
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,Q05940
CHEMBL772,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,reserpine,Launched,vesicular monoamine transporter inhibitor,Q05940
CHEMBL519344,CC(C)C[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2CC1=O)OC)OC,tetrabenazine,Launched,vesicular monoamine transporter inhibitor,Q05940
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P50993
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P50993
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P13637
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P13637
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,Q13733
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,Q13733
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P05026
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P05026
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P14415
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P14415
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P54709
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P54709
CHEMBL1614,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O,deslanoside,Launched,Na/K-ATPase inhibitor,P54710
CHEMBL254219,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,digitoxin,Launched,ATPase inhibitor,P54710
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P04083
CHEMBL1200562,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO,hydrocortisone,Launched,glucocorticoid receptor agonist,P04083
CHEMBL378081,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,dexamethasone,Launched,glucocorticoid receptor agonist,P51843
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P51843
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P05451
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,P08100
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P08100
CHEMBL1235338,CCCCCCCCCCCCCCCC=O,1-hexadecanal,Preclinical,sphingosine 1-phosphate receptor substrate,P08100
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q15796
CHEMBL180002,C(C(C(=O)O)N)OP(=O)(O)O,dexfosfoserine,Preclinical,membrane integrity inhibitor,Q9UL54
CHEMBL1201863,CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,dexlansoprazole,Launched,ATPase inhibitor,P20648
CHEMBL2146133,CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)C[S@](=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2],esomeprazole,Launched,ATPase inhibitor,P20648
CHEMBL480,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,lansoprazole,Launched,ATPase inhibitor,P20648
CHEMBL1567328,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2],omeprazole,Launched,ATPase inhibitor,P20648
CHEMBL1567328,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2],omeprazole-magnesium,Launched,proton pump inhibitor,P20648
CHEMBL1200408,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC(F)F)OC.[Na+],pantoprazole,Launched,ATPase inhibitor,P20648
CHEMBL4873462,,picartamide,Phase 2,H+/K+-ATPase inhibitor,P20648
CHEMBL1200930,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+],rabeprazole,Launched,ATPase inhibitor|gastrin inhibitor,P20648
CHEMBL1618279,CC1C2=CC=CC=C2CCN1C3=NC(=NC(=C3C)C)NC4=CC=C(C=C4)F,revaprazan,Launched,potassium-competitive acid antagonist,P20648
CHEMBL4861513,,SCH-28080,Phase 1,ATPase inhibitor,P20648
CHEMBL2079130,CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3,vonoprazan,Launched,potassium-competitive acid antagonist,P20648
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P13498
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P04839
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P14598
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P19878
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,Q15080
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,O00264
CHEMBL1201156,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl,nortriptyline,Launched,tricyclic antidepressant,O00264
CHEMBL4875091,,SM-21,Preclinical,sigma receptor antagonist,O00264
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P63000
CHEMBL4866420,,EHop-016,Preclinical,Ras GTPase inhibitor,P63000
CHEMBL52440,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,dextromethorphan,Launched,glutamate receptor antagonist|sigma receptor agonist,P15153
CHEMBL139,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,diclofenac,Launched,cyclooxygenase inhibitor,P14555
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,P14555
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,P14555
CHEMBL4850031,,oleamide,Preclinical,cannabinoid receptor agonist,P14555
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P14555
CHEMBL2105659,CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)OC)C(=O)C(=O)N,varespladib,Phase 3,secretory phospholipase inhibitor,P14555
CHEMBL171623,C(CCO)CO,"1,4-butanediol",Phase 1,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,P14555
CHEMBL1138328,,dicoumarol,Launched,NADPH inhibitor,Q08257
CHEMBL1138328,,dicoumarol,Launched,NADPH inhibitor,P15559
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P15559
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P15559
CHEMBL1256327,COC1=CC(=CC(=C1OC)OC)C(=O)OCCCN2CCCN(CC2)CCCOC(=O)C3=CC(=C(C(=C3)OC)OC)OC.Cl,dilazep,Launched,adenosine reuptake inhibitor,Q99808
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q99808
CHEMBL4867623,,lidoflazine,Launched,calcium channel blocker,Q99808
CHEMBL4863705,,N6-cyclopentyladenosine,Preclinical,adenosine receptor agonist,Q99808
CHEMBL1417783,CC(=O)OC1C(SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC.Cl,diltiazem,Launched,calcium channel blocker,Q06432
CHEMBL4855799,,fluspirilene,Launched,dopamine receptor antagonist,Q06432
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q06432
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q06432
CHEMBL2107333,COC(=O)/C=C/C(=O)OC,dimethyl-fumarate,Launched,nuclear factor erythroid derived|like (NRF2) activator,Q14145
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,trometamol,Launched,,P17707
CHEMBL1528028,C(CCN)CN.Cl.Cl,putrescine,Phase 2,tissue transglutaminase inhibitor,P17707
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,trometamol,Launched,,Q8WVQ1
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,trometamol,Launched,,P07585
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,trometamol,Launched,,Q96FI4
CHEMBL3186668,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O)O)O.COC(CO)(CO)N,trometamol,Launched,,P15692
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P15692
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P15692
CHEMBL3707366,C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)N,L-glutamine,Launched,,P15104
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P15104
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,O43924
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,O43924
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,P18545
CHEMBL1123546,,IBMX,Preclinical,phosphodiesterase inhibitor,P18545
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P18545
CHEMBL4792718,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.CC(=O)CC(CC(=O)C)(C(=O)C)O,sildenafil,Launched,phosphodiesterase inhibitor,P18545
CHEMBL3889385,,vardenafil,Launched,phosphodiesterase inhibitor,P18545
CHEMBL4873121,,dipyridamole,Launched,phosphodiesterase inhibitor,Q13956
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,Q13956
CHEMBL4792718,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C.CC(=O)CC(CC(=O)C)(C(=O)C)O,sildenafil,Launched,phosphodiesterase inhibitor,Q13956
CHEMBL3889385,,vardenafil,Launched,phosphodiesterase inhibitor,Q13956
CHEMBL1232164,C(CCCCC(=O)O)CCCC(=O)O,disodium-sebacate,Phase 1,,P68871
CHEMBL2107744,CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)[O-])C.[Na+],efaproxiral,Phase 3,hemoglobin oxygen release stimulant,P68871
CHEMBL4303433,C1=C(OC(=C1)CO)CO,"2,5-furandimethanol",Phase 2,hemoglobin modulator,P68871
CHEMBL964,CCN(CC)C(=S)SSC(=S)N(CC)CC,disulfiram,Launched,aldehyde dehydrogenase inhibitor|DNA methyltransferase inhibitor|TRPV agonist,P09172
CHEMBL1557,C1=CC(=C(C=C1CCN)O)O.Cl,dopamine,Launched,dopamine receptor agonist,P09172
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,L-mimosine,Preclinical,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,P09172
CHEMBL1188395,C1CC2=C(C[C@H]1N3C(=CNC3=S)CN)C=C(C=C2F)F,nepicastat,Phase 2,dopamine beta hydroxylase inhibitor,P09172
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P11137
CHEMBL1200721,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],estramustine,Launched,DNA alkylating agent,P11137
CHEMBL1756,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,estramustine-phosphate,Launched,DNA synthesis inhibitor|microtubule inhibitor,P11137
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P11137
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P27816
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P27816
CHEMBL92,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O,docetaxel,Launched,tubulin polymerization inhibitor,P10636
CHEMBL4297221,CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.CS(=O)(=O)O.CS(=O)(=O)O,leucomethylene-blue,Phase 3,nitric oxide production inhibitor|tau aggregation inhibitor,P10636
CHEMBL100910,CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,paclitaxel,Launched,tubulin polymerization inhibitor,P10636
CHEMBL1200453,CCCCCCCCCCCCCCCCCCCCCCO,docosanol,Launched,lipase clearing factor inhibitor,Q9NYK1
CHEMBL4851760,,DSR-6434,Preclinical,toll-like receptor agonist,Q9NYK1
CHEMBL2424598,,GS-9620,Phase 2,toll-like receptor agonist,Q9NYK1
CHEMBL1535,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,hydroxychloroquine,Launched,antimalarial agent,Q9NYK1
CHEMBL1282,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,imiquimod,Launched,interferon inducer|toll-like receptor agonist,Q9NYK1
CHEMBL383322,CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N,resiquimod,Phase 3,toll-like receptor agonist,Q9NYK1
CHEMBL4876078,,RWJ-21757,Phase 2,toll-like receptor agonist,Q9NYK1
CHEMBL1125125,,"5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione",Preclinical,,Q9NYK1
CHEMBL1204779,CCCCCCCCCCCCOS(=O)(=O)O,sodium-dodecyl-sulfate,Launched,,P02768
CHEMBL1204779,CCCCCCCCCCCCOS(=O)(=O)O,sodium-dodecyl-sulfate,Launched,,Q8TES7
CHEMBL51085,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,ebselen,Phase 2/Phase 3,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,P02768
CHEMBL51085,C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,ebselen,Phase 2/Phase 3,cyclooxygenase inhibitor|glutathione peroxidase agonist|H+/K+-ATPase inhibitor|nitric oxide synthase inhibitor,Q8TES7
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,P02768
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,Q8TES7
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,P02768
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,Q8TES7
CHEMBL1165268,C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,iodipamide,Launched,radiopaque medium,P02768
CHEMBL1165268,C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I,iodipamide,Launched,radiopaque medium,Q8TES7
CHEMBL4851326,,dofetilide,Withdrawn,potassium channel blocker,Q14500
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,Q14500
CHEMBL4303416,C[C@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O,dolutegravir,Launched,HIV integrase inhibitor,P09086
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,P36894
CHEMBL4869412,,LDN193189,Preclinical,bone morphogenic protein inhibitor,P36894
CHEMBL4862402,,ML347,Preclinical,ALK tyrosine kinase receptor inhibitor,P36894
CHEMBL4854698,,dorsomorphin,Preclinical,AMPK inhibitor,O00238
CHEMBL4870054,,DR-2313,Preclinical,PARP inhibitor,Q9Y6F1
CHEMBL4874011,,ME-0328,Preclinical,PPAR receptor antagonist,Q9Y6F1
CHEMBL4865450,,ME0328,Preclinical,PARP inhibitor,Q9Y6F1
CHEMBL1821568,,PJ-34,Preclinical,PARP inhibitor,Q9Y6F1
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q02641
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q02641
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q02641
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q02641
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q02641
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,Q08289
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q08289
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q08289
CHEMBL4855821,,nifedipine,Launched,calcium channel blocker,Q08289
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q08289
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q08289
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,P54284
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,P54284
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,P54284
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P54284
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,P54284
CHEMBL1201729,CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl,dronedarone,Launched,adrenergic receptor antagonist,O00305
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O00305
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,O00305
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,O00305
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,O00305
CHEMBL2103827,C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O,droxidopa,Launched,norepinephrine precursor,P00439
CHEMBL1256958,CNC[C@@H](C1=CC(=C(C=C1)O)O)O.C(C(C(=O)O)O)(C(=O)O)O,epinephrine,Launched,adrenergic receptor agonist|carbonic anhydrase activator|neurotransmitter,P00439
CHEMBL1256351,C1=CC(=CC=C1CC(C(=O)O)N)Cl,fenclonine-(+/-),Preclinical,tryptophan hydroxylase inhibitor,P00439
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P00439
CHEMBL1201775,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,P00439
CHEMBL3678938,C1[C@H]2[C@@H]1N([C@@H](C2)C(=O)NC3=NC(=CC=C3)Br)C(=O)CN4C5=C(C=CN=C5)C(=N4)C(=O)N,DU-728,Phase 1,structural glycoprotein antagonist,P08514
CHEMBL4303580,C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N,eptifibatide,Launched,platelet aggregation inhibitor,P08514
CHEMBL4854244,,GR-144053,Preclinical,integrin antagonist,P08514
CHEMBL3189072,CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O.O.Cl,tirofiban,Launched,platelet aggregation inhibitor|structural glycoprotein antagonist,P08514
CHEMBL1200969,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C,dutasteride,Launched,5 alpha reductase inhibitor,P18405
CHEMBL4777013,C[C@]12CC[C@H]3[C@@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,finasteride,Launched,5 alpha reductase inhibitor,P18405
CHEMBL4873643,,norgestrel,Launched,progesterone receptor agonist,P18405
CHEMBL1200969,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C,dutasteride,Launched,5 alpha reductase inhibitor,Q9H8P0
CHEMBL1209885,C1=CC=C2C=C(C(=CC2=C1)C(=O)N/N=C/C3=CC(=C(C=C3)O)O)O,dynasore,Preclinical,dynamin inhibitor,Q05193
CHEMBL4866528,,dynole-34-2,Preclinical,dynamin inhibitor,Q05193
CHEMBL1449747,COC1=C(C=C(C(=C1)N2C(=O)C3=CC=CC=C3NC2=S)Cl)Cl,mdivi-1,Preclinical,dynamin inhibitor,Q05193
CHEMBL1209885,C1=CC=C2C=C(C(=CC2=C1)C(=O)N/N=C/C3=CC(=C(C=C3)O)O)O,dynasore,Preclinical,dynamin inhibitor,O00429
CHEMBL1209885,C1=CC=C2C=C(C(=CC2=C1)C(=O)N/N=C/C3=CC(=C(C=C3)O)O)O,dynasore,Preclinical,dynamin inhibitor,P50570
CHEMBL4873653,,E-2012,Phase 1,gamma secretase modulator,Q96BI3
CHEMBL4873653,,E-2012,Phase 1,gamma secretase modulator,Q8WW43
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,Q8WW43
CHEMBL4873653,,E-2012,Phase 1,gamma secretase modulator,Q9NZ42
CHEMBL4303488,COCCN(C1=NC(=CS1)C2=CC=CC=C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC,eact,Preclinical,calcium-activated chloride channel inhibitor,Q5XXA6
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q5XXA6
CHEMBL1201082,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl,fluoxetine,Launched,selective serotonin reuptake inhibitor (SSRI),Q5XXA6
CHEMBL1534525,CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl,mibefradil,Withdrawn,T-type calcium channel blocker,Q5XXA6
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,Q5XXA6
CHEMBL4871860,,NPPB,Preclinical,chloride channel blocker,Q5XXA6
CHEMBL506247,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,tannic-acid,Launched,PARG inhibitor,Q5XXA6
CHEMBL4846629,,9-anthracenecarboxylic-acid,Preclinical,,Q5XXA6
CHEMBL2104585,CC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)S(=O)(=O)O,ecabet,Launched,gastrin inhibitor|urease inhibitor,Q8NFA2
CHEMBL808,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,econazole,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,P25929
CHEMBL4851280,,PD-160170,Preclinical,neuropeptide receptor antagonist,P25929
CHEMBL808,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,econazole,Launched,lanosterol demethylase inhibitor|sterol demethylase inhibitor,Q9NQA5
CHEMBL1559,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl.[N+](=O)(O)[O-],miconazole,Launched,bacterial cell wall synthesis inhibitor,Q9NQA5
CHEMBL4856097,,EED226,Preclinical,polycomb protein inhibitor,O75530
CHEMBL2107744,CC1=CC(=CC(=C1)NC(=O)CC2=CC=C(C=C2)OC(C)(C)C(=O)[O-])C.[Na+],efaproxiral,Phase 3,hemoglobin oxygen release stimulant,P69905
CHEMBL2103877,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)N3CCC(=C)CC3,efinaconazole,Launched,lanosterol demethylase inhibitor,Q16850
CHEMBL2218877,CCCCCCCCCCCCOS(=O)(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,erythromycin-estolate,Launched,bacterial 50S ribosomal subunit inhibitor,Q16850
CHEMBL1200688,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O,erythromycin-ethylsuccinate,Launched,cytochrome P450 inhibitor|protein synthesis inhibitor,Q16850
CHEMBL106,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,fluconazole,Launched,sterol demethylase inhibitor,Q16850
CHEMBL4845720,,morinidazole,Launched,other antibiotic,Q16850
CHEMBL830,C(CC(C(F)F)(C(=O)O)N)CN,eflornithine,Launched,ornithine decarboxylase inhibitor,P78540
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P78540
CHEMBL830,C(CC(C(F)F)(C(=O)O)N)CN,eflornithine,Launched,ornithine decarboxylase inhibitor,P11926
CHEMBL4872529,,MC-1,Phase 3,,P11926
CHEMBL1528028,C(CCN)CN.Cl.Cl,putrescine,Phase 2,tissue transglutaminase inhibitor,P11926
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P11926
CHEMBL4871143,,EG00229,Preclinical,neuropilin receptor antagonist,O14786
CHEMBL4871143,,EG00229,Preclinical,neuropilin receptor antagonist,Q92832
CHEMBL4866420,,EHop-016,Preclinical,Ras GTPase inhibitor,P60763
CHEMBL4866420,,EHop-016,Preclinical,Ras GTPase inhibitor,Q9Y6Q9
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P30532
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P30532
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q9UGM1
CHEMBL1257005,CN1[C@@H](CCC[C@@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O.Cl,lobeline,Launched,acetylcholine receptor antagonist,Q9UGM1
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,Q9UGM1
CHEMBL2103753,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75.OS(=O)(=O)O,strychnine,Preclinical,acetylcholine receptor antagonist,Q9UGM1
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P11230
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q05901
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,Q05901
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q07001
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,Q04844
CHEMBL1555,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O.Br,galantamine,Launched,acetylcholinesterase inhibitor,P07510
CHEMBL2105665,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H]([C@@H]([C@@H](O1)N2C=CC(=NC2=O)N)O)O,elacytarabine,Phase 3,antineoplastic agent,P27707
CHEMBL1096882,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N,fludarabine,Launched,ribonucleotide reductase inhibitor,P27707
CHEMBL554563,C1[C@H]([C@@H](O[C@@H]1N2C=CC(=NC2=O)N)CO)O,torcitabine,Phase 2,DNA polymerase inhibitor,P27707
CHEMBL2110588,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O,eliglustat,Launched,glycosyl transferase inhibitor,Q16739
CHEMBL4872847,,genz-123346,Preclinical,glucosylceramidase inhibitor,Q16739
CHEMBL1329690,CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O.Cl,miglustat,Launched,glycosyl transferase inhibitor,Q16739
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,Q8WTZ4
CHEMBL6246,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,ellagic-acid,Phase 2,glutathione transferase inhibitor|non-nucleoside reverse transcriptase inhibitor,Q9Y2D0
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,Q8WTZ4
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,Q9Y2D0
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q8WTZ4
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9Y2D0
CHEMBL4850223,,ELN-441958,Preclinical,bradykinin receptor antagonist,P46663
CHEMBL4863824,,EMD-53998,Phase 1,phosphodiesterase inhibitor,P19429
CHEMBL4863824,,EMD-53998,Phase 1,phosphodiesterase inhibitor,P63316
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,levosimendan,Launched,calcium sensitizer,P19429
CHEMBL2051955,C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N,levosimendan,Launched,calcium sensitizer,P63316
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P19429
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P63316
CHEMBL50588,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,emetine,Phase 2,protein synthesis inhibitor,P15880
CHEMBL197672,C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C,emricasan,Phase 2,caspase inhibitor,P29466
CHEMBL4303359,CCO[C@@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl,VX-765,Phase 2,caspase inhibitor,P29466
CHEMBL197672,C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)COC1=C(C(=CC(=C1F)F)F)F)NC(=O)C(=O)NC2=CC=CC=C2C(C)(C)C,emricasan,Phase 2,caspase inhibitor,P55210
CHEMBL4878486,,endo-IWR-1,Preclinical,PARP inhibitor,O95271
CHEMBL4847401,,exo-IWR-1,Preclinical,WNT signaling inhibitor negative control,O95271
CHEMBL4858072,,E7449,Phase 2,PARP inhibitor,O95271
CHEMBL4859658,,G007-LK,Preclinical,tankyrase inhibitor,O95271
CHEMBL4845874,,JW-55,Preclinical,tankyrase inhibitor,O95271
CHEMBL4846882,,JW-74,Preclinical,tankyrase inhibitor|WNT signaling inhibitor,O95271
CHEMBL2431867,CC(C)C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC=C3O2,MN-64,Preclinical,tankyrase inhibitor,O95271
CHEMBL4868885,,XAV-939,Preclinical,tankyrase inhibitor,O95271
CHEMBL4878486,,endo-IWR-1,Preclinical,PARP inhibitor,Q9H2K2
CHEMBL4858072,,E7449,Phase 2,PARP inhibitor,Q9H2K2
CHEMBL4859658,,G007-LK,Preclinical,tankyrase inhibitor,Q9H2K2
CHEMBL4845874,,JW-55,Preclinical,tankyrase inhibitor,Q9H2K2
CHEMBL4846882,,JW-74,Preclinical,tankyrase inhibitor|WNT signaling inhibitor,Q9H2K2
CHEMBL4865845,,NVP-TNKS656,Preclinical,tankyrase inhibitor,Q9H2K2
CHEMBL4303453,COC1=CC=C(C=C1)N2C(=NN=C2SCCCN3C(=O)C4=CC=CC5=C4C(=CC=C5)C3=O)C6=CC=NC=C6,WIKI4,Preclinical,tankyrase inhibitor|WNT pathway inhibitor,Q9H2K2
CHEMBL4868885,,XAV-939,Preclinical,tankyrase inhibitor,Q9H2K2
CHEMBL1314877,C=CCOC(CN1C=CN=C1)C2=C(C=C(C=C2)Cl)Cl.OS(=O)(=O)O,enilconazole,Launched,sterol demethylase inhibitor,P51589
CHEMBL1902981,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,eperisone,Launched,acetylcholine receptor antagonist,P51589
CHEMBL355200,C#CC1=CNC(=O)NC1=O,eniluracil,Phase 3,dihydropyrimidine dehydrogenase inhibitor,Q06278
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,Q06278
CHEMBL355200,C#CC1=CNC(=O)NC1=O,eniluracil,Phase 3,dihydropyrimidine dehydrogenase inhibitor,Q12882
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q12882
CHEMBL1730601,C1=C(C(=CNC1=O)Cl)O,gimeracil,Launched,dihydropyrimidine dehydrogenase inhibitor,Q12882
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q12882
CHEMBL566,C1=CNC(=O)NC1=O,uracil,Launched,,Q12882
CHEMBL4854670,C1=C(NC(=O)NC1=O)F,5-fluorouracil,Launched,thymidylate synthase inhibitor,Q12882
CHEMBL2106589,CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,enocitabine,Launched,DNA synthesis inhibitor,P30085
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine,Launched,ribonucleotide reductase inhibitor,P30085
CHEMBL3039516,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@@H]1[C@H](C([C@@H](O1)N2C=CC(=NC2=O)N)(F)F)O,gemcitabine-elaidate,Phase 1,apoptosis inhibitor|DNA synthesis inhibitor,P30085
CHEMBL953,CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N,entacapone,Launched,catechol O methyltransferase inhibitor,P21964
CHEMBL1256841,C1=CC=C(C=C1)CNC(=O)CCNNC(=O)C2=CC=NC=C2,nialamide,Withdrawn,monoamine oxidase inhibitor,P21964
CHEMBL167055,CC(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C(=O)C,nitecapone,Phase 2,catechol O methyltransferase inhibitor,P21964
CHEMBL1089318,CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-],opicapone,Phase 3,catechol O methyltransferase inhibitor,P21964
CHEMBL4873719,,OR-486,Preclinical,catechol O methyltransferase inhibitor,P21964
CHEMBL1324,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],tolcapone,Withdrawn,catechol O methyltransferase inhibitor,P21964
CHEMBL4869019,,U-0521,Preclinical,catechol O methyltransferase inhibitor,P21964
CHEMBL4875596,,2-methoxyestradiol,Phase 2,hypoxia inducible factor inhibitor,P21964
CHEMBL1983268,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,Q16288
CHEMBL2037226,CC1=C(C=C(C=C1)NC(=O)NC2=C(C=CC(=C2)C(F)(F)F)F)NC3=CC4=C(C=C3)/C(=C/C5=CC=CN5)/C(=O)N4,GNF-5837,Preclinical,growth factor receptor inhibitor,Q16288
CHEMBL4856292,C1C[C@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@H](C4)O)C5=C(C=CC(=C5)F)F,larotrectinib,Launched,tropomyosin receptor kinase inhibitor,Q16288
CHEMBL1983268,CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6,entrectinib,Launched,ALK tyrosine kinase receptor inhibitor|proto-oncogene tyrosine protein kinase inhibitor,P08922
CHEMBL4303155,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PF-06463922,Launched,ALK tyrosine kinase receptor inhibitor,P08922
CHEMBL2107337,CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7.Cl,enzastaurin,Phase 3,PKC inhibitor,P05129
CHEMBL4847929,,go-6983,Preclinical,protein kinase inhibitor,P05129
CHEMBL1863513,C/C=C(/C)\C(=O)O[C@H]1C(=C[C@@]23[C@@]1([C@@H](C(=C[C@H](C2=O)[C@H]4[C@H](C4(C)C)C[C@H]3C)CO)O)O)C,ingenol-mebutate,Launched,PKC activator,P05129
CHEMBL4790597,C[C@@]12C[C@@H](C[C@@](O1)(N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)C)N(C)C(=O)C9=CC=CC=C9,midostaurin,Launched,FLT3 inhibitor|KIT inhibitor|PKC inhibitor,P05129
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),P05129
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P05129
CHEMBL4848703,,EN460,Preclinical,endoplasmic reticulum oxidation inhibitor,Q96HE7
CHEMBL3545369,C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F,epacadostat,Phase 3,"indoleamine 2,3-dioxygenase inhibitor",P14902
CHEMBL4877357,,IDO5L,Preclinical,"indoleamine 2,3-dioxygenase inhibitor",P14902
CHEMBL4837181,,indoximod,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",P14902
CHEMBL4875078,,NLG919,Phase 1,"indoleamine 2,3-dioxygenase inhibitor",P14902
CHEMBL1475252,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=CC(=N3)OC,tenatoprazole,Phase 2,ATPase inhibitor,P14902
CHEMBL306946,C1=CC=C2C(=C1)C(=O)N3C4=CC=CC=C4C(=O)C3=N2,tryptanthrin,Preclinical,cyclooxygenase inhibitor,P14902
CHEMBL4853317,,tryptophan,Launched,serotonin receptor partial agonist,P14902
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P18846
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P15336
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P18847
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P18848
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,Q9Y2D1
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P18850
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P17544
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P01100
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,P60568
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,Q8WYK2
CHEMBL1523964,C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.C[C@@H]([C@@H](C1=CC=CC=C1)O)NC.OS(=O)(=O)O,ephedrine-(racemic),Launched,adrenergic receptor agonist,O95644
CHEMBL1474701,C1=CC=C2C3C4=CC=CC=C4C(C2=C1)C5=C3C(=O)C=CC5=O,INCA-6,Preclinical,calcineurin inhibitor,O95644
CHEMBL297453,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,epigallocatechin-gallate-(-),Phase 2/Phase 3,bacterial DNA gyrase inhibitor,P50281
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P50281
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P50281
CHEMBL4867936,,UK-356618,Preclinical,metalloproteinase inhibitor,P50281
CHEMBL1200981,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl,epirubicin,Launched,topoisomerase inhibitor,O14646
CHEMBL3707255,CC1(C2CC(C(O1)(C(C2)O)C)O)C,epomediol,Launched,cholesterol inhibitor,P22680
CHEMBL962,CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+],epoprostenol,Launched,prostacyclin analog,Q16647
CHEMBL4846367,,phenylbutazone,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,Q16647
CHEMBL4851587,,EPPTB,Preclinical,trace amine associated receptor antagonist,Q96RJ0
CHEMBL1230845,C[C@H](CC1=CC=C(C=C1)O)N,hydroxyamphetamine,Launched,trace amine associated receptor agonist,Q96RJ0
CHEMBL1367565,C1=CC(=CC=C1C(CN)O)O.Cl,octopamine,Preclinical,trace amine associated receptor agonist,Q96RJ0
CHEMBL2107338,C(CS(=O)(=O)[O-])CS(=O)(=O)[O-].[Na+].[Na+],eprodisate,Phase 3,amyloid protein inhibitor|antiamyloidogenic agent,P0DJI8
CHEMBL602389,CCOC(=O)C(=O)N1C2=C(C=C(C=C2)OC)C3=C(C1(C)C)SSC3=S,EPZ-5676,Phase 1,histone lysine methyltransferase inhibitor,Q8TEK3
CHEMBL4872868,,EPZ004777,Preclinical,histone lysine methyltransferase inhibitor,Q8TEK3
CHEMBL4848355,,EPZ015666,Preclinical,protein arginine N-methyltransferase inhibitor,O14744
CHEMBL4303685,CCN1C2=C(C=C(C=C2)CNCC3=CC=CC=C3OC)C4=CC=CC=C41,HLCL-61,Preclinical,protein arginine N-methyltransferase inhibitor,O14744
CHEMBL3588846,,EPZ020411,Preclinical,protein arginine N-methyltransferase inhibitor,Q96LA8
CHEMBL401989,CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl,erastin,Preclinical,ion channel antagonist,P45880
CHEMBL4871102,,ESI-09,Preclinical,EPAC inhibitor,Q8WZA2
CHEMBL4861335,,HJC-0350,Preclinical,GTPase inhibitor,Q8WZA2
CHEMBL1511,CCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C3C=CC(=C4)O)C,estradiol,Launched,estrogen receptor agonist,Q99527
CHEMBL1712246,C[C@]12CC[C@H]3C([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F,fulvestrant,Launched,estrogen receptor antagonist,Q99527
CHEMBL371202,C1=CC=C(C=C1)O/N=C/C2=CC=CC=C2C(F)(F)F,G-1,Preclinical,G protein-coupled receptor agonist,Q99527
CHEMBL4303158,C1C=C[C@H]2[C@@H]1[C@H](NC3=CC=CC=C23)C4=CC5=C(C=C4Br)OCO5.C1C=C[C@@H]2[C@H]1[C@@H](NC3=CC=CC=C23)C4=CC5=C(C=C4Br)OCO5,G-15,Preclinical,estrogen receptor antagonist,Q99527
CHEMBL1911053,C/C=C/1\[C@@H](C(=CO[C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)OC)CC(=O)OCCC3=CC(=C(C=C3)O)O,oleuropein,Phase 2,estrogen receptor agonist,Q99527
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q99527
CHEMBL1200721,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)([O-])[O-])CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl.[Na+].[Na+],estramustine,Launched,DNA alkylating agent,P78559
CHEMBL1756,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OP(=O)(O)O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl,estramustine-phosphate,Launched,DNA synthesis inhibitor|microtubule inhibitor,P78559
CHEMBL4852338,,ETC-159,Phase 1,beta catenin inhibitor|porcupine inhibitor,Q9H237
CHEMBL4852469,,IWP-L6,Preclinical,porcupine inhibitor,Q9H237
CHEMBL4858770,,LGK-974,Phase 2,porcupine inhibitor,Q9H237
CHEMBL4849533,,wnt-c59,Preclinical,porcupine inhibitor,Q9H237
CHEMBL3989529,CCCCCCCC/C=C\CCCCCCCC(=O)O.C(CO)N,ethanolamine-oleate,Launched,immunostimulant,P00748
CHEMBL4873281,,ethoxzolamide,Launched,carbonic anhydrase inhibitor,Q8N1Q1
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q8N1Q1
CHEMBL2051959,CCOC(=O)[C@]1(CO1)CCCCCCOC2=CC=C(C=C2)Cl,etomoxir,Phase 2,carnitine palmitoyltransferase inhibitor,P50416
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,P50416
CHEMBL4846041,,oxfenicine,Phase 1,carnitine palmitoyltransferase inhibitor,P50416
CHEMBL4082420,C1CCC(CC1)C(C[C@H]2CCCCN2)C3CCCCC3,perhexiline,Launched,carnitine palmitoyltransferase inhibitor,P50416
CHEMBL4303172,,EUK-134,Preclinical,catalase stimulant,P04179
CHEMBL4303631,C(CNCCNCCNCCN)N.Cl.Cl.Cl.Cl.Cl,tetraethylenepentamine,Phase 2/Phase 3,superoxide dismutase inhibitor,P04179
CHEMBL4871718,,EW-7197,Phase 2,TGF beta receptor inhibitor,P36897
CHEMBL202887,C1COCCC1NC(=O)C2=CC=C(C=C2)C3=NC=CC(=C3)C4=C(NN=C4)C5=CC=CC=N5,GW-788388,Preclinical,ALK tyrosine kinase receptor inhibitor,P36897
CHEMBL2447924,C1CC2=C(C(=NN2C1)C3=CC=CC=C3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6,LY2109761,Preclinical,TGF beta receptor inhibitor,P36897
CHEMBL4874987,,LY2157299,Phase 2/Phase 3,TGF beta receptor inhibitor,P36897
CHEMBL4864606,,LY364947,Preclinical,p38 MAPK inhibitor|TGF beta receptor inhibitor,P36897
CHEMBL4861955,,QX-314,Preclinical,sodium channel blocker,P36897
CHEMBL4303194,CC1=NC(=CC=C1)C2=C(C=NN2)C3=CC(=C(C=C3)F)C4=CN(N=C4)CCO,R-268712,Preclinical,serine/threonine kinase inhibitor,P36897
CHEMBL4858216,,repsox,Preclinical,TGF beta receptor inhibitor,P36897
CHEMBL1909378,C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5.Cl,SB-431542,Preclinical,TGF beta receptor inhibitor,P36897
CHEMBL4869296,,SB-505124,Preclinical,ALK tyrosine kinase receptor inhibitor,P36897
CHEMBL4870318,,SB-525334,Preclinical,TGF beta receptor inhibitor,P36897
CHEMBL4875437,,SD-208,Preclinical,TGF beta receptor inhibitor,P36897
CHEMBL4850318,,SIS3,Preclinical,serine/threonine kinase inhibitor,P36897
CHEMBL4861098,,examorelin,Phase 2,growth hormone releasing factor agonist,Q02643
CHEMBL3818130,C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C,exherin,Phase 2,cadherin antagonist,P19022
CHEMBL4874561,,ezetimibe,Launched,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,P15144
CHEMBL2103847,CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2,tosedostat,Phase 2,peptidase inhibitor,P15144
CHEMBL4874561,,ezetimibe,Launched,cholesterol inhibitor|Niemann-Pick C1-like 1 protein antagonist,Q9UHC9
CHEMBL4848722,,ezutromid,Phase 2,utrophin enhancer,P46939
CHEMBL108084,C1CN[C@@H]([C@H]([C@@H]1O)O)CO,fagomine,Phase 2,glucosidase inhibitor,P16278
CHEMBL4853405,,farnesyl-thiosalicylic-acid-amide,Phase 1,Ras GTPase inhibitor,P01112
CHEMBL4862540,,lonafarnib,Phase 3,farnesyltransferase inhibitor,P01112
CHEMBL4297216,CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4.O.Cl.Cl,fedratinib,Launched,FLT3 inhibitor|JAK inhibitor,P29597
CHEMBL3301607,C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5,filgotinib,Phase 3,JAK inhibitor,P29597
CHEMBL3545217,,NS-018,Phase 1/Phase 2,JAK inhibitor,P29597
CHEMBL1789941,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,ruxolitinib,Launched,JAK inhibitor,P29597
CHEMBL1256351,C1=CC(=CC=C1CC(C(=O)O)N)Cl,fenclonine-(+/-),Preclinical,tryptophan hydroxylase inhibitor,Q8IWU9
CHEMBL1201745,CC(C)(C(=O)[O-])OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl.C[N+](C)(C)CCO,fenofibrate,Launched,PPAR receptor agonist,Q9H239
CHEMBL1201745,CC(C)(C(=O)[O-])OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl.C[N+](C)(C)CCO,fenofibrate,Launched,PPAR receptor agonist,Q9NPA2
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9H239
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9NPA2
CHEMBL1785463,,fenofibric-acid,Launched,cytochrome P450 inhibitor,P35523
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P35523
CHEMBL4846629,,9-anthracenecarboxylic-acid,Preclinical,,P35523
CHEMBL1297,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,fenoprofen,Launched,prostaglandin inhibitor,Q8N695
CHEMBL3989408,CC(C)CC1=CC=C(C=C1)C(C)C(=O)[O-].O.O.[Na+],ibuprofen-(S),Launched,cyclooxygenase inhibitor,Q8N695
CHEMBL571,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,ketoprofen,Launched,cyclooxygenase inhibitor,Q8N695
CHEMBL4858783,,FG-2216,Phase 2,hypoxia inducible factor prolyl hydroxylase inhibitor,Q96KS0
CHEMBL4124446,,FG-4592,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,Q96KS0
CHEMBL3646118,C1COCCN1C2=NC=NC(=C2)N3C(=O)C(=CN3)N4C=CN=N4,molidustat,Phase 3,hypoxia inducible factor inhibitor,Q96KS0
CHEMBL4124446,,FG-4592,Phase 3,hypoxia inducible factor prolyl hydroxylase inhibitor,Q9H6Z9
CHEMBL4855249,,fingolimod,Launched,immunosuppressant|sphingosine 1-phosphate receptor agonist,Q9H228
CHEMBL4853225,,FK-866,Phase 2,niacinamide phosphoribosyltransferase inhibitor,P43490
CHEMBL17289,C1=CC(=CC=C1OCCCCCCN=C(NC#N)NC2=CC=NC=C2)Cl,GMX1778,Phase 1/Phase 2,NAMPT inhibitor,P43490
CHEMBL4862450,,GPP-78,Preclinical,NAMPT inhibitor,P43490
CHEMBL4878067,,P7C3,Preclinical,NAMPT inhibitor,P43490
CHEMBL4860344,,STF-118804,Preclinical,NAMPT inhibitor,P43490
CHEMBL4870975,,STF-31,Preclinical,NAMPT inhibitor,P43490
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q9UKU7
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P11310
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q15067
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,O95831
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q9UHQ9
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q86YB8
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P22570
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,Q92947
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P55789
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P26440
CHEMBL1232653,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)OP(=O)(O)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)N)O)O)O)O)O,flavin-adenine-dinucleotide,Preclinical,,P16435
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,P16435
CHEMBL23588,C1=CC=C(C(=C1)C(=O)O)NC2=CC=CC(=C2)C(F)(F)F,flufenamic-acid,Preclinical,chloride channel blocker,Q9NZQ8
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,Q9NZQ8
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,Q9Y6K9
CHEMBL4866492,,flurizan,Phase 3,gamma secretase inhibitor,P49810
CHEMBL1473,CCC(=O)O[C@@]1([C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2C[C@@H](C4=CC(=O)C=C[C@@]43C)F)F)O)C)C)C(=O)SCF,fluticasone-propionate,Launched,glucocorticoid receptor agonist,P47712
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P47712
CHEMBL4878174,,PACOCF3,Preclinical,phospholipase inhibitor,P47712
CHEMBL2161355,,folic-acid,Launched,folate receptor ligand,P14207
CHEMBL4849997,,tetrahydrofolic-acid,Launched,,P14207
CHEMBL2161355,,folic-acid,Launched,folate receptor ligand,P41439
CHEMBL2161355,,folic-acid,Launched,folate receptor ligand,P41440
CHEMBL1308,CC1=CNN=C1,fomepizole,Launched,alcohol dehydrogenase inhibitor,P14550
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P14550
CHEMBL4868051,,tolrestat,Withdrawn,aldose reductase inhibitor,P14550
CHEMBL1308,CC1=CNN=C1,fomepizole,Launched,alcohol dehydrogenase inhibitor,P04040
CHEMBL1276258,CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])COC[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])COC[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)O)NS(=O)(=O)[O-])O)O)OS(=O)(=O)[O-])NS(=O)(=O)[O-])O)OS(=O)(=O)[O-])O)NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+],fondaparinux,Launched,coagulation factor inhibitor,P01008
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,O95467
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,P63092
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,P84996
CHEMBL4853220,,forskolin,Launched,adenylyl cyclase activator,Q5JWF2
CHEMBL2105643,COC1=C(C=C(C=C1)/C=C\C2=CC(=C(C(=C2)OC)OC)OC)OP(=O)(O)O.C(C(CO)(CO)N)O,fosbretabulin,Phase 3,tubulin polymerization inhibitor|VE-cadherin antagonist,P33151
CHEMBL4297281,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC=O,foxy-5,Phase 2,WNT5a peptide mimetic,P41221
CHEMBL4875852,,FRAX486,Preclinical,serine/threonine kinase inhibitor,Q13153
CHEMBL4875852,,FRAX486,Preclinical,serine/threonine kinase inhibitor,Q16512
CHEMBL4874225,,IPA-3,Preclinical,p21 activated kinase inhibitor,Q13153
CHEMBL4874225,,IPA-3,Preclinical,p21 activated kinase inhibitor,Q16512
CHEMBL5091324,CN(C)C(=O)N1CC[C@@H](C1)N=C2C3=C(C=CC(=C3)Cl)N(C4=C(N2)C=C(C=C4)F)CC(F)F,NVS-PAK1-1,Preclinical,p21 activated kinase inhibitor,Q13153
CHEMBL5091324,CN(C)C(=O)N1CC[C@@H](C1)N=C2C3=C(C=CC(=C3)Cl)N(C4=C(N2)C=C(C=C4)F)CC(F)F,NVS-PAK1-1,Preclinical,p21 activated kinase inhibitor,Q16512
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q13153
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q16512
CHEMBL4875852,,FRAX486,Preclinical,serine/threonine kinase inhibitor,Q13177
CHEMBL4875852,,FRAX486,Preclinical,serine/threonine kinase inhibitor,O75914
CHEMBL4875852,,FRAX486,Preclinical,serine/threonine kinase inhibitor,O96013
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,O96013
CHEMBL3128043,CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)N[C@H](CN(C)C)C5=CC=CC=C5)SC=C2,PF-03758309,Phase 1,p21 activated kinase inhibitor,O96013
CHEMBL1241092,CCCC[C@@H](C)[C@H]([C@H]([C@@H](C)C[C@@H](CCCC[C@H](C[C@@H]([C@H](C)N)O)O)O)OC(=O)C[C@H](CC(=O)O)C(=O)O)OC(=O)C[C@H](CC(=O)O)C(=O)O,fumonisin-B1,Preclinical,,P27544
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O00555
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,O00555
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,O00555
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,O00555
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q15878
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q8IZS8
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,Q8IZS8
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q7Z3S7
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9Y698
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,O60359
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9UBN1
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9UF02
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q8WXS5
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,Q9BXT2
CHEMBL1628502,CC(C)C(=O)OC(C)OC(=O)NCC1(CCCCC1)CC(=O)O,gabapentin,Launched,calcium channel blocker,P62955
CHEMBL1398351,CCOC(=O)C1=CC=C(C=C1)OC(=O)CCCCCN=C(N)N.CS(=O)(=O)O,gabexate,Launched,serine protease inhibitor,Q15661
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,Q15661
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P24046
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P24046
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P24046
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,P28476
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,P28476
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,P28476
CHEMBL4854106,,gaboxadol,Phase 3,benzodiazepine receptor agonist,A8MPY1
CHEMBL540303,C1CNCC=C1C(=O)O.Cl,isoguvacine,Preclinical,benzodiazepine receptor agonist,A8MPY1
CHEMBL4866807,,muscimol,Phase 1,benzodiazepine receptor agonist,A8MPY1
CHEMBL1123536,,gallopamil,Launched,L-type calcium channel blocker,P16615
CHEMBL4864638,,GANT-58,Preclinical,GLI antagonist,P08151
CHEMBL4865729,,GANT-61,Preclinical,GLI antagonist,P08151
CHEMBL4865729,,GANT-61,Preclinical,GLI antagonist,P10070
CHEMBL4847961,,GDC-0068,Phase 3,AKT inhibitor,Q13976
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,Q13976
CHEMBL1741141,C1[C@@H]2[C@H]([C@H]([C@@H](O2)N3C4=C(C(=O)NC(=N4)N)N=C3Br)O)OP(=O)(O1)O,8-bromo-cGMP,Preclinical,PKA activator,Q13976
CHEMBL4847101,,GDC-0152,Phase 1,XIAP inhibitor,Q96CA5
CHEMBL4865181,,GDC-0980,Phase 2,mTOR inhibitor|PI3K inhibitor,P80192
CHEMBL4865660,,PRT062607,Phase 2,SYK inhibitor,P80192
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,P80192
CHEMBL457,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,gemfibrozil,Launched,lipoprotein lipase activator,O94956
CHEMBL4853974,,glyburide,Launched,ATP channel blocker|insulin secretagogue|sulfonylurea,O94956
CHEMBL236921,C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C,rifamycin,Launched,DNA directed RNA polymerase inhibitor,O94956
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,Q15596
CHEMBL4868759,,GW-9662,Preclinical,PPAR receptor antagonist,Q15596
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,Q15596
CHEMBL44,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,genistein,Phase 2/Phase 3,tyrosine kinase inhibitor,Q14289
CHEMBL960,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,leflunomide,Launched,dihydroorotate dehydrogenase inhibitor|PDGFR tyrosine kinase receptor inhibitor,Q14289
CHEMBL4860698,,PF-431396,Preclinical,focal adhesion kinase inhibitor,Q14289
CHEMBL1084546,CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C,PF-562271,Phase 1,focal adhesion kinase inhibitor,Q14289
CHEMBL515827,C[C@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.OS(=O)(=O)O,gentamycin,Launched,bacterial 50S ribosomal subunit inhibitor,P11142
CHEMBL3856258,,GGsTop,Preclinical,gamma glutamyltransferase Inhibitor,P19440
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P19440
CHEMBL3654058,CC1(CC(=C(CO1)CN2CCN(CC2)C3=CC(=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(N=C4)OCC5CCOCC5)C#N)OC6=C(C=C7C(=C6)C=CN7)F)C8=CC=C(C=C8)Cl)C,GGTI-298,Preclinical,GGTase inhibitor,P38936
CHEMBL4857129,,GKA-50,Preclinical,glucokinase activator,P35557
CHEMBL4857129,,GKA-50,Preclinical,glucokinase activator,Q12851
CHEMBL4196175,,GNF-7,Preclinical,glucokinase inhibitor|protein kinase inhibitor,P35557
CHEMBL4196175,,GNF-7,Preclinical,glucokinase inhibitor|protein kinase inhibitor,Q12851
CHEMBL4860292,,lonidamine,Launched,glucokinase inhibitor,P35557
CHEMBL4860292,,lonidamine,Launched,glucokinase inhibitor,Q12851
CHEMBL4297399,C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6,LY2608204,Phase 2,glucokinase activator,P35557
CHEMBL4297399,C1CCC(CC1)[C@@H]2C[C@@]2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC=C(S5)SCCN6CCCC6,LY2608204,Phase 2,glucokinase activator,Q12851
CHEMBL4849071,,PF-04937319,Phase 2,glucokinase activator,P35557
CHEMBL4849071,,PF-04937319,Phase 2,glucokinase activator,Q12851
CHEMBL4859016,,Ro-28-1675,Preclinical,glucokinase activator,P35557
CHEMBL4859016,,Ro-28-1675,Preclinical,glucokinase activator,Q12851
CHEMBL2105711,CCC1=CC=C(C=C1)CC2=CC3=C(CO[C@@]34[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C2.O,tofogliflozin,Launched,sodium/glucose cotransporter inhibitor,P35557
CHEMBL2105711,CCC1=CC=C(C=C1)CC2=CC3=C(CO[C@@]34[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)C=C2.O,tofogliflozin,Launched,sodium/glucose cotransporter inhibitor,Q12851
CHEMBL4303187,CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl,GKT137831,Phase 2,NADPH oxidase inhibitor,Q9Y5S8
CHEMBL4860075,,GK921,Preclinical,transglutaminase inhibitor,P21980
CHEMBL179945,C1=CC=C(C=C1)C2=CSC3=C2C(=O)N(C(=N3)SCC(=O)NN)C4=CC=CC=C4,LDN-27219,Preclinical,tissue transglutaminase inhibitor,P21980
CHEMBL3039333,C([C@H]1[C@@H]([C@H]([C@@H](C(=O)O1)O)O)O)O,gluconolactone,Launched,,P09848
CHEMBL1234222,C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O)F)O)O)O,2-fluoro-2-deoxy-D-galactose,Phase 1,,P09848
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P10768
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P35754
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q9NS18
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P07203
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P18283
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P22352
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P36969
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O75715
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P59796
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q96SL4
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q8TED1
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P08263
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P09210
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q16772
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O15217
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q7RTV2
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q9Y2Q3
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P09488
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P28161
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P21266
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q03013
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P46439
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P78417
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q9H4Y5
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P30711
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O43708
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q16775
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O60760
CHEMBL9514,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,nocodazole,Preclinical,tubulin polymerization inhibitor,O60760
CHEMBL4858415,,TFC-007,Preclinical,prostaglandin inhibitor,O60760
CHEMBL415324,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,tranilast,Launched,angiogenesis inhibitor,O60760
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q16873
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,P10620
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,Q99735
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O14880
CHEMBL2074781,C(CC(=O)C[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,glutathione,Phase 3,antioxidant,O95881
CHEMBL4539462,C1C[C@@H]2[C@H](C1)C3=C(C(=CC(=C3)F)F)NC2C4=CN=CC=C4,golgicide-A,Preclinical,ARF inhibitor,Q92538
CHEMBL4867795,,GR-159897,Preclinical,tachykinin antagonist,P20366
CHEMBL562,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,griseofulvin,Launched,tubulin polymerization inhibitor,Q99456
CHEMBL4303714,C1=CC=C(C=C1)CC\2=NN(C(=O)/C2=C/C3=CC=C(O3)C4=CC=CC=C4F)C5=CC=C(C=C5)C(=O)O,GS-143,Preclinical,ubiquitin ligase inhibitor,Q9Y297
CHEMBL4853986,,GSK-J1,Preclinical,histone demethylase inhibitor,O15054
CHEMBL4858116,,GSK-J4,Preclinical,histone lysine demethylase inhibitor,O15054
CHEMBL4879132,,IOX1,Preclinical,histone demethylase inhibitor,O15054
CHEMBL4858116,,GSK-J4,Preclinical,histone lysine demethylase inhibitor,O15550
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,O15550
CHEMBL4878131,,GSK-LSD-1,Preclinical,histone lysine demethylase inhibitor,O60341
CHEMBL4870201,,GSK2879552,Phase 1/Phase 2,histone lysine demethylase inhibitor,O60341
CHEMBL4854542,,OG-L002,Preclinical,histone lysine demethylase inhibitor,O60341
CHEMBL4849421,,ORY-1001,Phase 1/Phase 2,histone lysine demethylase inhibitor,O60341
CHEMBL4303584,C1CN(CCN1CC2=CC=CC=C2)S(=O)(=O)C3=C(C=C(C=C3)Cl)[N+](=O)[O-],RN-1,Preclinical,histone demethylase inhibitor,O60341
CHEMBL1255743,C1[C@H]([C@@H]1N)C2=CC=CC=C2.Cl,tranylcypromine,Launched,monoamine oxidase inhibitor,O60341
CHEMBL4871858,,GSK1292263,Phase 2,glucose dependent insulinotropic receptor agonist,P30550
CHEMBL4866582,,MK-5046,Preclinical,bombesin receptor agonist,P30550
CHEMBL4869988,,GSK2256294A,Phase 1,epoxide hydolase inhibitor,P34913
CHEMBL2387408,CCCC[C@@]1(CS(=O)(=O)C2=C(C=C(C(=C2)CNC(CC(=O)O)CC(=O)O)OC)[C@H](N1)C3=CC=CC=C3)CC,GSK2330672,Phase 2,bile acid transporter inhibitor,Q12908
CHEMBL4846704,,GSK2606414,Preclinical,protein kinase inhibitor,Q9NZJ5
CHEMBL4303573,C1CC(CCC1NC(=O)COC2=CC=C(C=C2)Cl)NC(=O)COC3=CC=C(C=C3)Cl,ISRIB,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,Q9NZJ5
CHEMBL4846704,,GSK2606414,Preclinical,protein kinase inhibitor,Q9H1R3
CHEMBL4847891,,GSK2801,Preclinical,bromodomain inhibitor,Q9UIF9
CHEMBL4847891,,GSK2801,Preclinical,bromodomain inhibitor,Q9UIF8
CHEMBL3613749,CC1=C(C=C(C=N1)Cl)NCC2=CC=C(S2)C(=O)N[C@@H](CC3CCCC3)C(=O)NC4CC4,GSK2830371,Preclinical,protein phosphatase inhibitor,O15297
CHEMBL4848147,,GSK650394,Preclinical,serum/glucocorticoid regulated kinase inhibitor,Q9HBY8
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,Q9NQU5
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,Q9P286
CHEMBL4866229,,GSK690693,Phase 1,AKT inhibitor,P51817
CHEMBL4303470,C[C@@H](C1=CC=CN2C1=NC(=C2)C3=CC=C(C=C3)C[C@@H](CNC(=O)CN(C)C)NC(=O)C4=CC(=C(C=C4)OC(C)C)Cl)O,GSK923295,Phase 1,centromere associated protein inhibitor,Q02224
CHEMBL2078034,,guanidine,Launched,HSP inhibitor,P78352
CHEMBL2078034,,guanidine,Launched,HSP inhibitor,Q15334
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P78352
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,Q15334
CHEMBL4303495,CSC1=NC2=C(S1)C3=C(C=C2)N=C(S3)NC(=O)C(C4=CC=CC=C4)C5=CC=CC=C5,Gue-1654,Preclinical,oxoeicosanoid receptor modulator,Q8TDS5
CHEMBL1256362,C1CNCC(=C1)C(=O)O.Cl,guvacine,Preclinical,GABA uptake inhibitor,P48066
CHEMBL1256362,C1CNCC(=C1)C(=O)O.Cl,guvacine,Preclinical,GABA uptake inhibitor,P48065
CHEMBL4847745,,NNC-05-2090,Preclinical,GABA uptake inhibitor|GAT inhibitor,P48065
CHEMBL1256362,C1CNCC(=C1)C(=O)O.Cl,guvacine,Preclinical,GABA uptake inhibitor,Q9NSD5
CHEMBL4863924,,GW-3965,Preclinical,LXR agonist,P55055
CHEMBL4875793,,LXR-623,Phase 1,LXR agonist,P55055
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,P55055
CHEMBL4863924,,GW-3965,Preclinical,LXR agonist,Q13133
CHEMBL4875793,,LXR-623,Phase 1,LXR agonist,Q13133
CHEMBL4877270,,T-0901317,Preclinical,LXR agonist,Q13133
CHEMBL4871823,,GW-803430,Phase 1,melanin inhibitor,Q99705
CHEMBL1199540,C1C[C@@H]([C@H](NC1)CC(=O)CN2C=NC3=CC(=C(C=C3C2=O)Cl)Br)O,halofuginone,Launched,collagenase inhibitor,P02452
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q9HB15
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q9HB14
CHEMBL931,C(C(F)(F)F)(Cl)Br,halothane,Launched,glutamate receptor antagonist,Q9H427
CHEMBL4303618,CCC1=CC=C(O1)/C=C/C(=O)NC2=CC=C(C=C2)C(=O)C,heclin,Preclinical,ubiquitin ligase inhibitor,P46934
CHEMBL4303645,CC1=CC(=C(C=C1)C)N2C=NC3=C2C=CC(=C3)C(=O)NCC4=CC=CC=C4Cl,NAB-2,Preclinical,ubiquitin ligase transport promoter,P46934
CHEMBL4303618,CCC1=CC=C(O1)/C=C/C(=O)NC2=CC=C(C=C2)C(=O)C,heclin,Preclinical,ubiquitin ligase inhibitor,Q9HAU4
CHEMBL4303618,CCC1=CC=C(O1)/C=C/C(=O)NC2=CC=C(C=C2)C(=O)C,heclin,Preclinical,ubiquitin ligase inhibitor,Q9H0M0
CHEMBL399121,COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O,hesperetin,Launched,ACAT inhibitor,P55157
CHEMBL2105662,CS(=O)(=O)O.C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F,lomitapide,Launched,microsomal trigylceride transfer protein inhibitor,P55157
CHEMBL496,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,hexachlorophene,Launched,potassium channel activator,O14521
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,O14521
CHEMBL2104293,CC(CC(C)(C)O)O,hexylene-glycol,Preclinical,,P49763
CHEMBL4849518,,HTH-01-015,Preclinical,protein kinase inhibitor,O60285
CHEMBL4853290,,ON123300,Preclinical,CDK inhibitor,O60285
CHEMBL4303523,CCC(=O)NC1=CC(=CC=C1)OC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC,WZ4003,Preclinical,AMPK inhibitor,O60285
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,Q07021
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,P16070
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,Q14520
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,P10915
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,Q96S86
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,Q86UW8
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,O75330
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,O14594
CHEMBL1697748,CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)NC(=O)C)O)O,hyaluronic-acid,Launched,,P13611
CHEMBL1535,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,hydroxychloroquine,Launched,antimalarial agent,Q9NR96
CHEMBL604677,C1=CC(=CC(=C1)OC2=CC=C(C=C2)[N+](=O)[O-])N3C(=O)C4=C(C3=O)C=C(C=C4)C(=O)O,H2L-5765834,Preclinical,lysophosphatidic acid receptor antagonist,Q9UBY5
CHEMBL403504,CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)C3(CC(CC(C3)(C)C(=O)NC)(C)C=O)C,KI-16425,Preclinical,lysophosphatidic acid receptor antagonist,Q9UBY5
CHEMBL4868233,,I-BET-762,Phase 2,bromodomain inhibitor,P25440
CHEMBL4862900,,I-BET151,Preclinical,bromodomain inhibitor,P25440
CHEMBL4849190,,LY303511,Preclinical,casein kinase inhibitor|mTOR inhibitor|PI3K inhibitor,P25440
CHEMBL4852290,,OTX015,Phase 1/Phase 2,bromodomain inhibitor,P25440
CHEMBL4867977,,XD-14,Preclinical,bromodomain inhibitor,P25440
CHEMBL4869267,,I-BRD9,Preclinical,bromodomain inhibitor,Q9H8M2
CHEMBL4846801,,I-CBP-112,Preclinical,bromodomain inhibitor,Q92793
CHEMBL4870447,,SGC-CBP30,Preclinical,bromodomain inhibitor,Q92793
CHEMBL4466205,C=CC(=O)N1CCC[C@H](C1)N2C3=CC=CC=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5,ibrutinib,Launched,Bruton's tyrosine kinase (BTK) inhibitor,P51813
CHEMBL2105872,CC(C)(C(=O)N[C@H](COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O,ibutamoren,Phase 2,growth hormone secretagogue receptor agonist,P10912
CHEMBL2028852,CC(=O)O.C1CC[C@H]2[C@@H](C1)C[C@H](N2C(=O)[C@H]3CC4=CC=CC=C4CN3C(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=CS5)NC(=O)CNC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](CCCN=C(N)N)N)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,icatibant-acetate,Launched,bradykinin receptor antagonist,P30411
CHEMBL294453,CCCC[P+](CCCC)(CCCC)CC1=CC=C(C=C1)NC(=O)[C@H](CC2=CC3=CC=CC=C3C=C2)NC(=NC4CCCCC4)NC5CCCCC5,WIN-64338,Preclinical,bradykinin receptor antagonist,P30411
CHEMBL594621,CCCCC[C@@H](/C=C/C=C\C/C=C\C/C=C\CCCC(=O)O)O,icomucret,Phase 3,mucin production enhancer,Q9NPC1
CHEMBL412510,CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)N,LTB4,Phase 2,leukocyte activator,Q9NPC1
CHEMBL4858439,,LY255283,Preclinical,leukotriene receptor antagonist,Q9NPC1
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,O95573
CHEMBL2095209,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,icosapent,Launched,platelet aggregation inhibitor,O60488
CHEMBL4878208,,iCRT-14,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,P15884
CHEMBL4878208,,iCRT-14,Preclinical,beta catenin inhibitor|WNT signaling inhibitor,Q9NQB0
CHEMBL4873440,,PNU-74654,Preclinical,beta-catenin inhibitor,P15884
CHEMBL4873440,,PNU-74654,Preclinical,beta-catenin inhibitor,Q9NQB0
CHEMBL4851872,,IC261,Preclinical,casein kinase inhibitor,P49674
CHEMBL4866343,,PF-4800567,Preclinical,casein kinase inhibitor,P49674
CHEMBL4878681,,PF-670462,Preclinical,casein kinase inhibitor,P49674
CHEMBL4303658,C1=CC(=C(C(=C1)F)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)F,TA-01,Preclinical,casein kinase inhibitor|MAP kinase inhibitor,P49674
CHEMBL508094,C[C@@H]([C@H](C)O)[C@@H](C(=O)O)N,ID-1101,Phase 1,insulin sensitizer,P01308
CHEMBL3763416,C1CCN2C[C@H]3C[C@H]([C@@H]2C1)CN4[C@@H]3CCCC4=O,lupanine,Phase 1,sodium channel blocker,P01308
CHEMBL298312,CC1=CC(=CC=C1)O,metacresol,Launched,,P01308
CHEMBL1957038,C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O,idronoxil,Phase 3,XIAP inhibitor,Q16206
CHEMBL1957038,C1C(=CC2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O,idronoxil,Phase 3,XIAP inhibitor,Q9NYA1
CHEMBL4872287,,SKI-II,Preclinical,sphingosine kinase inhibitor,Q9NYA1
CHEMBL4877119,,ilomastat,Phase 3,matrix metalloprotease inhibitor,P16112
CHEMBL1282,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,imiquimod,Launched,interferon inducer|toll-like receptor agonist,Q9NR97
CHEMBL4878797,,motolimod,Phase 2,toll-like receptor agonist,Q9NR97
CHEMBL383322,CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N,resiquimod,Phase 3,toll-like receptor agonist,Q9NR97
CHEMBL1496098,C1=CC=C2C(=C1)C(=C(N2)O)C3=C(C4=CC=CC=C4N3)N=O,indirubin-3-monoxime,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,Q15078
CHEMBL3989410,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)[O-].O.O.O.[Na+],indomethacin,Launched,cyclooxygenase inhibitor,Q8N8N7
CHEMBL264931,C[C@H](C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O,indoprofen,Withdrawn,cyclooxygenase inhibitor|prostanoid receptor antagonist,P25024
CHEMBL2103864,CC[C@H](C1=CC=C(O1)C)NC2=C(C(=O)C2=O)NC3=CC=CC(=C3O)C(=O)N(C)C.O,navarixin,Phase 2,CC chemokine receptor antagonist,P25024
CHEMBL191413,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)NS(=O)(=O)C,reparixin,Phase 3,CC chemokine receptor antagonist,P25024
CHEMBL4875818,,INH1,Preclinical,Hec1 inhibitor,O14777
CHEMBL1094982,C1=CC(=CN=C1)C(=O)OC2C(C(C(C(C2OC(=O)C3=CN=CC=C3)OC(=O)C4=CN=CC=C4)OC(=O)C5=CN=CC=C5)OC(=O)C6=CN=CC=C6)OC(=O)C7=CN=CC=C7,inositol,Launched,insulin sensitizer,O14735
CHEMBL4879132,,IOX1,Preclinical,histone demethylase inhibitor,Q9Y4C1
CHEMBL4879132,,IOX1,Preclinical,histone demethylase inhibitor,Q9H3R0
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,Q9H3R0
CHEMBL4864302,,IOX2,Preclinical,hypoxia inducible factor inhibitor,P41229
CHEMBL3989514,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.O.O.O.Cl,irinotecan,Launched,topoisomerase inhibitor,Q969P6
CHEMBL4860438,,topotecan,Launched,topoisomerase inhibitor,Q969P6
CHEMBL4102229,COC1=C(C=C2C(=C1)C3=C(CCCCC3)C(=O)O2)OS(=O)(=O)N,irosustat,Phase 2,steroid sulfatase inhibitor,P08842
CHEMBL352219,CC(C)C(=O)N,isobutyramide,Phase 2,gene expression stimulant,P02100
CHEMBL352219,CC(C)C(=O)N,isobutyramide,Phase 2,gene expression stimulant,P69891
CHEMBL64,C1=CN=CC=C1C(=O)NN,isoniazid,Launched,FABI inhibitor,P05181
CHEMBL151649,C1=CC=C(C=C1)CCN=C=S,phenethyl-isothiocyanate,Phase 2,anticancer agent,P05181
CHEMBL4857153,,ritonavir,Launched,HIV protease inhibitor,P05181
CHEMBL3038236,C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.C1=CC=C2C(=C1)C(=O)C(=CO2)C=NCC3=CC=C(C=C3)S(=O)(=O)N.Cl.Cl.[Zn+2],sulfanilamide,Launched,carbonic anhydrase inhibitor,P05181
CHEMBL250009,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,P33402
CHEMBL1311,C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O,isosorbide-mononitrate,Launched,nitric oxide stimulant,P33402
CHEMBL4855884,,ODQ,Preclinical,guanylyl cyclase inhibitor,P33402
CHEMBL2107834,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,riociguat,Launched,guanylate cyclase stimulant,P33402
CHEMBL4857295,,YC-1,Preclinical,guanylyl cyclase activator,P33402
CHEMBL250009,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,O75343
CHEMBL1311,C1[C@@H]([C@@H]2[C@H](O1)[C@@H](CO2)O[N+](=O)[O-])O,isosorbide-mononitrate,Launched,nitric oxide stimulant,O75343
CHEMBL2107834,CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC,riociguat,Launched,guanylate cyclase stimulant,O75343
CHEMBL250009,C1C(C2C(O1)C(CO2)O[N+](=O)[O-])O[N+](=O)[O-],isosorbide-dinitrate,Launched,nitric oxide stimulant,P16066
CHEMBL4303573,C1CC(CCC1NC(=O)COC2=CC=C(C=C2)Cl)NC(=O)COC3=CC=C(C=C3)Cl,ISRIB,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,P05198
CHEMBL4303573,C1CC(CCC1NC(=O)COC2=CC=C(C=C2)Cl)NC(=O)COC3=CC=C(C=C3)Cl,ISRIB,Preclinical,eukaryotic translation initiation factor inhibitor|PERK inhibitor,Q9BY44
CHEMBL1340458,C1=CC=C(C=C1)/C=C/C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=C(C=C2)Cl,sal003,Preclinical,eukaryotic translation initiation factor inhibitor,P05198
CHEMBL1340458,C1=CC=C(C=C1)/C=C/C(=O)NC(C(Cl)(Cl)Cl)NC(=S)NC2=CC=C(C=C2)Cl,sal003,Preclinical,eukaryotic translation initiation factor inhibitor,Q9BY44
CHEMBL4874293,,ISX-9,Preclinical,neural stem cell inducer,Q13562
CHEMBL4870966,,ITD-1,Preclinical,TGF beta receptor inhibitor,P37173
CHEMBL2447924,C1CC2=C(C(=NN2C1)C3=CC=CC=C3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6,LY2109761,Preclinical,TGF beta receptor inhibitor,P37173
CHEMBL2134092,CC1=CC(=C(N1C2=CC=CC=C2)C)/C=C/3\C(=O)N4C5=CC=CC=C5N=C4S3,ITX3,Preclinical,GEF inhibitor,O75962
CHEMBL4873396,,IU1,Preclinical,ubiquitin C-terminal hydrolase inhibitor,P54578
CHEMBL4862075,,VLX600,Phase 1,antitumor agent|ubiquitin C-terminal hydrolase inhibitor,P54578
CHEMBL4862486,,WP1130,Preclinical,deubiquitinase inhibitor,P54578
CHEMBL471737,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC,ivabradine,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,O60741
CHEMBL4851782,,zatebradine,Phase 3,HCN channel blocker,O60741
CHEMBL1852596,CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C,ZD-7288,Phase 2,HCN channel blocker,O60741
CHEMBL471737,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC,ivabradine,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,Q9P1Z3
CHEMBL4851782,,zatebradine,Phase 3,HCN channel blocker,Q9P1Z3
CHEMBL1852596,CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C,ZD-7288,Phase 2,HCN channel blocker,Q9P1Z3
CHEMBL471737,CN(CCCN1CCC2=CC(=C(C=C2CC1=O)OC)OC)C[C@H]3CC4=CC(=C(C=C34)OC)OC,ivabradine,Launched,HCN channel blocker|potassium channel blocker|sodium channel blocker,Q9Y3Q4
CHEMBL4851782,,zatebradine,Phase 3,HCN channel blocker,Q9Y3Q4
CHEMBL1852596,CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C,ZD-7288,Phase 2,HCN channel blocker,Q9Y3Q4
CHEMBL4869583,,JIB04,Preclinical,histone lysine demethylase inhibitor,B2RXH2
CHEMBL3115312,C1=C2C(=CC(=C1Cl)OC(F)(F)F)N=C(N2)N3C=C(C=N3)C(=O)O,JNJ-42041935,Preclinical,hypoxia inducible factor prolyl hydroxylase inhibitor,Q15119
CHEMBL3633720,C[C@@H](C1=CC=CC=C1)NC(=O)CNC(=O)C2=CC(=CC=C2)Cl,JNJ-63533054,Preclinical,G protein-coupled receptor agonist,Q6DWJ6
CHEMBL3633893,COC1=CC(=CC(=C1)C(=O)NNC(=O)NC2=CC=CC3=CC=CC=C32)OC,TC-O-9311,Preclinical,G protein-coupled receptor agonist,Q6DWJ6
CHEMBL4869769,,JQ1-(+),Preclinical,bromodomain inhibitor,Q58F21
CHEMBL4867977,,XD-14,Preclinical,bromodomain inhibitor,Q58F21
CHEMBL4862627,,JTE-013,Preclinical,lysophospholipid receptor antagonist,O00398
CHEMBL4303719,CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=CC(=C(C(=C2O)Cl)OCCN3CCN(CC3)C)Cl,JTE-607,Phase 2,cytokine production inhibitor,P22301
CHEMBL4858006,,JW-642,Preclinical,monoacylglycerol lipase inhibitor,Q99685
CHEMBL4859034,,JZL-184,Preclinical,monoacylglucerol lipase inhibitor,Q99685
CHEMBL4859034,,JZL-195,Preclinical,FAAH inhibitor|monoacylglycerol lipase inhibitor,Q99685
CHEMBL4861107,,KML29,Preclinical,monoacylglucerol lipase inhibitor,Q99685
CHEMBL1459534,C1C2(COC3(O1)C4=CC=CC=C4NC3=O)COC5(C6=CC=CC=C6NC5=O)OC2,JW-67,Preclinical,WNT pathway inhibitor,P25054
CHEMBL1459534,C1C2(COC3(O1)C4=CC=CC=C4NC3=O)COC5(C6=CC=CC=C6NC5=O)OC2,JW-67,Preclinical,WNT pathway inhibitor,O15169
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,O15296
CHEMBL150,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,kaempferol,Preclinical,bone resorption inhibitor|estrogen-related receptor inverse agonist,Q6NUS8
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,Q6NUS8
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,Q13003
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q13003
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,Q13003
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q13003
CHEMBL4863352,,kainic-acid,Preclinical,kainate receptor agonist,Q16099
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q16099
CHEMBL4860793,,SYM-2081,Preclinical,kainate receptor antagonist,Q16099
CHEMBL4868868,,topiramate,Launched,carbonic anhydrase inhibitor|glutamate receptor antagonist|kainate receptor antagonist,Q16099
CHEMBL3185782,C1=CC=C(C=C1)C2=CC=C(C=C2)NC(=O)C3=CC=CC=C3C(=O)O,kartogenin,Preclinical,chondrocyte differentiation stimulator,P21333
CHEMBL1433489,C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-],KB-R7943,Preclinical,sodium/calcium exchange inhibitor,Q13507
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q13507
CHEMBL4874755,,YM-58483,Preclinical,calcium channel blocker,Q13507
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q13507
CHEMBL896948,,KBG,Phase 2,neprilysin inhibitor,P08473
CHEMBL4266030,,omapatrilat,Preclinical,metalloproteinase inhibitor,P08473
CHEMBL2103772,CC(=O)SCC(CC1=CC=CC=C1)C(=O)NCC(=O)OCC2=CC=CC=C2,racecadotril,Launched,enkephalinase inhibitor,P08473
CHEMBL3137301,CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O,sacubitril,Launched,neprilysin inhibitor,P08473
CHEMBL4876900,,thiorphan,Phase 1,membrane metalloendopeptidase inhibitor,P08473
CHEMBL4867858,,kenpaullone,Preclinical,CDK inhibitor|glycogen synthase kinase inhibitor,P14635
CHEMBL4874931,,1-azakenpaullone,Preclinical,glycogen synthase kinase inhibitor,P14635
CHEMBL1256709,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O.C(C(C(=O)O)O)(C(=O)O)O,ketanserin,Launched,serotonin receptor antagonist,P54219
CHEMBL432,C1=CC(=C(C=C1C(CN)O)O)O,norepinephrine,Launched,adrenergic receptor agonist,P54219
CHEMBL772,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,reserpine,Launched,vesicular monoamine transporter inhibitor,P54219
CHEMBL519344,CC(C)C[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2CC1=O)OC)OC,tetrabenazine,Launched,vesicular monoamine transporter inhibitor,P54219
CHEMBL4871330,,KH-CB19,Preclinical,CDC inhibitor,P49759
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TG-003,Preclinical,CLK inhibitor,P49759
CHEMBL4871330,,KH-CB19,Preclinical,CDC inhibitor,P49761
CHEMBL4871330,,KH-CB19,Preclinical,CDC inhibitor,Q13627
CHEMBL4871073,,TC-S-7004,Preclinical,DYRK inhibitor,Q13627
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TG-003,Preclinical,CLK inhibitor,Q13627
CHEMBL4857171,,KHK-IN-1,Preclinical,hexokinase inhibitor,P50053
CHEMBL4873820,,KHS-101,Preclinical,neural stem cell inducer,Q9Y6A5
CHEMBL4855667,,kifunensine,Phase 1,mannosidase inhibitor,Q9UKM7
CHEMBL171623,C(CCO)CO,"1,4-butanediol",Phase 1,benzodiazepine receptor agonist|gamma hydroxybutyric acid agonist,Q9UKM7
CHEMBL4855667,,kifunensine,Phase 1,mannosidase inhibitor,Q16706
CHEMBL371197,C1C[C@H]([C@@H]2[C@@H]([C@@H](CN2C1)O)O)O,swainsonine,Phase 2,alpha mannosidase inhibitor,Q16706
CHEMBL4862209,,1-deoxymannojirimycin,Preclinical,alpha mannosidase inhibitor,Q16706
CHEMBL4849132,,KL-001,Preclinical,proteasome inhibitor,Q16526
CHEMBL4849132,,KL-001,Preclinical,proteasome inhibitor,Q49AN0
CHEMBL257839,C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O)O,kuromanin,Preclinical,ribosyl cyclase inhibitor,P28907
CHEMBL3186128,COC1=C(C=C(C=C1)CCC(=O)NC2=NC3=C(S2)C=C(C=C3)Cl)OC,KY02111,Preclinical,WNT pathway inhibitor,O94907
CHEMBL4872648,,K02288,Preclinical,bone morphogenic protein inhibitor,P13497
CHEMBL4860781,,UK-383367,Phase 1,procollagen C-endopeptidase inhibitor,P13497
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,P49588
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q5JTZ9
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,P24298
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P24298
CHEMBL4872529,,MC-1,Phase 3,,P24298
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,P24298
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q8TD30
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q8TD30
CHEMBL4872529,,MC-1,Phase 3,,Q8TD30
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,Q8TD30
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q16719
CHEMBL4872529,,MC-1,Phase 3,,Q16719
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q9Y697
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q9Y697
CHEMBL4872529,,MC-1,Phase 3,,Q9Y697
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q8IUZ5
CHEMBL4872529,,MC-1,Phase 3,,Q8IUZ5
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,P43007
CHEMBL226400,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)N[C@@H](C)C(=O)O,L-alanine,Launched,,Q9UHI5
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P04424
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,Q96A70
CHEMBL4872529,,MC-1,Phase 3,,Q96A70
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,P30825
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,P30825
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,Q8WY07
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,Q8WY07
CHEMBL212301,C(C[C@H](C(=O)O)N)CN=C(N)N,L-arginine,Launched,nitric oxide precursor,O43246
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,O43246
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,Q7L266
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q7L266
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,O43776
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,Q96I59
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,Q15758
CHEMBL58832,C([C@@H](C(=O)O)N)C(=O)N,L-asparagine,Phase 3,,Q99624
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q96HD9
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P30520
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q8N142
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P45381
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q12797
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q12797
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,O76075
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P27708
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q05682
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P14868
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q6PI48
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P17174
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P17174
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P17174
CHEMBL4872529,,MC-1,Phase 3,,P17174
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P00505
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P00505
CHEMBL4872529,,MC-1,Phase 3,,P00505
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P22234
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,P43005
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P43005
CHEMBL4303337,C1=CC=C(C=C1)CO[C@H]([C@H](C(=O)O)N)C(=O)O.C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,P43005
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,O75746
CHEMBL274323,C([C@@H](C(=O)O)N)C(=O)O,L-aspartic-acid,Launched,metallic radical formation stimulant,Q9UJS0
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,O94760
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,O95865
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,P00480
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q9ULC6
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q9Y2J8
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q9ULW8
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q9UM07
CHEMBL444814,C(C[C@@H](C(=O)O)N)CNC(=O)N,L-citrulline,Launched,nitric oxide stimulant,Q6TGC4
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P49589
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q9HA77
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P35520
CHEMBL4872529,,MC-1,Phase 3,,P35520
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q9Y600
CHEMBL4872529,,MC-1,Phase 3,,Q9Y600
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P32929
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q96IQ7
CHEMBL4872529,,MC-1,Phase 3,,P32929
CHEMBL4872529,,MC-1,Phase 3,,Q96IQ7
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P48506
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P48506
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,P16455
CHEMBL339133,C1=C(SC=C1Br)COC2=NC(=NC3=C2NC=N3)N,lomeguatrib,Phase 2,O6-alkylguanine-DNA alkyltransferase inhibitor,P16455
CHEMBL4853623,,O6-benzylguanine,Phase 3,O6-alkylguanine-DNA alkyltransferase inhibitor,P16455
CHEMBL4873781,,S-methylcysteine,Phase 1,,P16455
CHEMBL810,CN1C(=O)N2C=NC(=C2N=N1)C(=O)N,temozolomide,Launched,DNA alkylating agent,P16455
CHEMBL863,C([C@@H](C(=O)O)N)S,L-cysteine,Launched,,Q9BZV2
CHEMBL1547,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO,thiamine,Launched,vitamin B,Q9BZV2
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,P54868
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,P51003
CHEMBL1160508,C([C@@H](C(=O)O)N)S(=O)O,L-cysteinesulfinic-acid,Preclinical,glutamate receptor agonist,P32119
CHEMBL4878884,,L-cystine,Launched,,O60931
CHEMBL4878884,,L-cystine,Launched,,Q07837
CHEMBL4878884,,L-cystine,Launched,,P82251
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q8N5Z0
CHEMBL4872529,,MC-1,Phase 3,,Q8N5Z0
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P54886
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P54687
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,P54687
CHEMBL4872529,,MC-1,Phase 3,,P54687
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O15382
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,O15382
CHEMBL4872529,,MC-1,Phase 3,,O15382
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q6YP21
CHEMBL4872529,,MC-1,Phase 3,,Q6YP21
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9ULA0
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q5JPH6
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q07075
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P07814
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P07814
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q04609
CHEMBL4847192,,L-quisqualic-acid,Preclinical,glutamate receptor agonist,Q04609
CHEMBL4857301,,PMPA,Preclinical,glutamate receptor antagonist,Q04609
CHEMBL303352,C(CC(CCC(=O)O)C(=O)O)CS,2-(3-mercaptopropyl)pentanedioic-acid,Phase 1,glutamate carboxypeptidase inhibitor,Q04609
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q05932
CHEMBL140144,CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1,raltitrexed,Launched,thymidylate synthase inhibitor,Q05932
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O95954
CHEMBL4872529,,MC-1,Phase 3,,O95954
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q99259
CHEMBL4872529,,MC-1,Phase 3,,Q99259
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q05329
CHEMBL4872529,,MC-1,Phase 3,,Q05329
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,Q05329
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O75879
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9UI32
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P49915
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9ULK0
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O43424
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q5TDP6
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q6IA69
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q8N159
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O14841
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O15067
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9Y646
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9Y617
CHEMBL4872529,,MC-1,Phase 3,,Q9Y617
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P43003
CHEMBL4303337,C1=CC=C(C=C1)CO[C@H]([C@H](C(=O)O)N)C(=O)O.C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,P43003
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P48664
CHEMBL4303337,C1=CC=C(C=C1)CO[C@H]([C@H](C(=O)O)N)C(=O)O.C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,P48664
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,O00341
CHEMBL4303337,C1=CC=C(C=C1)CO[C@H]([C@H](C(=O)O)N)C(=O)O.C1=CC=C(C=C1)CO[C@@H]([C@@H](C(=O)O)N)C(=O)O,TBOA-(DL),Preclinical,excitatory amino acid transporter inhibitor,O00341
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9H1K4
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,Q9H936
CHEMBL4851459,,L-glutamic-acid,Launched,glutamate receptor agonist,P17735
CHEMBL4872529,,MC-1,Phase 3,,P17735
CHEMBL2108712,,plovamer-acetate,Phase 2,,P17735
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,Q9P2J5
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,Q15031
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,Q9UIC8
CHEMBL291962,CC(C)C[C@@H](C(=O)O)N,L-leucine,Phase 3,,O60294
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,Q15046
CHEMBL8085,C(CCN)C[C@@H](C(=O)O)N,L-lysine,Phase 2,serotonin receptor agonist,P52569
CHEMBL4851692,,L-methionine,Launched,voltage-gated calcium channel ligand,Q9H2M3
CHEMBL4851692,,L-methionine,Launched,voltage-gated calcium channel ligand,Q99707
CHEMBL4851692,,L-methionine,Launched,voltage-gated calcium channel ligand,Q9UBK8
CHEMBL4303668,C1C(=O)C(=O)C=CN1C[C@@H](C(=O)O)N,L-mimosine,Preclinical,dopamine beta hydroxylase inhibitor|eukaryotic translation initiation factor inhibitor,P63241
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q96EM0
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q32P28
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q32P28
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q8IVL5
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q8IVL5
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q8IVL6
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q8IVL6
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P13674
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P13674
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,O15460
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,O15460
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q7L3T8
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P23284
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,P45877
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q13427
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,O43447
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,O43272
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,O94903
CHEMBL4872529,,MC-1,Phase 3,,O94903
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q53H96
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q9UN76
CHEMBL54922,C1C[C@H](NC1)C(=O)O,L-proline,Launched,glutamate receptor agonist,Q99884
CHEMBL291747,C[C@H]([C@@H](C(=O)O)N)O,L-threonine,Phase 2,,P26639
CHEMBL291747,C[C@H]([C@@H](C(=O)O)N)O,L-threonine,Phase 2,,Q9BW92
CHEMBL291747,C[C@H]([C@@H](C(=O)O)N)O,L-threonine,Phase 2,,Q8IYQ7
CHEMBL4872529,,MC-1,Phase 3,,Q8IYQ7
CHEMBL4876484,,L-168049,Preclinical,glucagon receptor antagonist,P47871
CHEMBL4860615,,MK-0893,Phase 2,glucagon receptor antagonist,P47871
CHEMBL4866125,,L-655240,Phase 1,thromboxane receptor antagonist,O14684
CHEMBL4859879,,L-690330,Preclinical,inositol monophosphatase inhibitor,P29218
CHEMBL4297396,C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl.Cl,L-778123,Phase 1,farnesyltransferase inhibitor,P49356
CHEMBL4857005,,tipifarnib,Phase 3,farnesyltransferase inhibitor,P49356
CHEMBL4297396,C1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)C#N)C4=CC(=CC=C4)Cl.Cl,L-778123,Phase 1,farnesyltransferase inhibitor,P53609
CHEMBL480,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,lansoprazole,Launched,ATPase inhibitor,P51164
CHEMBL1567328,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.[Mg+2],omeprazole-magnesium,Launched,proton pump inhibitor,P51164
CHEMBL2103814,CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+],laquinimod,Phase 3,immunosuppressant,P19875
CHEMBL411879,C[C@H]/1CC[C@@H]2C[C@H](C[C@@](O2)([C@@H]3CSC(=O)N3)O)OC(=O)/C=C(\CC/C=C1)/C,latrunculin-B,Phase 1,actin polymerization inhibitor,P68133
CHEMBL1200823,,sucrose,Launched,,P68133
CHEMBL411879,C[C@H]/1CC[C@@H]2C[C@H](C[C@@](O2)([C@@H]3CSC(=O)N3)O)OC(=O)/C=C(\CC/C=C1)/C,latrunculin-B,Phase 1,actin polymerization inhibitor,Q969V6
CHEMBL411879,C[C@H]/1CC[C@@H]2C[C@H](C[C@@](O2)([C@@H]3CSC(=O)N3)O)OC(=O)/C=C(\CC/C=C1)/C,latrunculin-B,Phase 1,actin polymerization inhibitor,Q8WWL2
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,Q9NQS5
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,P41235
CHEMBL267476,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,linoleic-acid,Phase 3,oxidative stress inducer,P41235
CHEMBL108766,CCCCCCCCCCCC(=O)O,lauric-acid,Phase 3,bacterial permeability inducer,Q9Y6Y9
CHEMBL4870084,,LDN-212854,Preclinical,bone morphogenic protein inhibitor,O43353
CHEMBL4862022,,necrostatin-2,Preclinical,necroptosis inhibitor|RIPK inhibitor,O43353
CHEMBL4869189,,PP-2,Preclinical,SRC inhibitor,O43353
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,O43353
CHEMBL4859038,,SRC-kinase-inhibitor-I,Preclinical,SRC inhibitor,O43353
CHEMBL2105720,C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O,lesinurad,Launched,uric acid diuretic,Q96S37
CHEMBL28626,C1=CC(=C(C=C1O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,morin,Preclinical,cytochrome P450 inhibitor,Q96S37
CHEMBL4847000,,sulfinpyrazone,Launched,uricosuric blocker,Q96S37
CHEMBL3707347,CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N,verinurad,Phase 2,urate transporter inhibitor,Q96S37
CHEMBL1770,C1CSC2=N[C@H](CN21)C3=CC=CC=C3.Cl,levamisole,Withdrawn,acetylcholine receptor agonist,P05186
CHEMBL1286,CC[C@@H](C(=O)N)N1CCCC1=O,levetiracetam,Launched,calcium channel blocker,Q7L0J3
CHEMBL1615438,C[C@@H]1CN(CC[C@@]1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F,levocabastine,Launched,histamine receptor antagonist,O95665
CHEMBL4874039,,meclinertant,Phase 2/Phase 3,neurotensin receptor antagonist,O95665
CHEMBL4865011,,NTRC-824,Preclinical,neurotensin receptor antagonist,O95665
CHEMBL1149,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,levocarnitine,Launched,,Q9UKG9
CHEMBL4856882,,levodopa,Launched,dopamine precursor,P51810
CHEMBL4862828,,levomenthol,Launched,,Q8NET8
CHEMBL2103741,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.O.[Na+],levothyroxine,Launched,thyroid hormone stimulant,P10827
CHEMBL4857073,,liothyronine,Launched,thyroid hormone stimulant,P10827
CHEMBL4715778,,sobetirome,Phase 1/Phase 2,thyroid hormone receptor agonist,P10827
CHEMBL3137697,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C.C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)O,tiratricol,Launched,thyroid hormone stimulant,P10827
CHEMBL2103741,C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)[O-])N.O.[Na+],levothyroxine,Launched,thyroid hormone stimulant,P10828
CHEMBL4857073,,liothyronine,Launched,thyroid hormone stimulant,P10828
CHEMBL4715778,,sobetirome,Phase 1/Phase 2,thyroid hormone receptor agonist,P10828
CHEMBL3137697,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C.C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(=O)O)I)I)O,tiratricol,Launched,thyroid hormone stimulant,P10828
CHEMBL2105595,C1=CC(=CC(=C1)Cl)C(C2=CC3=C(C=C2)N=CN3)N4C=CN=C4.C(=C/C(=O)O)\C(=O)O,liarozole,Phase 2/Phase 3,cytochrome P450 inhibitor,O43174
CHEMBL459505,CCC(CC)C(C1=CC=C(C=C1)NC2=NC3=CC=CC=C3S2)N4C=NC=N4,talarozole,Phase 2,cytochrome P450 inhibitor,O43174
CHEMBL4303494,C[C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)CNC(=O)C(NC2=O)[C@@H](C)O)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)O)C(=O)N[C@@H](CSSC[C@@H](C(=O)N3)N)C(=O)N[C@H](C(=O)N5CCC[C@H]5C(=O)N1)CC(=O)N)CC6=CC=C(C=C6)O)CCC(=O)O,linaclotide,Launched,guanylate cyclase activator,P25092
CHEMBL1091644,CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O,linsitinib,Phase 3,IGF-1 inhibitor,P14616
CHEMBL419213,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O.O.O,lisinopril,Launched,angiotensin converting enzyme inhibitor,Q9BYF1
CHEMBL1200534,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC(=C(C=C3C[C@H]2C(=O)O)OC)OC.Cl,moexipril,Launched,angiotensin converting enzyme inhibitor,Q9BYF1
CHEMBL429844,CC(C)C[C@@H](C(=O)O)N[C@@H](CC1=CN=CN1CC2=CC(=CC(=C2)Cl)Cl)C(=O)O,ORE1001,Phase 1/Phase 2,angiotensin converting enzyme inhibitor,Q9BYF1
CHEMBL3891157,[Li+].CC(=O)CC(=O)[O-],lithium-acetoacetate,Preclinical,,P16930
CHEMBL5095406,CC1(CC(CC(N1)(C)C)OC2=NN=C(C=C2)C3=C(C=C(C=C3)C4=CNN=C4)O)C.Cl,LMI070,Phase 1/Phase 2,survival motor neuron protein modulator,Q16637
CHEMBL4439582,CCC(C)C(C(=O)NCCN1CCOCC1)N,LM11A-31,Phase 1,neurotrophic agent,P08138
CHEMBL4864608,,Ro-08-2750,Preclinical,NGF binding inhibitor,P08138
CHEMBL4868296,,lometrexol,Phase 2,glycinamide ribonucleotide formyltransferase inhibitor,P22102
CHEMBL2360464,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],pemetrexed,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,P22102
CHEMBL4862540,,lonafarnib,Phase 3,farnesyltransferase inhibitor,P01111
CHEMBL1707,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl,loperamide,Launched,opioid receptor agonist,P01189
CHEMBL4877217,,LPA2-antagonist-1,Preclinical,lysophosphatidic acid receptor antagonist,Q9HBW0
CHEMBL412510,CC(C)(CCCCOC1=CC(=CC(=N1)C2=CC=CC=C2)C3=CC=CC=C3)C4=NN=NN4CCCCC(=O)NCCCOCCOCCOCCCNC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)[C@H](CS(=O)(=O)O)NC(=O)CC[C@@H](C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)N[C@@H](CS(=O)(=O)O)C(=O)NCCCOCCOCCOCCCNC(=O)CCCCN5C(=NN=N5)C(C)(C)CCCCOC6=CC(=CC(=N6)C7=CC=CC=C7)C8=CC=CC=C8)N,LTB4,Phase 2,leukocyte activator,Q15722
CHEMBL4863734,,LY223982,Phase 2,leukotriene receptor antagonist,Q15722
CHEMBL4858439,,LY255283,Preclinical,leukotriene receptor antagonist,Q15722
CHEMBL2007389,CCN(CC)CCNC1=C2C(=C(C=C1)C)SC3=CC=CC=C3C2=O.Cl,lucanthone,Phase 2,endonuclease inhibitor,P27695
CHEMBL1609430,CON.Cl,methoxyamine,Phase 2,DNA repair enzyme inhibitor,P27695
CHEMBL4866305,,LX7101,Phase 1/Phase 2,LIM kinase inhibitor|rho associated kinase inhibitor,P53671
CHEMBL4303259,CC1=NOC(=C1)C(=O)NC2=CC=CC(=C2)C(=O)NC3=CC=CC(=C3)C(F)(F)F,T-5601640,Preclinical,LIM kinase inhibitor,P53671
CHEMBL1394135,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C,m-3M3FBS,Preclinical,phospholipase activator,Q00722
CHEMBL1394135,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C,m-3M3FBS,Preclinical,phospholipase activator,Q01970
CHEMBL1394135,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C,m-3M3FBS,Preclinical,phospholipase activator,P51178
CHEMBL1394135,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C,m-3M3FBS,Preclinical,phospholipase activator,P19174
CHEMBL1394135,CC1=CC(=C(C(=C1)C)S(=O)(=O)NC2=CC=CC(=C2)C(F)(F)F)C,m-3M3FBS,Preclinical,phospholipase activator,P16885
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P09238
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P24347
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P51511
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9ULZ9
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q99542
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,O60882
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,O75900
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q8N119
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9Y5R2
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9NRE1
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,Q9H306
CHEMBL4868475,,marimastat,Phase 3,matrix metalloprotease inhibitor,P09237
CHEMBL4872529,,MC-1,Phase 3,,Q6ZQY3
CHEMBL4872529,,MC-1,Phase 3,,P19113
CHEMBL4872529,,MC-1,Phase 3,,Q9UBI9
CHEMBL4872529,,MC-1,Phase 3,,Q6WRI0
CHEMBL4872529,,MC-1,Phase 3,,Q96EN8
CHEMBL4872529,,MC-1,Phase 3,,P04181
CHEMBL4872529,,MC-1,Phase 3,,Q6P996
CHEMBL4872529,,MC-1,Phase 3,,Q96GD0
CHEMBL4872529,,MC-1,Phase 3,,Q9NVS9
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q9NVS9
CHEMBL4872529,,MC-1,Phase 3,,P11216
CHEMBL4872529,,MC-1,Phase 3,,Q96I15
CHEMBL4872529,,MC-1,Phase 3,,P20132
CHEMBL4872529,,MC-1,Phase 3,,Q96GA7
CHEMBL4872529,,MC-1,Phase 3,,Q9HD40
CHEMBL4872529,,MC-1,Phase 3,,O95470
CHEMBL4872529,,MC-1,Phase 3,,O15269
CHEMBL4872529,,MC-1,Phase 3,,O15270
CHEMBL4872529,,MC-1,Phase 3,,Q9NUV7
CHEMBL4872529,,MC-1,Phase 3,,Q9GZT4
CHEMBL4877233,,MCC950,Preclinical,NOD like receptor inhibitor,Q96P20
CHEMBL3956407,COC1=C(C=C(C(=C1)C2=CC(=CC(=C2)Cl)F)F)N3C4=C(C=CC3=O)C=C(C=C4)S(=O)(=O)NC5=NC=C(C=C5)F,MD-920,Phase 1,NFkB pathway inhibitor,Q6P093
CHEMBL4874039,,meclinertant,Phase 2/Phase 3,neurotensin receptor antagonist,P30989
CHEMBL4860272,,ML314,Preclinical,neurotensin agonist,P30989
CHEMBL4876131,,TC-NTR1-17,Preclinical,neurotensin agonist,P30989
CHEMBL2105675,CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC2=C(C=C1C(=O)O)OC(=N2)C3=CC(=CC(=C3)Cl)Cl,tafamidis-meglumine,Launched,transthyretin amyloid inhibitor,P02766
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P46597
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P27797
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,P11678
CHEMBL4853343,,melatonin,Launched,melatonin receptor agonist|nitric oxide synthase inhibitor,Q92753
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,Q92753
CHEMBL2104708,C[N+](C)(C)NCCC(=O)[O-],meldonium,Launched,gamma butyrobetaine hydroxylase inhibitor,O75936
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,O75936
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P02818
CHEMBL1550,CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C,phytonadione,Launched,,P02818
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P08709
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P00740
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P04070
CHEMBL1200354,CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)[O-].[Na+],sodium-tetradecyl-sulfate,Launched,,P04070
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P07225
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,P22891
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione,Launched,mitochondrial DNA polymerase inhibitor|phosphatase inhibitor,Q8N0U8
CHEMBL2358118,CC1(CC(=O)C2=CC=CC=C2C1=O)S(=O)(=O)[O-].[Na+],menadione-bisulfite,Phase 2,vitamin K,Q8N0U8
CHEMBL1712842,CC(=O)O.CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,mepazine,Phase 2,MALT1 inhibitor (JH),Q9UDY8
CHEMBL4869448,,methoxsalen,Launched,DNA synthesis inhibitor,Q16696
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P98194
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P98194
CHEMBL1341,COC(C(Cl)Cl)(F)F,methoxyflurane,Launched,membrane permeability inhibitor,P30049
CHEMBL1200694,C(OC(C(F)(F)F)C(F)(F)F)F,sevoflurane,Launched,membrane integrity inhibitor,P30049
CHEMBL1096562,COC(=O)CCC(=O)CN,methyl-aminolevulinate,Launched,oxidizing agent,P12314
CHEMBL4860145,,metirosine,Launched,tyrosine hydroxylase inhibitor,P07101
CHEMBL2108712,,plovamer-acetate,Phase 2,,P07101
CHEMBL1201775,C[C@@H]([C@@H]([C@H]1CNC2=C(N1)C(=O)NC(=N2)N)O)O.Cl.Cl,sapropterin,Launched,phenylalanine 4-hydroxylase stimulant,P07101
CHEMBL4849876,,MI-14,Preclinical,PI4K inhibitor,Q9UBF8
CHEMBL4857460,,PIK-93,Preclinical,PI3K inhibitor,Q9UBF8
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,Q9UBF8
CHEMBL1561,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,miglitol,Launched,glucosidase inhibitor,Q14697
CHEMBL1561,C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O,miglitol,Launched,glucosidase inhibitor,Q8TET4
CHEMBL319144,C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,minodronic-acid,Launched,bone resorption inhibitor,O95749
CHEMBL4303669,C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O.O,zoledronic-acid,Launched,bone resorption inhibitor,O95749
CHEMBL570841,C1=CC(=CC=C1/C=C\2/C(=O)NC(=N)S2)O,mirin,Preclinical,MRE11A exonuclease inhibitor,P49959
CHEMBL443793,C1=CC=C(C=C1)C2=CC(=O)C3=CC=CC(=C3O2)CC(=O)O,mitoflaxone,Phase 2,antitumor agent,P04275
CHEMBL4871826,,MK-1775,Phase 2,WEE1 kinase inhibitor,P30291
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,P30291
CHEMBL4878716,,PD-407824,Preclinical,PKC inhibitor,P30291
CHEMBL4866582,,MK-5046,Preclinical,bombesin receptor agonist,P32247
CHEMBL4866582,,MK-5046,Preclinical,bombesin receptor agonist,P28336
CHEMBL4871898,,MK2-IN-1,Preclinical,MAP kinase inhibitor,P49137
CHEMBL4853060,,ML167,Preclinical,CLK inhibitor|DYRK inhibitor,Q9HAZ1
CHEMBL4303606,CC(C)(C1=C(C2=NC=C(N2C=C1)C3=CC(=C(C=C3)F)C4=C(C=C(C=C4)F)C#N)F)O,TG-003,Preclinical,CLK inhibitor,Q9HAZ1
CHEMBL4845844,,ML204,Preclinical,transient receptor potential channel antagonist,Q9UBN4
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,Q9UBN4
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9UBN4
CHEMBL2203125,,ML281,Preclinical,serine/threonine kinase inhibitor,Q9BYT3
CHEMBL2411647,,ML297,Preclinical,inward rectifier potassium channel activator,P48549
CHEMBL3352044,,ML323,Preclinical,ubiquitin specific protease inhibitor,O94782
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-632839,Preclinical,ubiquitin specific protease inhibitor,O94782
CHEMBL1398529,CN(C)CCCNC(=O)C1=CC=C(C=C1)C2=CC(=C3C(=C2)C=CC=N3)O,ML324,Preclinical,histone lysine demethylase inhibitor,O75164
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-636819,Preclinical,histone demethylase inhibitor,O75164
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,O75164
CHEMBL600764,C1CN(CCN1CC(=O)NC2=C(C=CC(=C2)C(F)(F)F)Cl)C(=O)C3=CC=CO3,ML348,Preclinical,lysophospholipase inhibitor,O75608
CHEMBL4863618,,MPI-0479605,Preclinical,mitotic kinase inhibitor,P33981
CHEMBL4854674,,Mps-BAY-2a,Preclinical,monopolar spindle 1 kinase inhibitor,P33981
CHEMBL1235786,CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC,Mps1-IN-1,Preclinical,monopolar spindle 1 kinase inhibitor,P33981
CHEMBL4872164,,pyrazolanthrone,Preclinical,JNK inhibitor,P33981
CHEMBL4848725,,TC-Mps1-12,Preclinical,monopolar spindle 1 kinase inhibitor,P33981
CHEMBL1321988,C1=CC(=CC(=C1)N=C=S)NC(=S)NCCCCNC(=S)NC2=CC(=CC=C2)N=C=S,MRS-2578,Preclinical,purinergic receptor antagonist,Q15077
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine-5'-triphosphate,Launched,purinergic receptor activator,Q15077
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,P15291
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,O60909
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,O60512
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,O60513
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,Q9UJ70
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,P54802
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,Q9UK23
CHEMBL4303483,CC(=O)N[C@@H](C=O)[C@H]([C@@H]([C@@H](CO)O)O)O,N-acetyl-D-glucosamine,Phase 2/Phase 3,,P51606
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P23526
CHEMBL4847721,,3-deazaadenosine,Phase 2,adenosylhomocysteinase inhibitor,P23526
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,P49366
CHEMBL1109,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,sulfaphenazole,Launched,dihydropteroate synthetase inhibitor,P49366
CHEMBL3039307,C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C(N=CN=C54)N)O)O)O)O)C(=O)N,nadide,Launched,free radical scavenger,Q14376
CHEMBL3989553,CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N,nafamostat,Launched,serine protease inhibitor,P00736
CHEMBL4870477,,naringeninic-acid,Phase 1,,Q14914
CHEMBL4303320,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C(C(=C3)O)C(=O)CCC4=CC=C(C=C4)O)O)CO)O)O)O)O)O,naringin,Preclinical,cytochrome P450 inhibitor,P46721
CHEMBL1909658,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C=N/N5CCN(CC5)C)/C,rifampin,Launched,RNA polymerase inhibitor,P46721
CHEMBL236921,C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=O)C3=C(C2=O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)/C,rifamycin,Launched,DNA directed RNA polymerase inhibitor,P46721
CHEMBL4588354,C1CC2=CC=CC=C2C(/C(=C\C(=O)O)/C1)O,NCS-382,Preclinical,GABA receptor antagonist,Q9HAB3
CHEMBL4303272,CCCCN1C(=C(N=C1C2=CC=CC=C2)C3=CC=CC=C3)CN(CC4=CC5=C(C=C4)OCO5)CC6=CC7=C(C=C6)OCO7,NDT-9513727,Preclinical,complement antagonist,P21730
CHEMBL5092226,CC(C)C1=CC=C(C=C1)N(CC2=CC=C(C=C2)N(C)C)C(=O)C3CCCC4=C3C=C(C=C4)OC.Cl,W-54011,Preclinical,anaphylatoxin chemotactic receptor antagonist,P21730
CHEMBL4864391,,necrostatin-1,Preclinical,RIPK inhibitor,Q13546
CHEMBL4877379,,nedocromil,Launched,histamine receptor antagonist,Q9NS75
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,Q9NS75
CHEMBL4848353,,zafirlukast,Launched,leukotriene receptor antagonist,Q9NS75
CHEMBL4303651,CCOC(=O)C1=CC=C(C=C1)N(C)C2=CSC(=N2)C3=CC=CC=C3,neuropathiazol,Preclinical,neural stem cell inducer,P12643
CHEMBL4303651,CCOC(=O)C1=CC=C(C=C1)N(C)C2=CSC(=N2)C3=CC=CC=C3,neuropathiazol,Preclinical,neural stem cell inducer,P15018
CHEMBL4850785,,NI-57,Preclinical,bromodomain inhibitor,O95696
CHEMBL4855506,,OF-1,Preclinical,bromodomain inhibitor,O95696
CHEMBL4850785,,NI-57,Preclinical,bromodomain inhibitor,P55201
CHEMBL4752253,CN(C)C(=O)C1=C(C=C(C=C1)C2=CC(=NO2)C(=O)N[C@@H]3CCC4=CC=CC=C34)O,PFI-4,Preclinical,bromodomain inhibitor,P55201
CHEMBL4850785,,NI-57,Preclinical,bromodomain inhibitor,Q9ULD4
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,Q96PD7
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,P40261
CHEMBL4859489,,niacin,Launched,NAD precursor|vitamin B,Q15274
CHEMBL1805766,,nicotinamide,Launched,protein synthesis stimulant,Q10588
CHEMBL1805766,,nicotinamide,Launched,protein synthesis stimulant,Q9NXA8
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,Q9NXA8
CHEMBL1201536,,nicotine,Launched,acetylcholine receptor agonist,P28329
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P51800
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,P51801
CHEMBL63323,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,niflumic-acid,Launched,cyclooxygenase inhibitor,O60656
CHEMBL63857,C1=CC=C2C(=C1)C(=O)OC2(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O,phenolphthalein,Withdrawn,indicator dye,O60656
CHEMBL4870251,,NK-252,Preclinical,nuclear factor erythroid derived|like (NRF2) activator,Q16236
CHEMBL4864388,,RTA-408,Phase 2,nitric oxide production inhibitor,Q16236
CHEMBL48802,CS(=O)CCCCN=C=S,sulforaphane,Phase 2,anticancer agent|aryl hydrocarbon receptor antagonist,Q16236
CHEMBL4871860,,NPPB,Preclinical,chloride channel blocker,P51798
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-632839,Preclinical,ubiquitin specific protease inhibitor,Q9HC62
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-632839,Preclinical,ubiquitin specific protease inhibitor,O75604
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-632839,Preclinical,ubiquitin specific protease inhibitor,Q93009
CHEMBL4853014,,P22077,Preclinical,ubiquitin specific protease inhibitor,Q93009
CHEMBL4872176,,P5091,Preclinical,ubiquitin specific protease inhibitor,Q93009
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-636819,Preclinical,histone demethylase inhibitor,O94953
CHEMBL1990474,CC1=CC=C(C=C1)/C=C\2/C(=O)/C(=C/C3=CC=C(C=C3)C)/CNC2.Cl,NSC-697923,Preclinical,ubiquitin-conjugating enzyme inhibitor,P61088
CHEMBL4849723,,NSC-663284,Preclinical,CDC inhibitor,P30304
CHEMBL1139895,,NSC-95397,Preclinical,CDC inhibitor,P30304
CHEMBL4849723,,NSC-663284,Preclinical,CDC inhibitor,P30307
CHEMBL4874366,,NVP-BHG712,Preclinical,ephrin inhibitor,P54760
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P54760
CHEMBL3544983,CN1C[C@H]2CC(C[C@H]2C1)COC3=C(C=C4C(=C3)N=CN=C4NC5=C(C(=C(C=C5)Cl)Cl)F)OC,XL647,Phase 3,EGFR inhibitor|VEGFR inhibitor,P54760
CHEMBL4303283,C1C2CC3CC1CC(C2)(C3)C(=O)NC4=CC5=C(C=C4)N=C(S5)NC(=O)C6=CC=CC=C6,NVP-231,Preclinical,ceramidase inhibitor,Q8TCT0
CHEMBL1464276,C1=CC=C(C=C1)C(=O)NC2=CC3=C(C=C2)NC=C3,OAC2,Preclinical,Oct activator,Q01860
CHEMBL3581764,COC1=CC=C(C=C1)COC2=CC=C(C=C2)CC#N,O4I1,Preclinical,Oct inducer,Q01860
CHEMBL1680,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O,octreotide,Launched,somatostatin receptor agonist,P30874
CHEMBL3039583,C1[C@@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,pasireotide,Launched,somatostatin receptor agonist,P30874
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P30874
CHEMBL1680,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O,octreotide,Launched,somatostatin receptor agonist,P32745
CHEMBL3039583,C1[C@@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,pasireotide,Launched,somatostatin receptor agonist,P32745
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P32745
CHEMBL1680,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O,octreotide,Launched,somatostatin receptor agonist,P35346
CHEMBL3039583,C1[C@@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,pasireotide,Launched,somatostatin receptor agonist,P35346
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P35346
CHEMBL4865522,,OICR-9429,Preclinical,WDR5/MLL interaction inhibitor,P61964
CHEMBL3906778,CN1CCN(CC1)C2=C(C=C(C=C2)C(=O)OC)NC(=O)C3=CC(=CC=C3)OC,WDR5-0103,Preclinical,histone lysine methyltransferase inhibitor,P61964
CHEMBL1256136,CC[C@H]\1CC[C@@H]2[C@@H]([C@@H]([C@H]([C@@]3(O2)CC[C@H]([C@H](O3)C[C@H](C)O)C)C)OC(=O)/C=C/[C@H]([C@@H]([C@H](C(=O)[C@H]([C@@H]([C@H](C(=O)[C@@]([C@H]([C@H](C/C=C/C=C1)C)O)(C)O)C)O)C)C)O)C)C,oligomycin-A,Preclinical,ATP synthase inhibitor|ATPase inhibitor,P25705
CHEMBL4864931,,piceatannol,Preclinical,SYK inhibitor,P25705
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P25705
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,P23297
CHEMBL1189432,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,olopatadine,Launched,histamine receptor antagonist,P29034
CHEMBL1201013,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)[O-])C(=O)O)C(=O)O)[O-].[Na+].[Na+],olsalazine,Launched,cyclooxygenase inhibitor,P01579
CHEMBL363535,CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C4=C3OC=C4C,tanshinone-I,Phase 2,AP inhibitor,P01579
CHEMBL4865042,,trofinetide,Phase 2,cytokine production inhibitor,P01579
CHEMBL446452,C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43,"3,3'-diindolylmethane",Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",P01579
CHEMBL1201013,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)[O-])C(=O)O)C(=O)O)[O-].[Na+].[Na+],olsalazine,Launched,cyclooxygenase inhibitor,P51580
CHEMBL1800955,CC1=NC=C(C=C1)NC(=O)NC2=CC=CC(=C2F)CN3CCN(CC3)C(=O)OC,omecamtiv-mecarbil,Phase 3,cardiac myosin activator,Q14896
CHEMBL4877952,,ONC201,Phase 2,AKT inhibitor|MAP kinase inhibitor,P50591
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,Q9Y4D2
CHEMBL4864437,,RHC-80267,Preclinical,triacylglycerol lipase inhibitor,Q9Y4D2
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,Q8NCG7
CHEMBL4864437,,RHC-80267,Preclinical,triacylglycerol lipase inhibitor,Q8NCG7
CHEMBL175247,CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,orlistat,Launched,lipase inhibitor,P07098
CHEMBL1200340,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O,oseltamivir-phosphate,Launched,neuraminidase inhibitor,Q99519
CHEMBL1200340,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O,oseltamivir-phosphate,Launched,neuraminidase inhibitor,Q9Y3R4
CHEMBL414779,CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)OC(=O)NCCCCCCNC(=O)C2=CC(=C(C=C2C(=O)NCCCCCCNC(=O)O[C@@H]([C@H]3[C@@H]([C@H](C=C(O3)C(=O)O)N=C(N)N)NC(=O)C)[C@@H](CO)O)C(=O)NCCCCCCNC(=O)O[C@@H]([C@H]4[C@@H]([C@H](C=C(O4)C(=O)O)N=C(N)N)NC(=O)C)[C@@H](CO)O)C(=O)NCCCCCCNC(=O)O[C@@H]([C@H]5[C@@H]([C@H](C=C(O5)C(=O)O)N=C(N)N)NC(=O)C)[C@@H](CO)O)C(=O)O)NC(=N)N,zanamivir,Launched,neuraminidase inhibitor,Q9Y3R4
CHEMBL4609986,,OTS167,Phase 1/Phase 2,maternal embryonic leucine zipper kinase inhibitor,Q14680
CHEMBL4846041,,oxfenicine,Phase 1,carnitine palmitoyltransferase inhibitor,Q92523
CHEMBL3039583,C1[C@@H](CN2[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN,pasireotide,Launched,somatostatin receptor agonist,P30872
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P30872
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,Q08881
CHEMBL477772,CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N,pazopanib,Launched,KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor|VEGFR inhibitor,Q9UQQ2
CHEMBL3545196,CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl,PD-166285,Preclinical,SRC inhibitor,Q99640
CHEMBL5040752,,PD1-PDL-inhibitor-1,Preclinical,programmed death ligand inhibitor,Q9NZQ7
CHEMBL2360464,C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].[Na+].[Na+],pemetrexed,Launched,dihydrofolate reductase inhibitor|thymidylate synthase inhibitor,P31939
CHEMBL4519671,,pentamidine,Launched,anti-pneumocystis agent,O14717
CHEMBL4862732,,pentoxifylline,Launched,phosphodiesterase inhibitor,P21589
CHEMBL3314610,CCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)[C@H](CC(=O)O)O)O,pepstatin,Preclinical,aspartic protease inhibitor,P07339
CHEMBL4873781,,S-methylcysteine,Phase 1,,P07339
CHEMBL2364622,C1CC2=CC=CC=C2[C@H]1NC3=C4C=CN(C4=NC=N3)[C@@H]5C[C@H]([C@H](C5)O)COS(=O)(=O)N.Cl,pevonedistat,Phase 3,nedd activating enzyme inhibitor,Q8TBC4
CHEMBL4303155,CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C,PF-06463922,Launched,ALK tyrosine kinase receptor inhibitor,P07332
CHEMBL4859896,,PF-429242,Preclinical,SREBP inhibitor,Q14703
CHEMBL4650213,C1[C@@H]2CN([C@H]1CN2C3=CC=CC=N3)C=CC(=O)C4=CC=CC=C4O,PFI-3,Preclinical,bromodomain inhibitor,Q86U86
CHEMBL4650213,C1[C@@H]2CN([C@H]1CN2C3=CC=CC=N3)C=CC(=O)C4=CC=CC=C4O,PFI-3,Preclinical,bromodomain inhibitor,P51532
CHEMBL4865035,,PFK-015,Phase 1,phosphofructokinase inhibitor,Q16875
CHEMBL4877685,,PFK-158,Phase 1,phosphofructokinase inhibitor,Q16875
CHEMBL4853106,,YZ9,Preclinical,phosphofructokinase inhibitor,Q16875
CHEMBL4848440,,3PO,Preclinical,phosphofructokinase inhibitor,Q16875
CHEMBL3545213,C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4,PGL5001,Phase 2,JNK inhibitor,P53779
CHEMBL4872164,,pyrazolanthrone,Preclinical,JNK inhibitor,P53779
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P53779
CHEMBL4850171,,SR-3306,Preclinical,JNK inhibitor,P53779
CHEMBL4854630,,SR-3576,Preclinical,JNK inhibitor,P53779
CHEMBL3545213,C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4,PGL5001,Phase 2,JNK inhibitor,P45984
CHEMBL4872164,,pyrazolanthrone,Preclinical,JNK inhibitor,P45984
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,P45984
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,P45984
CHEMBL4850171,,SR-3306,Preclinical,JNK inhibitor,P45984
CHEMBL1089,C1=CC=C(C=C1)CCNN,phenelzine,Launched,monoamine oxidase inhibitor,Q16853
CHEMBL45068,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O,phloretin,Launched,sodium/glucose cotransporter inhibitor,O14520
CHEMBL45068,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O,phloretin,Launched,sodium/glucose cotransporter inhibitor,O43315
CHEMBL45068,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O)O)O)O,phloretin,Launched,sodium/glucose cotransporter inhibitor,P51790
CHEMBL4303464,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,Q8WWX8
CHEMBL4303464,C1=CC(=CC=C1CCC(=O)C2=C(C=C(C=C2O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,phlorizin,Preclinical,sodium/glucose cotransporter inhibitor,P53794
CHEMBL4864931,,piceatannol,Preclinical,SYK inhibitor,P06576
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P06576
CHEMBL4864931,,piceatannol,Preclinical,SYK inhibitor,P36542
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,P36542
CHEMBL4864931,,piceatannol,Preclinical,SYK inhibitor,Q14653
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P0DUB6
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P19961
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,O43612
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,P0CG04
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,Q701N4
CHEMBL397976,C1CC(=O)N[C@@H]1C(=O)O,pidolic-acid,Launched,,Q03403
CHEMBL4857460,,PIK-93,Preclinical,PI3K inhibitor,Q8NEB9
CHEMBL4848911,,SAR405,Preclinical,PI3K inhibitor,Q8NEB9
CHEMBL1256391,CC1=CN(C(=O)C=C1)C2=CC=CC=C2,pirfenidone,Launched,TGF beta receptor inhibitor,P09958
CHEMBL1870796,CC(C)(C)C(=O)NCCCC(=O)O,pivagabine,Launched,corticotropin releasing factor receptor antagonist,Q13324
CHEMBL1821568,,PJ-34,Preclinical,PARP inhibitor,P13639
CHEMBL1821568,,PJ-34,Preclinical,PARP inhibitor,Q460N3
CHEMBL554014,C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl,plerixafor,Launched,CC chemokine receptor antagonist,P25106
CHEMBL4865329,,VUF11207,Preclinical,CC chemokine receptor agonist,P25106
CHEMBL2108712,,plovamer-acetate,Phase 2,,P54577
CHEMBL2108712,,plovamer-acetate,Phase 2,,Q9Y2Z4
CHEMBL4870077,,PP242,Preclinical,mTOR inhibitor,Q96RG2
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,P05113
CHEMBL11350,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,pranlukast,Launched,leukotriene receptor antagonist,Q02817
CHEMBL897,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,probenecid,Launched,uricosuric blocker,Q9NSA0
CHEMBL897,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,probenecid,Launched,uricosuric blocker,Q9NYB5
CHEMBL224867,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,taurocholate,Phase 1,G protein-coupled receptor agonist,Q9NYB5
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q16558
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q9NPA1
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q9Y691
CHEMBL569,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,procaine,Launched,HMGCR inhibitor,Q86W47
CHEMBL1518,CCCC1=CC(=O)NC(=S)N1,propylthiouracil,Launched,thyroid peroxidase inhibitor,P49895
CHEMBL1472,C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N,protirelin,Launched,thyrotropin releasing hormone receptor agonist,P34981
CHEMBL2107016,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(=O)N,taltirelin,Launched,thyrotropin releasing hormone receptor agonist,P34981
CHEMBL4303151,C1=CC=C2C(=C1)C(=O)C(=CC3=CN=CC=C3)C2=O,PRT4165,Preclinical,polycomb repressive complex inhibitor,O43663
CHEMBL1208118,C1=CC=C2C(=C1)C=CC=C2NC3=CC(=C(C4=C3C(=O)C5=CC=CC=C5C4=O)N)S(=O)(=O)O,PSB-06126,Preclinical,NTPDase inhibitor,O75355
CHEMBL4878475,,PT-2385,Phase 1,hypoxia inducible factor inhibitor,Q99814
CHEMBL4862810,,TC-S-7009,Preclinical,hypoxia inducible factor inhibitor,Q99814
CHEMBL4876445,,purvalanol-A,Preclinical,CDK inhibitor,Q9Y6M4
CHEMBL4872164,,pyrazolanthrone,Preclinical,JNK inhibitor,Q9UQF2
CHEMBL3181870,CC1=NC=C(C(=C1O)C=O)COP(=O)(O)O.O,pyridoxal,Launched,,O00764
CHEMBL1200756,CC1=NC=C(C(=C1O)CO)CO.Cl,pyridoxine,Launched,vitamin B,O00764
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,Q6NVY1
CHEMBL50,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,quercetin,Launched,polar auxin transport inhibitor,O94768
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,O00180
CHEMBL1200437,COC1=CC2=C(C=CN=C2C=C1)[C@@H]([C@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.C([C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O)O)O,quinidine,Launched,sodium channel blocker,Q9Y257
CHEMBL2359966,COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.COC1=CC2=C(C=CN=C2C=C1)[C@H]([C@@H]3C[C@@H]4CCN3C[C@@H]4C=C)O.O.O.OS(=O)(=O)O,quinine,Launched,hemozoin biocrystallization inhibitor,P14770
CHEMBL4876303,,R-59022,Preclinical,diacylglycerol kinase inhibitor|protein kinase inhibitor,P23743
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,P23743
CHEMBL4850356,,remodelin,Preclinical,transferase inhibitor,Q9H0A0
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,O75911
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q9BTZ2
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,O95237
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P49116
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P49116
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P10745
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q8TC12
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q96NR8
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q8NBN7
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q9HBH5
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q9NYR8
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,Q6NUM9
CHEMBL4872083,,retinol,Launched,retinoid receptor ligand,P12271
CHEMBL4862978,,reversine,Preclinical,Aurora kinase inhibitor,Q9NQS7
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,Q00526
CHEMBL3545083,COCCN1CCN(CC1)CC2=CC=C(C=C2)C3=NNC4=C3C(=O)C5=C4C=CC=C5NC(=O)NN6CCOCC6,RGB-286638,Phase 1,CDK inhibitor,O43318
CHEMBL4848561,,RI-1,Preclinical,,Q06609
CHEMBL1534,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](CO)O)O)O,riboflavin,Launched,vitamin B,Q969G6
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q969G6
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q9UJM8
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q9NYQ3
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,Q96CD2
CHEMBL3989697,CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)C[C@@H]([C@@H]([C@@H](COP(=O)(O)[O-])O)O)O.O.O.[Na+],riboflavin-5-phosphate-sodium,Launched,,O75676
CHEMBL3138633,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O)O)N.OS(=O)(=O)O,ribostamycin,Launched,bacterial 30S ribosomal subunit inhibitor,P07237
CHEMBL744,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,riluzole,Launched,glutamate inhibitor,Q9NYG8
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q5VT25
CHEMBL4868620,,RKI-1447,Preclinical,rho associated kinase inhibitor,Q09013
CHEMBL4864608,,Ro-08-2750,Preclinical,NGF binding inhibitor,P01138
CHEMBL4851032,,Ro-48-8071,Preclinical,oxidosqualene cyclase inhibitor,P48449
CHEMBL4864796,,Ro-61-8048,Preclinical,kynurenine 3-monooxygenase inhibitor,O15229
CHEMBL4858819,,rofecoxib,Withdrawn,cyclooxygenase inhibitor,P15502
CHEMBL4850820,,RU-SKI-43,Preclinical,hedgehog pathway inhibitor,Q5VTY9
CHEMBL4848410,,SANT-1,Preclinical,smoothened receptor antagonist,Q15465
CHEMBL4878387,,SANT-2,Preclinical,smoothened receptor antagonist,Q15465
CHEMBL4871888,,SB-203580,Preclinical,p38 MAPK inhibitor,O14976
CHEMBL4859622,,SB-218795,Preclinical,tachykinin antagonist,P29371
CHEMBL4865858,,SB-222200,Preclinical,tachykinin antagonist,P29371
CHEMBL414370,CC(C)C[C@H](C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)CNC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]3CCCN3C(=O)[C@@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCN=C(N)N)N,substance-P,Phase 1,neurokinin receptor antagonist,P29371
CHEMBL4856283,,talnetant,Phase 2,tachykinin antagonist,P29371
CHEMBL284954,CCOC(=O)[C@H](CC1=CC=C(C=C1)[N+](=O)[O-])NC(=O)C2=CC=CC=C2,SB-297006,Preclinical,CC chemokine receptor antagonist,P51677
CHEMBL1909378,C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5.Cl,SB-431542,Preclinical,TGF beta receptor inhibitor,Q8NER5
CHEMBL1257246,CC(=CCC[C@]1([C@@H]2CC[C@H]3CC4=C([C@@]3([C@]2(CC[C@@H]1O)C)C)NC5=CC=CC=C45)C)C,SB-683698,Phase 1,integrin antagonist,P26010
CHEMBL4863031,,SB-747651A,Preclinical,kinase inhibitor,O75582
CHEMBL3236507,COC/C=C/C1=CC(=C(C=C1)O[C@@H](CO)CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)OC,SC-12267,Phase 2,dihydroorotate dehydrogenase inhibitor,Q16552
CHEMBL4303340,CC1=C(C=NN1C2=CC=C(C=C2)Cl)C(=O)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCOCC5)C#N,Y-320,Preclinical,interleukin inhibitor,Q16552
CHEMBL4870993,,SCH-23390,Preclinical,dopamine receptor antagonist,P48051
CHEMBL3084722,CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4,scopolamine,Launched,acetylcholine receptor antagonist,P14410
CHEMBL4871195,,SF-11,Preclinical,neuropeptide receptor antagonist,Q8TDD5
CHEMBL1430530,CC1=CC(=C(C(=C1)C)C2=NOC3C2C4CCC3C4)C,SN-2,Preclinical,transient receptor potential channel agonist,Q8TDD5
CHEMBL4860631,,SHA-68,Preclinical,neuropeptide receptor antagonist,Q6W5P4
CHEMBL4861187,,SID-7969543,Preclinical,steroidogenic factor antagonist,Q13285
CHEMBL1214186,C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)C[C@H](CC[C@@H](C(=O)O)N)N)O)O)N,sinefungin,Preclinical,DNA methyltransferase inhibitor|RNA synthesis inhibitor,Q86X55
CHEMBL4850318,,SIS3,Preclinical,serine/threonine kinase inhibitor,P84022
CHEMBL4303491,CCOC1=C(C(=CC(=C1)/C=C/2\C(=NN(C2=O)C3=CC=CC=C3)C)Cl)OCC(=O)OC,SJ-172550,Preclinical,MDM inhibitor,O15151
CHEMBL4865853,,SKF-96365,Preclinical,calcium channel blocker,P48995
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",P48995
CHEMBL4856670,,SMER-28,Preclinical,autophagy inducer,P37840
CHEMBL3764926,,sodium-stibogluconate,Launched,tyrosine phosphatase inhibitor,P29350
CHEMBL1441961,CC(=CCOC1=CC=C(C=C1)/C=C/C(=O)C2=C(C=C(C=C2)OCC=C(C)C)OCC(=O)O)C,sofalcone,Launched,mucus protecting agent,P16152
CHEMBL4868602,,somatostatin,Launched,somatostatin receptor agonist,P31391
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,C0HM02
CHEMBL2105655,CC(=O)O.CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65,sotrastaurin,Phase 2,PKC inhibitor,P24723
CHEMBL2391504,C1=CC(=CC=C1CNC2=NC=NC3=C2C=C(C=C3)F)F,spautin-1,Preclinical,deubiquitinase inhibitor,Q14694
CHEMBL2391504,C1=CC(=CC=C1CNC2=NC=NC3=C2C=C(C=C3)F)F,spautin-1,Preclinical,deubiquitinase inhibitor,Q8NFA0
CHEMBL2391504,C1=CC(=CC=C1CNC2=NC=NC3=C2C=C(C=C3)F)F,spautin-1,Preclinical,deubiquitinase inhibitor,Q92995
CHEMBL1275761,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@]([C@@H]2C(=O)CCNCCCNCCCCNCCCN)(C)O)CCC4=CC(=O)C=C[C@@]43C)F)O,spermine,Preclinical,,P52788
CHEMBL1236027,CCCCCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)(O)OCC[N+](C)(C)C)N)O,sphingosylphosphorylcholine,Preclinical,gene expression stimulant,P47775
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P19099
CHEMBL1562223,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,spironolactone,Launched,mineralocorticoid receptor antagonist,P04278
CHEMBL570170,CC(=CCC/C(=C/CNCCNC1C2CC3CC(C2)CC1C3)/C)C.Cl,SQ-109,Phase 3,bacterial cell wall synthesis inhibitor,P37268
CHEMBL4871845,,SR-1078,Preclinical,retinoid receptor agonist,P51449
CHEMBL4859235,,SR-2211,Preclinical,retinoid receptor inverse agonist,P51449
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P51449
CHEMBL4867051,,SRPIN340,Preclinical,serine arginine protein kinase inhibitor,Q96SB4
CHEMBL4859642,,ST-2825,Preclinical,myeloid differentiation primary response inhibitor,Q99836
CHEMBL4870975,,STF-31,Preclinical,NAMPT inhibitor,P11166
CHEMBL4303562,C1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O,2-deoxyglucose,Phase 2,glycolysis inhibitor,P11166
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,O14756
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P55809
CHEMBL508338,,thiomersal,Launched,other antibiotic,P55809
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9BYC2
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q02809
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,O60568
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P31040
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P21912
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q99643
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9BZW2
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q13183
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q8WWT9
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9UBX3
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9P2R7
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,P53597
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q96I99
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9BXA5
CHEMBL576,C(CC(=O)O)C(=O)O,succinic-acid,Launched,,Q9NVH6
CHEMBL83626,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)OC(=O)CCC(=O)O)C(C)(C)C,succinobucol,Phase 2/Phase 3,antioxidant,P19320
CHEMBL983,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],succinylcholine-chloride,Launched,,Q494W8
CHEMBL1200823,,sucrose,Launched,,O00244
CHEMBL1200823,,sucrose,Launched,,Q9Y3I0
CHEMBL1363071,CC1=CC(=O)N(C(=C1C(=NC2=CC=CC=C2N)C)O)O,SUN-B-8155,Preclinical,calcitonin agonist,P30988
CHEMBL3040216,CC1=CCC(=CC1=NC(=O)C2=CC=C/C(=N\C(=O)/N=C\3/CC(=CC=C3)C(=O)N=C4CC(=CC=C4C)C(=O)N=C5CC=C(C6=C5C(=CC(=C6)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)/C2)C(=O)N=C7CC=C(C8=C7C(=CC(=C8)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,suramin,Launched,DNA synthesis inhibitor,P23945
CHEMBL83,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,tamoxifen,Launched,estrogen receptor antagonist|selective estrogen receptor modulator (SERM),Q15125
CHEMBL4532415,CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=C4C=C(C(=CC4=NC=C3)OCCCN5CCCCC5)OC,tandutinib,Phase 2,FLT3 inhibitor|KIT inhibitor|PDGFR tyrosine kinase receptor inhibitor,Q9GZP0
CHEMBL224867,C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,taurocholate,Phase 1,G protein-coupled receptor agonist,P19835
CHEMBL4871084,,TC-ASK-10,Preclinical,MAP kinase inhibitor,Q99683
CHEMBL4871084,,TC-ASK-10,Preclinical,MAP kinase inhibitor,O95382
CHEMBL2424812,C1CC1CCCCCCCCC(=O)N(CCC(=O)O)O,TC-E-5002,Preclinical,histone demethylase inhibitor,P29375
CHEMBL4846231,,TC-FPR-43,Preclinical,formyl peptide receptor agonist,P25090
CHEMBL4854703,,TC-G-1008,Preclinical,G protein-coupled receptor agonist,O43194
CHEMBL4860399,,TC-LPA5-4,Preclinical,lysophosphatidic acid receptor antagonist,Q9H1C0
CHEMBL4845918,,TC-OT-39,Preclinical,oxytocin receptor agonist|vasopressin receptor agonist,P01178
CHEMBL595354,CC(C)(C)C1=CC=C(C=C1)C(=O)NC(=S)NC2=CC=C(C=C2)NC(=O)CCCCN(C)C,tenovin-6,Preclinical,SIRT inhibitor,Q9NTG7
CHEMBL4874697,,TEPP-46,Preclinical,pyruvate kinase isozyme activator,P14618
CHEMBL4858264,,terameprocol,Phase 1/Phase 2,lipoxygenase inhibitor,O15392
CHEMBL4863597,,YM-155,Phase 2,survivin inhibitor,O15392
CHEMBL1236475,C1CN(C(=O)N[C@@H]1O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,tetrahydrouridine,Phase 2,cytidine deaminase inhibitor,P32320
CHEMBL4856673,,zebularine,Preclinical,DNA methyltransferase inhibitor,P32320
CHEMBL4096763,CCNC1=N[C@H]2[C@@H]([C@H]([C@@H](O[C@H]2S1)CO)O)O,thiamet-g,Preclinical,GLCNAC phosphotransferase inhibitor,O60502
CHEMBL1547,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO,thiamine,Launched,vitamin B,O60779
CHEMBL1547,CC1=C(SC=[N+]1CC2=CN=C(N=C2N)C)CCO,thiamine,Launched,vitamin B,Q9H3S4
CHEMBL2303629,CC[C@H](C)[C@H]1C(=O)NC(C(=O)NC(=C)C(=O)N[C@H](C(=O)N[C@@]23CCC(=N[C@@H]2C4=CSC(=N4)[C@H]([C@H](OC(=O)C5=NC6=C(C=C[C@H]([C@@H]6O)N1)C(=C5)[C@H](C)O)C)NC(=O)C7=CSC(=N7)[C@@H](NC(=O)[C@H]8CSC(=N8)/C(=C/C)/NC(=O)[C@@H](NC(=O)C9=CSC3=N9)[C@@H](C)O)[C@](C)([C@@H](C)O)O)C1=NC(=CS1)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)C)C,thiostrepton,Launched,FOXM1 inhibitor|protein synthesis inhibitor,Q08050
CHEMBL4851118,,tiplaxtinin,Phase 1,plasminogen activator inhibitor,P05121
CHEMBL4868051,,tolrestat,Withdrawn,aldose reductase inhibitor,O60218
CHEMBL4303636,C1=CC=C2C(=C1)C(=CC(=O)O)NN(C2=O)CC3=NC4=C(S3)C=CC(=C4)C(F)(F)F,zopolrestat,Phase 2,,O60218
CHEMBL554563,C1[C@H]([C@@H](O[C@@H]1N2C=CC(=NC2=O)N)CO)O,torcitabine,Phase 2,DNA polymerase inhibitor,O00142
CHEMBL2103847,CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2,tosedostat,Phase 2,peptidase inhibitor,P28838
CHEMBL2103847,CC(C)C[C@H]([C@@H](C(=O)NO)O)C(=O)N[C@@H](C1=CC=CC=C1)C(=O)OC2CCCC2,tosedostat,Phase 2,peptidase inhibitor,P55786
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,Q8NFJ5
CHEMBL4846375,,tretinoin,Launched,retinoid receptor agonist|retinoid receptor ligand,P49788
CHEMBL1257040,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl,trifluoperazine,Launched,dopamine receptor antagonist,P26447
CHEMBL203266,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,trimetazidine,Launched,3-ketoacyl CoA thiolase inhibitor,P42765
CHEMBL4853317,,tryptophan,Launched,serotonin receptor partial agonist,P23381
CHEMBL4853317,,tryptophan,Launched,serotonin receptor partial agonist,Q9UGM6
CHEMBL339427,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC,tubocurarine,Launched,acetylcholine receptor antagonist,Q401N2
CHEMBL4872912,,TWS-119,Preclinical,glycogen synthase kinase inhibitor,P01106
CHEMBL4868542,,U-0126,Preclinical,MEK inhibitor,O14733
CHEMBL4878152,,UAMC-00039,Preclinical,dipeptidyl peptidase inhibitor,Q9UHL4
CHEMBL4849355,,ubenimex,Launched,leukotriene synthesis inhibitor,Q9H4A4
CHEMBL4862363,,UNC1215,Preclinical,L3MBTL antagonist,Q96JM7
CHEMBL4851905,,UNC669,Preclinical,L3MBTL antagonist,Q9Y468
CHEMBL4477270,,UNC926,Preclinical,MBT inhibitor,Q9Y468
CHEMBL566,C1=CNC(=O)NC1=O,uracil,Launched,,Q9NWZ5
CHEMBL4872470,,URB597,Phase 1,FAAH inhibitor,Q6GMR7
CHEMBL4852012,,urea,Launched,hydroxy radical formation stimulant,P05089
CHEMBL5077459,C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)([O-])OP(=O)(O)[O-])O)O.[Na+].[Na+].[Na+],uridine,Phase 2,dopamine receptor agonist,P19971
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,Q92772
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,Q02779
CHEMBL4873030,,URMC-099,Preclinical,mixed lineage kinase inhibitor,Q16584
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,P45954
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q07699
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q07699
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,O60939
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,O60939
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q9NY72
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9NY72
CHEMBL109,CCCC(CCC)C(=O)O,valproic-acid,Launched,benzodiazepine receptor agonist|HDAC inhibitor,Q8IWT1
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q8IWT1
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P21709
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q5JZY3
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P29320
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P54764
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P54756
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q9UF33
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q15375
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P29322
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P54762
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P29323
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,P54753
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,O15197
CHEMBL4856658,,vandetanib,Launched,EGFR inhibitor|RET tyrosine kinase inhibitor|VEGFR inhibitor,Q13882
CHEMBL1280,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC.Cl,verapamil,Launched,calcium channel blocker,Q8IZF0
CHEMBL3039505,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/N=C/2\C=CC(=C\C2=C(\C3=CC=[N+](C=C3)[O-])/[O-])Cl.[Na+],vercirnon,Phase 3,CC chemokine receptor antagonist,P51686
CHEMBL1333097,C1CC[C@H]([C@@H](C1)N2CCC(CC2)C3=CC=CC=C3)O.Cl,vesamicol,Preclinical,acetylcholinesterase inhibitor,Q16572
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,Q9UJT1
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,Q9UJT0
CHEMBL22969,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,vinblastine,Launched,microtubule inhibitor|tubulin polymerization inhibitor,P23258
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,P67775
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,P62714
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,O76054
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,Q9UDX4
CHEMBL4864710,,vitamin-E,Launched,LDL oxidation inhibitor|PKC inhibitor,Q9UDX3
CHEMBL4226439,CCOC(=O)N[C@@H]1CCC2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C,vorapaxar,Launched,thrombin inhibitor,P25116
CHEMBL4875283,,WAY-316606,Preclinical,secreted frizzled related protein inhibitor,Q8N474
CHEMBL3774960,CN(C)C[C@H](CN1C2=C(C=C(C=C2)Br)C3=C1C=CC(=C3)Br)O,wiskostatin,Preclinical,actin related protein inhibitor|neural Wiskott-Aldrich syndrome protein inhibitor,O00401
CHEMBL4174555,CC(=O)O[C@@H]1C[C@@]2(C(=O)CC[C@]2(C3=C1[C@]4([C@H](OC(=O)C5=COC(=C54)C3=O)COC)C)C)C,wortmannin,Preclinical,PI3K inhibitor,P42356
CHEMBL4862486,,WP1130,Preclinical,deubiquitinase inhibitor,Q9Y5K5
CHEMBL4862486,,WP1130,Preclinical,deubiquitinase inhibitor,Q93008
CHEMBL4303156,CCOC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)OC(=O)N(C)CC3=CC(=CC=C3)C4=CC=NC=C4,WWL-113,Preclinical,carboxylesterase inhibitor,Q6UWW8
CHEMBL4303532,CN(CC1=CC(=CC=C1)C2=CC=CC=C2)C(=O)OC3=CC=C(C=C3)C4=CC=C(C=C4)C(=O)N,WWL-123,Preclinical,monoacylglycerol lipase inhibitor,Q9BV23
CHEMBL4303523,CCC(=O)NC1=CC(=CC=C1)OC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCN(CC4)C)OC,WZ4003,Preclinical,AMPK inhibitor,Q9H093
CHEMBL4857157,,XMD8-92,Preclinical,MAP kinase inhibitor,Q8N568
CHEMBL4857157,,XMD8-92,Preclinical,MAP kinase inhibitor,Q13470
CHEMBL4869494,,Y-27632,Preclinical,rho associated kinase inhibitor,Q16513
CHEMBL4875523,,YK-4-279,Preclinical,apoptosis inhibitor,Q01844
CHEMBL4875523,,YK-4-279,Preclinical,apoptosis inhibitor,Q01543
CHEMBL1356775,CC1(CC2=CC(=C(C=C2C3=CC4=NC5=CC=CC=C5N=C4N31)OC)OC)C,YM-90709,Preclinical,IL5 inhibitor,P32927
CHEMBL1356775,CC1(CC2=CC(=C(C=C2C3=CC4=NC5=CC=CC=C5N=C4N31)OC)OC)C,YM-90709,Preclinical,IL5 inhibitor,Q01344
CHEMBL4303374,C1=CC(=C(C(=C1)Cl)CSC2=NN=C(S2)C3=NC=CN=C3)Cl,yoda-1,Preclinical,piezo channel activator,Q92508
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,Q99712
CHEMBL537669,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O.Cl,yohimbine,Launched,adrenergic receptor antagonist,Q9UNX9
CHEMBL4856893,,Y16,Preclinical,rho associated kinase inhibitor,P61586
CHEMBL4851782,,zatebradine,Phase 3,HCN channel blocker,Q9UL51
CHEMBL1852596,CCN(C1=CC=CC=C1)C2=CC(=NC)N(C(=N2)C)C,ZD-7288,Phase 2,HCN channel blocker,Q9UL51
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9NS85
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,O75493
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,Q9NS71
CHEMBL750,C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N,zonisamide,Launched,sodium channel blocker|T-type calcium channel blocker,P35219
CHEMBL444172,C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47,zosuquidar,Phase 3,P glycoprotein inhibitor,P21439
CHEMBL3598020,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H]([C@@]2([C@@H]3CC(C(=O)[C@]3(CC(=C[C@H]2[C@H]4[C@@]1(C4(C)C)OC(=O)C)CO)O)C)O)C,12-O-tetradecanoylphorbol-13-acetate,Phase 2,PKC activator,Q6UVM3
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9BX84
CHEMBL4847963,,2-APB,Preclinical,"1,4,5-trisphosphate inhibitor",Q9H1D0
CHEMBL4303562,C1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O,2-deoxyglucose,Phase 2,glycolysis inhibitor,P11168
CHEMBL4303562,C1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O,2-deoxyglucose,Phase 2,glycolysis inhibitor,P11169
CHEMBL4303562,C1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O,2-deoxyglucose,Phase 2,glycolysis inhibitor,P14672
CHEMBL4861611,,2-oxoglutaric-acid,Preclinical,,Q96P68
CHEMBL4873391,,2-TEDC,Preclinical,lipoxygenase inhibitor,P18054
CHEMBL446452,C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43,"3,3'-diindolylmethane",Phase 3,"CHK inhibitor|cytochrome P450 activator|indoleamine 2,3-dioxygenase inhibitor",P19957
CHEMBL4303725,CN1C=NC(=N)C2=C1N=CN2,3-methyladenine,Preclinical,PI3K inhibitor,P19957
CHEMBL4858001,,3-alpha-hydroxy-5-beta-androstan-17-one,Preclinical,,Q8NBQ5
CHEMBL4858001,,3-alpha-hydroxy-5-beta-androstan-17-one,Preclinical,,P01859
CHEMBL177837,C(C(=O)C(=O)O)Br,3-bromopyruvate,Preclinical,hexokinase inhibitor,P52789
CHEMBL582878,C1=CC=C2C(=C1)C(=CN2)CCCC(=O)O,3-indolebutyric-acid,Preclinical,,P61769
CHEMBL582878,C1=CC=C2C(=C1)C(=CN2)CCCC(=O)O,3-indolebutyric-acid,Preclinical,,P04439
CHEMBL582878,C1=CC=C2C(=C1)C(=CN2)CCCC(=O)O,3-indolebutyric-acid,Preclinical,,P01848
CHEMBL582878,C1=CC=C2C(=C1)C(=CN2)CCCC(=O)O,3-indolebutyric-acid,Preclinical,,P01850
CHEMBL4846413,,4-chlorophenylguanidine,Preclinical,urokinase inhibitor,Q03405
CHEMBL4863736,,4EGI-1,Preclinical,protein synthesis inhibitor,P06730
CHEMBL1610008,C1=CC=C(C=C1)C2=C/C(=C\C3=CC=C(O3)C4=CC=C(C=C4)[N+](=O)[O-])/C(=O)N2C5=CC=C(C=C5)C(=O)O,4E1RCat,Preclinical,protein synthesis inhibitor,P06730
CHEMBL1610008,C1=CC=C(C=C1)C2=C/C(=C\C3=CC=C(O3)C4=CC=C(C=C4)[N+](=O)[O-])/C(=O)N2C5=CC=C(C=C5)C(=O)O,4E1RCat,Preclinical,protein synthesis inhibitor,Q04637
CHEMBL601,C(CC(=O)O)C(=O)CN,5-aminolevulinic-acid,Launched,oxidizing agent,P13716
CHEMBL4865868,,5-BDBD,Preclinical,purinergic receptor antagonist,Q99571
CHEMBL4870839,,5-hydroxytryptophan,Launched,neurotransmitter,Q495M3
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,Q9P0L2
CHEMBL1236539,C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)[C@H](NC6=O)O)NC)OC,7-hydroxystaurosporine,Phase 2,CDK inhibitor|CHK inhibitor|PKC inhibitor,P27448